<SEC-DOCUMENT>0001773427-22-000023.txt : 20220506
<SEC-HEADER>0001773427-22-000023.hdr.sgml : 20220506
<ACCEPTANCE-DATETIME>20220505070315
ACCESSION NUMBER:		0001773427-22-000023
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		66
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220505
DATE AS OF CHANGE:		20220505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SpringWorks Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001773427
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39044
		FILM NUMBER:		22893975

	BUSINESS ADDRESS:	
		STREET 1:		100 WASHINGTON BOULEVARD
		CITY:			STAMFORD
		STATE:			CT
		ZIP:			06902
		BUSINESS PHONE:		203-883-9490

	MAIL ADDRESS:	
		STREET 1:		100 WASHINGTON BOULEVARD
		CITY:			STAMFORD
		STATE:			CT
		ZIP:			06902
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>swtx-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:20c9ef3f-9e42-493b-a5cd-6a5cd47c499c,g:fe877b4c-7b58-4b84-8d3e-d0ed79a85bd8,d:14026a47930f410d91f89b4244285b77--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:swtx="http://www.springworkstx.com/20220331" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>swtx-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180L2ZyYWc6MTIzZGE5MzhmZmQzNGY3ZmFjNGQ1NTgxMTQ5MzE5OGQvdGFibGU6YTkxOWJhZTE0ZmE4NDhlMjkwNmY1ZWI1NzgyZmM3YTAvdGFibGVyYW5nZTphOTE5YmFlMTRmYTg0OGUyOTA2ZjVlYjU3ODJmYzdhMF8zLTEtMS0xLTE1NTIz_ff8ba708-378b-4ba9-95be-e69560685406">0001773427</ix:nonNumeric><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180L2ZyYWc6MTIzZGE5MzhmZmQzNGY3ZmFjNGQ1NTgxMTQ5MzE5OGQvdGFibGU6YTkxOWJhZTE0ZmE4NDhlMjkwNmY1ZWI1NzgyZmM3YTAvdGFibGVyYW5nZTphOTE5YmFlMTRmYTg0OGUyOTA2ZjVlYjU3ODJmYzdhMF85LTEtMS0xLTE1NTIz_3767b6e0-e34f-4b8a-8a14-a8fbd3f1f367">false</ix:nonNumeric><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180L2ZyYWc6MTIzZGE5MzhmZmQzNGY3ZmFjNGQ1NTgxMTQ5MzE5OGQvdGFibGU6YTkxOWJhZTE0ZmE4NDhlMjkwNmY1ZWI1NzgyZmM3YTAvdGFibGVyYW5nZTphOTE5YmFlMTRmYTg0OGUyOTA2ZjVlYjU3ODJmYzdhMF8xMC0xLTEtMS0xNTUyMw_43336016-4f39-45b4-b565-8cd4af6cf14a">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180L2ZyYWc6MTIzZGE5MzhmZmQzNGY3ZmFjNGQ1NTgxMTQ5MzE5OGQvdGFibGU6YTkxOWJhZTE0ZmE4NDhlMjkwNmY1ZWI1NzgyZmM3YTAvdGFibGVyYW5nZTphOTE5YmFlMTRmYTg0OGUyOTA2ZjVlYjU3ODJmYzdhMF8xOS0xLTEtMS0xNTUyMw_fc705efa-c086-440b-88b1-a6901b67fe43">2022</ix:nonNumeric><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180L2ZyYWc6MTIzZGE5MzhmZmQzNGY3ZmFjNGQ1NTgxMTQ5MzE5OGQvdGFibGU6YTkxOWJhZTE0ZmE4NDhlMjkwNmY1ZWI1NzgyZmM3YTAvdGFibGVyYW5nZTphOTE5YmFlMTRmYTg0OGUyOTA2ZjVlYjU3ODJmYzdhMF8yMC0xLTEtMS0xNTUyMw_2b13f03c-a5dc-4d81-9666-da0d4be211c1">Q1</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="swtx-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i9ccede58414f4148821842e315a905d7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48bbb6301e904262900e93986ab7878d_I20220429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i4858197abb9f421195cb86f9528f4108_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="id73789b2c218404991bfa981f4cb6592_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i658acb93480c4b5393f0f53a36eab567_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0990f9597e64307b0c20baeb0374ba3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3287fd7612614db4b178dca62d93314c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8966326533744dcb83a31d655df247a5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7145ff8fbb7347739deda6cecec6c32c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6aca392105844fb988854fc2a1e19f5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9db5cd8bf9aa4652801e6be37eb56232_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b30664e42c44ea2bdfe57102b7f8793_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7752062fa254d488520f76b3b98be23_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia179ee44b4324835983690644a8c2d55_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aeb1d4fe3aa413287784b210d8cb0c7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d19dcca70de49e18de075013224639e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e1848bac6dd4d3395a865c973884624_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib131c00375dd4d01a1d5a8ca99a78357_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a27a2ad8f5b4adabc882295f434ad85_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7c72970af33479486aedd56f27b30d3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib34b57b88c524fb2a5cfb417de744b4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0c1b343064f4976a0430d48302ee8dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cea465f2f2844ecbd14a5a3b0ba249c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic68434afffb54cf0b8787b66026e3164_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifee6028d47d94c659487fe06b58c5d96_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2b735c9c0ea4731a01282de2dda1e04_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5310686134dd466eb22c5118bf07c60a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3b4361b2bc8468a8261a967f49bda37_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17d85f9a1e034f45ac98309a4aa39e2b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie552d9ac6bf047888c1a1153ddd4b5f3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic22dfb0a26f1485a97ca52722464d5ad_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0538532efa4c481fb6287237941a7a83_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76cd6147b1f74623a56a60a92568ed2a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e643f8a8bad4d0685bb17341335398d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i774d25c476d6488093d122507b7e32fa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="trial"><xbrli:measure>swtx:trial</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>swtx:segment</xbrli:measure></xbrli:unit><xbrli:context id="ic96e90b96953469abcc2db764348a6e1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8b06dfad0e4445b9def4cf77df1caf8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67ce1d0e7f26429d9c2e120dd4006a6d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie516370bcc604882a6b3b1072c5423ed_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65431ed7c312413eb40bd20210448df7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">swtx:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i300f6154df4c49c19cae97a30ab27fca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i150fe21584a54235b4ee8a7eab45b761_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id08a9791d8bf499dbcb446a78165cc74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fe7159edfa24359996120ecad894ca9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">swtx:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4afc949d12f47acb07e3840b1a868ac_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaa89fe2a4c24ac598f43e035f41aa5b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7e42a60b7564e79bc3c7c48d5590c00_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb7ddd9a5fdb4cf3abb770f8dbe58b35_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a06e303f7d247fe94023b4d619218aa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd4bd8059ca34abfb81ea2cc6436bce6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26bf9156508046f3a787efd142360d06_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if81ad8f0dc3845e892842d063335a2c0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia50bc0b54e7b411cbc0c32ee73246291_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83db6194bc09401ea9d4f8dbf3dd05ef_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d2ba195827a4b65a9c8591347ec440e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac009ae2fcd34d3cad26b302a0e27bc8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60cfe3f50c6b4c5892a4f8065819a89a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id10a160829dd4d6988d22ab73639351d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1994ec146e34e20b804657cf2ba88e0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35144578669449479c826d121a4a39af_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07d72b0a1c1041edbe9b872760e69623_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b0faab11338417da46a57af69648a69_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96e7836def764eae8d4fccf746bff3ed_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52195f7f2e1149f0bfc9825b28eb3e9d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c5e5caf0cc0466db2575b43a6561e92_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34e57c62cb4b46b18943ea2ade2bb811_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if853b5ddc3f24be599e3d8610e8928e9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i685d1982ea314317b0b57e4839162cc6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16725e0ada024661899310a4ee93bfcc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25f5c527da6b4872a8eeb9f36a3e424e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i582a7aa81bf94063ad30c2ae9cd74ef1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4381bd10810f415e80d931113c9f98aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d343dab4b5444209fd3ed76c2203491_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafd101aebef746019f6ce6cfeb3ee12b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffe9941ac0af4829ae1f8653c196fcf8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b0bf57bc62646ee88f4c37260c3618a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if240cefa329a43f5985a94cbabaaf6bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadafdf4d3eea47f18794b5f1ab930fc6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9fd763563b24d6aa1f44bd42f945197_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b14ef11391b4c02b03d75aee65c957f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia01bf0d0d0004d6da16a34e81942ea85_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i310af46a88e3405dae093107956ce302_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3757e607d7cc45e0ae3411908f9b244f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5e9ce2dfe7e45279052b07d7cd8b812_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31f65ade5edf48fc9494eade358d77e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03111218aab744f3a7bce0157ba6e7fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i075a5d5199b1444fb36eab85ce242914_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i863575ed748a4e7b919599b8c6e813af_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eba2f99c15b49c2a91337a9f21c9f15_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">swtx:MapkureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i60df7d63a68a48d59113cc28df86b1f4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">swtx:MapkureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic15d05a5ead7496488cbe289375b0b77_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">swtx:MapkureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c3264a753fa40f19ce07bcf42665c50_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">swtx:MapkureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65b72505f5de4b88b1745e53289c8346_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="swtx:LesseeOperatingLeaseRenewalTermAxisAxis">swtx:LesseeOperatingLeaseRenewalOptionOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">swtx:StamfordConnecticutMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="option"><xbrli:measure>swtx:option</xbrli:measure></xbrli:unit><xbrli:context id="i7f3b13792a2240b6bb59248690c98652_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="swtx:LesseeOperatingLeaseRenewalTermAxisAxis">swtx:LesseeOperatingLeaseRenewalOptionTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">swtx:StamfordConnecticutMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37565722b4fa4a69ba807d2fba2e932f_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">swtx:StamfordConnecticutMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia34d861b8e7c40f69f8da029b428f1a0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74cc340c1aa4424ba3726c91ee26d876_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">swtx:ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i022436fef9574100a67fd5ee74396304_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">swtx:ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3948092549294997927bcdcb9f543aa4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09e3d5011a2c4255b31c3514190f2c5b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id21cc7dd1c9e49d7b59a05c489a69c95_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">swtx:ExecutiveOfficersAndEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf02bd13545f44a9bb747e767c85e226_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">swtx:ExecutiveOfficersAndEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia76c9558fc764171b39ba192df90d64a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">swtx:ExecutiveOfficersAndEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:EquityIncentivePlan2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i147d6c8ff5e4443d9e538dcf1cb66057_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:EquityIncentivePlan2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05cb736fa4db484e8bc7a1b84df8778d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e392b95e3564143b67b20dfaa88de74_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd87f05bb1d645db8de68c02ff92440f_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:CeoPerformanceAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2db6208a117f44e39e09d534da69e196_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:CeoPerformanceAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75b5d0e6891445328c454b9d1ec87a5a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c5e6b459a3f46278653aaa6c0dccad1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61eb5ddf4b7047d8bf7f1bfb229fd7ab_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f25ec114c634fc4865cc49981bd981f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1807ff5c5c8841e9b42432e38c96459d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc237dbb79e949169c0b49053a2a8980_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:EquityIncentivePlan2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3e71bacda9e4305913d6ceeac24be0d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d1841e76bd84918b42a921397d98d2e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:EquityIncentivePlan2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e6ea28cc5b746708a2447e6c1e2b5d9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i074022392378431ca43171749ce67e70_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i701fc5f7822543f5afa349b588446470_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8962a5ad7a90438bac9fc74322fc41db_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie455f786f4cb4de6b10f9237538eb2b1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6723bcf58742472287b2d9590f8e52df_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001773427</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i14026a47930f410d91f89b4244285b77_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">____________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGV4dHJlZ2lvbjo0MzU4NzJhNzIzYjA0MDlkOTA0NjA3YTg1OGFjMjc4YV8yMTM2_28e509dd-e18e-4856-b3ae-14c9f5320997">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________________________</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6YjA4YmY0MGNhYzg1NDFmZThhNDlkNDY0NDM0MDI4NWEvdGFibGVyYW5nZTpiMDhiZjQwY2FjODU0MWZlOGE0OWQ0NjQ0MzQwMjg1YV8wLTAtMS0xLTE1NTIz_41018154-50a4-44ac-ba6e-39d52b16b21b">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FOR THE QUARTERLY PERIOD ENDED <ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGV4dHJlZ2lvbjo0MzU4NzJhNzIzYjA0MDlkOTA0NjA3YTg1OGFjMjc4YV8xMDk5NTExNjI3OTkyMQ_5fbe7ada-7b0a-4233-b419-523e92e75ce3">MARCH&#160;31, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6YzFjNTUxMzJhNDgwNDdkYWIyNjVkNjQ4MDk4NjM4OGEvdGFibGVyYW5nZTpjMWM1NTEzMmE0ODA0N2RhYjI2NWQ2NDgwOTg2Mzg4YV8wLTAtMS0xLTE1NTIz_037f954b-80b8-4d0f-8167-9f0f783bd2b6">&#168;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FOR THE TRANSITION PERIOD FROM _ TO _</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGV4dHJlZ2lvbjo0MzU4NzJhNzIzYjA0MDlkOTA0NjA3YTg1OGFjMjc4YV8yMTMz_5336dc5b-7aa0-4eb5-af9c-185fd1f41ebf">001-39044</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">__________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGV4dHJlZ2lvbjo0MzU4NzJhNzIzYjA0MDlkOTA0NjA3YTg1OGFjMjc4YV8yMTM3_36906313-38c4-4c27-b5bb-5a5b3f8dc96f">SPRINGWORKS THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">__________________________________</span><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6MWE5ODY2Mjk0MWUxNGExNzg1ZWY4MDhmMDljODMxNWQvdGFibGVyYW5nZToxYTk4NjYyOTQxZTE0YTE3ODVlZjgwOGYwOWM4MzE1ZF8wLTAtMS0xLTE1NTIz_fc2858f8-ac5f-4e61-b641-a3cf011a07c3">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6MWE5ODY2Mjk0MWUxNGExNzg1ZWY4MDhmMDljODMxNWQvdGFibGVyYW5nZToxYTk4NjYyOTQxZTE0YTE3ODVlZjgwOGYwOWM4MzE1ZF8wLTItMS0xLTE1NTIz_c1aac0b2-1118-422d-8858-c23c1f1de195">83-4066827</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6MWE5ODY2Mjk0MWUxNGExNzg1ZWY4MDhmMDljODMxNWQvdGFibGVyYW5nZToxYTk4NjYyOTQxZTE0YTE3ODVlZjgwOGYwOWM4MzE1ZF8zLTAtMS0xLTE1NTIzL3RleHRyZWdpb246OTc2ZGVkNGQ5NTBmNGY3ZGJlY2IwZDYwNWM2NGE0YmFfNA_7289aa20-f990-4a01-8380-ef05c40123b1">100 Washington Blvd</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6MWE5ODY2Mjk0MWUxNGExNzg1ZWY4MDhmMDljODMxNWQvdGFibGVyYW5nZToxYTk4NjYyOTQxZTE0YTE3ODVlZjgwOGYwOWM4MzE1ZF8zLTAtMS0xLTE1NTIzL3RleHRyZWdpb246OTc2ZGVkNGQ5NTBmNGY3ZGJlY2IwZDYwNWM2NGE0YmFfNw_5811d20d-fc25-43e2-bdae-31523856177e">Stamford</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, <ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6MWE5ODY2Mjk0MWUxNGExNzg1ZWY4MDhmMDljODMxNWQvdGFibGVyYW5nZToxYTk4NjYyOTQxZTE0YTE3ODVlZjgwOGYwOWM4MzE1ZF8zLTAtMS0xLTE1NTIzL3RleHRyZWdpb246OTc2ZGVkNGQ5NTBmNGY3ZGJlY2IwZDYwNWM2NGE0YmFfMTE_7db26e90-d531-442b-ab9e-bb932d901877">Connecticut</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6MWE5ODY2Mjk0MWUxNGExNzg1ZWY4MDhmMDljODMxNWQvdGFibGVyYW5nZToxYTk4NjYyOTQxZTE0YTE3ODVlZjgwOGYwOWM4MzE1ZF8zLTItMS0xLTE1NTIz_45ae062c-4f1b-425d-b809-d4e9c20f4e0a">06902</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGV4dHJlZ2lvbjo0MzU4NzJhNzIzYjA0MDlkOTA0NjA3YTg1OGFjMjc4YV8yMTM0_586660d3-98bf-4b69-b280-297b12249f2f">203</ix:nonNumeric>) <ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGV4dHJlZ2lvbjo0MzU4NzJhNzIzYjA0MDlkOTA0NjA3YTg1OGFjMjc4YV8yMTM1_375ff953-4099-4fd9-a657-c69232d727f0">883-9490</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Exchange Act:</span><span style="font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6MGExYTNlMjJhMDE1NGM1M2EwMDEwYTNlMWE1ZjViNmEvdGFibGVyYW5nZTowYTFhM2UyMmEwMTU0YzUzYTAwMTBhM2UxYTVmNWI2YV8xLTAtMS0xLTE1NTIz_20edac4b-71b0-4852-9587-7143e08c6387">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6MGExYTNlMjJhMDE1NGM1M2EwMDEwYTNlMWE1ZjViNmEvdGFibGVyYW5nZTowYTFhM2UyMmEwMTU0YzUzYTAwMTBhM2UxYTVmNWI2YV8xLTEtMS0xLTE1NTIz_83f3298f-f3e9-4e10-b3c3-e6e649b4f066">SWTX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6MGExYTNlMjJhMDE1NGM1M2EwMDEwYTNlMWE1ZjViNmEvdGFibGVyYW5nZTowYTFhM2UyMmEwMTU0YzUzYTAwMTBhM2UxYTVmNWI2YV8xLTItMS0xLTE1NTIz_eb5b4ca1-a8ad-47f2-a304-c239d3c2e596">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGV4dHJlZ2lvbjo0MzU4NzJhNzIzYjA0MDlkOTA0NjA3YTg1OGFjMjc4YV8yMTM4_8d56a840-382a-4017-be02-088a88e23fdc">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#168;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGV4dHJlZ2lvbjo0MzU4NzJhNzIzYjA0MDlkOTA0NjA3YTg1OGFjMjc4YV8yMTM5_29dff919-1069-4b06-9c3e-9c15ead55f8b">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#168;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:22.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6MWFlMTcxNGM5ZWVjNDQ1NThmMTNjMDM5MDA0NmEzYjkvdGFibGVyYW5nZToxYWUxNzE0YzllZWM0NDU1OGYxM2MwMzkwMDQ2YTNiOV8wLTAtMS0xLTE1NTIz_ab7496ab-0ca7-45a1-ba2e-5944dbb20174">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#168;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#168;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6MWFlMTcxNGM5ZWVjNDQ1NThmMTNjMDM5MDA0NmEzYjkvdGFibGVyYW5nZToxYWUxNzE0YzllZWM0NDU1OGYxM2MwMzkwMDQ2YTNiOV8xLTMtMS0xLTE1NTIz_bf3cbd35-83c9-4f5d-993c-e7fae9df9d9d">&#168;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6MWFlMTcxNGM5ZWVjNDQ1NThmMTNjMDM5MDA0NmEzYjkvdGFibGVyYW5nZToxYWUxNzE0YzllZWM0NDU1OGYxM2MwMzkwMDQ2YTNiOV8yLTMtMS0xLTE1NTIz_963b2e78-40aa-4193-9829-e8a9d940f0b4">&#168;</ix:nonNumeric></span></div></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGV4dHJlZ2lvbjo0MzU4NzJhNzIzYjA0MDlkOTA0NjA3YTg1OGFjMjc4YV8yMTQw_26a2a64a-9ec4-4fb3-b772-44cda005b285">x</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of outstanding shares of the Registrant&#8217;s Common Stock as of April&#160;29, 2022 was <ix:nonFraction unitRef="shares" contextRef="i48bbb6301e904262900e93986ab7878d_I20220429" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGV4dHJlZ2lvbjo0MzU4NzJhNzIzYjA0MDlkOTA0NjA3YTg1OGFjMjc4YV8yMTI4_5a5736f3-5ece-4f15-aaec-e9020b5cbb2b">49,413,760</ix:nonFraction>.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i14026a47930f410d91f89b4244285b77_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, these forward-looking statements can be identified by the use of words such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;expects&#8221;, &#8220;intends&#8221;, &#8220;plans&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;predicts&#8221;, &#8220;potential&#8221;, &#8220;continue&#8221; or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success, cost and timing of our product development activities and clinical trials, including statements regarding the timing of our ongoing Phase 3 clinical trial of nirogacestat, the timing of our ongoing Phase 2b clinical trial of mirdametinib and the initiation and completion of any other clinical trials and related preparatory work, the expected timing of the availability of results of our clinical trials and the potentially registrational nature of the Phase 3 clinical trial of nirogacestat and the Phase 2b clinical trial of mirdametinib;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the fact that interim data from a clinical study, such as the interim data of the ReNeu clinical trial, including its interim primary efficacy, safety and tolerability data, may not be predictive of the final results of such study or the results of other ongoing or future studies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential attributes and benefits of our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to commercialize any of our product candidates that achieve approval either alone or in partnership with others;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain funding for our operations, including funding necessary to complete further development of our product candidates, and if approved, commercialization;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the period over which we anticipate our existing cash, cash equivalents and marketable securities, will be sufficient to fund our operating expenses and capital expenditure requirements;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential for our business development efforts to maximize the potential value of our portfolio;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify, in-license or acquire additional product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability and willingness of our third-party collaborators to continue research and development activities relating to our product candidates, including those that are being developed as combination therapies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval for our product candidates, and any related restrictions, limitations or warnings in the label of an approved product candidate;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefit of Orphan Drug Designation, Fast Track Designation and Breakthrough Therapy Designation for nirogacestat, mirdametinib and any other of our product candidates that may receive one or more of these designations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to compete with companies currently marketing or engaged in the development of treatments for desmoid tumors, NF1-PN and other oncology and rare disease indications;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding our ability to obtain and maintain intellectual property protection or market exclusivity for our product candidates and the duration of such protection;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and the potential to successfully manufacture our product candidates for preclinical studies, clinical trials and, if approved, for commercial use, the capacity of our current contract manufacturing organizations, or CMOs, to support clinical supply and commercial-scale production for product candidates and our potential election to pursue additional CMOs for manufacturing supplies of drug substance and finished drug product in the future;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth potential of the markets for our product candidates, and our ability to serve those markets, either alone or in partnership with others;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance of our product candidates, if approved;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the United States and foreign countries;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competing products that are, or may become, available;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks associated with the ongoing COVID-19 pandemic, which may adversely impact our business, preclinical studies and clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract and retain key scientific, medical, commercial and management personnel;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments and projections relating to our competitors or our industry.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events and future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part II, Item&#160;1A, Risk Factors and elsewhere in this Quarterly Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may from time to time provide estimates, projections and other information concerning our industry, the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information provided. Unless otherwise expressly stated, we obtained this industry information, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources, in each case, from sources we consider to be reliable, and in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i14026a47930f410d91f89b4244285b77_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPRINGWORKS THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE QUARTER ENDED March&#160;31, 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span><span style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:88.943%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.857%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_13">PART I &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_16">Item 1. Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i14026a47930f410d91f89b4244285b77_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_19">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i14026a47930f410d91f89b4244285b77_19">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_22">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i14026a47930f410d91f89b4244285b77_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_25">Condensed Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i14026a47930f410d91f89b4244285b77_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_28">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i14026a47930f410d91f89b4244285b77_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_31">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i14026a47930f410d91f89b4244285b77_31">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_34">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i14026a47930f410d91f89b4244285b77_34">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_64">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i14026a47930f410d91f89b4244285b77_64">17</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_91">Item 3. Quantitative and Qualitative Disclosure About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i14026a47930f410d91f89b4244285b77_91">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_94">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i14026a47930f410d91f89b4244285b77_94">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_97">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_100">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i14026a47930f410d91f89b4244285b77_100">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_103">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i14026a47930f410d91f89b4244285b77_103">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_106">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i14026a47930f410d91f89b4244285b77_106">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_109">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i14026a47930f410d91f89b4244285b77_109">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_112">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i14026a47930f410d91f89b4244285b77_112">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_115">Item 5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i14026a47930f410d91f89b4244285b77_115">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_118">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i14026a47930f410d91f89b4244285b77_118">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_121">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i14026a47930f410d91f89b4244285b77_121">83</a></span></div></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i14026a47930f410d91f89b4244285b77_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div id="i14026a47930f410d91f89b4244285b77_16"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements</span></div><div id="i14026a47930f410d91f89b4244285b77_19"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SpringWorks Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands, except share and per-share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfNC0xLTEtMS0xNTUyMw_242430e4-734a-446b-9bf6-e9c13b9e9c4d">81,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfNC0zLTEtMS0xNTUyMw_8ff7f0cc-94bc-48f4-9d5b-e74b8e651539">103,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfNS0xLTEtMS0xNTUyMw_f55e82a9-b04b-4ed6-b595-d8848732230d">266,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfNS0zLTEtMS0xNTUyMw_6ce6eb37-c054-4b0d-8182-efac84d3d997">269,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfNi0xLTEtMS0xNTUyMw_396e8a73-6b9a-43c2-8e69-e29a08a6464f">7,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfNi0zLTEtMS0xNTUyMw_ca0f37f9-0110-4b25-920b-5185876f5b30">9,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfNy0xLTEtMS0xNTUyMw_090fb400-3719-4cd5-999d-e281c562de85">355,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfNy0zLTEtMS0xNTUyMw_e4b0988f-c11a-4dd9-b3bf-0e302c1fd9c2">382,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfOC0xLTEtMS0xNTUyMw_30d00836-d56a-4b9b-8e0b-01760552e5ad">32,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfOC0zLTEtMS0xNTUyMw_d1a510c6-3766-4153-af5d-529e4701b015">59,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfOS0xLTEtMS0xNTUyMw_7dd86eae-3fe3-423f-88d2-3eca93e14c5e">6,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfOS0zLTEtMS0xNTUyMw_efc1c42a-aff2-4480-96fb-445ab9a6ba54">3,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTAtMS0xLTEtMTU1MjM_efc270fd-4b50-45b4-8a40-f6689804d706">5,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTAtMy0xLTEtMTU1MjM_23b582a1-4cfd-4f7a-9e1f-e1f83d75de50">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTEtMS0xLTEtMTU1MjM_434b9691-24b4-4824-a13c-7cd7bdac7dda">2,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTEtMy0xLTEtMTU1MjM_d48418b9-58b3-4fb1-9b9e-4ee108054fad">2,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTItMS0xLTEtMTU1MjM_e1e6b146-1521-4044-a943-d12653d2bf93">590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTItMy0xLTEtMTU1MjM_9418763c-12b7-4afa-ac78-f823a9812631">565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTMtMS0xLTEtMTU1MjM_20b863be-0211-4436-b74a-8eebc5451fd2">2,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTMtMy0xLTEtMTU1MjM_84dc1485-0e7f-4e9d-9143-dd2bf1a567e5">2,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTQtMS0xLTEtMTU1MjM_ec7f937a-4a43-48c0-91dc-d4e2ec815c1f">405,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTQtMy0xLTEtMTU1MjM_09720be6-ada0-49d5-82f1-8e972669dd96">452,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities and Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTctMS0xLTEtMTU1MjM_099810cb-358d-41f4-a9fb-1fc1511d3657">1,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTctMy0xLTEtMTU1MjM_e3a02afd-f581-4b73-b373-0095d9413860">3,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTgtMS0xLTEtMTU1MjM_99698a61-97ed-48c2-b29e-74542920fa0c">21,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTgtMy0xLTEtMTU1MjM_5f5d5f19-acaf-4a7b-8041-242d0365f663">25,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTktMS0xLTEtMTU1MjM_99f22738-47f2-4bf5-931e-dc0ff0d2fb6f">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTktMy0xLTEtMTU1MjM_eaf7ae92-aa5a-4cfb-8a97-cb3db6a67104">1,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjEtMS0xLTEtMTU1MjM_474f65ac-5ddf-493e-a012-bf78cf4cb64d">23,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjEtMy0xLTEtMTU1MjM_b5976b32-0d76-4647-9dc1-2b1f844f5fd7">29,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjItMS0xLTEtMTU1MjM_3bee008e-2cbc-44ca-96b0-1272c45c8239">5,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjItMy0xLTEtMTU1MjM_5294f4f4-8a67-4a04-a712-7d7bc116a12b">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjUtMS0xLTEtMTU1MjM_48b2ff7f-aa7d-4ca2-80e1-529b7db05caa">28,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjUtMy0xLTEtMTU1MjM_b3927548-df83-4425-9043-0de09c4bcaad">30,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjYtMS0xLTEtMTU1MjM_44d3ccfd-8fe5-4b7b-907f-37355b91757e"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjYtMy0xLTEtMTU1MjM_bad65b7a-0915-4d1f-95a4-cf246d68013e"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjgtMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjpiMDlkMDA1YTU0ZDY0ZDE0YmY5ODRhMmZlOThhOTkxYl8xMDk5NTExNjI3NzkxMw_452eca01-41b5-4323-be80-af60d3684dc5"><ix:nonFraction unitRef="usdPerShare" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjgtMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjpiMDlkMDA1YTU0ZDY0ZDE0YmY5ODRhMmZlOThhOTkxYl8xMDk5NTExNjI3NzkxMw_8977bda2-a724-4cbb-8306-6ca503693561">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjgtMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjpiMDlkMDA1YTU0ZDY0ZDE0YmY5ODRhMmZlOThhOTkxYl8xMjA5NDYyNzkwNTcwMg_9e6dbe48-533a-4429-a65d-277d4af0d9bf"><ix:nonFraction unitRef="shares" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjgtMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjpiMDlkMDA1YTU0ZDY0ZDE0YmY5ODRhMmZlOThhOTkxYl8xMjA5NDYyNzkwNTcwMg_dbc8168d-f3cc-4997-8489-02cabe2b7663">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjgtMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjpiMDlkMDA1YTU0ZDY0ZDE0YmY5ODRhMmZlOThhOTkxYl8xMjA5NDYyNzkwNTcwNw_0eceeaa3-fb96-497e-8e27-95214d9d840b"><ix:nonFraction unitRef="shares" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjgtMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjpiMDlkMDA1YTU0ZDY0ZDE0YmY5ODRhMmZlOThhOTkxYl8xMjA5NDYyNzkwNTcwNw_444fcd09-26ec-4c17-933e-c25863f1e3d1"><ix:nonFraction unitRef="shares" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjgtMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjpiMDlkMDA1YTU0ZDY0ZDE0YmY5ODRhMmZlOThhOTkxYl8xMjA5NDYyNzkwNTcwNw_a2f20e48-6996-463a-8c54-026593f45dd5"><ix:nonFraction unitRef="shares" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjgtMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjpiMDlkMDA1YTU0ZDY0ZDE0YmY5ODRhMmZlOThhOTkxYl8xMjA5NDYyNzkwNTcwNw_c0fd858c-5c4d-4548-bd07-7ea6f5495c60">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding at March 31, 2022 and December 31, 2021.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjgtMS0xLTEtMTU1MjM_0336deca-188d-4dd5-a477-ebf78ff7610e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjgtMy0xLTEtMTU1MjM_7b64f527-7dd1-4ddd-9afe-ce9731db5feb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjktMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjozYmFmMDU1OTYxNWM0YzBjOWI1OGJkNzZlNzc2MzFmOV8xMjA5NDYyNzkwNTc1NQ_4a6154e8-2a60-41d7-a3cb-99661ad25265"><ix:nonFraction unitRef="usdPerShare" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjktMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjozYmFmMDU1OTYxNWM0YzBjOWI1OGJkNzZlNzc2MzFmOV8xMjA5NDYyNzkwNTc1NQ_ca056256-938d-426f-995a-dd61e7ce4df3">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjktMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjozYmFmMDU1OTYxNWM0YzBjOWI1OGJkNzZlNzc2MzFmOV8xMjA5NDYyNzkwNTc2OQ_5f84bb25-892c-4ea4-896a-81956dcf9ac3"><ix:nonFraction unitRef="shares" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjktMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjozYmFmMDU1OTYxNWM0YzBjOWI1OGJkNzZlNzc2MzFmOV8xMjA5NDYyNzkwNTc2OQ_9c6a9b65-7529-434b-b375-e8f36e2c73ed">150,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjktMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjozYmFmMDU1OTYxNWM0YzBjOWI1OGJkNzZlNzc2MzFmOV8xMjA5NDYyNzkwNTc4Mg_132eae24-c7d0-41c2-a6a9-669cd2af81d9">49,423,827</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjktMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjozYmFmMDU1OTYxNWM0YzBjOWI1OGJkNzZlNzc2MzFmOV8xMjA5NDYyNzkwNTc5NQ_ea18339f-1a86-480d-9db5-eef297f71e4d">49,247,985</ix:nonFraction> shares issued, and <ix:nonFraction unitRef="shares" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjktMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjozYmFmMDU1OTYxNWM0YzBjOWI1OGJkNzZlNzc2MzFmOV8xMjA5NDYyNzkwNTgwOA_2928ddf2-31db-4a2c-b6b1-b42d579b8324">49,407,617</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjktMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjozYmFmMDU1OTYxNWM0YzBjOWI1OGJkNzZlNzc2MzFmOV8xMjA5NDYyNzkwNTgyMQ_1703de10-602c-4a68-862e-35bf4b82b8de">49,247,985</ix:nonFraction> shares outstanding at March 31, 2022 and December 31, 2021, respectively.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjktMS0xLTEtMTU1MjM_e1426987-6a13-4185-b21c-e108dcb9db89">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjktMy0xLTEtMTU1MjM_9b6d5194-2084-44f8-85e5-f620bcdf7455">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzAtMS0xLTEtMTU1MjM_6484ca5a-7371-4eda-aa62-cb3cc68d6055">733,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzAtMy0xLTEtMTU1MjM_84097ae3-3508-4741-b54d-a43ef6ef1f27">715,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzEtMS0xLTEtMTYwNjA_67f62757-c1e5-4979-a435-8fde911bb2a6">354,314</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzEtMy0xLTEtMTYwNjA_c30e694d-8ffd-48f3-a9af-264556336d62">292,513</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock, at cost (<ix:nonFraction unitRef="shares" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzItMC0xLTEtMTYwNjcvdGV4dHJlZ2lvbjpkMWZiZmJkZGE4NDM0YjFjODFlMjJkYmY4MWI5MmZhMF8xMjA5NDYyNzkwNTY2Mg_f9d0d27c-de43-4a68-a96a-01473ee22927">16,210</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="INF" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzItMC0xLTEtMTYwNjcvdGV4dHJlZ2lvbjpkMWZiZmJkZGE4NDM0YjFjODFlMjJkYmY4MWI5MmZhMF8xMjA5NDYyNzkwNTY2Ng_33a67f99-eef3-4369-8676-98d20d4e63ed">0</ix:nonFraction> shares of common stock at March 31, 2022 and December 31, 2021, respectively).</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzItMS0xLTEtMTYwNjc_9e973ef1-4b44-4840-9a1b-0d428089972b">906</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzItMy0xLTEtMTYwNjc_d3711ce9-af75-443a-bdb5-1ba6fcca5f3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzEtMS0xLTEtMTU1MjM_36c56be9-445a-4bc6-9b8e-bf7333b06542">1,458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzEtMy0xLTEtMTU1MjM_c85a0ede-df69-4f16-8fc1-930bbe60111f">312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzMtMS0xLTEtMTU1MjM_0eb89216-cf8b-42c9-9d2b-ad34fae4509d">376,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzMtMy0xLTEtMTU1MjM_738e1ffb-8825-4198-b555-1d1e50b748cd">422,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzQtMS0xLTEtMTU1MjM_3702044e-32fc-494b-b87e-4915809acc61">405,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzQtMy0xLTEtMTU1MjM_24e72145-7c3e-4dab-8452-e0d9b5b38ce0">452,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accompanying</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">unaudited notes to condensed consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i14026a47930f410d91f89b4244285b77_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SpringWorks Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations (Unaudited)</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"><tr><td style="width:1.0%"></td><td style="width:69.277%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.241%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands, except share and per-share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMy0xLTEtMS0xNTUyMw_f1111dc0-abe9-4836-b20d-da0f8c4de1c0">34,103</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMy0zLTEtMS0xNTUyMw_b4069584-7ba2-4b93-bfc1-da0b282d51a4">17,375</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfNC0xLTEtMS0xNTUyMw_222eb09e-3ba4-4244-92eb-3f13cfe94796">27,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfNC0zLTEtMS0xNTUyMw_8e758b29-6b36-469b-a473-6b2ff92426b7">12,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfNS0xLTEtMS0xNTUyMw_7d2cd436-a2b5-487a-ae50-b833e0a0e513">61,469</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfNS0zLTEtMS0xNTUyMw_cb6af7bd-0851-4d55-a0c0-fa31bcc9909f">29,756</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfNy0xLTEtMS0xNTUyMw_f570037a-5c49-4792-b333-dcdaf9bd5bd6">61,469</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfNy0zLTEtMS0xNTUyMw_5e23ed47-a784-455a-8c1c-f200f964396e">29,756</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest and other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfOS0xLTEtMS0xNTUyMw_04688301-0d48-4b20-9ce6-018ae92682a9">193</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfOS0zLTEtMS0xNTUyMw_0ea28b2e-70f8-4a9f-9f59-28b3a6fcc835">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMTAtMS0xLTEtMTU1MjM_78678581-9c3e-4797-94c5-c9cb41ca92a6">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMTAtMy0xLTEtMTU1MjM_80c4ead0-cff9-495d-afcd-9ae5858ce59b">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest and other income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMTEtMS0xLTEtMTU1MjM_e79aa78e-4b52-4ae7-bea5-4084ac567ddc">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMTEtMy0xLTEtMTU1MjM_0314e1bc-c569-4b84-bb42-b17bf5531724">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investment loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMTItMS0xLTEtMTU1MjM_bec46ad5-56d2-4bd7-aa60-2d547b14653e">337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMTItMy0xLTEtMTU1MjM_926d263b-cc0c-407a-9c69-172775d42513">261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMTMtMS0xLTEtMTU1MjM_4cfaa1ee-de5b-40af-97bf-a7675c08b958">61,801</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMTMtMy0xLTEtMTU1MjM_2e35236d-ea2e-4636-9eea-292561b2a4eb">29,787</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMjAtMS0xLTEtMTU1MjM_a9d5b808-bd93-4011-91ff-85ec4addfef8"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMjAtMS0xLTEtMTU1MjM_ddf7f94d-7ebf-4c22-9b46-81be15a3a2f6">1.26</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMjAtMy0xLTEtMTU1MjM_420a340f-8607-454f-b137-bbd51fd18e8c"><ix:nonFraction unitRef="usdPerShare" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMjAtMy0xLTEtMTU1MjM_b11eac6f-894f-43b9-9810-147d7f624309">0.62</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMjEtMS0xLTEtMTU1MjM_c9916e07-4bde-4f66-a92f-b05e2c5da9d2"><ix:nonFraction unitRef="shares" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMjEtMS0xLTEtMTU1MjM_decb64d6-8cd0-4458-84df-7b131ee015a2">48,937,756</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMjEtMy0xLTEtMTU1MjM_133ffbe0-17b7-4ca7-a526-1b7f224e1b5d"><ix:nonFraction unitRef="shares" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMjEtMy0xLTEtMTU1MjM_c273db81-6304-4145-932e-93b2eb1d8724">48,229,539</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accompanying</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">unaudited notes to condensed consolidated financial statements</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:30pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i14026a47930f410d91f89b4244285b77_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SpringWorks Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.853%"><tr><td style="width:1.0%"></td><td style="width:66.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.526%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yNS9mcmFnOmFlOWIyNjdlOGI2MDQ1OWQ5MWRlN2ZhNTBjM2RjMGY0L3RhYmxlOmE2ZDk5MGVmZjBkNDRhMjRhYjM2ZTI0MTNiMTAyNjY0L3RhYmxlcmFuZ2U6YTZkOTkwZWZmMGQ0NGEyNGFiMzZlMjQxM2IxMDI2NjRfMi0xLTEtMS0xNTUyMw_42c5a8fa-cf6b-45c2-b792-af4154145889">61,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yNS9mcmFnOmFlOWIyNjdlOGI2MDQ1OWQ5MWRlN2ZhNTBjM2RjMGY0L3RhYmxlOmE2ZDk5MGVmZjBkNDRhMjRhYjM2ZTI0MTNiMTAyNjY0L3RhYmxlcmFuZ2U6YTZkOTkwZWZmMGQ0NGEyNGFiMzZlMjQxM2IxMDI2NjRfMi0zLTEtMS0xNTUyMw_5e001efe-842c-4b4f-a651-c8356ab5de26">29,787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in other comprehensive income:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain (loss) on marketable securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yNS9mcmFnOmFlOWIyNjdlOGI2MDQ1OWQ5MWRlN2ZhNTBjM2RjMGY0L3RhYmxlOmE2ZDk5MGVmZjBkNDRhMjRhYjM2ZTI0MTNiMTAyNjY0L3RhYmxlcmFuZ2U6YTZkOTkwZWZmMGQ0NGEyNGFiMzZlMjQxM2IxMDI2NjRfNC0xLTEtMS0xNTUyMw_e9aab7ee-9722-4364-bd73-7124c2f74046">1,146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yNS9mcmFnOmFlOWIyNjdlOGI2MDQ1OWQ5MWRlN2ZhNTBjM2RjMGY0L3RhYmxlOmE2ZDk5MGVmZjBkNDRhMjRhYjM2ZTI0MTNiMTAyNjY0L3RhYmxlcmFuZ2U6YTZkOTkwZWZmMGQ0NGEyNGFiMzZlMjQxM2IxMDI2NjRfNC0zLTEtMS0xNTUyMw_263f389a-9a6a-4cc1-a8e7-a0f9158a25a7">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total changes in other comprehensive income</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yNS9mcmFnOmFlOWIyNjdlOGI2MDQ1OWQ5MWRlN2ZhNTBjM2RjMGY0L3RhYmxlOmE2ZDk5MGVmZjBkNDRhMjRhYjM2ZTI0MTNiMTAyNjY0L3RhYmxlcmFuZ2U6YTZkOTkwZWZmMGQ0NGEyNGFiMzZlMjQxM2IxMDI2NjRfNS0xLTEtMS0xNTUyMw_09026b1f-a8da-4a9a-a928-06d826afe910">1,146</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yNS9mcmFnOmFlOWIyNjdlOGI2MDQ1OWQ5MWRlN2ZhNTBjM2RjMGY0L3RhYmxlOmE2ZDk5MGVmZjBkNDRhMjRhYjM2ZTI0MTNiMTAyNjY0L3RhYmxlcmFuZ2U6YTZkOTkwZWZmMGQ0NGEyNGFiMzZlMjQxM2IxMDI2NjRfNS0zLTEtMS0xNTUyMw_feaa266e-bd07-49cc-afa0-5ac723927eb1">12</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yNS9mcmFnOmFlOWIyNjdlOGI2MDQ1OWQ5MWRlN2ZhNTBjM2RjMGY0L3RhYmxlOmE2ZDk5MGVmZjBkNDRhMjRhYjM2ZTI0MTNiMTAyNjY0L3RhYmxlcmFuZ2U6YTZkOTkwZWZmMGQ0NGEyNGFiMzZlMjQxM2IxMDI2NjRfNi0xLTEtMS0xNTUyMw_211917cb-201c-4d26-abe0-f743d7d88151">62,947</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yNS9mcmFnOmFlOWIyNjdlOGI2MDQ1OWQ5MWRlN2ZhNTBjM2RjMGY0L3RhYmxlOmE2ZDk5MGVmZjBkNDRhMjRhYjM2ZTI0MTNiMTAyNjY0L3RhYmxlcmFuZ2U6YTZkOTkwZWZmMGQ0NGEyNGFiMzZlMjQxM2IxMDI2NjRfNi0zLTEtMS0xNTUyMw_e63f19d5-9e0d-4f89-a625-098e45adaa0a">29,775</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">unaudited notes to condensed consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i14026a47930f410d91f89b4244285b77_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SpringWorks Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.977%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.099%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="48" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022 and March 31, 2021</span></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other Comprehensive<br/>Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except share data)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i658acb93480c4b5393f0f53a36eab567_I20201231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMy0xMC0xLTEtMTczMjE_777ba6f2-412a-41be-be3e-e7fee59d0fc7">48,819,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i658acb93480c4b5393f0f53a36eab567_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMy0xMi0xLTEtMTczMjE_3795dd47-9112-41a6-8699-6e318b067757">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic0990f9597e64307b0c20baeb0374ba3_I20201231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMy0xNC0xLTEtMTczMjE_91d4e25a-63d1-4f8c-bc7a-d4cf3d43f51f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0990f9597e64307b0c20baeb0374ba3_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMy0xNi0xLTEtMTczMjE_dc3e6a6a-0b0a-4d7b-869a-fd2d8ab8c776">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3287fd7612614db4b178dca62d93314c_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMy0xOC0xLTEtMTczMjE_eafbfa65-6d95-4b4a-bfa9-9cf03753db68">675,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8966326533744dcb83a31d655df247a5_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMy0yMC0xLTEtMTczMjE_d4a27611-5412-4db8-acc4-fd92889c68e6">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7145ff8fbb7347739deda6cecec6c32c_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMy0yMi0xLTEtMTczMjE_4194484a-2693-413f-9cb4-2b4db6e927d2">118,603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6aca392105844fb988854fc2a1e19f5_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMy0yNC0xLTEtMTczMjE_1fa9a939-a776-44d5-82b1-fe9dde392ea9">557,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9db5cd8bf9aa4652801e6be37eb56232_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfNC0xOC0xLTEtMTczMjE_49272a11-6a9f-4e52-97fd-c2ba10c40bce">7,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfNC0yNC0xLTEtMTczMjE_6aaca822-f489-4d9f-aaa7-29d433a0e17c">7,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of restricted stock awards</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b30664e42c44ea2bdfe57102b7f8793_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfNS0xMC0xLTEtMTczMjE_71ad16c9-c549-4180-ad6e-af37bd517cc0">145,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeitures of restricted stock awards</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b30664e42c44ea2bdfe57102b7f8793_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfNy0xMC0xLTEtMTczMjE_59466e89-d1df-4943-810b-4630676f5864">59,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9db5cd8bf9aa4652801e6be37eb56232_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfNy0xOC0xLTEtMTczMjE_45a8fadd-9b33-4653-b699-504a0bae9363">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfNy0yNC0xLTEtMTczMjE_7019f9b5-973d-40bb-99d9-7b2181e8a533">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7752062fa254d488520f76b3b98be23_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfOC0yMC0xLTEtMTczMjE_3f38a61a-b2bc-42d9-adcf-39d5fc0ea7e6">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfOC0yNC0xLTEtMTczMjE_01ed6b2f-cc88-4b24-84e6-d4cf6151acbb">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia179ee44b4324835983690644a8c2d55_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfOS0yMi0xLTEtMTczMjE_fab149f6-560e-45a4-af0d-7d3f7d874636">29,787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfOS0yNC0xLTEtMTczMjE_2f2a7758-87bb-4e0b-a987-43a2d0cf5ab8">29,787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5aeb1d4fe3aa413287784b210d8cb0c7_I20210331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTAtMTAtMS0xLTE3MzIx_bf2971c3-28a1-4bc7-9c08-8d6bce23d5ea">49,024,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aeb1d4fe3aa413287784b210d8cb0c7_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTAtMTItMS0xLTE3MzIx_fa9a684e-6892-4080-a937-3b6cc622c3e6">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4d19dcca70de49e18de075013224639e_I20210331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTAtMTQtMS0xLTE3MzIx_d1068638-945b-4825-84ab-9ba7ccd1e24c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d19dcca70de49e18de075013224639e_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTAtMTYtMS0xLTE3MzIx_85217009-79b0-449b-9118-f7f2d000030c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e1848bac6dd4d3395a865c973884624_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTAtMTgtMS0xLTE3MzIx_627d44cc-dd0d-4095-904a-53b0d16fc1b0">683,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib131c00375dd4d01a1d5a8ca99a78357_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTAtMjAtMS0xLTE3MzIx_3bbeb96b-b22f-44b9-91a7-39767f6b3ada">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a27a2ad8f5b4adabc882295f434ad85_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTAtMjItMS0xLTE3MzIx_330d5028-67df-42c3-881b-039c8ceea054">148,390</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7c72970af33479486aedd56f27b30d3_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTAtMjQtMS0xLTE3MzIx_b8df626f-a2cb-4d5d-83b3-4ef553efbd42">534,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib34b57b88c524fb2a5cfb417de744b4e_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTItMTAtMS0xLTE3MzIx_c8a16949-752f-4ee8-9293-0e2e958ef627">49,247,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib34b57b88c524fb2a5cfb417de744b4e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTItMTItMS0xLTE3MzIx_18b36607-4fbb-4e18-8076-8247ec4dff51">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0c1b343064f4976a0430d48302ee8dc_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTItMTQtMS0xLTE3MzIx_c3e3cef9-43f5-4540-8701-f9b44b0120c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0c1b343064f4976a0430d48302ee8dc_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTItMTYtMS0xLTE3MzIx_ee0cc5ce-6f79-40c2-be83-4fe78f55bfaf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cea465f2f2844ecbd14a5a3b0ba249c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTItMTgtMS0xLTE3MzIx_ea1a5fe3-c532-454f-bbb4-a0279884ea46">715,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic68434afffb54cf0b8787b66026e3164_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTItMjAtMS0xLTE3MzIx_bee41392-cd5a-4ffc-81fc-4034889209a2">312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifee6028d47d94c659487fe06b58c5d96_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTItMjItMS0xLTE3MzIx_a340bac6-2ec2-415d-912a-b5700907240a">292,513</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTItMjQtMS0xLTE3MzIx_e95ed9ae-ba7a-4cc0-a7b9-52a4868e0344">422,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b735c9c0ea4731a01282de2dda1e04_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTMtMTgtMS0xLTE3MzIx_50d68152-4961-4e2e-81bc-a0bda09cc1eb">17,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTMtMjQtMS0xLTE3MzIx_3d61e9ba-d967-44c0-bd70-35949f2963a1">17,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of restricted stock awards</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5310686134dd466eb22c5118bf07c60a_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTQtMTAtMS0xLTE3MzIx_32c1925c-b9d5-4a5d-97dd-b56b03320558">36,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5310686134dd466eb22c5118bf07c60a_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTUtMTAtMS0xLTE3MzIx_298b0c5c-a467-45c0-a0e3-3caa012f4d0b">142,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b735c9c0ea4731a01282de2dda1e04_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTUtMTgtMS0xLTE3MzIx_c0042f57-22a6-4d47-afab-fd593d696113">1,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTUtMjQtMS0xLTE3MzIx_e8a0cf6d-6c88-4517-ad53-eda76c19a55f">1,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeitures of restricted stock awards</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5310686134dd466eb22c5118bf07c60a_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTctMTAtMS0xLTE3MzIx_5d680ca6-2fdd-49f4-a7b2-55e63decac3b">3,440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares of common stock used to satisfy tax withholding obligations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3b4361b2bc8468a8261a967f49bda37_D20220101-20220331" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTgtMTQtMS0xLTE3MzIx_5889cdea-b780-4d3c-a79d-2f195aa8b19c">16,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3b4361b2bc8468a8261a967f49bda37_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTgtMTYtMS0xLTE3MzIx_63b4e201-5298-4392-a2db-3dfdd4c3b978">906</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTgtMjQtMS0xLTE4MzY3_91add851-5501-420c-a309-ff6cee42f42d">906</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17d85f9a1e034f45ac98309a4aa39e2b_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTktMjAtMS0xLTE3MzIx_655b1268-2953-4b5a-818e-536be534c26c">1,146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTktMjQtMS0xLTE3MzIx_58f218af-c5f8-4649-8463-0d86a34bc179">1,146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie552d9ac6bf047888c1a1153ddd4b5f3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMjAtMjItMS0xLTE3MzIx_af338377-884b-422f-983e-59bd0279f646">61,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMjAtMjQtMS0xLTE3MzIx_e95189b2-01d4-4416-b97b-ebe7cc55f490">61,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic22dfb0a26f1485a97ca52722464d5ad_I20220331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMjEtMTAtMS0xLTE3MzIx_7a3c0ecf-718e-4056-ae80-434e5da554cc">49,423,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic22dfb0a26f1485a97ca52722464d5ad_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMjEtMTItMS0xLTE3MzIx_60416e71-72ba-42cb-8c5d-72bbe3298a71">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0538532efa4c481fb6287237941a7a83_I20220331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMjEtMTQtMS0xLTE3MzIx_e1bff807-9d59-4c98-ac49-deb5d6bf7c09">16,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0538532efa4c481fb6287237941a7a83_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMjEtMTYtMS0xLTE3MzIx_782f4960-8490-4ec5-98bb-8bab4159405e">906</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76cd6147b1f74623a56a60a92568ed2a_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMjEtMTgtMS0xLTE3MzIx_f24ec4be-49f5-4c65-8644-749c96381918">733,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e643f8a8bad4d0685bb17341335398d_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMjEtMjAtMS0xLTE3MzIx_f15a6f3e-30b0-4520-a0a4-ffa044bb80f5">1,458</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i774d25c476d6488093d122507b7e32fa_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMjEtMjItMS0xLTE3MzIx_f69a2d2e-6c0a-4436-95ba-bc8385ce5faf">354,314</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMjEtMjQtMS0xLTE3MzIx_33cc0d31-2bf3-48b4-8615-7967e2c17734">376,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accompanying</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">unaudited notes to condensed consolidated financial statements</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"></td><td style="width:15.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i14026a47930f410d91f89b4244285b77_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SpringWorks Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMy0xLTEtMS0xNTUyMw_8a776bb9-86d8-41d8-891c-774f1ec8d86c">61,801</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMy0zLTEtMS0xNTUyMw_e02c6d88-087b-4812-88dd-72fe608502b7">29,787</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfNS0xLTEtMS0xNTUyMw_f70ae803-b3d7-400a-a441-922bdae7dd16">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfNS0zLTEtMS0xNTUyMw_a4e41718-b70c-4bf0-8293-fa5ed4433ddb">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" name="swtx:NonCashOperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfNi0xLTEtMS0xNTUyMw_f43e1880-b985-4750-af03-1ee1475906a4">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="swtx:NonCashOperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfNi0zLTEtMS0xNTUyMw_dd2f590e-6bc9-4149-8a6e-2c2afab24a1a">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfNy0xLTEtMS0xNTUyMw_43ad980f-682d-48b8-9855-c6ef7183b32a">17,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfNy0zLTEtMS0xNTUyMw_b5ddd4d9-9a26-4640-8054-28c3e58fe604">7,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investment loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfOC0xLTEtMS0xNTUyMw_0da24ab7-1731-412e-8208-f8a3e62bafd2">337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfOC0zLTEtMS0xNTUyMw_ef581b01-516b-46fe-9c4f-5f089ae8e867">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTAtMS0xLTEtMTU1MjM_b45af3d3-95e4-4e23-b0fd-c929b7e0c33d">1,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTAtMy0xLTEtMTU1MjM_2f940f67-5a4f-4c8e-91eb-5c75707b342b">697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTEtMS0xLTEtMTU1MjM_1d65e30b-7f14-43a0-89f5-cf09f4a7d1cb">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTEtMy0xLTEtMTU1MjM_3bcab435-0ce3-4adb-8d53-661700b79963">545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTItMS0xLTEtMTU1MjM_1be2e0e9-ea00-4714-bf55-0392a1f2f1c4">1,770</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTItMy0xLTEtMTU1MjM_cf61d89f-87a4-41d3-89a2-2feb06dead41">879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTMtMS0xLTEtMTU1MjM_e49a6f3f-add8-4b6f-b667-314e9173f229">4,695</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTMtMy0xLTEtMTU1MjM_f59ee2e8-dd5b-4887-a81a-0ce7471269ed">357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" sign="-" name="swtx:IncreaseDecreaseInLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTUtMS0xLTEtMTU1MjM_38a64443-e469-43a4-92a0-fdf774cbe11c">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" sign="-" name="swtx:IncreaseDecreaseInLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTUtMy0xLTEtMTU1MjM_5ab44fef-74a9-40cb-a9a6-c43c644b5924">355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTYtMS0xLTEtMTU1MjM_2f22c8a6-8dfa-4889-aafc-ae38dd225137">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTYtMy0xLTEtMTU1MjM_050a22ad-a1de-4767-a5e1-cfbc9687800a">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTctMS0xLTEtMTU1MjM_830f7b18-cabb-40fc-ace2-05179a584ee3">48,688</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTctMy0xLTEtMTU1MjM_3f93e5c0-7e15-4928-b7a9-78827f7d92e8">21,104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTktMS0xLTEtMTU1MjM_7af9fdbc-4c8f-461a-a29f-2bc8bb13b0c8">2,387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTktMy0xLTEtMTU1MjM_f29df5eb-85ca-4b50-a2ec-a642868483f6">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMjEtMS0xLTEtMTU1MjM_635e2144-9c99-4239-aa47-8fcdc076883c">23,242</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMjEtMy0xLTEtMTU1MjM_7dd7fecd-b75f-4d08-ab7c-6ff2a9979b31">86,373</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale and maturity of debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMjItMS0xLTEtMTU1MjM_1cdded7d-a3ed-4265-9943-8235a880b2c4">52,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMjItMy0xLTEtMTU1MjM_ce694c0f-3931-472d-9c5e-25b8015f9483">55,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMjMtMS0xLTEtMTU1MjM_e2cdf9d1-8e44-456e-b546-3387a75a800d">26,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMjMtMy0xLTEtMTU1MjM_bd85f0f6-1f61-4ab2-849b-b1bd4a6599f0">30,918</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares of common stock repurchased to satisfy tax withholding obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMjgtMS0xLTEtMTg5NzQ_cf4dc284-793b-41fb-953f-ac0543b24a19">906</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMjgtMy0xLTEtMTg5NzQ_f7733fc8-4552-491f-bcf2-860d4332003a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMjgtMS0xLTEtMTU1MjM_fc2aff8d-2b06-40e8-9357-bc0e9da995b2">1,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMjgtMy0xLTEtMTU1MjM_2b22cbbb-9a32-41a9-baa1-87b56dd82f51">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMjktMS0xLTEtMTU1MjM_fb64bfe2-bff5-4c0b-ab06-871fb8f4db41">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMjktMy0xLTEtMTU1MjM_ce740e13-70ef-41ad-8ff7-dc25e13b3e27">359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMzAtMS0xLTEtMTU1MjM_363f1f48-e4ef-46aa-b0ff-aa7654d61d77">22,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMzAtMy0xLTEtMTU1MjM_3a5df25f-67da-4d5c-84ee-55eae91c9af1">51,663</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents including Restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMzEtMS0xLTEtMTU1MjM_1a0001fe-3b39-49ed-849c-75efa1b1975e">104,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6aca392105844fb988854fc2a1e19f5_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMzEtMy0xLTEtMTU1MjM_73c1a603-5eef-4847-9a5e-cba1e3a2a0e7">147,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents including Restricted cash, end of period</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMzItMS0xLTEtMTU1MjM_8a24573d-e076-412f-8e77-bdbd4e7a6360">82,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7c72970af33479486aedd56f27b30d3_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMzItMy0xLTEtMTU1MjM_586c3440-e4f6-4602-9def-91fd89197aab">95,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease obligations</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOjA2NTkxZTE5OTE3MTRhMTNhOTIyOTI5ODhlNTAxNjcxL3RhYmxlcmFuZ2U6MDY1OTFlMTk5MTcxNGExM2E5MjI5Mjk4OGU1MDE2NzFfMS0xLTEtMS0xNzQ3NA_ed363e33-297c-4fdc-aba1-d24220f537b5">5,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOjA2NTkxZTE5OTE3MTRhMTNhOTIyOTI5ODhlNTAxNjcxL3RhYmxlcmFuZ2U6MDY1OTFlMTk5MTcxNGExM2E5MjI5Mjk4OGU1MDE2NzFfMS0zLTEtMS0xNzQ3NA_6e906543-fa1e-4793-8bbd-7861e25d1db3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying unaudited notes to condensed consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i14026a47930f410d91f89b4244285b77_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SpringWorks Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (Unaudited)</span></div><div id="i14026a47930f410d91f89b4244285b77_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;<ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zNy9mcmFnOjBkM2Y4ODY0NjI3MDQ3ZDY5ZTU5MThmMjZiMzU4MDQwL3RleHRyZWdpb246MGQzZjg4NjQ2MjcwNDdkNjllNTkxOGYyNmIzNTgwNDBfMjg1OA_6898819a-d7a0-4411-94b7-f3540a8233a5" continuedAt="iffbc0b250d7843e388f0c075dbcd2340" escape="true">Nature of Operations</ix:nonNumeric></span></div><ix:continuation id="iffbc0b250d7843e388f0c075dbcd2340"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SpringWorks Therapeutics, Inc., together with its wholly-owned subsidiaries, collectively, the Company, is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The Company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing <ix:nonFraction unitRef="trial" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="INF" name="swtx:NumberOfClinicalTrials" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zNy9mcmFnOjBkM2Y4ODY0NjI3MDQ3ZDY5ZTU5MThmMjZiMzU4MDQwL3RleHRyZWdpb246MGQzZjg4NjQ2MjcwNDdkNjllNTkxOGYyNmIzNTgwNDBfNDkw_0409f2e0-0b56-4a6d-8490-d2576cdb1b33">two</ix:nonFraction> potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. Two of the programs are late-stage clinical product candidates: nirogacestat and mirdametinib.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred losses and negative operating cash flows since inception and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zNy9mcmFnOjBkM2Y4ODY0NjI3MDQ3ZDY5ZTU5MThmMjZiMzU4MDQwL3RleHRyZWdpb246MGQzZjg4NjQ2MjcwNDdkNjllNTkxOGYyNmIzNTgwNDBfODYw_018f7c10-9e8c-47e1-96f3-503dc53ababa">354.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zNy9mcmFnOjBkM2Y4ODY0NjI3MDQ3ZDY5ZTU5MThmMjZiMzU4MDQwL3RleHRyZWdpb246MGQzZjg4NjQ2MjcwNDdkNjllNTkxOGYyNmIzNTgwNDBfODY3_2ac22f02-56b2-44a5-b14f-87e639a9dda5">292.5</ix:nonFraction> million, and working capital of $<ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-5" name="swtx:WorkingCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zNy9mcmFnOjBkM2Y4ODY0NjI3MDQ3ZDY5ZTU5MThmMjZiMzU4MDQwL3RleHRyZWdpb246MGQzZjg4NjQ2MjcwNDdkNjllNTkxOGYyNmIzNTgwNDBfODk0_fc432eb1-5cfa-4efa-9ffa-76405bb4da37">332.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-5" name="swtx:WorkingCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zNy9mcmFnOjBkM2Y4ODY0NjI3MDQ3ZDY5ZTU5MThmMjZiMzU4MDQwL3RleHRyZWdpb246MGQzZjg4NjQ2MjcwNDdkNjllNTkxOGYyNmIzNTgwNDBfOTAx_cb697c03-f6f7-49fa-9b7b-256dc9e00d64">352.9</ix:nonFraction> million, as of March&#160;31, 2022 and December&#160;31, 2021, respectively. The Company is subject to those risks associated with any biopharmaceutical company that has substantial expenditures for development. There can be no assurance that the Company&#8217;s development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees, advisors, consultants and vendors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had cash, cash equivalents and marketable securities of $<ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zNy9mcmFnOjBkM2Y4ODY0NjI3MDQ3ZDY5ZTU5MThmMjZiMzU4MDQwL3RleHRyZWdpb246MGQzZjg4NjQ2MjcwNDdkNjllNTkxOGYyNmIzNTgwNDBfMTUyNg_701b372f-428a-4f40-a80f-2ae9ae4b9025">380.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zNy9mcmFnOjBkM2Y4ODY0NjI3MDQ3ZDY5ZTU5MThmMjZiMzU4MDQwL3RleHRyZWdpb246MGQzZjg4NjQ2MjcwNDdkNjllNTkxOGYyNmIzNTgwNDBfMTUzMw_d2f649ec-b776-4321-9521-5b929e03bbc1">432.7</ix:nonFraction> million as of March&#160;31, 2022 and December&#160;31, 2021, respectively. Based on the Company's cash, cash equivalents and marketable securities as of March&#160;31, 2022, management estimates that its current liquidity will enable it to meet operating expenses through at least twelve&#160;months after the date that these financial statements are issued.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 11, 2020, the World Health Organization designated the outbreak of the disease associated with the novel strain of coronavirus known as COVID-19 as a global pandemic. This disease continues to spread, including recent acceleration of the spread of the Delta and Omicron variants of COVID-19 in the areas in which the Company operates. Governments and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including, but not limited to, shelter-in-place orders, quarantines, significant restrictions on travel, as well as restrictions that prohibit many employees from going to work. Uncertainty with respect to the economic impacts of the pandemic has introduced significant volatility in the financial markets. The global pandemic caused by COVID-19 (including the impact of emerging variant strains of the COVID-19 virus and stagnant vaccination rates) did not have significant impacts on the Company's financial condition, results of operations or cash flows during the periods presented. While the extent to which the ongoing COVID-19 pandemic impacts the Company&#8217;s future results will depend on future developments, the pandemic and associated impacts, including the duration, spread and intensity of the pandemic (including any resurgences), the impact of emerging variant strains of the COVID-19 virus and the rollout of COVID-19 vaccines, all of which remain uncertain and difficult to predict, could result in a material impact to the Company&#8217;s future financial condition, results of operations and cash flows.</span></div></ix:continuation><div id="i14026a47930f410d91f89b4244285b77_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;<ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180MC9mcmFnOjNjZGEwOGM2NDk5YzQ1MTliMmEzZTBiZWE0NTZhNmNkL3RleHRyZWdpb246M2NkYTA4YzY0OTljNDUxOWIyYTNlMGJlYTQ1NmE2Y2RfNDIzMw_41bc2552-4286-4ab9-9536-fe6f4a5c50fc" continuedAt="if405daeefa1043999bbfe8e3f34e8d58" escape="true"><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180MC9mcmFnOjNjZGEwOGM2NDk5YzQ1MTliMmEzZTBiZWE0NTZhNmNkL3RleHRyZWdpb246M2NkYTA4YzY0OTljNDUxOWIyYTNlMGJlYTQ1NmE2Y2RfNDIzNA_74902508-d039-4efa-b1ca-68c834de2501" continuedAt="i22a2eae5533b4faf9e1ec222e68cb55e" escape="true">Basis of Presentation</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="if405daeefa1043999bbfe8e3f34e8d58" continuedAt="i37744091eb884f17a58f637da18dc4ec"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i22a2eae5533b4faf9e1ec222e68cb55e">The Company&#8217;s unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the pet States, or U.S. GAAP, for interim financial information and Article 10 of Regulation S-X of the Securities and Exchange Commission, or SEC, and should be read in conjunction with the Company's consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February 24, 2022. The condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q are unaudited; however, in the opinion of management, such financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented.</ix:continuation></span></div><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180MC9mcmFnOjNjZGEwOGM2NDk5YzQ1MTliMmEzZTBiZWE0NTZhNmNkL3RleHRyZWdpb246M2NkYTA4YzY0OTljNDUxOWIyYTNlMGJlYTQ1NmE2Y2RfNDIzNQ_1c277a86-f039-4431-ab06-23c6ed5af628" continuedAt="i3de7e78265b14317ab2f9ea906b13f26" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses and the valuation of stock-based compensation awards. Management bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><ix:continuation id="i37744091eb884f17a58f637da18dc4ec"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3de7e78265b14317ab2f9ea906b13f26">Actual results may differ from those estimates or assumptions. On an ongoing basis, management evaluates its estimates, and adjusts those estimates and assumptions when facts or circumstances change. Changes in estimates are recorded in the period in which they become known.</ix:continuation> </span></div><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180MC9mcmFnOjNjZGEwOGM2NDk5YzQ1MTliMmEzZTBiZWE0NTZhNmNkL3RleHRyZWdpb246M2NkYTA4YzY0OTljNDUxOWIyYTNlMGJlYTQ1NmE2Y2RfNDIzNg_6ef8eb13-54c7-422d-b9ca-d04c387f4673" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 730, &#8220;Research and Development&#8221;, expenditures for clinical development, including upfront licensing fees and milestone payments associated with products that have not yet been approved by the U.S. Food and Drug Administration, are charged to research and development expense as incurred. These expenses consist of expenses incurred in performing development activities, including salaries and benefits, stock-based compensation expense, preclinical expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. Expenses incurred for certain research and development activities, including expenses associated with particular activities performed by contract research organizations, investigative sites in connection with clinical trials and contract manufacturing organizations, are recognized based on an evaluation of the progress or completion of specific tasks using either time-based measures or data such as information provided to the Company by its vendors on actual activities completed or costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of expense recognition. Expenses for research and development activities incurred that have yet to be invoiced by the vendors that perform the related activities are reflected in the consolidated financial statements as accrued research and development expenses. Advance payments for goods or services to be received in the future for research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180MC9mcmFnOjNjZGEwOGM2NDk5YzQ1MTliMmEzZTBiZWE0NTZhNmNkL3RleHRyZWdpb246M2NkYTA4YzY0OTljNDUxOWIyYTNlMGJlYTQ1NmE2Y2RfNDIzNw_67e0b73d-0b13-44f8-b5f3-772550a2b60d" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in <ix:nonFraction unitRef="segment" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180MC9mcmFnOjNjZGEwOGM2NDk5YzQ1MTliMmEzZTBiZWE0NTZhNmNkL3RleHRyZWdpb246M2NkYTA4YzY0OTljNDUxOWIyYTNlMGJlYTQ1NmE2Y2RfMzgzMw_d7cf5f9a-6a7d-488d-893e-8aa1c6943e10">one</ix:nonFraction> operating segment operating exclusively in the United States.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180MC9mcmFnOjNjZGEwOGM2NDk5YzQ1MTliMmEzZTBiZWE0NTZhNmNkL3RleHRyZWdpb246M2NkYTA4YzY0OTljNDUxOWIyYTNlMGJlYTQ1NmE2Y2RfNDIzOA_0f959ab3-fae9-4757-aefd-60898dc85ee8" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no recently adopted accounting pronouncements that had a material impact on the Company's financial statements, and no recently issued accounting pronouncements that are expected to have a material impact on the Company's financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i14026a47930f410d91f89b4244285b77_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RleHRyZWdpb246MDE4ZjcwZDNmZTMwNDI2Y2JlZmEwYTA2NWFlNDFiNTFfODk3_5f945bb6-2282-4e6b-94b9-1ffbc7f6e1ef" continuedAt="iec3c992288ef406482eff4bd799a217d" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="iec3c992288ef406482eff4bd799a217d" continuedAt="i4f936c91ad174b42b333dd1ae51ef72a"><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RleHRyZWdpb246MDE4ZjcwZDNmZTMwNDI2Y2JlZmEwYTA2NWFlNDFiNTFfODk4_60c79e6c-fa0f-4334-8da2-997b79f98444" continuedAt="ic4ae741db49b472cbbd13ad7828eb270" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s available-for-sale marketable securities as of March&#160;31, 2022 and December&#160;31, 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"></td><td style="width:23.740%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.212%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.212%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.212%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.216%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash Equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e90b96953469abcc2db764348a6e1_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNC0xLTEtMS0xNzcxNg_8855d957-21a3-4b41-9c81-76fb35418f67">11,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e90b96953469abcc2db764348a6e1_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNC0zLTEtMS0xNzcxNg_fdc2af08-08fc-42df-ab55-b76da9096974">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e90b96953469abcc2db764348a6e1_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNC01LTEtMS0xNzcxNg_48e756fb-90a7-426e-a1e5-c31ae9a77996">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e90b96953469abcc2db764348a6e1_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNC03LTEtMS0xNzcxNg_efd57af6-5f47-469c-b9ab-fa6fcace8bdb">11,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8b06dfad0e4445b9def4cf77df1caf8_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNC0xLTEtMS0xNTUyMw_152848c7-3f2e-42d0-8835-70471889f4ea">117,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8b06dfad0e4445b9def4cf77df1caf8_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNC0zLTEtMS0xNTUyMw_19e81a70-0a89-43a4-bba2-e7eaf7548c64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8b06dfad0e4445b9def4cf77df1caf8_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNC01LTEtMS0xNTUyMw_357f91b0-0f3a-48cc-ac82-ec05433fb950">645</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8b06dfad0e4445b9def4cf77df1caf8_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNC03LTEtMS0xNTUyMw_ab5914b7-cd10-4a00-9029-1dcf973b4fe3">117,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ce1d0e7f26429d9c2e120dd4006a6d_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNS0xLTEtMS0xNTUyMw_829bab5b-ae1e-486d-9294-c325b8687567">73,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ce1d0e7f26429d9c2e120dd4006a6d_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNS0zLTEtMS0xNTUyMw_4d8e8520-a16f-4c92-9ceb-80219efca339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ce1d0e7f26429d9c2e120dd4006a6d_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNS01LTEtMS0xNTUyMw_b13cb361-73d1-48f0-80a4-d54a61717d0f">300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ce1d0e7f26429d9c2e120dd4006a6d_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNS03LTEtMS0xNTUyMw_8a516ee0-0821-4af0-93db-e69959670348">73,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie516370bcc604882a6b3b1072c5423ed_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNi0xLTEtMS0xNTUyMw_cee2c783-793a-4858-adbd-d2456d99ad60">75,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie516370bcc604882a6b3b1072c5423ed_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNi03LTEtMS0xNTUyMw_af924523-142f-4415-9ae3-e68e68a2a4be">75,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65431ed7c312413eb40bd20210448df7_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfOC0xLTEtMS0xNTUyMw_01a9b208-7644-44c1-b0bf-1bb823c7b681">32,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65431ed7c312413eb40bd20210448df7_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfOC0zLTEtMS0xNTUyMw_258ff2aa-2415-453f-b58f-2151718bc2d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65431ed7c312413eb40bd20210448df7_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfOC01LTEtMS0xNTUyMw_3af59b45-fc66-427f-9c14-0f28de8e6ed0">515</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65431ed7c312413eb40bd20210448df7_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfOC03LTEtMS0xNTUyMw_602228f2-33f3-4c4e-b284-a9d0c4fe399e">32,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfMTAtMS0xLTEtMTU1MjM_9218ff50-f165-41b5-80e3-0dfeb4f91ebc">311,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfMTAtMy0xLTEtMTU1MjM_733df1e0-9010-4bb2-91fe-4d91547825f2">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfMTAtNS0xLTEtMTU1MjM_2ea5f9f8-fe47-4510-83b5-fa8437ef3e3a">1,460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfMTAtNy0xLTEtMTU1MjM_acf7b361-c412-4e2b-9f82-2adebfb43492">309,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><ix:continuation id="i4f936c91ad174b42b333dd1ae51ef72a"><div style="margin-top:12pt"><ix:continuation id="ic4ae741db49b472cbbd13ad7828eb270"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"></td><td style="width:23.740%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.212%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.212%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.212%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.216%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Government securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i300f6154df4c49c19cae97a30ab27fca_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfNC0xLTEtMS0xNTUyMw_6597575d-3a08-4555-9ef9-50fb460cbc67">105,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i300f6154df4c49c19cae97a30ab27fca_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfNC0zLTEtMS0xNTUyMw_65c03e49-5161-43b2-863e-0715b959e377">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i300f6154df4c49c19cae97a30ab27fca_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfNC01LTEtMS0xNTUyMw_763198d2-d14e-4614-a8c0-a22c53515aaa">79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i300f6154df4c49c19cae97a30ab27fca_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfNC03LTEtMS0xNTUyMw_d168d20b-b281-40cf-af09-88a0b2dbe23d">104,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i150fe21584a54235b4ee8a7eab45b761_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfNS0xLTEtMS0xNTUyMw_3504cf81-3f83-424e-9248-3790aad21c82">78,729</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i150fe21584a54235b4ee8a7eab45b761_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfNS0zLTEtMS0xNTUyMw_49706152-4ecf-4c40-a4ac-3311acb0494f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i150fe21584a54235b4ee8a7eab45b761_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfNS01LTEtMS0xNTUyMw_0427abd3-d94e-47d3-82c8-f085c1c5f648">52</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i150fe21584a54235b4ee8a7eab45b761_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfNS03LTEtMS0xNTUyMw_df1bddbb-b84b-4830-93fb-ffffa4ab5381">78,677</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id08a9791d8bf499dbcb446a78165cc74_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfNi0xLTEtMS0xNTUyMw_3df3b294-befe-45ce-ab0e-f92b1481edab">85,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id08a9791d8bf499dbcb446a78165cc74_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfNi03LTEtMS0xNTUyMw_0448954d-be58-4539-89de-438e5d75f2e8">85,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fe7159edfa24359996120ecad894ca9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfOC0xLTEtMS0xNTUyMw_ee76c545-59e8-47c0-917c-329a28485e8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fe7159edfa24359996120ecad894ca9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfOC0zLTEtMS0xNTUyMw_24e5b514-a23d-4885-8203-dcf31f5c099c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fe7159edfa24359996120ecad894ca9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfOC03LTEtMS0xNTUyMw_28148336-02cc-4336-be47-77bf60c674a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfOS0xLTEtMS0xNTUyMw_96a7cf4c-1380-4e8e-b085-b60b92cdafdb">269,668</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfOS0zLTEtMS0xNTUyMw_74ee428c-ebb0-4420-9eb8-7ee2879108f7">3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfOS01LTEtMS0xNTUyMw_9f8ad36e-cf71-41eb-a585-5bd65c0730dc">131</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfOS03LTEtMS0xNTUyMw_fa9a6c54-6c08-4c2b-959c-26c639fc4b41">269,540</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketable securities are available-for-sale securities and consist of high-quality, highly liquid debt securities including corporate debt securities, U.S. government securities and commercial paper.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s available-for-sale securities classified as short-term marketable securities in the condensed consolidated balance sheets mature within one year or less of the balance sheet date. Marketable securities that mature greater than one year from the balance sheet date are classified as long-term. As of March&#160;31, 2022, the Company did not hold any investments with maturity dates greater than five years. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of, and for the three months ended March&#160;31, 2022, the Company did not have any allowance for credit losses or impairments of its marketable securities.</span></div></ix:continuation><div id="i14026a47930f410d91f89b4244285b77_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RleHRyZWdpb246NmI1NjJkODJiNzE5NGQwNWJiNjg2N2E4MGM1OWFmYjNfMjQ0Mg_a5328e11-3232-4049-a9ef-8ddda1112e3d" continuedAt="i86937fe5d8f4447697a8ecc4b3f95d32" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i86937fe5d8f4447697a8ecc4b3f95d32" continuedAt="ia7e9bcfbf94a4875a4d2a29146ea22a2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s financial assets measured on a recurring basis are classified based upon a fair value hierarchy consisting of the following three levels:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#160;&#8212; Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets, or liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#160;&#8212; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the instrument.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#160;&#8212; Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy is based on inputs to valuation techniques used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources while unobservable inputs reflect a reporting entity's pricing based upon their own market assumptions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RleHRyZWdpb246NmI1NjJkODJiNzE5NGQwNWJiNjg2N2E4MGM1OWFmYjNfMjQ0Mw_b96e953a-4672-41ac-981d-3cdd7e85e6ba" continuedAt="i0a0c06146c4043b3a5e40956d228bfa3" escape="true">As of March&#160;31, 2022 and December&#160;31, 2021, the Company's financial assets and liabilities recognized at fair value on a recurring basis consisted of the following:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><ix:continuation id="ia7e9bcfbf94a4875a4d2a29146ea22a2"><ix:continuation id="i0a0c06146c4043b3a5e40956d228bfa3"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Hierarchy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic4afc949d12f47acb07e3840b1a868ac_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfNS0xLTEtMS0xNTUyMw_d5ecd255-414c-4f85-ab09-deac55719af1">26,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ieaa89fe2a4c24ac598f43e035f41aa5b_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfNS0zLTEtMS0xNTUyMw_a935ca4e-949a-48f4-90df-a5edeebe64cb">26,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7e42a60b7564e79bc3c7c48d5590c00_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfNS01LTEtMS0xNTUyMw_58abee60-c4ba-45ff-a0f7-9deff7a76db4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icb7ddd9a5fdb4cf3abb770f8dbe58b35_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfNS03LTEtMS0xNTUyMw_129a024f-8940-4892-bd9f-802630960b35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a06e303f7d247fe94023b4d619218aa_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfNi0xLTEtMS0xNjkzNA_182dccdf-6ac2-4ab4-a66d-6f54a25f28f0">11,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4bd8059ca34abfb81ea2cc6436bce6_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfNi0zLTEtMS0xNjkzNA_ac645ee6-8a53-4b87-b737-6eba676499a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26bf9156508046f3a787efd142360d06_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfNi01LTEtMS0xNjkzNA_4240480e-dfcf-49ac-871f-04f63a9a4f8b">11,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if81ad8f0dc3845e892842d063335a2c0_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfNi03LTEtMS0xNjkzNA_f17c7675-162a-4f85-b08b-b08fe9560627">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia50bc0b54e7b411cbc0c32ee73246291_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfNy0xLTEtMS0xNTUyMw_ea6769e7-1d49-4600-a63b-04ba0dbba30a">117,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i83db6194bc09401ea9d4f8dbf3dd05ef_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfNy0zLTEtMS0xNTUyMw_9ac07fbb-417a-4295-ad4c-374a84bf49e6">117,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d2ba195827a4b65a9c8591347ec440e_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfNy01LTEtMS0xNTUyMw_e6e53d85-eb4f-4e39-a9c3-0ca2ab3d6e30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iac009ae2fcd34d3cad26b302a0e27bc8_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfNy03LTEtMS0xNTUyMw_ca81afab-6dbb-4cf5-b562-042db0b4cf76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i60cfe3f50c6b4c5892a4f8065819a89a_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfOC0xLTEtMS0xNTUyMw_29b0e4b2-b066-4f58-a9c7-02afb7e63a3b">73,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id10a160829dd4d6988d22ab73639351d_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfOC0zLTEtMS0xNTUyMw_6f6909b4-e5df-4de9-9b66-b606850b6dab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib1994ec146e34e20b804657cf2ba88e0_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfOC01LTEtMS0xNTUyMw_13c4a3b6-6bdf-4d15-a578-d185e9dc2424">73,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i35144578669449479c826d121a4a39af_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfOC03LTEtMS0xNTUyMw_fdcf892e-3bf3-43a5-a049-0c95dd5bdeee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i07d72b0a1c1041edbe9b872760e69623_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfOS0xLTEtMS0xNTUyMw_86f169c8-9735-4f52-b3e6-d21c30340df7">75,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b0faab11338417da46a57af69648a69_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfOS0zLTEtMS0xNTUyMw_7016e5a5-ff2d-4b1d-b460-b467e60e4da3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i96e7836def764eae8d4fccf746bff3ed_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfOS01LTEtMS0xNTUyMw_6bc44ad0-f72e-4c5e-8621-4f72a1424891">75,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i52195f7f2e1149f0bfc9825b28eb3e9d_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfOS03LTEtMS0xNTUyMw_6e60e259-82e5-440a-bd0e-b14b6346c6ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia50bc0b54e7b411cbc0c32ee73246291_I20220331" decimals="-3" name="swtx:LongTermInvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfMTEtMS0xLTEtMTU1MjM_e06a91bf-5700-4b8e-9cb2-2963dd242969">32,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83db6194bc09401ea9d4f8dbf3dd05ef_I20220331" decimals="-3" name="swtx:LongTermInvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfMTEtMy0xLTEtMTU1MjM_d0c5478d-dbed-4cd6-b21f-f83f545c80e7">32,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d2ba195827a4b65a9c8591347ec440e_I20220331" decimals="-3" name="swtx:LongTermInvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfMTEtNS0xLTEtMTU1MjM_8bd430f1-4eeb-403d-ac96-c0e3c3089a16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac009ae2fcd34d3cad26b302a0e27bc8_I20220331" decimals="-3" name="swtx:LongTermInvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfMTEtNy0xLTEtMTU1MjM_054cd606-123a-462a-bd46-1e3fcabdcf3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6c5e5caf0cc0466db2575b43a6561e92_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfMTMtMS0xLTEtMTU1MjM_44fb357b-eb61-4286-b9b6-e97b3e3467f1">336,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i34e57c62cb4b46b18943ea2ade2bb811_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfMTMtMy0xLTEtMTU1MjM_ac69dc0c-038f-4415-86e9-9e2b4eab8b2a">176,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if853b5ddc3f24be599e3d8610e8928e9_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfMTMtNS0xLTEtMTU1MjM_853bbd5b-e571-4d37-8f70-1ee9db8b6b31">160,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i685d1982ea314317b0b57e4839162cc6_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfMTMtNy0xLTEtMTU1MjM_fe82f488-5b1f-4db5-a142-5d8960087f04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Hierarchy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16725e0ada024661899310a4ee93bfcc_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfNS0xLTEtMS0xNTUyMw_1a75996e-7d4d-4d27-9e58-e03db67473bb">89,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25f5c527da6b4872a8eeb9f36a3e424e_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfNS0zLTEtMS0xNTUyMw_5f0b3fd3-067e-4156-9079-62cd440472d9">89,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i582a7aa81bf94063ad30c2ae9cd74ef1_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfNS01LTEtMS0xNTUyMw_9e8323ac-1e9e-4763-af9a-6f18de063350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4381bd10810f415e80d931113c9f98aa_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfNS03LTEtMS0xNTUyMw_b90375a0-5789-4f2f-81ca-981a98fa1ea4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d343dab4b5444209fd3ed76c2203491_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfNy0xLTEtMS0xNTUyMw_8e0af25e-828d-47cb-b3ef-4e27f3c3117e">104,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafd101aebef746019f6ce6cfeb3ee12b_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfNy0zLTEtMS0xNTUyMw_2c888138-ae8d-452e-8788-0a65e9c5d791">104,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffe9941ac0af4829ae1f8653c196fcf8_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfNy01LTEtMS0xNTUyMw_466e103a-5943-48f2-8cf7-b1677fbda899">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b0bf57bc62646ee88f4c37260c3618a_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfNy03LTEtMS0xNTUyMw_1a7727f0-894b-4efe-bb08-bcacbbdfddc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if240cefa329a43f5985a94cbabaaf6bf_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfOC0xLTEtMS0xNTUyMw_4554caa1-71c6-4ff2-a025-7c5f8050502e">78,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadafdf4d3eea47f18794b5f1ab930fc6_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfOC0zLTEtMS0xNTUyMw_ef05002e-dab7-44cb-b2d8-5d77b31c135a">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fd763563b24d6aa1f44bd42f945197_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfOC01LTEtMS0xNTUyMw_e3333b20-81a3-48fa-9a5e-b75517075f72">78,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b14ef11391b4c02b03d75aee65c957f_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfOC03LTEtMS0xNTUyMw_0e9e52c8-179d-4a6a-9fe7-d0e0b505a60f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia01bf0d0d0004d6da16a34e81942ea85_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfOS0xLTEtMS0xNTUyMw_34900265-4a31-442a-a0c1-82948afb443c">85,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i310af46a88e3405dae093107956ce302_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfOS0zLTEtMS0xNTUyMw_d9588358-ff3e-4390-a31f-946e9bf7ebae">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3757e607d7cc45e0ae3411908f9b244f_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfOS01LTEtMS0xNTUyMw_80d2bc05-a885-4e1e-b25b-4f5b94ec64a4">85,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5e9ce2dfe7e45279052b07d7cd8b812_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfOS03LTEtMS0xNTUyMw_d94654c8-7163-4acf-986d-413d199ceabe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d343dab4b5444209fd3ed76c2203491_I20211231" decimals="-3" name="swtx:LongTermInvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfMTEtMS0xLTEtMTU1MjM_2c54d7b2-2d78-4797-9fa5-620192ecc176">59,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafd101aebef746019f6ce6cfeb3ee12b_I20211231" decimals="-3" name="swtx:LongTermInvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfMTEtMy0xLTEtMTU1MjM_b326476f-8729-4623-8331-04441f5974b9">59,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffe9941ac0af4829ae1f8653c196fcf8_I20211231" decimals="-3" name="swtx:LongTermInvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfMTEtNS0xLTEtMTU1MjM_6fda54d7-7689-4a5d-b84e-cdbc3067bfbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b0bf57bc62646ee88f4c37260c3618a_I20211231" decimals="-3" name="swtx:LongTermInvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfMTEtNy0xLTEtMTU1MjM_425f3d79-2716-442b-a822-ec393b49c5ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i31f65ade5edf48fc9494eade358d77e2_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfMTItMS0xLTEtMTU1MjM_dae00a52-e600-449a-819a-e5d61572d2c8">418,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i03111218aab744f3a7bce0157ba6e7fb_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfMTItMy0xLTEtMTU1MjM_2162815e-7247-421a-8653-dd9c4310fb17">254,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i075a5d5199b1444fb36eab85ce242914_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfMTItNS0xLTEtMTU1MjM_3f40a75c-2b09-4dea-a075-8e1a4fe5a24a">164,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i863575ed748a4e7b919599b8c6e813af_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfMTItNy0xLTEtMTU1MjM_16e10c58-8dcd-45d0-b4c0-588ac3def97a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, the Company&#8217;s financial assets measured at fair value on a recurring basis using a market approach included cash equivalents, which consist of money market funds, and marketable securities, which consist of high-quality, highly liquid available-for-sale debt securities including corporate debt securities, U.S. government securities and commercial paper.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s money market funds are readily convertible into cash and the net asset value of each fund on the last day of the quarter is used to determine fair value. The U.S. Government securities are classified as Level 1 and valued utilizing quoted market prices. The Company&#8217;s corporate debt securities and commercial paper are classified as Level 2 and valued utilizing various market and industry inputs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid instruments that have maturities of three months or less when acquired to be cash equivalents. The carrying amounts reflected in the Company&#8217;s condensed consolidated balance sheets for cash equivalents, accounts payable, and accrued expenses approximate fair value due to their short-term maturities.</span><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:continuation><div id="i14026a47930f410d91f89b4244285b77_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;<ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180OS9mcmFnOmRmNTJhYWE0MWI3YzQ1YTZhNDE1MzE1MDAzNjhkZTZhL3RleHRyZWdpb246ZGY1MmFhYTQxYjdjNDVhNmE0MTUzMTUwMDM2OGRlNmFfMTgyMQ_cd780436-eddb-4542-9561-c3ef58d63af2" continuedAt="i14bc329e5ff74e0bbae74a2b85e06870" escape="true">Investment and Variable Interest Entity</ix:nonNumeric></span></div><ix:continuation id="i14bc329e5ff74e0bbae74a2b85e06870" continuedAt="ibda6056f03d34c4ca6dc4ef018ab2121"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MapKure</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June&#160;2019, the Company announced the formation of MapKure LLC., or MapKure, an entity jointly owned by the Company and BeiGene Ltd., or BeiGene. BeiGene licensed to MapKure exclusive rights to BGB-3245, an oral, small molecule selective inhibitor of specific BRAF driver mutations and genetic fusions. MapKure is advancing BGB-3245 through clinical development for solid tumor patients harboring BRAF driver mutations and genetic fusions that were observed to be sensitive to the compound in preclinical studies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company&#8217;s ownership interest in MapKure was <ix:nonFraction unitRef="number" contextRef="i7eba2f99c15b49c2a91337a9f21c9f15_I20220331" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180OS9mcmFnOmRmNTJhYWE0MWI3YzQ1YTZhNDE1MzE1MDAzNjhkZTZhL3RleHRyZWdpb246ZGY1MmFhYTQxYjdjNDVhNmE0MTUzMTUwMDM2OGRlNmFfNjE0_47216429-bf64-4c7b-9f31-35fd70cfc823">38.9</ix:nonFraction>%. In addition to the Company&#8217;s equity ownership in MapKure, the Company has appointed a member to each of MapKure&#8217;s joint steering committee and board of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><ix:continuation id="ibda6056f03d34c4ca6dc4ef018ab2121"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">directors. The Company also contributes to clinical development and other operational activities for BGB-3245 through a service agreement with MapKure.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that MapKure is a variable interest entity. The Company is not the primary beneficiary, as the Company does not have the power to direct the activities that most significantly impact the economic performance of MapKure. Accordingly, the Company does not consolidate the financial statements of this entity and accounts for this investment using the equity method of accounting.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 323-10-35-6, the Company records MapKure&#8217;s earnings or losses based on a one quarter lag.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized an equity loss of $<ix:nonFraction unitRef="usd" contextRef="i60df7d63a68a48d59113cc28df86b1f4_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180OS9mcmFnOmRmNTJhYWE0MWI3YzQ1YTZhNDE1MzE1MDAzNjhkZTZhL3RleHRyZWdpb246ZGY1MmFhYTQxYjdjNDVhNmE0MTUzMTUwMDM2OGRlNmFfMTQ3Nw_3ca84002-065d-4e6d-8969-7bc69ab5d7a4"><ix:nonFraction unitRef="usd" contextRef="ic15d05a5ead7496488cbe289375b0b77_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180OS9mcmFnOmRmNTJhYWE0MWI3YzQ1YTZhNDE1MzE1MDAzNjhkZTZhL3RleHRyZWdpb246ZGY1MmFhYTQxYjdjNDVhNmE0MTUzMTUwMDM2OGRlNmFfMTQ3Nw_4c39e4aa-0ada-48c3-b28c-d2de47a01d19">0.3</ix:nonFraction></ix:nonFraction> million for each of the three month periods ended March&#160;31, 2022 and March&#160;31, 2021. The Company&#8217;s ownership interest in MapKure is included in &#8220;Equity method investments&#8221; in the condensed consolidated balance sheets. The balance of the Company&#8217;s investment was $<ix:nonFraction unitRef="usd" contextRef="i9c3264a753fa40f19ce07bcf42665c50_I20220331" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180OS9mcmFnOmRmNTJhYWE0MWI3YzQ1YTZhNDE1MzE1MDAzNjhkZTZhL3RleHRyZWdpb246ZGY1MmFhYTQxYjdjNDVhNmE0MTUzMTUwMDM2OGRlNmFfMTA5OTUxMTYyOTYzMA_4c9aecc9-b1b3-4293-bf27-7d8a0a566710">2.5</ix:nonFraction> million as of March&#160;31, 2022, representing the maximum exposure to loss as a result of the Company&#8217;s involvement with MapKure.</span></div></ix:continuation><div id="i14026a47930f410d91f89b4244285b77_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;<ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181Mi9mcmFnOmNhNDlkN2JjYWJhNjQwYTdiOGM0MDljYjFiYTI0OGJiL3RleHRyZWdpb246Y2E0OWQ3YmNhYmE2NDBhN2I4YzQwOWNiMWJhMjQ4YmJfNzA_0964b6e9-f568-48e0-ba8c-ad521c4cc2f6" continuedAt="i5deeba6415b94d8e8e32a660dc1523a4" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="i5deeba6415b94d8e8e32a660dc1523a4"><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181Mi9mcmFnOmNhNDlkN2JjYWJhNjQwYTdiOGM0MDljYjFiYTI0OGJiL3RleHRyZWdpb246Y2E0OWQ3YmNhYmE2NDBhN2I4YzQwOWNiMWJhMjQ4YmJfNzE_449eeb41-57d5-47a1-bed2-aab068f5bc58" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consists of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181Mi9mcmFnOmNhNDlkN2JjYWJhNjQwYTdiOGM0MDljYjFiYTI0OGJiL3RhYmxlOmM0MjY0ZjljZjIzMDQ5YTRiNDJjMDE1ZWM2N2FiYTcwL3RhYmxlcmFuZ2U6YzQyNjRmOWNmMjMwNDlhNGI0MmMwMTVlYzY3YWJhNzBfMi0yLTEtMS0xNTUyMw_26994d41-c018-4059-837c-dff4cbe4c649">975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181Mi9mcmFnOmNhNDlkN2JjYWJhNjQwYTdiOGM0MDljYjFiYTI0OGJiL3RhYmxlOmM0MjY0ZjljZjIzMDQ5YTRiNDJjMDE1ZWM2N2FiYTcwL3RhYmxlcmFuZ2U6YzQyNjRmOWNmMjMwNDlhNGI0MmMwMTVlYzY3YWJhNzBfMi00LTEtMS0xNTUyMw_6352aa47-5f04-4549-a670-59fe6f9f171e">1,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181Mi9mcmFnOmNhNDlkN2JjYWJhNjQwYTdiOGM0MDljYjFiYTI0OGJiL3RhYmxlOmM0MjY0ZjljZjIzMDQ5YTRiNDJjMDE1ZWM2N2FiYTcwL3RhYmxlcmFuZ2U6YzQyNjRmOWNmMjMwNDlhNGI0MmMwMTVlYzY3YWJhNzBfMy0yLTEtMS0xNTUyMw_3c7eb8c4-cbab-4825-bbe6-6cd87b374748">4,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181Mi9mcmFnOmNhNDlkN2JjYWJhNjQwYTdiOGM0MDljYjFiYTI0OGJiL3RhYmxlOmM0MjY0ZjljZjIzMDQ5YTRiNDJjMDE1ZWM2N2FiYTcwL3RhYmxlcmFuZ2U6YzQyNjRmOWNmMjMwNDlhNGI0MmMwMTVlYzY3YWJhNzBfMy00LTEtMS0xNTUyMw_9128585c-6c60-4a28-bf58-b4db5f57475f">12,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="swtx:AccruedResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181Mi9mcmFnOmNhNDlkN2JjYWJhNjQwYTdiOGM0MDljYjFiYTI0OGJiL3RhYmxlOmM0MjY0ZjljZjIzMDQ5YTRiNDJjMDE1ZWM2N2FiYTcwL3RhYmxlcmFuZ2U6YzQyNjRmOWNmMjMwNDlhNGI0MmMwMTVlYzY3YWJhNzBfNC0yLTEtMS0xNTUyMw_1132a91c-e6b9-4012-85db-0a8c2ac6edd5">12,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="swtx:AccruedResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181Mi9mcmFnOmNhNDlkN2JjYWJhNjQwYTdiOGM0MDljYjFiYTI0OGJiL3RhYmxlOmM0MjY0ZjljZjIzMDQ5YTRiNDJjMDE1ZWM2N2FiYTcwL3RhYmxlcmFuZ2U6YzQyNjRmOWNmMjMwNDlhNGI0MmMwMTVlYzY3YWJhNzBfNC00LTEtMS0xNTUyMw_e0d9b22e-28e5-4451-8e88-13774490ad79">10,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181Mi9mcmFnOmNhNDlkN2JjYWJhNjQwYTdiOGM0MDljYjFiYTI0OGJiL3RhYmxlOmM0MjY0ZjljZjIzMDQ5YTRiNDJjMDE1ZWM2N2FiYTcwL3RhYmxlcmFuZ2U6YzQyNjRmOWNmMjMwNDlhNGI0MmMwMTVlYzY3YWJhNzBfNS0yLTEtMS0xNTUyMw_80cccdc1-9e7a-4d6f-8c6f-a59cf4dff802">3,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181Mi9mcmFnOmNhNDlkN2JjYWJhNjQwYTdiOGM0MDljYjFiYTI0OGJiL3RhYmxlOmM0MjY0ZjljZjIzMDQ5YTRiNDJjMDE1ZWM2N2FiYTcwL3RhYmxlcmFuZ2U6YzQyNjRmOWNmMjMwNDlhNGI0MmMwMTVlYzY3YWJhNzBfNS00LTEtMS0xNTUyMw_d58a529a-e6ec-4880-bf3a-b7984caf99d1">2,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181Mi9mcmFnOmNhNDlkN2JjYWJhNjQwYTdiOGM0MDljYjFiYTI0OGJiL3RhYmxlOmM0MjY0ZjljZjIzMDQ5YTRiNDJjMDE1ZWM2N2FiYTcwL3RhYmxlcmFuZ2U6YzQyNjRmOWNmMjMwNDlhNGI0MmMwMTVlYzY3YWJhNzBfNi0yLTEtMS0xNTUyMw_b5126e5e-6869-4b95-ad67-3f3ea05b40de">21,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id73789b2c218404991bfa981f4cb6592_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181Mi9mcmFnOmNhNDlkN2JjYWJhNjQwYTdiOGM0MDljYjFiYTI0OGJiL3RhYmxlOmM0MjY0ZjljZjIzMDQ5YTRiNDJjMDE1ZWM2N2FiYTcwL3RhYmxlcmFuZ2U6YzQyNjRmOWNmMjMwNDlhNGI0MmMwMTVlYzY3YWJhNzBfNi00LTEtMS0xNTUyMw_3c03d0b8-8918-4fdf-9df6-3a971509a1a8">25,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i14026a47930f410d91f89b4244285b77_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;<ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RleHRyZWdpb246ZDE4Y2UzZjRkOGFkNGFmOTkyNGNmNzEyMDlkMWExYTNfMTQxNQ_f1a20a20-96e5-40f0-a1dc-74daa2c0dd02" continuedAt="i026e1ef5b28044969e105436358eb23f" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i026e1ef5b28044969e105436358eb23f" continuedAt="i607cd9812ef0442a9d1d895bf7ee9699"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into contracts in the normal course of business for clinical trials, preclinical studies, manufacturing and other services and products for operating purposes. These contracts generally provide for termination following a certain period after notice and therefore the Company believes that non-cancelable obligations under these agreements are not material.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company has excluded milestone or royalty payments or other contractual payment obligations as the timing and amounts of such obligations are unknown or uncertain.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into a lease for its corporate headquarters in Stamford, CT. In January 2022, the Company amended this lease agreement to extend the lease term through April 2028, with <ix:nonFraction unitRef="option" contextRef="i65b72505f5de4b88b1745e53289c8346_I20220131" decimals="INF" name="swtx:LesseeOperatingLeaseNumberOfRenewalOptions" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RleHRyZWdpb246ZDE4Y2UzZjRkOGFkNGFmOTkyNGNmNzEyMDlkMWExYTNfNjU5NzA2OTc3MDcyOA_6fb2f5d1-64aa-4cbf-80d8-c9bf1d976917">two</ix:nonFraction> <ix:nonNumeric contextRef="i65b72505f5de4b88b1745e53289c8346_I20220131" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RleHRyZWdpb246ZDE4Y2UzZjRkOGFkNGFmOTkyNGNmNzEyMDlkMWExYTNfNjU5NzA2OTc3MDc0MA_f113f825-d1ed-4e5f-bb06-30ddd3b7c83f">five-year</ix:nonNumeric> renewal options or <ix:nonFraction unitRef="option" contextRef="i7f3b13792a2240b6bb59248690c98652_I20220131" decimals="INF" name="swtx:LesseeOperatingLeaseNumberOfRenewalOptions" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RleHRyZWdpb246ZDE4Y2UzZjRkOGFkNGFmOTkyNGNmNzEyMDlkMWExYTNfNjU5NzA2OTc3MDc0MQ_167dd735-5078-4673-9146-74c409e03edd">one</ix:nonFraction> <ix:nonNumeric contextRef="i7f3b13792a2240b6bb59248690c98652_I20220131" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RleHRyZWdpb246ZDE4Y2UzZjRkOGFkNGFmOTkyNGNmNzEyMDlkMWExYTNfNjU5NzA2OTc3MDc1Mg_bc79ada3-1282-457e-8795-4426e338752e">ten-year</ix:nonNumeric> renewal option. Pursuant to the amendment, the Company is entitled to $<ix:nonFraction unitRef="usd" contextRef="i37565722b4fa4a69ba807d2fba2e932f_I20220131" decimals="-5" name="swtx:LesseeOperatingLeaseEntitledTenantAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RleHRyZWdpb246ZDE4Y2UzZjRkOGFkNGFmOTkyNGNmNzEyMDlkMWExYTNfNjU5NzA2OTc3MDc1Ng_dac4700d-a012-4691-99d4-4722942f53a2">0.5</ix:nonFraction>&#160;million in tenant allowances, which may be used to offset certain future capital expenditures, and the lease payments increase by <ix:nonFraction unitRef="number" contextRef="i37565722b4fa4a69ba807d2fba2e932f_I20220131" decimals="3" name="swtx:AnnualIncreaseInLeasePaymentsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RleHRyZWdpb246ZDE4Y2UzZjRkOGFkNGFmOTkyNGNmNzEyMDlkMWExYTNfNjU5NzA2OTc3MDc3MA_c30be0f2-e1c1-4dc6-9be2-293ae67fbf2a">2.5</ix:nonFraction>% in each year commencing December 1, 2022. The amendment was treated as a modification and the lease liability and Operating lease right-of-use asset were updated to reflect minimum lease payments and any other adjustments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RleHRyZWdpb246ZDE4Y2UzZjRkOGFkNGFmOTkyNGNmNzEyMDlkMWExYTNfMTQxNg_83dcf31d-40e7-43be-a924-7c80ba3da79c" continuedAt="i20e3b1c519ec4edca9af6ce03fd3cfa9" escape="true">As of March&#160;31, 2022, future lease payments under non-cancelable leases with terms greater than one year are as follows:</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><ix:continuation id="i607cd9812ef0442a9d1d895bf7ee9699"><div><ix:continuation id="i20e3b1c519ec4edca9af6ce03fd3cfa9"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.116%"><tr><td style="width:1.0%"></td><td style="width:74.629%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.442%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RhYmxlOjVkZDk2NDllNzQ4YTRhYjliZDVhZWE4ZTU4ZWU2NTNjL3RhYmxlcmFuZ2U6NWRkOTY0OWU3NDhhNGFiOWJkNWFlYThlNThlZTY1M2NfMS0yLTEtMS0xODY2OQ_35334997-fc72-40d6-9c2f-3109a94ecdf6">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RhYmxlOjVkZDk2NDllNzQ4YTRhYjliZDVhZWE4ZTU4ZWU2NTNjL3RhYmxlcmFuZ2U6NWRkOTY0OWU3NDhhNGFiOWJkNWFlYThlNThlZTY1M2NfMi0yLTEtMS0xODY2OQ_f9c048cf-bd31-4132-94ea-3f8cc3be6a81">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RhYmxlOjVkZDk2NDllNzQ4YTRhYjliZDVhZWE4ZTU4ZWU2NTNjL3RhYmxlcmFuZ2U6NWRkOTY0OWU3NDhhNGFiOWJkNWFlYThlNThlZTY1M2NfMy0yLTEtMS0xODY2OQ_eebb85af-00f2-4996-a476-7afb133855e6">1,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RhYmxlOjVkZDk2NDllNzQ4YTRhYjliZDVhZWE4ZTU4ZWU2NTNjL3RhYmxlcmFuZ2U6NWRkOTY0OWU3NDhhNGFiOWJkNWFlYThlNThlZTY1M2NfNC0yLTEtMS0xODY2OQ_e31fbd41-a371-40df-9801-342aa9ed0de5">1,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="swtx:LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RhYmxlOjVkZDk2NDllNzQ4YTRhYjliZDVhZWE4ZTU4ZWU2NTNjL3RhYmxlcmFuZ2U6NWRkOTY0OWU3NDhhNGFiOWJkNWFlYThlNThlZTY1M2NfNS0yLTEtMS0xODY2OQ_c9aa4240-4103-4137-af07-89b0f222f1bb">2,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RhYmxlOjVkZDk2NDllNzQ4YTRhYjliZDVhZWE4ZTU4ZWU2NTNjL3RhYmxlcmFuZ2U6NWRkOTY0OWU3NDhhNGFiOWJkNWFlYThlNThlZTY1M2NfNi0yLTEtMS0xODY2OQ_c86730c6-1557-4212-8b46-14a9d91da8fa">6,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RhYmxlOjVkZDk2NDllNzQ4YTRhYjliZDVhZWE4ZTU4ZWU2NTNjL3RhYmxlcmFuZ2U6NWRkOTY0OWU3NDhhNGFiOWJkNWFlYThlNThlZTY1M2NfNy0yLTEtMS0xODY2OQ_b94f92d0-a907-44fa-b5ea-92aec119b4e1">874</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4858197abb9f421195cb86f9528f4108_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RhYmxlOjVkZDk2NDllNzQ4YTRhYjliZDVhZWE4ZTU4ZWU2NTNjL3RhYmxlcmFuZ2U6NWRkOTY0OWU3NDhhNGFiOWJkNWFlYThlNThlZTY1M2NfOC0yLTEtMS0xODY2OQ_69cba53d-e7e9-4389-af01-479058ccf736">5,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in disputes or regulatory inquiries that arise in the ordinary course of business. When the Company determines that a loss is both probable and reasonably estimable, a liability is recorded and disclosed if the amount is material to the financial statements taken as a whole. When a material loss contingency is only reasonably possible, the Company does not record a liability, but instead discloses the nature and the amount of the claim, and an estimate of the loss or range of loss, if such an estimate can reasonably be made.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, there was <ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="INF" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RleHRyZWdpb246ZDE4Y2UzZjRkOGFkNGFmOTkyNGNmNzEyMDlkMWExYTNfMTMyOQ_110f1aee-c9c0-4257-b9aa-2b74449349e8">no</ix:nonFraction> litigation or contingency with at least a reasonable possibility of a material loss.</span></div></ix:continuation><div id="i14026a47930f410d91f89b4244285b77_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMjU2Mw_a9b5e3c8-a944-454f-a82a-47f282c24432" continuedAt="ibdeb6deac5a14cb4a39f6e67cf53d506" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="ibdeb6deac5a14cb4a39f6e67cf53d506" continuedAt="id8c8ccfad07941c59a22d330c65635cf"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019 Equity Incentive Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2019 Equity Incentive Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards and dividend equivalent rights to the Company&#8217;s officers, employees, directors and other key persons (including consultants). The number of shares reserved for issuance under the 2019 Equity Incentive Plan is cumulatively increased each January 1, through and including January 1, 2030, by <ix:nonFraction unitRef="number" contextRef="ia34d861b8e7c40f69f8da029b428f1a0_D20190101-20191231" decimals="INF" name="swtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfNTIy_e90296dd-2891-47a3-93e6-1987ee376f20">5</ix:nonFraction>% of the number of shares of the Company&#8217;s common stock outstanding on the immediately preceding December&#160;31 or such lesser number of shares determined by the Company&#8217;s compensation committee.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The terms of stock options and restricted stock units and awards, including vesting requirements, are determined by the Board of Directors or its delegates, subject to the provisions of the 2019 Equity Incentive Plan. Restricted stock units and awards granted by the Company to employees generally vest over <ix:nonNumeric contextRef="i74cc340c1aa4424ba3726c91ee26d876_D20220101-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfNjU5NzA2OTc3MTU2NQ_71b9485d-35da-4a95-a697-5a0160c48690">three years</ix:nonNumeric>, and stock options granted by the Company to employees generally vest over <ix:nonNumeric contextRef="i022436fef9574100a67fd5ee74396304_D20220101-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfNjU5NzA2OTc3MTU2Ng_ed45984f-a69a-40be-a686-dd7ec1e96c70">four years</ix:nonNumeric>. Restricted stock units and awards and stock options granted by the Company to directors generally vest over <ix:nonNumeric contextRef="i3948092549294997927bcdcb9f543aa4_D20220101-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfNjU5NzA2OTc3MTU2Nw_e049748a-1c53-4471-9730-8add067e9353">one year</ix:nonNumeric>.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i09e3d5011a2c4255b31c3514190f2c5b_I20220331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMTIxMA_74d7e858-7c89-42e4-85e5-02c982af9ff8">4,785,168</ix:nonFraction> shares available for issuance in connection with future awards under the 2019 Equity Incentive Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Awards</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, the Company granted <ix:nonFraction unitRef="shares" contextRef="id21cc7dd1c9e49d7b59a05c489a69c95_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMTM4NA_281a5b04-12bd-4886-a682-548f623dd5c0">1,350,479</ix:nonFraction> stock option awards, <ix:nonFraction unitRef="shares" contextRef="iaf02bd13545f44a9bb747e767c85e226_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMTA5OTUxMTYzMTI3MQ_ffc4eb89-5087-4810-8aeb-00ceff8c16f5">464,513</ix:nonFraction> restricted stock units and <ix:nonFraction unitRef="shares" contextRef="ia76c9558fc764171b39ba192df90d64a_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMTA5OTUxMTYzMjYzNg_279cf159-7f30-4528-9518-aaf030cbf5c5">36,625</ix:nonFraction> restricted stock awards to its officers, employees and directors under the 2019 Equity Incentive Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i147d6c8ff5e4443d9e538dcf1cb66057_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMTU0OA_51408795-0317-4526-9180-81913cfe5e52">104,985</ix:nonFraction> restricted stock awards previously issued to employees of the Company vested, and <ix:nonFraction unitRef="shares" contextRef="i05cb736fa4db484e8bc7a1b84df8778d_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMTYzMw_8ac9ce20-aee0-4306-b3c0-d1dab5535c33">142,657</ix:nonFraction> stock options were exercised.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i2e392b95e3564143b67b20dfaa88de74_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMTY4Nw_73b6a873-0c2c-419e-b32f-80d2fadb1073">2,991,905</ix:nonFraction> stock options vested and exercisable. In June 2019, the Company&#8217;s CEO received an award of <ix:nonFraction unitRef="shares" contextRef="idd87f05bb1d645db8de68c02ff92440f_D20190601-20190630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMTc4MQ_0b3d1fd0-adc6-4c2c-a8d0-b3f9369418f5">176,411</ix:nonFraction> stock options, or the 2019 CEO Performance Award. During the quarter ended March&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i2db6208a117f44e39e09d534da69e196_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMTg2Mw_625d5dba-30b6-48af-b64d-ab89f15012c1">11,026</ix:nonFraction> options of the CEO Performance Award became exercisable upon the satisfaction of the market condition applicable to this award.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfNjU5NzA2OTc3MTU2NA_7ee27594-9f23-4103-a715-75e8c90bcfd3" continuedAt="ifcf26411168141d28855dcb9ad47de55" escape="true">Stock-based compensation expense included in the condensed consolidated statements of operations for each of the periods presented is as follows: </ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><ix:continuation id="id8c8ccfad07941c59a22d330c65635cf"><div style="margin-top:12pt"><ix:continuation id="ifcf26411168141d28855dcb9ad47de55"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"></td><td style="width:66.672%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.700%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75b5d0e6891445328c454b9d1ec87a5a_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RhYmxlOmUwMGM5MDQ2NDgyZjQ3N2Y5OWVkNmJmMGNiNjVlYjJiL3RhYmxlcmFuZ2U6ZTAwYzkwNDY0ODJmNDc3Zjk5ZWQ2YmYwY2I2NWViMmJfMy0xLTEtMS0xNjMwMw_170d3377-50b7-411d-9948-801861100cbd">7,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c5e6b459a3f46278653aaa6c0dccad1_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RhYmxlOmUwMGM5MDQ2NDgyZjQ3N2Y5OWVkNmJmMGNiNjVlYjJiL3RhYmxlcmFuZ2U6ZTAwYzkwNDY0ODJmNDc3Zjk5ZWQ2YmYwY2I2NWViMmJfMy0zLTEtMS0xNjMwMw_23970200-920f-4c52-9403-f79a18b48ad7">2,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eb5ddf4b7047d8bf7f1bfb229fd7ab_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RhYmxlOmUwMGM5MDQ2NDgyZjQ3N2Y5OWVkNmJmMGNiNjVlYjJiL3RhYmxlcmFuZ2U6ZTAwYzkwNDY0ODJmNDc3Zjk5ZWQ2YmYwY2I2NWViMmJfNC0xLTEtMS0xNjMwMw_7aef7ccc-9a15-4c62-ac44-68a79a23c7b8">10,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f25ec114c634fc4865cc49981bd981f_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RhYmxlOmUwMGM5MDQ2NDgyZjQ3N2Y5OWVkNmJmMGNiNjVlYjJiL3RhYmxlcmFuZ2U6ZTAwYzkwNDY0ODJmNDc3Zjk5ZWQ2YmYwY2I2NWViMmJfNC0zLTEtMS0xNjMwMw_bcff033a-2ac8-4b6f-a76a-5db82af53ff3">4,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RhYmxlOmUwMGM5MDQ2NDgyZjQ3N2Y5OWVkNmJmMGNiNjVlYjJiL3RhYmxlcmFuZ2U6ZTAwYzkwNDY0ODJmNDc3Zjk5ZWQ2YmYwY2I2NWViMmJfNS0xLTEtMS0xNjMwMw_1259854a-a6d0-44d6-9476-512dcbf99089">17,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RhYmxlOmUwMGM5MDQ2NDgyZjQ3N2Y5OWVkNmJmMGNiNjVlYjJiL3RhYmxlcmFuZ2U6ZTAwYzkwNDY0ODJmNDc3Zjk5ZWQ2YmYwY2I2NWViMmJfNS0zLTEtMS0xNjMwMw_70ac8ee4-2090-4389-a741-62af1d33ae41">7,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the unrecognized compensation expense related to unvested stock options, restricted stock units and restricted stock awards was $<ix:nonFraction unitRef="usd" contextRef="i2e392b95e3564143b67b20dfaa88de74_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMjM0MA_d08352a9-d0a8-489d-9365-53ae970e6abb">153.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i1807ff5c5c8841e9b42432e38c96459d_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMTA5OTUxMTYzMTM2NA_26e2c562-d605-4787-94f5-8fc5941723cc">25.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifc237dbb79e949169c0b49053a2a8980_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMjM0Nw_15f8aebd-0b12-403a-97fd-4efe0f8f5581">18.4</ix:nonFraction> million, respectively, which is expected to be recognized over a weighted-average remaining period of approximately <ix:nonNumeric contextRef="i05cb736fa4db484e8bc7a1b84df8778d_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMjQ0NA_67f95167-1184-4e61-9353-d6772d82cb87">2.78</ix:nonNumeric>, <ix:nonNumeric contextRef="ia3e71bacda9e4305913d6ceeac24be0d_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMTA5OTUxMTYzMTM5Mg_4a587054-4973-4a62-9166-1122d155be1b">2.77</ix:nonNumeric> years and <ix:nonNumeric contextRef="i6d1841e76bd84918b42a921397d98d2e_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMjQ1MQ_7cf435f7-86da-4ac3-8e42-c297c26650b6">1.78</ix:nonNumeric> years, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company had <ix:nonFraction unitRef="shares" contextRef="i2e392b95e3564143b67b20dfaa88de74_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMjQ5NQ_9e11cbc1-2df8-4799-ad08-98d9ec034ec4">7,832,865</ix:nonFraction> stock options outstanding, <ix:nonFraction unitRef="shares" contextRef="i1807ff5c5c8841e9b42432e38c96459d_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMTA5OTUxMTYzMTQ2Nw_27d664b5-1b7a-45f7-a92a-e59d2cda178f">459,614</ix:nonFraction> unvested restricted stock units and <ix:nonFraction unitRef="shares" contextRef="ifc237dbb79e949169c0b49053a2a8980_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMjUyOA_9cb7db22-d884-4f3a-8497-3784bb43c9dc">398,510</ix:nonFraction> unvested restricted stock awards.</span></div></ix:continuation><div id="i14026a47930f410d91f89b4244285b77_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;<ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N182MS9mcmFnOjhiYmRlMDE3NzgxMDQwNDg5N2ZhZGEzMTg5MTExNWM3L3RleHRyZWdpb246OGJiZGUwMTc3ODEwNDA0ODk3ZmFkYTMxODkxMTE1YzdfMzQy_a5d24c69-5a7f-4d10-ad64-d9c1b33995b9" continuedAt="ibadfea2bb4054f84898958c396a13b8d" escape="true">Net Loss per Share</ix:nonNumeric></span></div><ix:continuation id="ibadfea2bb4054f84898958c396a13b8d"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Company had a net loss in each of the periods presented, basic and diluted net loss per share are the same. <ix:nonNumeric contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N182MS9mcmFnOjhiYmRlMDE3NzgxMDQwNDg5N2ZhZGEzMTg5MTExNWM3L3RleHRyZWdpb246OGJiZGUwMTc3ODEwNDA0ODk3ZmFkYTMxODkxMTE1YzdfMzQz_ead68837-5f74-4c2a-8129-c08fe6482675" continuedAt="i7c5ce94f82364178b43eac17073cdc7a" escape="true">The table below provides potentially dilutive securities not included in the computation of the diluted net loss per share for the periods ended March&#160;31, 2022 and March&#160;31, 2021, because to do so would be anti-dilutive:</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i7c5ce94f82364178b43eac17073cdc7a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock options issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e6ea28cc5b746708a2447e6c1e2b5d9_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N182MS9mcmFnOjhiYmRlMDE3NzgxMDQwNDg5N2ZhZGEzMTg5MTExNWM3L3RhYmxlOjI2ODQ0Y2FlMjMzZDRjZjFiNjE1NzUzMmJiNzU1ZTFhL3RhYmxlcmFuZ2U6MjY4NDRjYWUyMzNkNGNmMWI2MTU3NTMyYmI3NTVlMWFfMi0xLTEtMS0xNTUyMw_2e792c3a-f311-4460-a56b-e470852bd164">7,832,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i074022392378431ca43171749ce67e70_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N182MS9mcmFnOjhiYmRlMDE3NzgxMDQwNDg5N2ZhZGEzMTg5MTExNWM3L3RhYmxlOjI2ODQ0Y2FlMjMzZDRjZjFiNjE1NzUzMmJiNzU1ZTFhL3RhYmxlcmFuZ2U6MjY4NDRjYWUyMzNkNGNmMWI2MTU3NTMyYmI3NTVlMWFfMi0zLTEtMS0xNTUyMw_e76c7827-1863-4c24-af38-633bc30e0d11">5,692,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units subject to future vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i701fc5f7822543f5afa349b588446470_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N182MS9mcmFnOjhiYmRlMDE3NzgxMDQwNDg5N2ZhZGEzMTg5MTExNWM3L3RhYmxlOjI2ODQ0Y2FlMjMzZDRjZjFiNjE1NzUzMmJiNzU1ZTFhL3RhYmxlcmFuZ2U6MjY4NDRjYWUyMzNkNGNmMWI2MTU3NTMyYmI3NTVlMWFfMy0xLTEtMS0xNzYzMg_56db437e-8139-40cb-b106-3c01206fed48">459,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8962a5ad7a90438bac9fc74322fc41db_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N182MS9mcmFnOjhiYmRlMDE3NzgxMDQwNDg5N2ZhZGEzMTg5MTExNWM3L3RhYmxlOjI2ODQ0Y2FlMjMzZDRjZjFiNjE1NzUzMmJiNzU1ZTFhL3RhYmxlcmFuZ2U6MjY4NDRjYWUyMzNkNGNmMWI2MTU3NTMyYmI3NTVlMWFfMy0zLTEtMS0xNzYzMg_81e04f5a-4ab7-4153-bb27-c872003f6b5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock awards subject to future vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie455f786f4cb4de6b10f9237538eb2b1_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N182MS9mcmFnOjhiYmRlMDE3NzgxMDQwNDg5N2ZhZGEzMTg5MTExNWM3L3RhYmxlOjI2ODQ0Y2FlMjMzZDRjZjFiNjE1NzUzMmJiNzU1ZTFhL3RhYmxlcmFuZ2U6MjY4NDRjYWUyMzNkNGNmMWI2MTU3NTMyYmI3NTVlMWFfMy0xLTEtMS0xNTUyMw_14a6086f-0b97-464f-a4b4-08ca4e75e2af">398,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6723bcf58742472287b2d9590f8e52df_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N182MS9mcmFnOjhiYmRlMDE3NzgxMDQwNDg5N2ZhZGEzMTg5MTExNWM3L3RhYmxlOjI2ODQ0Y2FlMjMzZDRjZjFiNjE1NzUzMmJiNzU1ZTFhL3RhYmxlcmFuZ2U6MjY4NDRjYWUyMzNkNGNmMWI2MTU3NTMyYmI3NTVlMWFfMy0zLTEtMS0xNTUyMw_d584ff56-f383-489a-a914-8c4f043b2ebe">686,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total potentially dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N182MS9mcmFnOjhiYmRlMDE3NzgxMDQwNDg5N2ZhZGEzMTg5MTExNWM3L3RhYmxlOjI2ODQ0Y2FlMjMzZDRjZjFiNjE1NzUzMmJiNzU1ZTFhL3RhYmxlcmFuZ2U6MjY4NDRjYWUyMzNkNGNmMWI2MTU3NTMyYmI3NTVlMWFfNC0xLTEtMS0xNTUyMw_92fb91e9-d5ca-4c2f-a8ed-27ef2bc93911">8,690,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N182MS9mcmFnOjhiYmRlMDE3NzgxMDQwNDg5N2ZhZGEzMTg5MTExNWM3L3RhYmxlOjI2ODQ0Y2FlMjMzZDRjZjFiNjE1NzUzMmJiNzU1ZTFhL3RhYmxlcmFuZ2U6MjY4NDRjYWUyMzNkNGNmMWI2MTU3NTMyYmI3NTVlMWFfNC0zLTEtMS0xNTUyMw_0b5ec8fd-53ac-4457-958c-843d62ae8a55">6,378,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i14026a47930f410d91f89b4244285b77_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The following discussion and analysis of the financial condition and results of operations of SpringWorks Therapeutics, Inc. should be read in conjunction with the condensed consolidated financial statements and the related notes thereto included elsewhere in this Quarterly Report on Form 10-Q, or Quarterly Report, and our consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, or 2021 Form 10-K, filed with the Securities and Exchange Commission, or SEC, on February 24, 2022. Unless the context otherwise requires, all references to "we," "us," "our," or the "Company" refer to SpringWorks Therapeutics, Inc., together with its subsidiaries. This discussion and analysis contains forward-looking statements based upon current expectations that involve risks and uncertainties. We caution you that forward-looking statements are not guarantees of future performance, and that our actual results of operations, financial condition and liquidity, and the developments in our business and the industry in which we operate, may differ materially from the results discussed or projected in the forward-looking statements contained in this Quarterly Report. We discuss risks and other factors that we believe could cause or contribute to these potential differences elsewhere in this Quarterly Report, including under Item 1A. &#8220;Risk Factors&#8221; and under &#8220;Special Note Regarding Forward-Looking Statements&#8221;. In addition, even if our results of operations, financial condition and liquidity, and the developments in our business and the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report, they may not be predictive of results or developments in future periods. We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the Securities and Exchange Commission, or SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</span></div><div id="i14026a47930f410d91f89b4244285b77_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. We have a differentiated portfolio of small molecule targeted oncology product candidates and are advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. Our strategic approach and operational excellence across research, translational science, and clinical development have enabled us to rapidly advance our two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with industry leaders to expand our portfolio. From this foundation, we are continuing to build a differentiated global biopharmaceutical company intensely focused on understanding patients and their diseases in order to develop transformative targeted medicines.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most advanced product candidate, nirogacestat, is an oral, small molecule gamma secretase inhibitor currently in development for the treatment of desmoid tumors, a rare and often debilitating and disfiguring soft tissue tumor for which there are currently no therapies approved by the U.S. Food and Drug Administration, or FDA. We believe nirogacestat may address the significant limitations associated with existing treatment options and has the potential to become the first therapy approved by the FDA for both newly diagnosed and previously treated desmoid tumors. Since we licensed nirogacestat from Pfizer Inc., or Pfizer, in August 2017, the FDA has granted us Orphan Drug Designation, Fast Track Designation and Breakthrough Therapy Designation for this indication, and the European Commission granted Orphan Drug Designation to nirogacestat for the treatment of soft tissue sarcoma. In May 2019, we announced the initiation of the DeFi trial, a potentially registrational Phase 3 clinical trial of nirogacestat for adult patients with desmoid tumors, and in July 2020, we announced full enrollment of the DeFi trial. The primary endpoint for the DeFi trial is progression free survival, defined as the time from randomization until the date of assessment of radiographic progression as measured by RECIST v1.1, the date of assessment of clinical progression or death by any cause. Radiographic or clinical progression are determined by blinded independent central review. We have commenced the activities to enable the topline analysis from the DeFi trial and expect to report these data in the second quarter of 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second product candidate is mirdametinib, an oral, small molecule MEK inhibitor currently in development for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, or NF1-PN, a rare tumor of the peripheral nerve sheath that causes significant pain and disfigurement, and that most often manifests in children. We believe that mirdametinib has the potential to offer a best-in-class profile in order to enable the long-term treatment required for this patient population, as compared to other MEK inhibitors. As with nirogacestat, we licensed mirdametinib from Pfizer in August 2017; since then, the FDA has granted mirdametinib both Orphan Drug Designation and Fast Track Designation for NF1-PN, and the European Commission has granted mirdametinib Orphan Drug Designation for NF1. In October 2019, we announced the initiation of the ReNeu trial, a potentially registrational Phase 2b clinical trial of mirdametinib for pediatric and adult patients with NF1-PN. In February 2021, we reported interim clinical data from the first 20 adult patients enrolled in the Phase 2b ReNeu trial, and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">updated interim clinical data from these patients were presented in June 2021 at the Children's Tumor Foundation NF Conference. In November 2021, we announced full enrollment of the ReNeu trial. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are also evaluating mirdametinib for the treatment of solid tumors harboring other MAPK aberrations, in both monotherapy and combination approaches. In June 2021, we announced the initiation of Phase 1/2 clinical trial of mirdametinib in children and young adults with low-grade glioma. The study is sponsored by St. Jude Children&#8217;s Research Hospital and supported by SpringWorks. In August 2021, we announced the evaluation of mirdametinib in a Phase 1b/2a platform study sponsored by Memorial Sloan Kettering Cancer Center and supported by SpringWorks to explore the compound both as a monotherapy and as a combination therapy in advanced solid tumors harboring MAPK-activating mutations. The trial, which initiated in the third quarter of 2021, is initially exploring mirdametinib in two patient cohorts: the first in combination with fulvestrant, a selective estrogen receptor degrader in patients with estrogen receptor-positive metastatic breast cancer with MAPK alterations (particularly inactivating mutations in NF1), and as a monotherapy in advanced solid tumors harboring oncogenic MEK1 or MEK2 mutations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our late-stage programs in rare oncology indications, we have expanded our portfolio to develop targeted therapies for the treatment of highly prevalent hematologic malignancies and genetically defined metastatic solid tumors. To advance this strategy, we are taking a precision medicine approach in collaboration with industry leaders. In hematologic malignancies, we have announced collaborations with GlaxoSmithKline, or GSK, Janssen Biotech, Inc., Pfizer, Allogene Therapeutics, Inc., Precision BioSciences, Inc., Seagen, Inc., AbbVie Inc and Regeneron Pharmaceuticals, Inc., or Regeneron, to develop novel combination regimens of nirogacestat alongside our collaborators&#8217; B-cell maturation antigen, or BCMA, directed therapies for the treatment of multiple myeloma. In October 2021, we announced an update from our ongoing clinical collaboration with GSK evaluating nirogacestat in combination with BLENREP (belantamab mafodotin-blmf) in patients with relapsed or refractory multiple myeloma, or RRMM; the initiation of an expanded Phase 2 cohort from the first combination dose level that evaluated 0.95 mg/kg dose of BLENREP every three weeks plus nirogacestat based on encouraging preliminary data observed in the Phase 1 cohort. We also announced the addition of two new sub-studies that will explore BLENREP plus nirogacestat in combination with (i) pomalidomide plus dexamethasone and (ii) lenalidomide plus dexamethasone in patients with RRMM. In addition to our industry collaborations with leading BCMA-directed therapy developers, we are working with the Fred Hutchinson Cancer Research Center and Dana-Farber Cancer Institute to further explore nirogacestat&#8217;s ability to potentiate BCMA-directed therapies as part of sponsored research agreements. In genetically defined metastatic solid tumors, our current efforts center on the mitogen activated protein kinase, or MAPK, pathway. In collaboration with BeiGene, Ltd., or BeiGene, we are exploring the combination of mirdametinib with BeiGene&#8217;s lifirafenib in RAS mutated and other MAPK aberrant cancers. In addition, we are exploring the use of BGB-3245 in a distinct set of genetically defined BRAF mutated tumors via MapKure, LLC, or MapKure, an entity jointly owned by us and BeiGene.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Together, we believe that our portfolio provides multiple opportunities for value creation across three distinct categories of oncology programs, each of which has the potential to provide meaningful clinical benefit to patients suffering from severe rare diseases and cancer. In our late-stage rare oncology programs, we believe that our two potentially registrational trials with nirogacestat and mirdametinib each have best-in-class potential for the patient populations in which they are being advanced. In our malignant hematology programs, we believe that nirogacestat has the potential to become a cornerstone of BCMA combination therapy in multiple myeloma and we are seeking to achieve this goal by working with partners developing BCMA-targeted agents across modalities. In our biomarker defined metastatic solid tumor programs, we believe that our precision medicine approach to cancers harboring mutations in key MAPK pathway genes, such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, provides the opportunity for meaningful clinical benefit for biomarker defined patient populations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we intend to continue to build our portfolio by licensing additional programs with strong biological rationales and validated mechanisms of action, such as the TEA Domain, or TEAD, inhibitor program that we in-licensed from Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology, and the portfolio of epidermal growth factor receptor small molecule inhibitors that we in-licensed from Dana-Farber Cancer Institute. We also plan to continue using shared-value partnerships to maximize the potential of our therapies to serve patients. We continue to invest in building leading preclinical development, clinical development and commercial capabilities and have focused on structuring innovative partnerships that seek to align incentives and optimize business outcomes for each party involved. We believe that this approach will continue to allow us to expand our shared-value relationships with innovators, maximize the potential of our existing and future portfolio, and support the building of a scalable and sustainable business focused on the efficient advancement and commercialization of product candidates that hold the potential to transform the lives of patients living with severe rare diseases and cancer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2022, we entered into a clinical trial collaboration and supply agreement with Regeneron to evaluate nirogacestat in combination with REGN5458, Regeneron&#8217;s investigational bispecific antibody targeting CD3 and BCMA, in patients with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">RRMM. Pursuant to the terms of the agreement, other than expenses related to the manufacturing and supply of nirogacestat and certain expenses related to intellectual property rights, Regeneron is responsible for the clinical development and will assume all costs associated with the study. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Impact</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2019, a novel strain of coronavirus, severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2, was identified in Wuhan, China. On March 11, 2020, the World Health Organization designated the outbreak of COVID-19, the disease associated with SARS-CoV-2, as a global pandemic. The disease continues to spread, including the recent acceleration of the spread of the Delta and Omicron variants of COVID-19 in the areas in which we operate. Governments and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including, but not limited to, shelter- in-place orders, quarantines, significant restrictions on travel, as well as restrictions that prohibit many employees from going to work. Since the onset of the COVID-19 pandemic, we have undertaken a number of business continuity measures to mitigate potential disruption to our operations and in order to preserve the integrity of our research and development programs. To date, we have not experienced any material disruptions to the execution of the research and development activities that we currently have underway; however, as a result of the pandemic, or any impacts of emerging variant strains of the COVID-19 virus, stagnant vaccination rates and related factors, we may experience disruptions that could impact our research and development timelines and outcomes. We will continue to evaluate the impact of the ongoing COVID-19 pandemic, along with the impact of emerging variants, on our business. While the extent to which COVID-19 impacts our future results will depend on future developments, including the duration, spread and intensity of the pandemic (including any resurgences), the impact of emerging variant strains of the COVID-19 virus and the rollout of COVID-19 vaccines, all of which remain uncertain and difficult to predict, it is possible that the global pandemic and its associated economic impacts could result in a material impact to our business, future financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our cash, cash equivalents and marketable securities balance as of March&#160;31, 2022, of $380.7 million, management estimates that its current liquidity position will enable it to meet operating expenses through at least twelve months after the date this Quarterly Report is filed. For further details on our liquidity position, see the "Results of Operations."</span></div><div id="i14026a47930f410d91f89b4244285b77_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of our results of operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated any commercial revenue from the sale of products. If our development efforts for our current product candidates or additional product candidates that we may develop in the future are successful and can be commercialized, we may generate revenue in the future from product sales. We may enter into collaboration and license agreements from time to time that provide for certain payments due to us. Accordingly, we may generate revenue from such collaboration or license agreements in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses consist of expenses incurred in connection with the development of our product candidates. These expenses include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, which include salaries, benefits and stock-based compensation for our research and development personnel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees paid to consultants for services directly related to our research and development programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with third-party contract research organizations, or CROs, investigative clinical trial sites, academic institutions and consultants that conduct research and development activities on our behalf or in collaboration with us;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with preclinical studies and clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with the manufacture of drug substance and finished drug product for preclinical testing and clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with technology and intellectual property licenses; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an allocated portion of facilities and facility-related costs, which include expenses for rent and other facility-related costs and other supplies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">External costs for research and development expenses are tracked on a program-by-program basis. Internal costs for research and development expenses, such as compensation-related costs for our research and development employees, as well as depreciation and other indirect costs, are not tracked on a program-by-program basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for clinical development, including upfront licensing fees and milestone payments associated with our product candidates, are charged to research and development expense as incurred. These expenses consist of expenses incurred in performing development activities, including salaries and benefits, materials and supplies, preclinical expenses, clinical trial and related clinical manufacturing expenses, depreciation of equipment, contract services and other outside expenses. Costs for certain development activities, such as manufacturing and clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using either time-based measures or data such as information provided to us by our vendors on actual activities completed or costs incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in activities related to developing our product candidates and our preclinical programs, and as certain product candidates advance into later stages of development, including our ongoing potentially registrational Phase 3 clinical trial for nirogacestat, or the DeFi trial, and our ongoing potentially registrational Phase 2b clinical trial for mirdametinib, or the ReNeu trial. The process of conducting the necessary clinical trials to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs, including stock-based compensation, for personnel in executive, finance, corporate, commercial, business development and administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax and administrative consulting services; insurance costs; administrative travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support the continued development of our product candidates and expand operations to support the organization.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest and other income</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income consists primarily of interest income. Interest income consists of interest earned on our cash, cash equivalents and available-for-sale marketable securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity investment loss</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The equity investment loss represents the Company&#8217;s share of the losses from the MapKure investment, which is accounted for using the equity method of accounting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i14026a47930f410d91f89b4244285b77_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the three months ended March&#160;31, 2022 and March&#160;31, 2021</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended March&#160;31, 2022 and March&#160;31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,469&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,756&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,713&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61,469)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,756)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,713)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest and other income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest and other income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investment loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(337)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61,801)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,787)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32,014)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense increased by $16.7 million to $34.1 million for the three months ended March&#160;31, 2022 from $17.4 million for the three months ended March&#160;31, 2021, an increase of 96%.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in research and development expense was primarily attributable to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a $10.5 million increase in internal costs driven by the growth in employee costs associated with increases in the number of personnel, including an increase in stock-based compensation expense, and a $5.4 million increase in external costs related to drug manufacturing and trial costs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense was $27.4 million for the three months ended March&#160;31, 2022, an increase of $15.0 million or 121% from $12.4 million for the three months ended March&#160;31, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in general and administrative expense wa</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s primarily attributable to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a $9.5 million increase in internal costs driven by the growth in employee costs associated with increases in the number of personnel, including an increase in stock-based compensation expense as we continued to expand our operations to support the organization, and a $4.1 million increase in professional fees, as we continue to build new capabilities, including commercial. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest and Other Income</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in interest and other income was driven by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a decrease in other income, net, for the three months ended March&#160;31, 2022 as compared to the three months ended March&#160;31, 2021. This decrease was attributable to $0.2 million in miscellaneous expenses for the three months ended March&#160;31, 2022.</span></div><div id="i14026a47930f410d91f89b4244285b77_79"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred operating losses and experienced negative operating cash flows since our inception and anticipate that we will continue to incur losses for at least the foreseeable future. Our net loss was $61.8 million and $29.8 million for the three months ended March&#160;31, 2022 and March&#160;31, 2021, respectively. We had an accumulated deficit of $354.3 million and $292.5 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively. Based on our cash, cash equivalents and marketable securities balances as of March&#160;31, 2022, management estimates that our liquidity position will enable it to meet operating expenses through at least twelve&#160;months after the date that this Quarterly Report is filed. Our marketable securities consist of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">high-quality, highly liquid available-for-sale debt securities including corporate debt securities, U.S. Government securities and commercial paper.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our cash flows for the three months ended March&#160;31, 2022 and March&#160;31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,688)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,104)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,918)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,003)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,663)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,526&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,523&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,991&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Cash Used in Operating Activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $48.7 million for the three months ended March&#160;31, 2022, which was driven by a net loss of $61.8 million and a net decrease from changes in operating assets and liabilities of $4.7 million, partially offset by stock-based compensation expense of $17.1 million, non-cash operating lease expense of $0.3 million and an equity investment loss of $0.3 million. Net cash used in operating activities was $21.1 million for the three months ended March&#160;31, 2021, driven by a net loss of $29.8 million, offset by stock-based compensation expense of $7.1 million, a net increase from changes in operating assets and liabilities of $1.0 million, non-cash operating lease expense of $0.3 million and an equity investment loss of $0.3 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Cash Provided by and Used in Investing Activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $26.4 million for the three months ended March&#160;31, 2022 and net cash used in investing activities was $30.9 million for the three months ended March&#160;31, 2021. Net cash provided by investing activities for the three months ended March&#160;31, 2022 related to the sale and maturities of available-for-sale debt securities of $52.1 million, partially offset by purchases of available-for-sale debt securities of $23.2 million and capital expenditures of $2.4 million. Net cash used in investing activities for the three months ended March&#160;31, 2021 was related to the purchase of available-for-sale debt securities of $86.4 million, and capital expenditures of $0.1 million, offset by the proceeds from the sale and maturity of available-for-sale debt securities of $55.5 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Cash Provided by Financing Activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the three months ended March&#160;31, 2022 consisted of proceeds from stock option exercises, partially offset by stock repurchased to satisfy employee tax withholding obligations on restricted stock releases. Net cash provided by financing activities for the three months ended March&#160;31, 2021 consisted of proceeds from stock option exercises. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary use of cash is to fund operating expenses, primarily our research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable, accrued expenses and prepaid expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements will depend on many factors, including the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, progress, timing, costs and results of preclinical studies and clinical trials for our product candidates, including the DeFi trial and the ReNeu trial;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical development plans we establish for our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of product candidates that we develop;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA, the European Medicines Agency, or EMA, and other comparable foreign regulatory authorities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms of our existing and any future license or collaboration agreements we may choose to enter into, including the amount of upfront, milestone and royalty obligations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the other costs associated with in-licensing new technologies, such as any increased costs of research and development and personnel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of completion of commercial-scale outsourced manufacturing activities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree of commercial success achieved following the successful completion of development and regulatory approval activities for a product candidate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need additional funds to meet operational needs and capital requirements for clinical trials, other research and development expenditures, commercial activities and business development efforts. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical studies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, current ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect rights of common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div id="i14026a47930f410d91f89b4244285b77_82"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we entered into a lease for our corporate headquarters in Stamford, CT. In January 2022, we amended this lease agreement to extend the lease term through April 2028, with two five-year renewal options or one ten-year renewal option. Pursuant to the amendment, we are entitled to $0.5 million in tenant allowances, which may be used to offset certain future capital expenditures, and the lease payments increase by 2.5% in each year commencing December 1, 2022. The amendment was treated as a modification and the lease liability and Operating lease right-of-use asset were updated to reflect minimum lease payments and any other adjustments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, future lease payments under non-cancelable leases with terms greater than one year are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.116%"><tr><td style="width:1.0%"></td><td style="width:74.629%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.442%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(874)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,865&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, there were no other material changes to our contractual obligations and commitments than those described under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Contractual Obligations&#8221; in Part II Item 6. of our 2021 Form 10-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into contracts in the normal course of business for clinical trials, preclinical studies, manufacturing and other services and products for operating purposes. These contracts generally provide for termination following a certain period after notice and therefore we believe that our non-cancelable obligations under these agreements are not material.</span></div><div id="i14026a47930f410d91f89b4244285b77_88"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This management&#8217;s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts and the related disclosures in the financial statements and accompanying notes. These accounting policies involve critical accounting estimates because they are particularly dependent on estimates and assumptions made by management about matters that are uncertain at the time the accounting estimates are made. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based compensation awards. We base our estimates on historical experience, known trends and other market-specific or relevant factors that we believe to be reasonable under the circumstances, the results of which form the basis of making judgments; However, because future events and their effects cannot be determined with certainty, actual results may differ from those estimates, judgments or assumptions, and such differences could be material. On an ongoing basis, we evaluate our estimates, judgments and assumptions, and adjust those estimates, judgments and assumptions when facts or circumstances change. Changes in estimates are recorded in the period in which they become known. Although we believe that these estimates are reasonable actual results could differ.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenditures for clinical development, including upfront licensing fees and milestone payments associated with products that have not yet been approved by the FDA, are charged to research and development expenses as incurred. These expenses consist of expenses incurred in performing development activities, including salaries and benefits, stock-based compensation expense, preclinical expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. Expenses incurred for certain research and development activities, including expenses associated with particular activities performed by CROs, investigative sites in connection with clinical trials and contract manufacturing organizations, are recognized based on an evaluation of the progress or completion of specific tasks using either time-based measures or data such as information provided to us by our vendors for actual activities completed or costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of expense recognition. Expenses for research and development activities incurred that have yet to be invoiced by the vendors that perform the related activities are reflected in the consolidated financial statements as accrued research and development expenses. Advance payments for goods or services to be received in the future for research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect our estimates to be materially different from amounts actually incurred. For the periods presented, we have experienced no material differences between amounts accrued and actual expenses.</span></div><div id="i14026a47930f410d91f89b4244285b77_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosure About Market Risk</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There were no material changes to our market risks from those described in Part II Item 7A. Quantitative and qualitative disclosures about market risk, of our 2021 Form 10-K.</span></div><div id="i14026a47930f410d91f89b4244285b77_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective at a reasonable assurance level in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms; and (ii)&#160;accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely discussions regarding required disclosure. We believe that a control system, no matter how well designed and operated, cannot provide </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i14026a47930f410d91f89b4244285b77_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. Other Information</span></div><div id="i14026a47930f410d91f89b4244285b77_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Legal Proceedings</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of the date of this Quarterly Report on Form 10-Q, we are not currently a party to any material legal proceedings. In the future, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. The outcome of litigation cannot be predicted with certainty and some lawsuits, claims or proceedings may be disposed of unfavorably to us, which could materially affect our financial condition or results of operations.</span></div><div id="i14026a47930f410d91f89b4244285b77_103"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Careful consideration should be given to the following risk factors, in addition to the other information set forth in this Quarterly Report on Form 10-Q and in other documents that we file with the Securities and Exchange Commission, or the SEC, in evaluating the Company and our business. Investing in our common stock involves a high degree of risk. If any of the following risks and uncertainties actually occurs, our business, prospects, financial condition and results of operations could be materially and adversely affected. The risks described below are not intended to be exhaustive and are not the only risks facing the Company. New risk factors can emerge from time to time, and it is not possible to predict the impact that any factor or combination of factors may have on our business, prospects, financial condition and results of operations. Those risk factors below denoted with an &#8220;*&#8221; are newly added or have been materially updated from our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 24, 2022.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of company-specific material risk factors</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have included a summary of the material risks that we believe are specific to SpringWorks. The summary does not include all material risks associated with our business and is not a conclusive ranking or prioritization of our risk factors. Further, placement of certain of these risks in the summary section as opposed to others does not constitute guidance that the risk factors included in the summary are the only material risks to consider when considering an investment in our securities. We believe that all risk factors presented in this Quarterly Report on Form 10-Q are important to an understanding of our company and should be given careful consideration. In addition, the summary of company-specific material risks does not include the appropriate level of detail necessary to fully understand these risks, and the corresponding risk factors that follow provide essential detail and context necessary to fully understand and appreciate these company-specific risks associated with our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks related to our research and development</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Our business is highly dependent on the success of our lead product candidates, nirogacestat and mirdametinib, as well as the other product candidates in our pipeline. If we are unable to successfully complete clinical development of, obtain regulatory approval for, or commercialize our product candidates, or if we experience delays in doing so, our business will be materially harmed.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">We were not involved in the early development of our lead product candidates or in the development of third-party agents being developed in combination with our product candidates; therefore, we are dependent on third parties having accurately generated, collected, interpreted and reported data from certain preclinical and clinical trials for our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">If our clinical trials fail to replicate positive results from earlier preclinical studies or clinical trials conducted by us or third parties, we may be unable to successfully develop, obtain regulatory approval for or commercialize our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Interim &#8220;topline&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more data become available, are not necessarily predictive of the final results of the completed study or the results of other ongoing or future studies and are subject to audit and verification procedures that could result in material changes. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">As an organization, we have never successfully completed any registrational clinical trials, and we may be unable to do so for any product candidates we may develop.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">We expect to develop nirogacestat and mirdametinib, and potentially future product candidates, in combination with other therapies, and safety or supply issues with combination use products may delay or prevent development and approval of such product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">If we encounter difficulties enrolling patients in any of our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">The target patient populations of nirogacestat for the treatment of desmoid tumors and mirdametinib for the treatment of NF1-PN are small and have not been definitively determined, and if our estimates of the number of treatable patients is lower than expected, our potential revenues from sales of our product candidates, if approved, and our ability to achieve profitability would be compromised.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks related to our reliance on third parties</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to conduct certain aspects of our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for, or commercialize, any potential product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Because we rely on third-party manufacturing and supply partners, our supply of preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Despite entering into a manufacturing and supply agreement, we have not yet manufactured on a commercial scale and expect to rely on third parties to produce and process commercial quantities of our product candidates, if approved.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">We are dependent on a small number of suppliers for some of the materials used to manufacture our product candidates, and on one company for the manufacture of the active pharmaceutical ingredient for each of our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Our existing and future collaborations will be important to our business. If we are unable to maintain our existing collaborations or enter into new collaborations, or if these collaborations are not successful, our business could be adversely affected. In addition, our collaborators have broad discretion in many aspects of their performance of collaboration activities and they may take actions with which we do not agree.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks related to our intellectual property</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on intellectual property licensed from third parties, including from Pfizer Inc., or Pfizer, for our lead product candidates, and termination of any of these licenses could result in the loss of significant rights, which would harm our business.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to comply with our obligations under our patent licenses with third parties, we could lose license rights that are important to our business.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks related to government regulation</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">We have been granted Orphan Drug Designation for nirogacestat and mirdametinib and may seek Orphan Drug Designation for other product candidates, but we may be unable to obtain or maintain such designation or the benefits associated with such designation, including the potential for market exclusivity, which may negatively impact our financial performance.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">A portion of our manufacturing of our lead product candidates takes place in China, with additional capacity sourced from India, through third-party manufacturers. A significant disruption in the operation of those manufacturers, a trade war or political unrest could materially adversely affect our business, financial condition and results of operations.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks related to managing our business and operations</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">We will need to grow the size of our organization, and we may experience difficulties in managing this growth.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">We have no history of commercializing marketed products and we have not yet implemented our commercialization operations. We are preparing for commercialization by investing significant time and money into building these capabilities. There can be no assurance that we will successfully set up our commercialization capabilities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">We currently do not have the internal research capabilities required to independently discover new product candidates, and we plan to execute our growth strategy in part by identifying and in-licensing or acquiring additional product candidates that have been discovered and initially developed by others. We may not be successful in executing our growth strategy or such growth strategy may not deliver the anticipated results.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Our current operations are concentrated in two locations, and we or the third parties upon whom we depend may be adversely affected by natural disasters, including those that may be related to climate change, or other unforeseeable or uncontrollable events and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.*</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks related to our financial position and need for additional capital</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant net losses since our inception and anticipate that we will incur net losses in the future.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">We have a limited operating history, which may make it difficult to evaluate our prospects and likelihood of success.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">We will require additional capital to fund our operations and if we fail to obtain necessary capital, we will not be able to complete the development and commercialization of our product candidates.*</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks related to our common stock</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Our bylaws designate certain specified courts as the sole and exclusive forums for certain disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Company-specific material risk factors</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our research and development</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is highly dependent on the success of our lead product candidates, nirogacestat and mirdametinib, as well as the other product candidates in our pipeline. If we are unable to successfully complete clinical development of, obtain regulatory approval for or commercialize our product candidates, or if we experience delays in doing so, our business will be materially harmed.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not yet completed any registrational clinical trials or the development of any product candidates. Our future success and ability to generate revenue from our product candidates, which we do not expect will occur for several years, if ever, is dependent on our ability to successfully develop, obtain regulatory approval for and commercialize one or more product candidates. In July 2020, we announced full enrollment in our potentially registrational Phase 3 clinical trial of nirogacestat and we announced the initiation of a potentially registrational Phase 2b clinical trial of mirdametinib in October 2019. If either of our lead product candidates encounter safety or efficacy problems, development delays or regulatory issues or other problems, including as a result of the ongoing COVID-19 pandemic, our development plans and business would be significantly harmed.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our other product candidates are in earlier stages of development and will require substantial additional investment for preclinical development, clinical development, regulatory review and approval in one or more jurisdictions.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have the financial resources to continue development of, or to modify existing or enter into new collaborations for, a product candidate if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, our product candidates, including:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to demonstrate to the satisfaction of the U.S. Food and Drug Administration, or FDA, or comparable foreign regulatory authorities that our product candidates are safe and effective;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">insufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative or inconclusive results from our preclinical studies, clinical trials or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical studies or clinical trials or abandon a program;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product-related adverse events experienced by subjects in our clinical trials or by individuals using drugs or therapeutic biologics similar to our product candidates;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in submitting an Investigational New Drug application, or IND, or comparable foreign applications, or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial or a suspension or termination of a clinical trial once commenced;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditions imposed by the FDA, the European Medicines Agency, or EMA, or comparable foreign regulatory authorities regarding the scope or design of our clinical trials;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">poor effectiveness of our product candidates during clinical trials;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">better than expected performance of control arms, such as placebo groups, which could lead to negative or inconclusive results from our clinical trials;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in enrolling subjects in clinical trials;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">high drop-out rates of subjects from clinical trials;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inadequate supply or quality of product candidates or other materials necessary for the conduct of our clinical trials;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">greater than anticipated clinical trial or manufacturing costs;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfavorable FDA, EMA or comparable regulatory authority inspection and review of a clinical trial site;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our therapies in particular; or</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">varying interpretations of data by the FDA, EMA and comparable foreign regulatory authorities.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We were not involved in the early development of our lead product candidates or in the development of third-party agents being developed in combination with our product candidates; therefore, we are dependent on third parties having accurately generated, collected, interpreted and reported data from certain preclinical and clinical trials for our product candidates.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no involvement with or control over the initial preclinical and clinical development of any of our lead product candidates or third-party agents being developed in combination with our product candidates. We are dependent on third parties having conducted their research and development in accordance with the applicable protocols and legal, regulatory and scientific standards; having accurately reported the results of all preclinical studies and clinical trials conducted with respect to such product candidates; and having correctly collected and interpreted the data from these trials. If these activities were not compliant, accurate or correct, the clinical development, regulatory approval or commercialization of our product candidates will be adversely affected.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our clinical trials fail to replicate positive results from earlier preclinical studies or clinical trials conducted by us or third parties, we may be unable to successfully develop, obtain regulatory approval for or commercialize our product candidates.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our preclinical studies or early clinical trials of our product candidates, whether conducted by us or third parties, may not necessarily be predictive of the results of later clinical trials that we conduct. Similarly, even if we are able to complete our planned clinical trials of our product candidates, positive results from such clinical trials may not be replicated in our subsequent preclinical studies or clinical trials.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. For example, we are conducting non-clinical and clinical absorption, distribution, metabolism and excretion, or ADME, studies for mirdametinib, and we cannot predict whether findings from these ADME studies will adversely affect our development plans for our product candidates. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA, EMA or comparable foreign regulatory authority approval. Furthermore, the approval policies or regulations of the FDA, EMA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval, which may lead to the FDA, EMA or comparable foreign regulatory authorities delaying, limiting or denying approval of our product candidates.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim &#8220;topline&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more data become available, are not necessarily predictive of the final results of the completed study or the results of other ongoing or future studies and are subject to audit and verification procedures that could result in material changes. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, we may publicly disclose interim topline or preliminary data from our clinical trials, such as the interim data updates from adult patients in the ReNeu trial, our Phase 2b clinical trial of mirdametinib, announced in February 2021 and June 2021. These interim updates are based on a preliminary analysis of then-available data, and the data and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, any topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. For example, our interim data from the ReNeu trial reflected results from the first adult patients enrolled in the trial, but we have not yet reported final data from this trial across all patients, and those results may materially differ from our data in adults. Interim topline or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim topline or preliminary data should be viewed with caution until the final data are available. In addition, we may report interim analyses of only certain endpoints rather than all endpoints. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and more patient data become available. As a result, interim data may not be predictive of the final results of the same study or the results of ongoing or future studies. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of available information. You or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or our business. If the interim topline or preliminary data that we report differ from late, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, the product candidate being studied or any of our other product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As an organization, we have never successfully completed any registrational clinical trials, and we may be unable to do so for any product candidates we may develop.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to successfully complete registrational clinical trials in order to obtain the approval of the FDA, EMA or comparable foreign regulatory authorities to market any product candidates. Carrying out clinical trials, including later-stage registrational clinical trials, is a complicated process. As an organization, we have not previously completed any registrational clinical trials. In order to do so, we will need to build and expand our clinical development and regulatory capabilities, and we may be unable to recruit and train qualified personnel. We also expect to continue to rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval of or commercialize any potential product candidates. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to a New Drug Application, or NDA, submission and approval of our product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approval of any product candidates that we develop. Failure to commence or complete, or delays in, our planned clinical trials, could prevent us from or delay us in commercializing our product candidates.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to develop nirogacestat and mirdametinib, and potentially future product candidates, in combination with other therapies, and safety or supply issues with combination use products may delay or prevent development and approval of such product candidates.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to develop nirogacestat and mirdametinib, and likely other future product candidates, in combination with one or more other approved or unapproved rational therapies to treat cancer or other diseases. For example, we are currently evaluating mirdametinib in combination with lifirafenib, BeiGene Ltd.&#8217;s, or BeiGene's, RAF dimer inhibitor, and nirogacestat in combination with eight BCMA-directed therapies across modalities through our collaborations with industry leaders developing such therapies.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will not be able to market and sell nirogacestat, mirdametinib or any product candidate we develop in combination with an unapproved cancer therapy for a combination indication if that unapproved cancer therapy does not ultimately obtain marketing approval either alone or in combination with our product. In addition, unapproved cancer therapies face the same risks described with respect to our product candidates currently in development and clinical trials, including the potential for serious adverse effects, delay in their clinical trials and lack of FDA approval. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA, EMA or comparable foreign regulatory authorities outside of the United States, or U.S., could revoke approval of the therapy used in combination with our product or that safety, efficacy, manufacturing or supply issues could arise with any of those existing therapies. If the therapies we use in combination with our product candidates are replaced as the standard of care for the indications we choose for any of our product candidates, the FDA, EMA or comparable foreign regulatory authorities may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA, EMA or comparable foreign regulatory authorities do not approve these other drugs or revoke their approval of, or if safety, efficacy, quality, manufacturing or supply issues arise with, the drugs we choose to evaluate in combination with our product candidate we develop, we may be unable to obtain approval of or market such combination therapy.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we encounter difficulties enrolling patients in any of our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient eligibility and exclusion criteria defined in the protocol;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the patient population required for analysis of the clinical trial&#8217;s primary endpoints;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in our research programs or clinical supply chain resulting from factors related to the COVID-19 pandemic;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proximity of patients to clinical trial sites;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the design of the clinical trial;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience, and the ability of these investigators to identify and enroll suitable patients;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perception of the safety profile of our product candidates;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain patient consents; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that patients enrolled in clinical trials will drop out of the trials before completion.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we are developing nirogacestat for the treatment of desmoid tumors and mirdametinib for the treatment of NF1-PN, both of which are rare diseases with small patient populations. As a result, although we have completed enrollment in our DeFi and ReNeu trials, we may encounter difficulties enrolling subjects in other clinical trials for these product candidates due, in part, to the small size of these patient populations. In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a clinical trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site. In addition, in the case of mirdametinib, we may face difficulty with enrollment due to physician or patient perception of an adverse tolerability profile.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The target patient populations of nirogacestat for the treatment of desmoid tumors and mirdametinib for the treatment of NF1-PN are small and have not been definitively determined, and if our estimates of the number of treatable patients is lower than expected, our potential revenues from sales of our product candidates, if approved, and our ability to achieve profitability would be compromised.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of both the number of patients who have the diseases we are targeting, as well as the subset of patients with these diseases in a position to receive our product candidates, if approved, are based on our beliefs and estimates, and these estimates may prove to be incorrect. These estimates have been derived from a variety of sources, including scientific literature, input from physicians that treat patients with the diseases we are targeting, patient foundations and secondary market research databases. Further, new studies may change the estimated incidence or prevalence of these diseases, and any regulatory approvals that we may receive for a product candidate may include limitations for use or contraindications that decrease the addressable patient population. Accordingly, the target patient populations may turn out to be lower than expected, in which case the potential revenues from sales of our product candidates, if approved, would be lower than expected.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our reliance on third parties</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct certain aspects of our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for, or commercialize, any potential product candidates.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend upon third parties to conduct certain aspects of our preclinical studies and depend on third parties, including independent investigators, to conduct our clinical trials, under agreements with universities, medical institutions, contract research organizations, or CROs, strategic partners and others. We expect to negotiate budgets and contracts with such third parties, which may result in delays to our development timelines and increased costs.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commenced operations in August 2017 and we continue to build our infrastructure and hire personnel necessary to execute our operational plans. We rely especially heavily on third parties over the course of our clinical trials, and, as a result, may have limited control over the clinical investigators and limited visibility into their day-to-day activities, including with respect to their compliance with the approved clinical protocol. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with good clinical practice, or GCP, requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of clinical trial sponsors, clinical investigators and clinical trial sites. If we or any of these third parties fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to suspend or terminate these trials or perform additional preclinical studies or clinical trials before approving our marketing applications. We cannot be certain that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with GCP requirements. In addition, our clinical trials must be conducted with product produced under current good manufacturing practice, or cGMP, requirements and may require a large number of patients.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure or any failure by these third parties to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be adversely affected if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any third parties conducting aspects of our preclinical studies or our clinical trials will not be our employees and, except for remedies that may be available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our preclinical studies and clinical programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the preclinical or clinical data they obtain is compromised due to the failure to adhere to our protocols or regulatory requirements or for other reasons, our development timelines, including clinical development timelines, may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed or precluded entirely.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with these third-party CROs or others terminate, we may not be able to enter into arrangements with alternative CROs or other third parties or to do so on commercially reasonable terms.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Switching or adding additional CROs involves additional cost and requires management&#8217;s time and focus. In addition, there is a natural transition period when a new CRO begins work. As a result, delays may occur, which can materially impact our ability to meet our desired development timelines. The&#160;ongoing COVID-19&#160;global pandemic and government measures taken in response have also had a significant impact on our CROs, and we expect that they may face further disruption in light of resurgences of COVID-19 and emerging variant strains thereof, stagnant vaccination rates and related factors, which may affect our ability to initiate and complete our pre-clinical studies and clinical trials. Though we carefully manage our relationships with our CROs, investigators and other third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we rely on third-party manufacturing and supply partners, our supply of preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party contract manufacturers to manufacture all of our preclinical and clinical trial product supplies. We do not own manufacturing facilities for producing any product supplies. There can be no assurance that our preclinical and clinical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development product supplies will not be limited, interrupted, of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for a product candidate is subject to FDA, EMA and comparable foreign regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMPs. In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In either scenario, our clinical trials supply could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills or technology to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget. Furthermore, a manufacturer may possess technology related to the manufacture of our product candidate that such manufacturer owns independently. This would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another manufacturer manufacture our product candidates. In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our or a third party&#8217;s failure to execute on our manufacturing requirements and comply with cGMP could adversely affect our business in a number of ways, including:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an inability to initiate or continue clinical trials of product candidates under development;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of the cooperation of an existing or future collaborator;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subjecting third-party manufacturing facilities to additional inspections by regulatory authorities;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements to cease distribution or to recall batches of our product candidates; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, we contract with packaging providers with the appropriate expertise, facilities and scale to meet our needs. Failure to maintain cGMP can result in a contractor receiving FDA sanctions, which can impact our ability to operate or lead to delays in any clinical development programs. We believe that our current packaging contractors operate in accordance with cGMP, but we can give no assurance that FDA, EMA or comparable foreign regulatory authorities will not conclude that a lack of compliance exists. In addition, any delay in contracting for packaging services, or failure of the contract manufacturer to perform the services as needed, may delay any clinical trials, registration and launches, which could negatively affect our business. The extent to which the ongoing COVID-19 pandemic impacts our ability to procure our preclinical and clinical trial product supplies will depend on the severity and duration of the spread of the virus (along with emergent variant strains thereof and stagnant vaccination rates) and the actions undertaken to contain COVID-19 or treat its effects, and may cause delays. If our current third-party contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or at all. Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates and any drugs that we may develop may compete with other product candidates and drugs for access to manufacturing facilities. There are no assurances we would be able to enter into similar commercial arrangements with other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Despite entering into a manufacturing and supply agreement, we have not yet manufactured on a commercial scale and expect to rely on third parties to produce and process commercial quantities of our product candidates, if approved.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to rely on third-party manufacturers if we receive regulatory approval for our product candidates. While we have entered into a manufacturing and supply agreement for the commercial supply of finished nirogacestat product, we have not yet entered into other third party supply arrangements, including for the supply of active pharmaceutical ingredients. To the extent that we enter into future manufacturing arrangements with third parties for commercial supply of our product candidates, if approved, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA, EMA or comparable foreign regulatory authorities following inspections that will be conducted after we submit an application to the FDA, EMA or comparable foreign regulatory authorities. We do not directly control the manufacturing process of, and will be completely dependent on, our contract manufacturing partners for compliance with cGMP requirements for the manufacture of our product candidates. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, EMA or comparable foreign regulatory authorities, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no direct control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, EMA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on a small number of suppliers for some of the materials used to manufacture our product candidates, and on one company for the manufacture of the active pharmaceutical ingredient for each of our product candidates.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently depend on a small number of suppliers for some of the materials used in, and processes required to develop, our product candidates. We cannot ensure that these suppliers or service providers will remain in business or have sufficient capacity or supply to meet our needs, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of a small number of suppliers exposes us to several risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute materials. Our current vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Finding suitable replacement suppliers, materials and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption or delay in supply could compromise our ability to pursue development and eventual commercialization of our product candidates.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing and future collaborations will be important to our business. If we are unable to maintain our existing collaborations or enter into new collaborations, or if these collaborations are not successful, our business could be adversely affected. In addition, our collaborators have broad discretion in many aspects of their performance of collaboration activities and they may take actions with which we do not agree.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An important part of our strategy is to evaluate and, as deemed appropriate, extend our current, or enter into additional, partnerships in the future, including potentially with major biopharmaceutical companies. We have limited capabilities for product development and are currently in the process of building our preclinical research and development and commercial capabilities. Accordingly, we have entered into collaborations with other companies to provide us with important technologies in order to more fully develop our product candidates and we may enter into collaborations with other companies to provide us with important technologies or funding for our programs.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any current or future collaborations we may extend or enter into may pose a number of risks, including the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not perform their obligations as expected;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs or license arrangements </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as a strategic transaction that may divert resources or create competing priorities;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products and product candidates if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for collaborations involving combination therapies that have not yet been tested together, treatment-emergent adverse events may be unforeseen and may negatively impact the monotherapy development of our product candidates;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a product candidate or product;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated by the collaborator, and, if terminated, we could lose license rights to the applicable product candidates or could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration agreement with BeiGene, the combination of mirdametinib and lifirafenib is being evaluated in a Phase 1b/2 clinical trial. Additionally, under our eight collaboration agreements with industry leading BCMA-directed therapy developers, the combination of nirogacestat and the BCMA-directed therapy of each such developer is being evaluated in relapsed or refractory multiple myeloma patients. Under these existing collaboration arrangements, upon completion of the relevant clinical trials, we and our collaboration partners will have the opportunity to negotiate in good faith to provide for the expansion of the respective clinical collaboration and the potential establishment of a commercial relationship. However, our partners have no obligation to continue development of the combination products, regardless of the applicable clinical trial results. We also jointly formed MapKure LLC., or MapKure, with BeiGene for the development of BGB-3245, and although we contribute to clinical development and other operational activities and have representation on MapKure&#8217;s board of directors and joint steering committee, we do not control the development process. MapKure may pursue a development plan that differs from our expectations, which may or may not be successful.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our collaborations do not result in the successful discovery, development and commercialization of product candidates or if one of our collaborators elects not to enter into collaboration agreements to pursue future development, we may not receive any future funding or milestone or royalty payments under such collaborations. Risks relating to product development, regulatory approval and commercialization described in this report may also apply to the activities of our collaborators.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities could be adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we face significant competition in seeking appropriate partners for our product candidates and the negotiation process is time-consuming and complex. In order for us to successfully partner our product candidates, potential partners must view our product candidates as economically valuable in markets they determine to be attractive in light of the terms that we are seeking and other available products for licensing by other companies. In addition, there have been a significant number of recent business combinations among large biopharmaceutical companies that have resulted in a reduced number of potential future collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities or planning, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional expertise or capital, which may not be available to us on acceptable terms, or at all. If we fail to enter into collaborations or do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates, bring them to market and generate revenue from sales of drugs or continue to develop our technology, and our business may be materially and adversely affected. Even if we are successful in our efforts to establish new strategic partnerships, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such strategic partnerships if, for example, development or approval of a product candidate is delayed or sales of an approved product are disappointing. Any delay in entering into new strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates and reduce their competitiveness even if they reach the market.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our intellectual property</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on intellectual property licensed from third parties, including from Pfizer for our lead product candidates, and termination of any of these licenses could result in the loss of significant rights, which would harm our business.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on patents, know-how and proprietary technology, both our own and licensed from others. All patents covering nirogacestat and mirdametinib and any combination therapies using our product candidates are licensed from third parties. Any termination of a product license could result in the loss of significant rights and would cause material adverse harm to our ability to commercialize our product candidates.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations with respect to the use of licensed technology in relation to our development and commercialization of our product candidates and what activities satisfy those diligence obligations; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are generally also subject to all of the same risks with respect to protection of intellectual property that we own, as we are for intellectual property that we license, which are described below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could materially suffer.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under our patent licenses with third parties, we could lose license rights that are important to our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to license agreements pursuant to which we in-license key patents for our product candidates. At the time we began our operations in August 2017, we entered into four license agreements with Pfizer, three of which remain in effect, including a license agreement for each of our lead product candidates, nirogacestat and mirdametinib, both of which agreements were amended and restated in 2019. Each of our existing licenses imposes various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, our licensors may have the right to terminate the license, in which event we would not be able to develop or market the products covered by such licensed intellectual property. While we assigned the Pfizer license agreement covering our FAAH inhibitor program in connection with the sale of that program to Jazz Pharmaceuticals Ireland Limited, or Jazz, in October 2020, there can be no assurance that Jazz will comply with the terms of such license, which could result in its termination and our inability to recover that asset as a remedy for a potential material breach of Jazz&#8217;s obligations to us in connection with such sale.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may have limited control over the maintenance and prosecution of these in-licensed rights, activities or any other intellectual property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such activities by these licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. We have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights or defend certain of the intellectual property that is licensed to us. It is possible that the licensors&#8217; infringement proceeding or defense activities may be less vigorous than they would have been had we conducted them ourselves.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to government regulation</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have been granted Orphan Drug Designation for nirogacestat and mirdametinib and may seek Orphan Drug Designation for other product candidates, but we may be unable to obtain or maintain such designation or the benefits associated with such designation, including the potential for market exclusivity, which may negatively impact our financial performance.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Regulatory authorities in some jurisdictions, including the U.S. and Europe, may designate drugs and therapeutic biologics for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug or therapeutic biologic as an orphan drug if it is a drug or therapeutic biologic intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the U.S., or a patient population greater than 200,000 in the U.S. where there is no reasonable expectation that the cost of developing the drug or therapeutic biologic will be recovered from sales in the U.S. In the U.S., Orphan Drug Designation entitles a party to financial incentives such as opportunities for grant funding toward clinical trial costs, tax advantages and user-fee waivers. Such a designation, however, may be revoked by the FDA in certain circumstances, such as if the agency finds that the applicant&#8217;s request for designation request omitted material information required under the Orphan Drug Act and its implementing regulations. If a product that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full NDA, or Biologics License Application, or BLA, to market the same product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the FDA granted Orphan Drug Designation to nirogacestat for the treatment of desmoid tumors and in September 2019, the European Commission granted nirogacestat Orphan Drug Designation for the treatment of soft tissue sarcoma. In October 2018, the FDA granted Orphan Drug Designation to mirdametinib for the treatment of NF1 and in July 2019 the European Commission granted mirdametinib Orphan Drug Designation for the treatment of NF1. We may seek Orphan Drug Designations for nirogacestat and mirdametinib for other indications or for our other product candidates. There can be no assurances that we will be able to obtain such designations.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain Orphan Drug Designation for any of our future product candidates in specific indications, we may not be the first to obtain marketing approval of nirogacestat, mirdametinib or any other such product candidates for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing rights in the U.S. may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, even if we obtain orphan drug exclusivity in the U.S. for a product, that exclusivity may not effectively protect the product from competition because different drugs or therapeutic biologics with different active moieties can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same drug or therapeutic biologic with the same active moiety for the same condition if the FDA concludes that the later drug or therapeutic biologic is </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">safer, more effective or makes a major contribution to patient care. In Europe, we could be prevented from marketing our products if a similar medicinal product is granted Orphan Drug Designation for the same indications that we are pursuing. Once authorized, with a limited number of exceptions, neither the competent authorities of the EU member states, the EMA or the European Commission are permitted to accept applications or grant marketing authorization for other similar medicinal products with the same therapeutic indication. Marketing authorization could also be granted to a similar medicinal product with the same orphan indication if the latter product is safer, more effective or otherwise clinically superior to the original orphan medicinal product.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. composition of matter patents covering the chemical structure of nirogacestat expires in 2025 and three U.S. composition of matter patents that cover the polymorphic form of nirogacestat that is currently in clinical development expire in 2039. Two U.S. patents covering several polymorphic forms of mirdametinib, including the polymorphic form that is currently in clinical development, expire in 2041. Notwithstanding expected patent life, if orphan drug exclusivity does not protect these products from competition, our business and financial condition could be materially adversely affected. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug or therapeutic biologic nor gives the drug or therapeutic biologic any advantage in the regulatory review or approval process. In addition, while we may seek Orphan Drug Designation for our future product candidates, we may never receive such designations.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A portion of our manufacturing of our lead product candidates takes place in China, with additional capacity sourced from India, through third-party manufacturers. A significant disruption in the operation of those manufacturers, a trade war or political unrest could materially adversely affect our business, financial condition and results of operations.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently contract manufacturing operations to third parties, and clinical quantities of our lead product candidates are manufactured by these third parties outside the U.S., including in China, with additional capacity sourced from India. We expect to continue to use such third-party manufacturers for such product candidates. Any disruption in production or inability of our manufacturers in those countries to produce adequate quantities to meet our needs, whether as a result of a natural disaster or other causes, could impair our ability to operate our business on a day-to-day basis and to continue our development of our product candidates. Furthermore, since certain of these manufacturers are located in China, we are exposed to the possibility of product supply disruption and increased costs in the event of changes in the policies of the U.S. or Chinese governments, political unrest or unstable economic conditions in China. For example, a trade war could lead to tariffs on the chemical intermediates we use that are manufactured in China. Any of these matters could materially and adversely affect our business and results of operations. Any recall of the manufacturing lots or similar action regarding our product candidates used in clinical trials could delay the trials or detract from the integrity of the trial data and its potential use in future regulatory filings. In addition, manufacturing interruptions or failure to comply with regulatory requirements by any of these manufacturers could significantly delay clinical development of potential products and reduce third-party or clinical researcher interest and support of proposed trials. These interruptions or failures could also impede commercialization of our product candidates and impair our competitive position. Further, we may be exposed to fluctuations in the value of the local currencies in China and India. Future appreciation of the local currencies could increase our costs. In addition, our labor costs could continue to rise as wage rates increase due to increased demand for skilled laborers and the availability of skilled labor declines in such countries.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to managing our business and operations</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to grow the size of our organization, and we may experience difficulties in managing this growth.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had 190 full-time employees. As our clinical development and commercialization plans and strategies develop, we expect we will need additional managerial, clinical, manufacturing, medical, regulatory, sales, marketing, financial, legal and other personnel. Future growth would impose significant added responsibilities on members of management, including:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recruiting, integrating, retaining and motivating additional employees;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">managing our development efforts effectively, including the clinical, manufacturing and quality review process for our product candidates, while complying with our contractual obligations to contractors, collaboration partners and other third parties; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">improving our operational, financial and management controls, reporting systems and procedures.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to commercialize our product candidates, if approved, will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely, and for the foreseeable future will continue to rely, in substantial part on third parties, including independent organizations, advisors and consultants, to provide certain services to support and perform our operations. There can be no assurance that the services of these third parties will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality, accuracy or quantity of the services provided is compromised for any reason, our clinical trials may be delayed or terminated, and we may not be able to obtain, or may be substantially delayed in obtaining, regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other suitable outside contractors and consultants on economically reasonable terms, or at all.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully execute the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our development and commercialization goals.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have no history of commercializing marketed products and we have not yet implemented our commercialization operations. We are preparing for commercialization by investing significant time and money into building these capabilities. There can be no assurance that we will successfully set up our commercialization capabilities.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently in the early stages of building our commercial capabilities to allow us to market our product candidates, if approved, either alone or in combination with others. Establishing commercialization capabilities will require substantial investment of time and money and may divert significant management focus and resources. In addition, we will be competing with larger biopharmaceutical and biotechnology companies with established commercialization and marketing capabilities as we seek to recruit suitable personnel. Accordingly, there can be no assurance that our efforts to set up commercialization capabilities will be successful.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently do not have the internal research capabilities required to independently discover new product candidates, and we plan to execute our growth strategy in part by identifying and in-licensing or acquiring additional product candidates that have been discovered and initially developed by others. We may not be successful in executing our growth strategy or such growth strategy may not deliver the anticipated results.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we are currently building out internal discovery and preclinical research and development capabilities, there can be no assurance that we will successfully achieve the capacity to independently discover and initially develop new product candidates. We also plan to source new product candidates, including those that may be complementary to our existing product candidates, by in-licensing or acquiring them from other companies, academic institutions or other asset originators. If we are unable to identify, in-license or acquire and integrate product candidates, our ability to pursue our growth strategy would be limited.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research programs and business development efforts to identify new product candidates require substantial technical, financial and human resources, and we currently have limited internal drug discovery and preclinical research and development capabilities. In-licensing and acquiring product candidates or development programs often requires significant payments and expenses and may consume valuable resources. We will need to devote a substantial amount of time and personnel to develop and commercialize any in-licensed or acquired technology or product candidate, in addition to doing so for our existing product candidates. Our business development efforts or acquisition or licensing attempts may fail to yield additional complementary or successful product candidates for clinical development and commercialization for a number of reasons, including the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our identification or business development methodology or search criteria and process may be unsuccessful in identifying potential product candidates with a high probability of success for development progression;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able or willing to assemble sufficient resources or expertise to identify and in-license or acquire additional product candidates;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for product candidates we seek to in-license or acquire, we may not be able to agree to acceptable terms with the licensor or owner of those product candidates;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any product candidates that we do in-license or acquire may not succeed in preclinical studies or clinical trials;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not succeed in formulation or process development of such in-licensed or acquired product candidates;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such in-licensed or acquired product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unlikely to receive regulatory approval or be unmarketable if approved;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitors may develop alternatives that render such in-licensed product candidates obsolete or less attractive;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-licensed or acquired product candidates may be covered by third parties&#8217; patents or other exclusive rights that we may not be able to access;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-licensed or acquired product candidates that we develop may not allow us to best make use of our expertise and our development and commercial infrastructure as currently expected;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the market for a product candidate that we in-license or acquire may change during the course of our development of the product candidate so that such product candidate may become unreasonable to continue to develop;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate that we in-license or acquire may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate that we in-license or acquire may not be accepted as safe and effective by patients, the medical community or third-party payors.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, we may not be successful in executing our growth strategy or our growth strategy may not deliver the anticipated results.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current operations are concentrated in two locations, and we or the third parties upon whom we depend may be adversely affected by natural disasters or other unforeseeable or uncontrollable events and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current headquarters are located in Stamford, Connecticut. Our development operations are currently located in Durham, North Carolina. We currently outsource our manufacturing operations to third parties, and clinical quantities of our product candidates are manufactured by these third parties outside the U.S., including in Canada, China, France and India. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other natural or man-made accidents or incidents that result in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss of access to these facilities may result in increased costs, delays in the development of our product candidates or interruption of our business operations. Earthquakes or other natural disasters could further disrupt our operations and have a material and adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters or our development operations, that damaged critical infrastructure, such as the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. Disaster recovery and business continuity plans may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. As part of our risk management approach, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our financial position and need for additional capital</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant net losses since our inception and anticipate that we will continue to incur net losses in the future.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant net losses in each reporting period since our inception. To date, we have financed our operations principally through equity financings. We have derived all of our revenue from the nonrefundable upfront payment we received </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the Jazz asset purchase and license agreement and we do not have any products approved for commercial sale or sources of recurring revenue. If our product candidates are not successfully developed and approved, we may never generate any revenue from them. We continue to incur significant research and development and other expenses related to our ongoing operations. As a result, we are not profitable and have incurred losses in each annual period since our inception. Our net losses were $61.8 million and $29.8 million for the three months ended March&#160;31, 2022 and March&#160;31, 2021, respectively. As of March&#160;31, 2022 and December&#160;31, 2021, we had an accumulated deficit of $354.3 and $292.5, respectively. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, seek regulatory approvals for, and prepare for commercialization of, our product candidates, including our lead product candidates, nirogacestat and mirdametinib, and any future product candidates.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our expenses will increase substantially if, and as, we:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance the development of our lead product candidates, nirogacestat and mirdametinib, through potentially registrational clinical trials and potentially for other indications;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance our development programs for our other product candidates through clinical development and into later-stage clinical development;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approvals for any product candidates that successfully complete clinical trials;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">invest in or in-license other technologies or product candidates for further preclinical and clinical development;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional personnel, including clinical, quality control, scientific, medical, business development and finance personnel, and continue to build our infrastructure;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or jointly with third parties.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable, we or any potential future collaborators must develop and eventually commercialize products with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials, obtaining marketing approval for product candidates, manufacturing, obtaining reimbursement approval, marketing and selling products for which we may obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause stockholders to lose all or part of their investment. Market volatility resulting from the COVID-19 pandemic or other factors could also adversely impact our ability to access capital as and when needed.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop, register and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history, which may make it difficult to evaluate our prospects and likelihood of success.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company with a limited operating history. We were formed in August 2017 and our operations to date have been focused on preparing and executing our clinical trials for our product candidates, building our infrastructure, raising capital and executing partnerships. Consequently, we have limited operations upon which to evaluate our business, and predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing drug products. Investment in biopharmaceutical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate activity or an acceptable safety profile, gain regulatory approval, secure market access and reimbursement and become commercially viable.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we announced the full enrollment of the DeFi trial, a potentially registrational Phase 3 clinical trial of nirogacestat, in July 2020, and in November 2021 announced full enrollment in the ReNeu trial, a potentially registrational Phase 2b clinical trial of mirdametinib, we have not yet demonstrated the ability to successfully complete clinical trials for any product candidate, we have no products approved for commercial sale and we have not generated any revenue from product sales to date. In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields, or other known or unknown factors and risks that may be infrequent or unique.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are building out commercialization capabilities in order to transition from a company with a development focus to a company capable of supporting commercial activities and may not be successful in such a transition.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require additional capital to fund our operations and if we fail to obtain necessary capital, we will not be able to complete the development and commercialization of our product candidates.*</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts of cash to conduct further research and development and clinical trials of our product candidates to seek regulatory approvals for our product candidates and to launch and commercialize any products for which we receive regulatory approval. As of March&#160;31, 2022, we had $380.7 million in cash, cash equivalents and marketable securities. Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements through at least 12 months after the date this Quarterly Report is filed. However, our future capital requirements and the period for which our existing resources will support our operations may vary significantly from what we expect, and we will in any event require additional capital in order to complete clinical development and obtain regulatory approval of our product candidates. Our monthly spending levels will vary based on new and ongoing development and corporate activities. Because the length of time and activities associated with development of our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, progress, timing, costs and results of clinical trials for our product candidates; including any unforeseen costs we may incur as a result of clinical trial delays due to the ongoing COVID-19 pandemic, the Russia and Ukraine conflict, or other causes;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical and preclinical development and manufacturing plans we establish for these product candidates;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of product candidates that we develop or in-license;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of identifying and evaluating potential product candidates for acquisition or license, including the cost of preclinical activities or clinical activities;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms of any collaboration or licensing agreements we may choose to enter into;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA, the EMA, and other comparable foreign regulatory authorities;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of completion of commercial-scale outsourced manufacturing activities;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the establishment of sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own or jointly with third parties; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree of commercial success achieved following the successful completion of development and regulatory approval activities for a product candidate.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we successfully completed a follow-on public offering in October 2020 in which we raised approximately $269.5 million, net of expenses, if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates or one or more of our other research and development initiatives. Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any committed external source of funds or other support for our development efforts and we cannot be certain that additional funding will be available on acceptable terms, or at all. Until we can generate sufficient product or royalty revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. If we raise additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. Further, to the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, existing stockholder ownership interest may be diluted. In addition, any debt financing may subject us to fixed payment obligations and covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. We also could be required to seek commercial or development partners for our lead products or any future product candidate at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or technologies that we otherwise would seek to develop or commercialize ourselves.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our common stock</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Furthermore, future debt or other financing arrangements may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Any return to stockholders will therefore be limited to the appreciation of their stock.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers, directors and their affilia</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">te</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s and holders of more than 5% of our common stock beneficially hold, in the aggregate, as of March&#160;31, 2022, approximately 55.2% of our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding voting stock. Therefore, these stockholders will have the ability to influence us through this ownership po</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sition. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that stockholders may feel are in their best interest as one of our stockholders.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation, or the certificate of incorporation, and amended and restated bylaws, as further amended, or the bylaws, contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement that special meetings of stockholders be called only by the chairman of the board of directors, the chief executive officer or by a majority of the total number of authorized directors;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and the authority of the board of directors to issue convertible preferred stock on terms determined by the board of directors without stockholder approval and which convertible preferred stock may include rights superior to the rights of the holders of common stock.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our certificate of incorporation and bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors of their choosing or cause us to take other corporate actions they desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our bylaws designate certain specified courts as the sole and exclusive forums for certain disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware, or the Chancery Court, will be the sole and exclusive forum for state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (iii) any action asserting a claim pursuant to any provision of the General Corporation Law of the State of Delaware, our certificate of incorporation or our bylaws, (iv) any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws, or (v) any action asserting a claim governed by the internal affairs doctrine, or the Delaware Forum Provision. The Delaware Forum Provision does not apply to any causes of action arising under the Securities Act of 1933, as amended, or the Securities Act, or the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our bylaws further provide that, unless we consent in writing to the selection of an alternative forum, the U.S. District Court for the District of Connecticut will be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act or the Federal Forum Provision. Our bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to the foregoing Delaware Forum Provision and the Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Delaware Forum Provision and the Federal Forum Provision may impose additional litigation costs on stockholders in pursuing the claims identified above, particularly if the stockholders do not reside in or near the State of Delaware or the State of Connecticut. Additionally, the Delaware Forum Provision and the Federal Forum Provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable in an action, we may incur additional costs associated with resolving such an action. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Chancery Court or the U.S. District Court for the District of Connecticut may also reach different </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more, or less, favorable to us than our stockholders.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">General risk factors</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to research and development and the biopharmaceutical industry</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.*</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain the requisite regulatory approvals to commercialize any product candidate, we must demonstrate through extensive preclinical studies and clinical trials that such product candidate is safe and effective in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. We may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful, and a clinical trial can fail at any stage of testing.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Differences in trial design between early-stage clinical trials and later-stage clinical trials make it difficult to extrapolate the results of earlier clinical trials to later clinical trials. Moreover, clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in clinical trials have nonetheless failed to obtain marketing approval of their products. Additionally, we are conducting and plan to conduct some open-label trials, where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in those trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. Where a randomized, placebo-controlled clinical trial is designed to allow enrolled subjects to cross-over to the treatment arm, there may be a risk of inadvertent unblinding of subjects prior to cross-over, which may limit the clinical meaningfulness of those data and may require the conduct of additional clinical trials. As such, the results from an open-label trial may not be predictive of future clinical trial results with any of our product candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful completion of clinical trials is a prerequisite to submitting an NDA to the FDA, a Marketing Authorization Application, or MAA, to the EMA and similar marketing applications to comparable foreign regulatory authorities for each product candidate and, consequently, the ultimate approval and commercial marketing of any product candidates.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have initiated potentially registrational clinical trials for nirogacestat and mirdametinib, we do not know whether these trials or any of our clinical trials, including trials for our combination therapies using nirogacestat and mirdametinib, will be completed on schedule, if at all, or in some cases whether such clinical trials will begin.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience delays in initiating or completing clinical trials and preparing for regulatory submissions. We also may experience numerous unforeseen events during, or as a result of, any future clinical trials that we could conduct that could delay or prevent our ability to receive marketing approval or commercialize our current product candidates or any future product candidates, including:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in our clinical trials and preclinical programs resulting from factors related to the COVID-19 pandemic;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the potential impact that sanctions and other measures being imposed in response to the Russia-Ukraine conflict, or the global business disruption caused by the conflict, could have on revenue and supply chain;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">regulators, Institutional Review Boards, or IRBs, or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective clinical trial sites and prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of any product candidates may fail to show acceptable safety or efficacy, or produce negative or inconclusive results and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials or we may decide to abandon product development programs;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of subjects required for clinical trials of any product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or subjects may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may elect to, or regulators, IRBs or ethics committees may require, that we or our investigators suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of clinical trials of any product candidates may be greater than we anticipate;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be inadequate to initiate or complete a given clinical trial;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators, IRBs or ethics committees to suspend or terminate the clinical trials;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reports from clinical testing of other therapies may raise safety or efficacy concerns about our product candidates; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, EMA or comparable regulatory authorities may require us to submit additional data, such as long-term toxicology studies, or impose other requirements before permitting us to initiate a clinical trial.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs of the institutions in which such clinical trials are being conducted, or the FDA, EMA or comparable regulatory authorities, or recommended for suspension or termination by the Data Safety Monitoring Board, or the DSMB, for such clinical trial. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or clinical trial site by the FDA, EMA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product or treatment, failure to establish or achieve clinically meaningful trial endpoints, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Further, the FDA, EMA or comparable foreign regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our costs will increase if we experience delays in clinical testing or marketing approvals. We do not know whether any of our clinical trials will begin as planned, will need to be reassigned or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in our clinical development programs may harm our business, financial condition and results of operations significantly. The clinical trials sponsored by our partners with our product candidates in combination with our partners&#8217; therapies pose the same development risks.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The successful development of biopharmaceuticals is highly uncertain.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful development of biopharmaceuticals is highly uncertain and is dependent on numerous factors, many of which are beyond our control. Product candidates that appear promising in the early phases of development may fail to reach the market for several reasons including:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial results may show the product candidates to be less effective than expected (for example, a clinical trial could fail to meet its primary or key secondary endpoint(s)) or to have unacceptable side effects or toxicities;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to receive the necessary regulatory approvals or a delay in receiving such approvals. Among other things, such delays may be caused by patients who fail the trial screening process, slow enrollment in clinical trials, patients dropping out of trials, patients lost to follow-up;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">length of time to achieve trial endpoints, additional time requirements for data analysis or NDA preparation, discussions with the FDA, an FDA request for additional preclinical or clinical data (such as long-term toxicology studies) or unexpected safety or manufacturing issues;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical study results may show the product candidate to be less effective than desired or to have harmful side effects;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">supply issues, manufacturing costs and formulation issues, including our inability to successfully combine our product candidates with other therapies;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-marketing approval requirements; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proprietary rights of others and their competing products and technologies that may prevent our product candidates from being commercialized.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time necessary to complete clinical trials and to submit an application for marketing approval for a final decision by a regulatory authority varies significantly from one product candidate to the next and from one country to the next and may be difficult to predict.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in obtaining marketing approval, commercial success of any approved products will also depend in large part on the availability of coverage and adequate reimbursement from third-party payors, including government payors such as the Medicare and Medicaid programs and managed care organizations in the U.S. or country specific governmental organizations in foreign countries, which may be affected by existing and future healthcare reform measures designed to reduce the cost of healthcare. Third-party payors could require us to conduct additional studies, including post-marketing studies related to the cost effectiveness of a product, to qualify for reimbursement, which could be costly and divert our resources. If government and other healthcare payors were not to provide coverage and adequate reimbursement for our products once approved, market acceptance and commercial success would be reduced.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if any of our product candidates receive marketing approval, we will be subject to significant regulatory obligations regarding the submission of safety and other post-marketing information and reports and registration and will need to continue to comply (or ensure that our third-party providers comply) with cGMPs and GCPs for any clinical trials that we conduct post-approval. In addition, there is always the risk that we, a regulatory authority or a third party might identify previously unknown problems with a product post-approval, such as adverse events of unanticipated severity or frequency. Compliance with these requirements is costly, and any failure to comply or other issues with our product candidates post-approval could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Due to our limited resources and access to additional capital, we must prioritize development of certain programs and product candidates; these decisions may prove to be wrong and may adversely affect our business.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may fail to identify and acquire, through purchase or license, viable new product candidates for clinical development for a number of reasons. If we fail to identify and acquire additional product candidates, our business could be materially harmed.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to identify and pursue new product candidates and disease targets require substantial technical, financial and human resources, regardless of whether they are ultimately successful. We currently rely on third parties, including current and future collaborators, to perform all of our research and preclinical activities. Programs may initially show promise in preclinical studies, yet fail to yield positive results during clinical development for a number of reasons, including:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the methodology used may not be successful in identifying potential indications and/or product candidates; or</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product candidates may, after further study, be shown to have harmful adverse effects or other characteristics that indicate they are unlikely to be effective products.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and human resources, we intend to initially focus on programs and product candidates for a limited set of indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications with our existing product candidates that may later prove to have greater commercial potential or a greater </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">likelihood of success. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future clinical trials or those of our future collaborators may reveal significant adverse events not seen in prior preclinical studies or clinical trials and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If significant adverse events or other side effects are observed in any of our clinical trials, we may have difficulty recruiting patients to our clinical trials, patients may drop out of our trials or we may be required to abandon the trials or our development efforts of one or more product candidates altogether. For example, a prior Phase 2 clinical trial of mirdametinib was terminated and enrollment in the Phase 2 portion of a Phase 1/2 clinical trial was halted as a result of adverse events observed at doses of mirdametinib of 15 mg twice daily, or BID, or above using both intermittent and continuous dosing schedules. These adverse events included ocular disorders (visual disturbances, blurred vision and retinal vein occlusion), nervous system disorders (confusion, slowed ideation, slurred speech and hallucinations), musculoskeletal and connective tissue disorders (general weakness and neck muscle weakness associated with mild and moderate elevations in creatine phosphokinase) and cardiac disorders (decreased left ventricular ejection fraction and congestive heart failure). Although these doses were significantly higher than the maximum allowable dose of 4 mg BID in our ongoing Phase 2b clinical trial of mirdametinib in NF1-PN, we plan to treat patients in this trial for a period of up to 24 months, which would be longer than any subjects have been treated with mirdametinib in prior trials. In our ongoing Phase 2b clinical trial, we may observe adverse events similar to those that were seen at higher doses of mirdametinib in prior clinical trials owing to the potentially increased duration of treatment, or other factors. In addition, the trial is enrolling pediatric NF1-PN patients. There is limited safety data of mirdametinib in children under the age of 16 and it is possible that there may be unanticipated adverse events observed in this patient population.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we elect or are required to delay, suspend or terminate any clinical trial of any product candidates that we develop, the commercial prospects of such product candidates will be harmed and our ability to generate product revenues from any of these product candidates will be delayed or eliminated. Serious adverse events or other adverse events, as well as tolerability issues, observed in clinical trials could hinder or prevent market acceptance of the product candidate at issue.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, the FDA, EMA or comparable foreign regulatory authorities or an IRB may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, restrictions could be imposed on the approval or an approved product could be subject to a boxed warning, which is the FDA's most prominent warning regarding safety concerns, and undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increasing demand for compassionate use of our product candidates could negatively affect our reputation and harm our business.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing product candidates for the treatment of indications for which there are currently limited or no available therapeutic options. It is possible for individuals or groups to target companies with disruptive social media campaigns related to a request for access to unapproved drugs for patients with significant unmet medical need. If we experience a similar social media campaign regarding our decision to provide or not provide access to any of our current or future product candidates under an expanded access policy, our reputation may be negatively affected and our business may be harmed.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent media attention to individual patients&#8217; expanded access requests has resulted in the introduction and enactment of legislation at the local and national level referred to as &#8220;Right to Try&#8221; laws, such as the federal Right to Try Act of 2017 signed into law on May 30, 2018, which are intended to allow patients access to unapproved therapies earlier than traditional expanded access programs. A possible consequence of both activism and legislation in this area may be the need for us to initiate an unanticipated expanded access program or to make our product candidates more widely available sooner than anticipated. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, some patients who receive access to drugs prior to their commercial approval through compassionate use, expanded access programs or right to try access have life-threatening illnesses and have exhausted all other available therapies. The risk for serious adverse events in this patient population is high, which could have a negative impact on the safety profile of our product candidates if we were to provide them to these patients, which could cause significant delays or an inability to successfully commercialize our product candidates, which could materially harm our business. If we were to provide patients with any of our product candidates under an expanded access program, we may in the future need to restructure or pause any </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compassionate use and/or expanded access programs for a variety of reasons, which could prompt adverse publicity or other disruptions related to current or potential participants in such programs.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition from other biopharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry is characterized by intense competition and rapid innovation. Our competitors may be able to develop other compounds or drugs that are able to achieve similar or better results. Our potential competitors include major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and universities and other research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and well-established sales forces. Smaller or early-stage companies may also prove to be significant competitors, particularly as they develop novel approaches to treating disease indications that our product candidates are also focused on treating. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel therapeutics or to in-license novel therapeutics that could make the product candidates that we develop obsolete. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaboration partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products. We believe the key competitive factors that will affect the development and commercial success of our product candidates are efficacy, safety, tolerability, reliability, convenience of use, price and reimbursement.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval of our product candidates, the availability and price of our competitors&#8217; products could limit the demand and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if any product candidate we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any future product candidate we develop receives marketing approval, whether as a single agent or in combination with other therapies, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If the product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of any product candidate, if approved for commercial sale, will depend on a number of factors, including:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">efficacy and potential advantages compared to other treatments;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to offer our products, if approved, for sale at competitive prices;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">convenience and ease of administration compared to other treatments;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of marketing and distribution support;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to obtain sufficient third-party coverage, market access and adequate reimbursement; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing, including bridging or comparability testing to demonstrate the validity of clinical data obtained in clinical trials following manufacturing changes, FDA notification or FDA approval.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because all prior clinical trials of nirogacestat and mirdametinib were conducted by third parties, we will need to perform analytical and other tests to demonstrate that any new drug product material is comparable in all respects, including potency, to the product used in such earlier clinical trials. There is no assurance that any such product will pass the required comparability testing, that any other future third-party manufacturer that we engage will be successful in producing our product candidates or that any materials produced by any third-party manufacturer that we engage will have the same effect in patients that we have observed to date with respect to materials used in prior clinical trials.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the above could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence sales and generate revenue.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we have not yet manufactured or processed on a commercial scale and may not be able to do so for any of our product candidates if approved. We may make changes as we work to optimize our manufacturing processes, but we cannot be sure that even minor changes in our processes will result in therapies that are safe and effective and approved for commercial sale.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of testing our product candidates in clinical trials and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical trials, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to bring a product candidate to the market;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our products;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">harm to our reputation;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants and inability to continue clinical trials;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiation of investigations by regulators;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to defend the related litigation;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management&#8217;s time and our resources;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to clinical trial participants or patients who receive an approved product;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exhaustion of any available insurance and of our capital resources;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize any product candidate, if approved; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decline in our stock price.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with collaborators. Even if our agreements with any current or future corporate collaborators entitle us to indemnification against losses, that indemnification may not be available or adequate should any claim arise. Although we currently carry clinical trial insurance, the amount of insurance coverage we carry may not be adequate, and, in the future, we may be unable to maintain this insurance coverage, or we may not be able to obtain additional or replacement insurance at a reasonable cost, if at all. Our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay those amounts.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to intellectual property</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends in part on our ability to protect our intellectual property, and patent terms may be inadequate to protect our competitive position. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend in large part on obtaining and maintaining patent, trademark and trade secret protection of our proprietary technologies and our product candidates, their respective components, formulations, combination therapies, methods used to manufacture them and methods of treatment, as well as successfully defending these patents against third-party challenges. Our ability to stop unauthorized third parties from making, using, selling, offering to sell or importing our product candidates is affected by the extent to which we have rights under valid and enforceable patents that cover these activities. If our patents expire, or we are unable to secure and maintain patent protection for any product or technology we develop, or if the scope of the patent protection secured is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to commercialize any product candidates we may develop may be adversely affected. Patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions such as patent term adjustments and/or extensions, may be available, but the life of a patent, and the protection it affords, is limited. Our current composition of matter patents covering nirogacestat and mirdametinib, were licensed from Pfizer in connection with the formation of our company. U.S. composition of matter patents covering the chemical structure of nirogacestat expire in 2025 and three U.S. composition of matter patents that cover the polymorphic form of nirogacestat that is currently in clinical development expire in 2039. Two U.S. patents covering several polymorphic forms of mirdametinib, including the polymorphic form that is currently in clinical development, expire in 2041. Our earliest patents may expire before, or soon after, either product candidate achieves marketing approval in the U.S. or foreign jurisdictions. Upon the expiration of the current patents, we currently intend to rely on orphan drug exclusivity to market our lead products. Once the patent life has expired, we may be open to competition from competitive products, including generics. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. The expiration of the patents covering our lead product candidates, and our inability to secure additional patent protection, could also have a material adverse effect on our business, results of operations, financial condition and prospects.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patenting process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all relevant markets. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant on our licensors or licensees.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The strength of patents in the biopharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license now or in the future may fail to result in issued patents with claims that cover our product candidates or uses thereof in the U.S. or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, the patents and patent applications covering our product candidates may not adequately protect our intellectual property or prevent others from designing around our claims. If the breadth or strength of protection provided by the patents we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since patent applications in the U.S. and most other countries are confidential for a period of time after filing, there is no certainty that any patent application related to a product candidate was the first to be filed. Furthermore, for U.S. applications in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which at least one claim is entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third party or instituted by the U.S. Patent and Trademark Office, or USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of an application.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that we are the first to invent any inventions covered by a pending patent application and, if we are not, we could be subject to priority disputes. We may be required to disclaim part or all of the term of certain patents or all of the term of certain patent applications. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable or that even if found valid and enforceable, a competitor&#8217;s technology or product would be found by a court to infringe our patents. We may analyze patents or patent applications of our competitors that we believe are relevant to our activities and consider that we are free to operate in relation to our product candidates, but our competitors may achieve issued claims, including in patents we consider to be unrelated, which block our efforts or may potentially result in our product candidates or our activities infringing such claims. The possibility exists that others will develop products which have the same effect as our products on an independent basis which do not infringe our patents or other intellectual property rights or will design around the claims of patents that we have had issued that cover our products. In addition, some of our patent applications and patents may cover inventions owned jointly by us and our collaborators. There can be no assurance that we and our collaborators will agree upon matters related to patent filing and prosecution strategy required to execute an effective patent strategy or that decisions made by our collaborators will be consistent with our goals for protecting our solely owned intellectual property.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent or future patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. Under the enacted Leahy-Smith America Invents Act, or America Invents Act, enacted in 2013, the U.S. moved from a &#8220;first-to-invent&#8221; to a &#8220;first-to-file&#8221; system. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. The America Invents Act includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted, redefine prior art and establish a new post-grant review system. The effects of these changes are currently unclear as the USPTO only recently developed new regulations and procedures in connection with the America Invents Act and many of the substantive changes to patent law, including the &#8220;first-to-file&#8221; provisions, only became effective in March 2013. In addition, the courts have yet to address many of these provisions and the applicability of the act and new regulations on specific patents discussed herein have not been determined and would need to be reviewed. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of any patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make or use compounds that are similar to the compositions of our product candidates but that are not covered by the claims of our patents;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the active ingredients in our current product candidates will eventually become commercially available in generic drug products, and no patent protection may be available with regard to formulation or method of use;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a company or its licensor, as the case may be, may fail to meet its obligations to the U.S. government in regard to any in-licensed patents and patent applications funded by U.S. government grants, leading to the loss of patent rights;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such company or its licensors, as the case may be, might not have been the first to file patent applications for these inventions;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that a pending patent applications will not result in issued patents;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that there are prior public disclosures that could invalidate our or our licensors&#8217; patents, as the case may be, or parts of our or their patents;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that others may circumvent our owned or in-licensed patents;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our products or technology similar to ours;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the laws of foreign countries may not protect our or our licensors&#8217;, as the case may be, proprietary rights to the same extent as the laws of the U.S.;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the claims of our owned or in-licensed issued patents or patent applications, if and when issued, may not cover our product candidates;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our owned or in-licensed issued patents may not provide us with any competitive advantages, may be narrowed in scope, or be held invalid or unenforceable as a result of legal challenges by third parties;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inventors of owned or in-licensed patents or patent applications may become involved with competitors, develop products or processes which design around our patents, or become hostile to us or the patents or patent applications on which they are named as inventors;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that owned or in-licensed patents or patent applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have engaged in scientific collaborations in the past, and will continue to do so in the future. Such collaborators may develop adjacent or competing products to ours that are outside the scope of our patents;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies for which we can obtain patent protection;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that product candidates we develop may be covered by third parties&#8217; patents or other exclusive rights; or</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may have an adverse effect on our business.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent protection, we rely heavily upon know-how and trade secret protection, as well as non-disclosure agreements and invention assignment agreements with our employees, consultants and third parties, to protect our confidential and proprietary information, especially where we do not believe patent protection is appropriate or obtainable. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and technological security measures. Such measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, courts outside the U.S. are sometimes less willing to protect trade secrets. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual or entity during the course of the party&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or proprietary information, are our exclusive property. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology by third parties.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, inter partes review, post grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates and/or proprietary technologies infringe their intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our product candidates, technologies or methods.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a third party claims that we infringe its intellectual property rights, we may face a number of issues, including, but not limited to:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">infringement and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate and may divert our management&#8217;s attention from our core business;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial damages for infringement, which we may have to pay if a court decides that the product candidate or technology at issue infringes on or violates the third party&#8217;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#8217;s attorneys&#8217; fees;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a court prohibiting us from developing, manufacturing, marketing or selling our product candidates, or from using our proprietary technologies, unless the third party licenses its product rights to us, which it is not required to do;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our products; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">redesigning our product candidates or processes so they do not infringe, which may not be possible or may require substantial monetary expenditures and time.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert that we are employing their proprietary technology without authorization. Generally, conducting clinical trials and other development activities in the U.S. is protected under the Safe Harbor exemption as set forth in 35 U.S.C. &#167;271. If any of our product candidates are approved by the FDA, third parties may then seek to enforce their patent by filing a patent infringement lawsuit against us. While we do not believe that any claims of such patent that could otherwise materially adversely affect commercialization of our product candidates, if approved, are valid and enforceable, we may be incorrect in this belief, or we may not be able to prove it in a litigation. In this regard, patents issued in the U.S. by law enjoy a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof. There may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, if the breadth or strength of protection provided by our patents and any patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we or our licensors may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may assert that our employees, consultants, collaborators or partners have wrongfully used or disclosed confidential information or misappropriated trade secrets.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at universities or other biopharmaceutical or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, and although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to develop any future product candidates on acceptable terms.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates may also require specific formulations to work effectively and these rights may be held by others. We may develop products containing our compounds and pre-existing pharmaceutical compounds. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which could harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, thereby </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions may provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put any patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may choose to challenge the patentability of claims in a third party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in an ex-parte re-exam, inter partes review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third party&#8217;s patent in patent opposition proceedings in the European Patent Office, or EPO, or other foreign patent offices. The costs of these opposition proceedings could be substantial and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent offices then we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidates or proprietary technologies.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because some patent applications in the U.S. may be maintained in secrecy until the patents are issued, patent applications in the U.S. and many foreign jurisdictions are typically not published until 18 months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by issued patents or any pending applications, or that we or, if applicable, a licensor were the first to invent the technology. Our competitors also may have filed, and may in the future file, patent applications covering our products or technology similar to ours. Any such patent application may have priority over our patents or any patent applications, which could require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to those owned by or in-licensed to us, we or, in the case of in-licensed technology, the licensor may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the U.S. If we or one of our licensors is a party to an interference proceeding involving a U.S. patent application on inventions owned by or in-licensed to us, we may incur substantial costs, divert management&#8217;s time and expend other resources, even if we are successful.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with respect to our patents or any patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation or interference proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the U.S.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during such litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent application process and following the issuance of a patent. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent law in the U.S. and in ex-U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition, the U.S. has recently enacted, and is currently implementing, wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. We cannot predict how these decisions or any future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. Similarly, any adverse changes in the patent laws of other jurisdictions could have a material adverse effect on our business and financial condition.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on product candidates in all countries throughout the world is expensive. While certain of our licensed patents, including patents covering our lead product candidates, have been issued in major markets and other countries, our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as that in the U.S. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us or our licensors to stop the infringement of our patents or marketing of competing products against third parties in violation of our proprietary rights generally. The initiation of proceedings by third parties to challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and any patent applications at risk of not issuing and could provoke third parties to assert claims against us or our licensors. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and prospects could be materially harmed.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to government regulation</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval process for our product candidates in the U.S., the European Union, and other jurisdictions is currently uncertain and will be lengthy, time-consuming and inherently unpredictable and we may experience significant delays in the clinical development and regulatory approval, if any, of our product candidates.*</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug products are subject to extensive regulation by the FDA in the U.S., the EMA in the European Union, or EU, and comparable foreign regulatory authorities. We are not permitted to market any product in any jurisdiction until we receive marketing approval from the appropriate regulatory authority. We have not previously submitted an NDA to the FDA, an MAA to the EMA or similar </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marketing application to comparable foreign regulatory authorities. In the U.S., an NDA must include extensive preclinical and clinical data and supporting information to establish that the product candidate is safe, pure and potent for each desired indication. An NDA must also include significant information regarding the chemistry, manufacturing and controls for the product, and the manufacturing facilities must complete a successful pre-approval inspection.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety and efficacy data to support approval. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain approval of any product candidates that we develop based on the completed clinical trials.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, clinical trials can be delayed or terminated for a variety of reasons, including delays or failures related to:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining regulatory authorization to begin a clinical trial, if applicable;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of financial resources to begin and complete the planned trials;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining approval at each clinical trial site by an independent IRB or ethics committee;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recruiting suitable patients to participate in a clinical trial in a timely manner;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">having patients complete a clinical trial or return for post-treatment follow-up;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial sites deviating from clinical trial protocol, not complying with GCP requirements or dropping out of a trial;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the availability of materials or manufacturing slots for the products needed for our clinical trials, as a result of the ongoing conflict between Russia and Ukraine and resulting heightened economic sanctions from the United States, which could lead to delays in these trials; We could face higher costs or reduced availability of supplies, materials, components, or services for product candidates in the U.S., the European Union, and other jurisdictions; </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addressing any patient safety concerns that arise during the course of a clinical trial;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addressing any conflicts with new or existing laws or regulations;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adding new clinical trial sites; or</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing qualified materials under cGMP regulations for use in clinical trials.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment is a significant factor in the timing of clinical trials and is affected by many factors. Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such clinical trials are being conducted, or the FDA, EMA or comparable foreign regulatory authorities, or recommended for suspension or termination by the DSMB for such clinical trial, due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or clinical trial sites by the FDA, EMA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing any clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Since March 2020, when foreign and domestic inspections of facilities were largely placed on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> hold, the FDA has been working to resume routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis. Since April 2021, the FDA has conducted limited inspections and emplo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">yed remote interactive evaluations, using risk management methods, to meet user fee commitments and goal dates. Ongoing travel restrictions and other uncertainties continue to impact oversight operations both domestic and abroad and it is unclear when standard operational levels will resume. The FDA is continuing to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">complete mission-critical work, prioritize other higher-tiered inspectional needs (e.g., for-cause inspections), and carry out surveillance inspections using risk-based approaches for evaluating public health. Should the FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel,and the FDA does not determine a remote interactive evaluation to be adequate, the FDA has stated that it generally intends to issue, depending on the circumstances, a complete response letter or defer action on the application until an inspection can be completed. During the COVID-19 public health emergency, a number of companies announced receipt of complete response letters due to the FDA's inability to complete required inspections for their applications. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the ongoing COVID-19 pandemic and may experience delays in their regulatory activities. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA, EMA or comparable foreign regulatory authorities may disagree with our regulatory plan for our product candidates.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The general approach for FDA approval of a new drug is dispositive data from one or more well-controlled Phase 3 clinical trials of the product candidate in the relevant patient population. Phase 3 clinical trials typically involve a large number of patients, have significant costs and take years to complete.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial results may not support approval of our product candidates. In addition, our product candidates could fail to receive regulatory approval, or regulatory approval could be delayed, for many reasons, including the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, EMA or comparable foreign regulatory authorities may disagree with the dosing regimen, design or implementation of our clinical trials;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA, EMA or comparable foreign regulatory authorities that our product candidates are safe and effective for any of their proposed indications;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may encounter safety or efficacy problems caused by the ongoing COVID-19 pandemic; </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA, EMA or comparable foreign regulatory authorities for approval;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA, EMA or comparable foreign regulatory authorities to support the submission of an NDA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the U.S. or elsewhere;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, EMA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA, EMA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek regulatory approval of our product candidates based on an interim analysis conducted of a registrational trial, particularly if the interim analysis is statistically significant for the primary endpoint and the safety data demonstrate an acceptable safety and tolerability profile. The results of any such interim analysis would be discussed with the FDA at a pre-NDA meeting to assess the adequacy of the data to support the submission of an NDA; however, if the FDA does not agree that the interim analysis provides a sufficient basis for regulatory approval, we would not submit an NDA until the conclusion of such registrational trial.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Breakthrough Therapy Designation or Fast Track Designation from the FDA may not actually lead to a faster development or regulatory review or approval process.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has granted Fast Track Designation and Breakthrough Therapy Designation for nirogacestat for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis, and has granted Fast Track Designation for mirdametinib for the treatment of patients at least two years of age with NF1-associated inoperable PN that are </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progressing or causing significant morbidity. We may seek Breakthrough Therapy Designation or Fast Track Designation for our other product candidates.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product is intended for the treatment of a serious or life-threatening condition and the product demonstrates the potential to address unmet medical needs for this condition, the product sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe one of our product candidates is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A breakthrough therapy is defined as a product that is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For products that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy Designation may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if a product candidate qualifies as a breakthrough therapy, the FDA may later decide that the product no longer meets the conditions for qualification and rescind the Breakthrough Therapy Designation.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of clinical trials conducted at clinical trial sites outside the U.S. might not be accepted by the FDA, and data developed outside of a foreign jurisdiction similarly might not be accepted by such foreign regulatory authority.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the prior clinical trials for our product candidates were conducted outside the U.S., and we intend to conduct additional clinical trials outside the U.S. Although the FDA, EMA or comparable foreign regulatory authorities may accept data from clinical trials conducted outside the relevant jurisdiction, acceptance of these data is subject to certain conditions. For example, the FDA requires that the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles such as IRB or ethics committee approval and informed consent, the trial population must adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, acceptance of the data by the FDA will be dependent upon its determination that the trials were conducted consistent with all applicable U.S. laws and regulations. There can be no assurance that the FDA will accept data from trials conducted outside of the U.S. as adequate support of a marketing application. Similarly, we must also ensure that any data submitted to foreign regulatory authorities adheres to their standards and requirements for clinical trials and there can be no assurance a comparable foreign regulatory authority would accept data from trials conducted outside of its jurisdiction.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with healthcare providers and physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors in the U.S. and elsewhere play a primary role in the recommendation and prescription of pharmaceutical products. Arrangements with third-party payors and customers can expose pharmaceutical manufacturers to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute, or AKS, and the federal False Claims Act, or FCA, which may constrain the business or financial arrangements and relationships through which such companies sell, market and distribute pharmaceutical products. In particular, the research of our product candidates, as well as the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials. The applicable federal, state and foreign healthcare laws and regulations that may affect our ability to operate include, but are not limited to:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the AKS, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity can be found guilty of violating the statute without actual knowledge of the statute or specific intent to violate it. In addition, a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the FCA. The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. On November 20, 2020, the Office of Inspector General, or OIG, finalized further modifications to the AKS. Under the final rules, the OIG added safe harbor protections under the AKS for certain coordinated care and value-based arrangements among clinicians, providers, and others. These rules (with exceptions) became effective January 19, 2021. Implementation of this change and new safe harbors for point-of-sale reductions in price for prescription pharmaceutical products and pharmacy benefit manager service fees are currently under review by the Biden administration and may be amended or repealed. We continue to evaluate what effect, if any, the rule will have on our business;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal civil and criminal false claims laws and civil monetary penalty laws, including the FCA, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment to, or approval by Medicare, Medicaid or other federal healthcare programs, knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim or an obligation to pay or transmit money to the federal government, or knowingly concealing or knowingly and improperly avoiding or decreasing or concealing an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The government may deem manufacturers to have &#8220;caused&#8221; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off-label. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. When an entity is determined to have violated the FCA, the government may impose civil fines and penalties ranging, plus treble damages, and exclude the entity and its products from participation in Medicare, Medicaid and other federal healthcare programs;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the AKS, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose, among other things, requirements on certain healthcare providers, health plans and healthcare clearinghouses, known as covered entities, as well as their respective business associates, independent contractors that perform services for covered entities that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payments Sunshine Act, created under the Patient Protection and Affordable Care Act, as amended, or ACA, and its implementing regulations, which require some manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, of the U.S. Department of Health and Human Services, or HHS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2022, these reporting obligations will extend to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, and may be broader in scope than their federal equivalents; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures or drug pricing; state and local laws that require the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. Pharmaceutical companies may also be subject to federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies continue to closely scrutinize interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time and resource-consuming and can divert a company&#8217;s attention from the business.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Any action for violation of these laws, even if successfully defended, could cause a biopharmaceutical manufacturer to incur significant legal expenses and divert management&#8217;s attention from the operation of the business. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, the EMA or comparable foreign regulatory authorities must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the U.S., including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the U.S., a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the U.S. have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-marketing information, including both federal and state requirements in the U.S. and requirements of comparable foreign regulatory authorities. In addition, we will be subject to continued compliance with cGMP and GCP requirements for any clinical trials that we conduct post-approval.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA, EMA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations and applicable product tracking and tracing requirements. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA, BLA, or other marketing application and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. Certain endpoint data we hope to include in any approved product labeling also may not make it into such labeling, including exploratory or secondary endpoint data such as patient-reported outcome measures. The FDA may also require a risk evaluation and mitigation strategies, or REMS, program as a condition of approval of our product candidates, which could entail requirements for long-term patient follow-up, a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA, EMA or a comparable foreign regulatory authority approves our product candidates, we will have to comply with requirements including submissions of safety and other post-marketing information and reports and registration.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-marketing studies or clinical trials to assess new safety risks or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or holds on clinical trials;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention or refusal to permit the import or export of our product candidates; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The policies of the FDA, EMA and comparable foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, if approved, which could make it difficult for us to sell any product candidates profitably.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our product candidates, if approved, depends on the availability of coverage and adequate reimbursement from third-party payors. We cannot be sure that coverage and reimbursement will be available for, or accurately estimate the potential revenue from, our product candidates or assure that coverage and reimbursement will be available for any product that we may develop.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which drugs and treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a covered benefit under its health plan;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safe, effective and medically necessary;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">appropriate for the specific patient;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost-effective; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">neither experimental nor investigational.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., no uniform policy of coverage and reimbursement for products exists among third-party payors. As a result, obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our products on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require co-payments that patients find unacceptably high. Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term follow-up evaluations required following the use of product candidates, once approved. Patients are unlikely to use our product candidates, once approved, unless coverage is provided and reimbursement is adequate to cover a significant portion of their cost. There is significant uncertainty related to insurance coverage and reimbursement of newly approved products. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates. Further, due to the COVID-19 pandemic, millions of individuals have lost or will be losing employer-based insurance coverage, which may adversely affect our ability to commercialize our product candidates even if there is adequate coverage and reimbursement from third-party payors. It is unclear what effect, if any, the American Rescue Plan Act of 2021 will have on the number of covered individuals.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, the Middle Class Tax Relief and Job Creation Act of 2012 required that CMS, the agency responsible for administering the Medicare program, reduce the Medicare clinical laboratory fee schedule by 2% in 2013, which served as a base for 2014 and subsequent years. In addition, effective January 1, 2014, CMS also began bundling the Medicare payments for certain laboratory tests ordered while a patient received services in a hospital outpatient setting. Additional state and federal healthcare reform measures are expected to be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for certain pharmaceutical products or additional pricing pressures.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increasing efforts by governmental and third-party payors in the U.S. and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. There has been increasing legislative and enforcement interest in the U.S. with respect to specialty drug pricing practices.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. We expect to experience pricing pressures in connection with the sale of any of our product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on December 2, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to an order entered by the U.S. District Court for the District of Columbia, the portion of the rule eliminating safe harbor protection for certain rebates related to the sale or purchase of a pharmaceutical product from a manufacturer to a plan sponsor under Medicare Part D has been delayed to January 1, 2023. Further, implementation of this change and new safe harbors for point-of-sale reductions in prices for prescription pharmaceutical products and pharmacy benefit manager service fees are currently under review by the Biden administration and may be amended or repealed. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, Congress has indicated that it will continue to seek new legislative measures to control drug costs.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosures and transparency measures, and, in some cases, implementing regulations designed to encourage importation from other countries and bulk purchasing.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the Right to Try Act of 2017, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act of 2017.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Affordable Care Act, or ACA, was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. biopharmaceutical industry. The ACA, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs and created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been numerous judicial, administrative, executive and Congressional legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, various portions of the ACA are currently undergoing constitutional challenges in the U.S. Supreme Court, and the former Trump administration issued various Executive Orders eliminating cost sharing subsidies and various provisions that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. Additionally, Congress has introduced several pieces of legislation aimed at significantly revising or repealing the ACA. In December 2018, CMS published a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of the federal district court litigation regarding the method CMS uses to determine this risk adjustment. Since then, the ACA risk adjustment program payment parameters have been updated annually. It is unclear whether the ACA will be overturned, repealed, replaced, or further amended, and we cannot predict what affect further changes to the ACA would have on our business, especially given the transition to the Biden Administration.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other legislative changes have been proposed and adopted in the U.S. since the ACA was enacted. The Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs, including aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, including the BBA, will remain in effect through 2030, unless additional congressional action is taken. However, pursuant to the CARES Act, these reductions were suspended from May 1, 2020 through December 31, 2020 due to the COVID-19 pandemic. The Consolidated Appropriations Act of 2021, extended the suspension period to March 31, 2021. An Act to Prevent Across-the-Board Direct Spending Cuts, and for Other Purposes, signed into law on April 14, 2021, extended the suspension period to December 31, 2021. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As discussed above, there has been increasing legislative and enforcement interest in the U.S. with respect to specialty drug pricing practices. See &#8220;&#8212;Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, if approved, which could make it difficult for us to sell any product candidates profitably.&#8221; At the federal level, the former Trump administration&#8217;s budget proposal for fiscal year 2021 included a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients and increase patient access to lower-cost generic and biosimilar drugs. On March 10, 2020, the former Trump administration sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses and place limits on pharmaceutical price increases. Further, the former Trump administration also previously released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. HHS has already started the process of soliciting feedback on some of these measures and, at the same time, is immediately implementing others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January 1, 2020. However, it is unclear whether the Biden administration will challenge, reverse, revoke or otherwise modify these executive and administrative actions. In addition, there have been several changes to the 340B drug pricing program, which imposes ceilings on prices that drug manufacturers can charge for medications sold to certain health care facilities. On December 27, 2018, the District Court for the District of Columbia invalidated a reimbursement formula change under the 340B drug pricing program, and CMS subsequently altered the FYs 2019 and 2018 reimbursement formula on specified covered outpatient drugs, or SCODs. The court ruled this change was not an &#8220;adjustment&#8221; which was within the Secretary&#8217;s discretion to make but was instead a fundamental change in the reimbursement calculation. However, most recently, on July 31, 2020, the U.S. Court of Appeals for the District of Columbia Circuit overturned the district court&#8217;s decision and found that the changes were within the Secretary&#8217;s authority. On September 14, 2020, the plaintiffs-appellees filed a Petition for Rehearing En Banc (i.e., before the full court), which was denied on October 16, 2020. It is unclear how these developments could affect covered hospitals who might purchase our future products and affect the rates we may charge such facilities for our approved products in the future, if any. In 2020, former President Trump announced several executive orders related to prescription drug pricing that sought to implement several of the former administration's proposals. In response, the FDA released a final rule on September 24, 2020, which went into effect on November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, CMS issued an Interim Final Rule implementing the Most Favored Nation, or MFN, Model under which Medicare Part B reimbursement rates will be calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita. The MFN Model regulations mandate participation by identified Part B providers and would have applied to all U.S. states and territories for a seven-year period beginning January 1, 2021, and ending December 31, 2027. However, in response to a lawsuit filed by several industry groups, on December 28, 2020, the U.S. District Court for the Northern District of California issued a nationwide preliminary injunction enjoining government defendants from implementing the MFN Rule pending completion of notice-and-comment procedures under the Administrative Procedure Act. On January 13, 2021, in a separate lawsuit brought by industry groups in the U.S. District of Maryland, the government defendants entered a joint motion to stay litigation on the condition that the government would not appeal the preliminary injunction granted in the U.S. District Court for the Northern District of California and that performance for any final regulation stemming from the MFN Interim Final Rule shall not commence earlier than 60 days after publication of any such final regulation in the Federal Register. Further, authorities in Canada have passed rules designed to safeguard the Canadian drug supply from shortages. If implemented, importation of drugs from Canada and the MFN Model may materially and adversely affect the price we receive for any of our product candidates. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Individual states in the U.S. have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. See &#8220;&#8212;Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, if approved, which could make it difficult for us to sell any product candidates profitably.&#8221;</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These laws, and future state and federal healthcare reform measures may be adopted in the future, any of which may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Off-label use or misuse of our products may harm our reputation in the marketplace or result in injuries that lead to costly product liability suits.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing nirogacestat for the treatment of desmoid tumors and mirdametinib for the treatment of NF1-PN. If our product candidates are approved by the FDA, we may only promote or market our product candidates for their specifically approved indications and in a manner consistent with the approved labeling. We will train our marketing and sales force against promoting our product candidates for uses outside of the approved indications for use, known as &#8220;off-label uses.&#8221; We cannot, however, prevent a physician from using our products off-label, when in the physician&#8217;s independent professional medical judgment he or she deems it appropriate. Furthermore, the use of our products for indications other than those approved by the FDA may not effectively treat such conditions. Any such off-label use of our product candidates could harm our reputation in the marketplace among physicians and patients. There may also be increased risk of injury to patients if physicians attempt to use our products for any off-label uses, which could lead to product liability suits that that might require significant financial and management resources and that could harm our reputation. Additionally, the FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label uses and if we, or our collaborators, do not promote our products, if approved, in a manner consistent with the approved labeling, we, or they, may be subject to warnings or enforcement action for off-label marketing. Violation of the Federal Food, Drug, and Cosmetic Act and other statutes, including the FCA, relating to the promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state healthcare fraud and abuse laws and state consumer protection laws.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA, the SEC and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, including in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities. During the ongoing COVID-19 public health emergency, the FDA has noted that it is working to ensure timely reviews of applications for medical products in line with its user fee performance goals. However, the FDA may not be able to continue its current pace and approval timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required, and due to the ongoing COVID-19 pandemic and travel restrictions, the FDA is unable to complete such required inspections during the review period. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EU drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the European member states.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek approval to market our product candidates in both the U.S. and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">jurisdictions. In some foreign countries, particularly those in the EU, the pricing of drugs is subject to governmental control and other market regulations which could put pressure on the pricing and usage of our product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our product candidates and may be affected by existing and future healthcare reform measures.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Much like the AKS prohibition in the U.S., the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to physicians is governed by the national anti-bribery and other laws of EU Member States, and operations in the United Kingdom would be subject to relevant United Kingdom laws, including the United Kingdom Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, in most foreign countries, including the European Economic Area, or EEA, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the Company placing the medicinal product on the market. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of any of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for biopharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the EU do not follow price structures of the U.S. and generally prices tend to be significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales and the potential profitability of any of our product candidates in those countries would be negatively affected. Moreover, if the current conflict between Russia and Ukraine expands into the region, there is the potential for us to face higher costs or reduced availability of materials or manufacturing slots for product candidates in the EU and other jurisdictions.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may incur substantial costs in our efforts to comply with evolving global data protection laws and regulations, and any failure or perceived failure by us to comply with such laws and regulations may harm our business and operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The global data protection landscape is rapidly evolving, and we may be or become subject to or affected by numerous federal, state and foreign laws and regulations, as well as regulatory guidance, governing the collection, use, disclosure, transfer, security and processing of personal data, such as information that we collect about participants and healthcare providers in connection with clinical trials. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, which may create uncertainty in our business, affect our or our service providers&#8217; ability to operate in certain jurisdictions or to collect, store, transfer use and share personal data, result in liability or impose additional compliance or other costs on us. Any failure or perceived failure by us to comply with federal, state, or foreign laws or self-regulatory standards could result in negative publicity, diversion of management time and effort and proceedings against us by governmental entities or others. For example, California recently passed the California Consumer Privacy Act, or CCPA, which went into effect in January 2020 and provides broad rights to California consumers with respect to the collection and use of their information by businesses. While there is currently an exception for protected health information that is subject to HIPAA and clinical trial regulations, as currently written, the CCPA may impact our business activities. The CCPA created a new and potentially severe statutory damages framework and private rights of action for violations of the CCPA, including for failing to implement reasonable security procedures and practices to prevent data breaches. In November 2020, California voters passed the California Privacy Rights Act, or CPRA. The CPRA, which is expected to take effect on January 1, 2023, will significantly expand the CCPA, including by introducing additional data protection obligations such as data minimization and storage limitations, granting additional rights to consumers such as correction of personal information and additional opt-out rights, and creating a new entity to implement and enforce the CPRA. The uncertainty surrounding the implementation of CCPA and CRPA exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information. The new California law further expands the privacy and process enhancements and commitment </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of resources in support of compliance with California&#8217;s regulatory requirements and may lead to similar laws in other U.S. states or at a national level.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our operations in the U.S., which may be subject to healthcare and other laws relating to the privacy and security of health information and other personal information, we may seek to conduct clinical trials in EEA and may become subject to additional European data privacy laws, regulations and guidelines. The General Data Protection Regulation, (EU) 2016/679, or GDPR, became effective on May 25, 2018, and deals with the processing of personal data and on the free movement of such data. The GDPR imposes a broad range of strict requirements on companies subject to the GDPR, including requirements relating to having legal bases for processing personal information relating to identified and/or identifiable individuals and transferring such information outside the EEA, including to the U.S., providing details to those individuals regarding the processing of their personal information, keeping personal information secure, having data processing agreements with third parties who process personal information, responding to individuals&#8217; requests to exercise their rights in respect of their personal information, reporting security breaches involving personal data to the competent national data protection authority and affected individuals, appointing data protection officers, conducting data protection impact assessments, maintaining internal records and appropriately deleting personal information in line with retention periods. The GDPR increases substantially the penalties to which we could be subject in the event of any non-compliance, including fines of up to 10 million Euros or up to 2% of our total worldwide annual turnover for certain comparatively minor offenses, or up to 20 million Euros or up to 4% of our total worldwide annual turnover for more serious offenses. Given the limited enforcement of the GDPR to date, we face uncertainty as to the exact interpretation of the new requirements on our trials and we may be unsuccessful in implementing all measures required by data protection authorities or courts in interpretation of the new law.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, national laws of member states of the EU are in the process of being adapted to the requirements under the GDPR, thereby implementing national laws which may partially deviate from the GDPR and impose different obligations from country to country, so that we do not expect to operate in a uniform legal landscape in the EEA. Also, as it relates to processing and transfer of genetic data, the GDPR specifically allows national laws to impose additional and more specific requirements or restrictions, and European laws have historically differed quite substantially in this field, leading to additional uncertainty. Further, the impact of &#8220;Brexit&#8221;, whereby the United Kingdom formally withdrew from the EU on January 31, 2020 is uncertain and cannot be predicted at this time.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event we commence clinical trials in the EEA, we must also ensure that we maintain adequate safeguards to enable the transfer of personal data outside of the EEA, in particular to the U.S., in compliance with European data protection laws. We expect that we will continue to face uncertainty as to whether our efforts to comply with any obligations under European privacy laws will be sufficient. If we are investigated by a European data protection authority, we may face fines and other penalties. Any such investigation or charges by European data protection authorities could have a negative effect on our existing business and on our ability to attract and retain new clients or biopharmaceutical partners. We may also experience hesitancy, reluctance or refusal by European or multi-national clients or biopharmaceutical partners to continue to use our products and solutions due to the potential risk exposure as a result of the current (and, in particular, future) data protection obligations imposed on them by certain data protection authorities in interpretation of current law, including the GDPR. Such clients or biopharmaceutical partners may also view any alternative approaches to compliance as being too costly, too burdensome, too legally uncertain or otherwise objectionable and therefore decide not to do business with us. Any of the forgoing could materially harm our business, prospects, financial condition and results of operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional laws and regulations governing international operations could negatively impact or restrict our operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we further expand our operations outside of the U.S., we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The U.S. Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, authorizing payment or offering anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of any foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the U.S. to comply with certain accounting provisions requiring the Company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because in many countries hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various laws, regulations and executive orders also restrict the use and dissemination outside of the U.S., or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the U.S., it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing or selling certain products and product candidates outside of the U.S., which could limit our growth potential and increase our development costs.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations of any such laws and regulations.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations, which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors and other partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We also expect our non-U.S. activities to increase in time. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals, and we can be held liable for the corrupt or other illegal activities of our personnel, agents or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to managing business and operations</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public health outbreaks, epidemics or pandemics, such as the ongoing COVID-19 pandemic, could adversely impact our business, including our preclinical studies and clinical trials.*</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Public health outbreaks, epidemics and pandemics could adversely impact our business. For example, the novel strain of coronavirus, severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2, identified in Wuhan, China in December 2019, and the resulting disease from SARS-CoV-2, or COVID-19, has become a global pandemic. This disease continues to spread, including recent acceleration of the spread of the Delta and Omicron variants of COVID-19 in the areas in which the Company operates. The pandemic and government measures taken in response have had a significant impact, both directly and indirectly, on businesses and commerce throughout the world generally: worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. In response to the spread of COVID-19, our personnel have been continuing their work outside of our offices. While, as of the date of this report, we have not experienced any material disruptions to the execution of the research and development activities that we currently have underway, as a result of the pandemic, including the impact of emerging variant strains of the COVID-19 virus and the availability and utilization of COVID-19 vaccines, and with respect to any future epidemics, all of which remain uncertain and difficult to predict, we may continue to experience disruptions that could severely impact research and development timelines and outcomes, including, but not limited to:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in enrolling patients in our clinical trials;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal, state or foreign governments, employers and others or interruption of clinical trial subject visits and study procedures (such as procedures that are deemed non-essential under law, regulation or institutional policies), which may impact the integrity of subject data and clinical study endpoints and the inability of patients to travel to trial sites or complete scheduled study visits;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruptions in preclinical studies due to restricted or limited operations at our contracted research facilities;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen costs we may incur as a result of the impact of the ongoing COVID-19 pandemic, including the costs of mitigation efforts;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">deterioration of worldwide credit and financial markets that could limit our ability to obtain external financing to fund our operations and capital expenditures;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investment-related risks, including difficulties in liquidating investments due to current market conditions and adverse investment performance;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on employee resources that would otherwise be focused on the conduct of our research and development activities, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; or</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruptions or limitations of the types described affecting our service providers and collaboration partners, including contract research organizations running clinical trials and collaboration partners sponsoring clinical trials in which we are supplying our product candidates or otherwise participating.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Since the beginning of the COVID-19 pandemic, three vaccines for COVID-19 have received Emergency Use Authorization by the FDA and two of those later received marketing approval. Additional vaccines may be authorized or approved in the future. The resultant demand for vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, may make it more difficult to obtain materials or manufacturing slots for the products needed for our clinical trials, which could lead to delays in these trials. In addition, the trading prices for common stock of other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. The COVID-19 pandemic continues to evolve, including the recent acceleration of the spread of the Delta and Omicron variants of COVID-19 in the areas in which the Company operates, and the continuing and long-term impacts are difficult to predict. While the negative effects of the pandemic appear to be lessening and vaccines have been widely distributed and continue to be distributed in the United States, numerous other countries have not developed or distributed vaccines at all or on widespread bases, and, therefore, may continue to see widespread impact of the COVID-19 virus. The negative economic impacts on economies generally, resulting volatility in the stock market, and the negative impact on many industries, the workforce and retailers continue to be felt. Additionally, there have emerged numerous variant strains of the COVID-19 virus, and there is a possibility that the vaccines we currently have available will not be protective against such variant strains, as well as concerns around stagnant vaccination rates and related factors which continue to impede progress toward the return to pre-pandemic activities and levels of consumer confidence. The extent to which the current pandemic and any potential future resurgences or outbreaks impact our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread and distribution of the disease, the duration of the pandemic, travel restrictions and social distancing in the U.S. and other countries, business closures or business disruptions, the success of treatments and vaccines designed to combat the COVID-19 virus and the effectiveness of other actions taken in the U.S. and other countries to diagnose, contain and treat the disease. If we or any of the third parties with whom we engage were to experience shutdowns or other business disruptions, our ability to conduct our business and development activities in the manner and on the timelines presently planned could be materially and negatively impacted. There can be no assurance that any such disruptions or delays will not materially adversely impact our business, results of operations, access to financial resources and our financial condition.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we lose key management personnel, or if we fail to recruit additional highly skilled personnel, our ability to pursue our business strategy will be impaired, could result in loss of markets or market share and could make us less competitive.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biopharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel, including Saqib Islam, our Chief Executive Officer, Frank Perier, our Chief Financial Officer, Bhavesh Ashar, our Chief Commercial Officer, Badreddin Edris, our Chief Operating Officer, Michael Burgess, our Head of Research and Development and L. Mary Smith, our Chief Development Officer. The loss of the services of any of our executive officers, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other key employees, and other scientific and medical advisors, and our inability to find suitable replacements for these individuals, could harm our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Competition for skilled personnel in our industry is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms, in a timely manner or at all. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided equity incentive awards that vest over time and from time to time we will consider additional forms of incentives given then-prevailing company circumstances and market conditions. The value to employees of restricted stock units and awards and stock options that vest over time may be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams are at-will employees and may terminate their employment with us on short notice. We do not maintain &#8220;key man&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. Given the stage of our programs and our plans to expand operations, our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior personnel across our organization.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those used by our vendors, or other contractors or consultants, may fail or suffer security breaches.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems and those of our CROs and other third parties, including our contractors and consultants, are vulnerable to damage from computer viruses and unauthorized access. Like other companies of our size and in our industry, we have been the target of phishing attacks and attacks on our data and systems. Companies have experienced an increase in phishing and social engineering attacks from third parties in connection with the ongoing COVID-19 global pandemic. While we believe we have not experienced any material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of preclinical or clinical data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of financial or confidential information, we could incur liability and the further development and commercialization of our product candidates could be delayed.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also be subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental release or loss of information maintained in the information systems and networks of our company and our contractors or consultants. In addition, outside parties may attempt to penetrate our systems or those of our contractors or consultants or fraudulently induce our personnel or the personnel of our contractors or consultants to disclose sensitive information in order to gain access to our data and/or systems. We may experience threats to our data and systems, including malicious codes and viruses, phishing and other cyber-attacks. The number and complexity of these threats continue to increase over time. If a material breach of our information technology systems or those of our contractors or consultants occurs, the market perception of the effectiveness of our security measures could be harmed and our reputation and credibility could be damaged. We could be required to expend significant amounts of money and other resources to repair or replace information systems or networks. In addition, we could be subject to regulatory actions and/or claims made by individuals and groups in private litigation involving privacy issues related to data collection and use practices and other data privacy laws and regulations, including claims for misuse or inappropriate disclosure of data, as well as unfair or deceptive practices. Although we develop and maintain systems and controls designed to prevent these events from occurring, and we have a process to identify and mitigate threats, the development and maintenance of these systems, controls and processes is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures become increasingly sophisticated. Moreover, despite our efforts, the possibility of these events occurring cannot be eliminated entirely. In addition, there can be no assurance that our internal information technology systems or those of our third-party contractors, or our consultants&#8217; efforts to implement adequate security and control measures, will be sufficient to protect us against breakdowns, service disruption, data deterioration or loss in the event of a system malfunction, or prevent data from being stolen or corrupted in the event of a cyberattack, security breach, industrial espionage attacks or insider threat attacks which could result in financial, legal, business or reputational harm.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, consultants, academic collaborators, partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, academic collaborators, partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to comply with the laws of the FDA, EMA and comparable foreign regulatory authorities, provide true, complete and accurate information to the FDA, EMA and comparable foreign regulatory authorities, comply with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing standards we have established, comply with healthcare fraud and abuse laws in the U.S. and similar foreign fraudulent misconduct laws, or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the U.S., our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter misconduct by our employees, independent contractors, consultants, academic collaborators, partners and vendors, and the precautions we take to detect and prevent such activities may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of civil, criminal and administrative penalties, damages, monetary fines, imprisonment, disgorgement, possible exclusion from participation in government healthcare programs, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings and the curtailment of our operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our development activities involve the use of biological and hazardous materials and can produce hazardous waste products. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological waste or hazardous waste insurance coverage, workers compensation or property and casualty and general liability insurance policies that include coverage for damages and fines arising from biological or hazardous waste exposure or contamination.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax law could adversely affect our business and financial condition.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. Shareholders should consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain tax credit carryforwards may be subject to limitation.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had federal, state and city net operating loss carryforwards of $257.8 million, $151.1 million and $3.7 million, respectively, which are available to reduce future taxable income. Federal net operating loss carryforwards generated 2018 through 2021 of $253.5 million will be limited to offset 80% of taxable income for an indefinite period of time, until fully utilized. Federal net operating loss carryforwards of $4.3 million reported in 2017, and the state and city net </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operating loss carryforwards expire at various dates through 2040. We also have federal tax credits of $16.7 million, which may be used to offset future tax liabilities. These tax credit carryforwards will expire at various dates beginning in 2038.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under Sections 382 and 383 of the Internal Revenue Code of 1986, or the Code, as amended, changes in our ownership may limit the amount of our net operating loss carryforwards and tax credit carryforwards that could be utilized annually to offset our future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of our company of more than 50% within a three-year period. Any such limitation may significantly reduce our ability to utilize our net operating loss carryforwards and tax credit carryforwards before they expire. Private placements and other transactions that have occurred since our inception, as well as our initial public offering, may trigger such an ownership change pursuant to Sections 382 and 383 of the Code. Any such limitation, whether as the result of the initial public offering, prior private placements, sales of our common stock by our existing stockholders or additional sales of our common stock by us, could have a material adverse effect on our results of operations in future years. Generally, under current law, federal net operating losses generated after December 31, 2017 are not subject to expiration and may not be carried back to prior taxable years. However, the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, suspended the 80% taxable income limitation for net operating losses generated in 2018, 2019, and 2020 to the extent these losses are exhausted during the special five-year carryback period or during the 2018, 2019 or 2020 tax years. Additionally, as noted above, for taxable years beginning after December 31, 2020, the CARES Act provisions no longer apply and the deductibility of such federal net operating losses is limited to 80% of our taxable income in any future taxable year.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The United Kingdom&#8217;s withdrawal from the EU may have a negative effect on global economic conditions, financial markets and our business, which could reduce the price of our ordinary shares.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following the result of a referendum in 2016, the United Kingdom left the EU on January 31, 2020, commonly referred to as Brexit. Pursuant to the formal withdrawal arrangements agreed between the United Kingdom and the EU, the United Kingdom was subject to a transition period until December 31, 2020, or the Transition Period, during which EU rules continued to apply. Upon the expiration of the Transition Period, the EU and the United Kingdom entered into a post-Brexit trade and cooperation agreement on certain aspects of trade and other strategic and political issues, which became provisionally applicable on January 1, 2021 and entered into force May 1, 2021 following ratification by both the United Kingdom and the EU.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since a significant proportion of the regulatory framework in the United Kingdom applicable to our business and our product candidates is derived from EU directives and regulations, the ultimate effects of Brexit, following the Transition Period, could materially impact the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the United Kingdom or the EU. For example, as a result of the uncertainty surrounding Brexit, the EMA relocated to Amsterdam from London. The United Kingdom is no longer covered by the centralized procedures for obtaining EU-wide marketing and manufacturing authorizations from the EMA and, pursuant to the aforementioned trade and cooperation agreement, there will be separate processes for authorization of drug products in the United Kingdom and the EU. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the United Kingdom or the EU and restrict our ability to generate revenue and achieve and sustain profitability. In addition, we may be required to pay taxes or duties or be subjected to other hurdles in connection with the importation of our product candidates into the EU, or we may incur expenses in establishing a manufacturing facility in the EU in order to circumvent such hurdles. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom or the EU for our product candidates, or incur significant additional expenses to operate our business, which could significantly and materially harm or delay our ability to generate revenues or achieve profitability of our business. Any further changes in international trade, tariff and import/export regulations as a result of Brexit or otherwise may impose unexpected duty costs or other non-tariff barriers on us. These developments, or the perception that any of them could occur, may significantly reduce global trade and, in particular, trade between the impacted nations and the United Kingdom. It is also possible that Brexit may negatively affect our ability to attract and retain employees, particularly those from the EU.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. Portions of our future clinical trials may be conducted outside of the U.S. and unfavorable economic conditions resulting in the weakening of the U.S. dollar would make those clinical trials more costly to operate. In addition, regarding the current conflict in Ukraine, while we do not have any clinical trial sites or operations in Ukraine or Russia, if the current conflict expands into the region continues, resulting heightened economic sanctions from the United States and the international community, in addition to environmental regulations, could limit our ability to procure or use certain materials or manufacturing slots for the products needed for our clinical trials, which could lead to delays in these trials. Furthermore, the most recent global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn (including inflation or uncertainty caused by political violence and chaos) could result in a variety of risks to our business, including a reduced ability to raise additional capital when needed on acceptable terms, if at all. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A weak or declining economy or international trade disputes could also strain our suppliers, some of which are located outside of the U.S., possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Increasing scrutiny and changing expectations from governments with respect to Environmental, Social and Governance, or ESG, policies and practices may cause us to incur additional costs or expose us to additional risks.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been increasing public focus and scrutiny from investors and governmental and nongovernmental organizations on corporate ESG practices. Our ESG practices may not meet the standards of all of our stockholders and advocacy groups may campaign for further changes. A failure, or perceived failure, to respond to related expectations could cause harm to our business and reputation and have a negative impact on the market price of our securities. New governmental regulations could result in new regulations and new or more stringent forms of ESG oversight and disclosures which may lead to increased expenditures for sustainability initiatives.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to a company&#8217;s financial position and need for additional capital</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The amount of our future losses is uncertain and our quarterly and annual operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly and annual operating results may fluctuate significantly in the future due to a variety of factors, many of which are outside of our control and may be difficult to predict, including the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and success or failure of clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully recruit and retain subjects for clinical trials, and any delays caused by difficulties in such efforts;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain marketing approval for our product candidates, and the timing and scope of any such approvals we may receive;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and cost of, and level of investment in, research and development activities relating to our product candidates, which may change from time to time;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our product candidates, which may vary depending on the quantity of production and the terms of our agreements with manufacturers;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract, hire and retain qualified personnel;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenditures that we will or may incur to develop additional product candidates;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of demand for our product candidates should they receive approval, which may vary significantly;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and level of investment in commercialization efforts to support product candidates, both before and after regulatory approval is obtained;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk/benefit profile, cost and reimbursement policies with respect to our product candidates if approved, and existing and potential future therapeutics that compete with our product candidates; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future accounting pronouncements or changes in our accounting policies.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to common stock</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for our common stock may not be sustained.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our shares of common stock began trading on The Nasdaq Global Select Market on September 13, 2019. Given the limited trading history of our common stock, there is a risk that an active trading market for our shares will not be sustained, which could put downward pressure on the market price of our common stock and thereby affect the ability of our stockholders to sell their shares. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of common stock as consideration.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our stock may be volatile, and Stockholders could lose all or part of their investment.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk factors&#8221; section and elsewhere in this report, these factors include:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commencement, enrollment or results of our ongoing potentially registrational clinical trials for nirogacestat and mirdametinib;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse results from or delays in future clinical trials;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates or any future product candidate;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws or regulations applicable to our product candidates or any future product candidate, including but not limited to clinical trial requirements for approvals;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse developments concerning our manufacturers;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to establish collaborations or partnerships, if needed;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to commercialize our product candidates, if approved;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key medical, scientific or management personnel;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated serious safety concerns related to the use of our product candidates;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of new products or services offered by us or our competitors;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial results for other product candidates that could compete with our product candidates;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively manage our growth;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated variations in quarterly operating results;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our cash position;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publication of research reports about us or our industry, or product candidates in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the market valuations of similar companies;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overall performance of the equity markets;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock by us or our stockholders in the future;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our common stock;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting practices;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ineffectiveness of our internal controls;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general political and economic conditions; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other events or factors, many of which are beyond our control.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations resulting from the COVID-19 pandemic or other macroeconomic factors and have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. If the market price of our common stock does not exceed a stockholder's purchase price, such stockholder may not realize any return on their investment in us and may lose some or all of their investment. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to new and existing compliance initiatives.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we incur significant legal, accounting and other expenses. We are subject to the reporting requirements of the Exchange Act which require, among other things, that we file, with the SEC, annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#8220;say on pay&#8221; and proxy access.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline. As of March&#160;31, 2022, the Company had 49,407,617 shares of common stock outstanding, of which 398,510 shares are restricted shares subject to future vesting. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, approximately 55.2% of our shares of common stock are beneficially held by directors, executive officers and holders of more than 5% of our common stock and will be subject to certain limitations of Rule 144 under the Securities Act.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, shares of common stock that are either subject to outstanding options or reserved for future issuance under our existing equity compensation plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule 144 and Rule 701 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. Additionally, the number of shares of our common stock reserved for issuance under the 2019 Stock Option and Equity Incentive Plan will automatically increase on January 1 of each year, with January 1, 2020 having been the first of such increases and continuing through and including January 1, 2030, by 5% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as determined by our board of directors. Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act and the related rules and regulations of the SEC and the Public Company Accounting Oversight Board, or Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be required to disclose changes made in our internal controls and procedures on a quarterly basis and our management will be required to assess the effectiveness of these controls annually.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our independent registered public accounting firm is required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404. An independent assessment of the effectiveness of our internal controls over financial reporting could detect problems that our management&#8217;s assessment did not, and could lead to additional findings, potentially including material weaknesses. Material weaknesses in our internal controls over financial reporting could lead to restatements of our financial statements and require us to incur the expense of remediation.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.</span></div><div id="i14026a47930f410d91f89b4244285b77_106"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i14026a47930f410d91f89b4244285b77_109"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Defaults Upon Senior Securities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i14026a47930f410d91f89b4244285b77_112"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i14026a47930f410d91f89b4244285b77_115"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5. Other Information</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, we adopted a retention program for our senior Research and Development leadership to further incentivize their continued service during anticipated upcoming key research and development milestones. In connection with this program, on May 2, 2022, we entered into a retention agreement with Dr. Burgess, Head of Research and Development and one of our named executive officers, which provides for retention bonuses of cash and equity, subject to Dr. Burgess&#8217; continued employment through specified dates as further described below. If Dr. Burgess remains employed by the Company through June 30, 2022 and June 30, 2023, the Company will make lump sum retention payments of $200,000 to Dr. Burgess on each of those dates. In addition, if Dr. Burgess remains employed by the Company through June 30, 2022, the Company will grant fully vested stock awards for the number of shares of the Company&#8217;s common stock having a value equal to $300,000 to Dr. Burgess. If Dr. Burgess remains employed by the Company through June 30, 2023, the Company will grant restricted stock units for the number of shares of the Company&#8217;s common stock having a value equal to $300,000 to Dr. Burgess, which restricted stock units will vest as follows: 33% shall vest on June 30, 2024; 33% shall vest on June 30, 2025; and 34% shall vest on June 30, 2026, in each case subject to Dr. Burgess&#8217; continued employment with the Company through each such vesting date.</span></div><div id="i14026a47930f410d91f89b4244285b77_118"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT INDEX</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.437%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit <br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1773427/000114420419044905/tv529565_ex3-1.htm">Amended and Restated Certificate of Incorporation, as amended, of the Registrant, as currently in effect. (Incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 17, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1773427/000114420419044905/tv529565_ex3-2.htm">Bylaws of the Registrant, as currently in effect. (Incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 17, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1773427/000110465920066080/tm2020938d1_ex3-1.htm">Amendment to Bylaws of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrants&#8217; Current Report on Form 8-K filed with the Securities and Exchange Commission on May 27, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1773427/000114420419040443/tv525698_ex4-1.htm">Specimen Stock Certificate evidencing shares of common stock (Incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S 1/A (File No. 333 233351) filed with the Securities and Exchange Commission on September 12, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1773427/000114420419043091/tv527886_ex4-2.htm">Amended and Restated Investors' Rights Agreement among the Registrant and certain of its stockholders, dated August 30, 2018 (Incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-233351) filed with the Securities and Exchange Commission on September 12, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1773427/000155837020002563/swtx-20191231ex43074795b.htm">Description of the Registrant&#8217;s Securities (Incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, filed March 12, 2020.)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1773427/000155837021001708/swtx-20201231xex4d4.htm">Amendment to the Amended and Restated Investors&#8217; Rights Agreement, dated as of February 25, 2021 (Incorporated by Reference to Exhibit 4.4 to the Registrant's Annual Report on Form 10-K filed with the Securities and Exchanges Commission on February 25, 2021).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="stamfordsecondleasemodif.htm">Second Lease Modification Agreement, dated as of January 31, 2022, by and between Two Harbor Point Square LLC and SpringWorks Therapeutics, Inc.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="springworks-retentionbonus.htm">Retention Agreement, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="springworks-retentionbonus.htm">May 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="springworks-retentionbonus.htm">, 2022, by and between SpringWorks Therapeutics, Inc. and Michael Burgess</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="springworks-retentionbonus.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="springworks-retentionbonusa.htm">Retention Agreement, dated May 2, 2022, by and between SpringWorks Therapeutics, Inc. and L. Mary Smith.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="swtx-20220331xex311.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="swtx-20220331xex312.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="swtx-20220331xex321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="swtx-20210331xex322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Calculation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________________</span></div><div style="padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:40pt">Filed herewith. </span></div><div style="padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:40pt">This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, except to the extent specifically incorporated by reference into such filing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="i14026a47930f410d91f89b4244285b77_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i14026a47930f410d91f89b4244285b77_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.778%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SPRINGWORKS THERAPEUTICS, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 5, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Saqib Islam</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saqib Islam</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr style="height:14pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 5, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Francis I. Perier, Jr.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Francis I. Perier, Jr.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>stamfordsecondleasemodif.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>stamfordsecondleasemodif</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- stamfordsecondleasemodif001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="stamfordsecondleasemodif001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- stamfordsecondleasemodif002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="stamfordsecondleasemodif002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- stamfordsecondleasemodif003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="stamfordsecondleasemodif003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- stamfordsecondleasemodif004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="stamfordsecondleasemodif004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- stamfordsecondleasemodif005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="stamfordsecondleasemodif005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- stamfordsecondleasemodif006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="stamfordsecondleasemodif006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- stamfordsecondleasemodif007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="stamfordsecondleasemodif007.jpg" title="slide7" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- stamfordsecondleasemodif008.jpg -->
<DIV style="padding-top:2em;">
<IMG src="stamfordsecondleasemodif008.jpg" title="slide8" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- stamfordsecondleasemodif009.jpg -->
<DIV style="padding-top:2em;">
<IMG src="stamfordsecondleasemodif009.jpg" title="slide9" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- stamfordsecondleasemodif010.jpg -->
<DIV style="padding-top:2em;">
<IMG src="stamfordsecondleasemodif010.jpg" title="slide10" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>springworks-retentionbonus.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib4c1ac9506e74b8b973aa2ed16761580_1"></div><div style="min-height:136.08pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:49px;margin-bottom:5pt;vertical-align:text-bottom;width:682px"></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">May 2, 2022</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Delivered via Email</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Michael Burgess, M.B.Ch.B., Ph.D.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Retention Agreement</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear Dr. Burgess&#58;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This letter (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) confirms the details of our recent conversation. As we discussed, at this time, in light of the critical milestones anticipated for our R&#38;D organization during 2022, SpringWorks Therapeutics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) considers it to be in the best interests of the Company to provide further incentives to you to remain employed with the Company and has determined that appropriate steps should be taken to reinforce and encourage your continued attention and dedication to your duties and responsibilities.  Accordingly, the Company is pleased to offer you the opportunity to receive certain Retention Opportunities (as defined below), subject to the terms and conditions set forth herein&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Retention Bonuses</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt;text-decoration:underline">2022 Retention Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you remain actively employed by the Company through June 30, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2022 Milestone Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Company shall pay you a cash bonus equal to $200,000, less applicable tax withholdings and deductions (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2022 Retention Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  If earned, the 2022 Retention Bonus shall be paid within ten (10) days after the 2022 Milestone Date.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">2023 Retention Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you remain actively employed by the Company through June 30, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2023 Milestone Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and, together with the 2022 Milestone Date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Milestone Dates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and, each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Milestone Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Company shall pay you a cash bonus equal to $200,000, less applicable tax withholdings and deductions (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2023 Retention Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and, together, with the 2022 Retention Bonus, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Retention Bonuses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  If earned, the 2023 Retention Bonus shall be paid within ten (10) days after the 2023 Milestone Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Retention Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt;text-decoration:underline">2022 Retention Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to your execution of this Agreement and Board approval, and if you remain actively employed by the Company through the 2022 Milestone Date, you shall be eligible to receive a fully vested stock award on the 2022 Milestone Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2022 Retention Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The 2022 Retention Grant shall be granted on the 2022 Milestone Date for the number of shares of the Company&#8217;s common stock equal to approximately $300,000 determined as of the 2022 Milestone Date, based on the closing price of the Company&#8217;s common stock on such date and in accordance with the Company&#8217;s Equity Award Grant Policy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">2023 Retention Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to your execution of this Agreement and Board approval, and if you remain actively employed by the Company through the 2023 Milestone Date, you shall be eligible to receive restricted stock units on the 2023 Milestone Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2023 Retention Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and, together with the 2022 Retention Grant, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Retention Grants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) . The </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:136.08pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:49px;margin-bottom:5pt;vertical-align:text-bottom;width:682px"></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2023 Retention Grant shall be granted on the 2023 Milestone Date for the number of shares of the Company&#8217;s common stock equal to approximately $300,000 determined as of the 2023 Milestone Date, based on the closing price of the Company&#8217;s common stock on such date and in accordance with the Company&#8217;s Equity Award Grant Policy.  The 2023 Retention Grant shall vest as follows&#58;  33% of the 2023 Retention Grant shall vest on June 30, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2024 Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; 33% of the of the 2023 Retention Grant shall vest on June 30, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2025 Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; and 34% of the 2023 Retention Grant shall vest on June 30, 2026 (each, with the 2024 Vesting Date and the 2025 Vesting Date, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2023 Retention Grant Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), provided that you remain employed by the Company through each such vesting date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt">The Retention Grants (together, with the Retention Bonuses, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Retention Opportunities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall be subject to the terms of the Company&#8217;s Amended and Restated 2019 Stock Option and Equity Incentive Plan, as amended, supplemented or replaced from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and the Company&#8217;s standard form of restricted stock award agreement or restricted stock unit award agreement, as applicable, and as may be updated from time to time by the Company and the Board, which you will be required to sign as a condition to receiving your Retention Grants.  In the event that your employment with the Company is terminated for any reason prior to an applicable Milestone Date (or any 2023 Retention Grant Vesting Date ), your right to the corresponding Retention Grant (or portion thereof) shall be immediately forfeited as of the date of such termination.     </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">At-Will Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Your employment is and shall continue to be &#8220;at will,&#8221; meaning you or the Company may terminate it at any time for any or no reason, subject to the terms of your Amended and Restated Employment Agreement with the Company, dated July 30, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  For the avoidance of doubt, if your employment with the Company terminates for any reason&#58; (a) prior to the 2022 Milestone Date, you shall not receive any Retention Bonus or any Retention Grant and your rights to such Retention Bonuses and Retention Grants shall be immediately forfeited in their entirety as of the date of your termination&#59; (b) following the 2022 Milestone Date but prior to the 2023 Milestone Date, you shall not receive the 2023 Retention Bonus or the 2023 Retention Grant and your rights to such Retention Bonus and Retention Grant shall be immediately forfeited in their entirety as of the date of your termination&#59; or (c) following the 2023 Milestone Date but prior to any 2023 Retention Grant Vesting Date, your rights to any unvested portion of the 2023 Retention Grant shall be immediately forfeited.  Your rights to severance and similar benefits will remain governed by and subject to the terms of your Employment Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The parties intend that this Agreement will be administered such that all payments will be exempt from or comply with Section 409A of the Internal Revenue Code (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).&#160; To the extent that any payment to be made under this Agreement is subject to 409A and any provision of this Agreement is ambiguous as to its compliance with Section 409A, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A.&#160; The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.&#160; The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A but do not satisfy an exemption from, or the conditions of, such Section.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:136.08pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:49px;margin-bottom:5pt;vertical-align:text-bottom;width:682px"></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement contains the entire agreement between you and the Company relating to the Retention Opportunities and supersedes any and all prior agreements, representations or understandings (whether written, oral or implied) related to any retention- related compensation and benefits.  For the avoidance of doubt, this Agreement supplements and does not supersede the Employment Agreement, the Option Plan and&#47;or other employment, equity or restrictive covenant-related agreements between you and the Company.  This Agreement cannot be changed or modified except by a formal written instrument executed by you and the Chief Executive Officer of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CEO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or another person duly authorized by the CEO.  By signing below where indicated, you acknowledge and agree that the Retention Opportunities are entirely separate from your base compensation as well as from any performance bonus or severance to which you might otherwise be eligible and it is not a wage.  The terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or in any way connected with, this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) will be governed by Connecticut law, excluding laws relating to conflicts or choice of law. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the State of Connecticut in connection with any Dispute or any claim related to any Dispute.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">We hope that this incentive encourages your continued effective commitment to the Company during this important period.</font></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Very truly yours,</font></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SpringWorks Therapeutics, Inc.</font></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; __&#47;s&#47;_Saqib Islam__________</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Saqib Islam <br>Title&#58; Chief Executive Officer </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I have read and accept this Agreement&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47;_Michael Burgess_____________________________<br>Michael Burgess, M.B.Ch.B., Ph.D. </font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dated&#58;_____May 2, 2022____________________</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>springworks-retentionbonusa.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iaa518f6a5f5349a690361b0a6e477b9c_1"></div><div style="min-height:136.08pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:49px;margin-bottom:5pt;vertical-align:text-bottom;width:682px"></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">May 2, 2022</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Delivered via Email</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L. Mary Smith, Ph.D.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Retention Agreement</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear Dr. Smith&#58;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This letter (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) confirms the details of our recent conversation. As we discussed, at this time, in light of the critical milestones anticipated for our R&#38;D organization during 2022, SpringWorks Therapeutics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) considers it to be in the best interests of the Company to provide further incentives to you to remain employed with the Company and has determined that appropriate steps should be taken to reinforce and encourage your continued attention and dedication to your duties and responsibilities.  Accordingly, the Company is pleased to offer you the opportunity to receive certain Retention Opportunities (as defined below), subject to the terms and conditions set forth herein&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Retention Bonuses</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt;text-decoration:underline">2022 Retention Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you remain actively employed by the Company through June 30, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2022 Milestone Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Company shall pay you a cash bonus equal to $100,000, less applicable tax withholdings and deductions (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2022 Retention Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  If earned, the 2022 Retention Bonus shall be paid within ten (10) days after the 2022 Milestone Date.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">2023 Retention Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you remain actively employed by the Company through June 30, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2023 Milestone Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and, together with the 2022 Milestone Date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Milestone Dates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and, each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Milestone Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Company shall pay you a cash bonus equal to $100,000, less applicable tax withholdings and deductions (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2023 Retention Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and, together, with the 2022 Retention Bonus, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Retention Bonuses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  If earned, the 2023 Retention Bonus shall be paid within ten (10) days after the 2023 Milestone Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Retention Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt;text-decoration:underline">2022 Retention Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to your execution of this Agreement and Board approval, and if you remain actively employed by the Company through the 2022 Milestone Date, you shall be eligible to receive a fully vested stock award on the 2022 Milestone Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2022 Retention Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The 2022 Retention Grant shall be granted on the 2022 Milestone Date for the number of shares of the Company&#8217;s common stock equal to approximately $150,000 determined as of the 2022 Milestone Date, based on the closing price of the Company&#8217;s common stock on such date and in accordance with the Company&#8217;s Equity Award Grant Policy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">2023 Retention Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to your execution of this Agreement and Board approval, and if you remain actively employed by the Company through the 2023 Milestone Date, you shall be eligible to receive restricted stock units on the 2023 Milestone Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2023 Retention Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and, together with the 2022 Retention Grant, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Retention Grants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) . The </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:136.08pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:49px;margin-bottom:5pt;vertical-align:text-bottom;width:682px"></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2023 Retention Grant shall be granted on the 2023 Milestone Date for the number of shares of the Company&#8217;s common stock equal to approximately $150,000 determined as of the 2023 Milestone Date, based on the closing price of the Company&#8217;s common stock on such date and in accordance with the Company&#8217;s Equity Award Grant Policy.  The 2023 Retention Grant shall vest as follows&#58;  33% of the 2023 Retention Grant shall vest on June 30, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2024 Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; 33% of the of the 2023 Retention Grant shall vest on June 30, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2025 Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; and 34% of the 2023 Retention Grant shall vest on June 30, 2026 (each, with the 2024 Vesting Date and the 2025 Vesting Date, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2023 Retention Grant Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), provided that you remain employed by the Company through each such vesting date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt">The Retention Grants (together, with the Retention Bonuses, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Retention Opportunities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall be subject to the terms of the Company&#8217;s Amended and Restated 2019 Stock Option and Equity Incentive Plan, as amended, supplemented or replaced from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and the Company&#8217;s standard form of restricted stock award agreement or restricted stock unit award agreement, as applicable, and as may be updated from time to time by the Company and the Board, which you will be required to sign as a condition to receiving your Retention Grants.  In the event that your employment with the Company is terminated for any reason prior to an applicable Milestone Date (or any 2023 Retention Grant Vesting Date ), your right to the corresponding Retention Grant (or portion thereof) shall be immediately forfeited as of the date of such termination.     </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">At-Will Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Your employment is and shall continue to be &#8220;at will,&#8221; meaning you or the Company may terminate it at any time for any or no reason, subject to the terms of your Amended and Restated Employment Agreement with the Company, dated July 30, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  For the avoidance of doubt, if your employment with the Company terminates for any reason&#58; (a) prior to the 2022 Milestone Date, you shall not receive any Retention Bonus or any Retention Grant and your rights to such Retention Bonuses and Retention Grants shall be immediately forfeited in their entirety as of the date of your termination&#59; (b) following the 2022 Milestone Date but prior to the 2023 Milestone Date, you shall not receive the 2023 Retention Bonus or the 2023 Retention Grant and your rights to such Retention Bonus and Retention Grant shall be immediately forfeited in their entirety as of the date of your termination&#59; or (c) following the 2023 Milestone Date but prior to any 2023 Retention Grant Vesting Date, your rights to any unvested portion of the 2023 Retention Grant shall be immediately forfeited.  Your rights to severance and similar benefits will remain governed by and subject to the terms of your Employment Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The parties intend that this Agreement will be administered such that all payments will be exempt from or comply with Section 409A of the Internal Revenue Code (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).&#160; To the extent that any payment to be made under this Agreement is subject to 409A and any provision of this Agreement is ambiguous as to its compliance with Section 409A, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A.&#160; The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.&#160; The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A but do not satisfy an exemption from, or the conditions of, such Section.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:136.08pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:49px;margin-bottom:5pt;vertical-align:text-bottom;width:682px"></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement contains the entire agreement between you and the Company relating to the Retention Opportunities and supersedes any and all prior agreements, representations or understandings (whether written, oral or implied) related to any retention- related compensation and benefits.  For the avoidance of doubt, this Agreement supplements and does not supersede the Employment Agreement, the Option Plan and&#47;or other employment, equity or restrictive covenant-related agreements between you and the Company.  This Agreement cannot be changed or modified except by a formal written instrument executed by you and the Chief Executive Officer of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CEO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or another person duly authorized by the CEO.  By signing below where indicated, you acknowledge and agree that the Retention Opportunities are entirely separate from your base compensation as well as from any performance bonus or severance to which you might otherwise be eligible and it is not a wage.  The terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or in any way connected with, this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) will be governed by Connecticut law, excluding laws relating to conflicts or choice of law. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the State of Connecticut in connection with any Dispute or any claim related to any Dispute.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">We hope that this incentive encourages your continued effective commitment to the Company during this important period.</font></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Very truly yours,</font></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SpringWorks Therapeutics, Inc.</font></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47;_Saqib Islam__________________</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Saqib Islam <br>Title&#58; Chief Executive Officer </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I have read and accept this Agreement&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47;__L. Mary Smith____________________________<br>L. Mary Smith, Ph.D.</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dated&#58;__May 2, 2022_______________________</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>swtx-20220331xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i310b5bf000c84d29b1578c76a31ccc7c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ACT OF 2002</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Saqib Islam, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of SpringWorks Therapeutics, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))&#58;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:241.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:22.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:241.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 5, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Saqib Islam</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saqib Islam</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:30pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>swtx-20220331xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iea64b6e1017c49d5ad578cbcdf958f82_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ACT OF 2002</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Francis I. Perier, Jr., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">I have reviewed this Quarterly Report on Form 10-Q of SpringWorks Therapeutics, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))&#58;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:241.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:22.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:241.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 5, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Francis I. Perier, Jr.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Francis I. Perier, Jr.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>swtx-20220331xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i07cfbf867cff4b56876911e70cf879e8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of SpringWorks Therapeutics, Inc. (the &#8220;Company&#8221;) for the period ended March&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Saqib Islam, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge&#58;</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.34pt">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:241.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:22.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:241.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 5, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Saqib Islam</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saqib Islam</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:30pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:30pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>swtx-20210331xex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6e46d514a548406a93fd8e46f8449e11_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of SpringWorks Therapeutics, Inc. (the &#8220;Company&#8221;) for the period ended March&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Francis I. Perier, Jr., Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge&#58;</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.34pt">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:241.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:22.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:241.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 5, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Francis I. Perier, Jr.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Francis I. Perier, Jr.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:30pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:30pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>swtx-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:20c9ef3f-9e42-493b-a5cd-6a5cd47c499c,g:fe877b4c-7b58-4b84-8d3e-d0ed79a85bd8-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:swtx="http://www.springworkstx.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.springworkstx.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="swtx-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="swtx-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="swtx-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="swtx-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.springworkstx.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsUnaudited" roleURI="http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)&#8203;</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLossUnaudited" roleURI="http://www.springworkstx.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)&#8203;</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityUnaudited" roleURI="http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited)&#8203;</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)&#8203;</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofOperations" roleURI="http://www.springworkstx.com/role/NatureofOperations">
        <link:definition>2101101 - Disclosure - Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofOperationsDetails" roleURI="http://www.springworkstx.com/role/NatureofOperationsDetails">
        <link:definition>2402401 - Disclosure - Nature of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentation" roleURI="http://www.springworkstx.com/role/BasisofPresentation">
        <link:definition>2103102 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationPolicies" roleURI="http://www.springworkstx.com/role/BasisofPresentationPolicies">
        <link:definition>2204201 - Disclosure - Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationDetails" roleURI="http://www.springworkstx.com/role/BasisofPresentationDetails">
        <link:definition>2405402 - Disclosure - Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://www.springworkstx.com/role/MarketableSecurities">
        <link:definition>2106103 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://www.springworkstx.com/role/MarketableSecuritiesTables">
        <link:definition>2307301 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://www.springworkstx.com/role/MarketableSecuritiesDetails">
        <link:definition>2408403 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.springworkstx.com/role/FairValueMeasurements">
        <link:definition>2109104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.springworkstx.com/role/FairValueMeasurementsTables">
        <link:definition>2310302 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.springworkstx.com/role/FairValueMeasurementsDetails">
        <link:definition>2411404 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentandVariableInterestEntity" roleURI="http://www.springworkstx.com/role/InvestmentandVariableInterestEntity">
        <link:definition>2112105 - Disclosure - Investment and Variable Interest Entity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentandVariableInterestEntityDetails" roleURI="http://www.springworkstx.com/role/InvestmentandVariableInterestEntityDetails">
        <link:definition>2413405 - Disclosure - Investment and Variable Interest Entity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://www.springworkstx.com/role/AccruedExpenses">
        <link:definition>2114106 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.springworkstx.com/role/AccruedExpensesTables">
        <link:definition>2315303 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.springworkstx.com/role/AccruedExpensesDetails">
        <link:definition>2416406 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.springworkstx.com/role/CommitmentsandContingencies">
        <link:definition>2117107 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.springworkstx.com/role/CommitmentsandContingenciesTables">
        <link:definition>2318304 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.springworkstx.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2419407 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails" roleURI="http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails">
        <link:definition>2420408 - Disclosure - Commitments and Contingencies - Maturities of operating lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails_1" roleURI="http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails_1">
        <link:definition>2420408 - Disclosure - Commitments and Contingencies - Maturities of operating lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.springworkstx.com/role/StockBasedCompensation">
        <link:definition>2121108 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.springworkstx.com/role/StockBasedCompensationTables">
        <link:definition>2322305 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation2019EquityIncentivePlanDetails" roleURI="http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails">
        <link:definition>2423409 - Disclosure - Stock-Based Compensation - 2019 Equity Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationEquitybasedcompensationexpenserelatedtorestrictedstockandstockoptionsDetails" roleURI="http://www.springworkstx.com/role/StockBasedCompensationEquitybasedcompensationexpenserelatedtorestrictedstockandstockoptionsDetails">
        <link:definition>2424410 - Disclosure - Stock-Based Compensation - Equity-based compensation expense related to restricted stock and stock options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShare" roleURI="http://www.springworkstx.com/role/NetLossperShare">
        <link:definition>2125109 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareTables" roleURI="http://www.springworkstx.com/role/NetLossperShareTables">
        <link:definition>2326306 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareDetails" roleURI="http://www.springworkstx.com/role/NetLossperShareDetails">
        <link:definition>2427411 - Disclosure - Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="swtx_LesseeOperatingLeaseNumberOfRenewalOptions" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="swtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="swtx_ExecutiveOfficersAndEmployeesMember" abstract="true" name="ExecutiveOfficersAndEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="swtx_LesseeOperatingLeaseRenewalOptionOneMember" abstract="true" name="LesseeOperatingLeaseRenewalOptionOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="swtx_NumberOfClinicalTrials" abstract="false" name="NumberOfClinicalTrials" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="swtx_LongTermInvestmentsMember" abstract="true" name="LongTermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="swtx_WorkingCapital" abstract="false" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="swtx_CeoPerformanceAwardMember" abstract="true" name="CeoPerformanceAwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="swtx_MapkureMember" abstract="true" name="MapkureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="swtx_LongTermInvestmentsFairValueDisclosure" abstract="false" name="LongTermInvestmentsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="swtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="swtx_NonCashOperatingLeaseExpense" abstract="false" name="NonCashOperatingLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="swtx_ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" abstract="true" name="ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="swtx_LesseeOperatingLeaseRenewalTermAxisDomain" abstract="true" name="LesseeOperatingLeaseRenewalTermAxisDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="swtx_LesseeOperatingLeaseEntitledTenantAllowance" abstract="false" name="LesseeOperatingLeaseEntitledTenantAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="swtx_EquityIncentivePlan2019Member" abstract="true" name="EquityIncentivePlan2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="swtx_IncreaseDecreaseInLeaseLiability" abstract="false" name="IncreaseDecreaseInLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="swtx_LesseeOperatingLeaseRenewalTermAxisAxis" abstract="true" name="LesseeOperatingLeaseRenewalTermAxisAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="swtx_AnnualIncreaseInLeasePaymentsPercentage" abstract="false" name="AnnualIncreaseInLeasePaymentsPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="swtx_LesseeOperatingLeaseRenewalOptionTwoMember" abstract="true" name="LesseeOperatingLeaseRenewalOptionTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="swtx_AccruedResearchAndDevelopmentExpenses" abstract="false" name="AccruedResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="swtx_StamfordConnecticutMember" abstract="true" name="StamfordConnecticutMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>swtx-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:20c9ef3f-9e42-493b-a5cd-6a5cd47c499c,g:fe877b4c-7b58-4b84-8d3e-d0ed79a85bd8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="swtx-20220331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1e5644cf-c33f-40f0-8e9c-d7d4bc0a16d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_8ed10eac-0168-43db-b400-3f3f2db90af3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1e5644cf-c33f-40f0-8e9c-d7d4bc0a16d7" xlink:to="loc_us-gaap_AdditionalPaidInCapital_8ed10eac-0168-43db-b400-3f3f2db90af3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d0bd05cc-caa5-40e9-b07c-a459960bf3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1e5644cf-c33f-40f0-8e9c-d7d4bc0a16d7" xlink:to="loc_us-gaap_CommonStockValue_d0bd05cc-caa5-40e9-b07c-a459960bf3d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_676c78d1-79fe-4b8d-b01b-e02590042372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1e5644cf-c33f-40f0-8e9c-d7d4bc0a16d7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_676c78d1-79fe-4b8d-b01b-e02590042372" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_644ce90b-e0e7-4aab-83fb-9b3eaf8d2c79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1e5644cf-c33f-40f0-8e9c-d7d4bc0a16d7" xlink:to="loc_us-gaap_TreasuryStockValue_644ce90b-e0e7-4aab-83fb-9b3eaf8d2c79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5483ab85-a0da-4afb-a5dc-e8fb08b2e6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1e5644cf-c33f-40f0-8e9c-d7d4bc0a16d7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5483ab85-a0da-4afb-a5dc-e8fb08b2e6e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_1a436d64-830b-4377-b81a-7ce01812e22e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1e5644cf-c33f-40f0-8e9c-d7d4bc0a16d7" xlink:to="loc_us-gaap_PreferredStockValue_1a436d64-830b-4377-b81a-7ce01812e22e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_fd27c729-52c7-49c1-b9dc-3db7d9dc9e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_7614b999-400f-4549-a572-0e3d7c37e50e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd27c729-52c7-49c1-b9dc-3db7d9dc9e98" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_7614b999-400f-4549-a572-0e3d7c37e50e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a5732a8f-86e1-401d-8aff-d1154c504273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd27c729-52c7-49c1-b9dc-3db7d9dc9e98" xlink:to="loc_us-gaap_AssetsCurrent_a5732a8f-86e1-401d-8aff-d1154c504273" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_6253a133-dcc0-4f36-884b-45f573f9386b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd27c729-52c7-49c1-b9dc-3db7d9dc9e98" xlink:to="loc_us-gaap_EquityMethodInvestments_6253a133-dcc0-4f36-884b-45f573f9386b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a1676e93-1856-4153-88b1-d52c7c8e5465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd27c729-52c7-49c1-b9dc-3db7d9dc9e98" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a1676e93-1856-4153-88b1-d52c7c8e5465" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0dad2154-7ef3-4c94-ad44-c6fb213001ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd27c729-52c7-49c1-b9dc-3db7d9dc9e98" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0dad2154-7ef3-4c94-ad44-c6fb213001ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6147d470-8c5b-49dd-be5f-309f24f2e884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd27c729-52c7-49c1-b9dc-3db7d9dc9e98" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6147d470-8c5b-49dd-be5f-309f24f2e884" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_d5a5d0cb-f79c-448c-af81-119728f899d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd27c729-52c7-49c1-b9dc-3db7d9dc9e98" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_d5a5d0cb-f79c-448c-af81-119728f899d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6e01b135-82a7-4aac-aa51-19ed787aa44f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ecfdefb3-d430-47f0-86e6-c69e8ab966cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6e01b135-82a7-4aac-aa51-19ed787aa44f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ecfdefb3-d430-47f0-86e6-c69e8ab966cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_e952f1b8-a426-43e6-97b9-752612c406f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6e01b135-82a7-4aac-aa51-19ed787aa44f" xlink:to="loc_us-gaap_MarketableSecurities_e952f1b8-a426-43e6-97b9-752612c406f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_b8eb2d75-c4cd-4cd8-8e38-12768df44c02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6e01b135-82a7-4aac-aa51-19ed787aa44f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_b8eb2d75-c4cd-4cd8-8e38-12768df44c02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3f5c8702-6845-42ee-9830-c265120508af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_88d853e6-70b7-4a01-90ad-196d69f15ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3f5c8702-6845-42ee-9830-c265120508af" xlink:to="loc_us-gaap_AccountsPayableCurrent_88d853e6-70b7-4a01-90ad-196d69f15ee5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_568939f6-94cd-481f-a485-45ad96225635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3f5c8702-6845-42ee-9830-c265120508af" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_568939f6-94cd-481f-a485-45ad96225635" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a0188cb3-98e1-4ac7-999d-ffa5d1121304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3f5c8702-6845-42ee-9830-c265120508af" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a0188cb3-98e1-4ac7-999d-ffa5d1121304" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4355cf1d-d644-49a9-b8ee-528c6737687b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6a886e62-ea6c-4faa-a0aa-da40249b5733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4355cf1d-d644-49a9-b8ee-528c6737687b" xlink:to="loc_us-gaap_LiabilitiesCurrent_6a886e62-ea6c-4faa-a0aa-da40249b5733" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ace6ed2d-f79a-4e3d-8b90-3ebcf04633be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4355cf1d-d644-49a9-b8ee-528c6737687b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ace6ed2d-f79a-4e3d-8b90-3ebcf04633be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_820f4b24-a9a5-41ac-a93e-048e540ebaf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_14b3f0d2-6075-49fb-bccb-fb0316775733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_820f4b24-a9a5-41ac-a93e-048e540ebaf7" xlink:to="loc_us-gaap_Liabilities_14b3f0d2-6075-49fb-bccb-fb0316775733" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_256c12e0-805f-4451-b275-2a4dc6f09d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_820f4b24-a9a5-41ac-a93e-048e540ebaf7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_256c12e0-805f-4451-b275-2a4dc6f09d5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_46f23bad-fafa-4e50-b49f-5fd810201fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_820f4b24-a9a5-41ac-a93e-048e540ebaf7" xlink:to="loc_us-gaap_StockholdersEquity_46f23bad-fafa-4e50-b49f-5fd810201fe6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="swtx-20220331.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:calculationLink xlink:role="http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_37ff9a5a-b9a6-4fbe-a5e1-eaac8653b8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_960db623-a82a-475a-8e24-7cab05cae770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_37ff9a5a-b9a6-4fbe-a5e1-eaac8653b8bc" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_960db623-a82a-475a-8e24-7cab05cae770" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b392fb45-9669-43d8-ba04-3e48e791bb31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_37ff9a5a-b9a6-4fbe-a5e1-eaac8653b8bc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b392fb45-9669-43d8-ba04-3e48e791bb31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f8d0ab1b-208a-4b47-a98a-8e707a500557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f6b94612-76fd-410d-83c8-d26bb45b5591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f8d0ab1b-208a-4b47-a98a-8e707a500557" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f6b94612-76fd-410d-83c8-d26bb45b5591" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_88bad58c-1343-4938-8d93-293e06c191f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f8d0ab1b-208a-4b47-a98a-8e707a500557" xlink:to="loc_us-gaap_InvestmentIncomeNet_88bad58c-1343-4938-8d93-293e06c191f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f5c58e4a-04e0-4d4f-85eb-4fd6800e79c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_82175958-7a92-46c1-948c-7a968dd0703e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f5c58e4a-04e0-4d4f-85eb-4fd6800e79c9" xlink:to="loc_us-gaap_OperatingIncomeLoss_82175958-7a92-46c1-948c-7a968dd0703e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7a35bff1-f6e0-46c9-8ffa-a618161c7f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f5c58e4a-04e0-4d4f-85eb-4fd6800e79c9" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7a35bff1-f6e0-46c9-8ffa-a618161c7f0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_81082320-744a-49cc-aadb-ccc00bfae1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f5c58e4a-04e0-4d4f-85eb-4fd6800e79c9" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_81082320-744a-49cc-aadb-ccc00bfae1dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_aaa5c341-2bb7-48d5-8bd4-5364a549a8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d6ed43c8-248b-426a-a965-f646925dad16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_aaa5c341-2bb7-48d5-8bd4-5364a549a8f7" xlink:to="loc_us-gaap_OperatingExpenses_d6ed43c8-248b-426a-a965-f646925dad16" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="swtx-20220331.xsd#CondensedConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:calculationLink xlink:role="http://www.springworkstx.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2fe3b4db-89d6-4a0b-9a1d-d59bea12798c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6d3a3842-9762-4e00-a754-4d867ab88860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2fe3b4db-89d6-4a0b-9a1d-d59bea12798c" xlink:to="loc_us-gaap_NetIncomeLoss_6d3a3842-9762-4e00-a754-4d867ab88860" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4a67dde8-2f75-451e-a1cb-b1ab86381fea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2fe3b4db-89d6-4a0b-9a1d-d59bea12798c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4a67dde8-2f75-451e-a1cb-b1ab86381fea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_914cd393-fc84-4592-a448-159f9b325e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_27abb09e-1b09-4af8-9c1e-32b51106248b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_914cd393-fc84-4592-a448-159f9b325e1e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_27abb09e-1b09-4af8-9c1e-32b51106248b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="swtx-20220331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2fd3f71b-095e-42f8-b726-84d82bbe8cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_83eda1e1-f809-44bc-ac2f-1b5f8938e2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2fd3f71b-095e-42f8-b726-84d82bbe8cf2" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_83eda1e1-f809-44bc-ac2f-1b5f8938e2a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_72644f55-6420-44ec-954d-8092d254d40d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2fd3f71b-095e-42f8-b726-84d82bbe8cf2" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_72644f55-6420-44ec-954d-8092d254d40d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_d96efcde-85ca-4628-8996-347de9a8441b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_800cd749-ac22-4a82-9f44-329f0889e694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_d96efcde-85ca-4628-8996-347de9a8441b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_800cd749-ac22-4a82-9f44-329f0889e694" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e7aca5d6-fed6-426e-af92-df55259ab562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_d96efcde-85ca-4628-8996-347de9a8441b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e7aca5d6-fed6-426e-af92-df55259ab562" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c35a8b4c-ba67-4528-b495-29f95d638f17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_d96efcde-85ca-4628-8996-347de9a8441b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c35a8b4c-ba67-4528-b495-29f95d638f17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7000ac1d-21cd-40a0-9dc2-f79210230d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_18127797-37d2-434e-ad2d-4dcb6a1fac1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7000ac1d-21cd-40a0-9dc2-f79210230d3a" xlink:to="loc_us-gaap_Depreciation_18127797-37d2-434e-ad2d-4dcb6a1fac1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_310695a3-4a6f-44e3-a001-15f8b228ac1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7000ac1d-21cd-40a0-9dc2-f79210230d3a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_310695a3-4a6f-44e3-a001-15f8b228ac1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_00f4379b-7539-43e7-bb56-e8071867e077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7000ac1d-21cd-40a0-9dc2-f79210230d3a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_00f4379b-7539-43e7-bb56-e8071867e077" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_2197ad26-acb4-4391-a112-20ccec8779a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7000ac1d-21cd-40a0-9dc2-f79210230d3a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_2197ad26-acb4-4391-a112-20ccec8779a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_75423dd7-3d65-4470-a22c-68b7e7588ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7000ac1d-21cd-40a0-9dc2-f79210230d3a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_75423dd7-3d65-4470-a22c-68b7e7588ea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2e719341-66a7-414e-b437-1c8c0467cbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7000ac1d-21cd-40a0-9dc2-f79210230d3a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2e719341-66a7-414e-b437-1c8c0467cbbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d92d3d77-03ee-4b42-87a9-bf2b838774b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7000ac1d-21cd-40a0-9dc2-f79210230d3a" xlink:to="loc_us-gaap_NetIncomeLoss_d92d3d77-03ee-4b42-87a9-bf2b838774b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6ed1dd7b-3876-4463-a465-414ddce7ce6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7000ac1d-21cd-40a0-9dc2-f79210230d3a" xlink:to="loc_us-gaap_ShareBasedCompensation_6ed1dd7b-3876-4463-a465-414ddce7ce6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fcbc37ff-c8fd-40e5-a9ab-66d97fd5716b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7000ac1d-21cd-40a0-9dc2-f79210230d3a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fcbc37ff-c8fd-40e5-a9ab-66d97fd5716b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_IncreaseDecreaseInLeaseLiability_a2db5aed-c64c-481b-a1ec-a5ebc38486a0" xlink:href="swtx-20220331.xsd#swtx_IncreaseDecreaseInLeaseLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7000ac1d-21cd-40a0-9dc2-f79210230d3a" xlink:to="loc_swtx_IncreaseDecreaseInLeaseLiability_a2db5aed-c64c-481b-a1ec-a5ebc38486a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_NonCashOperatingLeaseExpense_052043b2-e3c8-4b31-bda8-fd08eb69a66a" xlink:href="swtx-20220331.xsd#swtx_NonCashOperatingLeaseExpense"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7000ac1d-21cd-40a0-9dc2-f79210230d3a" xlink:to="loc_swtx_NonCashOperatingLeaseExpense_052043b2-e3c8-4b31-bda8-fd08eb69a66a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_26d5d0d2-9a9f-4aaa-bf7d-935114b80afc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_85ec173e-c660-4e5b-85c8-3e47735d9db3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_26d5d0d2-9a9f-4aaa-bf7d-935114b80afc" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_85ec173e-c660-4e5b-85c8-3e47735d9db3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a9873ed3-15b1-4a0e-9634-d304119dec6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_26d5d0d2-9a9f-4aaa-bf7d-935114b80afc" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a9873ed3-15b1-4a0e-9634-d304119dec6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_a7db4c0b-dd89-4563-8b05-035c5f6e4c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_26d5d0d2-9a9f-4aaa-bf7d-935114b80afc" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_a7db4c0b-dd89-4563-8b05-035c5f6e4c08" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="swtx-20220331.xsd#MarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.springworkstx.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3541f517-7d26-4c3e-bbe9-5591f60c80cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5b4213cb-cc7c-49b3-a471-7ad254a69013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3541f517-7d26-4c3e-bbe9-5591f60c80cf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5b4213cb-cc7c-49b3-a471-7ad254a69013" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_21bbe0bc-96e7-45fb-a97c-2633243876b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3541f517-7d26-4c3e-bbe9-5591f60c80cf" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_21bbe0bc-96e7-45fb-a97c-2633243876b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_68293083-190c-4054-a031-a4f18bfc96cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3541f517-7d26-4c3e-bbe9-5591f60c80cf" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_68293083-190c-4054-a031-a4f18bfc96cc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="swtx-20220331.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.springworkstx.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4f8ce425-fc9a-4ac2-a40c-4bfd7e9ef253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_d69091af-7caa-4adc-b246-ae530748bd54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4f8ce425-fc9a-4ac2-a40c-4bfd7e9ef253" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_d69091af-7caa-4adc-b246-ae530748bd54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_08b198f6-e0e7-4370-9b24-6e36b9f95f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4f8ce425-fc9a-4ac2-a40c-4bfd7e9ef253" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_08b198f6-e0e7-4370-9b24-6e36b9f95f4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LongTermInvestmentsFairValueDisclosure_11173ff0-6404-4cea-91af-a7719c7b6416" xlink:href="swtx-20220331.xsd#swtx_LongTermInvestmentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4f8ce425-fc9a-4ac2-a40c-4bfd7e9ef253" xlink:to="loc_swtx_LongTermInvestmentsFairValueDisclosure_11173ff0-6404-4cea-91af-a7719c7b6416" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="swtx-20220331.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.springworkstx.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_80ba40e6-beb7-4075-81e9-9ca156783d72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_0859b03b-7d08-45c2-bf17-21d56fb7d14a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_80ba40e6-beb7-4075-81e9-9ca156783d72" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_0859b03b-7d08-45c2-bf17-21d56fb7d14a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2cbafb9b-fd4b-4bcd-8fc4-38c8e8f61f69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_80ba40e6-beb7-4075-81e9-9ca156783d72" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2cbafb9b-fd4b-4bcd-8fc4-38c8e8f61f69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_AccruedResearchAndDevelopmentExpenses_fdf9beea-7134-40f6-9398-58dbd1e591df" xlink:href="swtx-20220331.xsd#swtx_AccruedResearchAndDevelopmentExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_80ba40e6-beb7-4075-81e9-9ca156783d72" xlink:to="loc_swtx_AccruedResearchAndDevelopmentExpenses_fdf9beea-7134-40f6-9398-58dbd1e591df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2f0acc8d-0671-4e4a-a9a1-a0f8a72240d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_80ba40e6-beb7-4075-81e9-9ca156783d72" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2f0acc8d-0671-4e4a-a9a1-a0f8a72240d8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails" xlink:type="simple" xlink:href="swtx-20220331.xsd#CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f702d715-df66-4564-9c02-d94e8f271a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_81000a25-c7f6-4efd-bb37-e0198f84640d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f702d715-df66-4564-9c02-d94e8f271a18" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_81000a25-c7f6-4efd-bb37-e0198f84640d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear_150879ce-b4f4-44ef-b83f-49a1c6c23972" xlink:href="swtx-20220331.xsd#swtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f702d715-df66-4564-9c02-d94e8f271a18" xlink:to="loc_swtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear_150879ce-b4f4-44ef-b83f-49a1c6c23972" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_52cef523-546f-4603-8734-8a90c4087fae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f702d715-df66-4564-9c02-d94e8f271a18" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_52cef523-546f-4603-8734-8a90c4087fae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_859a940e-b861-4fb9-9621-1b306a01074f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f702d715-df66-4564-9c02-d94e8f271a18" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_859a940e-b861-4fb9-9621-1b306a01074f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a759407e-745b-4a98-a8fc-af3e015358b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f702d715-df66-4564-9c02-d94e8f271a18" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a759407e-745b-4a98-a8fc-af3e015358b6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails_1" xlink:type="simple" xlink:href="swtx-20220331.xsd#CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_27c703a7-0e5b-403e-a100-d75ffb884062" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e534c8d0-490c-4480-8497-a59bd70948c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_27c703a7-0e5b-403e-a100-d75ffb884062" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e534c8d0-490c-4480-8497-a59bd70948c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_767089e7-a0c8-43af-8990-f014cb6b8c72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_27c703a7-0e5b-403e-a100-d75ffb884062" xlink:to="loc_us-gaap_OperatingLeaseLiability_767089e7-a0c8-43af-8990-f014cb6b8c72" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>swtx-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:20c9ef3f-9e42-493b-a5cd-6a5cd47c499c,g:fe877b4c-7b58-4b84-8d3e-d0ed79a85bd8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="simple" xlink:href="swtx-20220331.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnaudited"/>
  <link:definitionLink xlink:role="http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="extended" id="i7ee6c9471595404eb54f33fa0cb69b0a_CondensedConsolidatedStatementsofStockholdersEquityUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a7330f48-73ed-49d5-a84a-dd989cffdcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a7330f48-73ed-49d5-a84a-dd989cffdcb4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_05f5da3f-2a5b-445f-897c-f19f0b29a6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:to="loc_us-gaap_SharesIssued_05f5da3f-2a5b-445f-897c-f19f0b29a6c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b517443c-d9bb-4580-b772-984a67a2e136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:to="loc_us-gaap_StockholdersEquity_b517443c-d9bb-4580-b772-984a67a2e136" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_824aac5c-b8da-497c-8140-c28b01d1ea70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_824aac5c-b8da-497c-8140-c28b01d1ea70" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3fdf8658-7adf-4c34-b70e-cbe2ed04338e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3fdf8658-7adf-4c34-b70e-cbe2ed04338e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_ae617165-435d-475f-99f0-6b198361dd23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_ae617165-435d-475f-99f0-6b198361dd23" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8e422598-f817-44cf-9b34-7cb3a903cd8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8e422598-f817-44cf-9b34-7cb3a903cd8f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5fbaa5f0-c926-4244-bebb-d05deae624f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5fbaa5f0-c926-4244-bebb-d05deae624f2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_275049bc-4896-46a7-a204-51b3d049b560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_275049bc-4896-46a7-a204-51b3d049b560" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_915b4255-d8d5-4ef5-82ba-65774b22054f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_915b4255-d8d5-4ef5-82ba-65774b22054f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d7484b3d-7d73-4360-a220-5bca6f6b4e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d7484b3d-7d73-4360-a220-5bca6f6b4e4d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6ac52248-aa08-4e29-a1ea-8e67af8f7d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:to="loc_us-gaap_NetIncomeLoss_6ac52248-aa08-4e29-a1ea-8e67af8f7d4f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_7e90415c-f9df-4812-9da2-dc6bf327357e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_81301e6a-994a-4b55-8bcd-a1da6288ba7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e8a56668-f640-4a81-8cb7-19243d92da38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a7330f48-73ed-49d5-a84a-dd989cffdcb4" xlink:to="loc_us-gaap_StatementTable_e8a56668-f640-4a81-8cb7-19243d92da38" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3036cb5d-6e82-4749-aff1-3be2e87e575d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e8a56668-f640-4a81-8cb7-19243d92da38" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3036cb5d-6e82-4749-aff1-3be2e87e575d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3036cb5d-6e82-4749-aff1-3be2e87e575d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3036cb5d-6e82-4749-aff1-3be2e87e575d" xlink:to="loc_us-gaap_EquityComponentDomain_3036cb5d-6e82-4749-aff1-3be2e87e575d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_26280e24-570f-4acf-a13d-b271d7719d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3036cb5d-6e82-4749-aff1-3be2e87e575d" xlink:to="loc_us-gaap_EquityComponentDomain_26280e24-570f-4acf-a13d-b271d7719d89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_18bc9ffc-4a35-4d64-97e0-18effc4e780b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_26280e24-570f-4acf-a13d-b271d7719d89" xlink:to="loc_us-gaap_CommonStockMember_18bc9ffc-4a35-4d64-97e0-18effc4e780b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_839c6ceb-e2b5-436f-ac1d-918f1da09fee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_26280e24-570f-4acf-a13d-b271d7719d89" xlink:to="loc_us-gaap_TreasuryStockMember_839c6ceb-e2b5-436f-ac1d-918f1da09fee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_61ebe335-4849-4f88-bf22-a376c66e7c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_26280e24-570f-4acf-a13d-b271d7719d89" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_61ebe335-4849-4f88-bf22-a376c66e7c8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6678326a-2b9a-4eaa-9bd8-9e1c6aba4566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_26280e24-570f-4acf-a13d-b271d7719d89" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6678326a-2b9a-4eaa-9bd8-9e1c6aba4566" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_85a7dfd7-4405-4e87-b470-dfc4c0d2417f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_26280e24-570f-4acf-a13d-b271d7719d89" xlink:to="loc_us-gaap_RetainedEarningsMember_85a7dfd7-4405-4e87-b470-dfc4c0d2417f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="swtx-20220331.xsd#MarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.springworkstx.com/role/MarketableSecuritiesDetails" xlink:type="extended" id="i24a4c58a85dd49afbda43f70d25b0d42_MarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_a8634861-7bfd-4616-837f-d2c7305716fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b4c2a2d3-b013-4ea8-8f1e-e50b7ad5b2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_a8634861-7bfd-4616-837f-d2c7305716fb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b4c2a2d3-b013-4ea8-8f1e-e50b7ad5b2d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_34bde379-b348-4054-8fbc-94b009d9da2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_a8634861-7bfd-4616-837f-d2c7305716fb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_34bde379-b348-4054-8fbc-94b009d9da2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_32593e06-60b4-4b7f-b491-b776ee5f1b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_a8634861-7bfd-4616-837f-d2c7305716fb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_32593e06-60b4-4b7f-b491-b776ee5f1b5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5b83101e-7359-4517-9514-dd828e359ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_a8634861-7bfd-4616-837f-d2c7305716fb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5b83101e-7359-4517-9514-dd828e359ed6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_234b9b1f-9e17-4cc8-b84a-0f97ae303f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_a8634861-7bfd-4616-837f-d2c7305716fb" xlink:to="loc_us-gaap_MarketableSecuritiesTable_234b9b1f-9e17-4cc8-b84a-0f97ae303f6a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_771bb64e-acb6-4db1-a8ea-2701b7e5c95a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_234b9b1f-9e17-4cc8-b84a-0f97ae303f6a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_771bb64e-acb6-4db1-a8ea-2701b7e5c95a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_771bb64e-acb6-4db1-a8ea-2701b7e5c95a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_771bb64e-acb6-4db1-a8ea-2701b7e5c95a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_771bb64e-acb6-4db1-a8ea-2701b7e5c95a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c21b65c-66be-4377-8a27-87a76fe88b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_771bb64e-acb6-4db1-a8ea-2701b7e5c95a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c21b65c-66be-4377-8a27-87a76fe88b4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_9fb37bc5-0652-422b-a26e-14d67e1f7bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c21b65c-66be-4377-8a27-87a76fe88b4b" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_9fb37bc5-0652-422b-a26e-14d67e1f7bac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_79f59660-67a5-4cc5-a74d-d4a25d8478b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c21b65c-66be-4377-8a27-87a76fe88b4b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_79f59660-67a5-4cc5-a74d-d4a25d8478b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_42492723-593c-4668-ad56-e9f95a2b8375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c21b65c-66be-4377-8a27-87a76fe88b4b" xlink:to="loc_us-gaap_CommercialPaperMember_42492723-593c-4668-ad56-e9f95a2b8375" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_76a12226-4550-4f55-827d-bef8eb217991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_234b9b1f-9e17-4cc8-b84a-0f97ae303f6a" xlink:to="loc_us-gaap_InvestmentTypeAxis_76a12226-4550-4f55-827d-bef8eb217991" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_76a12226-4550-4f55-827d-bef8eb217991_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_76a12226-4550-4f55-827d-bef8eb217991" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_76a12226-4550-4f55-827d-bef8eb217991_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_8c5ad514-1346-4e58-a152-b3b4a7debbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_76a12226-4550-4f55-827d-bef8eb217991" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_8c5ad514-1346-4e58-a152-b3b4a7debbe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_3537860f-c0ff-4eb1-98a1-fad70463f4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_8c5ad514-1346-4e58-a152-b3b4a7debbe3" xlink:to="loc_us-gaap_CashEquivalentsMember_3537860f-c0ff-4eb1-98a1-fad70463f4b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_3e3f8ce4-ded7-46e0-a259-061c04a3bf50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_8c5ad514-1346-4e58-a152-b3b4a7debbe3" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_3e3f8ce4-ded7-46e0-a259-061c04a3bf50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LongTermInvestmentsMember_a96217c5-13f6-4b46-b219-f6b18877e94b" xlink:href="swtx-20220331.xsd#swtx_LongTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_8c5ad514-1346-4e58-a152-b3b4a7debbe3" xlink:to="loc_swtx_LongTermInvestmentsMember_a96217c5-13f6-4b46-b219-f6b18877e94b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="swtx-20220331.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.springworkstx.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="ibfe3107a24734c46bd91b46d1575d67e_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a704f4c4-6961-4d8d-b8ce-6e3f79e55682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4241c6cc-38dc-46ba-b653-aaa66e609710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a704f4c4-6961-4d8d-b8ce-6e3f79e55682" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4241c6cc-38dc-46ba-b653-aaa66e609710" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_8f8564c6-52e5-49c3-982d-2cb733437a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a704f4c4-6961-4d8d-b8ce-6e3f79e55682" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_8f8564c6-52e5-49c3-982d-2cb733437a0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LongTermInvestmentsFairValueDisclosure_4fece997-2c39-4237-85ce-dceba6f45466" xlink:href="swtx-20220331.xsd#swtx_LongTermInvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a704f4c4-6961-4d8d-b8ce-6e3f79e55682" xlink:to="loc_swtx_LongTermInvestmentsFairValueDisclosure_4fece997-2c39-4237-85ce-dceba6f45466" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_15e8c4d0-423f-4336-aadd-e49e96f0ccb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a704f4c4-6961-4d8d-b8ce-6e3f79e55682" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_15e8c4d0-423f-4336-aadd-e49e96f0ccb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ebf1c8a-8577-4ec5-a016-42616f0d4f84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a704f4c4-6961-4d8d-b8ce-6e3f79e55682" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ebf1c8a-8577-4ec5-a016-42616f0d4f84" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7946e345-85b7-44b9-9e2d-fe41271e495f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ebf1c8a-8577-4ec5-a016-42616f0d4f84" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7946e345-85b7-44b9-9e2d-fe41271e495f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7946e345-85b7-44b9-9e2d-fe41271e495f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7946e345-85b7-44b9-9e2d-fe41271e495f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7946e345-85b7-44b9-9e2d-fe41271e495f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f17a19b-2919-423d-9441-cd72fdb4e9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7946e345-85b7-44b9-9e2d-fe41271e495f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f17a19b-2919-423d-9441-cd72fdb4e9fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_742242d7-097d-4ae0-9a01-857f8a29bbae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f17a19b-2919-423d-9441-cd72fdb4e9fd" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_742242d7-097d-4ae0-9a01-857f8a29bbae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2e8943fc-f24a-4849-80dc-ef06394eef7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f17a19b-2919-423d-9441-cd72fdb4e9fd" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2e8943fc-f24a-4849-80dc-ef06394eef7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3e3d56b7-f589-4e57-974c-3aab4cb1614c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f17a19b-2919-423d-9441-cd72fdb4e9fd" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3e3d56b7-f589-4e57-974c-3aab4cb1614c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d3087b02-c0ca-49d9-aa27-d9668aafde49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ebf1c8a-8577-4ec5-a016-42616f0d4f84" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d3087b02-c0ca-49d9-aa27-d9668aafde49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d3087b02-c0ca-49d9-aa27-d9668aafde49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d3087b02-c0ca-49d9-aa27-d9668aafde49" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d3087b02-c0ca-49d9-aa27-d9668aafde49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c5b4c77a-c19e-4675-9e3a-8216be48e58f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d3087b02-c0ca-49d9-aa27-d9668aafde49" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c5b4c77a-c19e-4675-9e3a-8216be48e58f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1d999bea-779b-4b9e-ac52-86a4deefa4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c5b4c77a-c19e-4675-9e3a-8216be48e58f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1d999bea-779b-4b9e-ac52-86a4deefa4dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_5d57f8bc-8312-46ee-bcbc-64253239a7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ebf1c8a-8577-4ec5-a016-42616f0d4f84" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_5d57f8bc-8312-46ee-bcbc-64253239a7b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5d57f8bc-8312-46ee-bcbc-64253239a7b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_5d57f8bc-8312-46ee-bcbc-64253239a7b0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5d57f8bc-8312-46ee-bcbc-64253239a7b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2f7f2600-deda-4005-85af-4a9e239a3828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_5d57f8bc-8312-46ee-bcbc-64253239a7b0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2f7f2600-deda-4005-85af-4a9e239a3828" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_979689ed-1aa0-4040-aa67-73bc7731922d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2f7f2600-deda-4005-85af-4a9e239a3828" xlink:to="loc_us-gaap_MoneyMarketFundsMember_979689ed-1aa0-4040-aa67-73bc7731922d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_05c469e1-3697-430f-98aa-3164a91fb04e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2f7f2600-deda-4005-85af-4a9e239a3828" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_05c469e1-3697-430f-98aa-3164a91fb04e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_bdbba2dc-ed9d-4b40-af28-7d8edc157f82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ebf1c8a-8577-4ec5-a016-42616f0d4f84" xlink:to="loc_us-gaap_InvestmentTypeAxis_bdbba2dc-ed9d-4b40-af28-7d8edc157f82" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_bdbba2dc-ed9d-4b40-af28-7d8edc157f82_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_bdbba2dc-ed9d-4b40-af28-7d8edc157f82" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_bdbba2dc-ed9d-4b40-af28-7d8edc157f82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b64efdfc-ada8-47ff-bd6a-6bd2c4dfb844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_bdbba2dc-ed9d-4b40-af28-7d8edc157f82" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b64efdfc-ada8-47ff-bd6a-6bd2c4dfb844" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_32674e51-6da8-455a-a346-265d39e1ea8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b64efdfc-ada8-47ff-bd6a-6bd2c4dfb844" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_32674e51-6da8-455a-a346-265d39e1ea8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0014b540-7d31-439d-8a1e-46474bbfd686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b64efdfc-ada8-47ff-bd6a-6bd2c4dfb844" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0014b540-7d31-439d-8a1e-46474bbfd686" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_32c77a9e-0151-4e44-ad33-d4eb9fa44966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b64efdfc-ada8-47ff-bd6a-6bd2c4dfb844" xlink:to="loc_us-gaap_CommercialPaperMember_32c77a9e-0151-4e44-ad33-d4eb9fa44966" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/InvestmentandVariableInterestEntityDetails" xlink:type="simple" xlink:href="swtx-20220331.xsd#InvestmentandVariableInterestEntityDetails"/>
  <link:definitionLink xlink:role="http://www.springworkstx.com/role/InvestmentandVariableInterestEntityDetails" xlink:type="extended" id="icc09c82c66ec4c44b5b7e691af163e60_InvestmentandVariableInterestEntityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_000301ae-3a9f-447b-8e4e-1c850acb05f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_59169e7f-92fa-48cc-826d-10796aecd0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_000301ae-3a9f-447b-8e4e-1c850acb05f0" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_59169e7f-92fa-48cc-826d-10796aecd0e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2e96673e-78dc-4a37-8863-9cd593752e27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_000301ae-3a9f-447b-8e4e-1c850acb05f0" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2e96673e-78dc-4a37-8863-9cd593752e27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_a6f9b2ca-8717-4277-8646-be6e4a46b626" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_000301ae-3a9f-447b-8e4e-1c850acb05f0" xlink:to="loc_us-gaap_EquityMethodInvestments_a6f9b2ca-8717-4277-8646-be6e4a46b626" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_87c49fd3-6bd4-4ec0-b183-2c63500fb57a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_000301ae-3a9f-447b-8e4e-1c850acb05f0" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_87c49fd3-6bd4-4ec0-b183-2c63500fb57a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bd3b14cf-bc20-4f63-bd28-fc2d1eb18196" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_87c49fd3-6bd4-4ec0-b183-2c63500fb57a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bd3b14cf-bc20-4f63-bd28-fc2d1eb18196" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_bd3b14cf-bc20-4f63-bd28-fc2d1eb18196_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bd3b14cf-bc20-4f63-bd28-fc2d1eb18196" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_bd3b14cf-bc20-4f63-bd28-fc2d1eb18196_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_467560a7-22a9-4ecf-8cd7-b32965b99aad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bd3b14cf-bc20-4f63-bd28-fc2d1eb18196" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_467560a7-22a9-4ecf-8cd7-b32965b99aad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_MapkureMember_d5c50a10-8a1d-492e-8cad-826f1b4214c7" xlink:href="swtx-20220331.xsd#swtx_MapkureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_467560a7-22a9-4ecf-8cd7-b32965b99aad" xlink:to="loc_swtx_MapkureMember_d5c50a10-8a1d-492e-8cad-826f1b4214c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6bcc710e-0c24-45bf-bbfd-461a54b244a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_87c49fd3-6bd4-4ec0-b183-2c63500fb57a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6bcc710e-0c24-45bf-bbfd-461a54b244a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6bcc710e-0c24-45bf-bbfd-461a54b244a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6bcc710e-0c24-45bf-bbfd-461a54b244a8" xlink:to="loc_us-gaap_ClassOfStockDomain_6bcc710e-0c24-45bf-bbfd-461a54b244a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ec49d631-60e4-476a-8462-81886ebb8f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6bcc710e-0c24-45bf-bbfd-461a54b244a8" xlink:to="loc_us-gaap_ClassOfStockDomain_ec49d631-60e4-476a-8462-81886ebb8f5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_aeeec0f2-5e4e-47f3-90f6-d130787e831c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ec49d631-60e4-476a-8462-81886ebb8f5b" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_aeeec0f2-5e4e-47f3-90f6-d130787e831c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="swtx-20220331.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.springworkstx.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i509ed4462e36447c8d145f0f4ae1b60f_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_8656ff91-2cbc-4c11-ae68-f7082c2c764f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LesseeOperatingLeaseNumberOfRenewalOptions_c0493948-4f2e-4867-b8fd-fbcc76570081" xlink:href="swtx-20220331.xsd#swtx_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8656ff91-2cbc-4c11-ae68-f7082c2c764f" xlink:to="loc_swtx_LesseeOperatingLeaseNumberOfRenewalOptions_c0493948-4f2e-4867-b8fd-fbcc76570081" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_af5e4d89-06f9-46d6-b872-a07da6e5b4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8656ff91-2cbc-4c11-ae68-f7082c2c764f" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_af5e4d89-06f9-46d6-b872-a07da6e5b4b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LesseeOperatingLeaseEntitledTenantAllowance_e0a220b7-d5d1-42fa-af93-de274905cb2a" xlink:href="swtx-20220331.xsd#swtx_LesseeOperatingLeaseEntitledTenantAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8656ff91-2cbc-4c11-ae68-f7082c2c764f" xlink:to="loc_swtx_LesseeOperatingLeaseEntitledTenantAllowance_e0a220b7-d5d1-42fa-af93-de274905cb2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_AnnualIncreaseInLeasePaymentsPercentage_f62b98f1-1014-4fd7-9a0c-fa29037d1cc8" xlink:href="swtx-20220331.xsd#swtx_AnnualIncreaseInLeasePaymentsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8656ff91-2cbc-4c11-ae68-f7082c2c764f" xlink:to="loc_swtx_AnnualIncreaseInLeasePaymentsPercentage_f62b98f1-1014-4fd7-9a0c-fa29037d1cc8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_2ebba47f-128c-45d0-8743-587b78b70259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8656ff91-2cbc-4c11-ae68-f7082c2c764f" xlink:to="loc_us-gaap_LitigationSettlementExpense_2ebba47f-128c-45d0-8743-587b78b70259" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_6c6d86fb-6502-4221-82df-b089571a4da5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_8656ff91-2cbc-4c11-ae68-f7082c2c764f" xlink:to="loc_us-gaap_LossContingenciesTable_6c6d86fb-6502-4221-82df-b089571a4da5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4f216d0b-cb97-43f8-b372-052d373747d8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_6c6d86fb-6502-4221-82df-b089571a4da5" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4f216d0b-cb97-43f8-b372-052d373747d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_4f216d0b-cb97-43f8-b372-052d373747d8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4f216d0b-cb97-43f8-b372-052d373747d8" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_4f216d0b-cb97-43f8-b372-052d373747d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_343ecbe5-3736-4dbc-ac59-805911c77657" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4f216d0b-cb97-43f8-b372-052d373747d8" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_343ecbe5-3736-4dbc-ac59-805911c77657" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_StamfordConnecticutMember_22b22f7c-90da-466e-bece-2b02e8556e8f" xlink:href="swtx-20220331.xsd#swtx_StamfordConnecticutMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_343ecbe5-3736-4dbc-ac59-805911c77657" xlink:to="loc_swtx_StamfordConnecticutMember_22b22f7c-90da-466e-bece-2b02e8556e8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LesseeOperatingLeaseRenewalTermAxisAxis_e734f817-a953-4286-b152-7e3ded525795" xlink:href="swtx-20220331.xsd#swtx_LesseeOperatingLeaseRenewalTermAxisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_6c6d86fb-6502-4221-82df-b089571a4da5" xlink:to="loc_swtx_LesseeOperatingLeaseRenewalTermAxisAxis_e734f817-a953-4286-b152-7e3ded525795" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LesseeOperatingLeaseRenewalTermAxisDomain_e734f817-a953-4286-b152-7e3ded525795_default" xlink:href="swtx-20220331.xsd#swtx_LesseeOperatingLeaseRenewalTermAxisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_swtx_LesseeOperatingLeaseRenewalTermAxisAxis_e734f817-a953-4286-b152-7e3ded525795" xlink:to="loc_swtx_LesseeOperatingLeaseRenewalTermAxisDomain_e734f817-a953-4286-b152-7e3ded525795_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LesseeOperatingLeaseRenewalTermAxisDomain_a048efaa-8aa2-4829-a3c9-6e72ebfd996f" xlink:href="swtx-20220331.xsd#swtx_LesseeOperatingLeaseRenewalTermAxisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_swtx_LesseeOperatingLeaseRenewalTermAxisAxis_e734f817-a953-4286-b152-7e3ded525795" xlink:to="loc_swtx_LesseeOperatingLeaseRenewalTermAxisDomain_a048efaa-8aa2-4829-a3c9-6e72ebfd996f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LesseeOperatingLeaseRenewalOptionOneMember_b9d65884-bc3c-418b-8e8f-3976e26f37b1" xlink:href="swtx-20220331.xsd#swtx_LesseeOperatingLeaseRenewalOptionOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_swtx_LesseeOperatingLeaseRenewalTermAxisDomain_a048efaa-8aa2-4829-a3c9-6e72ebfd996f" xlink:to="loc_swtx_LesseeOperatingLeaseRenewalOptionOneMember_b9d65884-bc3c-418b-8e8f-3976e26f37b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LesseeOperatingLeaseRenewalOptionTwoMember_3a5f5a51-a981-4f70-a69f-eb8a335c8b55" xlink:href="swtx-20220331.xsd#swtx_LesseeOperatingLeaseRenewalOptionTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_swtx_LesseeOperatingLeaseRenewalTermAxisDomain_a048efaa-8aa2-4829-a3c9-6e72ebfd996f" xlink:to="loc_swtx_LesseeOperatingLeaseRenewalOptionTwoMember_3a5f5a51-a981-4f70-a69f-eb8a335c8b55" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails" xlink:type="simple" xlink:href="swtx-20220331.xsd#StockBasedCompensation2019EquityIncentivePlanDetails"/>
  <link:definitionLink xlink:role="http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails" xlink:type="extended" id="i3ad81a7cf0e54ab28492902c49295681_StockBasedCompensation2019EquityIncentivePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock_67a737dd-c9d5-4e92-92d1-24894ec3d9b0" xlink:href="swtx-20220331.xsd#swtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_swtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock_67a737dd-c9d5-4e92-92d1-24894ec3d9b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8185c1c1-fd98-4584-a75c-6dc97490d40e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8185c1c1-fd98-4584-a75c-6dc97490d40e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_17e949ab-a7c5-4230-aaa7-23989944899d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_17e949ab-a7c5-4230-aaa7-23989944899d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90088656-149b-4da4-b750-3792d4517131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90088656-149b-4da4-b750-3792d4517131" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_27b75012-5293-4ac1-bf8d-b988085df369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_27b75012-5293-4ac1-bf8d-b988085df369" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e905b557-c199-465e-8767-4022b3d9ff4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e905b557-c199-465e-8767-4022b3d9ff4b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_3a158449-8614-4465-b7b1-a403854689c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_3a158449-8614-4465-b7b1-a403854689c1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ec8bc103-8fbb-46d8-adaa-49be4ed0abb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ec8bc103-8fbb-46d8-adaa-49be4ed0abb4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638516fb-f837-4de4-ae9c-0cc5989372d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638516fb-f837-4de4-ae9c-0cc5989372d2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_046120b7-5274-4f7f-9216-dc8bbd97c144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_046120b7-5274-4f7f-9216-dc8bbd97c144" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b9dc0f37-b3a2-4c3e-b3bc-96bcf875e528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b9dc0f37-b3a2-4c3e-b3bc-96bcf875e528" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e5cb5c6e-0ab0-4d59-8456-9970c2d690db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e5cb5c6e-0ab0-4d59-8456-9970c2d690db" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d6cec9d6-70d7-4f7a-a35d-9a2b9025b49d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d6cec9d6-70d7-4f7a-a35d-9a2b9025b49d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85663c98-66c0-4c5b-a613-d128e7989063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85663c98-66c0-4c5b-a613-d128e7989063" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_966a2661-e86f-4b93-b81a-c49c00a5bd10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85663c98-66c0-4c5b-a613-d128e7989063" xlink:to="loc_us-gaap_PlanNameAxis_966a2661-e86f-4b93-b81a-c49c00a5bd10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_966a2661-e86f-4b93-b81a-c49c00a5bd10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_966a2661-e86f-4b93-b81a-c49c00a5bd10" xlink:to="loc_us-gaap_PlanNameDomain_966a2661-e86f-4b93-b81a-c49c00a5bd10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a3e3f614-b78a-4998-9528-3ff22cb195ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_966a2661-e86f-4b93-b81a-c49c00a5bd10" xlink:to="loc_us-gaap_PlanNameDomain_a3e3f614-b78a-4998-9528-3ff22cb195ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_EquityIncentivePlan2019Member_a8d4799e-4df0-4e98-8a47-e23cb20dd0e8" xlink:href="swtx-20220331.xsd#swtx_EquityIncentivePlan2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a3e3f614-b78a-4998-9528-3ff22cb195ba" xlink:to="loc_swtx_EquityIncentivePlan2019Member_a8d4799e-4df0-4e98-8a47-e23cb20dd0e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_CeoPerformanceAwardMember_d2eada92-31b6-4053-abb0-70ef891673a4" xlink:href="swtx-20220331.xsd#swtx_CeoPerformanceAwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a3e3f614-b78a-4998-9528-3ff22cb195ba" xlink:to="loc_swtx_CeoPerformanceAwardMember_d2eada92-31b6-4053-abb0-70ef891673a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_39e8f5ce-2543-4a67-96af-63f024774c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85663c98-66c0-4c5b-a613-d128e7989063" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_39e8f5ce-2543-4a67-96af-63f024774c8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_39e8f5ce-2543-4a67-96af-63f024774c8f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_39e8f5ce-2543-4a67-96af-63f024774c8f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_39e8f5ce-2543-4a67-96af-63f024774c8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1065c965-1b3f-4878-96b0-0ca9c2896295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_39e8f5ce-2543-4a67-96af-63f024774c8f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1065c965-1b3f-4878-96b0-0ca9c2896295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_23f381d8-48cf-4d8f-9aed-5c6965abd275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1065c965-1b3f-4878-96b0-0ca9c2896295" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_23f381d8-48cf-4d8f-9aed-5c6965abd275" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_09271741-3fc6-4fe6-bc55-0703735da72e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1065c965-1b3f-4878-96b0-0ca9c2896295" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_09271741-3fc6-4fe6-bc55-0703735da72e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_35c25a15-2cdb-48b6-9ded-021aae30a7a1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85663c98-66c0-4c5b-a613-d128e7989063" xlink:to="loc_srt_TitleOfIndividualAxis_35c25a15-2cdb-48b6-9ded-021aae30a7a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_35c25a15-2cdb-48b6-9ded-021aae30a7a1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_35c25a15-2cdb-48b6-9ded-021aae30a7a1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_35c25a15-2cdb-48b6-9ded-021aae30a7a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1bd4c2a4-75b7-4607-9424-7ce7546f7543" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_35c25a15-2cdb-48b6-9ded-021aae30a7a1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1bd4c2a4-75b7-4607-9424-7ce7546f7543" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember_0dfbe70a-66c4-49c9-8c0e-1433ce36f7b2" xlink:href="swtx-20220331.xsd#swtx_ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1bd4c2a4-75b7-4607-9424-7ce7546f7543" xlink:to="loc_swtx_ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember_0dfbe70a-66c4-49c9-8c0e-1433ce36f7b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_2f5f2413-b527-45b6-b1fd-3bee5aadfa26" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1bd4c2a4-75b7-4607-9424-7ce7546f7543" xlink:to="loc_srt_DirectorMember_2f5f2413-b527-45b6-b1fd-3bee5aadfa26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_ExecutiveOfficersAndEmployeesMember_320cf390-9297-4ddd-abbf-b61757a68843" xlink:href="swtx-20220331.xsd#swtx_ExecutiveOfficersAndEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1bd4c2a4-75b7-4607-9424-7ce7546f7543" xlink:to="loc_swtx_ExecutiveOfficersAndEmployeesMember_320cf390-9297-4ddd-abbf-b61757a68843" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_99052735-8e1f-48e1-b43f-81aafc118089" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1bd4c2a4-75b7-4607-9424-7ce7546f7543" xlink:to="loc_srt_ChiefExecutiveOfficerMember_99052735-8e1f-48e1-b43f-81aafc118089" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_50dfe054-f420-4c62-9448-83d1078d9c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85663c98-66c0-4c5b-a613-d128e7989063" xlink:to="loc_us-gaap_AwardTypeAxis_50dfe054-f420-4c62-9448-83d1078d9c6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50dfe054-f420-4c62-9448-83d1078d9c6b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_50dfe054-f420-4c62-9448-83d1078d9c6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50dfe054-f420-4c62-9448-83d1078d9c6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03f38e47-2f40-4f0c-8803-8b1420a0a507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_50dfe054-f420-4c62-9448-83d1078d9c6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03f38e47-2f40-4f0c-8803-8b1420a0a507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1707b3b7-c68e-47e7-8728-184ca81dbd14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03f38e47-2f40-4f0c-8803-8b1420a0a507" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1707b3b7-c68e-47e7-8728-184ca81dbd14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_774c3ad5-def8-4c03-9620-61cefc68d143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03f38e47-2f40-4f0c-8803-8b1420a0a507" xlink:to="loc_us-gaap_EmployeeStockOptionMember_774c3ad5-def8-4c03-9620-61cefc68d143" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e7418299-4131-431b-951f-f856160517e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03f38e47-2f40-4f0c-8803-8b1420a0a507" xlink:to="loc_us-gaap_RestrictedStockMember_e7418299-4131-431b-951f-f856160517e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_2e6547b3-4038-421b-821d-54a6c8183a56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85663c98-66c0-4c5b-a613-d128e7989063" xlink:to="loc_us-gaap_GranteeStatusAxis_2e6547b3-4038-421b-821d-54a6c8183a56" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_2e6547b3-4038-421b-821d-54a6c8183a56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_2e6547b3-4038-421b-821d-54a6c8183a56" xlink:to="loc_us-gaap_GranteeStatusDomain_2e6547b3-4038-421b-821d-54a6c8183a56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_b0e42a99-70b8-40b4-9d21-b35d3d51f505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_2e6547b3-4038-421b-821d-54a6c8183a56" xlink:to="loc_us-gaap_GranteeStatusDomain_b0e42a99-70b8-40b4-9d21-b35d3d51f505" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_5892e904-1338-4638-ba1c-97c676c2f0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_b0e42a99-70b8-40b4-9d21-b35d3d51f505" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_5892e904-1338-4638-ba1c-97c676c2f0bd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/StockBasedCompensationEquitybasedcompensationexpenserelatedtorestrictedstockandstockoptionsDetails" xlink:type="simple" xlink:href="swtx-20220331.xsd#StockBasedCompensationEquitybasedcompensationexpenserelatedtorestrictedstockandstockoptionsDetails"/>
  <link:definitionLink xlink:role="http://www.springworkstx.com/role/StockBasedCompensationEquitybasedcompensationexpenserelatedtorestrictedstockandstockoptionsDetails" xlink:type="extended" id="ic38eca73cd42473588f27e6216d628a4_StockBasedCompensationEquitybasedcompensationexpenserelatedtorestrictedstockandstockoptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b97a3322-96df-4224-807d-67fb74ea19b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_67ec9ab1-711f-42cf-aa70-40db57c2bf74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b97a3322-96df-4224-807d-67fb74ea19b8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_67ec9ab1-711f-42cf-aa70-40db57c2bf74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e1d2db0d-52bf-44c5-b41f-91c9fb81e7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b97a3322-96df-4224-807d-67fb74ea19b8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e1d2db0d-52bf-44c5-b41f-91c9fb81e7ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d66ecc21-fbe4-4429-8dac-070d677dae1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e1d2db0d-52bf-44c5-b41f-91c9fb81e7ba" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d66ecc21-fbe4-4429-8dac-070d677dae1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d66ecc21-fbe4-4429-8dac-070d677dae1e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d66ecc21-fbe4-4429-8dac-070d677dae1e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d66ecc21-fbe4-4429-8dac-070d677dae1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fd7fa277-cc5f-447f-a9cf-8dec8939d24a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d66ecc21-fbe4-4429-8dac-070d677dae1e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fd7fa277-cc5f-447f-a9cf-8dec8939d24a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d9cbc523-c10e-4e4b-b2d7-3675a438f89d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fd7fa277-cc5f-447f-a9cf-8dec8939d24a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d9cbc523-c10e-4e4b-b2d7-3675a438f89d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7e1df002-4f84-4b37-bc2c-d2706a384f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fd7fa277-cc5f-447f-a9cf-8dec8939d24a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7e1df002-4f84-4b37-bc2c-d2706a384f96" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/NetLossperShareDetails" xlink:type="simple" xlink:href="swtx-20220331.xsd#NetLossperShareDetails"/>
  <link:definitionLink xlink:role="http://www.springworkstx.com/role/NetLossperShareDetails" xlink:type="extended" id="ie3748ac6e8144c72933c2b36ea6f78b7_NetLossperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_86c82a4e-743f-47f6-afd0-bd3d600868b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_79155e4f-6de0-4277-9952-c41f9b3b944f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_86c82a4e-743f-47f6-afd0-bd3d600868b2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_79155e4f-6de0-4277-9952-c41f9b3b944f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_53b6d017-bd77-49c4-a3f0-627e0d8e56e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_86c82a4e-743f-47f6-afd0-bd3d600868b2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_53b6d017-bd77-49c4-a3f0-627e0d8e56e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b1176f4e-9dbc-4bd7-955f-e9378c464bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_53b6d017-bd77-49c4-a3f0-627e0d8e56e3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b1176f4e-9dbc-4bd7-955f-e9378c464bb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b1176f4e-9dbc-4bd7-955f-e9378c464bb7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b1176f4e-9dbc-4bd7-955f-e9378c464bb7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b1176f4e-9dbc-4bd7-955f-e9378c464bb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72f587e2-5013-416a-bd06-783174896c38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b1176f4e-9dbc-4bd7-955f-e9378c464bb7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72f587e2-5013-416a-bd06-783174896c38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_34fe7a70-d0d4-4ab5-829c-e00b4a1d0561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72f587e2-5013-416a-bd06-783174896c38" xlink:to="loc_us-gaap_CommonStockMember_34fe7a70-d0d4-4ab5-829c-e00b4a1d0561" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b0ed9b71-6c17-43c1-844a-847aa5a1ccc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72f587e2-5013-416a-bd06-783174896c38" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b0ed9b71-6c17-43c1-844a-847aa5a1ccc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_30f3d473-987b-4943-8b08-cab4891e709d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72f587e2-5013-416a-bd06-783174896c38" xlink:to="loc_us-gaap_RestrictedStockMember_30f3d473-987b-4943-8b08-cab4891e709d" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>swtx-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:20c9ef3f-9e42-493b-a5cd-6a5cd47c499c,g:fe877b4c-7b58-4b84-8d3e-d0ed79a85bd8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_InvestmentIncomeNet_17d4bd16-06e6-4b10-8152-0b67a8a9f7fa_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a8a6440c-72e0-4790-b61f-f5fc582adc5d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, long-term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_c1912a2e-8f44-4189-b01b-46fa1dc8c761_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_87b13618-a8f2-494c-bc43-1ad17b7099c0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_88187973-7076-4364-a268-6fe693ce5f68_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_d9c34874-0df0-4faf-9e3f-042d022a9070_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_03eb17d5-bfff-4f3e-8375-2a5ccde3a879_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_95ac6c9b-ddc6-4801-a050-7e23d5d07033_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_3f15ed37-7491-4d52-99b3-39f6c61c5b06_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_9dfb6eed-454b-4e54-b676-90f49503370c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_4de186f3-f364-4557-89ed-074028f5c1f4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c314a1a8-2f41-4c73-a4c4-b02b2b76c677_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_022a09d4-6199-4d8e-a4a3-0b0f8ba652aa_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_4e2ed3c0-588b-4e8c-804a-34f9d3133c36_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units subject to future vesting</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_f9eea58f-633e-4087-9d87-114e65fcab45_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_61d4a96d-54d4-4710-8770-71ed50295bf7_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_734d1e16-a918-4b9b-bc41-073c96fce34c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_44b5e5f3-a843-4e11-99cc-a7b9b07e60cf_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of each exchange on which registered</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_e9f7fb71-4e9f-4f12-8b70-f1e2d876177a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_358b4111-aae0-46bd-b45a-73410fe0fc25_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_47c228fb-98d3-42ce-9ebc-c2efb8a4b228_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_074fab4e-4931-44ee-bc01-9df0fddd20a9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Mapkure</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_fd4f26ef-7cba-4b7f-9ca1-1e4c98f61600_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_be6ec07c-5147-489d-b1db-cf041808ce25_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_20668e13-e05a-4b79-ab6f-64ff9494ab8d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f6644c46-d713-412a-8126-bc2c6a418ef3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9a7bdf66-5197-47ce-8b12-1c58cd0b71aa_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_swtx_LesseeOperatingLeaseRenewalTermAxisDomain_4abaeac2-6cd1-453c-b88e-d05beebed9f7_terseLabel_en-US" xlink:label="lab_swtx_LesseeOperatingLeaseRenewalTermAxisDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Renewal Term Axis [Domain]</link:label>
    <link:label id="lab_swtx_LesseeOperatingLeaseRenewalTermAxisDomain_label_en-US" xlink:label="lab_swtx_LesseeOperatingLeaseRenewalTermAxisDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Renewal Term Axis [Domain]</link:label>
    <link:label id="lab_swtx_LesseeOperatingLeaseRenewalTermAxisDomain_documentation_en-US" xlink:label="lab_swtx_LesseeOperatingLeaseRenewalTermAxisDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Renewal Term Axis [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LesseeOperatingLeaseRenewalTermAxisDomain" xlink:href="swtx-20220331.xsd#swtx_LesseeOperatingLeaseRenewalTermAxisDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_swtx_LesseeOperatingLeaseRenewalTermAxisDomain" xlink:to="lab_swtx_LesseeOperatingLeaseRenewalTermAxisDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_4150457e-815d-4cd1-877e-67cdff5cb45d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_swtx_LongTermInvestmentsMember_344ffdb3-2d29-4464-a31b-aa83bf826ae3_terseLabel_en-US" xlink:label="lab_swtx_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments:</link:label>
    <link:label id="lab_swtx_LongTermInvestmentsMember_label_en-US" xlink:label="lab_swtx_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investments [Member]</link:label>
    <link:label id="lab_swtx_LongTermInvestmentsMember_documentation_en-US" xlink:label="lab_swtx_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments which are not otherwise included in another category or item that the entity has the intent to hold for more than one year from the date of the balance sheet.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LongTermInvestmentsMember" xlink:href="swtx-20220331.xsd#swtx_LongTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_swtx_LongTermInvestmentsMember" xlink:to="lab_swtx_LongTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_94c3ec78-ced2-474e-be73-bbb76f7e64a2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of restricted stock award (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_04f500bb-e298-439b-8089-31e9585e695d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_56ff327d-8b4e-47de-9877-9e4c2daccad2_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a20bbd23-4208-498e-a40e-6d1e90eb2d0e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_aabd5d4a-3f6d-4b4b-bfb2-f6004c4b754d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_430ee668-35c6-48df-9460-aebc36445e39_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_50eae1c3-275c-4fc4-8072-26c189c9fe87_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1a748353-5571-4710-b255-ea05074a4725_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_80ff6ba7-aba2-4e47-9b76-321e07d74985_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_39c89f91-f093-4e6e-87a7-3ab20616ee35_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_25635a02-3a14-4be6-9345-233f0162d5ed_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7653ac97-d6d2-4f7a-87dd-d522ae8ac02c_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_8ba09b6a-72e9-4e4d-9eab-526e569b7635_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation or contingency expense</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_80c09d50-9487-4cd6-a9ef-d6febb0243af_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5ebbcb3f-afa3-449f-9ae9-dc7bcc02423b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_bfe8422a-a756-42bd-8c79-341879ffa38c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f557053a-548b-4c6f-843d-cdc263287939_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total potentially dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0970b896-b662-405a-b483-06982287d427_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense related to unvested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_320c1285-f934-4d66-ba67-c7587f681e41_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_d89020bf-e430-47b2-b7c2-a9acdd7368df_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_d272df3b-d18f-46b1-b831-cd4b2358d4ce_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_e4ddf9fe-ad6f-41b8-befc-026f10ce4454_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense related to restricted stock awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_13ed496c-56be-4874-b880-80b13087739c_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEO</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_f1565b6b-8535-4d8a-8620-37a46f9cad61_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_59e396e2-25cc-44aa-bb70-8dea321d7ac0_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e1776bd6-1d96-410e-ab15-22b2efe01a80_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on marketable securities, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b2e85534-fb6b-43f4-8d63-2484e3088f76_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_swtx_NonCashOperatingLeaseExpense_e66802f4-6e96-426c-bfc4-6d63f12cb8cb_terseLabel_en-US" xlink:label="lab_swtx_NonCashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating lease expense</link:label>
    <link:label id="lab_swtx_NonCashOperatingLeaseExpense_label_en-US" xlink:label="lab_swtx_NonCashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash Operating Lease Expense</link:label>
    <link:label id="lab_swtx_NonCashOperatingLeaseExpense_documentation_en-US" xlink:label="lab_swtx_NonCashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of non cash operating lease expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_NonCashOperatingLeaseExpense" xlink:href="swtx-20220331.xsd#swtx_NonCashOperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_swtx_NonCashOperatingLeaseExpense" xlink:to="lab_swtx_NonCashOperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c75ced0-ade4-47b2-8669-162b611c9bd1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6bb47e4f-d706-44db-91bd-4b17721edf55_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4c46fc88-7999-4c70-afec-cd10d0379929_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_4b74217d-0079-4f38-8790-872e22bdc8b4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_d25c9526-2fb9-4b23-8c42-bbf61c039aea_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_swtx_LesseeOperatingLeaseEntitledTenantAllowance_ea8e6f80-b7fd-4a5b-923b-fbfa5f095481_terseLabel_en-US" xlink:label="lab_swtx_LesseeOperatingLeaseEntitledTenantAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant allowance</link:label>
    <link:label id="lab_swtx_LesseeOperatingLeaseEntitledTenantAllowance_label_en-US" xlink:label="lab_swtx_LesseeOperatingLeaseEntitledTenantAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Entitled Tenant Allowance</link:label>
    <link:label id="lab_swtx_LesseeOperatingLeaseEntitledTenantAllowance_documentation_en-US" xlink:label="lab_swtx_LesseeOperatingLeaseEntitledTenantAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Entitled Tenant Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LesseeOperatingLeaseEntitledTenantAllowance" xlink:href="swtx-20220331.xsd#swtx_LesseeOperatingLeaseEntitledTenantAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_swtx_LesseeOperatingLeaseEntitledTenantAllowance" xlink:to="lab_swtx_LesseeOperatingLeaseEntitledTenantAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_0ef9d693-0608-4d29-bcd5-f9fc14441e15_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_31049a5c-470a-46c1-a686-d554596fe6dc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeiture of restricted stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5b955ba1-2102-465a-a22c-1dcfe0717212_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_8c9c8c00-19f2-454e-ac69-18c0e4db4887_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_a0c68001-2e34-40b7-9bb1-fc39ddff7d0d_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_c8eafc10-984a-4b03-92a0-6b15f23fa84f_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents:</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_f63ed816-be1d-40c6-9eff-620564197110_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5890ab63-ada8-48c9-9076-493de3b72cbf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f842cbcb-0012-4c08-8b2f-7dec232eb6ed_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_10be9405-8a8f-4e17-81f2-93d251c1715d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_d42e0983-fa52-437b-af89-81e6d333b03d_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments:</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e724111f-ba7e-4f78-bfc2-9e40bdd5d8f1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_dfb869f5-6271-4e55-b623-5e40df6a4c9f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ecdf86dc-abde-4558-aeea-3abe2194eef7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_a5224eaf-9198-449b-8874-73171ee1e193_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_swtx_IncreaseDecreaseInLeaseLiability_9efbd37b-7d57-4368-9731-8dd34e8bd61a_terseLabel_en-US" xlink:label="lab_swtx_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_swtx_IncreaseDecreaseInLeaseLiability_label_en-US" xlink:label="lab_swtx_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Lease Liability</link:label>
    <link:label id="lab_swtx_IncreaseDecreaseInLeaseLiability_documentation_en-US" xlink:label="lab_swtx_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in lease liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_IncreaseDecreaseInLeaseLiability" xlink:href="swtx-20220331.xsd#swtx_IncreaseDecreaseInLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_swtx_IncreaseDecreaseInLeaseLiability" xlink:to="lab_swtx_IncreaseDecreaseInLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_050b3ec2-3206-4018-8ea5-89b5ea4c372d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d8e16b9d-edaa-4073-9a7f-fd33610a4ee1_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0864e1e7-99ad-4a33-ace3-a4c5b540d1a6_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_1693a32e-e3f9-41a5-a6e6-c440d15ca162_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_75432ca4-dcc2-4b9f-a477-bdd445adc490_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3425fb63-e00b-44ae-b55c-c9d59871147a_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total changes in other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ab09cc23-5d49-41f7-ace1-1bca8c125d99_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9ee0e9bf-d187-4858-99be-e773f435061f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of equity-based compensation expense related to restricted stock and stock options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_caa298ff-f850-44b4-8540-17b89e5eef6d_terseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock used to satisfy tax withholding obligations (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_accdbfec-afe1-4dec-98f0-6abcbec1337d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5c01b5ac-4c74-4f57-a339-b4ab6d917b48_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of each class</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_fd9aaf42-5dbf-4de3-aecb-40a0c81dc998_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_cae56142-6ce7-4f3c-92af-24623e791682_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_d9f3e0bd-1e27-49e9-809c-cd78ad52bf43_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_dd015032-0cd9-4f0d-a1fc-ff071dd9ea23_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_655649ec-05fd-4f82-9292-c6d6c9c00ff0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_555b7108-96db-47ba-91d4-3fa5eddbbecc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_116f0e0a-90eb-42e7-aa43-f1f822fc3c92_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_92307796-6a27-47b8-8f6d-50dbc95b9d85_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_a9abf2dc-eaff-43bb-9112-c5ff02f44fda_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9656af8a-a5de-425c-9d0a-6edc0df01d01_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_2facac57-da3b-4aeb-a892-7879efb484ef_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1ab39b9d-4dfd-4774-90c8-59d71ecc7bee_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_swtx_StamfordConnecticutMember_2b7a1ee1-d0d9-4449-b124-c4100f7f1739_terseLabel_en-US" xlink:label="lab_swtx_StamfordConnecticutMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stamford, CT</link:label>
    <link:label id="lab_swtx_StamfordConnecticutMember_label_en-US" xlink:label="lab_swtx_StamfordConnecticutMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stamford Connecticut [Member]</link:label>
    <link:label id="lab_swtx_StamfordConnecticutMember_documentation_en-US" xlink:label="lab_swtx_StamfordConnecticutMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stamford Connecticut</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_StamfordConnecticutMember" xlink:href="swtx-20220331.xsd#swtx_StamfordConnecticutMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_swtx_StamfordConnecticutMember" xlink:to="lab_swtx_StamfordConnecticutMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a691bbe2-b120-45a8-909e-6ad9e39978e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock award outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_0b08a7c3-058b-4eff-bf8b-6a6bbf03dd89_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8aed7d50-f12f-4fd5-9e6b-f63c1e3b7ee1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_10616868-4756-44dd-9e7d-e82cbe4e3114_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_398a45c9-b24f-4a0c-98c1-6a0e2f294fa8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_63edeb05-79f3-4761-80ed-37be4a020ad3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_98c12531-a731-47dd-ac09-f647a215b18b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_ce6dc45c-5757-4773-968d-bad39ba32e0e_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_3a74d775-b07d-4818-9105-ac2eb66b7bdc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock used to satisfy tax withholding obligations</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_swtx_LesseeOperatingLeaseRenewalTermAxisAxis_53fe6f9d-0e98-4dab-b156-907de2495b46_terseLabel_en-US" xlink:label="lab_swtx_LesseeOperatingLeaseRenewalTermAxisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Renewal Term Axis [Axis]</link:label>
    <link:label id="lab_swtx_LesseeOperatingLeaseRenewalTermAxisAxis_label_en-US" xlink:label="lab_swtx_LesseeOperatingLeaseRenewalTermAxisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Renewal Term Axis [Axis]</link:label>
    <link:label id="lab_swtx_LesseeOperatingLeaseRenewalTermAxisAxis_documentation_en-US" xlink:label="lab_swtx_LesseeOperatingLeaseRenewalTermAxisAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Renewal Term Axis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LesseeOperatingLeaseRenewalTermAxisAxis" xlink:href="swtx-20220331.xsd#swtx_LesseeOperatingLeaseRenewalTermAxisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_swtx_LesseeOperatingLeaseRenewalTermAxisAxis" xlink:to="lab_swtx_LesseeOperatingLeaseRenewalTermAxisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_3d2e94fc-aa06-40f2-bfd6-65ab44cb704b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_150cf54f-0dab-4800-808f-4580c7b6fb01_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_15f0d410-aba0-455d-916c-7331ae877d1f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_b24014e2-0f52-4672-abab-3a32b7923721_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_4b969cc7-07ca-4034-abc4-8b95c8fc016f_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_24dc46e1-0b5f-413d-ab64-df793397b367_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_5f4215f2-b6ee-4a50-b8b9-fafe32c5917c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a70da12a-f32e-407d-9b60-cf7e60e9669f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_37d91a6a-b1ee-4d58-8641-414c244ef361_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8704b331-6d13-45f4-bef4-89c64c7d3deb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_83b13160-077e-465e-bd6c-6459601ed2bd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_5f6bd826-cdc4-4584-a8de-14d5aa3d6546_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b0f9f356-9634-46bc-a4b8-2e224bcb63ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_6059ea1b-cdba-4d4a-ae56-f09afbc932b7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment loss</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_6c373db1-b66c-46b3-ae46-6a586cca3e99_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment loss</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_09e8f933-5435-4054-843f-a6474a01f9ae_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment loss</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_3d38b02f-a0ac-4467-a519-c4c4ef7ed53a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_47e8a8b2-7433-457e-98ff-3d76785be11c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_ec990bcb-6158-4681-ad24-1bb69e97c136_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_swtx_ExecutiveOfficersAndEmployeesMember_a971286c-c07d-493e-973d-5f523fdcf6f8_terseLabel_en-US" xlink:label="lab_swtx_ExecutiveOfficersAndEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive officers and employees</link:label>
    <link:label id="lab_swtx_ExecutiveOfficersAndEmployeesMember_label_en-US" xlink:label="lab_swtx_ExecutiveOfficersAndEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officers And Employees [Member]</link:label>
    <link:label id="lab_swtx_ExecutiveOfficersAndEmployeesMember_documentation_en-US" xlink:label="lab_swtx_ExecutiveOfficersAndEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents executive officers and employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_ExecutiveOfficersAndEmployeesMember" xlink:href="swtx-20220331.xsd#swtx_ExecutiveOfficersAndEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_swtx_ExecutiveOfficersAndEmployeesMember" xlink:to="lab_swtx_ExecutiveOfficersAndEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_13a229dd-0ae5-4876-ac03-805ee3333264_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_33bf1908-3b0e-400d-98ae-199279d0fa58_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_db710b3d-ed77-4014-843b-35b54e366420_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale and maturity of debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a5b750ba-8654-4cf5-9ee5-2d49e2784b1f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_abf02b77-2519-40f4-869f-a6276b50c3f0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_ffa59afc-8068-49f2-8570-8711fe6008ac_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of financial assets subject to fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eabd9f7b-4488-44b1-ba60-a1efbd37464e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_swtx_LesseeOperatingLeaseRenewalOptionOneMember_fb1064dd-f2c0-4855-b175-6443bcb457c7_terseLabel_en-US" xlink:label="lab_swtx_LesseeOperatingLeaseRenewalOptionOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option One</link:label>
    <link:label id="lab_swtx_LesseeOperatingLeaseRenewalOptionOneMember_label_en-US" xlink:label="lab_swtx_LesseeOperatingLeaseRenewalOptionOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Renewal Option One [Member]</link:label>
    <link:label id="lab_swtx_LesseeOperatingLeaseRenewalOptionOneMember_documentation_en-US" xlink:label="lab_swtx_LesseeOperatingLeaseRenewalOptionOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Renewal Option One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LesseeOperatingLeaseRenewalOptionOneMember" xlink:href="swtx-20220331.xsd#swtx_LesseeOperatingLeaseRenewalOptionOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_swtx_LesseeOperatingLeaseRenewalOptionOneMember" xlink:to="lab_swtx_LesseeOperatingLeaseRenewalOptionOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_7bba3bce-0e95-4de4-b395-37341a722d55_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_swtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock_8ce0d45a-0caf-4706-9453-fbad3ad47a58_terseLabel_en-US" xlink:label="lab_swtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of annual increase in the shares</link:label>
    <link:label id="lab_swtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock_label_en-US" xlink:label="lab_swtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Annual Increase in Outstanding Stock</link:label>
    <link:label id="lab_swtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock_documentation_en-US" xlink:label="lab_swtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of annual increase in the shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock" xlink:href="swtx-20220331.xsd#swtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_swtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock" xlink:to="lab_swtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_afb4a8d7-f771-4079-87de-9dfc0db028cf_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_dbf976e2-8e53-453f-8440-dcf8606abbf7_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTable" xlink:to="lab_us-gaap_MarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_53d17b0a-8c52-4d7b-8407-90a9a1985bad_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_46ac3cbd-3dd9-4e45-812b-0a068dad0498_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b6e57a27-38e9-4948-a74c-7e57a2c4493e_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_81c1ee2b-7129-454d-a7e7-d6934636a58a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest (in percent)</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_ced8f207-f6eb-4b72-a008-b2ce4f8adc41_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f494dcf4-5ed9-4515-87d6-d535fb852be3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_dc7e8644-885e-440e-a51a-25742e51cc26_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_089a4dc5-e729-49a1-b7b9-696d9d8e4db8_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_66084c88-184f-4483-9102-e14b1ce02dda_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c91b5967-a8df-4cd4-8eba-553164137ffe_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1caeed08-601a-469b-bd7e-48ba67b93321_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_2924a2d7-7d41-4f2d-a98d-e59dab7f9cee_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_79ec0bf6-ee57-43d8-8eb8-643c9ae0acfa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4a452d4f-5148-4e35-ae5c-ba1e07f97ce6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_4f43d507-0916-4315-a5ae-520f21673cea_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_9ecda855-432d-4bac-9392-4682ead69f2d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c3f4e7f4-b9ff-4686-8a2e-df7d76f2b5c0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7d0eb219-c8e7-483f-8583-73c3088f7c0b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_73eb6d27-82f3-4348-ad1c-8fe305c10e93_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f3e24a81-1e08-4794-9667-a9a217381347_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_56762b7c-623e-47e1-bce4-978d836f4059_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7252f347-54da-4e2e-ae3d-f2be0bc2fab1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_dd4e4917-4b7d-4e58-8435-39e010eec1f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_c5765f05-0cf3-4a47-b9ab-6c52b21ccb7a_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5cb0b340-d7c2-457b-96a4-ab433322d310_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_59d00be7-0945-4071-ba61-c5d8cae78ffb_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_0f7e34fa-31cd-466a-b60a-0c1b66de73f0_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol(s)</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_b3372a72-787f-4f42-860f-22ef529cc58d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_swtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear_5c5bda17-1379-4f15-bb83-dcd629feeb7e_terseLabel_en-US" xlink:label="lab_swtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 and thereafter</link:label>
    <link:label id="lab_swtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear_label_en-US" xlink:label="lab_swtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Payments Due After Three Year</link:label>
    <link:label id="lab_swtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear_documentation_en-US" xlink:label="lab_swtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Payments Due After Three Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear" xlink:href="swtx-20220331.xsd#swtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_swtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear" xlink:to="lab_swtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_017000b7-42a2-4b1d-915d-00d13eddbce9_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_swtx_CeoPerformanceAwardMember_d53e4dd2-8de9-4c0e-9ed5-b22111d529ca_terseLabel_en-US" xlink:label="lab_swtx_CeoPerformanceAwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEO Performance Award</link:label>
    <link:label id="lab_swtx_CeoPerformanceAwardMember_label_en-US" xlink:label="lab_swtx_CeoPerformanceAwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceo Performance Award [Member]</link:label>
    <link:label id="lab_swtx_CeoPerformanceAwardMember_documentation_en-US" xlink:label="lab_swtx_CeoPerformanceAwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represent information pertaining to CEO Performance Award.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_CeoPerformanceAwardMember" xlink:href="swtx-20220331.xsd#swtx_CeoPerformanceAwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_swtx_CeoPerformanceAwardMember" xlink:to="lab_swtx_CeoPerformanceAwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_5e1242de-eef7-4f75-bc0d-9a5dc170eda6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_8c09c490-4055-43b7-8c2e-78c3ef2db04d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_3144e9f4-0f84-4d3d-8b47-76dc49ae4537_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_82fe9ae4-791e-40aa-a1cf-a5861423daa1_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_983e2c31-c6ea-4f91-94ff-19015d94ee42_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_e0bcc109-5f9a-44b4-92cd-85996cab6833_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_swtx_LesseeOperatingLeaseRenewalOptionTwoMember_18099559-0b44-4f7e-bd51-ed718f9d59b7_terseLabel_en-US" xlink:label="lab_swtx_LesseeOperatingLeaseRenewalOptionTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Two</link:label>
    <link:label id="lab_swtx_LesseeOperatingLeaseRenewalOptionTwoMember_label_en-US" xlink:label="lab_swtx_LesseeOperatingLeaseRenewalOptionTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Renewal Option Two [Member]</link:label>
    <link:label id="lab_swtx_LesseeOperatingLeaseRenewalOptionTwoMember_documentation_en-US" xlink:label="lab_swtx_LesseeOperatingLeaseRenewalOptionTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Renewal Option Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LesseeOperatingLeaseRenewalOptionTwoMember" xlink:href="swtx-20220331.xsd#swtx_LesseeOperatingLeaseRenewalOptionTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_swtx_LesseeOperatingLeaseRenewalOptionTwoMember" xlink:to="lab_swtx_LesseeOperatingLeaseRenewalOptionTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7ae62220-f638-4f76-8c34-20312c61cd29_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_38672deb-835d-4e0c-90a0-667341b2b691_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total interest and other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_6ff08df2-ad07-4d9d-8d3f-9d566790863e_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bd1b9990-0b44-429e-b770-035a723a4ce7_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense expected to be recognized over a weighted-average remaining period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_898fe450-3bf6-4f05-b64c-d1de3eb677fb_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_aa7a31ed-806d-402e-9737-0f0e259799be_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_swtx_NumberOfClinicalTrials_adf9af25-5928-41a0-983b-216740d25b42_terseLabel_en-US" xlink:label="lab_swtx_NumberOfClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of clinical trials (trials)</link:label>
    <link:label id="lab_swtx_NumberOfClinicalTrials_label_en-US" xlink:label="lab_swtx_NumberOfClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Clinical Trials</link:label>
    <link:label id="lab_swtx_NumberOfClinicalTrials_documentation_en-US" xlink:label="lab_swtx_NumberOfClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of clinical trials reported by the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_NumberOfClinicalTrials" xlink:href="swtx-20220331.xsd#swtx_NumberOfClinicalTrials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_swtx_NumberOfClinicalTrials" xlink:to="lab_swtx_NumberOfClinicalTrials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_3a8f1878-5149-4ad6-8772-7d0175fa620c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_95d187c7-bd43-43dc-afe6-8ae0934c97a4_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_95bf2594-0fbf-483d-8162-ebbdf0b2da43_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_swtx_LongTermInvestmentsFairValueDisclosure_c13642f4-ff50-47ee-ae50-bc1a5924a7f0_terseLabel_en-US" xlink:label="lab_swtx_LongTermInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term investments</link:label>
    <link:label id="lab_swtx_LongTermInvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_swtx_LongTermInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investments, Fair Value Disclosure</link:label>
    <link:label id="lab_swtx_LongTermInvestmentsFairValueDisclosure_documentation_en-US" xlink:label="lab_swtx_LongTermInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value portion of long-term investment securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LongTermInvestmentsFairValueDisclosure" xlink:href="swtx-20220331.xsd#swtx_LongTermInvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_swtx_LongTermInvestmentsFairValueDisclosure" xlink:to="lab_swtx_LongTermInvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fc400330-acf8-4e2b-b04e-a931039195fc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_swtx_LesseeOperatingLeaseNumberOfRenewalOptions_c2e260be-89b8-4b6d-a43d-db30df987fd5_terseLabel_en-US" xlink:label="lab_swtx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of renewal options</link:label>
    <link:label id="lab_swtx_LesseeOperatingLeaseNumberOfRenewalOptions_label_en-US" xlink:label="lab_swtx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:label id="lab_swtx_LesseeOperatingLeaseNumberOfRenewalOptions_documentation_en-US" xlink:label="lab_swtx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:href="swtx-20220331.xsd#swtx_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_swtx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:to="lab_swtx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5b852c59-8db9-4126-a131-edab7588af35_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6377fc9d-cd65-45ed-8c7b-1ac8a23d9321_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_b847206a-1bf7-462d-91ee-7be72598b183_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_35fc157a-d04f-42fe-81cc-ec5d78d65a0d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_0f579bf8-0cfb-4f3c-bc37-7fd93fa445ec_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards subject to future vesting</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_34963b4b-fa7d-46b1-a99e-3334e8127b76_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred units</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_88bd6d27-7dd3-44a2-903b-02aec327cf41_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_2f26388e-efe1-460a-a7dd-c0d0daa289d1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_e37a0309-a075-4245-beba-364f50d74220_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_3b1f66ff-0343-4cab-9233-0edf10a66acf_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_0dafe4c3-4ecc-40d1-beb6-f948421cf8b2_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dc59d4b4-d535-4edd-86a8-4c50e1c8cfc5_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents including Restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6184092d-dc3f-4fe3-9bb6-46bdbb45859e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents including Restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_08afbe43-deb2-4685-9aa8-a10e6ede9cfc_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_fdff543c-299a-4320-9074-45be03fb8eb7_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_0ed619bf-f2cb-4ced-be89-e0dce8087bc8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_swtx_WorkingCapital_a19801f2-0af5-4907-ae68-c6e7f614c216_terseLabel_en-US" xlink:label="lab_swtx_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_swtx_WorkingCapital_label_en-US" xlink:label="lab_swtx_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital</link:label>
    <link:label id="lab_swtx_WorkingCapital_documentation_en-US" xlink:label="lab_swtx_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The capital of a business which is used in its day-to-day trading operations, calculated as the current assets minus the current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_WorkingCapital" xlink:href="swtx-20220331.xsd#swtx_WorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_swtx_WorkingCapital" xlink:to="lab_swtx_WorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_e7d71795-ce29-499a-a4f1-41d8b0a5471d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_31d01c13-a538-48c9-a573-67156f619bbd_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9e1d95e5-df13-4230-a124-46401d390e96_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_fd53060e-c1c5-4180-8bed-c7d7b0ba2ec1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f6136927-6013-410c-90b4-3beadf70bf98_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4952c7a1-8fd7-4cb3-a783-0f58afbdab2f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4987394b-77d5-40a7-b6f0-efaa4a01cf25_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_73426a81-e589-40d1-b0dd-de10ba5a025d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_62a0cb8c-4aee-4e9c-adec-4556e20597a9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_59d0b2a8-2a7e-409f-9992-6bbefbb24721_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_2df9a640-b500-415f-9b70-4e5cb6d6e48c_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_0a450342-1fb8-47aa-9a1b-9841823b28fd_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a3cc2f0d-9cca-40d9-b3c6-6fb51b9c9529_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_6d93bc6c-484e-49d0-a600-f87b9da69392_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_swtx_EquityIncentivePlan2019Member_8274c32e-4e13-4941-9d54-af7b1fbb8bda_terseLabel_en-US" xlink:label="lab_swtx_EquityIncentivePlan2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Equity Incentive Plan</link:label>
    <link:label id="lab_swtx_EquityIncentivePlan2019Member_label_en-US" xlink:label="lab_swtx_EquityIncentivePlan2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan2019 [Member]</link:label>
    <link:label id="lab_swtx_EquityIncentivePlan2019Member_documentation_en-US" xlink:label="lab_swtx_EquityIncentivePlan2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to 2019 Equity Incentive Plan ("2019 Public Company Plan").</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_EquityIncentivePlan2019Member" xlink:href="swtx-20220331.xsd#swtx_EquityIncentivePlan2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_swtx_EquityIncentivePlan2019Member" xlink:to="lab_swtx_EquityIncentivePlan2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_f32d8cb1-1c2a-40e5-aa90-ca66fda91e32_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and marketable securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_3ef73bee-0b43-4621-bd4d-216c27cce421_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_00de7766-ad4c-40ac-94de-8f5e2db9746a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_53b996fe-3605-46ba-bb8d-3e52891601ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of potential common shares not included in the calculation of the diluted net loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_48063da0-f13c-403f-a944-2b8748069947_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_2581f3d4-0d07-487e-b2eb-d06d5e7ffacb_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_babe1043-8122-4b30-9be2-159ca4ab6adb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_34567a28-b431-414e-870f-6095bfebf62f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options vested and exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_a5aeecc1-9210-417c-a094-ab6f2eff3a45_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_39569104-5a5a-43f9-8381-da29364a8d32_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_73b4a946-7e3f-45be-8c0e-07304ba8b7a7_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options issued and outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_045062ac-dea2-469e-9387-383632416285_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Street</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1150a6a7-3a57-4496-8227-be0dd0bf8b50_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_d99cd41d-63d1-46a8-b4d6-97865e15f43b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_5c18dfe5-6c9b-4eb8-a5f1-df2a5e07ead5_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems" xlink:to="lab_us-gaap_MarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_ae39d039-f1d5-47e1-8764-b696e802b8ca_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_swtx_MapkureMember_756b42f2-c78b-4a3f-8fc2-a8baa691690c_terseLabel_en-US" xlink:label="lab_swtx_MapkureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MapKure</link:label>
    <link:label id="lab_swtx_MapkureMember_label_en-US" xlink:label="lab_swtx_MapkureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mapkure [Member]</link:label>
    <link:label id="lab_swtx_MapkureMember_documentation_en-US" xlink:label="lab_swtx_MapkureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">n/a</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_MapkureMember" xlink:href="swtx-20220331.xsd#swtx_MapkureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_swtx_MapkureMember" xlink:to="lab_swtx_MapkureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_87fd7f54-1190-460b-89cb-aed9a2cb37b1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_5ddbe430-5f79-46ab-8541-180a202f2cff_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_6d7b15bf-b06e-4035-b138-fe6d52993f73_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_10fdd271-b7b6-4755-8d47-9e196795fbf9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_swtx_AnnualIncreaseInLeasePaymentsPercentage_ea798013-14c3-48e7-95b2-5057d332b6eb_terseLabel_en-US" xlink:label="lab_swtx_AnnualIncreaseInLeasePaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in lease payments (as a percent)</link:label>
    <link:label id="lab_swtx_AnnualIncreaseInLeasePaymentsPercentage_label_en-US" xlink:label="lab_swtx_AnnualIncreaseInLeasePaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Increase In Lease Payments, Percentage</link:label>
    <link:label id="lab_swtx_AnnualIncreaseInLeasePaymentsPercentage_documentation_en-US" xlink:label="lab_swtx_AnnualIncreaseInLeasePaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Increase In Lease Payments, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_AnnualIncreaseInLeasePaymentsPercentage" xlink:href="swtx-20220331.xsd#swtx_AnnualIncreaseInLeasePaymentsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_swtx_AnnualIncreaseInLeasePaymentsPercentage" xlink:to="lab_swtx_AnnualIncreaseInLeasePaymentsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6f65ea35-6409-436e-9daf-6bd8357b4fa3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1fedeaa7-a437-408f-b852-ae99c34036ff_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_92448d43-f8a7-4e50-a32f-6f4d035e030a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9ffc30b3-22be-43a8-916e-e923caa39d15_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock repurchased to satisfy tax withholding obligations</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d3aa732d-9cb1-4955-96cb-89199257a5a6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_9da11ff5-765e-46d1-ab52-f43ceef4d6e6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_49926c6a-d434-438d-a16f-ef1d49ad79a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_93b38397-1b1f-4519-8aa3-00e0df76c39a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e804f05b-b9ff-442b-b692-e2f4d8bf7c12_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract_8d0c10b1-427d-46d1-99ea-ef49b5e1685e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Description [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_6780db93-5a20-44a9-a2ca-2eb2c2d8c97b_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_swtx_ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember_22cd818d-6411-4f82-a19b-aecbdb28e84a_terseLabel_en-US" xlink:label="lab_swtx_ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee and Non Employee</link:label>
    <link:label id="lab_swtx_ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember_label_en-US" xlink:label="lab_swtx_ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Payment Arrangement Employee And Non Employee [Member]</link:label>
    <link:label id="lab_swtx_ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember_documentation_en-US" xlink:label="lab_swtx_ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Payment Arrangement Employee And Non Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" xlink:href="swtx-20220331.xsd#swtx_ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_swtx_ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" xlink:to="lab_swtx_ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_81e25eb4-34e8-4696-815c-9f94e16975de_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_2f055a9a-9d17-465f-85f5-104b31ba45e1_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_eec6ffe9-eead-4f97-bf73-a52cefc70fc8_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_c969dc81-6824-4173-acbd-d36978674a34_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_cd5f06c8-3d4c-4d8a-b127-dd579f840b5e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_479dbdb5-ce09-45d2-83c8-77cd4cae573d_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of available-for-sale marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_b276d222-c869-48a4-9197-44104e245a9d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f01a17be-37b6-4430-88a2-68032ac2e41a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_19a2ce5e-40a1-4be6-ab45-3dbe127adf65_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_651c7d05-af2a-4f86-a7f1-b979516a0816_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_64ef097d-e3f6-4737-993c-f047886321c6_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_1da01c7d-ba83-465d-8fc0-fc8e90026de2_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_57c39179-c401-47f1-898d-98d1c0dbbef6_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_f38cf082-5807-4a5c-935b-3cbe86549840_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_037d7109-2b51-4854-abed-1268d9f10b82_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_513df0c4-b7f3-47c6-a3f6-9033012b2b69_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5451a809-6c4a-41d9-9f83-b58ca5f2b90c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of future minimum lease obligations</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_402d3522-410f-41fc-810c-f2fdcfc4bae3_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_935280c3-327a-4c03-9f47-f6b23e4d8615_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ac552b3e-cbe0-4635-be72-74bdc78c85d9_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_7b9f6dc3-5a87-4a44-9a84-c4a198e39cef_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_557e2985-ada3-4b30-925e-da41d00d3c19_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_0a8be3ad-1ad7-4257-9e9b-29211b692af5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d8a8cae1-46ac-465d-a7b8-d208d0e30d39_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_b0578fab-a89e-4ace-8121-74a936cf21d6_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3b7ab71f-1f66-40d7-a753-00921d650b94_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_a1edd62d-5ce2-414d-95df-ba4506e140cf_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment and Variable Interest Entity</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_swtx_AccruedResearchAndDevelopmentExpenses_856ee24e-3745-46fe-bf0b-899dfb73d81f_terseLabel_en-US" xlink:label="lab_swtx_AccruedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development</link:label>
    <link:label id="lab_swtx_AccruedResearchAndDevelopmentExpenses_label_en-US" xlink:label="lab_swtx_AccruedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Expenses</link:label>
    <link:label id="lab_swtx_AccruedResearchAndDevelopmentExpenses_documentation_en-US" xlink:label="lab_swtx_AccruedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of research and development expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_AccruedResearchAndDevelopmentExpenses" xlink:href="swtx-20220331.xsd#swtx_AccruedResearchAndDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_swtx_AccruedResearchAndDevelopmentExpenses" xlink:to="lab_swtx_AccruedResearchAndDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_669ce0e0-2375-4a55-8352-8c4e74e1683c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_21a63edc-e751-432d-a7a0-fd3dafcb7454_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>swtx-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:20c9ef3f-9e42-493b-a5cd-6a5cd47c499c,g:fe877b4c-7b58-4b84-8d3e-d0ed79a85bd8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.springworkstx.com/role/Cover" xlink:type="simple" xlink:href="swtx-20220331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_43ac646c-67af-4ca0-b6d9-ac4676d18ece" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_DocumentType_43ac646c-67af-4ca0-b6d9-ac4676d18ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_8a81d173-11ab-4d85-b86c-e35f90b098eb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_DocumentQuarterlyReport_8a81d173-11ab-4d85-b86c-e35f90b098eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_0e6364ea-336c-4a29-b9e0-c71d5d29a8bf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_DocumentPeriodEndDate_0e6364ea-336c-4a29-b9e0-c71d5d29a8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_221a0d16-5a54-424a-a5b7-726e36e37e8d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_DocumentTransitionReport_221a0d16-5a54-424a-a5b7-726e36e37e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8395f8a1-f4cd-4e2d-928d-865a0f6585a1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_EntityFileNumber_8395f8a1-f4cd-4e2d-928d-865a0f6585a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_19ab3b8d-3117-421e-8116-cafda8e2177f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_EntityRegistrantName_19ab3b8d-3117-421e-8116-cafda8e2177f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ff6e70ef-72a4-42ed-af12-1da967f08436" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ff6e70ef-72a4-42ed-af12-1da967f08436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e5434feb-0473-4cd1-a437-3984b471ec77" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_EntityTaxIdentificationNumber_e5434feb-0473-4cd1-a437-3984b471ec77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_7f16f2b8-6047-49f3-87e1-dc5bbd27c506" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_EntityAddressAddressLine1_7f16f2b8-6047-49f3-87e1-dc5bbd27c506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_5a3f3fa2-9142-484b-88c2-a4e2133ec7f1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_EntityAddressCityOrTown_5a3f3fa2-9142-484b-88c2-a4e2133ec7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c4b42a84-ac44-4d97-8bba-1e2c3d38ce90" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_EntityAddressStateOrProvince_c4b42a84-ac44-4d97-8bba-1e2c3d38ce90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_332b6194-fde7-4a7b-b93a-c13754875029" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_EntityAddressPostalZipCode_332b6194-fde7-4a7b-b93a-c13754875029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_2ee9792f-5628-47a9-b18d-1fa1ab32cfa5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_CityAreaCode_2ee9792f-5628-47a9-b18d-1fa1ab32cfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_0af9867a-00ff-44c8-b31d-e838d9f0ad32" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_LocalPhoneNumber_0af9867a-00ff-44c8-b31d-e838d9f0ad32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_7f4cd6ac-330e-45db-bc18-73b6552ea227" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_Security12bTitle_7f4cd6ac-330e-45db-bc18-73b6552ea227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_dddf28ed-4e98-4beb-a06d-f8bdf4bd6255" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_TradingSymbol_dddf28ed-4e98-4beb-a06d-f8bdf4bd6255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ee82a139-cfe8-4fec-bc51-f136deaf9484" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_SecurityExchangeName_ee82a139-cfe8-4fec-bc51-f136deaf9484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c5bdb399-2a47-461e-b280-945a5c24a928" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_EntityCurrentReportingStatus_c5bdb399-2a47-461e-b280-945a5c24a928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_384c9da2-99e4-4c74-9b4c-7c582e4efb43" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_EntityInteractiveDataCurrent_384c9da2-99e4-4c74-9b4c-7c582e4efb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_20d6b931-718e-4457-99e6-52e7e921f784" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_EntityFilerCategory_20d6b931-718e-4457-99e6-52e7e921f784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_4f031540-8061-49f3-b7fe-a10975ad5ab1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_EntitySmallBusiness_4f031540-8061-49f3-b7fe-a10975ad5ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_adafcf62-a410-423c-ba75-0368b6c683b0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_EntityEmergingGrowthCompany_adafcf62-a410-423c-ba75-0368b6c683b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b6710649-bf5d-4b1b-8585-8c2e69f761b3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_EntityShellCompany_b6710649-bf5d-4b1b-8585-8c2e69f761b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_94209031-dc44-4b8a-8a39-6235afb75ebc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_94209031-dc44-4b8a-8a39-6235afb75ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_83d3a306-06ae-40b9-9d4d-3daea1449e2f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_EntityCentralIndexKey_83d3a306-06ae-40b9-9d4d-3daea1449e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0f8fb36d-1873-4428-ab2c-e84920da35e4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_AmendmentFlag_0f8fb36d-1873-4428-ab2c-e84920da35e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_289ff4c3-fed2-4a98-9a61-f4bb2634eb31" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_CurrentFiscalYearEndDate_289ff4c3-fed2-4a98-9a61-f4bb2634eb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_460ffaa9-a08e-4846-ada0-571690b04ef2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_DocumentFiscalYearFocus_460ffaa9-a08e-4846-ada0-571690b04ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_aa84633f-5c30-42a5-8193-55e47e48e556" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4a6d54a7-91f7-424b-a187-d0b0452b3d2d" xlink:to="loc_dei_DocumentFiscalPeriodFocus_aa84633f-5c30-42a5-8193-55e47e48e556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="swtx-20220331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_24e37bf2-0eee-4fc0-9397-9c319fe69d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d2ea0d7b-db33-4973-bc7b-9fc3b7e8c5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_24e37bf2-0eee-4fc0-9397-9c319fe69d65" xlink:to="loc_us-gaap_AssetsAbstract_d2ea0d7b-db33-4973-bc7b-9fc3b7e8c5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6d5b104e-a647-4308-ae63-7122d9deeb37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d2ea0d7b-db33-4973-bc7b-9fc3b7e8c5c9" xlink:to="loc_us-gaap_AssetsCurrentAbstract_6d5b104e-a647-4308-ae63-7122d9deeb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_98ca7d05-3a49-4b86-8c21-51f5c176b195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6d5b104e-a647-4308-ae63-7122d9deeb37" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_98ca7d05-3a49-4b86-8c21-51f5c176b195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_b9fb4466-7bd4-4fd6-8102-b89880d0f1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6d5b104e-a647-4308-ae63-7122d9deeb37" xlink:to="loc_us-gaap_MarketableSecurities_b9fb4466-7bd4-4fd6-8102-b89880d0f1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_e30f6fd9-c7d8-4dc8-a54d-e65cf459f139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6d5b104e-a647-4308-ae63-7122d9deeb37" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_e30f6fd9-c7d8-4dc8-a54d-e65cf459f139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5954f732-9e41-4b6b-9034-df5034ca16ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6d5b104e-a647-4308-ae63-7122d9deeb37" xlink:to="loc_us-gaap_AssetsCurrent_5954f732-9e41-4b6b-9034-df5034ca16ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_f67ef271-bdf8-4f0a-9eea-e42d49fab3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d2ea0d7b-db33-4973-bc7b-9fc3b7e8c5c9" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_f67ef271-bdf8-4f0a-9eea-e42d49fab3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8fd7fe0a-8cfa-4482-9ef6-939a8914dc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d2ea0d7b-db33-4973-bc7b-9fc3b7e8c5c9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8fd7fe0a-8cfa-4482-9ef6-939a8914dc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5ec42ca0-b409-4c7b-97e2-c38ab99458b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d2ea0d7b-db33-4973-bc7b-9fc3b7e8c5c9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5ec42ca0-b409-4c7b-97e2-c38ab99458b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_1f25faa5-9df9-4189-8282-7a8f1e94e730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d2ea0d7b-db33-4973-bc7b-9fc3b7e8c5c9" xlink:to="loc_us-gaap_EquityMethodInvestments_1f25faa5-9df9-4189-8282-7a8f1e94e730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_f8518a5a-3549-4a7e-baf9-b196beeb8981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d2ea0d7b-db33-4973-bc7b-9fc3b7e8c5c9" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_f8518a5a-3549-4a7e-baf9-b196beeb8981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4c1ced29-dae5-4be5-b2c4-187bc7c0ff5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d2ea0d7b-db33-4973-bc7b-9fc3b7e8c5c9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4c1ced29-dae5-4be5-b2c4-187bc7c0ff5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d112f747-367b-40e2-b538-f8e4f5bc5eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d2ea0d7b-db33-4973-bc7b-9fc3b7e8c5c9" xlink:to="loc_us-gaap_Assets_d112f747-367b-40e2-b538-f8e4f5bc5eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2184fd8c-3360-4343-8cc0-e074d5ead531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_24e37bf2-0eee-4fc0-9397-9c319fe69d65" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2184fd8c-3360-4343-8cc0-e074d5ead531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2bb71330-d81a-4277-8fbe-00925848276d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2184fd8c-3360-4343-8cc0-e074d5ead531" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2bb71330-d81a-4277-8fbe-00925848276d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a3024dbd-6d0c-4ad2-bb04-e77188edd9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2bb71330-d81a-4277-8fbe-00925848276d" xlink:to="loc_us-gaap_AccountsPayableCurrent_a3024dbd-6d0c-4ad2-bb04-e77188edd9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c8bb2c4c-a708-4bd2-ad6e-c375108aac58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2bb71330-d81a-4277-8fbe-00925848276d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c8bb2c4c-a708-4bd2-ad6e-c375108aac58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ae52b27f-8b87-4891-aa14-5ffc68596a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2bb71330-d81a-4277-8fbe-00925848276d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ae52b27f-8b87-4891-aa14-5ffc68596a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8ce84d2e-5d33-40e2-8cd8-7ba14b4d2d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2bb71330-d81a-4277-8fbe-00925848276d" xlink:to="loc_us-gaap_LiabilitiesCurrent_8ce84d2e-5d33-40e2-8cd8-7ba14b4d2d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6d5ea86b-3144-4abe-b7e2-2349b92165d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2184fd8c-3360-4343-8cc0-e074d5ead531" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6d5ea86b-3144-4abe-b7e2-2349b92165d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_01db1f68-2f67-464d-b34a-1b00c0938db5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2184fd8c-3360-4343-8cc0-e074d5ead531" xlink:to="loc_us-gaap_Liabilities_01db1f68-2f67-464d-b34a-1b00c0938db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_76574d1a-090c-4829-83e2-b5e6c90e6245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2184fd8c-3360-4343-8cc0-e074d5ead531" xlink:to="loc_us-gaap_CommitmentsAndContingencies_76574d1a-090c-4829-83e2-b5e6c90e6245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7ab9dbbd-e013-49b2-b51e-d8c506a790f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2184fd8c-3360-4343-8cc0-e074d5ead531" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7ab9dbbd-e013-49b2-b51e-d8c506a790f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8e7fa07c-6b42-4689-9fa5-0fd9a61cd536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7ab9dbbd-e013-49b2-b51e-d8c506a790f1" xlink:to="loc_us-gaap_PreferredStockValue_8e7fa07c-6b42-4689-9fa5-0fd9a61cd536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_34e81e68-36c8-4281-ac49-6138ccfe8607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7ab9dbbd-e013-49b2-b51e-d8c506a790f1" xlink:to="loc_us-gaap_CommonStockValue_34e81e68-36c8-4281-ac49-6138ccfe8607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_46e5a1fd-2733-4cbe-8463-09f265f4ef30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7ab9dbbd-e013-49b2-b51e-d8c506a790f1" xlink:to="loc_us-gaap_AdditionalPaidInCapital_46e5a1fd-2733-4cbe-8463-09f265f4ef30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_92575bf1-2af2-44fb-b708-beccfc50f89d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7ab9dbbd-e013-49b2-b51e-d8c506a790f1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_92575bf1-2af2-44fb-b708-beccfc50f89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_5247f24a-dcc6-47d8-900c-0e3162cb75a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7ab9dbbd-e013-49b2-b51e-d8c506a790f1" xlink:to="loc_us-gaap_TreasuryStockValue_5247f24a-dcc6-47d8-900c-0e3162cb75a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_53d6ea21-4bc9-4763-b34a-9de495b40653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7ab9dbbd-e013-49b2-b51e-d8c506a790f1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_53d6ea21-4bc9-4763-b34a-9de495b40653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_20afb677-5350-4e20-b051-64048e421d28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7ab9dbbd-e013-49b2-b51e-d8c506a790f1" xlink:to="loc_us-gaap_StockholdersEquity_20afb677-5350-4e20-b051-64048e421d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_51f40416-27c8-48fd-be44-6ed9b9355fff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2184fd8c-3360-4343-8cc0-e074d5ead531" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_51f40416-27c8-48fd-be44-6ed9b9355fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="swtx-20220331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_cc6961cc-fb75-46d4-a229-4cc6ab5796d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c7730378-95ea-4a2d-b4e6-9150f9ef16ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cc6961cc-fb75-46d4-a229-4cc6ab5796d3" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c7730378-95ea-4a2d-b4e6-9150f9ef16ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9264140d-baec-42a3-9d46-f03c305f63a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cc6961cc-fb75-46d4-a229-4cc6ab5796d3" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9264140d-baec-42a3-9d46-f03c305f63a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_22343f16-b9bb-47d0-b5ac-50d6c33d4b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cc6961cc-fb75-46d4-a229-4cc6ab5796d3" xlink:to="loc_us-gaap_PreferredStockSharesIssued_22343f16-b9bb-47d0-b5ac-50d6c33d4b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7af815bc-587d-4598-8fd0-1a32db4bd9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cc6961cc-fb75-46d4-a229-4cc6ab5796d3" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_7af815bc-587d-4598-8fd0-1a32db4bd9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5d1933c1-3340-4bb6-abb4-76c72241522a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cc6961cc-fb75-46d4-a229-4cc6ab5796d3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5d1933c1-3340-4bb6-abb4-76c72241522a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_fb5cb3dc-d4c0-49a8-b0d3-23deb9dfd3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cc6961cc-fb75-46d4-a229-4cc6ab5796d3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_fb5cb3dc-d4c0-49a8-b0d3-23deb9dfd3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b3d4abd7-ee3d-48cd-8647-d0cc5f9418f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cc6961cc-fb75-46d4-a229-4cc6ab5796d3" xlink:to="loc_us-gaap_CommonStockSharesIssued_b3d4abd7-ee3d-48cd-8647-d0cc5f9418f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bcdbe673-8915-49cc-b8a0-185a32f774cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cc6961cc-fb75-46d4-a229-4cc6ab5796d3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bcdbe673-8915-49cc-b8a0-185a32f774cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_69517d78-6630-4163-87f3-1c624a7ce546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cc6961cc-fb75-46d4-a229-4cc6ab5796d3" xlink:to="loc_us-gaap_TreasuryStockShares_69517d78-6630-4163-87f3-1c624a7ce546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="swtx-20220331.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_04dd3dd6-6287-4348-bde2-59ad0d13dfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_3b63d31b-e980-408a-ac28-dc210c9372f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04dd3dd6-6287-4348-bde2-59ad0d13dfbc" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_3b63d31b-e980-408a-ac28-dc210c9372f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_50bab2f0-4e31-4f60-9589-35ce1e8d13ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3b63d31b-e980-408a-ac28-dc210c9372f8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_50bab2f0-4e31-4f60-9589-35ce1e8d13ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_fd0a459b-c8f5-473b-ba39-fd0a850620b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3b63d31b-e980-408a-ac28-dc210c9372f8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_fd0a459b-c8f5-473b-ba39-fd0a850620b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_78311031-2df7-46ee-822a-ecca61f4ebea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3b63d31b-e980-408a-ac28-dc210c9372f8" xlink:to="loc_us-gaap_OperatingExpenses_78311031-2df7-46ee-822a-ecca61f4ebea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8c5ec0d5-235d-4538-b748-5a01645671e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04dd3dd6-6287-4348-bde2-59ad0d13dfbc" xlink:to="loc_us-gaap_OperatingIncomeLoss_8c5ec0d5-235d-4538-b748-5a01645671e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0626efdc-3ad1-402e-b824-6bc4e67994cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04dd3dd6-6287-4348-bde2-59ad0d13dfbc" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0626efdc-3ad1-402e-b824-6bc4e67994cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6ab936d5-880d-442b-bea7-92bf29209382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0626efdc-3ad1-402e-b824-6bc4e67994cf" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6ab936d5-880d-442b-bea7-92bf29209382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_d5a7d636-fb6f-4fc6-ab81-c7bc923ddebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0626efdc-3ad1-402e-b824-6bc4e67994cf" xlink:to="loc_us-gaap_InvestmentIncomeNet_d5a7d636-fb6f-4fc6-ab81-c7bc923ddebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_815c9e7c-bb03-42f6-a13d-a1d6ebd12645" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0626efdc-3ad1-402e-b824-6bc4e67994cf" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_815c9e7c-bb03-42f6-a13d-a1d6ebd12645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2b1dd96d-6f48-4625-aa08-16e86f9c39d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04dd3dd6-6287-4348-bde2-59ad0d13dfbc" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2b1dd96d-6f48-4625-aa08-16e86f9c39d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fa26c2a0-31b7-4bc9-8ee7-df998cc3dca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04dd3dd6-6287-4348-bde2-59ad0d13dfbc" xlink:to="loc_us-gaap_NetIncomeLoss_fa26c2a0-31b7-4bc9-8ee7-df998cc3dca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_416c13b7-3b91-4635-ad83-e5891ba7aa79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04dd3dd6-6287-4348-bde2-59ad0d13dfbc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_416c13b7-3b91-4635-ad83-e5891ba7aa79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_2364a24d-0931-434b-a531-5c72a2a3b199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04dd3dd6-6287-4348-bde2-59ad0d13dfbc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_2364a24d-0931-434b-a531-5c72a2a3b199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7a4fbd47-0366-49d0-8569-3423ae18e41c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04dd3dd6-6287-4348-bde2-59ad0d13dfbc" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7a4fbd47-0366-49d0-8569-3423ae18e41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7f473de8-ef97-4b4e-bb16-cd827367ed0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04dd3dd6-6287-4348-bde2-59ad0d13dfbc" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7f473de8-ef97-4b4e-bb16-cd827367ed0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="swtx-20220331.xsd#CondensedConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_63f053d2-ec1c-4795-b015-b5d6b31873ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3a2d9352-1a54-4780-b998-fd3a539dfd02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_63f053d2-ec1c-4795-b015-b5d6b31873ea" xlink:to="loc_us-gaap_NetIncomeLoss_3a2d9352-1a54-4780-b998-fd3a539dfd02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ab783877-f9b6-493b-9a7e-2589cd3aab1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_63f053d2-ec1c-4795-b015-b5d6b31873ea" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ab783877-f9b6-493b-9a7e-2589cd3aab1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e737ba42-242e-41b3-b9f0-dc45ea2af57d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ab783877-f9b6-493b-9a7e-2589cd3aab1d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e737ba42-242e-41b3-b9f0-dc45ea2af57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7f6e045f-4b0b-4683-b5f0-16c40043ed76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ab783877-f9b6-493b-9a7e-2589cd3aab1d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7f6e045f-4b0b-4683-b5f0-16c40043ed76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b4a83aa0-f836-41dd-94aa-4ec4634d2095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_63f053d2-ec1c-4795-b015-b5d6b31873ea" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_b4a83aa0-f836-41dd-94aa-4ec4634d2095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="simple" xlink:href="swtx-20220331.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnaudited"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7a2f3c1d-e1a0-4afc-983b-db5d0bdaa7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e8a56668-f640-4a81-8cb7-19243d92da38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7a2f3c1d-e1a0-4afc-983b-db5d0bdaa7cf" xlink:to="loc_us-gaap_StatementTable_e8a56668-f640-4a81-8cb7-19243d92da38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3036cb5d-6e82-4749-aff1-3be2e87e575d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e8a56668-f640-4a81-8cb7-19243d92da38" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3036cb5d-6e82-4749-aff1-3be2e87e575d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_26280e24-570f-4acf-a13d-b271d7719d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3036cb5d-6e82-4749-aff1-3be2e87e575d" xlink:to="loc_us-gaap_EquityComponentDomain_26280e24-570f-4acf-a13d-b271d7719d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_18bc9ffc-4a35-4d64-97e0-18effc4e780b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_26280e24-570f-4acf-a13d-b271d7719d89" xlink:to="loc_us-gaap_CommonStockMember_18bc9ffc-4a35-4d64-97e0-18effc4e780b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_839c6ceb-e2b5-436f-ac1d-918f1da09fee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_26280e24-570f-4acf-a13d-b271d7719d89" xlink:to="loc_us-gaap_TreasuryStockMember_839c6ceb-e2b5-436f-ac1d-918f1da09fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_61ebe335-4849-4f88-bf22-a376c66e7c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_26280e24-570f-4acf-a13d-b271d7719d89" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_61ebe335-4849-4f88-bf22-a376c66e7c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6678326a-2b9a-4eaa-9bd8-9e1c6aba4566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_26280e24-570f-4acf-a13d-b271d7719d89" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6678326a-2b9a-4eaa-9bd8-9e1c6aba4566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_85a7dfd7-4405-4e87-b470-dfc4c0d2417f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_26280e24-570f-4acf-a13d-b271d7719d89" xlink:to="loc_us-gaap_RetainedEarningsMember_85a7dfd7-4405-4e87-b470-dfc4c0d2417f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a7330f48-73ed-49d5-a84a-dd989cffdcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e8a56668-f640-4a81-8cb7-19243d92da38" xlink:to="loc_us-gaap_StatementLineItems_a7330f48-73ed-49d5-a84a-dd989cffdcb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a7330f48-73ed-49d5-a84a-dd989cffdcb4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_05f5da3f-2a5b-445f-897c-f19f0b29a6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:to="loc_us-gaap_SharesIssued_05f5da3f-2a5b-445f-897c-f19f0b29a6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b517443c-d9bb-4580-b772-984a67a2e136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:to="loc_us-gaap_StockholdersEquity_b517443c-d9bb-4580-b772-984a67a2e136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_824aac5c-b8da-497c-8140-c28b01d1ea70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_824aac5c-b8da-497c-8140-c28b01d1ea70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3fdf8658-7adf-4c34-b70e-cbe2ed04338e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3fdf8658-7adf-4c34-b70e-cbe2ed04338e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_ae617165-435d-475f-99f0-6b198361dd23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_ae617165-435d-475f-99f0-6b198361dd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8e422598-f817-44cf-9b34-7cb3a903cd8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8e422598-f817-44cf-9b34-7cb3a903cd8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5fbaa5f0-c926-4244-bebb-d05deae624f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5fbaa5f0-c926-4244-bebb-d05deae624f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_275049bc-4896-46a7-a204-51b3d049b560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_275049bc-4896-46a7-a204-51b3d049b560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_915b4255-d8d5-4ef5-82ba-65774b22054f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_915b4255-d8d5-4ef5-82ba-65774b22054f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d7484b3d-7d73-4360-a220-5bca6f6b4e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d7484b3d-7d73-4360-a220-5bca6f6b4e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6ac52248-aa08-4e29-a1ea-8e67af8f7d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:to="loc_us-gaap_NetIncomeLoss_6ac52248-aa08-4e29-a1ea-8e67af8f7d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_7e90415c-f9df-4812-9da2-dc6bf327357e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:to="loc_us-gaap_SharesIssued_7e90415c-f9df-4812-9da2-dc6bf327357e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_81301e6a-994a-4b55-8bcd-a1da6288ba7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f88730d8-d0f9-4fe5-a96e-807a6ee6d476" xlink:to="loc_us-gaap_StockholdersEquity_81301e6a-994a-4b55-8bcd-a1da6288ba7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="swtx-20220331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_345f8328-31e4-4273-928a-bdad9fa8246d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dc7b3433-dd04-40ad-affb-be9bb493550a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_345f8328-31e4-4273-928a-bdad9fa8246d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dc7b3433-dd04-40ad-affb-be9bb493550a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f3d624c8-f667-423b-8e5e-3581e76e4d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dc7b3433-dd04-40ad-affb-be9bb493550a" xlink:to="loc_us-gaap_NetIncomeLoss_f3d624c8-f667-423b-8e5e-3581e76e4d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_610cc4fa-5090-4b7b-88ef-52d80457f11c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dc7b3433-dd04-40ad-affb-be9bb493550a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_610cc4fa-5090-4b7b-88ef-52d80457f11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_276cd50e-1526-463a-b71d-da150ab06740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_610cc4fa-5090-4b7b-88ef-52d80457f11c" xlink:to="loc_us-gaap_Depreciation_276cd50e-1526-463a-b71d-da150ab06740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_NonCashOperatingLeaseExpense_d04f2d60-d388-4d08-abaa-d19e8fdb1b97" xlink:href="swtx-20220331.xsd#swtx_NonCashOperatingLeaseExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_610cc4fa-5090-4b7b-88ef-52d80457f11c" xlink:to="loc_swtx_NonCashOperatingLeaseExpense_d04f2d60-d388-4d08-abaa-d19e8fdb1b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c13a7bf0-859b-4b51-a0f7-a21bad4d3cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_610cc4fa-5090-4b7b-88ef-52d80457f11c" xlink:to="loc_us-gaap_ShareBasedCompensation_c13a7bf0-859b-4b51-a0f7-a21bad4d3cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f39ed5da-30a0-4a3f-82ff-708f0d629143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_610cc4fa-5090-4b7b-88ef-52d80457f11c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f39ed5da-30a0-4a3f-82ff-708f0d629143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_f0b44aae-bd46-4857-9f4e-647efc2c45f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_610cc4fa-5090-4b7b-88ef-52d80457f11c" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_f0b44aae-bd46-4857-9f4e-647efc2c45f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e37cc89-5b59-4ac4-b3e8-e84aab40f39a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_f0b44aae-bd46-4857-9f4e-647efc2c45f7" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e37cc89-5b59-4ac4-b3e8-e84aab40f39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_97cfffd5-1e0c-4eee-9105-a77ceedeee27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_f0b44aae-bd46-4857-9f4e-647efc2c45f7" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_97cfffd5-1e0c-4eee-9105-a77ceedeee27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a617553c-5c1b-4cd4-a7ce-35e2410f186f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_f0b44aae-bd46-4857-9f4e-647efc2c45f7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a617553c-5c1b-4cd4-a7ce-35e2410f186f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_21074ce4-855f-4480-9f7a-56d4630319c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_f0b44aae-bd46-4857-9f4e-647efc2c45f7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_21074ce4-855f-4480-9f7a-56d4630319c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_IncreaseDecreaseInLeaseLiability_dcec5b5f-187e-49f0-9a4a-46a5790e8941" xlink:href="swtx-20220331.xsd#swtx_IncreaseDecreaseInLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_f0b44aae-bd46-4857-9f4e-647efc2c45f7" xlink:to="loc_swtx_IncreaseDecreaseInLeaseLiability_dcec5b5f-187e-49f0-9a4a-46a5790e8941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_42fcc199-294c-409e-8464-23583ac21fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_f0b44aae-bd46-4857-9f4e-647efc2c45f7" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_42fcc199-294c-409e-8464-23583ac21fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_104c0387-b097-4d50-aa91-504daa1ff77b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dc7b3433-dd04-40ad-affb-be9bb493550a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_104c0387-b097-4d50-aa91-504daa1ff77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6c11a5d9-d8cb-4691-bd4d-c82405f6aea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_345f8328-31e4-4273-928a-bdad9fa8246d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6c11a5d9-d8cb-4691-bd4d-c82405f6aea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_caf64496-5b28-4fd1-9100-4a469853e4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6c11a5d9-d8cb-4691-bd4d-c82405f6aea3" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_caf64496-5b28-4fd1-9100-4a469853e4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_6b5523d0-a046-4e8c-b25a-3eef8184f332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6c11a5d9-d8cb-4691-bd4d-c82405f6aea3" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_6b5523d0-a046-4e8c-b25a-3eef8184f332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_1e922588-f790-4318-b5b6-7acc185dede0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6c11a5d9-d8cb-4691-bd4d-c82405f6aea3" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_1e922588-f790-4318-b5b6-7acc185dede0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_370d6825-6241-49ef-aafd-acdcb2c00fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6c11a5d9-d8cb-4691-bd4d-c82405f6aea3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_370d6825-6241-49ef-aafd-acdcb2c00fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f20a228b-986e-4269-ae87-d878c92cd700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_345f8328-31e4-4273-928a-bdad9fa8246d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f20a228b-986e-4269-ae87-d878c92cd700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9fc7b68a-92bf-43ba-ae59-650ba9f6f28d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f20a228b-986e-4269-ae87-d878c92cd700" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9fc7b68a-92bf-43ba-ae59-650ba9f6f28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_84f316ab-16d4-410d-8331-ab09ab3b7f42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f20a228b-986e-4269-ae87-d878c92cd700" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_84f316ab-16d4-410d-8331-ab09ab3b7f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_af670867-c119-40c8-8cf8-78298518cf9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f20a228b-986e-4269-ae87-d878c92cd700" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_af670867-c119-40c8-8cf8-78298518cf9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_928b22fa-c221-4c2c-9947-3fd4af8b8d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_345f8328-31e4-4273-928a-bdad9fa8246d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_928b22fa-c221-4c2c-9947-3fd4af8b8d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_352e7c89-9908-45f0-9034-e78f4baae2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_345f8328-31e4-4273-928a-bdad9fa8246d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_352e7c89-9908-45f0-9034-e78f4baae2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7e7d8f3c-d26a-4bf1-91cb-f8caba3852de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_345f8328-31e4-4273-928a-bdad9fa8246d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7e7d8f3c-d26a-4bf1-91cb-f8caba3852de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0d19c163-735b-43f0-bf8c-27c8adb562bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_345f8328-31e4-4273-928a-bdad9fa8246d" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0d19c163-735b-43f0-bf8c-27c8adb562bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/NatureofOperations" xlink:type="simple" xlink:href="swtx-20220331.xsd#NatureofOperations"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/NatureofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_623fc40f-c6f4-42cf-a9ab-503f58b98271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_d13c7bdb-c181-4cc9-ad6e-a6f2c3702e75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_623fc40f-c6f4-42cf-a9ab-503f58b98271" xlink:to="loc_us-gaap_NatureOfOperations_d13c7bdb-c181-4cc9-ad6e-a6f2c3702e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/NatureofOperationsDetails" xlink:type="simple" xlink:href="swtx-20220331.xsd#NatureofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/NatureofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2a8ff65d-d374-4839-9dca-d29fbe30eef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_NumberOfClinicalTrials_77ddd593-fc3b-4ffe-9034-58d491f5f29e" xlink:href="swtx-20220331.xsd#swtx_NumberOfClinicalTrials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2a8ff65d-d374-4839-9dca-d29fbe30eef4" xlink:to="loc_swtx_NumberOfClinicalTrials_77ddd593-fc3b-4ffe-9034-58d491f5f29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_51476937-5b73-4f1d-a79f-2f62ca613c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2a8ff65d-d374-4839-9dca-d29fbe30eef4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_51476937-5b73-4f1d-a79f-2f62ca613c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_WorkingCapital_1d259a57-34dc-4df6-8c1b-8bcda7598c6a" xlink:href="swtx-20220331.xsd#swtx_WorkingCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2a8ff65d-d374-4839-9dca-d29fbe30eef4" xlink:to="loc_swtx_WorkingCapital_1d259a57-34dc-4df6-8c1b-8bcda7598c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_d7bfcb06-9e8d-40ad-b556-92c21fda0710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2a8ff65d-d374-4839-9dca-d29fbe30eef4" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_d7bfcb06-9e8d-40ad-b556-92c21fda0710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/BasisofPresentation" xlink:type="simple" xlink:href="swtx-20220331.xsd#BasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/BasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_db826b80-3388-4f99-bce3-858aa9fd1d44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_83792518-1370-44c8-a091-c71f0431a1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_db826b80-3388-4f99-bce3-858aa9fd1d44" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_83792518-1370-44c8-a091-c71f0431a1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/BasisofPresentationPolicies" xlink:type="simple" xlink:href="swtx-20220331.xsd#BasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/BasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_48c55147-fadd-4978-af37-9c7c25208724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c3481deb-5120-49c5-89d7-f89a7e9e38be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48c55147-fadd-4978-af37-9c7c25208724" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c3481deb-5120-49c5-89d7-f89a7e9e38be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_58e7692b-27ce-4367-80a7-9138b2b22ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48c55147-fadd-4978-af37-9c7c25208724" xlink:to="loc_us-gaap_UseOfEstimates_58e7692b-27ce-4367-80a7-9138b2b22ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_25dfd59d-a2f6-433b-9d6a-bf64c7a0e2da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48c55147-fadd-4978-af37-9c7c25208724" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_25dfd59d-a2f6-433b-9d6a-bf64c7a0e2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_8a3252eb-110b-46b4-b21c-e0730bf9ca91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48c55147-fadd-4978-af37-9c7c25208724" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_8a3252eb-110b-46b4-b21c-e0730bf9ca91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f7292b48-4a6e-4aae-9714-e1402cf21355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48c55147-fadd-4978-af37-9c7c25208724" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f7292b48-4a6e-4aae-9714-e1402cf21355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/BasisofPresentationDetails" xlink:type="simple" xlink:href="swtx-20220331.xsd#BasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/BasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d97fd013-ce09-4c1d-ad99-56a224437035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_b18fdb34-aa8a-4412-9da7-2050f91587d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d97fd013-ce09-4c1d-ad99-56a224437035" xlink:to="loc_us-gaap_NumberOfOperatingSegments_b18fdb34-aa8a-4412-9da7-2050f91587d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/MarketableSecurities" xlink:type="simple" xlink:href="swtx-20220331.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_60e551e8-289d-4911-b88a-8b28000fdc55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_749ea6a6-c3ae-4f77-9139-9ba30d83ce9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_60e551e8-289d-4911-b88a-8b28000fdc55" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_749ea6a6-c3ae-4f77-9139-9ba30d83ce9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="swtx-20220331.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_47b8b224-6e54-48d9-8cc1-6ec3595624fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_1906177c-de0e-4d69-b363-5ddc68e7ec67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_47b8b224-6e54-48d9-8cc1-6ec3595624fb" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_1906177c-de0e-4d69-b363-5ddc68e7ec67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="swtx-20220331.xsd#MarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f676105c-36fc-4876-8cc3-da012c5df3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_234b9b1f-9e17-4cc8-b84a-0f97ae303f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f676105c-36fc-4876-8cc3-da012c5df3e6" xlink:to="loc_us-gaap_MarketableSecuritiesTable_234b9b1f-9e17-4cc8-b84a-0f97ae303f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_771bb64e-acb6-4db1-a8ea-2701b7e5c95a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_234b9b1f-9e17-4cc8-b84a-0f97ae303f6a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_771bb64e-acb6-4db1-a8ea-2701b7e5c95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c21b65c-66be-4377-8a27-87a76fe88b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_771bb64e-acb6-4db1-a8ea-2701b7e5c95a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c21b65c-66be-4377-8a27-87a76fe88b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_9fb37bc5-0652-422b-a26e-14d67e1f7bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c21b65c-66be-4377-8a27-87a76fe88b4b" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_9fb37bc5-0652-422b-a26e-14d67e1f7bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_79f59660-67a5-4cc5-a74d-d4a25d8478b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c21b65c-66be-4377-8a27-87a76fe88b4b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_79f59660-67a5-4cc5-a74d-d4a25d8478b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_42492723-593c-4668-ad56-e9f95a2b8375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c21b65c-66be-4377-8a27-87a76fe88b4b" xlink:to="loc_us-gaap_CommercialPaperMember_42492723-593c-4668-ad56-e9f95a2b8375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_76a12226-4550-4f55-827d-bef8eb217991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_234b9b1f-9e17-4cc8-b84a-0f97ae303f6a" xlink:to="loc_us-gaap_InvestmentTypeAxis_76a12226-4550-4f55-827d-bef8eb217991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_8c5ad514-1346-4e58-a152-b3b4a7debbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_76a12226-4550-4f55-827d-bef8eb217991" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_8c5ad514-1346-4e58-a152-b3b4a7debbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_3537860f-c0ff-4eb1-98a1-fad70463f4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_8c5ad514-1346-4e58-a152-b3b4a7debbe3" xlink:to="loc_us-gaap_CashEquivalentsMember_3537860f-c0ff-4eb1-98a1-fad70463f4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_3e3f8ce4-ded7-46e0-a259-061c04a3bf50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_8c5ad514-1346-4e58-a152-b3b4a7debbe3" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_3e3f8ce4-ded7-46e0-a259-061c04a3bf50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LongTermInvestmentsMember_a96217c5-13f6-4b46-b219-f6b18877e94b" xlink:href="swtx-20220331.xsd#swtx_LongTermInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_8c5ad514-1346-4e58-a152-b3b4a7debbe3" xlink:to="loc_swtx_LongTermInvestmentsMember_a96217c5-13f6-4b46-b219-f6b18877e94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_a8634861-7bfd-4616-837f-d2c7305716fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_234b9b1f-9e17-4cc8-b84a-0f97ae303f6a" xlink:to="loc_us-gaap_MarketableSecuritiesLineItems_a8634861-7bfd-4616-837f-d2c7305716fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b4c2a2d3-b013-4ea8-8f1e-e50b7ad5b2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_a8634861-7bfd-4616-837f-d2c7305716fb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b4c2a2d3-b013-4ea8-8f1e-e50b7ad5b2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_34bde379-b348-4054-8fbc-94b009d9da2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_a8634861-7bfd-4616-837f-d2c7305716fb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_34bde379-b348-4054-8fbc-94b009d9da2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_32593e06-60b4-4b7f-b491-b776ee5f1b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_a8634861-7bfd-4616-837f-d2c7305716fb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_32593e06-60b4-4b7f-b491-b776ee5f1b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5b83101e-7359-4517-9514-dd828e359ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_a8634861-7bfd-4616-837f-d2c7305716fb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5b83101e-7359-4517-9514-dd828e359ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="swtx-20220331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2b6c265b-b5c1-4494-b121-37ff536a2c98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_3db64f8b-654f-49b7-b245-853c8f0e3102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2b6c265b-b5c1-4494-b121-37ff536a2c98" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_3db64f8b-654f-49b7-b245-853c8f0e3102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="swtx-20220331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_38ca00fd-392c-4040-a0d9-f5b901a4b7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_a3dce6da-0a01-4b51-b3c9-607961432f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_38ca00fd-392c-4040-a0d9-f5b901a4b7ff" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_a3dce6da-0a01-4b51-b3c9-607961432f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="swtx-20220331.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_747fffe1-09fd-40f4-8207-0bd282bd3659" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ebf1c8a-8577-4ec5-a016-42616f0d4f84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_747fffe1-09fd-40f4-8207-0bd282bd3659" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ebf1c8a-8577-4ec5-a016-42616f0d4f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7946e345-85b7-44b9-9e2d-fe41271e495f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ebf1c8a-8577-4ec5-a016-42616f0d4f84" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7946e345-85b7-44b9-9e2d-fe41271e495f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f17a19b-2919-423d-9441-cd72fdb4e9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7946e345-85b7-44b9-9e2d-fe41271e495f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f17a19b-2919-423d-9441-cd72fdb4e9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_742242d7-097d-4ae0-9a01-857f8a29bbae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f17a19b-2919-423d-9441-cd72fdb4e9fd" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_742242d7-097d-4ae0-9a01-857f8a29bbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2e8943fc-f24a-4849-80dc-ef06394eef7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f17a19b-2919-423d-9441-cd72fdb4e9fd" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2e8943fc-f24a-4849-80dc-ef06394eef7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3e3d56b7-f589-4e57-974c-3aab4cb1614c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f17a19b-2919-423d-9441-cd72fdb4e9fd" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3e3d56b7-f589-4e57-974c-3aab4cb1614c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d3087b02-c0ca-49d9-aa27-d9668aafde49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ebf1c8a-8577-4ec5-a016-42616f0d4f84" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d3087b02-c0ca-49d9-aa27-d9668aafde49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c5b4c77a-c19e-4675-9e3a-8216be48e58f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d3087b02-c0ca-49d9-aa27-d9668aafde49" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c5b4c77a-c19e-4675-9e3a-8216be48e58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1d999bea-779b-4b9e-ac52-86a4deefa4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c5b4c77a-c19e-4675-9e3a-8216be48e58f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1d999bea-779b-4b9e-ac52-86a4deefa4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_5d57f8bc-8312-46ee-bcbc-64253239a7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ebf1c8a-8577-4ec5-a016-42616f0d4f84" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_5d57f8bc-8312-46ee-bcbc-64253239a7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2f7f2600-deda-4005-85af-4a9e239a3828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_5d57f8bc-8312-46ee-bcbc-64253239a7b0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2f7f2600-deda-4005-85af-4a9e239a3828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_979689ed-1aa0-4040-aa67-73bc7731922d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2f7f2600-deda-4005-85af-4a9e239a3828" xlink:to="loc_us-gaap_MoneyMarketFundsMember_979689ed-1aa0-4040-aa67-73bc7731922d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_05c469e1-3697-430f-98aa-3164a91fb04e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2f7f2600-deda-4005-85af-4a9e239a3828" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_05c469e1-3697-430f-98aa-3164a91fb04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_bdbba2dc-ed9d-4b40-af28-7d8edc157f82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ebf1c8a-8577-4ec5-a016-42616f0d4f84" xlink:to="loc_us-gaap_InvestmentTypeAxis_bdbba2dc-ed9d-4b40-af28-7d8edc157f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b64efdfc-ada8-47ff-bd6a-6bd2c4dfb844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_bdbba2dc-ed9d-4b40-af28-7d8edc157f82" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b64efdfc-ada8-47ff-bd6a-6bd2c4dfb844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_32674e51-6da8-455a-a346-265d39e1ea8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b64efdfc-ada8-47ff-bd6a-6bd2c4dfb844" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_32674e51-6da8-455a-a346-265d39e1ea8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0014b540-7d31-439d-8a1e-46474bbfd686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b64efdfc-ada8-47ff-bd6a-6bd2c4dfb844" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0014b540-7d31-439d-8a1e-46474bbfd686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_32c77a9e-0151-4e44-ad33-d4eb9fa44966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b64efdfc-ada8-47ff-bd6a-6bd2c4dfb844" xlink:to="loc_us-gaap_CommercialPaperMember_32c77a9e-0151-4e44-ad33-d4eb9fa44966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a704f4c4-6961-4d8d-b8ce-6e3f79e55682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ebf1c8a-8577-4ec5-a016-42616f0d4f84" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a704f4c4-6961-4d8d-b8ce-6e3f79e55682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4241c6cc-38dc-46ba-b653-aaa66e609710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a704f4c4-6961-4d8d-b8ce-6e3f79e55682" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4241c6cc-38dc-46ba-b653-aaa66e609710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_8f8564c6-52e5-49c3-982d-2cb733437a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a704f4c4-6961-4d8d-b8ce-6e3f79e55682" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_8f8564c6-52e5-49c3-982d-2cb733437a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LongTermInvestmentsFairValueDisclosure_4fece997-2c39-4237-85ce-dceba6f45466" xlink:href="swtx-20220331.xsd#swtx_LongTermInvestmentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a704f4c4-6961-4d8d-b8ce-6e3f79e55682" xlink:to="loc_swtx_LongTermInvestmentsFairValueDisclosure_4fece997-2c39-4237-85ce-dceba6f45466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_15e8c4d0-423f-4336-aadd-e49e96f0ccb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a704f4c4-6961-4d8d-b8ce-6e3f79e55682" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_15e8c4d0-423f-4336-aadd-e49e96f0ccb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/InvestmentandVariableInterestEntity" xlink:type="simple" xlink:href="swtx-20220331.xsd#InvestmentandVariableInterestEntity"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/InvestmentandVariableInterestEntity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_65f8134e-96e5-4eff-9b03-917cf38d3240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_b0e48c6c-720c-41b7-9503-37dbab2a99dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_65f8134e-96e5-4eff-9b03-917cf38d3240" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_b0e48c6c-720c-41b7-9503-37dbab2a99dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/InvestmentandVariableInterestEntityDetails" xlink:type="simple" xlink:href="swtx-20220331.xsd#InvestmentandVariableInterestEntityDetails"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/InvestmentandVariableInterestEntityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_ba61c023-0212-48c4-9f1d-71cc50bb1a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_87c49fd3-6bd4-4ec0-b183-2c63500fb57a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_ba61c023-0212-48c4-9f1d-71cc50bb1a3c" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_87c49fd3-6bd4-4ec0-b183-2c63500fb57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bd3b14cf-bc20-4f63-bd28-fc2d1eb18196" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_87c49fd3-6bd4-4ec0-b183-2c63500fb57a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bd3b14cf-bc20-4f63-bd28-fc2d1eb18196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_467560a7-22a9-4ecf-8cd7-b32965b99aad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bd3b14cf-bc20-4f63-bd28-fc2d1eb18196" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_467560a7-22a9-4ecf-8cd7-b32965b99aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_MapkureMember_d5c50a10-8a1d-492e-8cad-826f1b4214c7" xlink:href="swtx-20220331.xsd#swtx_MapkureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_467560a7-22a9-4ecf-8cd7-b32965b99aad" xlink:to="loc_swtx_MapkureMember_d5c50a10-8a1d-492e-8cad-826f1b4214c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6bcc710e-0c24-45bf-bbfd-461a54b244a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_87c49fd3-6bd4-4ec0-b183-2c63500fb57a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6bcc710e-0c24-45bf-bbfd-461a54b244a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ec49d631-60e4-476a-8462-81886ebb8f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6bcc710e-0c24-45bf-bbfd-461a54b244a8" xlink:to="loc_us-gaap_ClassOfStockDomain_ec49d631-60e4-476a-8462-81886ebb8f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_aeeec0f2-5e4e-47f3-90f6-d130787e831c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ec49d631-60e4-476a-8462-81886ebb8f5b" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_aeeec0f2-5e4e-47f3-90f6-d130787e831c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_000301ae-3a9f-447b-8e4e-1c850acb05f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_87c49fd3-6bd4-4ec0-b183-2c63500fb57a" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_000301ae-3a9f-447b-8e4e-1c850acb05f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_59169e7f-92fa-48cc-826d-10796aecd0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_000301ae-3a9f-447b-8e4e-1c850acb05f0" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_59169e7f-92fa-48cc-826d-10796aecd0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2e96673e-78dc-4a37-8863-9cd593752e27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_000301ae-3a9f-447b-8e4e-1c850acb05f0" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2e96673e-78dc-4a37-8863-9cd593752e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_a6f9b2ca-8717-4277-8646-be6e4a46b626" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_000301ae-3a9f-447b-8e4e-1c850acb05f0" xlink:to="loc_us-gaap_EquityMethodInvestments_a6f9b2ca-8717-4277-8646-be6e4a46b626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/AccruedExpenses" xlink:type="simple" xlink:href="swtx-20220331.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_e77443b6-4b29-49c5-aad8-0004bf34fb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_5f00d52a-98cc-4e64-acd4-0aeb7be57b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e77443b6-4b29-49c5-aad8-0004bf34fb1a" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_5f00d52a-98cc-4e64-acd4-0aeb7be57b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="swtx-20220331.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_4b47665e-a899-487a-a9e1-ff2b86f1a6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b38e3718-dd28-4bf0-90c1-860e3992f4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4b47665e-a899-487a-a9e1-ff2b86f1a6cc" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b38e3718-dd28-4bf0-90c1-860e3992f4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="swtx-20220331.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_fec517b0-c6f0-42af-808a-e31f909cbbdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_1c3f67dc-1cdd-47ce-bbbc-a4ad347eafe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fec517b0-c6f0-42af-808a-e31f909cbbdc" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_1c3f67dc-1cdd-47ce-bbbc-a4ad347eafe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_db937d02-4b69-4f71-bf80-d2915103f5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fec517b0-c6f0-42af-808a-e31f909cbbdc" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_db937d02-4b69-4f71-bf80-d2915103f5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_AccruedResearchAndDevelopmentExpenses_5ac39134-fe37-4262-bad9-d476040fcd00" xlink:href="swtx-20220331.xsd#swtx_AccruedResearchAndDevelopmentExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fec517b0-c6f0-42af-808a-e31f909cbbdc" xlink:to="loc_swtx_AccruedResearchAndDevelopmentExpenses_5ac39134-fe37-4262-bad9-d476040fcd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_098c4d4f-66d4-428e-8997-cae4fe2e9ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fec517b0-c6f0-42af-808a-e31f909cbbdc" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_098c4d4f-66d4-428e-8997-cae4fe2e9ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_63310825-7e7e-424f-ba50-d9d55a70694b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fec517b0-c6f0-42af-808a-e31f909cbbdc" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_63310825-7e7e-424f-ba50-d9d55a70694b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="swtx-20220331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_80855674-70c8-4c82-8373-36e7a75d18dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b14e90b4-c7c8-4098-80da-3e1c2eedbc19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_80855674-70c8-4c82-8373-36e7a75d18dd" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b14e90b4-c7c8-4098-80da-3e1c2eedbc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="swtx-20220331.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b74af757-f41c-4b7e-9115-c53e204e3bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_624244d7-4a29-46ea-bc66-da9b94576f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b74af757-f41c-4b7e-9115-c53e204e3bd1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_624244d7-4a29-46ea-bc66-da9b94576f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="swtx-20220331.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_57dfeb48-0a4e-442d-9bc8-32061ec2522a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_6a17a273-dded-4dfe-9228-445b24391459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_57dfeb48-0a4e-442d-9bc8-32061ec2522a" xlink:to="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_6a17a273-dded-4dfe-9228-445b24391459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_6c6d86fb-6502-4221-82df-b089571a4da5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_57dfeb48-0a4e-442d-9bc8-32061ec2522a" xlink:to="loc_us-gaap_LossContingenciesTable_6c6d86fb-6502-4221-82df-b089571a4da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4f216d0b-cb97-43f8-b372-052d373747d8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6c6d86fb-6502-4221-82df-b089571a4da5" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4f216d0b-cb97-43f8-b372-052d373747d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_343ecbe5-3736-4dbc-ac59-805911c77657" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4f216d0b-cb97-43f8-b372-052d373747d8" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_343ecbe5-3736-4dbc-ac59-805911c77657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_StamfordConnecticutMember_22b22f7c-90da-466e-bece-2b02e8556e8f" xlink:href="swtx-20220331.xsd#swtx_StamfordConnecticutMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_343ecbe5-3736-4dbc-ac59-805911c77657" xlink:to="loc_swtx_StamfordConnecticutMember_22b22f7c-90da-466e-bece-2b02e8556e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LesseeOperatingLeaseRenewalTermAxisAxis_e734f817-a953-4286-b152-7e3ded525795" xlink:href="swtx-20220331.xsd#swtx_LesseeOperatingLeaseRenewalTermAxisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6c6d86fb-6502-4221-82df-b089571a4da5" xlink:to="loc_swtx_LesseeOperatingLeaseRenewalTermAxisAxis_e734f817-a953-4286-b152-7e3ded525795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LesseeOperatingLeaseRenewalTermAxisDomain_a048efaa-8aa2-4829-a3c9-6e72ebfd996f" xlink:href="swtx-20220331.xsd#swtx_LesseeOperatingLeaseRenewalTermAxisDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_swtx_LesseeOperatingLeaseRenewalTermAxisAxis_e734f817-a953-4286-b152-7e3ded525795" xlink:to="loc_swtx_LesseeOperatingLeaseRenewalTermAxisDomain_a048efaa-8aa2-4829-a3c9-6e72ebfd996f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LesseeOperatingLeaseRenewalOptionOneMember_b9d65884-bc3c-418b-8e8f-3976e26f37b1" xlink:href="swtx-20220331.xsd#swtx_LesseeOperatingLeaseRenewalOptionOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_swtx_LesseeOperatingLeaseRenewalTermAxisDomain_a048efaa-8aa2-4829-a3c9-6e72ebfd996f" xlink:to="loc_swtx_LesseeOperatingLeaseRenewalOptionOneMember_b9d65884-bc3c-418b-8e8f-3976e26f37b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LesseeOperatingLeaseRenewalOptionTwoMember_3a5f5a51-a981-4f70-a69f-eb8a335c8b55" xlink:href="swtx-20220331.xsd#swtx_LesseeOperatingLeaseRenewalOptionTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_swtx_LesseeOperatingLeaseRenewalTermAxisDomain_a048efaa-8aa2-4829-a3c9-6e72ebfd996f" xlink:to="loc_swtx_LesseeOperatingLeaseRenewalOptionTwoMember_3a5f5a51-a981-4f70-a69f-eb8a335c8b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_8656ff91-2cbc-4c11-ae68-f7082c2c764f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6c6d86fb-6502-4221-82df-b089571a4da5" xlink:to="loc_us-gaap_LossContingenciesLineItems_8656ff91-2cbc-4c11-ae68-f7082c2c764f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LesseeOperatingLeaseNumberOfRenewalOptions_c0493948-4f2e-4867-b8fd-fbcc76570081" xlink:href="swtx-20220331.xsd#swtx_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8656ff91-2cbc-4c11-ae68-f7082c2c764f" xlink:to="loc_swtx_LesseeOperatingLeaseNumberOfRenewalOptions_c0493948-4f2e-4867-b8fd-fbcc76570081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_af5e4d89-06f9-46d6-b872-a07da6e5b4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8656ff91-2cbc-4c11-ae68-f7082c2c764f" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_af5e4d89-06f9-46d6-b872-a07da6e5b4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LesseeOperatingLeaseEntitledTenantAllowance_e0a220b7-d5d1-42fa-af93-de274905cb2a" xlink:href="swtx-20220331.xsd#swtx_LesseeOperatingLeaseEntitledTenantAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8656ff91-2cbc-4c11-ae68-f7082c2c764f" xlink:to="loc_swtx_LesseeOperatingLeaseEntitledTenantAllowance_e0a220b7-d5d1-42fa-af93-de274905cb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_AnnualIncreaseInLeasePaymentsPercentage_f62b98f1-1014-4fd7-9a0c-fa29037d1cc8" xlink:href="swtx-20220331.xsd#swtx_AnnualIncreaseInLeasePaymentsPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8656ff91-2cbc-4c11-ae68-f7082c2c764f" xlink:to="loc_swtx_AnnualIncreaseInLeasePaymentsPercentage_f62b98f1-1014-4fd7-9a0c-fa29037d1cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_2ebba47f-128c-45d0-8743-587b78b70259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8656ff91-2cbc-4c11-ae68-f7082c2c764f" xlink:to="loc_us-gaap_LitigationSettlementExpense_2ebba47f-128c-45d0-8743-587b78b70259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails" xlink:type="simple" xlink:href="swtx-20220331.xsd#CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b18b86f4-f788-4b66-aece-3e0842428dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_fd306403-cf2a-44a7-b780-6d23616c51c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b18b86f4-f788-4b66-aece-3e0842428dc9" xlink:to="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_fd306403-cf2a-44a7-b780-6d23616c51c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_63101e0d-25b7-49ef-9239-ed1d4b419696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_fd306403-cf2a-44a7-b780-6d23616c51c8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_63101e0d-25b7-49ef-9239-ed1d4b419696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f6ad1326-b040-4eca-9529-cd6df0c589e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_fd306403-cf2a-44a7-b780-6d23616c51c8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f6ad1326-b040-4eca-9529-cd6df0c589e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_14ddfc0e-6cac-4c3f-8453-a82a9329f7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_fd306403-cf2a-44a7-b780-6d23616c51c8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_14ddfc0e-6cac-4c3f-8453-a82a9329f7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bcde7453-3554-497c-8df9-9da200d8af41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_fd306403-cf2a-44a7-b780-6d23616c51c8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bcde7453-3554-497c-8df9-9da200d8af41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear_b8455f52-0f4b-4dbe-90f1-58f219375ece" xlink:href="swtx-20220331.xsd#swtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_fd306403-cf2a-44a7-b780-6d23616c51c8" xlink:to="loc_swtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear_b8455f52-0f4b-4dbe-90f1-58f219375ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_42243b39-be68-4794-8543-f6330aea47b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_fd306403-cf2a-44a7-b780-6d23616c51c8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_42243b39-be68-4794-8543-f6330aea47b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9d7c671f-3237-4d96-9399-4e2382532cde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_fd306403-cf2a-44a7-b780-6d23616c51c8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9d7c671f-3237-4d96-9399-4e2382532cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_977405b7-f282-4e40-aa3c-948bd2a0c37f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_fd306403-cf2a-44a7-b780-6d23616c51c8" xlink:to="loc_us-gaap_OperatingLeaseLiability_977405b7-f282-4e40-aa3c-948bd2a0c37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails_1" xlink:type="simple" xlink:href="swtx-20220331.xsd#CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.springworkstx.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="swtx-20220331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5ba73ebb-c00a-4b5a-974e-36163b7d4655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_71d294fe-c0e9-435d-87b7-7c57501177d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5ba73ebb-c00a-4b5a-974e-36163b7d4655" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_71d294fe-c0e9-435d-87b7-7c57501177d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="swtx-20220331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fbd16b96-669f-4b72-8cb8-0681616f784d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_eba7856c-a3ad-4f57-998f-eba0dca673d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fbd16b96-669f-4b72-8cb8-0681616f784d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_eba7856c-a3ad-4f57-998f-eba0dca673d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails" xlink:type="simple" xlink:href="swtx-20220331.xsd#StockBasedCompensation2019EquityIncentivePlanDetails"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_93415371-8d68-47bf-b7b4-eebd478f9864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85663c98-66c0-4c5b-a613-d128e7989063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_93415371-8d68-47bf-b7b4-eebd478f9864" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85663c98-66c0-4c5b-a613-d128e7989063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_966a2661-e86f-4b93-b81a-c49c00a5bd10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85663c98-66c0-4c5b-a613-d128e7989063" xlink:to="loc_us-gaap_PlanNameAxis_966a2661-e86f-4b93-b81a-c49c00a5bd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a3e3f614-b78a-4998-9528-3ff22cb195ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_966a2661-e86f-4b93-b81a-c49c00a5bd10" xlink:to="loc_us-gaap_PlanNameDomain_a3e3f614-b78a-4998-9528-3ff22cb195ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_EquityIncentivePlan2019Member_a8d4799e-4df0-4e98-8a47-e23cb20dd0e8" xlink:href="swtx-20220331.xsd#swtx_EquityIncentivePlan2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a3e3f614-b78a-4998-9528-3ff22cb195ba" xlink:to="loc_swtx_EquityIncentivePlan2019Member_a8d4799e-4df0-4e98-8a47-e23cb20dd0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_CeoPerformanceAwardMember_d2eada92-31b6-4053-abb0-70ef891673a4" xlink:href="swtx-20220331.xsd#swtx_CeoPerformanceAwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a3e3f614-b78a-4998-9528-3ff22cb195ba" xlink:to="loc_swtx_CeoPerformanceAwardMember_d2eada92-31b6-4053-abb0-70ef891673a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_39e8f5ce-2543-4a67-96af-63f024774c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85663c98-66c0-4c5b-a613-d128e7989063" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_39e8f5ce-2543-4a67-96af-63f024774c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1065c965-1b3f-4878-96b0-0ca9c2896295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_39e8f5ce-2543-4a67-96af-63f024774c8f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1065c965-1b3f-4878-96b0-0ca9c2896295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_23f381d8-48cf-4d8f-9aed-5c6965abd275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1065c965-1b3f-4878-96b0-0ca9c2896295" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_23f381d8-48cf-4d8f-9aed-5c6965abd275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_09271741-3fc6-4fe6-bc55-0703735da72e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1065c965-1b3f-4878-96b0-0ca9c2896295" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_09271741-3fc6-4fe6-bc55-0703735da72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_35c25a15-2cdb-48b6-9ded-021aae30a7a1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85663c98-66c0-4c5b-a613-d128e7989063" xlink:to="loc_srt_TitleOfIndividualAxis_35c25a15-2cdb-48b6-9ded-021aae30a7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1bd4c2a4-75b7-4607-9424-7ce7546f7543" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_35c25a15-2cdb-48b6-9ded-021aae30a7a1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1bd4c2a4-75b7-4607-9424-7ce7546f7543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember_0dfbe70a-66c4-49c9-8c0e-1433ce36f7b2" xlink:href="swtx-20220331.xsd#swtx_ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1bd4c2a4-75b7-4607-9424-7ce7546f7543" xlink:to="loc_swtx_ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember_0dfbe70a-66c4-49c9-8c0e-1433ce36f7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_2f5f2413-b527-45b6-b1fd-3bee5aadfa26" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1bd4c2a4-75b7-4607-9424-7ce7546f7543" xlink:to="loc_srt_DirectorMember_2f5f2413-b527-45b6-b1fd-3bee5aadfa26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_ExecutiveOfficersAndEmployeesMember_320cf390-9297-4ddd-abbf-b61757a68843" xlink:href="swtx-20220331.xsd#swtx_ExecutiveOfficersAndEmployeesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1bd4c2a4-75b7-4607-9424-7ce7546f7543" xlink:to="loc_swtx_ExecutiveOfficersAndEmployeesMember_320cf390-9297-4ddd-abbf-b61757a68843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_99052735-8e1f-48e1-b43f-81aafc118089" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1bd4c2a4-75b7-4607-9424-7ce7546f7543" xlink:to="loc_srt_ChiefExecutiveOfficerMember_99052735-8e1f-48e1-b43f-81aafc118089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_50dfe054-f420-4c62-9448-83d1078d9c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85663c98-66c0-4c5b-a613-d128e7989063" xlink:to="loc_us-gaap_AwardTypeAxis_50dfe054-f420-4c62-9448-83d1078d9c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03f38e47-2f40-4f0c-8803-8b1420a0a507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_50dfe054-f420-4c62-9448-83d1078d9c6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03f38e47-2f40-4f0c-8803-8b1420a0a507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1707b3b7-c68e-47e7-8728-184ca81dbd14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03f38e47-2f40-4f0c-8803-8b1420a0a507" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1707b3b7-c68e-47e7-8728-184ca81dbd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_774c3ad5-def8-4c03-9620-61cefc68d143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03f38e47-2f40-4f0c-8803-8b1420a0a507" xlink:to="loc_us-gaap_EmployeeStockOptionMember_774c3ad5-def8-4c03-9620-61cefc68d143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e7418299-4131-431b-951f-f856160517e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03f38e47-2f40-4f0c-8803-8b1420a0a507" xlink:to="loc_us-gaap_RestrictedStockMember_e7418299-4131-431b-951f-f856160517e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_2e6547b3-4038-421b-821d-54a6c8183a56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85663c98-66c0-4c5b-a613-d128e7989063" xlink:to="loc_us-gaap_GranteeStatusAxis_2e6547b3-4038-421b-821d-54a6c8183a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_b0e42a99-70b8-40b4-9d21-b35d3d51f505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_2e6547b3-4038-421b-821d-54a6c8183a56" xlink:to="loc_us-gaap_GranteeStatusDomain_b0e42a99-70b8-40b4-9d21-b35d3d51f505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_5892e904-1338-4638-ba1c-97c676c2f0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_b0e42a99-70b8-40b4-9d21-b35d3d51f505" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_5892e904-1338-4638-ba1c-97c676c2f0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85663c98-66c0-4c5b-a613-d128e7989063" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_swtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock_67a737dd-c9d5-4e92-92d1-24894ec3d9b0" xlink:href="swtx-20220331.xsd#swtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_swtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock_67a737dd-c9d5-4e92-92d1-24894ec3d9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8185c1c1-fd98-4584-a75c-6dc97490d40e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8185c1c1-fd98-4584-a75c-6dc97490d40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_17e949ab-a7c5-4230-aaa7-23989944899d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_17e949ab-a7c5-4230-aaa7-23989944899d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90088656-149b-4da4-b750-3792d4517131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90088656-149b-4da4-b750-3792d4517131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_27b75012-5293-4ac1-bf8d-b988085df369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_27b75012-5293-4ac1-bf8d-b988085df369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e905b557-c199-465e-8767-4022b3d9ff4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e905b557-c199-465e-8767-4022b3d9ff4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_3a158449-8614-4465-b7b1-a403854689c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_3a158449-8614-4465-b7b1-a403854689c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ec8bc103-8fbb-46d8-adaa-49be4ed0abb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ec8bc103-8fbb-46d8-adaa-49be4ed0abb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638516fb-f837-4de4-ae9c-0cc5989372d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638516fb-f837-4de4-ae9c-0cc5989372d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_046120b7-5274-4f7f-9216-dc8bbd97c144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_046120b7-5274-4f7f-9216-dc8bbd97c144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b9dc0f37-b3a2-4c3e-b3bc-96bcf875e528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b9dc0f37-b3a2-4c3e-b3bc-96bcf875e528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e5cb5c6e-0ab0-4d59-8456-9970c2d690db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e5cb5c6e-0ab0-4d59-8456-9970c2d690db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d6cec9d6-70d7-4f7a-a35d-9a2b9025b49d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a7bffb-7177-4fd5-9eb4-b8c7f59571ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d6cec9d6-70d7-4f7a-a35d-9a2b9025b49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/StockBasedCompensationEquitybasedcompensationexpenserelatedtorestrictedstockandstockoptionsDetails" xlink:type="simple" xlink:href="swtx-20220331.xsd#StockBasedCompensationEquitybasedcompensationexpenserelatedtorestrictedstockandstockoptionsDetails"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/StockBasedCompensationEquitybasedcompensationexpenserelatedtorestrictedstockandstockoptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89e3e7f8-431f-43d3-bd47-52f57b2e2379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e1d2db0d-52bf-44c5-b41f-91c9fb81e7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89e3e7f8-431f-43d3-bd47-52f57b2e2379" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e1d2db0d-52bf-44c5-b41f-91c9fb81e7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d66ecc21-fbe4-4429-8dac-070d677dae1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e1d2db0d-52bf-44c5-b41f-91c9fb81e7ba" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d66ecc21-fbe4-4429-8dac-070d677dae1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fd7fa277-cc5f-447f-a9cf-8dec8939d24a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d66ecc21-fbe4-4429-8dac-070d677dae1e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fd7fa277-cc5f-447f-a9cf-8dec8939d24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d9cbc523-c10e-4e4b-b2d7-3675a438f89d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fd7fa277-cc5f-447f-a9cf-8dec8939d24a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d9cbc523-c10e-4e4b-b2d7-3675a438f89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7e1df002-4f84-4b37-bc2c-d2706a384f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fd7fa277-cc5f-447f-a9cf-8dec8939d24a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7e1df002-4f84-4b37-bc2c-d2706a384f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b97a3322-96df-4224-807d-67fb74ea19b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e1d2db0d-52bf-44c5-b41f-91c9fb81e7ba" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b97a3322-96df-4224-807d-67fb74ea19b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_67ec9ab1-711f-42cf-aa70-40db57c2bf74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b97a3322-96df-4224-807d-67fb74ea19b8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_67ec9ab1-711f-42cf-aa70-40db57c2bf74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/NetLossperShare" xlink:type="simple" xlink:href="swtx-20220331.xsd#NetLossperShare"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/NetLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0475a872-8e56-4323-b59d-055f5e457b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_3db655f6-ce7e-479c-b85a-32865a86358a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0475a872-8e56-4323-b59d-055f5e457b6e" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_3db655f6-ce7e-479c-b85a-32865a86358a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="swtx-20220331.xsd#NetLossperShareTables"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/NetLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_41aa7890-7a00-41da-8b6e-c733c2fa01f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_92687078-5075-4d14-961f-cdefc00258f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_41aa7890-7a00-41da-8b6e-c733c2fa01f1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_92687078-5075-4d14-961f-cdefc00258f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.springworkstx.com/role/NetLossperShareDetails" xlink:type="simple" xlink:href="swtx-20220331.xsd#NetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.springworkstx.com/role/NetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_07baea25-e5f4-4155-b0db-dff62a1bead4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_53b6d017-bd77-49c4-a3f0-627e0d8e56e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_07baea25-e5f4-4155-b0db-dff62a1bead4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_53b6d017-bd77-49c4-a3f0-627e0d8e56e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b1176f4e-9dbc-4bd7-955f-e9378c464bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_53b6d017-bd77-49c4-a3f0-627e0d8e56e3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b1176f4e-9dbc-4bd7-955f-e9378c464bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72f587e2-5013-416a-bd06-783174896c38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b1176f4e-9dbc-4bd7-955f-e9378c464bb7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72f587e2-5013-416a-bd06-783174896c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_34fe7a70-d0d4-4ab5-829c-e00b4a1d0561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72f587e2-5013-416a-bd06-783174896c38" xlink:to="loc_us-gaap_CommonStockMember_34fe7a70-d0d4-4ab5-829c-e00b4a1d0561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b0ed9b71-6c17-43c1-844a-847aa5a1ccc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72f587e2-5013-416a-bd06-783174896c38" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b0ed9b71-6c17-43c1-844a-847aa5a1ccc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_30f3d473-987b-4943-8b08-cab4891e709d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72f587e2-5013-416a-bd06-783174896c38" xlink:to="loc_us-gaap_RestrictedStockMember_30f3d473-987b-4943-8b08-cab4891e709d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_86c82a4e-743f-47f6-afd0-bd3d600868b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_53b6d017-bd77-49c4-a3f0-627e0d8e56e3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_86c82a4e-743f-47f6-afd0-bd3d600868b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_79155e4f-6de0-4277-9952-c41f9b3b944f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_86c82a4e-743f-47f6-afd0-bd3d600868b2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_79155e4f-6de0-4277-9952-c41f9b3b944f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! 0 !>@%Z  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      %Z     0   7H    !  .@ 0 #     0 !  "@ @ $     0  "DZ@
M P $     0   ,,     _^T .%!H;W1O<VAO<" S+C  .$))300$
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M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" C_W0 $ *7_V@ , P$
M A$#$0 _ /[^**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(VRK91<,K#'%?N_\//'7ASXE^ ]'^(OA*X6YTK7-+MM6T^<$?/;W48EC)P2
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MGP;_ ,%,?V=;;]G;QQXBU3PS9VOB>Q\3+J.CPQ33F6RBN(5B*S IM87!)[Y
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M[75Y);*>R,<MRKR1*!.B%LA&Y'''-?YQ7_!<_P#9+;]D3_@I%X]\*Z;:_9=
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M!T;R1(&_#K0F^QSU,90B[2J+[S^H_>I.WOZ4ZOQB_9]_X+X?\$K_ -H76H-
M\._$BW\/ZE=.(X+3QE9W&C;R>[7$ZFU09X)>9?QK]BM.UG2]7L8-4TFXANK6
MZ@2ZMKJV=989H91N22.1"5=6'*E201R.*?J:0J0FKPE<TZ*;O4G;GGTIU,JP
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M29V_@22=1$6)P I<%B0%!S7NQX5S65#ZU'!S=/?FY96MWO:UO,\:7$67*O\
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MK=KK6[5^J5CRGG^!^M_4%63J?R]=KZ]$[='J?J!12#I2UXB/484444 %%%%
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MBL94]CA*,JDNT4V_N1CCL?A\+3]MBJJA'O)I+[V?HX'5N5Y'J*=7YA_LY_\
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M\R,LOOR*_0,W,2XWY (!#8XY.,9]:E2/7C)27-#5'^9;_P ',Q_XVR^*,?\
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M@IXXUZ1IKI/"<F@M*W!D&@WESI$98]2?+M%R>_7FJJ?S+J<>0UY*4\//[/\
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M!U?0O&=C:JPLY;AYK>2&\M2<[8KA0Y\LDM&RLIRNQF_U O'/@+PC\2/!VH^
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M\$-G_9[\26J6^J_&GPGK'B;4OM?,<5QXAM@FDN2HW!8[:.TFVG)5BW SBO\
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MD\[S7 4 GY02> ,+CG P,\8]^U6I8W==JDCG.124I;W/36285*W+^+/\@O\
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M<.K&VMPZO+_SU?\ =G@/7^B'H&AZ?X>T>TT+0;.SL+&QMH[2SLK&-8;:WAB
M5(HHD 1$10 JJ % P*KGY59!0P$L8_;5W9=$?S<?\&_'_!*3]JO_ ()PW7Q$
MUS]I$^%L>,;728;"U\/ZA+>S0-8/<&59PT$4:_ZT;2COTK^3S_@X861/^"NG
MQ5$N-V[0R0#D#.D6G .!P.E?ZDUO!Y2%6 'S$@9SQG\*_P M_P#X.(/^4O7Q
M7_WM"_\ 3/:5-->]=CSNA&EA8TX;)_YG]SW_  04./\ @DI\&S_U KC_ -*Y
MZ_8.2XA4X8XQCL>YP/U%?CS_ ,$%B!_P24^#*MQNT*X(![_Z7.:\J_X+1?\
M!8KP1_P33^&H\(>!OL>M?%?Q':O+X;T9PKP:7 ^5.HWX!W!<D^5&<&1A_=!S
M+;O8]JE6A3P\9S=DD<!_P6U_X+6>#?\ @GSX&NO@O\%[NVU;XS:U88L[=0D]
MOX:M9N4U"^1@RF9E.;:V();(ED'E[5E_AO\ V%_V%?VH/^"LG[4%SX>\-W%]
M=O=:@-8\?_$#6#+<0Z?'<NS27%S,6S+<SL&$,6[?(XZA0[*?LB?LG_M1_P#!
M7O\ ;$N-$M[ZZU#5]=U"37/'?CG4D:6WTZV=LS74Y'!<CY8(@1N;:HPN2/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[54;F.=H K^JW]HGXX^%OV=?@9XK^./BILV'AC1;K5I4QS*T$99(E'&6=L*
M#GGBOYTO^"IX_P"-WO[,"@_\P[3O_3M>U]__ /!>[4M5T[_@F!X]FTHNK3WN
MBVMP$SCR)=2A63)!'!7KGCVK]CSW#2S*IP[1Q,W)UHI2;=V^:K)/7N?EF48F
M.74\_K8>"2I2;22LO=HP:T1^>?\ P2G_ &-+#_@H-XEU_P#X*6?MS6B>*[_7
MM=N+?P=X?U,F73;6UM2,2B$G:T<9;RH$/"["Q&3S^XG[2/\ P3O_ &2OVFOA
ME<_#?Q[X)T*W1K(VVFZII=E#:WVFN!B.2WEB56!0\XY##(/!KD?^"4^GZ-I7
M_!/3X26>@%&M?^$521!'@J))9I7EY&.?,9L^_N*_0Z8 QGD]N?QKX_C#BK&2
MS:M4HU94U1DXTTG90C%VBDNFVNFKO<^IX7X<PL,LITZM-3=6*E4;5^>4E=M]
M]].RV/YA_P#@CG\2?BC^R)^UU\0/^"5/QOU6;4[;1A)K'@.\N';;]GC^>1(0
MW1)XI$D\L'Y75MHP2:_2C_@L-^VEJW[%7['&I>*_ \JQ>+?$M['X3\*N>L-W
M=QNTETHX.;>%'9#RHE\L-P:_-G]JN*+2/^#AOX(ZCX:#"\U#0$@U@IR6MTM[
MH)O [8QR:H?\'%"QZC\3/V9_#>ML/[$O/&6L'4C*2(P4DTA$W$_*/DDEZ@]^
MV17WZRK#YGQ#E6)Q$%;$TU5FK63E!3YM/[[AKZL^)EF=?+LBS+#4)N]"I[.#
MW:C-PY=?[BJ6\E$^J_\ @E;_ ,$G?A+\$?A1I?QO_:!T>S\7?%'Q3:QZ]JVH
M^($%\-/%Z!.EO$LVY?- (,TA!8OD X )]._X*2?\$E/@/^UM\)]1UGX=Z%I7
MA3XC:7#)J'A[Q%H]NEH9[B%2ZVUV(0H:*4C&[&Z,G<O((/[#09$SAB3[G\NM
M/G RO)Z]!WY'%?F%;CS-7F#S7V\E4O=:Z)?RVVY;:6ML?H<.#<L6 _LQT$Z=
MK.ZU;_F;WYKZWWOJ?B'_ ,$+_P!MSQ?^T_\ LWZE\,OC)<2S^-?AG?1^']4N
M;IBUU=VAWBWDFSRTL7EM%(PZ[5+?,23^XB2I*,IZ_P J_E;_ ."0T,>C_P#!
M7S]J'P_X=5ET8G4KAE3F/[4VL0D]/E!S))QC/6OZGK8JT>Y.A[?A7H^)>!HX
M?.*CP\>6%11FHKISQ4FOO;MY'!P!C*U;*Z:Q$N:4'.#??DDXW^:2N^K/%OVC
M?A%IWQ\^!OB[X*:J8_)\3^'+[1@THRL<MS"R1R,.>(Y"K<>E?@)_P;J_&/6]
M*\"_$3]BGQ_(R:O\.O$4MU96LIS*EG=2/'.H!R,)<(6.T\;QD<\_TQSQL[;A
MQ@>O7]:_E)^+EH_[ /\ P7Y\,_$J-?L7A/XVVRV.H."$MVN]6/V>8L?NEAJ$
M<4I!P55\YP>>W@F/UW+LRR9[RC[6'^.GJTO.4&U\CEXN?U/'9?FRVC+V4_\
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M?^"E7["_[,&NMX6^-_Q(T+2-5C&9M*@%QJ5[#SC$UO817$L1]G53CGIS71?
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M%X/TGQ]X/N?MFD:YIEKK&E7@1XO/L[V)9X)/+E5)$WQNK;74,,X(!XK\)O\
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MM\K?>3C9M:*[Z6UZOX>?\%BO^":7Q1\21>$_"7Q9T$7T\PMX4U:WO](B>0]
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M_P /_LW3?9/&GB7P1I'A71=0R5-DVJ1S0S70*Y(:*'>P;JOWARHK]QOV/_\
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M;2ZI7=[ZK9]#Z2EB</6RK,'DM/V=:T[QY>62J<NG,N[TL^NC3=SXV_X)"_\
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MQ7]0< \*4\LP$8/6I.TIR>\I-:MO?39?\%L_:^&\EC@,+&&\Y:R;W<GO=_D
M&!BEHHK[NQ[84444 %(1D8J*:7R@#@GKP.M9MUKFG6$#76H2Q01(P5I9G5$!
M)VC+$@ EC@ \D\4N9%*+W+LML';("GY2O(Y^F?2N6\2>#/#_ (TTB30_&.FZ
M;JUG*P+V.J6T=Y;Y (R8YE*DX/I_,UTJWZ,X0*>I#\C*D=B,\GZ9JQ%(LX)
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MQ?!F@^$/^"4/@&]TB,>?K.H:QJM[( !)+<37<O4CKA4"C/0>U?R,?\',O/\
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M?_\ @CE$DO\ P5#^!2L ?^+BZ4P!&1N63*_D<'VZ]J_UJ8 ?+&>N.:_R6O\
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M1^T5\&_"W[1/P1\8? SQN@ETCQ;X?O\ P_>$*'>(7D+Q"1%;Y3)$Y21"2 '
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M(05*XZXY!Z$8]:GJA;DM)GL1NX;CG!Z?7/-7Z46>_)684444R0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ICG'%/ICKN7'2DQQW/Y8/^
M"I;>9_P6Z_9@=>AT_3@#]-6O:_>S]MS]G=?VJ/V4_'7P'++'/K^A3VVG2,<"
M.\0"2W8G!'$JKR17S3^T]_P31M?VD_VU?AC^V-<^,Y=(E^&]O;0)X?CTL727
M_P!GNYKK)NC<Q&'=YNS B?&W/? _49U+(0.IZ$BOO,]XDISH91/"5/WF'A9Z
M/22J.2W5GTV/C\GR&I&OFBQ,/<KSNM=XNG"+]-4]S^;G_@@;^UMIEC\,[[_@
MGW\:+DZ-\0OA_K.H6VF:/J1\J2ZT[?ODB@#X+R0S&5F0<E&#@$9-?T'?$/XC
M>!/A?X*U'X@_$?5;'1M#TJW:ZU#4M1E6"WAC7N7<@9)X5>K'  R0*_-K]M__
M ((__LS_ +;?B1/B?K$NI^#_ !S"B1IXM\,N(IIQ%_J_M4+?+*4&<,K))TRY
M  'QE9?\&^UCXTUFP/[4/Q[^*'Q*T/3' L="U":6%(X8_P#5PK)=7=\$0=&\
MN-"1D*5/->MFKX?S7$RS*KBY8=S?-.GR.3YOM<DD[6D]N:UK_(\K+5GF6T(Y
M?2PT:ZAI"?/R^ZOAYTTW=+1\M[VZ'BG_  3;N-5_X*)_\%2OB'_P42FM9XO!
MGA"S'A;P6;I&43LZM'"5W8^9(@\K #Y3( V#BOL?_@OO^RKXE_:!_8TC^('@
M&VDN_$'PVU<>*H((-S2RV'EE+Y(U4$LRILE '/[K Y-?K]\&_@O\,O@#X T_
MX5_!_1+'P_X?TN/R['3; $(F>69F;<\CL?O/(S.W4L:])NX/M,)A(4JV0RN,
M@@CD?2O+QG'<EG-#,\%3Y84.6-.+_DBK6;[R3=WYL]'#<&1EE-;+L9/FE6YI
M3DOYI.]TNT7;E\DC\V_^"87[?'PZ_;F_9ST?Q+I^I0GQAHVF6VG^,]&ED'VJ
M&^B01M=;>"T-RPWH^, L4)R.?9_VW_VQ/A1^Q5\!-7^,7Q+U"UBGBLYT\/Z2
M\JI=:KJ&S]U;6\9^9\N5\QE!$:9=N!7YY?M _P#!!WX _$'XE2_&?]G+Q9XH
M^#/B>ZG>ZN;GP=(WV0SR$NTL4*RP20L7Y(CF5/1!UK!^$?\ P0+^#&G?$:#X
MJ_M8^/O&7QLU>V=)(H_%LTJ6<DBY.ZX62>YN)@&PRH9U0XPZNI(KNJX+A>==
MXWZU.--OF='D?/WY5._);M+>W2YQT\9Q)"BL)]7A*HE;VO/[G;F<+<U^KBM+
M];'(_P#!OW^SCX^\/_"3QG^V-\7(GCU_XOZY)J]FDX*R?V>)996GY.Y5N;B1
MBH89VQJPRK G^AV*/8N#QZ8JGI>FVFE64.GV,44$$$:PP00*$CBCC&U$15 "
MJJ@    #@5I5\?Q+GM3-,?6Q]2/+SO1+9):17R22/J.'\FAEV"I8*G+FY%JW
MNV]6WZMMC&'%?@3_ ,'#?[/M[\3OV,K7XV>&8W&M?"_78->BGB/[U+"\:.VN
M?+QSN67[/+GLL;&OWY/3BO-OBG\-] ^+WPZ\0?"[Q;&LVE>)-&N]#U&+^];7
ML#P2@9! .UR01R#CTHX8SN66YEAL?'_EW)-^:VDOFKH.(LGCF&7XC!2^W%I>
M3MH_D[,_E0_9 ^+%Q_P5;_X*L^!OCKJD1FT#X3?#/2]5O8W0I$OB%X$:X,>1
M@L-1G&.!N2+('%?UC^)_"FC^-O"^H>$/$D"W&G:O8W&FZC:OP);6ZC:*:,X[
M-&Q4^QK\WO\ @F=_P3!\+_\ !-WP?XIT#1/$K^+=1\5ZC;75[JT^GC3"EO:(
MZPVZQ+-<\*TDC%MX!R!CCG]28D,<0BQG  XX_E7M^(6=X7%YA&&6O]Q1BHT]
MT[+5NSLU>3?;H>3P-E.+PV!<LQM[>K)RG:UKO1+Y126[/\]KQ+\>/B)^RY^S
M!\9/^"2T_P!JDUR?XOPZ3I$D",XDTR5F2]P<;O+G^S6C(N.1,QP#7]R/[(/P
M,B_9P_9A\"?!"*)(W\-^&K&QNPK AKP1*UTV0.<S,_/.1WKX'^+G_!'7X9?%
MS_@HGI/[?>I^(6A-C/INH:AX.?3%G@U"^TM/*AGDNS<+M4HD(,9@<?N^I#<?
ML>JG [GO]?SKW_$?C+!YEA\-3P:LY?O*NC7[UQ47O:]K7NKI\S/$X!X3Q67U
ML1+%O2/[NEJG^Z3<HW[/WK6T^%'\BOP9^&?P^_X*"?\ !:;XR^&?VS7;6;3X
M?W.H6/@GP/JDK)9W%KIMV+2%A#D+(@M_W[(O+F0R'(#&OWX\8?L&?\$_X/"=
MQ'XX^&GP_M=%L;9[F[N;ZQAM[6V@B7YY);AMJHJKDDLP  R<5X!^VI_P1^^"
M7[7/Q'@^/>@:_P"(/AU\1X!$#XO\*2E9)O(4)$TT0:,F2-%"K)'+$V  Q8!0
MOB?A?_@B;J_BO4+2/]L?X^_%+XP:'82I/#X7U2ZN-/TR9XV! NHVN[LRJ<8;
M#(Q'\0QSTYIGV!QT,-7IYE/#JG"$?9*,G9Q5FX.+4'S/6\G%ZZ]C++,GQN#E
MB*,\!&LZDYR]HY1LU*3:4[KF7*GRVBI*RTL?#O\ P0$O?A;=_MB_M+W_ ,$H
MTMO!DNJP/X5@B5HUCTHZE>BR0;LD8A*#!).,<GFOZ'?B9I7[+'[1.K:E^S=\
M4D\+>*]1LK6+4]1\(ZDT%Q>6T%R#Y=QY!/FHK 8WIP.,GD5\R_L9_P#!-30/
MV-/VA?BM\;_"_B.._L_B9JC7]OX9ATJ/3K;0X#=SW*6T$L<\GFI&LPB7$<0P
MN<#.!R7[8?\ P1V_9O\ VLOB WQLTV_U_P  ?$!F$K^+O"%RT$MQ*H"H]Q"3
MM9U5<!XGB<_Q,V!CS>)\WRW,L^GB_K4Z<'"'+-)MJ4817O?"WJFFUK?57.SA
MO*LPR_)8X;ZO&<U*;<6U%.,IR>FDDM&K)Z=';I^:7_!1/_@CI^SS^S3\$_$_
M[8'[)>O:Y\,O$7@NR;7T@MK^5K&X:U((@BW'?%+(2%B"M@N1D=17[)?\$POC
MQX^_:4_8;^'OQI^*B$Z]JNF26]]=%=OVMK.YEMA<8'>18@S'N^X]*_/V+_@A
M7XC^(5_9Z9^UE^T5\5/B=X6LKE+B/PM?S36MO+Y9R@F>:\O0_(&YQ&KD9PRD
MY'[I>"? /A;X:>$M-\"^ [&VTO1]'M(K#3=.M5VQ000@!$7J3TY+$DG)))))
MCC'B*CB,MHX*6+>*JQGS>T<6N6'+;DO*TI7>NNBMH:\*Y#6HX^KBX898:G*-
MN1-/FE>_.U'W8Z:::OKLC^:#_@V:8#0/C>N>3XSM#] $F_QK^DKXRL%^$?BD
M'OX<U0?^2LE?!'_!-?\ X)L6G_!.RP\;6%IXRE\7#QEK$.KN9=,&F?9#$KC8
M +FY\S._D_+TZ5^COC+PX?%WA74O#/G>0-1T^YL#-MW[/M$31[]N1G;NSC(S
MCK7F<?YYAL=GM?&X67-"3C9V:VC%/1I/==CT>",IKX+**.$Q$>6<5*ZNGO)O
MH_,_G-_X-G)$C_9?^)JL<9^*UP!GC_F'V?\ G]*X#]F=BO\ P<B?&,D'_D"8
MQ_W"+&OUN_X)M?\ !/&V_P"">'PT\2_#>S\6/XN7Q%XI?Q,UY+IPTTP-);Q0
M&'RQ<7.\#R@V[<O7&WC-<_\ #?\ X)J6WP]_X**^+_\ @H$GC*2[G\6V9LW\
M*MI8BCMA]D@M<B\^TN7_ -3NP8!UQVR?JL?Q?E]3-,\Q$:MXXBDXP=I:MN&F
MUU\+U=EYGS&7\*XVGE^38>4+2H5%*>JT7+47?7XEM<^)?^#E]@?V!?#SD8 ^
M*^C.3UP/[-U3KBOVZ_9R8R?L]^!''&?!NBC_ ,D8:^5_^"D7[ T'_!0WX#V/
MP.O/%+^$H[#Q59^)QJ46GC4V<V=K=6WD>2T]L%#?:=V[?QMQM.<C[:^''A%O
MA_\ #[0_ K7!O/[&TBRTG[9L\LS_ &2!(?,*9;:7V[MNXXSC)KX_,<YP]3(<
M%@82_>4YU&U9Z*7+9WM9WL^I]5E^4UZ>=8S&2C[DX4TGIJXN=]+WTNMT?S<?
M\'0AW?LU_#M.[>+[O'OBU7BOTD_X*W_LG>)?VQ?V$M>^'?@.W$_B'3Q:>(=$
MMR?FFN+ [V@3MNEBW*/? [BNB_X*:_\ !.2#_@H_\//#WP_O/&$G@^/0=6EU
M47<.F#4S<-+%Y6PQM<VX3:,G=N;.<8K[4^+WQ5\&_ 'X4ZS\6/B3=-;:-X<T
MN34-2GAC,C^3 HY1!EBQ.%5>F3^->I'BCV>!R6G@7>O0J5)<MGO*4''IK>VR
M?J>9+AIU<?FU3&*U&O3IQO=;153FZZ6YNMO(_$K_ ()B_P#!7O\ 9NUWX%Z!
M^S]^TKKEG\//'O@JPMO"NH6GBL_8+2Z73D%O'*MS*%BB8*BK(DS(58<$@DCW
M[]KO_@K+^SYX0\.7/PI_9;U>T^*OQ.\0V\FF^&?#W@N5=3M_M$\97S[B[M]U
MLL4*DN0)&8D8(4;F7!T_PW_P1D_X*@V<'Q5U33_ FO:O=6R3WPFNWT+78G?Y
MF2]^R3VD[2*3@EV?CH2M<;\=?'W_  3"_P""2'P/\0ZU\$](\':9XLU#1[BS
MT32]&G&H:W?33HT<:O=SO<W*VZG#/NDV\9QDBO8K9?E6(S)>SR^NJ\I?P790
MYF_YOCY+].5.WVDM3SJ.-S*A@;U<;1=",?XROS<JZ\OP<UNO,U?7E>Q\\_\
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M5]ERJSUY9WEMHK+NT?19QE=:KFN7XF"O&G[3F?;FC9:>;[7/9O\ @HM<(_[
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MUTNKM/K9VV=OU5;I7SW^T[\#=&_:2^ 7C+X$^(&V6OBK0+O2A+C/DRRH?)E
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M !3\$ZE\./B3IMAK.AZO:M9:CIE]'YD%Q"V,JZ\<@@,K AE8 @@@&O.XHSK
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M%_P3N_X*R?L^_MZ^#[;3HKFU\->/8(0NK>#=0N<2/(!AI;!WV_:(6(SQ\ZY
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M^P?^QSX)_9NTY();_2]/6]\2:A!@K=ZU?8FO9=W!8"0^7$2,^2B DXK^0?\
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MR6.DV\S!LD.%@N)0A'&$E1AU#5=X]CSXT<QC[JE^7^1_,=^T7_P40_X*9?\
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M\;OV%K?X[>'K(W&M_#'6DU)GB0R2'2-0(M[Q<@\(C>7(>#]WMS7\1W_!-?\
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M$MWH^J)LN88[B]D>-F7/1@0P]11.2<4?/9=1G'&U9.+MK^:/V.6SC1@4+*%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *C=B/N]
M<9IY.*\0_:)\;^(OAY\!?&?COPM%YNI:1X9U&_L8P"<SP0.R' (/! /X5I2I
M.I.--;R:7WBE+EBYOH?(_P"U5_P5B_8I_8ZUR3P;\7?%2R^(H%5[GP[H,)U"
M^A##(\W:5BC;&#L>0/@@[<$5\X_"[_@X&_X)P?$W5XM&N?$.N>&'G81QS^)]
M+:"#>3A0SVSW.W)[G &>2!FOBO\ X(&?LS? +XQ? _6/VOOBKI^G>,_B/KOB
MN_BU34/$"K>RZ>(I R>6LN_8TW^L+E03]W.!7[=?'O\ 8+_9"_:9T&XT+XP^
M O#U^+B(Q1ZA!:):W\#%=HD@N8 DJ,HQ@ANV.E?I6:X#AW+<74RS%PK3E3?+
M*I&45[RWY8..L;[7E=GY_E>.SW,<+3S'"SI0C47-&$HR?NO;FFI*S:WM%VVU
MW/I_PCXV\/>.=!LO%?A&^L=5TO4(1/9ZCILZ7%K/&>C1RQEE8<$$@\&NP'2O
MC/\ 8L_8W^&/["7P1B^"OPKN-1N[&/4;K59;[6)EGN9IKD@?,RK&JJL:(JJJ
MJHQGJ23>LOVX?V==0_:@U+]C>SUV3_A86CZ>NIZAHSV%VD,5N]I%?"3[8T0M
M"/(F1O\ 79&<=0:^ JX'GKUXX%2JPA>5^77D3^*25^5:J^MC[2&,Y*-%XQQI
MSG96YM.9KX8MVOL[:79]?T5^7'Q/_P""RO\ P3E^$'C-O 7B_P")FDR:A',;
M><:1;W>IP02+PPEGLXI8DP>""_!K[6^"W[0WP?\ VBO!D?C[X(>)-'\3Z2Y"
M?;-)N!,$D(SY<J@[HG'=7 88P16F-R/'8:C&OB,-.$);-QDD_1M6,\)G&#Q%
M6="A7C.4=TI)M>J3N>XT&O%?CA\=_A_^SE\*M:^-OQ?OCIOAO0(([G5+V.WF
MNC#'+*D"8BMUDE?,DBCY4. <D  FO'X_V]?V51^SQ8?M5ZCXQT[3? NJQF33
MM:UA9K#[00S($C@N$2=I"RG""/<<<"N?#Y?B:L(U*5&4HN7*FDVG+?E];:VW
M.FMC:%.;IU*D4TN9IM7Y>_IY['T-\5/B7X<^#_P[UKXG^+S,-+T#3+C5]0-L
MGF2B"V0N^Q25#-@<#(SZ]Z\(_8U_;6^"O[=/PXO/BI\"Y-3DTJQU631[C^U;
M86LPN(XTE.$#R97;(N#G\*P_!/[5'[+7[6'[-'B7XS>';V#Q)\.+6VU:U\0R
MW^FW(AEMM-@\Z^1[6XC625/*.0%C8.#A0:R?^"?OCO\ 8H^(_P &;OQ7^PCI
MNCZ9X1FUJ:.[31-&DT2&34(XXUD9K>6"!F;8$7?MY  SQ7JO+E3P>(]OAJBJ
M0DE>UHQ[QDFM)/IJO0X/KSJXFA["O!TYQ;M>\I;6E&SUBKZ^JU1]VT5\?>-_
MVYOV;?A]^TKI?[(GBC7Y+7Q[K6GQ:GI^DFPO'B>WF\W:[7B1&VC'[E\[Y!C'
M.,BOF_Q[_P %H?\ @F[\-?%LG@?Q-\3M+EOX9S;SG2K6\U&VC=?O!KBUAEA&
MWD$E^#Q6&%X;S*NTJ.$G*ZYE:$G>/?1;>>Q6(S[ 44Y5<3"-GRN\DK2_E=WO
MKMN?JC17C/P>^.WPK_:!\%6_Q'^"OB#2_$FB71VQW^E3">,. -T;X.4D7/S(
MX##N*]#U3Q!INAZ;<:UK=U;VEE:1M/=7=RXBBABCR7=W<A0H ))/'%>15A*G
M-TIQ:DG9IJS3[6[^1ZM*4:D%4A)-/5-;->1T=,8D'BOR;\6_\%OO^"9?@OQ*
M?"FJ_$^QGN5F,#3:7IVHW]H'5MI_TJVMY(=N?XM^,<YQS7OOB/\ X*,_L?\
MAOX!2_M0R^.-*O\ P1;W-O97&L:(D^J&&YN6PD,MO9I+-$_'*N@P>N*]JOPM
MFE-4W/!U%SM*-X25V]DM-6^ECQZ'$N6S=10Q<'R)N5I1?*EJV]=$O,^G_B;\
M2;+X5_#O6_B5K5GJ%[::#IEQJMU::5")[V6*V0NZP1,Z!WV@X!90?45X#^QE
M^W#\&?V[OA9+\7?@<=433+;5Y=%N8-;MTMKM+B%$D.8XY9E"LK@JV[GG@8KV
MCP'XU\%?'7X6Z5\0/"DIU#PWXNT&WU73I9(G@^T:=J< DC9HI KKOBD'RLH(
MZ$"OYN/^"3-]>_L2_P#!3'XR?\$]]?<Q:/K5U-XF\)J[;4<PG>FP'KOMI H&
M,GRSUKTLCX?IXO+LQ;NJ]!*27>*?+--6WCH_OT.+-\[GAL;@4K.C6;BWVDUS
M0:?:5FO5K4_JB=RJEO09KX0U7_@HO^SOHO[9EE^PE?7&I'QS?V:7<3QP1G3%
M=XFF6W>X,P<3E$)V"(_6OM?Q#KMAX8T"]\1ZNXCM=/M)KVYE) "PPH9'.3Z!
M37^=5XR\8_&77_BUJG_!8:R6>31[+XX06ENX4J)(54RQ(IXQFVC$;#@?-QUK
MV_#?@>EG,L3[>;BHQM#SJ2^!>>SNCQ^/^,*F4PP[HT^9RE>?E3CK.7RNC_1E
M^U-DCC(/3OCI_C7RK^V%^V?\(?V'?A$WQJ^.']I#2!J=OI$<6D0+<W<MS<AV
M18XGDB4@*C%B6&,5[MX&\9:/\0/!6E?$#P[.D^G:SIMMJEE-"=RM#=1K(I!'
M!&#P?\:_FV_X+.:A=?M;?MM_ W_@G1X<D::&;58O$_BA(P,1P2$J"_48^SI+
M@L, D<'-?.\%9%#'YE##XJZIQ4I5&MU&*;EZ;6]6CW>+<YG@L!.OATG.3C&"
M>SE)I1^5W?T70_HZ^#WQ2TGXT_#+0?BOX=M=1L=.\1:3!K-E:ZM"L%['!<H'
MC$T2-(J/M/(#M]:]1KC=.LM'\&Z)'96IAM=/TZQBM8FE*QQQ0VZ!%W'*J%50
M/3 K\VOB/_P6I_X)M?"OQ++X4\2_$[2[F[AE\B0Z%:7NK0J_0@SV4,T7RGAL
MN,'KCI7E8#*<5C:LXX##SJ=;1BY-+I>R/1QV9X;!TXSQM>,/.344W\V?JO17
MS'^S]^U_^SE^U5H<OB#]GWQ?HWB:&V_X_(;&7_2K;.=OGVS[9H@<<%U&>U>S
M>,O'&B^!/"6J>.?$TWV?3-$TVYU?4IUC>4Q6MG$TTS[$!=BJ(QVJ&8XP!FN*
MOAZM*JZ-6FXRVLTT[]K;G71KTZE-5:<U*+ZIIK[]CM3TJHUPXE$0')QR>GI7
MQQ\(_P#@H!^RG\;?@AJ7[2/@?Q;:)X)TBXEM-2U_6H)])MX)8@"X/VY(6.-P
MQA<'H#FM7]F+]M/]G+]LK^W-2_9T\0+XA@\-7L%AJUQ':7-O$DERKM%Y3SQQ
MB4$(WS1[E]^:Z<3D^-IQJSJ8><53=I-Q:Y7V>FC\F84,TPLY4XPK1;FKQLT^
M9=UW7FCYV_X)X?\ !3#2?^"@FH>-['1?"-UX7_X0K5$TR=[K4([X71=G4.NR
M&+9]SH=W7K7Z?V\K2IN;U;I['%?RQ?\ !MO'G7/CT22?^*N@X'3(>>OZ0OC/
M\;_AI^SY\.]1^*OQ=U>TT/0-)C\V^U"[+;5!Z*BH&=Y&)PJ*I9CP*^HX^R*E
M@\[K8# P?*N516K;;C%];MMMGA<'9Q4Q>54\9BY*[YKO1*RDUY+1(]CHKYN_
M9P_:D^%'[5WP^C^*?P5N=2OM!GG,%MJ.H:5?:8EP4.',"WL,)D0<C>@9<]Z^
M9?CK_P %</V!/V</&4_P[^*?Q"T^/6K-VCOK#2+6\U5[5U)#1S_889O+=<?,
MK8([BOG,/DF.K5Y86EAIRJ1WBHMR5NZ2NCU\1G&#I4(XJKB(QIO:3DE%WVL[
MV=S]*B<5PWC3XB^"OAOH,_BKXB:SI/A_2K>1$FU36[N&QM(S*P2,//.Z1J7=
M@J@MR3@9/%> _L^_MP_LN?M4P-+\ _&^@>(98E9IK""X\N^C5>[VDH291[E
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M:HEY!'>6K1R0RQB6*:-MR.C %65E)!!!!!'&.<U\B^/_ -OC]FCX9_M"Z/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&*/#]:6-Q%7VE5JRLK**ZVZMOOI;IN6!THH''%%?AQ^W!1110 4444 %%%%
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MG[,UE=QQSQ3?$IHY89%#HZM=:8-K*V001D$'@YYK[A^'7_!/C]CSX3^-M/\
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M:QTY<O7EG1HN$K;VDD[/K9GXX^&D\S_@N#XC1B<?\*G0#';)LN:_6'5?AO\
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M['4HV@>*UO?+6.]LW==HDMKA0'C93@C!VG^)2,@_GC_P4D^!&H?#S_@FU/\
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M\$]_"&I?L ?\%K?&'[#G@._N9_ WBW2+G4[&PFD,HMUALSJ-LSYQF:$))!O
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M;-M)1ESQT88_2M *H[#@8J(P0G@H/Q^N:\[$8BI6J2JU9<TGJV]S[/*,IPF
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ****  UG7^FZ?J%G-IVH0QSV]Q$T,\$J!XY(V!#*ZL"K @D$$$'O6C12:&F
M?A+^T'_P04_9"^*OC2X^)OPBOO$7PLU^:7SY+CPE,%L@[<NT=KE&B+'G$4J(
M.R 5X]I'_!OEX7\5:G#'^TA\<?BE\1-'MF1X=&OIW@C 4Y1/,N+F\  [[4!Q
MT(K^C@(F>@H,:'J/;\*^TP_B1GU*DJ4<8[+1-V;2\I-.2^3/DZ_ >35*CJ3P
MD==6M4FWWBFHOYH\:^#?P9^&/P"^'VF_"GX0Z-9Z%H&FQ&&UT^S0@9QR\C$E
MI)6QEW<EF[GI7\U7_"M? 7Q;_P"#C7XI_##XDZ19:SH&L> ;6RU#2[^,20S1
M-X9TWC'564X*NI#(P#*0P!K^K&=56-MO'0\<8]37Q[HG[$/[/6E?M<ZG^VY:
M:9?CXAZK8IIM[J1OKAK5X$LX;-0+4MY((@A100O7+=367"?%$<#/'U*\I.=:
ME*":WYG*+3;NG]G?>_0TXFX=EC/J,:*2C1JQFT]N51E%I*S7VMMC\F?%/_!O
MOX)@OI=)^!WQJ^)O@;PG=3F6Z\)V]S)=VK*3GRU9+FV0*"3C?&Y /))&3^D?
M["O_  3:_9F_8(TJ]B^$%C<WVOZK$L>L^+-:=9]3N8E8/Y"NH40P;QO,: ;R
M%,A<HA7]#1&@' Q2A$!R ,_2L<RXWSC&8=X7%8IR@]UHKV_F:2<O^WFS? <(
MY5A:ZQ&'PRC);/M_AOI'Y)'RS^V;^S99?M<?LR>+/V;[[5I=!@\56D%I)JL-
MN+M[807,-SN6%I(@V?)VXWKC.>V*;^Q=^S=9_LA_LW>&OV>-/U>778/#EK);
M1:K/;BU>?S)6D),*O(%QNQPY^M?4CQ+)]\ ]^13U0*V0/:O$_M3$_5/J//\
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MY+GV/RZJZV"KN#>]MFNS3NG\TSULVR;!8ZFJ6+HJ:6U^C[I[I^:/P ^%G_!
M;X"V7CNV^(G[4?COQM\9+^Q;-O!XHN)([4D8.)0T]Q*ZY ^43*#WR.*_=G2M
M)TK0=-M-!T*V@L[*TMXK2SL[5%B@AAB4(D<:( JHB !5&  !QQ72,B$<#]*;
MY$1()09'0^E7GO$6/S*498VLY\NRV2](JR7R1.3Y%@L I+"4E#FW?5^K=V_F
MS\P_V2?^"=&E?LJ?M1_%G]I[3_%USK4_Q4UB^U6ZT>;3DMDTYK[4)+]D2=9Y
M#+L,FS)C3.,X!XK]"/&^@#QCX-U?P?+<&V75M+NM.:=0':$74+1%@AQG;NR
M2,^U=F;>)B"5!QSDCGO2B"+)^48/7BN3,<UQ>,KK$XFIS322OI]E66RMHDNA
MTY?EN'PE'V&'ARQNW;SDVW][;9^=/_!.+]@W3?\ @G=\&-8^#.C^)KGQ3#JW
MBV[\5-J-S8)8/%)=6EK;& 1I-,"%^RAMVX<L1C@$^S?MF?LWVO[8/[-'BO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#_]'^_BBBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH 8RAN" 1[BD"JIX7KUQ4E%%A\
MP4444""BBB@ HHHH **** "D(!X-+10!$L4:$D*!] *D 'H*6BE8=PHHHIB"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __
MTO[^**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]/^_BBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
8B@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
M_]C_X  02D9)1@ ! 0 !>@%Z  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      %Z     0   7H    !  .@ 0 #     0 !  "@ @ $     0  "DZ@
M P $     0   ,,     _^T .%!H;W1O<VAO<" S+C  .$))300$
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M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" C_W0 $ *7_V@ , P$
M A$#$0 _ /[^**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(VRK91<,K#'%?N_\//'7ASXE^ ]'^(OA*X6YTK7-+MM6T^<$?/;W48EC)P2
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MGP;_ ,%,?V=;;]G;QQXBU3PS9VOB>Q\3+J.CPQ33F6RBN(5B*S IM87!)[Y
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M[75Y);*>R,<MRKR1*!.B%LA&Y'''-?YQ7_!<_P#9+;]D3_@I%X]\*Z;:_9=
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M!T;R1(&_#K0F^QSU,90B[2J+[S^H_>I.WOZ4ZOQB_9]_X+X?\$K_ -H76H-
M\._$BW\/ZE=.(X+3QE9W&C;R>[7$ZFU09X)>9?QK]BM.UG2]7L8-4TFXANK6
MZ@2ZMKJV=989H91N22.1"5=6'*E201R.*?J:0J0FKPE<TZ*;O4G;GGTIU,JP
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M29V_@22=1$6)P I<%B0%!S7NQX5S65#ZU'!S=/?FY96MWO:UO,\:7$67*O\
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MK=KK6[5^J5CRGG^!^M_4%63J?R]=KZ]$[='J?J!12#I2UXB/484444 %%%%
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MBL94]CA*,JDNT4V_N1CCL?A\+3]MBJJA'O)I+[V?HX'5N5Y'J*=7YA_LY_\
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M\R,LOOR*_0,W,2XWY (!#8XY.,9]:E2/7C)27-#5'^9;_P ',Q_XVR^*,?\
M0J^'_P#T2]=KX._X+1>)?V2_^"2'@7]B_P#99NY;+X@ZL^MW'BOQ3!\K:%IM
MU?2&&WLB>?MMRIW&0 >1&1LS*^8>*_X.9>?^"LGB@CD'PIX>(_&!S7N?_!ME
M_P $R/"G[7/QPU7]J'XZ:9%JG@?X<W4$&FZ5?1>9:ZMXAE'F1K.C K)!:)ME
M>,_*[O&K;E#*=96Y4V?&I5)8NI3I:.5U?LKZGSK^P_\ \&_W[>W[>&G0?%WQ
M.+;P#X8U=$OX?$GC7S7U'48Y>1<6U@O[]TD!W1RS-$CK\R%A7Z^ZE_P9]-_8
MS?V1\<2M^$X>Z\.AK8MCG*I=JX'_  +-?VO103ID29Y(X)!Z=>1V/TK1=6,9
M*\G' ]ZS4Y,]ZGD6'BES*[[G^4)_P4&_X(W_ +:/_!.I?^$F^+.D6FN>$'G6
M"'QGX9>2YTY)'.(UNU95ELW8?=\Q-C'A78@U^D'_  1 _P""[7C[]E'QCHW[
M,'[5&KW.N?"O49X]-TG5M2E,USX4D=ML;QS,&9[ G DB;B+/F*5 <-_H.>._
M /A;XD>$=4\ ?$?3+/6M!UFRET_5=,OD$D%S;2KMD1T.<YR2,8(/(((!K_*:
M_P""M_[#$O\ P3^_;>\5?!#3PQ\-W3#Q!X,G;+E]%U!C)!&S/@L]N=T#MT+H
M>HY-P;EI(\K&X.6#DJU!Z=5_70_UA--N[._MXKFSE2:.1!-'+$V8RK'JI&?E
M;J!DU_!7_P '=G'[6'PNQT_X5Y+^FIW5?O\ _P#!N;^UOJG[5'_!.C1-(\77
M)N_$'PWU*;P+J$\S[IY;.U1)M,E?/86LHMP>=QA8YR37X _\'=O/[6'PN_[)
MW+C_ ,&=US6=->\>EFM95,%SQZV,;_@C=_P48^'G_!-?_@E+\7?C!XE2#4O$
MFH_$N/2_!'AN4\ZEJATN%E9\%2+>W!$D[CHH"CYF4'\#?&?BK]M?_@J+^T==
M^*;VW\3_ !,\=:PQD2TT>WEN_LEON^6&&*,%+6UBS@#Y44=2*XW]D[]G[XO_
M +:'QP\'?LD_#"226YU[7)'M8G+&VL/.CC;4-0D5<X2.WMP\K8SMC^@K_5!_
M8)_8'^ W_!/KX'VGP7^!VGQJY6*Y\0>(9% O]:OP@5[JX<EL D'RX 3'$O"Y
M)9FN3Y7IJSRL%AJF,@H-VA'\6?Q._L,_\&Z?_!3CPU^T#X#^-/CS0O"?AC3O
M#'BW2/$.H66M:['+>&&QNH;AT6.P6ZC\PIDJK2 <')!(S_1__P ',BR+_P $
MI_$88!?^*JT7&/0R2$?B*_H*MTF1BKC"\;><G'H?\XK^?_\ X.;1C_@E/XAQ
MC_D:=$_]#DJ6VVFSV98&G0P]6-/JF?RX?\&LY_XV@KC_ *)UKW_H=K7]MG_!
M8L?\:P?C1C_H2I__ $;%7\27_!K/_P I05_[)WKW_H=K7]M__!8O_E&%\:/^
MQ*N/_1L5.JK-G-E"_P!C?S_(_P P/]A?X^Z+^RS^UKX!_:)\0VD]_9^#-=C\
M0OI]NVR2Y:T4ND*N<A?,<*FXC"@Y[5^A_A'X'?\ !2W_ (.!OVE]7^+L4;WU
MHEVT$^OZM(]MX9\.6A.8K"VVA\E$(Q% CRL29).KO7Y&?!7X6>)?CA\7/"WP
M7\'()-5\6^(=.\.::A. ;G4KB.VCW$\ ;G&23@#)-?Z]O[*/[,'PT_9!^ 7A
MK]GGX1V45MH_AO3TL_.V!)[ZZ  N+ZXQD&>YD#.YYQG:N%  NIIJMSRLGP4L
M0G";M%/[V?R*^'?^#/O7Y/#V_P 4_&^VCU9X@0FG>'F:T20CYE)DNP[@'C(V
M9ZX%?C]_P4._X($?MH?L"^'+KXHK_9_Q#\#61)O/$?AI)(Y[!>\M[8/ODBC_
M .FB/*B_QLN17^H+&A" ']>:YOQ!X:T?Q/I-[X<\1V4%[IVHVTEG?VEPJO%<
MV\ZLDD4B'AE9&((/J>YJ%.2/<K9%AY1M%69_EV?\$9O^"J_Q#_X)Q_M!Z?I>
ML7US=_"OQ/J,%GXTT*1FDCM8Y2(UU.U4\1W%L#N8*/WL89&YVLO^I3INJZ;K
M&EP:OI<\=S:W4"W%O<PL'CECD7<KHRY#*P(*D<$<BO\ (2_X*+_LRP?L=_MM
M_$7]G;3?-.G^'O$EPNC&X WMIMP?/M'<#C+0.I].:_TI/^")GQ1UKXR?\$KO
M@IXXUZ1IKI/"<F@M*W!D&@WESI$98]2?+M%R>_7FJJ?S+J<>0UY*4\//[/\
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M!U?0O&=C:JPLY;AYK>2&\M2<[8KA0Y\LDM&RLIRNQF_U O'/@+PC\2/!VH^
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M\$-G_9[\26J6^J_&GPGK'B;4OM?,<5QXAM@FDN2HW!8[:.TFVG)5BW SBO\
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MD\[S7 4 GY02> ,+CG P,\8]^U6I8W==JDCG.124I;W/36285*W+^+/\@O\
M:;_9#_;)_P"":?QKL]%^,&EZKX/U^TG-YX=\3:/<-]CO#;2!EN-/U"#"ML.T
ME<K+&<"1%-?V?_\ !!?_ (+HZI^U[=VO['W[6UW$OQ$L[3?X7\5L4A3Q';VZ
MC=!<J3C^T$'SAUXN$#%L2K^\_>?]N']BWX2?MU?LYZ[^S[\8[*"2UU*+S=*U
M)$5KG2]216%O>V[L#MDB9CN('SQED;(8@_Y17C_PC\9?V&/VI-3\(7$TND^-
MOAKXJ,<5W#E=EWITH>">,D E)5".N1RCX/6JOSJSW/)JTIX"JIP=X,_V+WE5
M[&5D786C=V&""2>_..N*_P ;/XZ#/[3'C3!//Q!UD9S_ -1.7^=?ZS?[#G[2
M^F_MA?L?>"/VD-+"I_PE/AFWOKV $$P7ZKY5W$<<#9,K<5_DM?M SR6W[1/C
MNZA)#Q^.M==#Z,-0F(.#P<'FE1W->(Y*4*4E_6Q_6?\ \%PO^"UOBGP+X)TG
M]@;]DK5CIU];>%M,L_B7XNTUR+J)VLXPVC64RG]WM#'[8ZGS,GR,H%E#_P Y
M_P"RG_P2X_;V_;<@_P"$A^ /P[UK5=(D=MWB74VCTW2G8-A]M[>-$D[ D;EB
M,C]R*_6G_@WY_P""3FE?M_\ Q0U;]JW]IR"75_ /A?5#!'I=XQ(\1ZYA9&6X
M<.K&VMPZO+_SU?\ =G@/7^B'H&AZ?X>T>TT+0;.SL+&QMH[2SLK&-8;:WAB
M5(HHD 1$10 JJ % P*KGY59!0P$L8_;5W9=$?S<?\&_'_!*3]JO_ ()PW7Q$
MUS]I$^%L>,;728;"U\/ZA+>S0-8/<&59PT$4:_ZT;2COTK^3S_@X861/^"NG
MQ5$N-V[0R0#D#.D6G .!P.E?ZDUO!Y2%6 'S$@9SQG\*_P M_P#X.(/^4O7Q
M7_WM"_\ 3/:5-->]=CSNA&EA8TX;)_YG]SW_  04./\ @DI\&S_U KC_ -*Y
MZ_8.2XA4X8XQCL>YP/U%?CS_ ,$%B!_P24^#*MQNT*X(![_Z7.:\J_X+1?\
M!8KP1_P33^&H\(>!OL>M?%?Q':O+X;T9PKP:7 ^5.HWX!W!<D^5&<&1A_=!S
M+;O8]JE6A3P\9S=DD<!_P6U_X+6>#?\ @GSX&NO@O\%[NVU;XS:U88L[=0D]
MOX:M9N4U"^1@RF9E.;:V();(ED'E[5E_AO\ V%_V%?VH/^"LG[4%SX>\-W%]
M=O=:@-8\?_$#6#+<0Z?'<NS27%S,6S+<SL&$,6[?(XZA0[*?LB?LG_M1_P#!
M7O\ ;$N-$M[ZZU#5]=U"37/'?CG4D:6WTZV=LS74Y'!<CY8(@1N;:HPN2/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[54;F.=H K^JW]HGXX^%OV=?@9XK^./BILV'AC1;K5I4QS*T$99(E'&6=L*
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M<4I!P55\YP>>W@F/UW+LRR9[RC[6'^.GJTO.4&U\CEXN?U/'9?FRVC+V4_\
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M?^"E7["_[,&NMX6^-_Q(T+2-5C&9M*@%QJ5[#SC$UO817$L1]G53CGIS71?
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M%X/TGQ]X/N?MFD:YIEKK&E7@1XO/L[V)9X)/+E5)$WQNK;74,,X(!XK\)O\
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MM\K?>3C9M:*[Z6UZOX>?\%BO^":7Q1\21>$_"7Q9T$7T\PMX4U:WO](B>0]
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M_P /_LW3?9/&GB7P1I'A71=0R5-DVJ1S0S70*Y(:*'>P;JOWARHK]QOV/_\
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M;2ZI7=[ZK9]#Z2EB</6RK,'DM/V=:T[QY>62J<NG,N[TL^NC3=SXV_X)"_\
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MQ7]0< \*4\LP$8/6I.TIR>\I-:MO?39?\%L_:^&\EC@,+&&\Y:R;W<GO=_D
M&!BEHHK[NQ[84444 %(1D8J*:7R@#@GKP.M9MUKFG6$#76H2Q01(P5I9G5$!
M)VC+$@ EC@ \D\4N9%*+W+LML';("GY2O(Y^F?2N6\2>#/#_ (TTB30_&.FZ
M;JUG*P+V.J6T=Y;Y (R8YE*DX/I_,UTJWZ,X0*>I#\C*D=B,\GZ9JQ%(LX)
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MQ?!F@^$/^"4/@&]TB,>?K.H:QJM[( !)+<37<O4CKA4"C/0>U?R,?\',O/\
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M?_\ @CE$DO\ P5#^!2L ?^+BZ4P!&1N63*_D<'VZ]J_UJ8 ?+&>N.:_R6O\
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M1^T5\&_"W[1/P1\8? SQN@ETCQ;X?O\ P_>$*'>(7D+Q"1%;Y3)$Y21"2 '
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M(05*XZXY!Z$8]:GJA;DM)GL1NX;CG!Z?7/-7Z46>_)684444R0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYF_YOCY+].5.WVDM3SJ.-S*A@;U<;1=",?XROS<JZ\OP<UNO,U?7E>Q\\_\
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M5]ERJSUY9WEMHK+NT?19QE=:KFN7XF"O&G[3F?;FC9:>;[7/9O\ @HM<(_[
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MUTNKM/K9VV=OU5;I7SW^T[\#=&_:2^ 7C+X$^(&V6OBK0+O2A+C/DRRH?)E
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M !3\$ZE\./B3IMAK.AZO:M9:CIE]'YD%Q"V,JZ\<@@,K AE8 @@@&O.XHSK
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M%_P3N_X*R?L^_MZ^#[;3HKFU\->/8(0NK>#=0N<2/(!AI;!WV_:(6(SQ\ZY
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M^P?^QSX)_9NTY();_2]/6]\2:A!@K=ZU?8FO9=W!8"0^7$2,^2B DXK^0?\
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MR6.DV\S!LD.%@N)0A'&$E1AU#5=X]CSXT<QC[JE^7^1_,=^T7_P40_X*9?\
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M\;OV%K?X[>'K(W&M_#'6DU)GB0R2'2-0(M[Q<@\(C>7(>#]WMS7\1W_!-?\
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M$MWH^J)LN88[B]D>-F7/1@0P]11.2<4?/9=1G'&U9.+MK^:/V.6SC1@4+*%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?"FJ_$^QGN5F,#3:7IVHW]H'5MI_TJVMY(=N?XM^,<YQS7OOB/\ X*,_L?\
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M@J@MR3@9/%> _L^_MP_LN?M4P-+\ _&^@>(98E9IK""X\N^C5>[VDH291[E
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M:HEY!'>6K1R0RQB6*:-MR.C %65E)!!!!!'&.<U\B^/_ -OC]FCX9_M"Z/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&*/#]:6-Q%7VE5JRLK**ZVZMOOI;IN6!THH''%%?AQ^W!1110 4444 %%%%
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MG[,UE=QQSQ3?$IHY89%#HZM=:8-K*V001D$'@YYK[A^'7_!/C]CSX3^-M/\
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M:QTY<O7EG1HN$K;VDD[/K9GXX^&D\S_@N#XC1B<?\*G0#';)LN:_6'5?AO\
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M['4HV@>*UO?+6.]LW==HDMKA0'C93@C!VG^)2,@_GC_P4D^!&H?#S_@FU/\
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M\$]_"&I?L ?\%K?&'[#G@._N9_ WBW2+G4[&PFD,HMUALSJ-LSYQF:$))!O
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M;-M)1ESQT88_2M *H[#@8J(P0G@H/Q^N:\[$8BI6J2JU9<TGJV]S[/*,IPF
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1:K/;BU>?S)6D),*O(%QNQPY^M?4CQ+)]\ ]^13U0*V0/:O$_M3$_5/J//\
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MY+GV/RZJZV"KN#>]MFNS3NG\TSULVR;!8ZFJ6+HJ:6U^C[I[I^:/P ^%G_!
M;X"V7CNV^(G[4?COQM\9+^Q;-O!XHN)([4D8.)0T]Q*ZY ^43*#WR.*_=G2M
M)TK0=-M-!T*V@L[*TMXK2SL[5%B@AAB4(D<:( JHB !5&  !QQ72,B$<#]*;
MY$1()09'0^E7GO$6/S*498VLY\NRV2](JR7R1.3Y%@L I+"4E#FW?5^K=V_F
MS\P_V2?^"=&E?LJ?M1_%G]I[3_%USK4_Q4UB^U6ZT>;3DMDTYK[4)+]D2=9Y
M#+L,FS)C3.,X!XK]"/&^@#QCX-U?P?+<&V75M+NM.:=0':$74+1%@AQG;NR
M2,^U=F;>)B"5!QSDCGO2B"+)^48/7BN3,<UQ>,KK$XFIS322OI]E66RMHDNA
MTY?EN'PE'V&'ARQNW;SDVW][;9^=/_!.+]@W3?\ @G=\&-8^#.C^)KGQ3#JW
MBV[\5-J-S8)8/%)=6EK;& 1I-,"%^RAMVX<L1C@$^S?MF?LWVO[8/[-'BO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#_]'^_BBBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH 8RAN" 1[BD"JIX7KUQ4E%%A\
MP4444""BBB@ HHHH **** "D(!X-+10!$L4:$D*!] *D 'H*6BE8=PHHHIB"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __
MTO[^**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]/^_BBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
8B@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>stamfordsecondleasemodif001.jpg
<TEXT>
begin 644 stamfordsecondleasemodif001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M:BM_]2GTJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (K
M?_4I]*EJ*W_U*?2I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4**2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** (X/]2GTJ2HXO]6GTJ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** &)]P"GTU/NTZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** $ P*6DI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH 2EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBD+ 4 +12 @]*6@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ***,T %% ((R** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBL/7_$L
M.B7FF6 A,U[J<IBMXRVQ>,%BS8. ,CL>M &YFC-<R_BB\B.KI+I!$NEQ1S2H
M+@8D1@Y)0XYP$[XSSTJCIGCR35=&76+?1I/L,@8H6N4$A"N%8[/0$]B>WK0!
MVE&:YW5?%D-CKMOH5E:O?ZK,AD,$;A1$@&=SL?N@]NO\J;!XHF36H],U32WL
M':VENC.TZ/%L0KGYA_O<Y Q[YH Z2BN3T_QG-KFGW6I:'H\MY8V\C1AWE$3S
ME>IC4@Y'/&2N>E,N?B%IR>$$\36=O->6.0LJQLJR1,6"[2I/7+=OKTH Z^BN
M7B\;VEYX7MM?T^UENK::1(F0.JO&[.$"L">NYA^'-.E\9PVWBJV\-W&FW8U"
MZB,T(C,;(4&[DDL,?<;B@#IJ*R-#\1V.O_:TMA+'<6<IAN;>==LD3^A )'KR
M"1Q6?XJ\:VOA&2V%]97,J73;(7A*G+^A!(P.>M '3T54FNKB+36N19N\ZIN^
MSJZ[B?3<3C]:Y6P^(\&JZ-+J^GZ)J4UC")/,D9H5.47<0JF3+<>E '8H7+MN
M7 SQS4E0&ZB2Q-Y*XCA$?FLS'[JXR2?PJ'2=4M]9TBUU*U),%S$)$W=0#V/N
M.E %VBN37QU!+ILVK0:5?S:1&647B;,.5;:<(6W8SD9Q4M_XVM-/\5P>&VTW
M4)=0N(_-A$8BV2+ACD$R#'W&ZXZ4 =/165HVNPZS)>1):W-M):.J2+.$YW*&
M!4JS @@CG-9GB7QWIWA2<1ZG:7P5E+I)$B.K %03PV5&6 RP&3TS0!U%%87B
M+Q9IOAC2XM0OFD>&5@J"%=S$'DMCT Y)J&?QKIMGH-KJ]]%<VD5V5%M#(JM+
M-N *[51FZY[_ (XH Z.BL&;Q5;65[9VVIV=WIS7LGE6[W'EE7?\ NY1VP?KB
MHI?&=A#XJ3PW):WBZE*I>)-J%9% 8[@V[ &%/7!]J .CHK$T[Q38:M%>_8$G
MFN;%]EQ:%!'*C>A#D#UYSC@XK,TWXAZ=K&G76HZ=IVI7-C:Y\Z=8T 7 R?E+
MAC@8/ - '745RUKX]TR\T=-7@L]1?3W?8)Q " =VWD9R!GOBIK/QG87WB2?0
M([6]74;==\T;Q !%X^8G.,?,O3/6@#HZ*PO^$KT^74[C3[%+C4+BV'^D"TCW
M+$<XVLQ(&[KQG/!JUHFOV/B""YEL#*5MIS;RB6)HV60 $C# 'C<* -.BJ.G:
MM::J;L6DF\VEPUM+QT=<9'ZBL:]\?Z!IT2S74UU'"UP]LDGV.4J\BG#*"%YY
M!'O@^E '3T5S<WCG1;>&]FF-Y&EAL^U[[.13"'!*EE(S@XZ@59M_%>DSZ$=;
M:X\C3<92XG&P2#U4'D]",8S[4 ;=%<[#XTTM[R"VN([ZQ-R^RWDO;5X4F;L%
M9AC)[ X)HN?&^AV/B"/0[VXDM;^5@(DFA95D!R 0V-N"00#GKQ0!T5%9RZU:
M-K1TG;<?:PGF8,#[-G3._&W&>.M:- !15+2]5M-9T]+ZRD\R!V90V,<JQ4_J
M#56\\2Z99:A]@::2>]"[VM[6%YG1?5@@.T?6@#7HK$B\6Z/.=1$<\I;351KM
M3;R!H@V<94KGHI)XX'-0V_CGPY<V0O8]27['O*&Y>*1(@WH7*A0>G4]Q0!T-
M%8VK>*M'T.*.;4KIH()=OES&%VC<MD@!@",X4G'7%/7Q)ICWQLA).+L0-<"!
MK657:,=2H*C/T'- &M17-6?C[PY?B7[+>3S&$XE5+.9C&>>&PG'0]?2I+KQO
MX>LM-M-2N;_R[*[4-!.87*/G/&0O!X/!YH Z&BL^]UO3M/T<ZM=W<<5@$5_/
M.2-K8P>.3G(K/7QMX??23JJWLC:>O6Y%K+Y8YQ][;CKQ0!T%%8-OXRT*Z-KY
M5W)MNW6."1K:54D9N@#%0.?K3M/\8:'J>K2:5;WNW48\[K6:)XI!CKPP&?7Z
M<T ;E%<__P )KH8EN8WN)XY+:589%>TE!#L?E4#;R3VQU'-1+X^\-,;D+?R$
MVO\ Q\8M)OW/7[_R?+T/7TH Z6BFHZR(KJ<JPR#ZBG4 %%%% !4-S;)=0/#)
MNV.,$*<'\ZFHH 15VC Z4M%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5$5D\\G<OE[>F/FS]?2I:* $'2EHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X
M/QW::+K^LZ;X=UA!"]Q!+-:7RR!7AD!4;1GC!'YX'U'>56N-/L[M]]S:03-Y
M9CS)&&^0D$KSV)4''L* //-&;5-.\/\ B_2-7U./4(["UVP7Q&"ZO$YVECU(
MXXR<9Z]*QOAW(FE>%]-U^\NX_P"S[73;R)X'=01(;A6&!U)8+C\!ZUZP=(TP
MV8LSIUH;4-N$/D+L!]=N,9J.30-&ED,DFDV#N<?,ULA/'3G% 'GEHSZ)\<;R
M[U8"*'6+,)9S.-J[@$^3)XW#81^(]:ZSQ*]MKFGZGHECMGU*33Y@CH 1%N&
MK/\ PENP[XSVKHKFTMKV$PW=O%/$>2DJ!E_(TEK96MA$8K.VAMXR=Q2&,(,^
MN!0!P_PSU*SL?A_%;WFRPFTYY8KN.9@A1@2Q)!QC@BN6\*Z?=:?X'M[B^A:W
M6_\ $EK<PI*-K&,S1@$C\#^'->NSZ7I]U<K<W%A:S3IC;+)"K,N.1@D9I+[2
M=.U,QF_L;:Z\L,$\^(/MSC.,^N!0!Y+KGAZ]\&^*K>'2\+X<UR^MA,C E;:5
M9E88],XX]B1V%:^M.H_:"\/98?+ICYYZ<3UZ1-96UQ;+;2P1O I0K&1P"I!7
M'T(!'TK.F\*>'KF[>[GT/3I;AVWM*]LA9CZDD4 <=X#3[7\0O&6K6NYM/DF2
M%)2>'D7.['J ?YBH?B\8_MWA$2%=G]IC=NZ8RN<^U>F0PQ6\*PP1)%$@PJ(H
M4 >@ K/U#PYHFK7 N-1TBQNY@NT23P*[8],D4 ,O=;M(]0M=-C=);BZ21L(X
M.Q%7)8CTS@?C[5Y-\+[&5_#FEZE+.K:;9:C<R744NT)$IMR!)GKQD@CG[W;%
M>KV_A/P[:,[6VAZ="SH8W,=LBEE/4' Z'TJ,>#/# 4J/#VEA3U M$P?TH Q/
M$M[)K]CI&EZ?8R7-MJ$:WES;AUB;[,NTA#G[NYF4'V#"L/X67]SI5]K/@_4K
M=H)K.1KFWB9MV(FQE0>X&5.?]HUZ'#H6DVUZ+V#3;2*Z"A/.2%0^T  #(&<8
M X]J:GA[1H]1.HII=FMZ22;@0J).F/O8STH \=O-,U#PKX9?Q/X7U=)_#=V$
MDGTN<AU"R$*T?IP3M.,,.?2M;Q:MS<_&_0ELY/)NGTB01/C.UBEQBO0X_!_A
MN*>.=-#L!)&%"'R%XQC!QZC YZTM]X1\.ZE</<7FBV4L[G<TQB <GW8<T 4_
M!HM;+2[725@$.HVMA;?;4&"4?9M 8@GGY2<>A'K6/XPT4^(O%(TC<J+<Z)<*
M6/8B6(J1_P ""_AFNMTG0M+T*.5-+L8;596#2>6.6(X&34AT?3#J0U(V%L;X
M# N?+'F ?[W6@#Q;;J%[\([_ %/5W*&PL_[+MT8CG$Z[F./HB8.?N$]ZU?$L
M1B7X9:G<#&G6_D+-(?NHQ6(J3Z?=//M7J-UH6DWUL+:ZTVTG@#M((I(59=S$
MDM@C&223GWJ1-)TY--.G+8VPL2,?9Q$/+Q_N]* //OC/&][HFC:=:)YFH7.H
MI]G56^;(5@2!Z<CGMFJ-\KK^T+H"R'+C3R&/J?*FS7HUCX;T;3;A+BTTZ".=
M$\M)2-S(O]U2<D#V%0S>$- GOWOY-+A-XSF0W'(DW?[V<CZ4 <5X>B:Y^-7B
MB_M(F^Q1VGV>60#Y3-^[R/<_*U9'PF./A9XESTWS_P#HA:]:CT?3H+%[*WLX
M8+9SEHX%\L$\<_+CG@5GP>#?#]K8SV5OIL<5I/\ ZZ!'8))_O*#@T <)\,=,
MO9-*T"2;9-I$FG7BF,18"2&=?O-GG<!QT^Z:O>&V2X^-OBV8)ATMHHP3_NH#
M_P"@BN\TS1[#1[/[)IUN+>WYQ$C':N<DX&>.O:J]KX9T>RU234[:R6.^D_UD
MX=M[_P"\<\]!UH X7X( 0^&]4M9HWCOXK]OM"2##CY5QG//4-^M=1K&IVNCZ
M1K%SHB)/J<]R(O*B;<7NV154$'@$*%)'H"3WK0O/"VBWU[+>S606[E4+)/#(
M\3N!T!9"">WY4Y/#.C1_8Q%8I$+(LUN(V9 C-U; /+'U//)]30!YUX*<>%OB
M5J&AO'=V]AJ<*RVS7BLIEG4#>1GKDE_R'M4WQ>MD$/ABQ@18UEU/C&< D\\?
M5B:[[4?#&CZMJ,%_?VAGN;?_ %+M*^(SP<JN< \#D#/%-UCPKH^O3P3:G;2S
MO 0T7^DRJ$([@*P /OUH Q?B3:P1^ _$%TD:B>:V1)''5@K_ "@_3<?SKS_Q
M%"T7@/X<[U/]DB:)KL=1N;:1G/L9/SKU_4?#^G:MIBZ=?1SSV@&#&US*-X_V
MB&RW3N344/A?2(=#?13:&;36_P"7>XD:55&!@+N)( QD8Z'D4 <=\;B7\#6\
M:?-))?Q"-5ZL=K\ =S4&O>$5\7:Q<:?=L8K^+0[.2&9NL<PDFZX['D'\^PKM
MH_"FE+<6L\L4UR]F0;;[3.\JPD="H8D9]^OO5F/0M/BUJ35TBE%]*@1Y//D(
M91T!7=MP,G''% '"?#74]2U+6;VVUF)X]2T>SCLIRYR9"9'(;\@.>_6NK\8Z
ME+9Z2EK:B8W5[*(5%NF^18^LCJHY.$!Z=R*UX].M8=2N-0CA5;JXC2.60?QA
M<[<_3<>:BN=%LKK5;;4Y4E^UVRE8G69U"@]1M!VG/&<CG ]* /.?A9J TC7=
M9\(2QW$,:2M=6"W,91S$<<$'G.-I_P"^JD^%L\XN_%\]U%--K0O<RQOA79<'
M8.< <[OTKN6\+:0^O+KCV\AU)1A9_/D!"\_+@-C')XQ1<>&-,FU5]42*6VOI
M%VR3VTK1-(/1MIPW0=?2@#FM!U[3/$-YXEN;/2;VUNQ"(+]YRFS>@<!1AB2>
M6YQV%>:Z;>7-E\(K/39H5CTS6;YEFU$9<6BAU!W)@<G:2.>F:]ILO!^D:?97
MUK:1SPB_<R7,BSOYDC'.<MG(ZGIZU7LO 6@V.B7FC103-IMW]^VDF9E!_O+G
MD'@<Y["@#B_BU:6]A\,]"L[24S6T-Y;I%(6W%U$4@!SWR*[+10ZZM=SZR-MZ
MVIW$.GEMPW0E$8!1W&V/)/3*FF7/P[T&[TJWTNX%]+8V[!H8'O)"J$ @8Y[
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 <L/'NEF:PB%IJ1?4 S6@^RG]\%&25_ @U:M/%VG7FK6>
MF)'=)<W23.JR1;=OEL58-DY!R#6)XH54^)?@-$4*JF^  & !Y2U'K5N)OBWH
ML*R/#OTRX^>(@,,GD@^M '9:E?\ ]FV@N#:W%R#(D>RW3>WS,%SCT&<GVJY7
MG-_K.IV?PYL[@ZG-]M&I_9#/@;I56Y:/!X_N+UZ\=:75-8U.P\07IO;Z>'39
M+R&.VU"U99(+< KNAFCZJQR1N/\ >'0#% 'HA.*Y\^,M*$8F_P!*-HTHACNE
MMV,4CEMH"MCD9XSTXZUOL0%);ICFO,)5F\)Z9:W%MMU;P1=R1R+;E=LMF'<.
MK*>"R[B#@\C('O0!ZC17G<^H>(]5O_$3V&H6=J=,N1%#YUT8TB15#%I$\MMP
M8$\DCIQC&:=!J&I:['KE^-<_LVXTN[\N) V;<1*B,7D4C+JV7P>.,8H ]"HK
MBTO]0UV?Q+]EU22U;3W$=HD03&?*5P[Y!)!8].!@?C6+IWB+7/$-W:[M1DL8
MW\."_=+>-.9C(R[@6!P,*./0_C0!Z=6;HNMVFO6DEU9>;Y4<SP'S8RAW*<'@
M\CGUP:X_PQXDU3Q##X<M9[HP/<Z?+=W,R*NZ8I((PJY&!UW'CVK1^&ZLFA7Z
M/(9'75;L,[  L?,/)QQ^5 &UK'B73="F@BOVN4:X94B,=I+(KNQ("@JI&XX/
M'6M96W*&&>1GD8KEO&"1S:EX6AD4LK:NCC#8Y2.1A]>0*TO$FK_V/H=Y/%-
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MO0!VP.1D4M<)H/BF_3X73:G<6K2:KID$D4]NY^;S(^/F'4< $BK?AW7-2O\
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M6%U8V=YIS:,9$CFG. CRA6D V'#X &!V'WJ[^*-884B0$(BA5R<\"@!]%%%
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MA $,Q8++'M.4(*@#*\<XYQS5:3P):W.DS6E]J6H7=U(T;K?32#SHFCR4VD
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVNZ;PLBY8[0#T/SGOV'K3;K1[C0I_&VOW4T#6NHV@8)'G?'Y4;*.V#D$GVH
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M6\US"BM''(S!=IYW'!(S@'&?K5/4=3">*GFGN&ATS1;)KBZ<$A3(_"@X^]A
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MWG82O:80G*MWC/W>?7%<U9WE@NA>&XOM%L+JW\3E=F]=\41EDXQU53A?;@4
M>H3:O-IYUBYU.V6WTRR19(;D2!C,NS+_ "]B#P/6M."9;B".9,[)%#KGK@C-
M>4^*83=0_$N'=O6*.SD42,6"X3<<9Z=ZL:RUF/%5KI(U6QM-%DTT_8Q=!Y;=
MI-["3!$J#>!C!)..V#0!ZE6-JNNR65]'86.GRZA>M$T[0QR*FR,'&26(')X
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M"0-HVXQ\O3F@#U#-&:\M\-ZC?'Q!HRM>7;PW6CS3DSW;2/.-RE96C^[&3S@
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M(S7F>NW.H#Q1\.KF2U:;4/LLK/"\@4L_EKG)QP>M2_#B4>(?'GB+Q.T@M)G
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MN/,7RV;#'.2,@=:X_P ;C5?#=QX1M$UO4FFO+EDO9%O9<2_/'P!NX W$#&*
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M$=VC27D/GVZC/[V/ .X>O!'YT ,MM$LK36;O585E6YNPOG#SFV,0  =F=N<
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M5RL4R3QM&Y5DD7HP/YUI57NK^TL?+^UW,4'F,53S'"[B 20,]> 3^% '/2^
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M.]W?9+J"?9][RI V/KBK% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %&**:V_>,8V]Z '4444 %%%% #$1D15W%B.I-/HHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ANGN([9VM84FF'W8WDV \]VP<
M?E7&_#SPUK7A#2;K3;Y;2X$DKW*SQ3MDN0HV$%?]D_-G\*ZC5=9M-'C@-P7:
M6XE$,$,8R\KGLH_4]@*;IFM6VJ374$4=Q%/:E1-%/$492PR.O!''4$B@#BO#
M?A+Q%H_CS5_$=S#8/'J,<N(8[ELQDL&4$E.?N@$^^>V*3PIX:\3^&M1\0WCV
M.GSG5I_.51>LOE\N<$^6<_?_ $KTBJ>IWZ:7IT][)#/,D*[C' F]VYQP.] '
MG/A3P=XD\,Z$EI_9^FW%];SRSVMP;YU5&D38<KY?/'O^57=0\,>)KO6/"UY(
MEI<_V,A\^66Z(>Y=U4,<;..0?7\*]$I: //M(\*:]X1\4:A-H8M+C0;T^;]B
MFG,1AD/]S"D =OICTI'\$WNH^"M2M-53S-:O&ED=DOY?(:1CE&*_= 7Y0!M/
M"#FNOUG7;+0HX)+[S@D\JPHT<3.-[< ' XS[U$OB33F\1_V 6F74?*\X1M"P
M4ICJ&Q@CMUZ\4 <-J7A#Q7JOPUMO#%PEB;N!T N3=,59%)QD;,YQ@5Z5$\YM
M%>6 +/M^:-7R,^@-16VI6]W?7EG$)#+:,JRDH0H+#< &Z$X(.!TR,]:N4 >6
M^'?!?B#2-1UBYO;"QNX[Z^COHHUOF3R9$=G'/EG/+#TZ5>\0^"-:\4^ _L&H
MWD']LB\>[0[V:)<LV(P<9VA6 ''&*[6_U>TTVZL;>Z:17O9?)A(C9E+XS@D#
M R >OH?2KXH Y8:9JNM:IH]WJMI!91Z:6FV13^:TDQ4H!T "X)/J>.E9/C_P
MKJ_B;5]#N-/BA$>ESF9S-+M\W)0X7 /]P]<=:[^JVH7]KI=C+>WLHBMXAEW(
M)QS@<#D\D4 <QX_T+4O%?A Z98Q117$SH[>?)@1X()&0#D]N*RM8\#7^M>%M
M 2,0VFN:&(A"\C;HY-@ (R.@)4$<9XZ5U">+M(=Y(]UX)8HUEDB-A/O1&S@D
M;,X.#^56])UVPUOSC82/(L.S<S1L@(=0ZD9 )!!!S0!36Z\17C6<8TV&P&Y&
MNYI)UDP <LD:KUSTW'& <XS6'JVBZIK&D:CI6K:)%J*R7%P]C<?:5S"&9BA;
M=@KC( V[N!C Q@]U10!P&G-KWAO7_"GAM6@GTTZ>8YRN-_F(IW-ZA1\@'KFN
M_IOEIYADVKO(P6QSCTS3J /.[31=>B^*=YXGETDBRFM1;(BW$9D'W/F(SC^$
M\ FKVC>#Q=>!I?#VO6F \TTF5=3MW2,RLI!.",C_ .O7;4F* /.'^'-S>?#*
MU\.SW"QZC87$LUM<'E2WFN5)QGAE8>XS[8KI(;OQ1+I$5N^FPP:IM5)+IY5:
MW!Z%P =QXR=I [#/>N@,L8F$)D02LI8)N^8@8!./3D?F*KZ=J5MJMJ;FT<O$
M)'B)*E?F1BK<'W!H J6DFN'Q+?QW4%NNC+%']EE4_O'?'SY&>G7T[=:U)D\V
M"2/.-ZE<^F13Z* ..^&,<MGX,ATJY0QWFG32V\\9ZJ=Y8'Z%6!'L:[ D+R2!
MSCFJLMO8VUU)JDHCBE6'9).S;1Y8.?F[8'/)Z9/K67<W?AWQ39G3+ETN;:X*
ME5</&LV/F&QN-^,9^4GI0!S%OI>M-\6V\2/HMU'ILEJ+4.TD6X'(&XJ'SM_7
M':GZYH&L1?$*;6;?2GU;3;S3C:S0K=+$4(_A(+#*G SUZGCI6K_PK#P9_P!
M2/\ [_2?_%4?\*P\&?\ 0$C_ ._TG_Q5 &%_PC>KV?C7P]=1:5FRT_3&M9&M
MY!L61E?"KO;<1R!D^M9%AX8\2Z;X*T'2VT'?=P:DTDSK)"TL$9.=\3%MJMCN
M>A'T-=I_PK#P9_T!(_\ O])_\549^%7@PR%_['[@X^T2XX_X%0!Q^G>$/$4'
MA#QGILFES-=:A=9MMUPC>8,YW%V89^IY.?KC8T?0-9M?'GAV^N-,ECM;;0H[
M&:3?&P25020<,>.0,UJ7GP]\"6%E/>76DQ16\"%Y7,TN%4#)/#5+%\-?!,\2
M2Q:-$\;J&5A/)@@\@_>H K_#31M2\/Z?J6GZCIY@8WTLPGWJ5E!VA<8.>@/7
M'^';2R)#$TDC!40%F8G  '4UCZ+X0T+P[<R7&DV MI9$V.1([9&<]"2.U7]2
MTRUU:U^RWJ&2#<&9 Y4-@YPV#R/4'@]Z /-+&_UOPE\-_P"U]*M(;IKO4I+E
MH[ASCR)&.TH-P.6PF ,_>Z9S7J]02V=M,8#+!&_V=P\.Y0?+8 @$>AP2/QJG
M+XBT:"=X9=4M%D1MC@RCY&SC!/8^QH YGQAI^K7^LS16^G7$]F^E21QRVKI&
MYG)8;'<L&V8P=O0GJ#BNC\+B9/"VE1W%M+;31VL<;Q3 !@54#G!/I]?7%:4%
MQ#=6Z3V\J2PR#<DB,&5AZ@BI* .7\=0W=UHMO;V=E<74IO()2L(!VJDBNQ.2
M.PXJOKL.H^+$BT9-+N+33'E22[N[EE0E497"QJ"222.IP![UV%% 'F<V@7T&
MK:[8S>&AJB:A=M=6EW)*/(0N!Q(I8$!2N> 2?RK3U2&_?5O%,MOICW1;3+>*
M)9[;=%.Z&0LH#<-PXXKN:* //?#NESR>+=7>[L=4-CJ&G0Q>=?J,O]X," <+
MU^[@?3%9@\*^((=-M;Q#+_:.AW2V>FDC?YEL'9#(5XZHXX](AZUZK10!Y[K&
MCRVFKVEA#IUW+80Z.T N;2$-/*^X#RFD/W01ECR,DGGFF:!I=TVN>&9+O3)U
MA@\/&SF\Z'A)04!4YZ9 ;Z@^]=_<W5O96[7%W<100K]Z25PJCZD\57L]:TK4
M7=+'4[*Z=!N98)U<J/4X/ H \_MM%N+>XU;3+[0]0O9Y-0:ZM)S-)]D?>VY6
M<!PH*'J,9..*].JF-7TTMM&H6A8G&/.7.?SJV655+,0 !DD]J .!O ^D>*==
MBO\ 1;O4[77(XS 8(]ZML3:87[(.X)XY-6(;NYT37-0EUFQED.IVD#1FT@>9
M?,1-KP\9P-QRN>#N//6NOAO[.Y($%U!+DX^20-SC../8&K% 'F.@Z?/8>*/#
M>FZA#-(\.B2V\^Z)GC5F(81E\%3A01UQQ[@5!=3V9U;Q_I;6DT]U>F*&".*V
M9PS& !1N PN&P>2,=:]2>6./;O=5W':NXXR?0>]9.E:78Z=J-_?PWSS2ZI*'
M?>Z$%D7;A-H'0#WZ4 <MHD-SX6U;4(=<BFN(;NPM$BEBC>=9&BB$<B8 )!+$
MD9Z[OK5/2=(>T\2^%M.U*R9_)T>:&17B,L<;,00C-@KG:&'7M[BO1S>VHF:$
MW,/FH,LF\;E^H_$4S^T[#SC#]MMO-!(*>:N01UXS0!Y1>F9M4B9+"]@6U\3B
M>:VMK%_+,8<CSRV"SLPQ]TX _A[UMW#/';_$&S-I=>;<K)+"!;N0X-LJC!Q@
MDMQ@<UWD6IV$S%8KVVD(!8A95. .IZTC:KIRJK-?VH5QE29EP1G''/K0!PVC
M>;I>L:)J%[#<-8S:%%:H_E,1;RH 64J.1N ZXZKBH]/TVWM!HD>H6#O%/K=U
M=VD;6Q86T+B3RPPP=GS,AP<8)YQBO1(YX9HA+%+&\9Z,K C\Z42QDX#J3]:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4M);IFE2(1Q#GYF W'T SD_2N5OO&EU?:!J3:7%%#?6FHQ:?(QEWIEY$7<C
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M'3UKHO!DRGP/HV0ZF&QABD5T*E61 &&",\$&@#)T[7?$&I2>(E6[TJ :5<O
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M;IG><XZG<#6#HNF0MJ?A+3->A62X.DW4;PRID[&93'&^1U";N.H(- 'JP(8
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M2K#;PH7DD<X"@=36;:^)]*N[ZWLDEFCN;E#)!'/;21&10,DC<HS@4 ;%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 (  <@"EHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *:3\P%.HH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** .'^+W_),=5^L/\ Z.2N6,L^J_$#PSIGBA(K
M."SMEN=.:W<E;J;Y",L>GW?N^HZG(KTW7/#NE^)+-;35K=KBW5MXC$SH"?4[
M2,_C5>^\(:)J5E9VE[:23163[[<O<2[XS[/NW?AGL/04 >;^+%OW^-42Z88Q
M>G2)/*\Q21GRY?3O5WQOY4/PLU&TLXR+_P FRFU)<'<-VU06ST/[L9'H.>M=
MLW@G0GU1-4:"[-^B;%N3?W'F!>> V_..3^=7;/P]I=BMZL5L7%ZP:Y\^5YO-
M(&!G>3VXH @\-)9KX,TI(2C6?V&, G !78,D_KFO/_%D%K:_$KP#!8A!:1J$
M@"-N78" N#W&,5WD?@O0(K8VL=FZVA;<;9;F40D_]<]VW]*DOO"6BZEJMMJ=
MU:R/=VN/(D%S*HBQ_= 8 ?E0!Q7QFM;:W\%64*CRHGU97<J,\N)&9OS)-=]J
M+V>DQ7NMO"6F2V"N4Y:14+%4 ]<L0/4M576/"6E:\T']II/<1VY#11&X=55@
M,!N"#GWS5J\T2VOK*.UN);IHXW$BD7#*VX'<I)!R<$ C/H* /(O#NMSZ#\2[
M2>\74(HM?@5;PW=N\2_:B2<)O RJDJH] U:_BG_DOOA;_KS'\YJ[S6_"6D>(
MI+5]5BEN!:\Q+Y[H%;^]\I!S[U7OO ^D:AKD&LS->?;[=0D,JW+@H!G@<^YZ
M^IH A\:W&GW^EW7AR>Z>"YO8D".%R$+R!$)]M^/PS7+:%J/B33?&.C:#XQMH
MKF3]Z=.U*%LER$(;<>XV^H!S@G-=?<>"-(O#<M=M>7#7)B\UI+EBQ$;;E .<
MJ,^F*N1^&[ :I;ZC,UQ=75J&%N]Q,S^5N&&*CIDCC/6@"MX7&N!]5&M7UK=
M7CBV$!&8X^RM@#!]CDUT-8^A^&=.\/27[V"R*;ZX-Q-O?=\Q]/:MB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHI"><4 +1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %(1SFEHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-W;74M];1M.TP,0"[XV9N=LFPMC^$D8Z5VUE=1WUC;W<6?+GB65,]<,,C^=
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M6?=ZYI5BY2[U&U@81>>1)*!B/(&[Z9(&:IZ7XKTK5Y=0%M>6[163;6E\Y<,
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M:1R+#/")U4KEMI&1P,Y..PIND:M#K-F]U;I(L0FDA&\8+%'*$X[<@]: ,/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-)%NY(UC;$K!"%! .S.W.#C.*U* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** ."\300R?%3P<KQ(RR+=LX*_>*Q@J3ZX(XKJ?$.MQ
M>'M%FU&6)YMA5$B3J[LP51[<D5BZ]H&M7_B_2=:L9+!$TQ95C2=GS)YB[3G
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M>?;L^-^%VE6Z'&2,$].U "ZCX_@TZ#4;AM(OW@TZ\%M=2+LQ&"%._&[)!W#
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M:06E^LDEVA>#",!)@9(#8QD#J,Y'I6-XI\41Q?8(=,OYEE.K6]K*8X"8WS(
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M[+'B($*#NXSC&1S7/>&+&>.?P-]JL+V-["QNDE+VS@12-M"ACC R%?'X>HR
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M7<,CNR/[UTM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% %>:\CBF, #27'E-*L2#E@N <9P,Y(')'6L_PQKT?B;P[:ZQ% T$=P7VQ
MNP) 5V7G'^[G\:R/LL;_ !8F=A)_R!XY,"1@I;SF&<9P?NK^5<;X2:XL]#\!
M:I!<RH+BYEL)[<2MY;H3)@[.F04R3UR1^ ![#3)94AB>61@L:*69CT '4UY7
M::AJ-[]IUF77(+>>UU5HYD+2-(L:R;!"(A\N&!'8\G.<\CN/&UG%>^"M8CF,
MFU+.60>7(R<JA(SM(R,]CP>] &U;W$=U;17$+;HI4#HV",J1D<'D5+7G$T4T
M_B33?#:W<MO8BP6Z3S;^<23.6PQ5PVXE0!A2<<]..$M(KO4]8\,VMQKU[,JV
MM['<36TC1+<F)T0-US_$?G!R<<&@#TBBO.;6\N+G3-,TN2]U&XN?[2O(8T2X
M>-YXX7=1YDRD,H7*DGDD@#!K/AU359O".C>9J5TDZ>)5LGECG)9X_.9=K,>7
M&..1S@9% 'IUY>V^GVDEU=2"."/&YR"<9..WN:L5Y/XDMFETW4-,N+B^GMK?
MQ%:PQ/+=.QV2)$S)G=DX+$C/3(QTX]2@MH[:U6W1I2BC:#)*SO\ BS$L?J30
M!-17EUC>WRZ%8'^T;YGC\5?9=[W+LS1>:5V,2<LN.QS5G6)+^5/'DHU?4(CI
MNR:U6*<H(R+=9,<=LY!'0Y.>>: /0;VZ6RLI[ID=UAC:0J@&X@#/&2!FJ^C:
MFFM:+9:G%&T<=U"LJHW501G!KD]<CDUO5O$%I/J-Y;06.EH\,5M<-#EG#EG;
M;C=]P#!R.O'-8FBRWE];^%M$CO&@@;01<*B7;VQDER%^\GS-@9.T?4T >K45
MY7'-JNH>)-!T:X\07;&2QO+>XN+.1X@\D;L@<#NPQU]1Q7HFHF6TT&X$5_%;
MS1P%4N[K!56Q@,W;KS0!H45Y+>7-[::%XEMY[C6K#5+738IO+EOY)1N5F_>Q
M2[ONMP"..F,>G2:SJ-WHVIWU];S7$I709;H6[RLT?F(5P0O0'GG'6@#K[RZ6
MRLI[J179(4,C!!DD 9.*ATC4H]8T:RU*)&2.ZA694;J PR :XU4:UTF"Y.O7
M-P-3TF5I(+AVF\Z3R]^]#TC !8' "GY1UQ5#P]-/ILG@%H[ZZ9-2L3!+;/,?
M*"K &!5.F01UZ_,?; !V7B0:-8:=<:UJ>E1W@M(][$6RRR!0>V>PZ]>.36O;
ME6MHF2,QJ4!"%=I48Z8[5C>-?^1%U_\ [!\__H!K#U"XU76/$^K:3::@;$V%
ME&]MMG\O<[ACYC *=RJ0HP>.O7(H [JBO+-9U[7);6>YL-6^T2V6C)=L;,A8
MDDY+22;E&X,%.U<'OP.#5SQCJNJ6:27DEU>P:?\ 8H]ES8N#]EG8G+31CYF4
M_+CJ.#ZT >CT5YW+J.M:VNO7%CJL5G-I=T$@WS[8A&JH^^1 IW!P6Y)^F,&N
MSU.VEU;1)8[2[FM9IHMT4T+[2K8R#G'3- &C17DUCXIO(IO#=]>:A=QP62FU
MUP22@QK*3(B%_0[T)/H"E;$5SK-_J&F:/->W=F;^"?4I2)E255,@V0JQ4XVJ
MPR!SQUQF@#T&BO.KJYUV74/#VB#Q#LFN([VWNI;>,'YXEPK[B =XW+D=,YZ8
M%2^;KVIOK,MOK#6MUHTX@C28B.&0+&C-)*H4DA\MCD #&.YH [^LY-=T]Y=0
M19CML,"XEVG8K8)*[NY Z@=,BF:IJ$EMX4O=2C*^;%8R3J4/&X(6&,U7\&VX
MMO!FCKG<SVD<KN>K.RAF8^I)))- $Z^(M-DT ZY#*\VGC),L<;-\H;:S8QG:
M,$D^@)K3BE2:))8G5XW4,K*<A@>A!KE_AXJOX!T]64,I\X$$9!'FO47PZGD?
M1=1M&W^58:I<VD&[_GFK?*![#./PH ["DKSOQ?XDUO2;K5Y[*\9XK-K8)##'
M&T<0=@&\\L-VXDG"H>!M) !YL:UK6KV/B<VEQ?W-C;W%W EA*L,;VSK\N^.1
MMK.LC?.!T'W?>@#O*HZ;J]KJKWJ6XE#6=RUM*)$*_.N#QZCD<UR::WJB>+[;
M3[^_GLGEO)?*BDBC-M=P -M6-PI82#Y"0S#G</05"?$^K0^$O%%])=AIK#5I
M+2*7R0?*A#QJ3M Y(#,W.?RXH ]!I*X=M0UEHO$\MMK$DEK8VRO97#01,'?R
MR[9(4 XP![;N<FG+J^L:5>+<WVH&]@DT.>_:V6!$5)(O*^X0-V"'/!)Y_( '
M;UG7VMZ?IVHV-A<SE+F^8I;IL)WD#)Y P,>]<G!KNOV.AV>OW4T=U9R:=+=W
M,3-&N'\KS$$6T D<,""2<<\XK.OH]3O?%'@"\O+T3/<M+.T(C54B/DAR%/4@
M#CG)XH ] U;5K+0],FU'4)3%:P@%W"%L9.!P 3UJW'(LL:2(<JX# ^QKD?BG
M_P DTUK_ *YI_P"C%JN)?$T.IV^F1:E;F*]TYIK67[. 898RF5(YRA# 'OR<
M$$4 =S4%W=V]A:2W=U,D-O"I>21S@*!W-<?X;\0:KK-OHMK)*5U"-YFU;<BC
M:(RT93 '!+E2,8X4_0[7B[3UU7P]-8?;$M)YG06TK]!,&#(,=_F4<4 36GB7
M2+V[:TM[LO<K!]H,/E.'$?'S8(SCYACUSQ3++Q9H.HRQQ6FJV\CRL4C&[&]A
MU4$]3STZU@Z'JMP_BZWLO$FG"T\0)9RQPW$#!H+N$LC,0?O @K]T],D]ZPM)
MT6_\0^"H;"T"0JFN2SR7#O@JJ3L3M YW>G2@#T.PU[2]3O9[.SO8I;F 9EB!
MPR#U(-37NJ6&G/"EY=PP/.VV%'<!I&]%'4GD=*\^U.9]&\=7?B&*-1%%J,-C
M?,,Y,,L$."?7:X!_X$:BNR-;\?>'-8=R]K+J,\5EAN/*BB.6'^](&.>X"T >
MF3VL%SY?GPI+Y;AT#C(5AT/U%35F^(+ZXTW0+V\M!;FXAB+)]ID"1@^K'L*Y
M:#Q%J[:+XCDANTGDT^U6YMI[BS:(N"C,<ID<?+P<#Z&@#NZI7>K6%C>V=G<W
M*1W%ZY2WC/60@9./H/Z5SEKX@U>UU-DU3[,T#:0VHB.%"&B*E04+9(;[W7 Y
MK.%QK%]K7@?4+^:U,5U)+*T,*8\IFMG*@-N.X8)!/KB@#T"EK)\2ZA<Z5X=O
M;VS:V6XB3*&Y;$8.0.<<_@.2>*Y9/&&LRZ7XA-K:&ZN=-FA2%A:.CO'(%8L8
M2=V5!)QQG':@#OZ*X)_&5VN@?VG#=V]Y8_;A$]];6S,8(/+!+219W!@_RD>F
M#CFK$'B?4C)X;9I]/N(M3NYK>1[?YD9%WE'4AC@D*,CG!)':@#M:*X-_%VKI
M!;C;9LQ\1C2)'\MAF/.-P&[AOQQ4.I^,M?L+/Q+,L>FO_8DRJ6,3CSE94*C&
M_P"4C<<G)[<4 >A4UV5$9W8*JC)). !7&W_BK4[G57L-'MAOBL8[IV: RY>3
M.Q,!EP..6Y^E/M?$^J:IJUCHT-O%8:B;#[;>BX0R"([M@0 ,,Y;)SGI[G@ Z
M?3]1LM5M!=V%S'<V[,RK+$V5)!(.#WY!H@U&RN;ZXLH+J*6YM@IGB1@6CW9Q
MN],X-<O\+A(/ \(FV^:+JYW[/N[O.?./:L2*36XOB-XYDT**RDN4BLVV71;#
MXAX48(Y/J3@?R /3:*XBP\9WEQJ^@&YBMHM)UJR,L,FUM\<X4,8RV<8QG!P,
MUO\ AN]U#4M+-]?B)1/*[VRQQE"(,X0L"3R0-W_ @.U %ZZU*PLI$CNKVW@>
M3[BRRJI;KT!//0_E3&U?3%6(G4+4"7_5DS+\_...>>>/K7'ZS'J>B>+=0URW
MT]=9TJZMTAOH(V4SVVP'[JG[RD-DKU.<U7O].TR?X8:?J&A,UU%I!74+%V'S
M'RV+,I&/3<,>HH U[#2_#<EY<Z19:T\H5Y&FTR*_R$RWS@J#N4;CTSCG'M6Q
M;^(= +M:6^KZ<7@&UHDN$RF.,$9XQTKS_P#X22V@^)\6MPHL6E7=G]CN9F'6
M58_/!)[84JO7U]*=XKTR6+X13,\0-_J-W%=SKP/WLLJG;Z<9"_A0!Z5_:-C]
ME>Z^V6_V>/[\OFC:OU.<"F0:QI=U)Y=OJ-I*^[9M2=6.[TP#UKG[31[L_$)]
M8CT\6-@-.%N^63,\A?</E0G[H'4^O%>=6""X^#")'X?DDV/(3J64/V?$Q+2@
M ^9\H]!V/:@#VVXN(+6!Y[F:.&%!EI)&"JH]R:@L=5T[4U#6%_:W2D;@8)E?
MC.,\'UKD;.2#7O&UG;7#?;+&QTF&\M6E0$32.Q'G8/)X48ST.:ZA=$LXM=35
MHHUCN%MGMB$4 ,I96Y]P5_4T :5%<[XCUG4],U#2+;3[>UE^WW#0$SNPVG8S
M \#I\OO_ %K%?QKJ=LRV-U;6JZE;ZQ;6%T$#&-HIN5D3G()'8YQCWH [RBN#
MU/QQJ-B?&,<=I:R2:"L#Q,Q8"02 M\PYY XX//M5F_\ %.K:5)9?VHNGV-K=
MSN%NW#O''&$5E#X("L6+#)( VYYH [.J.KZ5;:WI<VGW?F"&7:=T;E65E8,K
M ^H8 _AWK%L];UF?Q!8:?-%8I'=:8]VVS<QCD5D4@'.&7+CT^M9@\7ZW)X=T
MN]%K80SSR7$=S)*S&)&B=E"(H.YF<J< 9Z'K0!U$&BHE]'>7-[=7LT.?)-P5
M"Q9&"0J*HR1D9()Y(S@UIUPECXXU+5(?"[6MA:H=:2XSYLK?NWB1SC '0E1S
MR<9&.]5]0\2ZW>^'M,FA%G#<G6X["ZQOVEDN-OR]PIVC.><$CWH ]#HJJ?MW
M]G\?9_MNSON\O=_/%<-X3\3:M+X<T87'V>>_U>YG\@DL H5Y&D+^P PH'L*
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M+?F/RVA;=<E=RM"00"IR.X[4 : \/:4NH6]^ME&MS;1^7 X)'E+SPHS@=3G
MY[U;OK&VU*QFLKR(2VTZ%)(ST8'MQ6?>>*=%T^6:.ZOEC\F18I7*,4C=AD*S
M ;02.Q/<>HI+KQ9H5FTZS:C&'MT5Y456=D5AD$@ G&!U[=Z 'VOAK2+2WN((
M[,/'<1^5+YTC2EDQC;ER3MY/'2DLO#&CZ=<13VUBJS11-"DC,SL$)R5)8DD9
M/>I+KQ#I-G+Y4U]&)/(^T!%RS&/(&X 9)ZBH[7Q1H=[<VMO:ZE!/)=*6A$9W
M!L G&1P#@$X//!]* (;;P=H-G!=06VG+%'=*R2JDCCY6.2J\_*#Z+@4^+PGH
ML+Z8\=HP;2P5LSY\A\D'J!\W([<YXXZ5/)X@TJ*^%G)>QK,91  0=OF$ A-V
M,;B"/ESFJTWC+P[!<O;RZO;)+'/]F<$GY9/0GH/KTSQG- &AJ6F6FL:?+87T
M1EMI1B1 [+N'H2I!Q5"^\(Z%J36S7E@)GMH_*C=I'W;/[K'.6'LV?UJ&T\6V
M=YXQN_#T0)DMH5=I"",N2<J!CL #G/>M+4]:T_1HT>_N/*$A(4!&=FQR2%4$
MX'<]!0!2N_"&AWTUQ+/8*6N8!;RA9&56C P!M!QP#P<9':EF\):-<6[036LC
MQ-"D#H;B3#HARH8;OFP>YYJ:;Q-HENMHTNJ6J+=QF6 F0?O$ SN'MCO^'6I_
M[8TXZ;'J(O(39R8V2ALAB3@ >ISQCK0!2N_".@WVH_;[C38WN2JJS!F4.JD%
M0R@X8# X(/05M#BN5\':[<ZY?>(/,O([FVMK[RK9HXPH5-@./4G)Y)[^G2K?
MC+6Y]$\.SRV*-)J4P,-G&JABTI!(.#UP 6/TH N3>'M,GL[NT>V'D7=P+F90
MQ^:0%6S^:+2:UX=TW7U@%_"[/;OOAEBE:.2-NY5E((I-$UVUU?PS::V)%BMY
MH/-=G8 1X'S9/08(.?I4O_"0:-]FN+@:K9-#;A3,ZSJPCW?=S@\9[>O:@"O'
MX6TF&[TZYA@>)].5UM@DK!4#_?R,\D]R<YIE]X0T74=7_M2XM&-T5"2%)719
ME'02*" X]B#5N/7](FDACBU*UD::4PQ[) 0T@&2F1QN _AZTK:[I2)=N^HVR
MK9N([AC( (W/12?7GI0!<EA2>"2&10T;J49?4$8(K%\.:=>:5I1T2Z+O%:+Y
M=O=@@>9$<[1UR&48!XQT(Z\6)/%/A^*.:1];T_;#CS,7*'9G@9 /'0_E5BYU
MK2[+R/M6HVD(N%+Q&295#J!N)!)Y&.<T 5(].;P]X>>ST*U:9XPWV>&67(#,
M<_,S'.W)R>_7%.\-Z-_86CI:LXDN'=I[F4=))G.YR/;)X]L54U7QKHNFVMA,
ME]:W"WUPL$#).-A^8!VWC( 4$D_EWJY:7;W6NW'E:I9SV:V\;+;18,B,Q)#E
M@?NL!QQV_, J:AX+T74CJ!FBG7^T&1[@1SNH=EQM; .,C [58?PQITKN91<2
M*\\=PR/<.5,B!0K8S_LK]<<U<M=8TR]D>.TU&TN)$&YEBF5BH]2 :9;:]I%Y
M+!%;:I9RRSJ6BC2=2T@!()49R0"#^1H KKX9TU;F"=DFD,%S)=1)),S(DKDD
ML%)Q_$<>F>,5B>(/"Z0:)>0:;9W5Q%?WR76H117!\Q@&WLT>X@!B57H1782R
MQP1-++(L<:#+.YP /4FJ=OK>DW<4TMMJ=E-'  97CG5A&#TW$'C.#UH YS3?
M#[S7$L876(-*N;1XYX;^^,C.S;<;1N9EP-P/(Z].];B^';)+^WO UQYMO;_9
M5#3%E,1QE2IX.<+D]3@<UE>%]7U?7EM=4^UZ9)ILZR,\$()DA^8[!NR03@<\
M#G.*FTO6-4OO&>L:7)]E6RTT1?,L;;Y#(NY>2V!C!SZ^U $MAX,T;34,4$4S
M6P1TCMY9VDCB#\/L!/RY!Q],XQDYKV/@73[&]T^Y6]U.7^SBQM(I;G<D*E=N
MT#&<8XY)KH+N^M-/A\Z\NH;:+.-\T@1<^F345QJ^FVEM%<W.H6D-O+_JY9)E
M57[\$G!H ;K&D6FNZ3<:9?HSVUPNUPK%3UR,$>X%9S:4FAQR:K%#?:O?PVZV
M\:LZ>88\C*J/E4>I.,G%:\VH65O;I<37=O'!)C9(\BA6R,C!)P>*274K&"**
M6:]MXXY1F-WE4!_H2>: ,SPWI;6KZCJEQ:BWO-4G$\D6X$QJ%"HI(XS@9..[
M'DU=U?28M9LUMI9YX565)0\#A7#*<C!P<<@5H=:JKJ=@_G;+VV;R 3-B53Y>
M.N[GCH>M %&/P[ -4&ISW5S<WT<1BAGEV9A4G)"A5 Y]2":DT+0K;P_9/:6D
MD[Q/*TO[YPQ#,<M@X'4\UR+>/[A=,E\0QS:7-I"M,#:B7%PH7<(R#G!+LO3
MP#GG!KHM*UBX;?+J-]I3V<@7R+B"7;ES]Z,@DCCC!SD^E $DGA>VGMM7@N+J
MZG354VW&_8,'9LRN%&#M"CN/E'OF.[\)6EU>:/.EW=VR:20;6& H$'&WG*DG
M(XZUM375O;1AYYXXD) #.X4$GIUJJ^LV2:VFD&9?M;0&<IN'RJ&51GW);CZ&
M@ US1[?7]'GTR[>5(9MN6B8!@58,""01U ZBLFZ\(&X2^ UJ_5KZU6UG9EB;
M>!D;B-@^;:Q'&![9K3TN]NI8)?[2-I%-]IECC6&7<"@8A<_[6,9'\N@T/.B\
MQH_,3S%&YEW#('J1Z4 8@\,HVIVU[+>S2&*R-C)$439-&?O9XR"2%/![8[U5
MTWP3;Z;<:4ZZKJ<\6EEC:P3R(R(&0ICA 2 &XR3BNC@N(+F/S+>:.5.FZ-@P
M_,4DEY;0SQP2W$232?<C9P&;Z#O0!0\1:%!XBTHV,\LL.)$ECEBQN1U(((SD
M'IWK-C\%PQSWTZZOJ0FO)8)I)=T>[S(L8;[F.0 ",8]JZ)[F".987FC65QE4
M+ ,1TX'XU)F@#F[?P@EI+-<VVI7,-[/=&ZEEC2,*[;=FTIMQMQ^.><U%%X%L
M;:PL+>UNKF"6RNVNXYTV%M[Y#_*5*@$$X&..*Z2.\MIK?SXKB)X>GF*X*^G7
MI6'X<U^^U^SL=0^Q0I9743N2LN7B(8; P[[ER>.E $;>";-P-U]>\:K_ &L
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M)$>"CJ"OY4BV\"V_V=88Q#C;Y84;<>F.E 'ENHC3O^$2UL6.J)-9O>6;)/;
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M **** "BBB@ HHHH **** "BBB@ HHHH XB\EO--\<ZSJLUX)+2RT=)Q;B$
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M=Z@EVU[<_:/E@\K8=JKC[QSPJU')H=W;:I=W^CWT5M)>E6N8KFW,T;,H"AE
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M)0,!=@;*KC:.I/'O0!'!X[N8Y-1L-0TH)JUG=00>1#-OC<3<HV_&>F<\$\<
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M_P"$AF"G>FL75NA+$[(D;Y47/11GH*U-;\3IHUS+$UE-,L%HUY-*&546,$C
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MB!':+"\KY3$?.AZN,\9&.H!V-]XUMK&?4X6TS4I)--A2XN L:#]VP8[@2P!
MVG..?3.#B;4_%UEIY"0V]Q?2_9Q=/%;; R1'HQWLO7!P!D^U9)TS5+N;Q#JU
MM;I)'K6F0):Q-+M9&","&R./]9GC/0TQ-&UW3M3MM7L]*M+J2:PBM+NTGN0A
MC>,G:ZOM8$8)R,>GO0!N-XGL;FSMGL5N;TW=L;B-;1076/\ O') '/ '4D'
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MS)Y8'''RH%''7;GO5:'0M7OK#PW87]K% -'FBGEG24.)3$I50G0C<<$Y P*
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M4 >@T5BZ9J4NJZQ=RVTP;2X(HT7"_P"LE8;R0<= K)^)/I6U0 4444 %%%%
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MPQ31MM)ED*(J")<]QMZ]<T =:RA@58 @C!![U%;V=M91,EI;0P*>=L2! 3^
MKB?&VJ&_\%Z_;R6UU9W5DD3%2^ 0Y&"&4X88W CV^E='IOB2VU'6[O2/LMW;
M7=M&)2MPBJ)(R2 RX)XR.^#0!5\,>&CHTNI7-VMI+=WE]-="6./YD60@[-QY
MXYKH&AC:02-&A<=&*C(_&EFWF%_+($FT[<^O:O,O"\T%[)96SZA?V'B:&X5M
M0MKZY<&[ ;+E5/!4XR-H& ,=.H!Z3%9VL$C216T,;MD,R( 3DY.3]231]EMP
MR,((@8R2AV#Y2>N/2N(D']C_ !/EM[B^O!8ZQ82/$&NGVPRH<OM!.%^49XZ<
M]JR=#U^[N_AK/;RWER-?FO/L2O*[>:)9&'EOUR $PW&!A3P><@'I)TRP9&0V
M-L59R[ Q+@L1@D\=2.":0Z7I[(Z-8VQ23[ZF%<-SGGCGGFN,\7Z?=^'?!6KW
M]IK&H"6W2/[(!.X$*C8F#DG>3\Q)/][VJ+Q'J&I>%]#L]3L-2EDFU!8;-(;M
MFE59G(/F D\84-QTZ>G(!L:EX6NGUAKVP31Y(WACA\K4+,R>2J9P(]K  '<2
M1CKW]-O1-)BT33$LH2I4.\AV($4%F+$*HZ#)X%8'B6ROM$\-76KZ9J5S_:%E
M%]HD:XE9X[A4Y=60Y"Y&<;0N#CG%0V.N2>+O$3:?%)+:Z=;6,%U,L3E))7F7
M<JEAR%"]=IR3CGM0!UDNG6-Q.L\UG;R3+TD>)2P_$C-27%I;7<7E7-O%-'G.
MR1 P_(UEZ=I-WIVM2LE]-+I;6X6.WFD+F.3<23N8DD$>IXQ6C?WUOIFGW%]=
M/LM[>-I9& SA0,GB@!)=-L)F@:6RMI&@&(2T2DQ\@_+QQRH/'H/2H#H.CGS,
MZ58GS6WR?Z.GSMSR>.3\S?F?6LS_ (3;3H[*^NKFVOK9;*WCN9$DB!8Q29VL
M-I((^4_3'.*FT[Q;INHW:6RK<V[R6@O$-S%Y8>+C)!/7&>?\.: ,U_!JW7CN
M;6+ZTT^YTTV*VL,$J;VC*G.0I7 '4<&NCFTC3+F6&6?3K262!=D3R0JQC7T4
MD<#Z5QUYXB_M7QGX/^R1WT5G<2W,BO(NV*X40MM88/X@, <$'%=]0!GQZ)I,
M+1-%I=DC0ILB*VZ@HO/"\<#YFX'J?6LG4_#<[6@TO0AIVE:7<K(M\L5MM<[E
M"Y0+@!L9Y/MUQBLJ_36=.UKPOI\VO7<CW\DR7;1K&JDK$6^0%>!D>_%;*ZG_
M & XL+^[GU*[GD>2V2.,&7R1@_,!@84DC/&>.] $^M>'8-6T.'1U6&.S4HI#
M1!RB*.-F?NMT ;L,UIWEA9ZC;FWOK2"ZA)R8YXPZG\#Q6"GCS1)H=,E@:YG&
MI([VXBMV8G9G<O'\61C'7\.:L_\ "6::=(L]147#+>3&""#RB)6E!(*;3T(*
MMG/H: +PT>PC:U\JRM(TM@5B46Z_(I!&%_NCGM2C1M+6QDL1IMF+.4YDMQ O
MEN>.JXP>@_(5F?\ ":Z,+33KDO.%U"X-M"IA;<)%)#*P[$$'\N,UG:QXZ2'P
MMJ&I:5974MU;7'V3R9[<J8Y3MP74D$+\PY]Z .E.CZ8;2*T.G6GV:%@\4/D+
ML1AT*KC (]14.O:+!KVG"UED>*2.19H)HS\T4JG*L/7'I5RTN#=6R3&&6$MG
M]W,N&7GN*S=2\3Z;I5Y)9SM,UPD N#''&2=F]4R/7EA] #F@#3M/M/V2+[9Y
M7VG:/,\G.S=WQGG%<UX@TOQ%?:F[V5KX:N+,QA5&I0.\@[D9'&,@'\*T7\5Z
M1'<K$T\@5KG[()O)?RO.SC9OQC.>.O7CK5*[\?Z!8W&H1337'_$O<)<NEL[K
M&3ZD#@<XSTH H6=AXYT^$PV5MX/MHB2VR&*=%R>IP*=#:>/;>2>2&/PG&\[^
M9*RI< NV ,GU. !^%;%YXMTBRNFMGFD>91 66.)FP)6VH<],$U);>*-)NKR*
MVBN&S.[I#(T;+'*R_>".1AC]/0^AH PK2S\>V%JEM:1^$X8$SMC1;@ 9.3CG
MU)K.G\*>)[FY>YFTKP5)<N^]IVAG,A/^]U_#.*ZVV\4:5=W'E1RR!3'+(LSQ
M,L3+&VUR'(VD ^_OTI+3Q7I%[.\,<\JN(#<J)('3S8AU=,CYQ],]1ZT 9%^G
MC2[A>UGT?PW=V[KAEDN)"K?@4JE9Z=XLL)A-:^&_#,<P7:)?M,A<+Z;BF<>W
MO6_9>,M&U":SBMY+AFO(FEMR;=PL@4$D!L8)P"<9S3?"WB7_ (2.*ZE^R7$"
M1W$B1&2!U#(K;<[CP6R#D#IT[4 8NH67B[5?+^W^'?#-P8CNC:2XD+(?53LR
M/PK2\-6>N65[*+_1]'M+>1<M+9S.\CL.FXLHR,9ZGCBKWBK7U\-:&^H-"\K;
MTC151F&68#)QT'/].I%2R^)-)MU8SW)C*(975HGS&F2-SC&57@X)QF@"WJ?V
M[^SY1IHA^V, L;39V*2<;CCK@9..^*Y]/!D$$&@V<!3R-,G^TM<.29GDSN..
MP#$G=[< >G40S17$"302+)%(H9'0Y# ]"#7,^)KC4K;6]"BM-4GMH+ZZ-M-&
MD<3<"-WW LA(.5 ]* -;6- T[7DMUU&*606\@EB\NXDBVN.C?(PY'8]NU1W7
MA?2+V99I[:1I!$('87$BF:,?PR8;]X/9\]3ZFM&ZNK>QM9;JZF2*")2SR.<!
M16=)XGT>*PO+R2\6.&R :X$B,CQ@C(RI ;GMQSVH >/#NEC6H-76W=;V"+R8
MF69PJ1XQM" [<>V.O/6JLG@S0I;:]MWMIS%>SBXN1]LF'F2#H2=^?PZ<#T%:
M%KK&GWMS+;07*M-$@=T(*D*21N&>HR",CN*Y:]\4F[\=^'=-TG45:UN5GDN8
M_*XD14)0JQ'()SR#CY: .DCT#3H]2DU#RI7N9(!;.TMQ(X:,?PE68J?RSDD]
MS5.S\%>'=/MKVWM--6&*]0QSA)7!*GJH.<J#Z+@50\*Z]<'2]9N->U")C9ZK
M/:B8J(UVH0%  ]3T'))/>M?_ (2?1?L%W>MJ$206;!;DOE6B). &4C()SQQS
M0 R?PIH]SH<&BRV\S:?!M\N+[5*,;3E?F#9(!Q@$\8&.E4%T_5-6\06QU+3H
M;73=)G:2U<W/G27+;2B,1C*@!F/))SCZUI3>*=$@$YDU&)3!/]GD7DL),9VA
M<9)QSQ6;X&UFYUNRU:>XO$NUAU2:""5%"J8E"[<8^N?QH Z*\LX+^RFM+E2T
M$R%)%5RI*GJ,@@UE+X1T5)[2>.WGBEM+<6L+Q7<R,(@<["0PW#ZYI_BFYEL_
M#MU/#JT&DNFW%Y/&'2/YAU4]<]/QJS<ZYI=E.T%S?P12J4#*SXVEN%!],]O6
M@"E!X.T.VM["WAM95AT^4S6J?:I<1N223][GJ>N>I]:?-X3T2>XFEDLL^?*)
MIHA*XBED'.YHP=C'/<CG STK:KB[[QM'<KXIL]+ECCN]'MBZ2R+O$CA69@%X
MZ;0,YZGI@<@'57&G6MU>VEW-$K3VA8PL0/EW#!Q^%5VT'3_L&H621&*+4'>2
MX\IBA9G&&.1T)JIX=\06FIZ?I\,E_;RZF]E%/-$K /DHI)VCIR?UJ]::WI=]
M=-:VM_;S3J"QC20$X!P3[C/% &=:^#=)LYM)EA^U#^RD9+13<,50-D'([D@X
MY[8JUJWAO3=:O+.[O8Y3-:$^6T<S)D'!*G:1D' X-:QZ5AV.MVL5G+<7^LV$
MD;WCQ0RHX5<;OEC']Y@.#C/- $*^"=(AM+.VMC=VL=HDL<7V>Y9"$D;<RD@\
MC/3/2M:WTNRM-*73+:W2*S6+REB08 7&/\FFV^LZ9=V\]Q;W]M+#;G$TBR K
M'QGD]N.:YV#Q4+SX@1Z?:W\3Z8-+>YD39M*N'4!BQYP5.1VQSS0!HVW@W2+5
MK4(MTT%HZR6]O)=2/%$Z]&"DXR/?@9K3U'2[358X([N(2+!/'<1_[+H<@_T^
MA-9>D:Y;1:/;RZGKMA<R3SRI'<1NJI+AVPJ^N ,''I5J3Q1H,4=M))K%DB72
M[H&:90)!G&1STSWH MKIMLFKRZF%/VF2!+<GML5F8?JQ_(53_P"$;L?^$E/B
M#?<?;S#Y&[S3M\O.=FWIC//UJ>^US2M-ECCOM1M;=Y &5990I(SC//;/&:IP
M^*M.G\4S:"D\1N(HE9CY@R7.[Y .Y 7)^HH FUSP[9>(%MDO7N MM*)HQ#,8
M\2#HW'<=J6T\.V%K?)?-Y]S=QJ4CFNIFE:,'J%R<+GN0,FM0D $D@ =S6=:^
M(=&OGACMM5LY9)L^4BS+NDP2"5&<D?*>1Z4 5Y?"^G/?37<+75I+<',_V2Y>
M%93_ 'F"D#=_M=?>J]YX<"S:-'I8-I!97)FD*3LNY>K CGS"QZECW)ZUKIJF
MGR79M([ZV:Y#%3"LRE\@9(QG.0",TV'6--N+@V\-];R3!I%*+("<IC>/^ [E
MSZ9% $&K:#:ZS/9SSRW44EHS-&UM.T1(888$KS@CTQ5&W\%Z7:1644$MZD=G
M>/>0I]H+ 2,>>N>,%AC_ &F[G-:@UK2FAEF74K-HX5#2.)U(0'H2<\4G]MZ4
M?. U*T)@C\V51,I*)_>(SP.10!EGP5I;P:I#,]S,NHW'VIR[C=%*.CQD %2.
M,?0>^;&E>%K#2-3FU*&:^FO)HEBEEN+IY-X7H2"<9_#CMC)JQH.MVOB#28=1
MLV_=2@L%)&X#) R.Q.,XJ[<W=O90&>ZGB@B'!>5PH'XF@# U3P+HNK2W[SB[
MC^WA3<)#<NB.PQA]@.W=\HYQ4[>$=/>X=WGO7BDDAEDMY)RZ2/$%",=V6S\B
MY.?FQSFM+^U=/^P"_P#MMN+0\><9 $SG&,^N>,>M(FKZ;):BZ2_M3 7$8D\U
M=N_IMSG[V>,=: *-OX7LK;4+:Z6:Y9;2266VMV<>7$\F0Q'&3PS<$D#/%5%\
M"Z4LT+":^\JWO/ML$ N6$<4F6)V@=B7.16JVOZ,D<DC:O8!(G\N1C<IA'Y^4
MG/!X/'L:ENM6TZR>-+J^MH&D4N@DE"[E R3SV &<T 95QX.TZZTR^L)IKMH+
MZZ^US_O1EI./;@953@=QZ<5;_P"$>LGU2XU"X::XFN+46DJRMF-HA_"4  ZE
MC_P(]N*MG5=.6P%^;^U%FW2X,R^6><?>SCKQ0NJ:>\$,Z7UJT,[!(I!,I61C
MT"G/)]A0!E:3X,TC1]PA%U-%L:*.&ZN7FCA1L;E16) !Q]?>HK/P+I-E=6$\
M<M^PT]V:TB>[<I"",;0,],<8].#D<5J'7]&6T^UG5K 6WF>5YQN4V;\9V[LX
MSCM5DW]F)+:,W< >Y!,"^8,R@#)*C^+@@\4 5=6T2VU=K269YHI[.7SK>:%@
M&C;!&<$$'@G@@UF3PGPY 8=.TB[U2;499&GE+J<R%>#(6(PIP!P, =N@/2U3
MCU73IY9HHM0M9)( 3*B3*3&!U+#/'XT 5_#NC0^'] L],A5 ((P&*# 9SRS8
M]R2:U*XNU\3ZAK>N7,>A7>BS6EK<I$T#R;II8\+YDJLK$  M@?*<X//:NTH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P?%VE7^M
MZ)]@L1;;FFBD9IY60 )(K\85LYVX[=:9XFT2]U:/3KS3IH;?5=.G$\#2Y:-L
MJ5=&QS@@]<9XJY<Z];07\MG%#<74L"J]R+=0_D*WW2PSG)&3A03@=.E59_%^
ME6]II-TQG,.K,B6CK$<,S?=!/\).>^._I0!DZ[X;U_Q!9V@NKBQ2:/48;HQ(
M[^7'''GA25RS'.22 .E1:IX4UZZOO$=S97MM:G4WM?+VRN"4B!5E8A<KN!ZK
MFNAM?$EE=^(;C0ECN8[^W0RNDD>!LS@,&Z$'(QC\<<U!'XOT^:X-O%!>R3":
M2#8MN22R %_P&Y>?>@#FY?!^M1OXK-I;Z7%%K%A';00Q,46(A2A'W>0 Q.<<
M\# K9AT74O\ A)XK]XH%MVT=;&0B4EDD#%N!CD=LY%6;7QEIUXB216]_Y370
MM#(UJP592X3!]/F.,]*G?Q/9?:Y[>UAN[XVQVSO:0F18FQG:2.K>PR1WQ0 G
MA#3K_2/#5GINH"W$EK&L*F!RP95 &22!R3GCM5'QBLMK=Z#K*0231:??9N @
MSLBDC:-GP.<+N!/MFMK^V]-&D'56O(EL0NXS,< =L'N#GC'7/%4I?%>FP&W-
MS'>PQ74BQ02R6DFV1F("C@9!.>,@4 5/$FB'Q%)H]S8S@Q+*Z3RQN,-:R(1(
M ??" 8^O:G:'X:FT?6]6O6D66&21S80@@>4LF'D'3C=)]>@KH8+>&U@2&WB2
M*)!A4C4*JCV J6@#@[7PMK-OH?AZR,=HTNFZFU[,1.=K*6D.U?EZXE[X^[[T
MZ]\*:O?R^(Y5DM[2>ZO;>[T^7>7 :$*!O&!C.P=,XW=\<]U68VNV8\1IH6)O
MMC6[7 S&0FP$#[QX)R>V: .<US1O%.O>'K^WN6L8YKB%88[2&0F-2'#&0N5R
M3@  8P*NV^AZ@OQ&E\02)"+273A:;1)EU8,'R1C&.HZ]JZ.2YABE2)Y%$L@8
MHF?F8#K@=3C(JIHVLVFO637EEYOE+,\)\V,HVY&P>#R.1WP: )M5AN;C1[V&
MRD\NZD@=(7W8VN5(4Y[<XKE]7\-:EXCBTI-0ALK>[L9XICJ$+EW^7DA 5!&X
MXX)P/?%=G10!R/Q!\.W7B#2+06 Q>6]VCJPP"(V^23!/^RQ/X4R+P:L7Q$;6
MEBC%A]EC*QC'_'RFY%;'M&Q ^OM78UB6_BO2KG4H[**25FEEDABD\IO+D>/[
MZJW0XP?;@T 4/B%8ZGJWA"[TK2K W5Q=@)GS418P&!R=Q'IVI=:\-2^(_!]I
M8R#['?6_E30F0!_+E3UVD@CJ.#WKJ:* .2UB'7_$>BSZ*^G?V:;E?*N;PSI(
M@CSAO+ .YBPR!N"XSSTQ40\.7WAWQ)_:VB01W5I-:16MS9LX23]V,(Z,>"=O
M!!(^M=E10!F6!U>>_EGO$BMK/8%AM@0\F>I9V' /;:,CODTGB*'4KCPYJ$.D
M.J:@\#+ 6QC=CWX_.M2B@#S2Z\*:NVGZ[#;:3'"=2TF*+F\$CF=6<G>S=6.\
M<YQ\O6K=QX5U._N],@EMS#;#P]+IT\V]3Y4CJ!C&<G&.HXYKT"JEYJ=I8V5[
M=RS*8[*-I+@(=S(%7><@<YV\X]Q0!QMOI7B2?5O"C7NG6\::094GF2Y!60&+
MRPRKC/.<X/I^-=[4,-U#<1PR1R B9/,C!X++QSCKW'YU-0!Q_B2+49_&/AR>
MVTF[GMK":1YIT,87#QE!C+ G!//'YU%XPT>];6[36K70K37HH[=K:6QG*JPR
MP8.I<$<$8/?!KLU=6+!6!*G# 'H<9P?P(_.G4 <);Z;JL.M>%Y)-%C@CM!=2
M7"V000V_F@[$'(W$<9(')YJA'8>(AI=A#_95UY0UBYFGA62-)A#(SLI5]WRC
M+X;!!P2.AKTJB@#RFW\.Z^EMX>MI-'E3^S]?DN9&6=''DERV\$D$CYN_)P>*
MOW.CZQ-8>,ECTJ?S+N_AN+56=!YRJ4SCYN/N'KCJ*[Z_U"TTNT:YO)A%$"%S
M@DL3P% '+$GH "346GZQI^J/,EE<I*\.WS4 (:,G. P/(/!X/- %BUDEFM8Y
M9[=K>1AEHF8,4]B1QGZ5STMO>R?$BUO!8S?8HM.E@:YRNS>SHP&,YZ*><=ZZ
M>B@#S.W\+:C:O<:9_P (S832_:'DMM9<HRJK.6#-&?F+KG&.Y Y[U6T^2[DU
MKQ_I]II4M[)=W(B4[D$2ED*_.2<XYSP#7JM9>E^'[#1[N_NK191-?R"6X:25
MGW,,\\GCKV]J .?\.Z)>Z1XNE#V\ILX])M;..Y)!5WCSGOGOW'K6+X9\*W^F
M&PTN7PS:)-87&\ZS(Z.'0.6RB_>#D8'.,=:].HH \SM_#&K7#S6EK;7&G6%_
MI]S%<V]RRO%:S., P$$L Q))' Q[\4_0])NX$B\SPA;V,UA!)%->@!WG(C*_
MN0/F^8D')[9'4UZ310!YEH>G:E;:5X#M9=,O%DLIY&NLQ8$(*2*-Q^K#\*ZC
MP9'>V>GW>G7FGSVYM[RX9)G*[)U>9W!3!SC##J!72T4 <UX^MKF[\&7L=I;R
MW$P>"010KN=@LR,<#N< \5GVLFHZ=XDUB_DT>ZGM-6BCF@"("Z/&@3RY!GY=
MV 03P,G..:[6B@#"\&:-<>'O!^FZ5=R"2X@BQ(0<@$DM@>PSC\*H^*_.;6O#
MKPV=W.EK>M/.\,+.$3RG7MU.6' KJZAFNK>WEACFFCC>=]D2LP!=L$X'J< G
M\* .5U_4-0U2PU"TLM%N)+=;7):YMO\ 62%UP$1B-VU0Y.1UVUR][H^IRP^-
MTBL-4F^W6-JMM+<KEYV7<#]#STP,#L*]3N;F"SMI+FYF2&"-2SR2-A5 [DUF
MS>*-#M[9[B75+58DD,3'?DAP,E2!SD#GZ<T <IK>E:E?ZIJ"6EO<*USX;^R1
M2%&5?.W,VPMC .".N.N*+<WM[XF\%RC1=0MX[*VN$N6E@VK$QB50"?J/U^N.
MJB\5:#-IEQJ46JVK6-L^R6X$@V*V <9[GD=/6KBZK8M?162W41N9H?/CBW<O
M'G&X>W- 'FMII^KRZ;<:A'IMTCVGBB34WM9(75YH#GE 0-QP20/;UP*G\56M
MW?V_BJ^M-.U%HKVSMK6"/[+)OGE5F)8)MW  $#+ #WKT_-% '&:NSZ?XLTK7
MTTJZNK&:VDBE^SVQ:6"1]A$C(!O)*H$/&0!CVJ?P'%+%9:OYNFW-AYFJW$RI
M/'L+JS9# >F,#\*ZRB@#C/BI:W-_\/K^SLK6XNKF5H@D4$32,<2*3PH/8&LG
MQ):W7_"0W-[I%IJ!N99[:.YM)+-Y+6_3"$.6(Q&5Z$YXV^]=Y>ZQINFNB7U_
M:VSOC:LTJJ3DX& 3Z\5/<75O:1^9<SQ0IG&Z1PHS]30!-7G4R3Q3?$.V:SO6
MEO(]UOLM9'$H, 0;2%()W<8^OH:[YKVU79NN(1OSMRX^;'7'K0;RVWJAN(=S
MD!5WC))Z8H \Z.E:A=77AV"*VNH)!X<FM7F:!U$,K1JJAFQP<@\>U3>%81->
MZ.C^&]9MM1TZ,Q37%_+-Y,2[-K>42Q5MQ"X &,<]J[XW]HL[0-=0"91EHS(-
MP''4?\"7_OH>M+]MM?\ GYA_[^"@"<]*\UU:&2Y\&:G&UA=L)-=$OER6D@+1
M_:%8MM*_=V@G/2O0[J]M;& SW=S#;PC&9)7"*/Q-2JRNH92&4\@@Y!H \TUW
M2[_4)O'4&GV%R#<PV9B#0,B3M&3Y@4L &.T <=>*T[&ZEU3XC6&I1Z5J5M:_
MV1)"SW-F\020R*VPDCK@'V]*[%[ZSCN/L[W4"S;=WEM( V/7'7'(_.K P0"#
MD'O0!X_I]O./"?@NWO-.NH;J/Q 9I8&MW#1+YDAR>.!\Z=:V+NUL=&\1:Y8Z
MAH]]-8ZI#&EFMDDGE,@3:T)\O&WYBQYX^?M7I.*,4 >;1L=!N=1M-:T2]NH-
M4L[=+>"V1KA0$B"-;E^V&SACP=Q).<UJ:"US9>-;S[9I\]NU]I]F(UCC9XT*
M"3>I<# VE@.3SD5U]U=6]C;27-U/'#!&"SR2,%51ZDFI>M $%]_R#[G_ *Y-
M_(UY%X7MHM4\!^$;73;5FU"#4TN)9$B*^6JR.79GP 1MP.ISD#MQZUJ4]K;Z
M?,;R[BM864H997"A<\=3QWK/\*Z79:'H,6E:?>F[M[1FC#LRLRG)8J=H R,T
M ><*DTFJZ+=_9;N +X@DD:SBM)"EN&9PS.Y!+,YP>#@ XP*T[;1Y[_PGXQ@L
M[%C?/J=Y]F4KY;&-V3.TG& P7\<5Z=2XH \P==,U'3M5OK?3]8,S:/+:2M?1
MNH0\%(@I&&;<3RN<8]Q6GI-I!;:UHL,$"B1/#KPR/'$0I;=$57.,9X<XZ]:[
MDRQB983(@E92P0D;B!U./3D?G36GA2=(&E199 2B%@&8#J0.^,C\Z ,#P%*'
M\$Z3$8IHI+>V2&5)8FC(=5 /4#//<5'XQDFLIM$U3[/-<V=C>F2ZCA0NRJT;
MH)-HZ[2V:Z>@G R>E 'G]QL8Z=JEAH]W#I0UG[9< Q.7FWQ,//,9!95#D<8[
M;L5E:YISW-SXBU!+9_[*O;K3_)3R2/-D65?-D QD87.6QR,\\5ZH&5@"I!!&
M1@]J6@#RJ_T^!O%7CYVLE8-I:);'R<@OY)!"<=<D<#FH99;"/Q#\.9-3,*P1
MZ9(LAN ,*ZQ*!G/0AAWZ$5ZYBL#4=#@N?%^CZU+?"*6S66*&W('[TNIW<DYS
M@9X]#0!QEF#9V$4D4/V;3[OQ$\M@\L+ 01F-B'"#G#,&V@\?,#C'%4]/AM[G
M0OLUQ;2N%\6B0K<VQ0[&DZD%0!E3SP,9QQ7KU&* //K72K+77\::&R>7Y]T)
M(=Z8"GRD42)QR ZGD>GO5[P/-?ZX#K&KQ*+JUC_L]"?[Z$B9QCC#,%'']RNC
MU;39M3MHXH=2N[!TD#^;:E0S<$;3N!!'/IV%3:=86VE:?#8V<?EP0KM5<Y/J
M23W).23[T 0Z]%=3^'=3ALMWVN2TE6#:<'>4(7!['.*X,M8ZJ_@Z'0H1'J%C
M,AN!Y.&MK<1D2I(#C&25&#WY%>F4E ')>#+O3;J[UW[') TG]HR,H4 ,4VH,
MCOMR#STKKJ0$'(!!P<'VI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** .'U33K]/$.J:YX6O5.I0^7%?Z;.H\JYVHK+@_PML8 -T[
M>M,U2WC\7?"B.?3;<V\@MTN[2(?,8Y(_F"C/N"N?>NCN_#&DWMU<7,L$JS7.
M//:&XDB\T!0N&VL-PP ,'CKZFM2"WAMK>.W@B2*&-0B1HH"JHX  ["@#Q^3Q
M3-_;^G^/ 0=-EC_LSRPA^;,/F]?7SMR=/X??->E>&-';1O#]E:SD27:HSSRD
M<M(YWOS_ +Q_04#PIHPT6VTA;3;8VTXN(HM['#A]_4G)^8GCWK7EC66)XV+
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M'G;?*J]%+9R%]A@<GU-+K'A72];L;6UN8Y4^R$&VGAE9)8N,?*_7D<'U_ 4
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M3O#8M9E(+=DWY8'=DL>?ES^./>K]_INHS^)+'4H)K406L,L?E2*VYBX&3D'
M *)QCN?:@#"L?'\US%H=W+I:PV.JWCV:2&?+J^]PIV@<CY>>1R>F.3I>.K'4
M[_0X/[,M4O)+>[BGELY'VK<QJ3F,YX.>#@\<5EP^ KJ'1/#VG_VE"S:/J/VW
M?Y) E&]FV_>X^\>?IQ72:SIEW?S6%Q8WJ6L]I*9 SQEU<%2I4@,.#GZ\<8H
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MB"=26<8)4#/)&1Q[BO,;(W4VOZ#?2V>HVP_MJZ>:R%H_EVY??R7V_.S<$G)
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M#M)\/=&=V+.T!+,QR2=QY-94'B+3?#^F^)-4M=)O?W.K&*Z1IE8M(Q0;QEB
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MW)X]Z73]*T_2HFBT^RM[2-CN98(@@)]3BL>3QQHT<>G.INY1?LZ0B*UD9@R
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M%%% !1110 4444 %(1FEHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-2GN&7S]1O9+QXUY$>X !<]R HR?7-7;/6+*]N&MHW=+E5WF":)HGVYQN"L
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M=6U*[.C:LJ7NA>2'N61G:8;N" Q"YR %&/H*NV.G:HD'@FW?3+N(VEE+!<S
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MK2 GY6RWWN>@X ';I4<.C:NG@7PO"NBS2:CH]]"\MNSQJV$W;BK%MI!R._-
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M"HHP% P *=UI" 0?>A%"(%'0#% "T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 &D"A<X&,
MTM% !1110 444A8 @'O0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !13)1(T3B)U20J0K,NX ]B1D9^F17G
MVE>*O$NH>%+WQ#YND".U>8&V>%TW",_\]-YP3@]1W% 'HE%4=&U%=7T2QU)8
MC$MU DPC8Y*[@#C]:O4 %%%% !1110 454U.:[M]+NI;"!9[M(F,,3' =\<
M^V:YD:OXF/BUM \S2=RV"WIF^SR8Y<IMQO\ ;.<T =C17):5XBU)M<%MK:VM
MC%_9R7#(?E*R&0H<DGH=N0/0^M=+=:A964 GN[N"WA/2260(OYDT 6**:DB2
MQK)&ZNC#*LIR"/4&H&U&R6]%D;RW%VPR(#*N\CUVYS0!9HKF=,\2RR^)=?T_
M46M;>VL)(([>0G;YA>/>023@GIP*MOJMZGC:'26AB%C+I\ERLO.\NLB*1UQC
M#YZ=Q0!MT5EZ3=WG]D+/K$MBLZNX>2UD)BP&('+=#CK[U?CN8)8_,CGC>/&=
MRN",>N: ):*S-4UZPTO1WU*2>.2$<1[)%_>,> JG."2:>TU^=;@2(VATYK=V
M<ECYQD##&!TVX)R?7]0#0HJ)+F"2=X$FC:9.6C# LOU':G":)C@2(3G;@,.O
MI0 ^BH_M$/GF#SH_- !,>X;@/I4A( R3@4 %%0?;;8VC72SQ- H),BN"O'OT
MK"\-:YJVN06NH265K'IUY"9D*2GS(>?E5A_$2#G(QB@#I**YJ\\1:EIYMFN=
M*A$=UJ/V&'_26#8+,JNPV="%!X/0UL6EW<R3W4=W:K;B%EV.LA99%(SD$J,8
M/&* +M%,,L:JK&10&.%)/4^@H26.2/S$D1D_O*P(_.@!]%(&4KN# KZYXI&=
M55F+ !1EO:@!U%4]+U*WUC3+;4;4L;>X021EA@X/M5M65QE2"/4&@!:*0LH.
M"PSQQFF3.R1MLV&3!V*[;0S=AG!Q^1H DHK-\/ZG)K7A^QU.6!8'NHA+Y:ON
M"@].<#/'M6D3@9/2@ HJ&ZN8;.TENKB18X8D+N['@*!DFL,^*E?5?#MM!:E[
M;6H7FCG9]I0+'OP5QUP5[^M '144 @C(.0:* "BN<L?$\]]XLOM 73=KV(5[
MBX,XV!7&5V\9+$8XP .>>!GHZ "BBB@ HHHH **** "BBB@ HHHH **** "B
MDI: "BBH([N&:ZGMT?,L&WS!CIN&1^E $]%%% !16-?>(H;#Q-I.AO;RM-J0
ME:.4$;%$:ECGG.>G;OUK9H ***2@!:*** "BBDH 6BH;JZ@LK:2YN9%BAC&6
M=N@%2T +14-K=07ENL]O*LL3$A77H<$@_J#4U !15.^U.WL(YBY,DL4)G,,>
M#(4'4@9INC:G'K6C6>IPHZ1742RHKXW $9YQWH O445%<W,-I;O/<2K'$@RS
ML< 4 2T4E+0 44E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0?-C@9]<4OV6W\X3>1%YH!4/L&[!ZC/X#\J ,/P0-/'@[2QITEO)&MK$LCP
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M?VD6&DV=N+D;9A'"H#CT(].3QTH XC^SX(_B'X)NK:\GN1+:74SR37+R[\Q
M;EW$@9W=!@<>U;GQ N;ZWA\/I874UN]QK,%O(8F +1L&+#GZ5K67A+P_IUW#
M=6FD6D,\.[RG6,93.,X].G\_4UE>/M!O?$5KH]K:VWG1P:E%=7&90G[M0P8
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M;>743B6YN0YD8L 3P<+SZMZ"MBQANM4\:+K3VD]M:6^G?9XUG38[2.X9N#V
M51GIGIF@"7PYJM_?ZUXAM+R2)TL;I(H?+CV *8PW/))//K^5<YI_BS7+[51
MKH-135C:SZ48UQ%:CDS9^]TP=V=I)  Y%;?A:&>/Q'XFGEMKB**[NTE@>2%D
M#J(U4D9'J#Q7,6FAZV-6L[V:SN5\0KK#O/>J/W3V9 !5FZ%=@ 5>H(Z#)H ]
M3HK,TS6/[2O-1MFL[BV>RF\K]\ /-7LZX/W3@XK3H **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHIJ;^=Y!],4 .HHHH **** "BBB@ HHHH
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M$3S(HB.-JXSD].].\+120^/_ !DDEQ)<-FS.^0*#@QL0/E ''3IVYS4NJ?\
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MBBB@ HHHH **** "BBB@ HQBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%9+^)=)5Y0MT95ASYLD$3RQQXZAG4%5(QT)S0!K45!9
MW<%_90WEK();>=!)&XZ,I&0:GH **** "BBB@ HJ*XN(K6!IIGV1KC+8)QDX
MJC:^(]$OIHH;75[&:27/EK'.I+XZXYY_"@#3HHHH **** "BBB@ HI,@D@$9
M'44$A022 !R2>U "T444 %%%% !11574-2LM*MOM-_<QV\.X('D; +'H![T
M6J**KQ7UK/>W%G%.C7-N%,T0/S(&R5)^N#^5 %BBBB@ HHHH **** "BBJYO
MK1;U;(W,(NV4NL&\;RHZG;UQ0!8HHHH **** "BBB@ HJ&YN[>RA\ZZGC@CW
M!=\C!1DG &3W)(%/EFC@B:6:1(XT&6=V  'N30 ^BF0S17$*302I+$XRKHP9
M6'J".M/H **CDGAA>-)98T:0[45F +GT'J:DH ***:716VLZ@X)P3V'4_K0
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MQHXFC#;@"N ,@DX(]><U!:Z/+HU[HFGZ5]I6QMA,UT68>7('!.6]7\S!&
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M5]K8!&&4D$$$?J.HK6K&T&RU" 3SZA#96TDNT+;61)C0#/))498YYX["MF@
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MMAH2/+;3:*TUW$LA=1=!P58Y/^L*Y/J< T >KUS4_B/4-.TW2I-4TQ;>\O\
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MDY..]='IEG-J.O:]+-J5]MTW4V:*(3'8P:W4;6']T;C@4 =1H.JKKNA6>J)
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M/M",O#)R3UQP>@KHS<7^B>,='TTWT][::E!,)!.03')$H;>"!T;.".@[8Z4
M;=YK=K8ZQIVF3"7[1J!<0E4ROR*6.3VX%:5<#\0+ZXTSQ#X8O;6T>[G@-XZ0
M)U<BW/\ ^OU]*=?W5XG@:QU#3/$4UQ-<7=KF["JRN'E5"H4]%&X\9SQ@D\T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<Q2-=6)9K=UF=0A88/R@@'(XY!XJ@W@S1#;FWC@GA@,PG\J*ZD5!(#N#!=V
M=W/ ZX]*-/U>TNM:OY8];BFMEM89?LNS;]G4@MO8G^\"#@],5;A\2:1.EPZW
MT8%O")Y=X*;(SDAOF X.#S0 U_#6DR7FHW,EKYCZE&L=XKNS)*%&%RI. 0.,
M@"I;+0M/L+E;B%)FF6/REDGN))BJ9!(4NQP#@9QUP/2BSUW2[^&>:VO8F2W&
MZ;.5,8QG+ X(&.<FL33_ !''J_C@6MCJ0FLDT]I7@$6W#EU 8DC)R"<8X^M
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MA[D)@<8YR?0""Q\&W-HVFZ>;N$Z)IMVUW;Q*A$I.241CTPI8G(Z\#'!SV-%
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M4WR2L?X57OQD_0$T >9>%H[C2AH.HS/I-[)(%CB@AO9'FC69AO,<?W!C<"P
MX -;UEX&U.UTBXLEO;59(=2.I6$P5B1)N)Q(#VP<<9ZDULZ=KF@KIM]J-I8-
M;26TA2YMUM0EP)"0 I0<DMD8]<BKNA^(8=:ENH/L=W8W=J5\VVNT"N%895A@
MD$'!YSV- &1>^&-3U5M9O+Q[..\O-+;38$B9BD:MN)8L5!)R1QC^'WXN6FC:
MG#JVBW,OV3R;'3WM9 LC;F9_+R1\N,#RA^9K3U+6K;3;BUMG62:ZNGVPV\(#
M.P');!(PH[D\5';>(;"[T>?4XFE,-N76:,1,98V7[R,@Y##TH DU^QGU/P]J
M.GVQC$MU;20*TA(5=RE<G /3.:Y!_"OB#4/!EIX3O4TZWLDMX89KJ*X>20[&
M4_*A0#G:.IXKJ8?$=C-X8C\0?O$LY(1,H9?G(/0  \L3@ =R0*73/$%MJ=Y+
M9&WNK2[B193!=1[&9#T8<D$9X.#P>#0!GC1M2TG6]1O]'6WG34(X_-CN9F3R
MY8UV*RX4Y!7&1[51M/"-[HEQX9.F-;3Q:9!+;W'GNR%A(4+.N <G*G@XZ]:[
M2B@#SZV\'ZS!X1T#3/\ 0S<:?JJWTF96 *"5WV@[3\WS8]*O)X=\06-_JMKI
MUU9)I.J7#W#S,6%Q;,X^?8,%6/'&2,'UZ5V=1^='YPA\Q/-*[PF[YMN<9QZ4
M <W?^&);GQA;ZBC1BPDA3[;&0,RR1-NA/3L6.?\ =%9/B3PIK>J7NN2Q1Z=<
M)=1QK9-<R,6@"J-RJNW"EFR=V>_.>E=U/,EO!)-(<)&I=CCL!DU!IFH1:KI5
MIJ-N&$-U"LT8<8.UAD9]^: ,33-(U2+QC>ZQ>1VJ175E# 5BF9BKH23U4<?-
MQ]*Q+7PQXBL=*TS0H(M/:RTS44FCN99FWRPJ^\ H%.'YQG...*[#2=:MM9^V
M_9DF4V=RUK*)4VG> I.!Z885HT <7<2&^^(<M[:O%Y&CZ9)%+/(V(Q/(P(0G
MV"9;TR/6NA\/7]WJF@6EY?6Z07,JG>D9)4D$C<N>=I ##/8BKD%G;6UN8(((
MXX26)C50%))R>/<DU/0!S]U#K$>OWTZ6<-YIDUI%$('FPQD#.20#\N"& .>3
M@=<5@VWA?5=*TO13:6MO)-:ZI)>/9K-LC@CD61=B,1R%WCMZX[5WU% 'G&I^
M&?$=[?WL[VMM<L-3@N[622[/RPHR'RU7;A3PV3QGWJ?6_#&NZII'C"T\N$R:
MG-"]HQE&"JA 0>.,;/QS7H%% '(P:1JL'C6TU;[-&;5-&%G(/-&X2!]^![<8
MS[UEVGA?7)]#N1=6]O!J<6LG5[8>;F)W+$["1R!C(_$5WMQ<0VEM+<W$BQPQ
M(9)'8X"J!DD^P%96C>)K36[B6"&"[@E2))PMS%L+QOG:PYZ<'K@T <_K'AS5
M-=N]2U*:SC@F.CRZ?:0&8,QDDSEV(X"C. /J?2IY] U,>$?#L5K:Q"_T:2"7
M[*TWRR;$*,H;W#$@^N,UV=-9U4J&8 L<*">IZX'Y&@#B<ZWI%WXIU^33[6#S
MX+=K=)[H8)12"&(Z=?7J,#/6NQLKAKNQM[EH7A:6)9#$XPR$C.T^XZ5))%',
M@66-74$-AAD9!R#]00#3Z .3L=&U+PYK^JW.GP1WNG:G-]I>,RA)89B/FQGA
ME/U!'O3-:T;7M46TU(&T6]T^\6YM+,,=I0 JRNY'WB">0,#@<]:Z^B@#A/$/
MAC4M;_MV]6W$5Q>::FG6T!E4\!V<NYZ#D@#!/0^O%^73M276X+U;%GCCT:2U
M(61,^:2K <GI\N,^I';FNLHH X&UT+5XAX#WZ>__ !*HGCO,2Q_N\P^7G[WS
M<\\9X]^*=X>T77=,BM-'ETFQ$=E*H75]R,9H5.1A,;@Y'RY/3DYKO** .)\-
MZ?XCTNRL=!EL+>.VL)1MU(S*_FQ!B<+'C*L5.TDXQDD54?1]=3P3)I*Z27N;
M?45FBQ<1XF471F)&3P-N!SSD]*]!HH XU[/Q#8:MK4-IIMO>66IL+B&:615%
MO*45&$BGEE^0'Y0?3Z4-1T+7?M'C.*"P6X36;5!!/YRJNX0>65*]0<].,>XK
MT&B@#E(+#4[?QA;:DU@S0/I$=K(4E3]U('9B#D@D<@9 -:OA[6)=:TPW,]D]
MG/',\$L3.' 9#@X8<,,]ZU)(TEC:.10R."K*1D$'J*;#!%;P1PPQK'%&H5$4
M8"@= !0!S/C'1+^_DTJ_T<B/4K2YV"4X^6&0;)#CO@'=CVJOH'A3^Q?$-ZT<
M##3+8>;IZ;@?GE51+C)XQY8QT_UC\G/'944 ><6V@ZS%I/ANU;3)0]CKCW=P
M?,CPL3/(0WWN>)1T_NM[9LZCX>U74K;Q*$LVBDFU*&\M!)(@$PB$8QP3MSY9
MQG'4>]=]10!PNO1ZYK6A7\D>AO;^>L,:VS&,SNRRABS,&QM"@X&<]>*T+6UO
M3\2;C4FL9TLI=*CA69MN X<L5(SG.&].QKJJ* ,3Q?!<W?@_5[2TMWN+BXM9
M(8XTQDLRE1U('?-<V^G7UCXAFU'_ (1R74[?4K.W5HS)&'MY(P5*L'8 *0W8
MGD&N_HH \VU?0-6GM[BS;1^FC""V.GRB%/-(;=&[9#%5XVK]TY.1D\1ZCHFH
M7.FP36FEZC;:M%I4$,<L;1F.<XP8)T9MI4'D\=">N,'TVB@#S^33-7L=9U]+
MC04U6SUA(G3RW38LBQJI617887(SD9X%12:+K=C8>*[![!KMM5L\6\UL5$>_
M[/Y93#,"H##CKP:]%HH SM BFM_#NFP7$+0S16L<;QL02K!0"."1VKCS<_9_
MC#JN+*6Z9M&CPL8!/W_N\D#GCK7H-94/A^RA\27&O*9C>SPB!]TF5V#!  [<
MC]30!PWACPMJNB^*M$:XM&-O;Z9+!-(C!DCD>5I @Z$@!L9QBM%-.U."[U?3
MI]"-VMS?-<VEVTBFW =MP,BE@04/H#G KO:* //M1TK4+G2?%\":9.TE[?1R
MV^0O[Y L0..>Q1NN.H]:UX[2Z3XCSZG]DF^Q/I"0+* ,>8)&8KCKG!'\JZK%
M&* /+;+2KJS\(:'I^HZ=K%M<PRW4@N]/!>6U<R,R9"YRK*YS],58LH-:TBZT
M;6]2T>\O6?3S:7%O8HH:%_-+JYC! ^8'YL' (KTK%&* /.KNPDT^QMDM]/U/
M2;J"":2S.E1-/&F^1F$,B#<I.-A.>,EL$ "NYTM)X])LTNH8H;A8$$D4/W$8
M*,A?8'I5S%&* /-[R#SIO&$5WHNI75M=7MLRB."12Z 1HSQD#DH5+#'7;Z5T
M'@Y-3B.IQWYFG@6=1:WES#Y4]PNP [UP#\O0,0,UU&*,4 <WKDMSIGB&PU=;
M"[OK5;:6VE2U3S'B+,C!@N<D':0<=,"LBWM+RRUK1M:;2)(+%;>XMC:6T>YK
M822AD8H,G) ^;;G!]J[NC% 'E-UI-_':^>NFWBQW_B6+4([=('=HH5*[G< '
M83@G'7GZXL:U:7-S;_$!8=-O6EOA$+8BTD_?;8D0[3MY^8'^?2O3L48H \]E
MO+>#XKFYEM+N4-X=0!8[9W8 S,=I0#()QW';%16FD7-GK/@V!]/N1!;"^:9?
M)+I DV?+1F4;>!\I^E=@F@0)XGDU_P"TW)N9+<6QC)7RQ&#D #;GKDYSWK7Q
M0!YW?03-XF\4^;H]Y<V$FF16T4<<#HLP7<75& QGYCCUZ"LVZT36)])U>TM;
M6\U."%+1K2>]C,%S*B2^8T)8[2P49(.!RV*]6Q1B@#SB_P!/EU73-4O=*T/4
M+>62*'SOMS/YUUL<,8@KL>-H(SW)P.]:MA?C4?B#%=1:5J4"'2VB>:XM7B4'
MS P4[NXP>GK798HH P/&%M=3Z!OM8WF:VN8+IX(QEI4BE5V5??"\>I '>LB.
M4:CXXB\16MM=QV-GI<D5Q+);R1M(2P945" S$8)X'<#K7;48H Y?X>RE_!=C
M$\-Q!+#N22.>%HV4[B>C 9X(Y%=1110 4444 %%,20/G /!QS3Z "BBB@ HH
MHH **** "BBB@ HHHH ****  ]*CB+'=N'?BI** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@OITM=/N;B24Q1Q1,[2!
M<[  23COBIZ1E#*58 J1@@C@B@#RGPW>79\2^'HGO9_LNIZ9,91)=L99_P"(
M2LH/[MCNR-K$@<9XJQH5M/9^'/#>JC5KRXU Z@MO-ON6=95>5ED3;G'&2^2,
MC;Z5VR>&M&L/+N+#1+!+FWW- 5B5-K$8/S <9X&:H>$_"L&CZ= ]WIUFFJ(T
MC-+$=XW,<Y!(')&!G':@#E-6M[G3_"NO:M:ZQJ#WUCJKFU5KIV"?O4 B*Y^8
M$'&&S][\]D:7+>>*?$,[WL\HM9+2ZM[5+AOED2-FV,IZ*20<?X5H^'O"Z6CW
M=UJFGV37LM]+=)(A\P@.Q9<D@<KDJ#CMQBMZWTNPM+N:[@M(8[F?_6S*H#R?
M[QZGVSTH \_MM0NY/!GAK7H-6N9-0GOH%G1K@[;@R2!)(MA.T8R<8'&W\:K:
ME=+8>*9].34KP^&Y[B&*]F\R0BRG!W")9-V55OE!Q]W.,C->A)X?T>.\^UII
MMLL_F&4.(QPYZL!T#>_6D'AW15MI[?\ LJS:"XE,TT;PJRO(>K$$<G@4 <]>
MFX7QIK$2377V<:$DJL+A@L4ADD'RC/!(0<_[/O6%9RWSS> %;5=1QJ]G(+W%
MRP$@6!6&!T4Y_B7#>^>:[X>']*$SS"RC$CPBW9@2"8AT3K]WVI4\/Z3&UBR6
M$(-@"+4A?]2#UV^E '(?;[FU\/6]JVJWC3_V[):Q#.^6Z19GQ$9"05&!RV<@
M#'.<5A:@;G4_!GB&+4+BX8VGB&.")1=N_EH9(1MW<%@-S8ST/TKTJ3PYHTUI
M]EETVWDM_/\ M/ER+N'FGJV#WY/YU&/"F@+;7=NFCV<<-X )TCB"A\=.GOSQ
MWYH Y?5'O+SQ%K&EV^N+8K#90BW,MU(IC+;R9!AOG.0!SG &.AJI)G4/'WA3
MS;MIFN-#EW7,.8BY91EU[J3G([BNSN_"GA^_$ N]&L9OLZA(B\*DJHZ#/I[4
M^^T:V>Y.IV]I"VJPPE+:21V4+@'"G'123R .?P% ''Z'/?W,D7A2XU"]>_TZ
M_=[VZ\]P\MNN&0DYR ^]5QG^%O2NWU2YL=/M3J5\J;;4$H^S<P)^7"]\G.,#
MKG%4M TN[MY;O4]5%O\ VG>E!*MODQQH@PJJ2,GJ3D]V]A5W5-(L-9ME@U"T
MBN8E;>J2C(#=CB@#'\,VX@N=3OKLI;ZCJ<JW+VC."T,>!'&&&>I"\^Y('2JV
MA&ZL_'GB"UO)$N#/!!=K<)'M$:?,@B;DXQM)'KDFM2'PGH<5E<6J:9!'%<[#
M,L8*[]AW+R#G@\BK"Z+96NE75G:6<>R>-E='=OWN5QAFY;IQGDT 9.NZ?=C7
MM-\3:?+:O'9V\L=Q'/+L1H6 ;<'"MC!4'IR*SO"#7%WX5U_5IX! FJ74]W"@
M).8S&J@\@'!V$C@<$5M:1X3L]/\ #]MI-U_I4,+.VPEEB(9RVTIN(*C=@!L]
M!6U+:PS6C6K)B%DV%4)7Y<8P,8Q^% '%:)IMSJOPDT:WLY(H[I+>WGA,H)0O
M&ZR*&QS@E0#]:CTE=2U?XH/J%U;VL TS3_LLXM[AI5,CMN"Y*+R!R1@XR.?3
ML+31[*PTI=,M(Y(;1!M5$F<%1Z!LY'X&I[.QM=/MQ!:0)#%DMM4=23DD^I)Z
MDT <IKC:E>>/;?1[;5;FSMKC29W;RB,J^]5#K_M#(_7&,YK)74/$.KQZU>PZ
MA;V']GZDR;IKEE$,,6,JT8C((89.2<_-QTKNY-(L9=7BU5X2;V)#&DN]N%.<
MC&<8.?T'H,5+CPIH-WJXU6?2[>2]R"92/O$="1T)'J10!QNK7&LHWBN[MM=O
M"-,NX?L\0*! &6)G!PO( 9ACV[FMYK:.'X@:A=R7L\:II<4Q+RGRT^>4'(Z;
M1C./K6I)X5T:6"^A>U=H[^437(\^3]XX.03\W'0=.P [5/)H.G37T5[)"[SQ
MP?9\M,Y#QX(PXSA_O-RV3R: ..\+7^I2Z]9)<7-Y+;7NF2W#-</E9W5XP)43
MGRT(<X7C(/('%9^DW&K>'_#_ (%NTU&>[CU"2WLI;1U41K%(F5*X&04 Z\Y[
MUVUCX-T+3;FTN+6R9)K162%S,[$*<9!RW(X& >!VJ2P\+:1IMS'/;6\FZ$$0
M))/)(D /!\M&8JG''R@<4 <9<ZC?Z-:ZH+"2))]3\4"U$CMCRU9$!.<'!^3&
M<'&<X-=5X<@U*QO]1LM1U-;L8CFMXFD,DD2,"#N?8N064XX[&IE\(:(+*\LW
MM7FM[U_,G2>=Y-S_ -\;B<-[C!X'H*MZ/H6FZ#;M#IUMY2N078NSLV!@99B2
M<?6@#E-1US4;+Q.\=]<3PV#7L,=K=VX5[=5)7?%,.2KGD GU&,<UFWWB#6KC
MP7JFOQZI)!(FIBWA@B1-L<8G$14D@DD@Y)X[8Q79MX3T=[R:Y>"5C/<"YEC:
MXD,3R#&&,>[:>@[=AZ5SWC+P9;OHMZVB:;,]]=W,4K10SE8RP=69RA8(#A2,
MXR2?>@".]U[51KGCJU2^>.+3-/CGM J)^[?RBQ/(YR1WS5/4?$6N2:7&UCJ+
MRW:Z"ET\-M''OCE*AO-E+C:%X("CDY/'<=A>^%=&U6[GO;JS?SKJW^SS[970
M2)@\.JD D9X)Y';H*9+X,T*9G)LW7S+5;.01SR('B4856 ;G [GF@#FS?Z_J
M_B:QTVWU66UBNM#BO6E2%6$4OF+DXXX8*1@GN:;8:KXBU6%M92\AM+>'4GCE
M6:<!$MTDV-&4V?>P,@[LY([<5UUGX:TVPOX+VW2<3P6PM$9KB1@(AT4@M@^O
M/-1#PCH8U5]2%B!.[^8RB1O+9\YWF/.TMD YQGB@"E\14=O &LE)Y(BMLY.S
M'S#&"IR.ASVK%BO-9?4;#0=.O=N-'2\+O(B2$N=B@9C8;5VY]26&3Q7;:KI=
MIK.FS:??([VTPVR(KLFX>F5(.*S[WPCHVH6UI!<V\K?9%V0R+<2+(JXQMWA@
MQ'3@GM0!S$>L^)+O4].T$WMLMZE@\UU-;2JHFD60QX4M&P^7:2PVCD^@JO?Q
M:Q<ZSX*BO]9*WPENH;AK(HR"58G^?E<;L<'(P,G %=;?>#="U""TBDLO+^R?
MZAX':-T!.6&Y3G!YSZY/?FGW?A/2KN#3X?+F@6PD:2 P3,C L"'!8')W9.>Y
MSUH VZ6J-AID6GSWLL4D[F[G\]UDD+!#M PH/0<9QZD^U7J "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&
MSM..O:EHH 9$9"O[T -[4^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** #%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSCS(9 ZY],BJ'BH ^#]:! (^P3]?^N;5'X59(?!.BNS*B+IT#,Q. !Y8))H
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M%<1W"L\7F(2ASADR-P/IFM<D#K6-X=UU]=74V>V$ L[^6S #[BWEX!)X]2:
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M7J&VU*1)7@,7S!E4KC=GISGIFNCJA<:O:P:A_9P)DOS;M<K;KU9%(4G)X')
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M,CD#YP",&G'/%,A(*G'K0!)1110 4444 %%%% !1110 4444 %%%% !1110
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M48%+35).<T .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS%3EE'=0">?IBN-M/#-]JOA[Q3':RZA::E-?RW4%LWF1I>P=0-AP&!R<'N<
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M&R-Y0K-G., GO@_D:X""6TB;6--U'0[JXU4:TUW:QA'_ -(S(##)Y@&U55<
MY/ 4YZXI+F!5\-^-=,U.TEDO;BZGFAC$99K@,!Y+1@=<;0..FV@#OKC5M-LY
M&CN=0M8'4!F6695(!Z$Y-.NM2L+%8VN[VV@60$H9950-CKC)YKSO3M/9/&%R
M^JJKSIX9B@N&9/E>0_?Y/4XQ^!JDJLNAZ5-9W!AU&U\.QI+;W<)>WN8SD-$,
M'*R!DYQSRO7L >BS7TK>(+"""]L?LLD,CR0L^9I#\I4H/[N,Y/TJGKNOFRN;
M*"QNK%Y6OH(+F%WS(J.ZKPH/!Y[US&)I/'_ANXAM?LC_ -AL@CE!(@D(RL;G
M@Y'3'4U0TZ:UC\&^';>[MITU>'5X7N4D@;S1*)<R2-QD@J?O=#D>G !Z>=0L
MEO19F[@%T1D0&0;R/7;G-(FHV,EP;=+RW:8,4,8D!;< "1C/4 @_C7E-DMO)
M<7^G:S_:IUF+6&O(;..!!]I;S/W<BN8R=F."=V H].*TM"73W7QQ?M ERUI?
M7,\0B;YB##@[2/[PW#_]5 '?R:WI<=G<W?\ :%JT-JI:9DF4A.O7GCH>M9L/
MB%-8TW2;_2+RR6.YFB,R7$@W!&7+( #_ *SE>*XG38H/*O+=9+>X$_AL) L%
ML50[ QVJ3]\KD9/7)Z#H(;MM/72?AO\ 9WA)@O+='E";<D1KO.3[XS[\'D4
M>J/J-E%>)9R7ENETXRD+2J'8>RYR>AI6O[-)GA>Z@65,;D,@!7/3([9P?RKR
MN]C1_!'B73=2^?Q"VH2R0QN!YTK[AY3Q ?,5VX (Z $=!3M4TZP#>-[^_P#L
M;7O]D1Q?=7_7^4P8K_M;]HXYSB@#UJH)[ZTMI8HI[F&*24D1I)(%+D>@/6JV
MB2+-H.G2*X<-;1G<#G/RCO7%W"6;ZGXSM=?C&;I4^S>:!F6$1958B>I#!C@<
M@T =)K^NRV-_IVFV<UI%=7COF6Z^9(D52Q)4,I)/ '(ZGTP=/39+XZ7#)JJ6
M\5V%/G"!B8Q@GD$]B.?;.,GK7"VT=O#?> [75%A%^MFXN$F +@B!0 V>^>F:
M]&95=2K %2,$$<$4 <EJ'C-9+#3;O0S;W45SJD=E*7))"&0HS* ?]DD$\8YP
M:ZE;B%X3,LL;1#)+A@5&.O->2P2:8?#'AB%!9EWUQ(+U=JY*;YR%?VYZ'U]Z
MC>.*WMO&5E!$(M,M]7M)&A@MPZ)%N7S#Y8&&7"G(QC@^] 'K\4\4Z;X9$D7.
M,HP(_2LOQ+KT7AW1);]U5W#+'%&S;0SLP4<^F3D^P-8?@B*P74]9N--OGOH;
MKR9))D@6*!9,$%4 Q\V-I;ZC/-+\3A"?"($OEEC>6VT-C/\ K5SC\,Y]J -R
MSU*>,3-JDMC'!YBI;W4<H5)LCI@DX(;(Z\UIRW$,"%YI4C4*6+.P  '4\]A7
M!O'IQ^(5[;ZS%;?V9+IB#3_."B J2?-"]MQ)&><X]L5SFBZ;9WM]X1LM0=?+
MEM-1B6/S-K26[-B)&/4C:6*CVSV- 'K[3PJ4#2H#)]P%A\WT]:5IHDD6-Y45
MW^ZI8 GZ"O(+Z.U_M;Q#I^HZA)9WZ7*/IUO';[II(HU4P"!V_BW C /4G/6I
M/$EY:7>K>(M$O)+7[3>K;+%=7=S'#]B(16*G<V["GYQL!R6(H ]<>6.,J'=5
M+':NXXR?053OI[V*ZL5M887@DF*W#2/M9%VD@J.YR ,>]<@EMH/_  E.JVFL
M1V8@;3X4LC+M6-K=@WF;,< E\DG.>E8&GI<_8?AT^J22+>F\D >7Y96B"OY8
M;/J-HQ[^] 'K2NK9VL#@X.#T-(TT:.B-(BN_W5+ %OIZUXU?6=E9>%=9OK<)
M]LLO$N+:9FW/"/.3[I/0$>G7 STK0\7B+4M;\3:0'MI;Z>.T6TEN+B.+[*0-
MQ WL&QCY\H#][!Z4 >L4FY=Q7<-P&2,\X_R*K:;!';:9:PQ,C(D2@-']UN.H
M^O6O/;S3-&U#QOXQBU58VB6QMI1&\I5>$?+[<@$CCGMGWH ]*9U1"[L%4#))
M. *=FO,[#2(=8E\-VFM!OM-WX>FCN@LA5W :#;NYSG!)^H]!6 (H)[O5Q<:L
MMKK-AJ9-O$UL9;UT1CY*PEI1N4J<;0.YSUR0#VH,"2 02.H]*-REB 02.H]*
M\3U:QLY;#XCW<JAIK6]62!RY_=N<<CGKG_"NHTZU@T[XN"UM"T<-WH(GG D8
MF63S2-[$G);'?K0!W.F7-[=6GF7]@+*?>R^4)A+\H. VX =1SCM5S->7Z=ID
M-SX,TZQM&LSLU>[D2VN\M%=JDDP\MVY_AP03G[HZU15[24^'+29[?2]/87WD
MP7L?GP).)R"N591E5W!23P.G)H ]>S17D_D!M(T\6^I+K*Z;;W2M;WA,/VR
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M4N;E84>)0,2%FZ D@8&3G/H:U/#?B&U\3Z+'J=FKHC,R,CXRK*<$9'!^HXH
MOO86<K.TEI [2,&<M&"6(& 3QR<<5S<O@^9KW4IO/TVYCO9_/5;_ $[SVA;8
M$PIW@8 48&/6N:\.:]+H-WXGE>REGL5U]H99A*H%NK,B#@G)&6' XQ70Z_\
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M/UJ]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "&D7;C"TXT@
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M*))A$<;0[#(+=>YXQ6]110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:*;O7UIU !12%@#@T @T +1110 44@8'H:,B@!:*3< <4HY% !1110 4444
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M[6;R65&D"+N7.!SG-)H^DW.I>%H8[2SU.'68=(EL) \9B2/C@9(&\EAQ@]Z
M.SU7QG/;^*O#]CILUG<6>JRM$QSED*C)(QU':M[Q+=:G9Z*TVCVR7%[YB(B.
M"5 9@"2!SP#7E.G6\Z7/PV_XEMV#IP>.[D^S-^[;&W#<>O>O;&)4=A@9)_R/
M:@#SFT\7^);GX@:AX5CATP2VUI]H$Q5P'/R\8Y_O5UVE^(%_L2QN-;:&PO9H
MM\D,D@7&#@GGMT_.O/=&+/\ '75-4:WN%L9[/R(+DQML=ODX!Q]:9XGM[B/X
MF7<FKQWTFC:CIIM8)+>'S0A.-R=#@G% 'JLNL:=#.L$M[;I,R>8L9D&2N,Y
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MK(I4!HCDEX\_-C@ 9]ZZ_P"(%H;WP%K42P"9Q:NZKMR<J,Y'N,4 =%O4L5#
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MZ:7A-C,J]\YXXQGFJ^D_;#\7;IK^QMK6X;1%)-O*9%E_>XW$E5.?X>1_".:
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M2XA_OG:#@=<>N#Z&H9O&6C17$4"S33O+9_;8Q! \F^(D %0HRQ.[H,X .<4
M;%E96NGVD=K9P1P6\8PD<:[0*GJKINHVNK:=!?V4GF6TZ!XVP1D?0]#[5:H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#TJ.W $7'J34AZ5'
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M@0JQ!&>#N^3VWGT%=S7/&#P]X1O7NDMQ;W.LWRHSJC.99G;@$\[1DDXX'7%
M'0@   # '0"N(MM"U2XTW1M*N+-K=+'4!=S7!D1E8)(SJ$ ).22H.0,<]:ZF
MSUFSOM4O].@=S<V'E_: R%0I<$J 3UX&>..15^@#SFR\*WUI?7-L_A?19V-Z
MT\&KR)&S+&TA?YE(W%P,@8XZ<\5JZ'H5XI\5:;J5DR66IWT\R3B5"'CD15P
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M3&HK4Y@'U- $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWLK6SA^UI!:7GVZ!?/)V2YR#SU&><'U- %;P_P#\E&\8_2Q_]%-6AJNI3_\
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MF .&E#@ -@C .%&1VP<9SQH^*-$U#5YM+DLI+-EM9S))!>!S$_'RMA2,LIY
M/'/M0!A>(=4C\1> ;+4UMQ&[:C;J%WA]K+="-L,.""5.".HQ6I8(J?%#6"H
M+:9;,WN=\@_H*@7PWK2^'!IQN+%KB/5/MJ2C>JLOV@S\C!P23C'./4UK6VD7
M47C&^UAGA-O<6D5NJ G>"C,<GC'.X_E0 ^^UWR-;BT6SM3<W[P&Y92^Q(XP=
MN6;!/)R  #T[5SE]XUO+G^R?[.M1"9-9&FWL<SC?&ZY+(, @@@?>S_\ 6VK_
M $*]'BZW\1:=+"T@M#9SVT[%5DCW%@0P!P02>QS[5CWO@W5I+6*YM[NR;51K
M(U1S*K"(@*4"<<G"[?J10!7.JGPSKWBZ^CTV:X@C:WGN"DHQ&#'EB,G)ZDX
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MG9B L+ADDBF4!4EC<)G&!DCW'7%65\+:H^O:'<W<Z7$5GIKV=U.7(DE=UP7
MP>X[G^*@#1A\86LJ:?<_8[I=/U"40VUX0NTLW"[AG<H8C ..XZ9J*7QK:0O.
M9+"\2&WOUL)YF50L;-MP?O<@EP/ER1U..,T[#P[K$&D:;X?F6V-A87,<GVL2
M'?)%$X>,!-O#;@H/., XZC%34O#6MW>CZO;1VUN);O6([^(&?C8I0D,<<']W
MVS][VH Z&X\3I#J<EG#87%PL-U#:3RQE<1/(%()!.=H#KDX[^QJ_J^KVNBV7
MVJZ+E6=8HTC7+R.QPJJ.Y)KF]7\,W^H>)+?5((H+>ZAN8BE[',P86Z@%XG0
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M$,[2<<QYP>S#WK/T;2]:.FSV\_A?3=-G@M)8&FMVCW7;E-J[>!M4]22>P]Z
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MWT[W4-M%:%;-R)"I0/M;'." >.N,]J[G_A6VFCIK&OC_ +B3TA^&NG9XUGQ
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M/"OC:0?R]_3#IUB3(39VY,GWR8E^?G//'//-.>RM9(4A>VA:).51D!5?H.U
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH 0YP<=:;$K*@#$$^U/HH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7[H,^T+N("9.!P,]>*7Q?:W4WCWPCY.H2VX>2Y5=D:-Y9$))8;@<Y''.?;%
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MN:\MKP-=PW4,"VS2P7#1M-&.BN5QD?D:N1>(=%GE2*/5K%I'=HT07"[F9>&
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MI]F9XYC%%YIC,JJ$?:,D@$<D=,U4\,W'_"/:#JE]<:??+IUWJ\LEM EN[/%
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MLEW"8B\FY=J+$5&Y@"V7 XXP3VU-<BM_["\'W,$*\:E9W,\D<?(41X:1B!T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %(1D4M% " 8&*6BB@ HHHH **** "BBB@ HHHH ****  ]*;&NQ,4
MX]*9&Q= 30 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1O
MNFDC "#%*>E H 6BBB@ I*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@!K#*XSBA!A<9S0YPI.,XH0Y0$C&>U #J*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HI"<#-"G(R* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** $89&/6D48&/2AQN7&<4(-HQG- #J*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@!KJ&0@G'O1&H5  <^Y[T/]TT1_<% #J*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ (S0!BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>stamfordsecondleasemodif002.jpg
<TEXT>
begin 644 stamfordsecondleasemodif002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M $-O_J(SZBIJBMQB%![5+0 4444 %%%% !1110 4444 %%%% !1110 4444
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M-YTF\.H#9X& YY&<X[5"_@[Q#>^%1X<NM1L(K&"U6"%H(V9IF1E*.^?N\)R
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MCRH(]:-8\(C?ITEC90:E%:O*TEIJEU)*'WJHW!Y-Y!&WIC')Z&NPHH \XM/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UB1BG4R3JM "0
M\1(/:I*CC^XGTJ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *C
ME(!7-25%,,E?K0 Y!A0/2GTQ#N0$4^@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *BF."OUJ6H9_P"#ZT /0810HQ]:?24M !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3YL>&SM^8<XZX^E2*P8 @@@C(([T +1110 44UI$169G4*HR23P*=0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !137D2)"\CJB#DLQP!3J "B
MBB@ HHIKR+$C.[*J*,EF. !0 ZBF1R)+&LD;JZ,,AE.0?QH,L8E$1=1(PR$S
MR1ZXH ?1110 44F]?[P_.F>?$9_(\Q/."[_+W#=MSC./2@"2BBB@ HI"0.I
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M"U6>.>'3Y[>-G)"F(^:,[MQ7!'!&3QC%%I!J4GQ.L)=5%F)TT:5MUJK $F5
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MUDEK8-=)-.(YW$@7R$P3O.>O(' ]:O5X_#>W[Z7X-,M_<W$?]OM!'.TC?Z3
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M-L5B+ -G*KSCCH&-6-<U"WTC3[T:9JUQ-9&^M7NW#M*EI"S895<,#@[<D9R
MWO0!Z/17+^%(+*UOM3AT_4Q=VQ$4@BB):& D$$(Q9N3@,1GC(/>JOB K/X]T
M6PU"1AI<UK.RQ,Q6.:<%<!NQ(7) /UH [*BO']7DN(K"VL(+VX?38_%L%K;N
M)VW&(J2T>\')56) ]-OM77>#)A'XC\5Z9 TOV*TNXC#'(Y8H6C!< DG@L"<>
M] '822)#$\LKJD: LS,<!0.I)]*R/"_B.T\5:)'J=I\J,[QLF[)0J<8/U&#]
M"*S?'4ES=V5IX>L5C>ZU67RV#S>6! GSR\@$C(&W@'[U9/AY[GP[\0+_ $S4
M(+>WCUQ1>6D=O.TJ)(@VR+EE4Y(PW3MB@#T&BO'8K<P^"KC4;>ZN?[4M]?=;
M4_:&R[&X"%",\@J3FNR\/Z=;W7B'7+IKJYF-GJK"$&X9@FZVC##KTRQX[8&,
M4 79/$5_:V6E2WND&">^OA:/'YX/D@LP5\XYR #CWK>N;B.TM9;B7=Y<2%VV
MJ6. ,G ')^E><6S/)X.\'2-<,=NMIN+L6+CS)1@DG/H?PKTF21(HVDD=411E
MF8X 'J30!BV'B.2ZUM-,N]*N;&2:V-S TK*0Z@@$$ G:PW+D>]5K;QE!<7MO
MFTDCTV[N6L[6]9QB68;LKLZ@'8P![D=*IV]I/!\3(KO^U7O8KO39B(648MT$
MD97:5 &TYQD\G;U/;F--CDG\!^$=+C&^_BUM4ECSS&8I)'DSGT4'\QZT >LU
MCZKKLEC>1V5EIT^H7C1F9HHF5-D8R 2S$ 9(P!WY]#6A:WUI?"4VES#.(I#%
M)Y3AMCCJIQT(]*S/$.N+I$$,,,EL-0NFV6R7$@1/]IV/]U1R?7@#DT 5_P#A
M,+0^';'54MKAI+V<6L-IMQ)YY8J4.>!@JV2>,*:<?%2B"X0:?</J,-W]C^Q1
ME2S.5WJ0Q(&TI\V3CC/?BN<O?L=I!X8-M?1WEK8ZR(KR5%^1IY$8^83R/OR9
MZGEL9S5RUUBRTG7/&.O7<ICTZ*2WMMX'WY43# #N<NJ_AUQ0!K6?BV%X=6.I
M6-QITVE1+-<Q2E7_ ';*S!E920V0K?B*31_%J:K>V=O+I\]I]OM#>6C2,K>9
M&,==I.TX93CWK*LM1MK?3==U6]^SWFI7-L]U-90.)=EO&I"1$C([G/J6;&0*
MP_ D4^DZYHJ@I=VFKZ4T\.TY-@,AVC7))$66 ]<@9/% 'I6HZC::3IT]_?3+
M#;0(7D=NP_J?:JEMK<<B:>+N%K6;4'9;:%CERH4OEA_"=JY(YQD#-4/'$*7/
MA^*WFS]GFOK2.?C/R&=,Y_2J7B.VTYO'?AF:\2')CNUW2D#.$7 Y^IH VO#V
MN#7[.YN!;&W\B[EMBI?=DHVTG\:UZ\BE9(_"E]JENS07=MXE<1-'*PV;KD!A
MC.#D$YR.AK0U2YLKK5?$<>H:PMCJ%K.C6X\MVGCC"H4,(W@$LQ/ ')/.<B@#
MTVBJ&HS?9="NYY[AXO*MG=YXT^9<*26"G/(ZXKS3P_=36FHQ*+I(X+OP]+<!
M?M)>25]R[99>PD.YNF<=,G H ]:HKR;0;:&6U\ ,\DWG:A',ER1.X:5%@8X.
M#G&54X'&<^IS5@U*[L_!^JH+MHM/M/%+VLKMN80VFX9'!!*Y8#&>A- 'L=%>
M3ZD+6#2]4_L_6S=QF[T^0):+Y=O 6E52$(8\LO)&>X/>K>IRS^&]6\8#1))
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M&.YLK:9("#$LD2L(R!@%01QQZ5SX\1:7IM]XEO)[R_=+)X?M,3PL4M\K@>6
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MS6L7GB\-W'N-UQ@ 9X7KSZ8KT7_A"?##'+>'M+_\!$_PH/@CPN1@^'M+_P#
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M^SM&ICN(5;C!(!#%R,CH1Z53T;0-8\-7&D7BV_VI#%/#>V\!7=%YDK3*REL
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !2$9I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "L/5=3N3J]GHNG8%U.IGGF.#]GA4@%L'JS'
MY1VSDGI@[E<M WD_$^\65L?:=*B,()^]LD?=CZ;U_.@!]SJ4\-IXBD/B"PC$
M#8@E=1MLSM'RR>IW?CS^%2S:U+I>K:?%?3))8ZEMAMYU7:4GVYVGU#@$CT/'
MTY+4;6\?2OB#$EA?-)>2@VP%K(?.'EJN5^7GD'I6KXY26]TSPU;0,S7LVJVS
MQ%D*/\H+,Y4C*X )/I0!W-%%% !1110 5R/Q UW4_#?AFYUG3WA_T8 O%,A(
M<$XX(Z5UU<)\6DDNOA]J-A;QR2W5PH$4:(6+88$]* &:?XAUZ>32I7FM9HKB
M&*>[B2,J;>.1"5;)/(R.?QK1T+Q-C0(KW7M2TV)Y)71)89P8BH)V\D]<5G^$
M=(M;+1QJD,IVSZ9##)"X8LKQJ0<9Y[],5QNA:5;7WP5;1-1L+D7,]V\<2"!P
M\<C2$H_3@<Y)],T >O)K&GS-.L=_"6@&Z;:X/ECW]*(-:TZZMY9X+^"2&$9D
M<.,(,9RWI7C@CUO4/A3JNC)I]VNMVLV;@B%D:[C5L%@V/FR!C'7 J35]*FO_
M  CKEWHEKJDM[>6%O'/%);F$ (P!55P"6VY_*@#KF\=SR?$;2=%LI[2[TS4(
M&E$D9^9"N>,]\XK>\:ZKJ&A^%[S5=/:'S+1#(5FSAQZ<5YSI\0N_B3X*O+/3
M;I+>WTSRKB5K9T57"D8)('3I^-=Y\2F$W@'5;2))9KBXA*0Q0H79VR.P% &%
M<>/=4TO0/#VNWD5O-::HT2/%&2KQE^Z_WJ[F]US3M-:);V^@@>7[@E?;G_"O
M'5TO4]*L?!OB&.RO=2M+*"*WO-+DA=S;OL ,BKC.0?:K^MVEQ>_$*_N+V#56
MT;5M-6WBGM;;S,8Y*$%"5.>_'.* /4;G7M)LI3%=ZE;02JOF%'E .WUK/UOQ
MEI6C>&VUO[9#-;$ PE9!B4G@ 5YI=::X\>Z-YVGW<T%MHCQ.;F(R,'$;[58@
M8+XQT[UG-IM\_P "HK=[*Y^T6^IJ[1-;DM&GF9X7&<8H ]UL[N*]MHKB"021
MN 05;(JLNNZ7+=BUBU*W:X8D+&L@RQ'8>M+8S0/I*36T3"$1Y5?+*$\'H#BO
M"K1YG?PM/;Z=>VMK;ZY(?+DMV9T5B#EWQSDD].* /<9_$FCVXN#-JEH@M2!.
M&F ,9/\ >]*DO-7LK:UB9[^")KGY;=V;(<GICU%>0^)=,FF\1?$6>&QF8SZ9
M$D1%NQ$C #=M..36C;6]W#XA\ 7MS:W']GQ::82WE,1#,1_$,9!^M '5?#?Q
M7J'BO1[RZU!8%>WO'MQY(."%[UT^LZG!H^D76H7$@2*WC+L2?;@?B<#\:X#X
M,V]S9^'=3@NK6>V<ZC(ZK+$5RIZ'D5I^*S+K/B+3=!C(CBC;[9.TT3-$Y7A$
M)Z'YB&QGM0!K>"O$B^*O"]GJ^0LLH*RQ*<B-P>5/TK,\6>,I-*GTW^R[FTN%
MEU".SND.24+'MCI7*^#A?>&_&OB/PVBM):W"_:;:9866-9F'0=AUQ_P&L(6T
MR>#/"MC)I]XNJ6>NH]^!;LS9W,2[-CH<@T >I>-O%1\.^'[R[M+BT:^MHQ-]
MGE?EDS@U%:>)-0O(?##*]C&=1B$MRCS;7QL+?(IZ\X_#->;^)K>Y\WXC1WUG
M<2W%VL7V$_9VDW1[N-K <8ZXK4GB9-6^&<CVEQFVMR)_W+_NLQ[?FXXYH ZW
M_A8%I=ZCK=A8W-F'TZ %)YI\1O*0<K]!QD^];&D:\#X<L+W6+RQCGGC&YHI@
M8V;OL/>O+8;:6SU#XBVTVFW"O<QEK8K:,58;2.#CN2.!4GAVSU"UD\ W%_;3
MKI=II\Z2HT+$QS;6^\N,@XZ<4 >NRZUIL%M#<RW]NEO*VV.0R##'T![T^'5K
M"?[2(KV!_LQQ-MD!\L]?F].E>)ZAIUZ/A&EO?6<S"XUGS;2+RB72 RYZ8R!W
MY]:NW4,%KJ7Q$#V-V;*:"W:..V1D,@&[E3CDY(S[&@#UE]6M[FVNCI]Y#--#
M&6*JX;:<9&1UK'\ >)KKQ9X4BU6\C2.9II(RL6<?*V*X3PS+*GCRXDE69(I]
M 1$ MG1-RKG;G'S, .IY[5TGP;CDM_A[#!/%)#*ES-N25"A&9"1U]J )#XIU
MT_$)_"Z&RV_9#<1SD-GV!%7_  =XR?7WU>UO84M[K2KEK>9D8M&^"1N!/TKB
M]8MSJWQFND@GN+99M,-M%=QHRA)<< '&*K:&VIP^ /$_A46$T&NVR2A)UA8?
M; 3DONQ@L1GOWH ]<CUK3IED>/4;=DB :1ED!"CU^GO2PZSI]Q+%%#?V\CRK
MO0)("6'J/:O*M'2QO-$;4(3J'VF'0Y+.>WDMO+CC 4X4C:"QW=,9KG?"%O)9
MZC\/':&2+9%/'.WEG()<X5N.!0![5IGBK2]5UJ_TRUN5:>R=4?GAB1G ^E;H
M.<^U>4>$)H-$\4>.Y9;&9Y8KR2YB2.U)9T )PC8QSVYKTG1=276-'MM02WFM
MUG3=Y4Z[73M@C\* (/$VN)X;\.7NKR0M,ML@;RU."Q)  SV&2,GTJA8ZGK9U
M#2X[A].N[*]CD9[FTC==C!<A>68>O.>W05>\3:@-+T&:Y:U^U(9(HG@V%_,6
M2148!1U.&.!WKD-+TV+2_%L5OX1OG.E7,,QO;16+PVDFW*,"?N,6*C9UQVQ0
M!WL>H64UP;>*\MWG&[,:R M\IP>,YX/!I@U;33-+"-0M/-A!:5/.7<@'4L,\
M8[YKS#PK9--9Z#:O<:X-8TXRJ+62W6.*V8JP9V;RP64Y'&\DEA6OX2N[!K;0
M=-?3+G^WM-W).AB9/(9@RR2LV-K!B#@Y.2?R -F/Q?'K.B7-WH=YID<L-UY&
MZ^FPFP/MW':<C< 2OKQ717.H65FR+=7EO SG"B64*6/MD\UY-KES:W?POFMH
M 7GL=6)N (C^Z/VAR23C .T\^QKHKR?2K?4?%EOKP1)+T*+9IR";B#RE 2+/
M4APQVCG)SB@#MY]1LK5G6XO+>%D3S&$DJJ57.-QR>!D@9]ZFAFBN84F@E26)
MQN1T8,K#U!'6O+?#>F&#Q5I9\0Q1&XB\.A9GG P)!)G#$\;Q'USR ,UU/PTW
MCX?Z6DFX/&)$*MP5Q(P ([<8H M^(?$ITB\L+*V@\^XGN(%F)^[#%)*L>X^Y
M+$*.^">@-=">G%<1K>E7UE:-,TMO<37>M6<KR"-E8*+B,(O4\* !V[GKFNKB
MU*W?4Y-,WDWD4*S2*$.T*Q(!STY*GC.>* *FBZI<W\FJ17L$$$EC=^1^ZD+J
M1Y4<F<D#^_CIVJ'1=?&K6=QJ[/;PZ-DBVE=B&=5)#2,3@*I(X'IR>N!D6MPE
MV?&]G97$;WLDS/%&C@L0;6)58 =MP(SZBJ2:C:0_"CP],51[<I9(TIW>7"RE
M?G?;R55UY&1GIGF@#J]1U27^QYK[13;7[0?.T2/N\U1R55@>&],YYX[Y%K2=
M3M]9TFUU*T),%S$LB;NH!'0^XZ5Q_@"X3^TO%4<LQDE^WB5V:$Q%E,:_-M(X
M!Y(]1Z]:M?"Q)T\ V1F#!7DE>'/_ #S+DKCT% '4R:C8PW MY+RW2<D 1-*H
M8D]!C.><'\JYO5O%#-XA.AZ9J6F07"6S2-)<L'S*6VI$ '&#D'/4XQ@<USTQ
MM(=(\6Z+JNTZU>74TEM$P_>7.1FW:/\ O;<*./NE3G%:=AJ,$?Q1CLY]1M9;
MM=$C@E&\;WF$A8@>AQDD=<$&@#H]5U^WT+3[2;4Y(8[BXDBA$2R8W.S*IVYZ
M@9)^@JK:^(E76M6CU"[L8-/@6W:UF,H4.)%8Y+$XS\O&.PJK\076'0+2:0[8
MXM3M'=NRJ)ER36%KMWITP\=SL8_,&D(BM(FT@F.3Y1D=<N@QU!8 \T >@7&H
M65H ;F\MX05+#S957('4\GI4X8.@9&!##*L.0?>O*TO(;+4+&_UB74/L.IZ-
M:PVUU:1&3Y@I+Q':K'+;MWOCVKT/P_;FR\.V-NT#VRQ0A1%+)O:-1T!/J!B@
M"GX=U>_U>[U47*6R0V-Y)9KY8;=(5VG<<G@8/3GZ\<[%U>VED@>[NH;=3G!E
MD" XY/6N4\)W]K:2>)/M$RQ;M6FF3?QO0JN&7^\.#TS69J-^)]?T[5=2AU*V
MTZ\LI8(GMXF<(1*2/,782N]-IZ=L'.. #O)]1L;6..2XO;>&.7B-I)54/]"3
MS27.IV%F%-U?6T&Y=R^;*JY'J,GI7FUQMAFT[1K>UGTT+I%PUO)) ;F5HVDQ
MY2KMP&(5"<@D!MN!UILLS'0]/N]/G8W,6@0QS65Q:L\-]$008@1\P?.>GJ."
M,T >ERZG86\JQ37MM'(P#*KRJ"03@$ GU(JR2 "20 .237EUS#!)JVN6VL:=
MJ\2ZI!;R00VR,RSJ(54P[@ORLKANI'WL\5Z-IJR6^CVBW2F*6.!!*'EW[2%&
M<N?O8]>_6@"KI5^RZ/!-J>I:?+*SNAGMVVQ.P9L!<GJ ,'GJ#6E!/#<P)/;R
MI+$XRLD;!E8>Q'6O-])5X_!&D0QW<^F746H74L-P+;S$B;?-A9%/0,CG'3J,
M5V7A6>>Y\-VLMS:+:S'>&C4$*2'8;U#<@-]X9[-0!5T/Q"UQ=:O%J=U:1-!J
MKV=L,B/>H2,J,$G<WS'Z^@Z5M3ZG86MQ';W%[;0SR?<CDE56;Z G)KS?4(UE
M\-^+\K*6_MU+F+RD+,P!@PRXZC*D9'H:74HX#X@\2VVKPZM-;:D(I;06D3-'
M=*(U 0,JG#!AWQC.: /1SJ5B+EK8WMN)U*JT9E&X%L[1CU.#CZ&@:E8R7;64
M=[;&[7K")5+CZKG-<3H.G1W'CGQ U[9(LXM[!H?-4L%E2-LE6(^8J2O(YJCX
M6B@E&BVM[9ZLVM6%RWFQSHRQQOM;S)MX3:5;)(R>2P[\T ='X.\61ZUI$3:C
M?62ZDT\T1A1@A.UR!A"2>@'K6_#JVG7-M-<0:A:RP0Y\V5)E98\#)W$' X]:
M\JT[0@WA&32Q821:^^L>;&_V5A);@3@^:6Q]T("<YP<@=ZZ.]TR\MO%EUHEG
M$/[*UM5NYL$ 0[&43C'^V"@^K'WH [M9HF@$ZRH82N\2!AM*XSG/ICO4,&I6
M-TS"WO;>8JH=A'*K87U.#TX//M5;7USX;U1?LYN ;24>0N09/D/RC'//3BO-
M=+1SXC2^V7312>&98 19/%#"58$1)E<X SRQ))[\@4 >FC7-)8 C4[/#1^</
MWZ\I@'=UZ8(.?>I5U*P:R^VK>V[6G3SQ*I3KC[V<=>*\\L/EN?AI&;202PVC
M^=*8B#"!;[-K''&6]?2J4MK?2^&)YA9ZE)%;^*);MTMU=)?(+,P=!C)'SJPQ
M0!Z:-8TUH$F6_MC%)((E82C!<D +]<D<=>:DMM0LKU9&M+N"X$9VN8I ^T^A
MP>#7FUQ8Z:^F7-Q;:?J\MM<ZI82M<WB2L\I60;WVD;D4)D;C@'.!VIVMVE]<
MWOQ#CTZ"9I9K:SV!$(\[:K"15]3MXX]10!U47B9;SQM;:58W=E<V+V,L[M#(
M'8.KH "03@88]OY5N6VIV%[-)#:WUM/+']](I58IVY /%>=S:A!KOC"&71$E
M(D\/W5O"_P!G=%$@9<+EE X/'IDXZFD\/W-CJ;646EQZL^K6-E);R+<AHULQ
MY>-I)7#?,$PN3_>[4 =3J/B9(_$>BZ=I][83+<W,D-U&L@>5-L;L, 'CE<'/
MMZUTU>4Z=?:?-<> 8+&&938S26]S&8&W02F$@J^!PQ;).?J?6O5J "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN5^(]_J6F>!=2
MN]+D2*9$PTA8AD0G!*8_BY&.F.O:G+J>O>;'I-K;V#:C;VJSW4DLLAB 8NL8
M4XW$G8<D],=Z .HHK)\.:XGB'1X[Y8'@?>T4L3'.R1"58 ]QD'!K"A\6:G?:
MY-8V5M9YBNWMGMIF99XT"$B9A_SS+ <@=&% '9U1O]*M]0EMIWW)<VLF^&:,
MX9.1N'T8#!'<&O/_  WXN\0?\(G)JU[':3?:-2,*R%W"6X+D.SYZ1K@8 -79
MO$VMZKHL3VJV=M<P:XFGW!#.R2;9%&5(P=IR,@]LB@#T&J']E0-K7]JR,\DZ
MQ>3$&/RQ*>6VCU;C)Z\ 5RNH^.+RSO+R"WLQ<G3VCCN$B@F9IG(#.(R 5& P
MQN//MUK=\4WEY;>#]3OM/9(YXK.296E!!4!"> .=W''O0!KM<P1SQP/*BS29
MV(6&YL=<"I:\X0ZD/$?@R:6*VFO9-/NPKJ2H*^7$5WDY/4GIG[W3K6I#XNU&
M;0(;D6$$=X-2?3[EGD/D0%&8-(3_ '<J!VY8"@#LZ,UYP?%FK^(M,TZ73A:V
M^S7!8W9\QB)=A# H0/NMCG//:NN\0W6HV7A._N[00F_AM7D .=NX*2<=_I0!
MK&6-9%C9U#N"54GDXZX%8.N^&)M:O(;B+7=2T[RT*E+.0*'SW.0>:Y]?[0'B
M'PM*ZV\VI-IUT(V+L%9-L1!D8Y8G/7&>M36GQ!:[\.Z9=BT6*\O;B6W*[7DC
MC,>[<V%!8C &!CO[9H G/@&Y\HJ/%_B#/]XW"_\ Q-0GP7*'8-XWUOTPUQ'D
M?^.\5T7AS6)=;TQIY[22WECF>%@\;('VG[Z!@#M(P1D9[=JY&>.PL/B!XEN'
MT,7Q^P6\QVPHP#8DSG<>-V!T].: +C>!W_=?\5KK@WG:@^TI\YYX'R]>#TJ<
M> [H=/%^O^G^O3_XFHK6&UT_3_"-M::1:F.ZN&FC,W(M'>-YB$'7^\!Z "E@
M\8:O+J4^A'3K9==AN$'E;G\IK8J"TX8@<9W#'K@=: )?^$#NCC/B[7_3(G7G
M_P =J.?P*\<?F2>+]>18^2[72@#Z_+4>J^/I[34[U+.P^TVNG3"&Y5(Y'ED.
M%+>7M4H-H;HS#.#TJGXR\076L>&O$L&FV-O/I]E;M%<O<%E<N4#91<'[@(/.
M.1VQF@#0/@>:2'S1XQUQHV&X.+A ,=CD+TJ)? KRR@KXRUQV]$NU'U. M=A9
M)#+I-LJHI@:!0%V\%2HXQZ8[5XXJV2>'+S1[.P2+5[[7;BWL+KRQ&L3+)D'S
M,<8 Q@<]@* .Y3P!,F['BO7SN];D?_$T?\*]<A0WBOQ"=O0_:@#_ "K0U;Q)
M/IVK6.C6T$-Q?36[3R232-'&BKQDD*>IX'']*SU\;WT\VAV\&BLMQJ4D\+I<
M2&/RVC0D]5R5/!W8Z9XSQ0 'X>,2#_PE?B'C_IZ'^%(/A]+MV_\ "6>(!QC/
MVH?_ !-4-0\5:UJ>CH+6&TT^YAUQ=-NC).V-RNI&U@!\K=#D=#C!S7<74M[#
MI3S116[7BQABCR,(\]_FQG'7''Y4 <?'X'B-T;=/&NNM<(,M$+Y2P^HQFIU^
M'CJ=P\5^(0?^OL$?RKF?#VHRV_@G0O$5[I=M=W;Z@5MYEG82;IY721F& .AP
M!DCH>,5W4>N:J]['I?\ 9]NFI>7+/(KW'[M8@Y2,Y )R^ <8XYSR,4 9/_"N
M7Z_\);XBS[W8(_E3E^'TZ@@>+O$ R?\ GY!_]EIW_"=S.VF1Q:8GGW=[-82Q
MO/CR9XP>/N\J2!SZ'IVJN?'>J6UA?75YHL")INH"SNREUD'<Z!3&-N6X=2=V
MW^8 !*/ %XH(7QEK_/\ >F1OYK2+X U!?^9UUX'.<ATR?K\O-=M)%'-&T<J*
M\;##*PR"/0BO+M-LM"O=*_L>?0YHWNM2NK7^T$ME01_O92I20CG 0*,<9XH
MW?\ A ]1SD>-=<'I\T?'_CM1_P#"#WLS,$\;:TQ0A6 DCR#UY^7K3+KXE06N
MLS6@M3+;V]W]CE8;S,6!PSJH3:5#?[0/!XZ5D:)K&HZ)=^-;ZTTM;VWM]7EE
MN?W^Q@@'S;!@[B!S@XH W3X!O^/^*TUXX/>1/_B:&\ 7[$Y\::Z5)S@NG/\
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M-7N-8#SS+@-)&TYB,1(&2FT 8[8% ';Z;X9O;#6(KJ;Q/J-ZB(VZUN"FU\\
M\ 'BNFW*I"EAN;H">M<+XC\,6$ @NHY)Y?$5Q?H;2Z,A\W)?<5XX\M4#<'C
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MC9 &.>O6LB^NQ%X^TO5-1@BM%AT:ZG)$H8D H2I) ^Z"3Z=: .\IK2(C*K,
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M/[@= =G;CTX]*!I=@&M&%G #9Y^S8C \G(P=OIQQQ0!;HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\_Z!-U^:_P#Q5(=3NQUTB[/TV_\ Q5:M% &3_:MW_P! B\_)?_BJ3^V+H?\
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MN1#Y"02;KA=Q!(.\[3A20,&@#L#K+8;;INJ9'3_1P,_G3#K=SVT?4S[^6O\
MC6/HFOZUJ/C/6]!FGLQ%IBH1*ELP:0NN1GY\#!_/':LWPGXQUWQ);^('E>S@
M;2B8T*6['S&&XY.6]%Z#UH ZH:W<]]'U,?\ ;-?\:4:Y< ?\@35#[^6G_P 5
M67\.O$&I^*?#2ZMJ3VX:21D6.&(J%VG&<DG-4/&7BC7/"OB+22TEI_8-],(I
M)3 3) <\@G< >.<X['TY .C_ +?N,X_L+5/^_:?_ !5._MR?_H#:E_W['_Q5
M1QZA>7?B^>QMKB$V-G"INE,)W"1N54-G'W<L>./E]>-Z@#$_MR?_ * VI_\
M?L?_ !5(=>F'_,%U0_2(?XUN44 8?]OS?] 35/\ OR/\:#K\V#_Q)=4_[\C_
M !K<I#T- '-Q>*1/>W5I;Z9J#RVI03((@-FY=PZGWJRNN7 )!T74NF?]6/\
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MICN)(U>*,QK(@/RL 23R/>@#6HKD_"OB]?$6O>(+)6C\NQG5;?'5X\8+>XW
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M]'NKV5HM826&.>6%RIW&-MPRO7D?3TK<\,6$&HZK;:GIY,,6F2&TF'FO^_S
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MM:2EMC*/,G9< A5!;'3D?EV]% 'DMWH>K>$?B!H>IV7VG4;9[<6=XEI8L!#
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M^)>BX&?^);=_^AQ4 =6.E+2#I2T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 <GX!'_$FO#_U$KO_ -&FNLKE/A^<
MZ'>'UU*Z_P#1K5U= !1110 4444 8>O^$])\3+&NJQSS1QX*QK<R(F1GG:K
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M)]31?>'-*U*_@OKRU\VZMSNAD:1\Q'_9P>.@Z5JT4 9UMH>GVE_+?0Q.MU*
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M'YT +12;E_O#\Z-R_P!X?G0 M%)N7^\/SHW+_>'YT +12;E_O#\Z-R_WA^=
M"T4F]?[P_.DWK_>'YT .HIN]?[P_.EWK_>'YT +12;E_O#\Z-R_WA^= "T4F
MY?[P_.C<O]X?G0 M%)N7^\/SHW+ZC\Z .4^'W_( N_\ L)77_HUJZRN2^'S
M:!<Y(_Y"-U_Z-:NLW#U% "T4FX>HHR/44 +129'J*,CUH 6BC(]:,CUH **3
M(]11D>M "T49'K1D>M !129'K1D>HH 6BDR/44N1ZT %%&1ZT9'K0 449'K1
MD>M !7)^%?\ D:?%O_7[%_Z*6NK)]ZY/PH6_X2;Q:6  ^VQX/J/*6@#K:*,C
MUHS0 449%% &8OAS1$OA?)H]@MX&W_:!;()-WKNQG-/O]$TK56#:CIUI>$
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M87MR@//02M[UT?\ PB^D=!I\>/\ >85G^ !CP_,#_P _]R?_ "*U=70!B?\
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M&MX\;8"O.S>67(]1AB/3=GK70^ [F:Z\'637$KRR1M+!YDC99A'*Z D^N%%
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MI_\ %4 4]/\ "%U!J&E2WU]'=0:+%)'8*%*LVX!0TAZ$JHV\#GKQTIEOX?\
M%D,KLWB"R87%PLERZVC++L!'R(Q<@84;1\O<GJ2:T%T_Q #SXD0_]N"?_%4\
M6.N8P?$*D^UD@_K0!F2:!XK;5;S4HM9TM)YAY40>R9_(B!.%5MX&><DE>3[
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MX6NN8^;6X"?^O''_ +/0!MT5B_9=:_Z#4/\ X"#_ .*IOV/6SS_;L8^EDO\
M\50!N45A&QUP@@:^@/K]A7C_ ,>IHL-=V8/B)<_WA8I_C0!OT5SXT_7NWB//
M_;@AQ^M-.F>(._B<#_MPC']: .BHKG?[,\1=O$PQ_P!@]/\ &E.G^(<''B1!
M_P!N"?\ Q5 $?AX?\5-XI/\ T^Q?^DT5=+7G^B6.MOXA\2>3KZ(ZW<0D_P!!
M4[F\B/G[W'%;XT[Q#W\1I_X+U_\ BJ .AHKG_P"S_$'_ $,4?_@ O_Q5']G^
M(?\ H8H__ !?_BJ .@HKG_[/\0?]#%'_ . "_P#Q5*NGZ_GGQ$A_[<%_^*H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRQXS-']DD/!W?*X?=R< 86@"76M3UG3M'T>&]OY+":2-FO\ 48++STB95'#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9\$:B^IP:LRZ@;^SAOFBM+ABK,T813@D 9PQ;DC)]Z +_G^)/^@=IW_@6_\
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M2;3/;_33_P#&Z7[3KF?^059@9_Y_&Z?]^ZU\>YHVCL /PH R#<:[VTRRZ_\
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M_P#,(M!_V_?_ &%*;G6.VF6O_@7_ /85K;?>C;ZDGZT 9!N-9_Z!=G^-V?\
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M5/\ P*?_ !H WZ\G\7Z7KGB/Q':6KZ2PFC@N4M[I,>4F9%,<N[/RL ,XZY'
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M?>*+VVDE7Y$EO0I(SC/(_6KP\-Y4XUG52&'7[1_]:@#H**P#X:) _P")QJW
MQ_Q\?_6I/^$9/_08U;_P)_\ K4 =!16!_P (TX_YC&J_^!/_ -:E_P"$=?\
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M+"\N4MX?M?F/T\RRFC7IGEF0 ?B:S/B'#%+X"UAI(T<I;,R%E!VGU'H:U/\
MA(=(_P"@C;?]_!67XANM(UW1IM,?7(+:&X&R9D92Q3'(&> >G.#0!O7\4<VG
MW$<L:R(8SE7&0>/2N7TG5/[&^$NFWX&9(M+A\I<9W2%%"+^+$#\:T'UJQ?2C
M;-K]D;DIL:X^7GU.W.,X_#/;M62MOH*Z1HNEG7X9+;2YHY5\QTW2B,'8I(P.
M#M/3G;0!)?\ AZ73O!LL=IIT6I:P=-^R222,/GX9F//7+LQQU)(S6787-K<W
M/PZMK+S3IS6\\R),<MNCA55W8X)&YOQZ5LZGJ-I?7@:V\9)8VS1>7+#"8F).
M3\RLV2IYQWZ#&#S3+E?#3:?IUO8ZO;6<NF8-E,KAS%A=N"#]X$$@@]?4'!H
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M6]GI'CWP]91Z3]DM$@FAM+F)5(DD*@E&/W@  QYZDY[&FZ4=!L9K:2;Q9:7
ML8'MK$&2-3 A.,GD[F"A5SQP.G)J>UN]'-[:7>K^+K+4)K,L;?YHXE5F&-Y
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MQ@\1:#(@+6]T;N"3F.9HY$C=<?PNV ,CJ57WR >@>*-=L/#&EFZEMA/,QQ%
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M/R\G  _"H]FL!W;^QM,W."'/F<L#US\O.:DU:5KS5](TH;U+L;RXVMC$<8&
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M?VGQ'G_D&V7_ (%'_P")I/M7B0?\PRR_\"3_ /$UNT4 8'VOQ'WTFW_"Z_\
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M76OJ,?V1;@ < 7/_ -:F:U)?0^(?#T=O?R16\]R\<\.Q2) L,CCG&1RH[UT
MH Q1=:\3DZ7 /^W@?X4_[5KO_0-@_P# @?X5L44 8_VG6_\ H&VW_?\ _P#K
M4IN-: XT^W/_ &W_ /K5KT4 8QN==[:;;?\ @1_]:D-SK_;3K7\;@_X5M44
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MSG(QR*]"_P"$?Y)_MC5N?^GG_P"M65=G1['4H=-N_%5[!>2*62*2\ )''7C
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MH7/MD<U;7P[C_F,ZO_X$_P#UJ -G>*7=[&L?_A'O^HQJW_@3_P#6H_X1\_\
M07U3\9E/_LM &QGV-+61_8)_Z"VI?]_%_P#B:4:&X.?[7U+_ +^)_P#$T :U
M)FLO^Q7_ .@OJ7_?Q/\ XFF_V$Q?=_:^I9_ZZ)_\30!J%R#CRV/N"/\ &N=\
M8[GTZQ 0C.HVO4C_ )Z#WJ\="8D$ZQJG7/$RC_V6L'Q-I;65M8S_ -HWTY&H
M6PV32AE_U@[ "@#LDZD_6GTQ.I'UI] !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 !Z5RFF_P#)1M>_Z\+3_P!"FKJCTKC;>_M++XC:W]JN(XM]A:;=YQG#2_XT
M =D*6LY=<TL]+^#_ +[H.O:4#_R$+?\ [[H PQ#%'\6 \<2(TFBLSLJ@%CYR
MC)]>*J^,/#UC-I4]E86L1UK4[@/#<,,RHV\,TF_JH11Q] !UJY(^G-XHCUQ-
M=MU=;<VIA*@J8RP8X.00V0.>GM6?<V4$NJ7FH1^-Y[>2Y(&(TA/EH"=J*64D
M#GGU/- &S<I)?^,=/M@P:WTR W4N>\KAHX_Q"B4_B/6C1HHXO%OB,1QJ@8V[
M-M&,DH<D^]1Z;?:)I'VDG5XYVF96+R/E@JHJ $]3]W.3W)J@9K)+_6;J+Q(B
MMJ,/E[/+'[EPNU&4@YXSR#U/I0 :5HNG^)KG4-=OX_.@GO5-NC_<:* ,B9!Z
M@L7?'3[IK)U G3_"_C36]&C^SV=S&JVGV?Y 2B['F4#H"2>1U" ]Q6KJ"Z%=
M^%HO#]MKK65JD:PEH2I9D Z$D=\<^O/K4%G#HL5G=VNI>)I=1M9[;[-Y,P1$
MC3OM5% STY[8XH @U;3XK+Q?X4TZS>1(;W3[JQG>V;83$L:E6!'.022#ZFM
MZ/:+XZTA='T^&VBTF&3[7+$@0;9$(2+C[QR=_M@'J:IV2:);7L5[<>)1<75K
M:&SLI60 P*>K$=&<\9/ XZ4S2HM*TQ8(3XTNIK:.X-P\;>6IF<L6^=PH9AD\
M@GD#'2@"CI&OW<<]YXMU/3(9K.XU'['#/YV9;>$/Y:[4VX W]<,"2<XX%>A:
MIK.GZ+ DVHW'D1NVU3L9LG&>P-<BUEX7>W>T365339+T7S6H<8+@AMH/4)N
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M4,0"?1/F^G-5]!\01^&O UM-<&&.\U2[GELH+B01A@\A(9B?NJ%(8GTQW(%
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M_L</_/*+_O@4GV*'_GE'_P!\59HH K&S@7GR8S_P$5S7A2VB?4/$8**0NIN
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M!%IUHR !OM]L!@#_ )Z#/:NFKF_&7_(,L_\ L(VW_HP4 =$O0?K3J:IYQ3J
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M,4 <L7U5KW[:W@^S-U@#SS=1[\#_ &MN:MKJGB'^+PX@_P"W]/\ "M[%% &
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M444 %%%% !3'D",H/\5/JK=MMDA^I_E0!:HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **Q]6UXZ9>0VD.EWVH3RQM(4M AV*"!EM
M[+U)X^AK-T7QS!K3Z>R:-JMM;7Y9;>YGCC$;$*S8.UR1D*<<=J .JHHS1F@
MHHS1F@ HJ&*Z@FGF@CD5I8"!*HZJ2,C/X<U-0 45DZWKT6B2::DMO-*+^\CL
MU9,81GZ%LG..#TS6M0 45F>(-9C\/Z%=ZK-!+/';)O9(L;B,X[FH?^$CM_\
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MC>VK6DT:6VS;.XPDVX9.WUQT-7* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *CD*@KN7.>E25'*,LA],T 24444 %%%%
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M,L.G./M$DRCR/.,)N%&2T8<<J2H/(QTJ_#HNFP:M/JD5G$M].H62<#YF _\
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MZ]>0:C#9R:5?.H:6^DQ;PQ8X>%4(<,H8Y)).>,8KLD\(:!#8)8Q:;'';)/\
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M.PA\YY X.XEAA@.Y)SUZUT7C2QNM1\*7=O9V_P!HG#Q2K#D#S DJ.5Y[D*:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!G:CKFG:3/;PWLYBDN6V0CRV;S&_NC .3[5H Y
M/KZUQ'C[_D/>#/\ L+K_ "-;_B?7X?#F@W=\QC:>.%Y(868 RLHS@#J1ZXZ"
M@#8(W*1R,C'!JCI6CV>BVC6MBLB0M(TI#RM(=S<L<L2>3S]23WKGK:[U^SG%
MU<ZA#)8SV3R9OO*C$4X7<-GE\F/&<@Y( SD\U1T+6O$$^H7-FUPUV7T@7=O)
M<Q)&&GR5.S:JGRB<8W#.* .^HKS%?&M_96-_%)>RMJ<,<2R6=[;JDL$TDJKN
M&,*T0WC'S'MD\YKKM&;68-8NK74KGS[5XEEMFF$2S!@<.-L?!097!QGYL$F@
M#H*2N.U[6-0T+Q/&;K4'CT:ZLYVC(@5C#<( V,XR05#$ \DEN>F(?#/B+5=:
MN--L[N9(=1M3<'5X(T4@;241<\XR2&&#R%/- '2Z5KFGZWI,>HVLN;25C&K2
M#9EMVS&#ZMP/6FZ5?:6UU=Z/IL:Q'3=BRPI%Y:Q[P2 !@#L3Q7 66HZEXE\-
M>&+Z\OY8Y)=>V.L"HJ$*TC+D;>VP?UR:FU&[U#3-5\>W^G78AN+%+2=G:(.9
ML0?=.> .#T //48H ].HK)?4IKCPD=4MBL<TEC]ICWKN"DIN&1G^M<K:ZWX@
M&D:'<7-ZCMKOV5(C'"FZWS"7D(S@$MM&,Y"DG@@8(!Z!17$7=]XCL-+F2:>X
MG\F_ DN+:*&2Z2U*$[FC V;@V!P#E><9JG!J^O7B>&$TWQ':W4=_-=++=&V4
M^8B[V0D +A@NT%0!\PZXSD ]#HKS2T\5Z\=1/A>>Z\S41J+VO]H10(&,2Q>:
M&"D[ YQCG@>A(K4EUS6["2#1KNZM1>3ZB+6*\^5F\AD=U=T& LAVX Q@GG':
M@#MF=44LS!0.Y.*7->8>,!KD>EV^EWFLQR2/K5LD;X17D@=LH954 ##J1D
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MO$'*<\\Y(!XR<5U]WX,T^_LM9M;FXNVBU>19;@!E&UEVXV_+QPJCG/2NCHH
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MN6".K%6VD YP?3ZT /HHHH **** "BBDS0 M%)N&0#WZ4M !1110 449HS0
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M:/-YT2/*VZ0DJ3NQP.4[5:L];MK.^DNHM<T"%8X)5M;6*=_*$DL@=W?/)Y'
M&.XXSP ;OA+QW-XN=?LNC-"D9<7;23_ZAA]U<;?F)].P'/;.?#\4)GT:^U:3
MP],EGI]W]FNY%N5;9RH)48!8C=TP!C'/IA>'I+#0?%LFJQ>*]*:&[B']HQ&4
MXFF/+2)P .>@[9-<_H5W%JGAKQ'HO]NZ986M]JKR-)+(?-V94DJ.A4@8Z^M
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M6CW^G3VL=S);-*NWS8_O*.^/0XR,]JPKF34]$TOP_96\UJ;A9(;>:':S&=
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M.N6D]U8VVKPQZ)<W#W! C(N8@[%G1&!Q@DGDC(!/M71:Q:37^B7UG;M&LUQ
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M!\J57.\+CMM48Z\FNHKGM*T.[L/%>L:I)+$UO?101QJ&)=?*!&6XQSN-=#0
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MA2%#(#M)[YP3GDDUV?C2<1:79Q?:)HFN;^"!8XCM\\LW^K+#E%(SEAS@=^A
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M&L<H4GY&*Y...Q_SS4VJ3Z/X=TV;4;N&&*!,9VQ99F)P% [DGC%8'PQF@M?
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M0!Z-]F@_YXQ_]\"D-I;GK!%_WP*\^NKJ>_\ #OBS5I=0OK/4M-FG\J)+MT6
M1+F,; =K!L G(.=QH@34=:N=::YUC48%71[6<0PRF,)+)'(21CD8*]._?H*
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M:C!H7AGQC?7EW);1LUKJ*+,XB:,NR)<% =I(P">#G</04 >IT5A^%H[XZ/\
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MNH//A+1,JNHQD!B,%AD94'([UM4 %%%% !1110 4444 %%%% !1110 4444
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M_2L30+;4+=/ BSZ5?QFQAGCN=T!_=%EV*3CL2,^PP3BO3#2$A5+,0 !DD]J
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MT,EV&4#RCY9CYYY&[GCM@UZ-110 4444 %%%% !1110 4444 %%%% !1110
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M ^TY&]E4%N0#U&<<TR[\(17#:C%#?SVUCJ;^9>6L:KB0D8?!QE=X&&Q[]":
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M8'''&>:UJ\JOKC1#I%U+J9MDU^#7(WE:XP)D NE"L,\A/)Q@CC%>K @C(Y%
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M_P!GTR*.]LK@8,T;C(>(_P!\8(]<T[5A)=>-M:M-5O/L%M/I\/\ 9;SQ[RF
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 48HI#0 M% Z44 %%%%
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M*D@01X!Y+;LYZ=>>#0!0C\'>*H5\N'QIY4?=$TJ$+^7>E'@_Q2H0CQD%9/N
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M6,C-J5R8! T@#Q!2VYC_ +H0DCWKH+B7R+>67&[8A;&>N!F@!Z(B($1551V
MP*=@>E<7X6L%\4>&H-:UGS9+S4%:4;9646ZDD*L6#\F  <CDGJ:HZ3XUN=.M
MWT^]M[G4KB#6GTE)X]H9EQN1GR1EL9' P=O)&>0#T+%1SV\-U"8;B&.6(]4D
M4,I_ UR\GCJULK/5I-2LY;.YTV:.)[=I%8N9 #&0V=H#>I( P<]*A'Q$L3IV
MJ7"VQN)-.,?FK:3)*A5QPZOQD \' )![&@#HM3TB'4[=;:1VCMVDWSQH !.,
M'Y6XZ$X)Q@\=:T*YNY\3WEO<R6QT.?SPT[('E54:&(+^\W<@;BP 'YXK"O\
MQQ?W.K^$O['LVDL]7268J[JK2[(R3'R/EP2#G/.,>M '?[$WE]J[R,%L<X]*
M7 ]*XV76;+0;OQ;JJ:/>>;:^2URPE4^?A#AE!;"@ \]\'IGBM.W\3[]8O;"[
MTVXLQ;VGVQ99&5O,CR03@$D'(Z'GZ4 =!17*V7C.6XOM+MI]"O8?[40RVCK)
M&WR#!9G&X%<!E.!GK[5U5 !1110 4444 %%%% !1110 4444 %%%% !1110
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M41AW% Q(!;)=\\="/2EN](\6:OH5XM_+IR7LZQQI;Q2/Y$:JVXOG!)9CQCH
M!S79TM '*^(M"UC5]1TJY@:R\FW1_/MKF1S&)&P X"C#E1NQG'7M7/6?@SQ)
M90>$9$;36N=#>>-E9WV-'(H4-G&<C!./<<UZ710!PNL^'_$.I6/BR"**RB.J
M")+5C.3E5 1BWR\949P,\G&>]6-475+"YGUJ\M++[+#HSQ7#[R[F3[V-NWYE
MR,=>YKLJ0C(P>E 'E'AIM3T27P[)J%KIUS%M2QMVAOVEDA$I&2J8QZ9.>%&
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MR-&CQKT1E4@,HR>"".36%;>%C<^,]?O=0LY%L+N&"*#9<E%=44JZLB,,@Y&
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M*** "BBB@ HHHH **** "BBB@ I*6FE@" >] #J*!10 4444 %%%% !1110
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MZ*X! 89PPP?Q%<=J::AH_C>XU4:5<ZGI]_8I;%;90[Q.C,=I4D#8P;KGKUH
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M"=4M9='>X%L%^ZS-%G+9^;J.PZ>]=>.E !1110 4444 %%%% !1110 4444
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MT(VH6(V+W8GWY+8=%QCM]X_I0 S3_#IM-=;6)[I9KMK-;5RD(C$F#G>W)RW
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M110 4444 %%%% !1110 4444 8][XACL]7_LP6-[/<&#SU$$88,-V.N<#O\
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MNHY7@\UD,[JC?,6+, >2.,YQVX-6_!5B^G>#[7="RR3&2Z,0ZCS'+A>> 0&
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MY8Y/,)<C@$DX'7@>]='JFF3^(?"MSI]ZD=I<7,)7$<AE$3]5(.%S@@'H/ZT
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MG1)MNXHIA8M@'C)VCKT_2L_^W]<L)KK1VO?MEQ'K<%E'=2(B-Y$D8DP<#:6
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M$4:0Q)%&,(BA5'H!45Q;6E_'Y5Q##<(CAMLBA@&'(.#W%<KIFH:CJ=G%K_\
M;,<%NM[(D]K(%\E(5=H]N=N[?PIR3C)Z8J+X<0W9LM4N;G4[NZW:C<QA)@F!
MM?&[A0=QQZX] * .U+JK*K, S<*">3]*=7*:I9S2_$'1W74;J)#9W+")1&44
MJT(X#*>2'()Z^F.<Y7_"0:U+X1L?%<%['MFNT:2R94\L6[R[-@; ;>,CYL]0
M>.@H [?4+^VTNPFO;R3R[>%=TCA2V!] "3^%8_\ PFVB?:C:[M0^TB/SC#_9
M=SO"9QNQY>=N>,]*WY(TE7;(BLN0<,,C@Y%<E_S6 _\ 8 _]N* .GL;ZVU*P
M@OK23S+:=!)&^TC<IY!P>15BN'O+G7GU75;#0E6&+35BCMH46)8MQ0.?,#<X
M.<87&,9ZU2NM>UN]\0Z[9PZE]DMK32HKR,0(CD/M+$!R""I/7@Y &,4 >BT5
MYKJ7BC6I]&LKZTO"LK:&+YK:TB1G$I ;?(7&T1  C .3SC.*TK?4M9U?4?#T
M2:F;2+4=&:[N!%"A*N/*Y0L#@Y?ON&,\9Y !VS.J8W,%R<#)QD^E48-;L+G6
MKO1XYP;^U1))8B""%8<$>H^G3(KSQ;W4=>T+P9>WNH3+<OJ[6\C0*J!BGG*'
MP0?FP@]N3Q7H!TJ*"^NM5C9I+][<0J\K#:BCG  P ">3_P#6% &G17$^#M6U
M"ZU%;+5;N]348[(/<V5Y$BG?E09(RBX*9)'7CBM/Q1?W5M=:7:6MV\1NI) T
M5N@:XE 0X$>X%1@D$EL #OS0!T=%>>:-XDU>^NO!4DUVVW4A=QW<010LGE*V
MUNF0<@9P0/:DL_$>IRPQZ:-3#7%QK\^G_:PJ$Q1("^ ,8W8  )'?- '6Q^(K
M":?5X8_.,FE &Y!B*D94L N<9X&<]#D8-7++4(+ZRM+N,E$NXUDB60;6(*[L
M8]<=J\]@>]T:Z^)$\&H32W=K%#/'<S(A;*V^X @ +Z#IT]ZL:3;W.KZSX.U&
MZU2],TFBO<D*4"AP( QQM_B#MG/X8H ]%S5'4M4@TP6QG65OM-PELGEINPS=
M"?0>I[5D>/M3O=%\%:CJ6G3B&ZMU5D8H&'WP",'V-4YCK=J-*FDUAY4O=4C;
M8L"@K"T9)BSCH"IYQG!ZT =C679Z[97VMW^DP^=]JL51IM\95?GSC!/7IU''
MO7':AKNM3ZEJ$%E?SQ74&L0V26D44;?Z.R(6DPRDDX+'.<# _&MJBZA:^)?%
M]U9:I-;W%CI5O/Y@CC8S%$D.&!7&"1S@#VQ0!Z9O4.$+ .02%SR0,9/ZC\Z=
M7GVC->7WCRPOI]2N<W.@)=-$ GEH6=<JHVY"YYZD^]6O#6K:E)KZ:=JEW<QW
M9AEEEMKB)2DW*[9('48V 9!!.>1QUH [>BL'Q)J-Q:2:59VTWV9M1O!;-<[0
M?+78S<9XW';@9SUZ'&*Q;S5-6TV^L-"EU:.6XO=2,?VG:ADBMMA=588"ASM*
M@XQWH [BFNZQHSNP55&2Q. !ZUYYK6O:QI<.O:<+Z1Y+&2SD@N]BAFCGE"E'
MP,9'S8( XQZ<S>(UO%TSQEI<VIW<T2:5]NB9BBLFX3 QY51\O[H<=<$\\T =
MY%+'-$DL3J\;J&5U.0P/0@]Q56ZU*"TU"QLI%D,MZSK$57*@JI8Y/;@5QM_?
M7NC65AI]E?7<@BTMIQ'!&C2@J %9RR[!$ &]&)Z9J_9:Q?W\?@N[6^7R]1B/
MVN-(U(=_L[/D'MAE/ _IR =A17EK>(?$L>FW6J?VC))'8>(38&,PQJLMOY@3
M+G;DG) !7'?KVUI]5U[4UU>]TO4K:U_LV_: Q7#*(5CC(WF3Y2WS#)R"N./3
M) .MUG5K;0M(N-3NQ*;>W7<_E(7;&<9P/K^'6KD;^9$C[67< <,,$?6O-O%%
M]>Z]X8\:,M[);1::[VJ6\84JZJJLQ8D$_-N(X(Q@5Z4GW%^E %'3-6@U871@
MBN(Q;7#6[^=$8\LN,D9ZCGK6A7F=QKWB"#0]4F&JYGB\1+90R&%,"+>B[2,#
M/4]"#[UT6B7VHIXUUK1[J^>[MH(()X6E10Z%]P894 $97/2@"_J,NC^'IWU>
MXC9;JZ98,Q*\DD[?PH$&2Q&#@8XYZ9-3Z3X@L-:EN(;7[0EQ;!#/#<6TD+Q[
M\[<AU'7:>E9OB[24U@:?#;ZBUAK$4K3:?.%W#>J_,".A4@\_Y%<S<>+[S1DU
ML:GID</B6SL8B9XG+0W,7F;5DVY&-K2$D'ISS0!Z92$@ D\ 5P&M:QK_ (8A
MNKJ6_AN;.2R!A,I5Y(YO,53( JJ#&!(I.2<8]ZL>)4U"RTK7(GU]Y()M*FFM
MD;8)]Z*Q<@J@&P@K[YZ$4 =5<:K;V\E@N))1?2>7"\*[U^Z6R2.@PIYJ]7!6
M=Y?:1I7@>**\FFBO'CBF20+DJ;<D $*,!2,^OJ:HS^*-9D\":CXLM[MXY+:]
M<QVDD:A/)679Y;<9SCDG.<^W% 'I=%><W>K:O<WWC&6'6I[5=.L8KBVM1%&2
MA,!DYRIXSP?Y\5W>E7,EYH]E=2X\R:WCD;:,#)4$X_.@"OJ&NV.FW,=K(TLM
MW(-R6UO$TLA7^\54' ]S@5;O+VVT^SDN[N588(UW.[]O_K^U>:0:AJVE6.O^
M+XI8I6.JM'<V30?O##')Y00-GA@IR.._<FO2KF&VN;<?:HT:)&6;]YT4J0P;
M\" ?PH IZ-XCTS7O-6QG<RPX\R&6)HI$!Z$JP!P?7I6K7,Z(?[6\0W7B%%:.
MSDMTL[7>NTSJK,QE'^R2WR^H&>XI_BO5;NQFT6RM)?(;4;];=Y@ 61-I8[00
M1DXQ[9H Z":6.WADFE8+'&I9F/8 9)K+TOQ%9ZM<I#!%=)YMN+J%Y82JRQDX
MR#^(X.#R.*Y+66U&*P\8Z-/J=Q-;VVE"ZMY&V>9M:.4,CG;R"4Z]<'K74>$;
M=X/"VFE[J:?S+6%@)=O[L>6ORK@#COSD\]: -2ZOK>TAFDE<GR8_,=(U+N%Y
MYVC)/0]NQJM9S6/B#2K'4! )8)52Z@$R#*G&5;'8C-<U'82)XM\37#ZA=R[;
M&+$<A3:%83'9PH^4'D=_4FHO#C7FD6'A-&OI9;>ZL!&UMM38I6 ."#MW9^4]
M3_%[4 =P(8A,9O+3S2H0OM&XJ#G&?3DT^O.?#VM^*+^#1M8FDA^PWLP\XRW,
M0CV.2%6-0NX.#@ %CD@@]>/1J "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *0TM(: %'2B@=** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH RKWPYIFH374ES#(WVN-8KA1,ZK*J] 5!QWQT
MZ<5#?^$](U&:>66&5'N+8VLODSO&KQ[64!E4[6P&;!(.*HW^N:C!X]T_08FM
MA;7<#W!=HB74)C*CYL<\\XXS733316T#S32+'%&I9W<X"@=230!CW7A'1+N&
MQCDM&7[#$(;9X9GB=(\;=NY2"1CL35A?#^FIJ%K>Q0O%+:P&WA$4KHB1GJH0
M';V';L/04MEX@TC4+&:]M-1MY+:'/FR!P!'@9^;/3CGFDL_$.CW]C->VNI6T
MMM "9I!(,1\9^;TX]: )-(T>RT.P%EI\;QVRLS*C2,^"Q).-Q/4DG\:BO?#V
MF:A>R7EQ S3RP?9I"LK*)(\D[64'##D]0>M)!XET2YT^>_AU2U>U@ ,T@D&(
M\]-WH?8U:T[5+'5[076GW45S 25WQMD CJ#Z'VH Y%O#'E^.-,2"UO8])M-*
M:U2:*X9-K;P0I8,&(P#[=*Z:XT#3;G06T1[91I[($\H>@.<Y]<\YZYYJM/KI
M;Q&^F0;%BL[<7-_._.Q3G8@'J<%B>< =.>+5MX@T>\2![?4[25;ABD)64$.P
MQD#U/(X]Z )CIEH=6CU3R1]K2 VZO_L%@V/S%9<W@O0YV+-;S@FZ-X-MU*-L
MQ;<64!OE)).<8ZU4\6>(WL8(8]+OK?[5'J%K;W<> [HDK#@C/RDCN0>,_6M5
M]:L;[2K^73-7LBT$; W D5T@?'!?!Z#K0!-::-9V3WK1B1_MKEYUED+J['@G
M!X'&!QV4#M6;:>"=$L[JRN(X[EI;!F-H7NY"( >"BC=C;CC'IQ5R+6+.RT.S
MN]2U:R*R1K_I0<)'*Q&<KD]#R>M8^H^*I=/\;Z=I\EQ9KI%S8R7+S.,%=O0[
M]V,'CM0!T.K:5:ZUI[V5XKF)F5P4<JRLI#*01T((!K,3P9HJ_P!I!XIYAJ2*
MET)[AY-^T8!^8GYAQ@]1@8Q6W;W$-W;QW%O*DT,BADDC8,K ]P1UJL^LZ9'J
M(TY]0MEO20!;F4!\D9''7D<T <Y>:$NAW\-YINEZAJ=U/;/:2SO?$M&H!*[@
M[8(+<>W6K.E>$XQX1T32]3>0W.GHC+-!(8VCD"D':R]L$K[BM5O$&CI!=3OJ
MEFL5H_EW#F9<1-G&&.>#]:;K>NV.BZ?)-<WUI;RF)FA$\@ <@<<9&1G'2@"!
M/".DP^>88YHI9KUK\RI,P=9R"I8'/'!(QTY/%12>"](DM(("+D&&[:]$JW#+
M(TS9W,6!SSD]*S/#WB*_U7P]X:O[G4+&WEO6D:YCD7!F55<XC&>,;02?0?@=
MC0_%>D>(;J]@TZ\AF:UE\OY'!\P!5)=1_=RVW/J* (9_!>EW']L[WN@-8*_;
M LN-^WH!QP,<<=JM1^&[&/58=1W3-/%9_80&8%6BSG!&.>0#FKEUJNGV)<7=
M];P&.(S.)) I5 0"QST&2!GWJO874LVIZFKW]G/;QM'Y44)^>$%<GS/<G)'M
M0!2TWP5HFDJZ6<,Z(5=8T:X=T@WC#>6K$A2<GD#/)[<5)%X2TJ"'2X8UG6+2
MW+VB^<Q\LGZ\GC(YSP:D;Q!IUY97!TK5;":Y1&* 2"3Y@N>5# GCWJ#PUXBC
MU/1].-_<VD6J7%HMU);*X!"D9W!220.10!=TW0K/2KV]NK5IPUY*TTJ-,S('
M;DD+T!-&H:%::C=I=O)<0W*Q-#YD$Q7*$Y*D=",^HJAI?C70M5L;N]BOX$@M
M9'5V:0?=#;0^.P)Z>M;-C?VFIVB7=C<1W%N^=LD;9!P<$?@: ,RV\):397\5
M[:QRP3Q6?V&-DD.$@'1 #QP?FSUSW[5#!X(T2VBLXH8[E$LTDCAV7+J1&YRR
M%@<E<]B:TYM:TR#4$T^74+6.]DQL@:4!VSTPN<\X-8?ACQ.UZU];ZQ>627D>
MJ364")^[\P(!C:I).>IZF@"Y:^#M(L],L=/@2X2"QF,]L/M#YC<YYZ\_>/!X
MY/K6G;:7:6=_>7L*.)[QE:<F1B&*@*#@G X '%-GUK2[;4(["?4+6.\DQL@>
M4!VSTP.O.#6:NJ7[>-[O1]\ METY+J$^6=P9G*?-SR/E)XQU_&@#2U'2+35'
MMI+A7$UJYD@ECD*-&Q!4D8]B>#D53E\*:/<:9+87%LTT4TWVB1WE8R-+QA]^
M=P88 !!X  '%-\':K<ZWX0TW4KPH;BYBWOL7 SD]!5&P\3B'6];L]:O[&WCM
M;N."U)(BW[XU<#YB<M\U &WI>C6.CQR+9QN&E;=))+*TLCGMN=B6..V3Q5;4
M_#5EJUQ/)<RW02X@6WGACG*)*@+$ @?[S=.H.*O76I6-@T:W=Y!;M*<()9 N
MX^V:M9 H QKKPQIUW?S7C>?$\\'D3)#,R)*H# ;E'!(#'%)-X8L)&MWBDN[>
M:"V%JDL-RX;RO[I))ST!R>?>K,'B#1KIYD@U6RD: ;I0LZG8,XR>>!GBI'U*
MT>YDL8+VW-\(3,L.X,P7LQ4')7)% '.)IMQ-J6D6-KHQT[3]'O9)0[.I25/+
M=%*8.26,A)R.,')YYOP>"M"M]6DU&*T=99)O/:(3/Y)E_O\ EYV[O?'!&>M0
M>"_%$>NZ!ITM[>6O]J7$)E>W1@&QN(!"YSC K0TO5@]G?SWVHZ;(MK<2!Y+9
M_DAC'(#DGA@N": *L7@C08-;?58[1UG>43&,2L(O,X^?R\[=V0#G'49J]I>@
M66CW-Y-9^>OVN5IGC:9C&K,<L57.%R?2IX-6TZZL&O[>_MI;-<[ITE!08ZY/
M08K+U?QGHNDZ&FK&]@GMI)E@C:*4$,Y;!&>G R3[ T :-]HMIJ&H65],TZSV
M>\1F*9H\AMI(;:1D91>#Z543PII23,RQRB!I_M)M?.;R?-SNW[,XZ\XZ9YQG
MFM&74K*'2VU-[J(6(B\[S]V4V8SN![C%96E>,=$U70DU8:A:PP' ?S)E'EL>
MBMZ'':@#?K+30+)/$!UL&8WS1&%G,I*F/.0NWI@'FK]O<07=NEQ;S)-#(-R2
M1L&5AZ@BI"P52S$  9)/:@##U#PCI&I:J=2FBGCN701S&"X>(3H.BR!2 P^O
MTZ4^3PII+WEU=K \4MU:BTF\J1E#1 8"@ X&!P",&K5IKNDWUO-<6FIVD\,
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ME+O(YPJJ.22>PK,7Q3H#BW*ZU8$7+;8,7"_O#G&%YYYXH L:MH]AKEE]DU"
M2QAA(A!*M&XZ,K#E6'J*IGPII3:6EBT<SA)1.MPTS&?S0,"3S,[BP'&3V '3
MBDUC5,Q&'3=5TZ"[BNX8IOM#YVAF'R8'\;#H._ZUE:EX[LC;^([?2[JW:_TJ
MU:5-[!ED=49F  ()QC!YX)]J ->3PII,UE<VT\,DHNI4EN)&E822LA!4LP(.
M 0,#H,=*DG\-Z9<3:A++%(SZA;?9;D^<_P \>",8S@<,>1SR:30-;M=7L( M
MY;S7JV\3W,4;@M&S*#RHZ=ZUZ ,)?"&D*T3E;MY(X#;>8]Y*6:,G)5OF^89[
M'@5)!X7TRW32E5;ACI:E;1FN'R@(VXZ\\<<]JYK5?B%#=>&=9OM N+=KBPN$
MB4-\YD3?&K.%XP,N0#S]WWX[.UU*QO9;B*UO()Y+9MDZQR!C&WHV.AX/6@#-
M;P?HS:>]B89S;O=&\=?M4OS2D[MQ.[)Y&<=,\XI9O"&B3ZC+?O:/YTS*TP6>
M18YBOW2Z!MKX]P:T+#5M.U42'3[ZWNA&0'\F0/MSTSBLS6_%NEZ#JNFZ?>3Q
MI+>NW+R!1$@4G>V>Q("CU)]J )+WPGH]\]\\EO(AOX_+NA#,Z+*,$990<$X)
MY(S^5;,<:Q1+&N[:H &YBQ_$GDU5_M73A>I9&^MOM3C*P^:-Y'L.M1+K^D.[
M(NI6I<221$>:,[T&YU^J@@GTH IR>#]%ELY[5X)C#/=?;)!]IDR9LYW9W9'(
M!XXXJ]#HUC;ZS<:M'&XO+B-8I7,K$,J]!M)P,>P[FHH_$>BRR3(FJ6A:&%9Y
M/WH^6-AD,3Z$8_,>M3C6--.FKJ(O[;[$PRMQYH\L_1NE ":AH]EJDMM+=1N9
M;9F:%XY7C9"PP2"I':J\?AO24-TSVOVA[J+R9GN9&F9X_P"YER3M]NE:%M=6
M]Y")K6>*>(]'C<,/S%0-K&FKJ/\ 9[:A:B]X_P!',J[^>GRYS0!0LO"&AV-K
M);1V;20R0F I<3/,%C/5%WD[5X' QT'H*2S\'Z'86\T$-FQ2:W-JWFS/(1">
ML:EF)5?88%6Y_$.C6TY@GU2TBE$HA*O,H.\C(7GOR./>H/$6N6NC:7=2/?VE
MM=+ [PB=ARP''RY!(S@4 +'X8TN%+!$CG T]_,MLW,A*';LZEN1MXP<C%-D\
M*:-*\Y>V<QSS>?-!YSB&23()9H\[220">.34OAB_GU3PMI6H714SW-I'+(5&
M!N903@5.=9TP:@-/.H6WVPMM$'FC>3C.,=<XYH KS>'-,N)K^22*0G4$"706
M9U$J@  $ ^@QQV)'>K]G:0V-G#:P!A#"H1 SEB .@R235=]<TJ/4%T]]2M%O
M&.T0&9=Y/IC.<TEUKND632+=:G9PM$RJXDF52I;.T')X)P<?2@""7PQI,UU)
M</!(3+,L\D0G<1/(N"&,8.TG(!Z=0#4M[H5EJ O%N//:.\1(YXQ,P5E7/& >
M 02#CJ.M)K&KV>EVC?:-3L[&61&\E[IP%W8ZD9&0.,\U@Z)K.JWOA_PQ>75_
M9137C;KE9%^:="&P(P._W3]/U -JP\-:;IM\MY!]K:9$:-#/>33!%.,A5=B!
MT'0=JM:II5GK%H+:]B+HKB1"K%61QT96&""/45SZ>,K'7-%UJ71=3LX)K/<D
M<]R?DR%&'9>"%W$KGGIGGI6S-KNFZ?:V[:AJ-M&TL8<,3M##'+ =E]STH @/
MA73&L;RUD%Q)]M18[J5[AS+,HXVE\YQ@D8&.":T=.L(M+L(K*!I6AA7;&)'+
M%5[#)YP!Q4<^LZ9:F,3W]M'YD33(6D !08RWTY'--?7=*338]1.H6YLI2!',
MKAE<DXPI'4Y]* &RZ%92ZC=7S>>);J 6\H6=E5E&<< XS\QYZU'#X;TRW;3"
MD<W_ !+ RV@:XD8("NWD%OFX.!G.!TJ_:7EM?VL=U9SQSV\@RDL3!E;G'!%0
M7.M:79W*VUSJ%M#,Q50DDH4Y;H.>YP<4 9]CX.T33K\W=M;.N)#*D!F<PQ2'
M.72,G:K<]0/IBMZN3U7Q+YWB;_A'].U2VMKE+1YG=U#_ +S<JHA';J21UQCI
MWZ:T^TBR@%X8C=>6OG&('87Q\VW/.,YQF@":BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH ***0DCH* %HH'2B@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** //M:OHH/BSI=TT=RUO:V4L4\L=M
M(ZH[?,H)53U!%-\9W=YXHT"^M]&M;R2*R>"=\1/$]P0Y+(@8 G"@'([X KT*
MB@#RV]-O=>&]>U*PT/5KGS+:**4ZH92SX<' C)W$("6)'!Z>M06WER7_ (R6
MZ36;FWO8K.19FM&BF,8^4NHV 94D$+C)"G@\UZS3#-$)A"9$\TJ6";AN(&,G
M'IR/S% 'E,PU>Z^T7\MH^IV^F:G#*]Y:1-#-?0")U) !&YDWC[N!P<5V?A*.
MT>XU+4+'3+JSMKMHV\V[:3S;AP"&8HY)4#@9X)P>V*Z?%,:2-#AI%4^A.* .
M0\.1RVOQ"\60W,F9+@6US""<YBVLO'T((K'O= U*YN->T*V3R[2";^U;&<KP
M)G!94''02!B<=B.W7N[K2K>ZU&TU EX[JVR%ECP"R'JC<<J>#CU (Q5Z@#S7
M5H9I_!^GZF]E*MWJ.KVU[.B1,SHNX$!L#/RQJ <^E272;-3^(L;6D[)<6,0A
M586 EQ 5(0XP3N('%>CXJ*">&YC\R":.5-Q7=&P89!P1D=P00?I0!YOH\DVA
M0^&=0OM+N)[%M&2QE>*W:22UE')!0#< PX.!U S3=/LGA\=^&R-(DL+*WT^Y
M"Q$,XA0LQC#L<@,0,E<G!KTZB@#E?AT)4\'01S1O$R3S@(\90JOFL5X('8@_
MC7&:Y=AM;N)19W$(L_$=M/<116DCEHTP/.9L'.>-JKV['K7KM-CDCE4M'(K@
M$@E3GD=10!Y3XG62*W\>V9M[AKC4$@N;9$A9M\8103D# P5(P>:U[C48M,\5
MZE)J5E+)_:&G1)ILGV9I RJIW0\#()=@=O?CVKT#<-VW(SUQ38I8IU+12(ZA
MBI*L#@@X(^H- 'EWARXM['0? ,%[');W4-U,'6:!E9%,<R\Y' +.@]#^%=-X
M/EC@UOQ18%'CF_M-[@+Y3!?+,<0!SC')!P,]C77XHQ0!P^N)977Q.T2WFBAE
M#65S'<(Z!@P8+M5L\'.&P#[U@ZBULL7Q*C0R)"4AV_9TSP(@IQT! 8$'TYKU
M;%9VMZ-;:]I;V%T\J1LRN'B;:RLK!E(ZC@@=010!P&C:II.J^(KO4C=1"^&D
M?8XH([:53)M!9VRZ+ENP49.!3O#\EM8:=X 66()<?/'(-@#J3$R?-W'S8'/>
MNZAT0+>6]U=W]W>R6Q)@\_RP(V*E2P"(N3@D<YZFM3% 'G-W/I]QH$MA="^M
M9+369G^TVENQ6UD\Z5XY#QAEQ@'&<;AG'6NA\%S7<VF7;WD,0D-Y)BYAR([L
M# \U5)^7..W!()'6NEQ1B@#S>\W6'BV632VEG>[U2(7NFW*?>P!BXA(P0% Y
MZ@[3FJ)A1/"WB>Y>V83KXC\]&\D^8(Q/&VX<9QM#'/IFO5L48H \L\2S27$W
MB-3:W%LHG@=?(M&D^UA0A$CR$%0HZ +@@CUKH8;Z!_B=<S N$&AQDYC8%<2N
MQ!&,@X93@\\UV6*,4 <K\-F!^'VCIGYXX=CKW5LG@^AK&N8;&#6O&B:E8F66
M^5/LR&$E[E/(52L9QS\PZ \=>*]#HH \DEL6TC4I[#Q-/J9BO=*M;6.:R@\X
M2[(]LL9;8S ELMVZY)KT:T+V'A>$RVTRM;V8W0!O,D^5/NY_B;C'N:U<48H
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MJ],HQ0!PMB7M_B?;)<&1F&A):--Y3!&F$FXJ&QC. 3BNZHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4R1BI7 SDXI](: %HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *,8HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **AN[F*RLY[J=ML,$;2.WHH&3_
M "KCKBZ;_A!;[7-9U/4+9+^%9LVF0UG&V"BH!T."-S=R3T&* .WHK,MM6LEU
M)-$%Q(UZEJLX$JG+QY"[MV,$YZXKG]6\1FQ@TKQ1;3S'2KF6.WN89?NB)V(6
M91V(..G53TZ4 =G1110 4444 %)D]>U+7F'C_4O$WAGPUK6N1:K+%(MTJVD?
MEQLD<9('.5R?QH ].&>]+7$:/>ZE9V\&N:KJC-I4NEQW$QE5 L4I +8P ><]
M*UU\6Z:UO=R^<RFSB$TT90[Q&1D/C&2"/2@#H**Y?3_'_A_4[ZPM+:\+27T9
MDMR8V42 $@XR/8TI\>Z )X%^W#RY[@VL<VT[#+G[F?6@#IZ*YF^\<Z-INH7E
MC=3RK<VD7GS1K"S%8\9W<#&*H^(/',=C%H/]F#[2VLS(L#[<KLQDGCOB@#LR
M<4@;U!J)7,B*P)^8 C(QP?ZUYK:Z]JT_Q4U3PS+JTL6F6=JLZ,%17R0I.6(Z
M<YYH ]1'(HKS[P3XROM2T[6KK6)X_L6GW4D<-_L"+/$I/S>G&.HZYK:_X3/3
MY]-OKBUF9Y;:V^TB,H0SQD':P'4@XXH Z8'-+7EGA;QE>?V9I_B;7M4D2SU!
M1;?93;<>>6X92!G!7BNVA\6:9-<ZK;(\QGTM ]TC1$%002,9'/ /2@#<S@XH
M)XXKB+WQ[I.I:&W]CZB[75U:32V;)&<EHQD]1@$'L:H^!O'T5YX7T%=8O2VJ
MZ@'19'CVJ\@8@+D#&>!0!Z+DYZ4$X[9KA=&\66T4WB*ZN]9-S#;W:1B VQC:
MU+<"/'5B35+Q[XTG@\&7U_H5U-;W5E>Q6\C/!@@E@&!#CI@]: /2**YZQ\6:
M;=/=VJW!-Q8P)+< H00K#AAZ]ZJ0?$7PW<16<L>HYCO6*6[F)P'8<%<XZT =
M917/6_C+0[BSU"\74%$&GRF&Z9U*^4X.,$$9ZU'_ ,)MI L[ZYEGDA2QV-<K
M)"P9%;[IQZ&@#I:*YVQ\8Z3J5['96ETSSR6OVN-3$P+Q^HR!53P9XO;Q6VH3
M+$8X(KEH8 8RIVKP2V>YH ZVD/M3))5C1G<[44$L3V ZFO/_  EXXGUOQEK>
ME7"M'&H6?3]P \R'.TM[Y.#]* /0^:7\*\ME\2:U#X[\7:8E\YM;'3/M5LI1
M?DDV@XZ<CZUK>$O&?G>"] O=8NC+J.IC:JH@W2-DYPH&, "@#O**Y9_'6BI;
M6EP;N7R[V7R(=L).),XV'CY6SV-(?'NB>9J<8FG,FF?\?4?D-N3YMOIR3[4
M=517+:AXZT737F%U=L@MPC3GRB1#O.%W^G)JQ?\ C'2=,U>VTZ[N&2>ZC,D
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MR\PEM#?+Y,+R?N!_&<#@<_6IT\2:8^LVVE+-(;NY@^T0CRFVO'C.0V,?AG-
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MM_J?A76G30#::A>62VY$EP'FD=2,=\;>*Z+_ (59X2_Z!TF/3[3+_P#%4O\
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M?UKMV95&6( SC)I: //M3T_7]3N()[[2+F1GTY@8[2ZCA"2LS'RY9 P<JHV
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M-GE+60+E9 O$8P!QGU)Z]:ZVJEQJ5G:W]I8S3JMS>%A!%W?:I9OP '7Z>HH
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M0-*6Q6\N+H"1Y#)/MW$LQ8_= [DG\: ,E9;MOB=-;FX!@CTI)539TW3,"/\
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M/^HC_P!T?RKAOA;(][I.K:K=1XO[S4YC.S?>&W "_11P!7=*NQ%4= ,5A?\
M",BVU"ZN]*U&XT[[6WF7$42H\;R=WVL#M8]\8SWH JW$7]@7L-AHYBCGUG47
MGE:9=R1_N]TF "#DA1@>I)JOJ/B/5]/MM=MX[87E]IY@DB^SPL2T,K$9V9Y9
M0KG .#@=,U?E\(63VL:QW%U'>1W9O$O=X,HF(P6.1M(*_+MQC':G2^%(9X)6
MFOKEKZ6:*<W@VJ^Z/_5C &W:/3'.3ZT <IK>M7>IZ1IDMIK-O/;G7K6$M#$
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MG0/%*A1T/1E(P1^5<SI_@>*PO=+G.K7\Z:47%G%+LQ'&R[2F0N2,8Y)SQUH
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M#*9K6QEDS#;N>K*,9[G&<XR:ZB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"8)XI0,9,;AL9 8=/4$'Z$5Y/:3:!>V=SJ6G7-Y<W,&D3PW,<T"0Q0KLSLD
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M]JTP-;7 )^8F,=3]0/TKB?%7B6?Q,W@S6H[#[-;W6L*EO*DWSE-X4JP'KC-
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M-2.5H5F5_,B<A0ZD>YP1BM?_ (2&=;ZUL9-+E2YNYG$*&1<>0@4M,Q'W1\P
M4\Y(Z=@#=P,YP,CC-#!2A#@%2.0>F*Y>Z\:1V^F7MT;)M]A>+:W<3R!?)!8
M2$X/R88-GTJ3Q)K-@NC:Y'=6;7EG9VRM<JDFW?N!)0'L=N&^C"@#I!C QC';
M%&Y=VW(W8SCO7.3^)X;*Z@TVVLFEN#IXO(X1*JET'&Q,_>;CIQ]:K/JNEQ>,
MWN9K&6*[BT3[5)=.Q&VWWD[-GKG<3WXH ZO8F2=BY.,G'7'2EP,DX&3U-<XG
MBSRVTIM0TZ6S@U4A+5V<,0Y7<J2 #Y21G&">G.*J0^.9&&FRSZ)=0VUY>M8-
M,9$81R^8R 8'497D\ 9XS0!UH159F50"W)('6FR00S$&6)'QTW*#BL&R\5K?
MWTL$%B[QQ7[V$C*X+QLN[+LN/E0[>#GG(X%:&LZNFCV]N[0R3RW-PEM#$A +
M.Q]^P )/L#0!H&-"<E%)QCD=O2E"J"2  3U.*YB;Q5(IUG3Y+,0ZII]I]J\O
MS\I+&0?F1]N>,$'*CG'KFH/ VCV:Z)I6L_8XX[^>PC\RY1R7G\Q4=VDXY;<.
MIS]><4 =;Y<>XML7+$$G'7'2A41!A%"CT Q7GVL72:#XTO;_ ,1V<TVCW0A6
MQOERZV+!<,#CF/+$G<OM^&G9Z_;Z1;:3H-K)!>W(TY;CSGN0D31#"AMY!R6/
M08]2<4 ==L3!&U<$Y/'4TH  P  .O%<M9^-8M6CLDTJQDFO+FT:\,$[&+RXP
MVSE@&R2P( '7!.1QFJOB;4+WQCH=G!:/;VEU8273PW!*29W*,,N#@J,\=\]J
M .R(2564A77H0>13/LT 96\F/*C .P<"N6T_6[6RAU>2WTMX9VU@VOD^<"9Y
MV5/GSR%'.3C. N<9XJ2_\9#2?[2AU&P*7EE9_;1%#+O6:+."58A>01R,=QUH
M N>(/#PUBTM8(&MX%M[N.Z*M%E7*'(!P1Q6XBK&@5%"J.@ P!7/Z9XKCU#4;
M"SDL9[9K^T-W;,[*P=!MSG:3@X8$9[>AXJ]JFD+JTUNMQ/*+.,,9+>-R@F8X
MVEB""0/FXZ$D'M0!I,JR*5=0RGJ",@TI52A0J"I&,8XQ7%>'M+FU30EA.HWC
MZ4FHS-'YDC%[FV&0B[\[MF<'_: ]#5WP?@7&O1VLTLFF17_E6@=RX7$:>8%)
M_A#E@.W!H Z@8 P.E+7(>*]#M'M-3UC4+^Y5XH?]"\NXDB%NP4!=H5L%B^.<
M<Y [5T6C+=KH>GK?L6O!;1B<GO)M&[]<T 7:0LJXW,!DX&3U-<W-XO2/3[G5
MDLS+I%O,T+W*29?Y7V.X3'* YYSG@X%4KJP?7?%M];7^GV]SIYTZ)(V-QPJR
M22;F7"YW$(IXQC:.><T =E31(AD,8==X )7/(!Z''X&N9\4ZAJ&C0Z-;Z=$C
MK<7T%L7EG96QG."=IR"%()Z\]#7,0:A-HGQ"\:WT-@LZPVMK/.BS;-JB,LQ&
M1R>I[=^?4 ]/HKF-6\8P6&HS6%M'#//!;K<2>9<>4"&SM5?E.6.TGL.1SS6[
M87<>J:7;7BQ2)'=0K((Y5PRAAG##UYY% %JBN$^'T:IJ_BU0/EBU5XHP3G8F
M,[1Z#VK7UGQ?;Z7JS:5'$DEVMO\ :6\Z7RDVDD  X)+$@\8QZD4 =)17'MX[
M1["TNX-,F5)K.2[<WC^0J!&VE-Q!&_/0' (YS4Q\:QSV^DO96BR2ZE9O=PQ7
M$XB)"[?D'#;G.[@>QYH ZJBN0NO'UK;M)#]G1;N"TBNI[:><12?.I81Q@CYW
M&.G'4<UTL%X;S2XKVUC+>=")8DERA.1D \9'7TXH M4C.J8W,!DX&3WKD!X]
MB.FZ9J#6!BM[N^-A*LLP62WDWE<E0"",CGGC([<A?$.LV<MG,-0TMY[2WU2W
MMHF67:7ERIWXXP%8X[YP: .N) !). .]"L&4,I!!&01WKS_6+W5=0;QO9W<%
MNVG6MELC'G$E#Y+R!@NSDDE<\C&."<5I>%]<$,'A[1)K<K]HT>*>"</D/M1
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M::S $ ]Z %'(I:!10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% #7SM.#S7F6J:YX:F\9O/K.KZ7);V<36\=K)N+0N2"3TZ
MG&#]/>O2#=VQOOL/FK]I$?G>5WV9QN^F>*3[':AF;[-#N8[F.P9)]: /&=+N
M_"ND:]K%S#XKTN+3-71HY;&,%?*)&-RGUY).1WK-$6A1:5H6E_\ ";Z.;71;
M[[1"VQM[C=N ;G@>]>WW2Z58K&US%;1":584+1CYG8X5>G<UFZ;JUA?^)]4T
M1-*$,NGQQF21U3#A\D8 SQC!Y]>@H \POYO#4NH^*&LO&&CQ6OB&)4D\UR6A
M< Y8#N#D_2K4U_X=*>$2GC'1';P^,-F3 F^4+QSQQ7L!LK4];:(_5!5+4_[.
MTO3I;R:P65(\?NXH59V)(  '<Y(H \O.J^'([WQ1+#XNT01:XI +.=\9VE?7
MIS5>ROO#.DCPY<0^*],EOM'ADMB-QV3HQ/?L:[TZ[I;ZM-I?_",W;WT$ N'A
M\B D1DX!^_@_0<^U=!90Z=?6%O=0VD(AGC65 8@#AAD9'KS0!XMJ7_")7GAF
M^TU?&&FK=:AJ)O[J<JV =Q("KZ<^M6!J>B0ZYK&IVOC;2XI;^P2TA81$M&50
M#=R/7->T_8K3_GUA_P"_8H^Q6G_/M#_WP* /$=%N_#^G^(-$U2?QAHTLEA9R
M6T^=X+EOXLD]>?I[5T7@#Q%X3\):'-ILWBO3+@O=23AHV(QN.<5Z9]AM <BV
MAS_N"H)XM,BFMXIH;99)V,<*M&,L0I8@<>BD_A0!YQX^\2^&/%OAN?1[?Q9I
M%L)F4M)(Y8@ YZ"F:KKG@_7? 0\-W'BO3TG6WCB69"<*R 8;Z'%=UK][I7AO
M3&U&ZTLRVZ$"0V\",4![D$CC-:$-C930J[:;%$77+1O$FX>QQD?K0!Y&VK:)
M<^&KS3+KQ9H,=P]D;16BA**V0!O<G))P..0.>E065WX<M/$'A?4!XNT9X]&L
M?L<B!SF0X/S#CWKV8:7IX.18VH/_ %Q7_"E.F6!.396Q/O$O^% '@4QL+^*V
M>]\;:++/#J_V[S#NRR] O&.@K<U"^\.7?B7Q)JJ^,-&0:MIXLHT+G,? RS5Z
M^=)TTXSI]J<?],5_PH_LK3L8^P6O_?E?\* /%[F?P]-IOA$Q>+](2\T%P26+
M&.7&!G\@*]#D^)'A0VK"'Q+I9F"X&Z7"[L?RKI#I&F$Y.G6A/3_4K_A2_P!D
MZ=_T#[7_ +\K_A0!XA8+H-E\/-7\-KXPT22?4)7F$@<[5#$97]*U(-4\.0^)
M-*U7_A+M&VV>F&P=#)@LQ_B^E>MG2=-/73[0_P#;%?\ "C^R=-_Z!]I_WY7_
M  H \&U>[T/2O@Y)X>A\1Z=>W*72M&;>0G<#*&/Y#D_2NGL=>\-S>*K?Q!<^
M*-*62#3?LB0QR'ECRQ.>WI7J!T72FZZ;9G_M@O\ A0=&TMCDZ;9GZP+_ (4
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MTR\CU".X,%L]O<R7*$O)N='++@X!^4C'09'7&*Z*BB@ HHHH **** "BBB@
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MT59& B)SD]><Y/7/4UB:+X.B\_7CK%F)$O=3:[C'G$HR?*4#*#C(()Y'<=:
M*=LNH:WXBG9]5U&W1+.PU%+>%PH!/F;HL8Y5L<YYS[#%48;[5)OA];>+(=6N
M6U/S1.\)D_<R9?9Y&S.T#L.^><UZ!'IEG%JDVI)#MNYXUCDDW'YE7H,9QQS^
M9JH/#&CB]^UBR7S?.\_&]MGF?WMF=N>^<=>: .5U:^U72=>UO36OYI&U2T4Z
M/E\>5(S[&4>ZM(KY[*/1>%G;4]1U[5]#2^GMSIMC!]EF-XT)=G5MTK8#%P"
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M88-+B98 F=^2"NWT"8Y]2<=,<[U !1110 4444 %%%% !1110 4444 %%%%
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MV96F5PP.?[H_3'7BKVOZ%J&M:GXD2WAFB2^TB*WMY6&T-(I=BI]/O '..IH
MZNQ\0:;J-V;2WG?[1Y0G$4L+Q,T9. ZAP-RY[C(J*_\ %.D:;?2V5U=,MQ%"
M)WC2)W8(3C.%!)_#T-9/A]+^ZU.TO+K07TZ6&T:*XFN9!*[,2N$C8,3LX))(
M]*JM=-:_%C4&%M-/G1(SB)<G(E? _'\J -V;Q=HL,-K-]K,B74)G@\N)F,B
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MAM\L[6\;>2^QI%!+*'QMR,'OV/H:IZ5K-G'I%Q>R:I+>PF]E1',#!P2Y B5
M,L0?E&!SBL6WTO4;;7[2[T^VNK:V>_F:^L)@LD(7Y\3QD\JS<'"_WSQUS5M=
M%U)=.MYQ92&6Q\037[0.N&DA=GY7/!(5]V/48ZT =0WC#1DTN^U"2XECBL,"
MZ22!TDB) (#(1GG/IBI[3Q+I-[/=0PW8#VL8FD\Q2@\L_P 8+ !EX/S#(XKC
MO$VBWVJV?BF]LK&?.HV=O;6\1CVO,Z,27(."N 0OS8^[Z8J_>Z?=R>,+Z[.F
M37-I-X>^RA?NB23>S&,GJN00,^_K0!TNEZ_8:Q))':--O1%D(EMWBRC$A6&X
M#(.TX(]*34?$.G:7<?9[B25I@@E=(('E,:9QO8*#M7@\GT-8?A;3[JQUR[6%
MKYM'%LBPB_C(DA<,Q,:LWS.@!X)R!G )J46\^E>+]9O)K&6YM-3MX/+>&(OA
MT#*8V S@'(()XY.: (_$7BI()M AL)Y3#J=PK&YMX&ES"%+83"D$G '&2 2<
M=Z->O=;\.> ;V\ANWU*^C.])WM@C)&SCED'4JI/8=.1UK"TSP_JNEZ9X%LY[
M>6673YVENBBY$*NK@ D<'!8 XSTSTYKMO$%U?V>FI-I]I)=RB>(/#& 6>,L
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M3^T6T:@9E3]WR.?]DU7\26FJ7]QKF-(O!O-M)!]DB"K<*I0EI6^\SKAE"]
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M./3M7DBO=&,"2W,JMNE'F8RH;"??   []!S0!V%EXDTG4+BU@MKHM)=P?:(
MT3J)$P#D$C!(R,C.1Z5):Z]IM[<)#!<;C("8F,;!)0.3L<C:_'/RDUQ]MI6I
M3CP/"MK<1+9Z=+#>LZ%1$6MP@!SC/SKV]CT(JSH4>LSZ3IVCWN@_8I[&)K=[
MUF5D51&4#PD'=N8XZCIGGI0!TMMX@TN[EACAN2?/_P!2[1LJ2GKA'(VL>#P"
M>E:=><^%=(N[:/3-,N_#"Q7FF2*LE_,^Z%D4$"2(YSO/'&.,G/I7HU !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %,<;F7V.:?2$ G- "T444
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M9N@:FVM>'M/U-HA$UW;I,8P<A=PSC-:5 !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %-9@I&>YQ3JCDP60$]Z )** <T4 %%%% !1110 4444
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MC()ZD4?9X/D_<Q_NR2GRCY2>I'I0!XQJJVZ>$-2M,1BY@\4LPAXWHK2\''4
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ML=,.FSJ+EAN'[LJRG9ZQG@C^+K59?!E];_V2T(M3+'K+ZK>G>57+[@50;><
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MIQP3N[YQSC&:K"^U'5-%\+Q2:C=&6YCD>XCLG$5Q<[%P"&R J@G+9(SP.<T
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M@>E;M% "*-J@9)P,9-9NL>']/U]8$U&.66."02QHDSQA7'1LJ0<CMSWK3HH
MPO\ A$-(:?S9DNKG]T\02ZO)IU <;6P'8X)4D9'8FHK7P3H]G-:SPF]\ZUB>
M&*1[R5RJ,,;?F8C &,#H.N*Z*B@#!B\'Z/##ID4<<ZIIC,]F/M#GRB3SU/(Q
MQ@YX-0OX$T&1!&8;D6ZW'VE(%NI%C27(.X*&X.1^IQC-=)10!E1>'=/CU74-
M1*R237\8BN5DD+(Z#@#;TX!(_$TRT\,Z;920/$LQ:VC:.U\R5G%NK#!" ].
M!]!BMBB@#$3PGI(\/G0Y(I9[$L7"S3,S*V[=D-G(.>>#3M,\+Z;I.H/?VXN7
MO'B$+S3W,DK.H.1DL3GK^&*V:* *=_IEMJ0A^T*X>"3S89(Y"C1MM*Y!!]&(
MQTYINEZ19Z-:M;V4;(CR--(6<NSNQRS$DDDDU>HH R/%$,]UX6U2TM8'GN+F
MUD@CC3 RSJ5&22 !D\FJ^E>&[&*WM+EDN_M26@AC>XG9I($*C*KSA3QR1SQU
MK?HH R%\,Z2N@C1/LS-IRD%(6E<E,$,,-G<,$ CGBJ6N>'P_AO7(K&*6YU"]
MLI(%:6;<S95@JY8X"@L?3N>M=)10!@Z)X>M;2VLKFXM7%]'9K;D33-+Y2X&Y
M%RQ&,CZGU-+8>#=!TM)$L[$Q(Z/'M\^1@BM]X("Q"9_V<5NT4 82>$=)3P[#
MH0BE-C"X>)3,VY&#;@0V<\'FL^32]0U36[&WN=,%KI>D77VB"XDN1,]R0I"8
MSEEP6).XYX'X=;10 5G:QHEGKL$$-YYNV"=;B/RI"A#K]TY'/%:-% &)+X5T
MV<ZIYQNI%U3:+I&N7PP'&!@_*,<<8XXJ.Y\&Z->$&XCN'/V3[&V+F1?,BYP'
M"D!L9.,^M;]% &-:^&=/LY;:6!KI7MK;[+"?M#G;'@#')YZ \]P*C7P?HRQ6
M:"*X'V+>+=ENY5:-7P67<K D' X)-;M% '#ZCX0@M'TRRL=(FN-$@:61X+>^
M>.6.5@ "I9Q\F-V5##DY]<SZ=X/BNK2_LM5MYFT>:1)+6PN;EI9(&7.6\P,2
M,G' 8@>O)%=C10!B+X2T1--:P6S;R&F6X;]_(7,BD%6+[MQ(P,<]JBN-#GG\
M9V&L(1'%:V[Q.WGN3*"#A=GW0 3DMG)P/2N@HH *S9M!TVXOKJ\EMRT]W;?9
M9V\Q@'BY^4@''<\XSSUK2HH S(?#^FV[Z<\4#JVFQ&&UQ,_R(0 5(S\PP!][
M/05IT44 86H>#M$U/4GO[BVD$\JA)_*G>-9P.@D52 ^/>IKSPUIM]=SW,BSQ
MR7,8BN/)N'C$R#@!@I Z<9ZX[UKT4 9L>@V$.L)JD<;)<I:BS7:Y"B+.[:%Z
M=:JVWA'2+,Z7]FADC72VE>T42L0ADSNSD\]3U]:W** .>;P5H;V&H63V\C6]
M]=->2J96XF/5U.<J>G3TJ3_A#M";1'TB6R,UI(XD?S979V<8PQ?.[/ []..E
M;M% &'+X0T632DTX6\B0I.MRKI.XE$HZ/YF=V>V<].*GA\.Z;#?RW@B9I)+1
M;-A(Y9?)7HN#UZGD\G-:M% &+8^%=+TZ6"2W2;-LC1VHDG=Q;JW78&)QZ?3C
MI3$\)Z='96MHDEX(K:Y-U%_I#;A(<Y.>N/F;CIR:W:* "JFH:9::HD"7<0D$
M$Z7$?.-LB'*G\ZMT4 58-.M;:_N[V*/;<7>SSFS][:,+^E9;>#]';2TTYHIS
M;I="\3_29-Z2YR65L[ER23P1RQ]:WJ* ,5O"NELFHKLF U"!;:Y_?L=\:@@#
MD\8!(_$UJ6ELEG9PVL18QPH(TW')P!@<U-10!GZQHMEKEK%;WR2%8IEGC:*5
MHW1UZ$,I!!Y/YU6'A;2!_:0,$K#4XQ'>![B1O- 7:,Y;(.WC(Q6S10!@7G@O
M0;]+(75F\C647D02"XD214Z;2RL"1]2>_J:VX((K:WC@@C6.*)0B(HP%4#
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M[A\BX5;AU21<$<J"!G!(SZ&E3PW81W>FW*&X5]-B,-LHF;:J$8((Z'@ 9//
MK7HH Q+'PCH.FZD^H6>G)%<,[29#L55VX+*A.U3CC( ."1WK;HHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ IK ]C3J* $'3FEHHH **** "BBB@ HHH
MH **** "BBD(YS[4 +13(D,:;26/).6ZT^@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0G% "T444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4USA"<$X&<#J:RM<CUJ
M6&,:+=VMO*&RYN(RX*_@:LZ;]MCLHEU&XAFN0O[R2%"J$^P)- '-:CJWB;2;
M.VUF<6/V*2XB6>P,+":&.1P@Q(&(9P6&1M ZX]^SKS^_\7Z!J6I^;=ZU8)IN
MES&1;=9U:2[E4'!VY^ZIS@<[F /  SV-\][-IDC::\45V\>Z(W*$JI_V@"/Y
MT 7Z*Q-"BU]#,VMWEE.& \L6T)0*>_4G^=;= !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %(:6F29RF#CGF@!XZ4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4$9&#THHH 1555"JH"@8  Z4M%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !2&EHH !THHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "C-%!&: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
(@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>stamfordsecondleasemodif003.jpg
<TEXT>
begin 644 stamfordsecondleasemodif003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5[C_ %L7
MU/\ *K%5[C_61?4_RH ?!_J5]Q4M10?ZE:EH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 57N?]9#]3_*K%5KDXDA^I_E0 ^U&VW0'L*FJ*#_4K]*EH ***
M* "BBB@"AK>GMJV@:CIJ2"-KNUE@#D9"EU*YQ^-<];^&=8N(M*L]6O[/^SM.
M,3""VA;=.T8&PLS'@ @' '-=A10!Q</@R^:\M(;O487TJQFGFMXXXBLI,@8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *J7G^M@^K?RJW56[&9(?J?Y4 2P?ZE/I4M16_\ J4^E2T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5$9T$_D[AYF-P7VJ6FE%+;BHW=,]Z
M'4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5
M[G_60_4_RJQ56[)$D/U/\J );?\ U2?2I:BM_P#4H?:I: "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ JK=_ZR'ZG^56JJW?^LA^I_E0!);C$$8]
M!4U10?ZI/I4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !114,MW;PW,%O),JS7!81(3R^T9./H* )J**JVFI6=]+<16ES',]L_ES"-L
M[&QG:3ZT 6J*K+J%H^H/IZW$;7<<8D>('+*I. 3Z4ZSO+>_M([JUD$D$@RC@
M$9_.@">BJUMJ%K>3W4%O.LDMK((YE'5&(!P?P(JS0 444UW6-&=V"JHR6)P
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MO;^:RNV@BNM/2P6$Q[Q&JC 8$G).,]:?!X0^R7FAW-KJ,L4FF60L7_=JWG1
M+Z_=.5'//&1[T 1:#XEO=8U=X&-G&B-*DUDP*75OM.$9@6^96'.0H'(Y-=77
M.6GAB>/4K"^O-1%U-8QRQPN(-C$/TWG<=VT<#IZUKZ5:W5EID%O>WIO;E ?,
MN#&$\PY)SM!.* +E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5[C_ %D7U/\ *K%5
M[C_61?4_RH +,[K2(CH5%6*K6(Q9PKZ(*LT %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !5>Y.)(?J?Y58JO<DB2''J?Y4 %IQ:Q?[HJQ4%K_P >
MT7^Z*GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHKF?$EY+-KNB^'E)2#43,]RZDAC'$H)0$<C<6 )],T =-17.R>*;
M>RO-9M+JV:W_ +*MEN=Q<;98VW8V]^JXZ=:AO;J32O$&C7C*+>/5W^RWD);<
M!+Y9:,CW&PIGN"/08 .HHHHH **** "FEB#TX]:=7$?%B66V^'FJ75O-)#<1
M(IC>,X8'<.E ':,Y4'( /YT(^[C(SZ5XR-0FEU+P7;>&;^6;4MBR:E%YK,HC
M*#<9,].I_&NCAUC3;'XEZ]))+J"3VVG"6<.X, 08.47KD_E0!Z(3@TF^N+LO
MB#;:GJ&DV4>G7B/JMNT\.XJ,("1D]^V>/6N4\.^,AX>U'Q4]^MW<6<.LBVC8
M,66)6+!1SVSB@#V*BN!U;Q7J$?Q'TG0;6WE-N\3W,K C]ZNW  ]@:Z7Q%X@M
MO#>CRZE=L?+1E547EI&)P%'OF@#8)((Z8[TF[FN:3Q;#-?WVF"&9-1MK47(A
M;;F12N1M/<]L5S'PL^V:]I,/B*^O+S[5YEQ'(KR?NY1O^4[1TV@8Q0!Z6&8Y
MZ'\:-_OQC/(_K7D/C*Z33?BUH\,US<1:9=6LDUU''*P#D!N<+SV%1ZC=Q6_@
MZ+7;BZU&WT[4Y;9H8K60NT+!CW;^%@!Q0![("3C.,TM<C>^-K73=>?1&L[N:
M[6Q-W&(5#>:@SP/]KBH5^(%G++Y,5I=FX1X$FA( DA$HX9E/89YH [2DSCK7
M#:+XKO\ 5OB%K.E-:S16FG1QQXW#[[?-N/U%5_B#X@U&UU3P_P"'].N7M7U>
MX*2W" %TC&,[?1O2@#T -G_"E).*\W^(M]?>#-/TO7-)G94BNUAN()&++.C#
M'/OQUJCK6O:EK'Q.M/#D4UW:V4NFM,&A;!#LN5D'KCI]: /5=W(&"3Z4X<UX
MKIOB>>;Q'XEO=6U._M;+0IX2@ROS* RF,KZL1G\*[FV^(&GR0:FSVUVDNG6J
MWDT!"[VB*[LKR 3CJ,T =C17.:'XPM==NK:"WL=107%H+M)Y80(RI.,;@Q^;
M/;VKHZ "BN3\=7=U8V=A=".\ETN*YSJ*61(F,>U@",$':&P3@YQ4.EZQ9:?8
M:IK<6K_;M"/DBU19FDDB?[K)\YX)8K@$]^<4 =E17,Q>.-)DGU" B99K%(F=
M!L?S/,("A"C$$[B%ZCDU7U[QD;+0]<>"SN8-0T^T6;RYU7 W@A3D,0<$'(SV
MH ZZBN9DO[1_$^BI=K?17S6T[0C<ODLHV[F< ]<8(],\XJ2+QC82_895@N_L
M=_/Y%M>%%\J1\D#^+< 2."0,T =%17.#QC9 ;I;._BC6\%D\DD:@1R$J!N^;
M@$N.:U]3BOI]/>+3ITM[EF0"5AG8NX;R 01NV[L9&,XS0!<HKD+)-2LO&-SI
M-MJ%W<V3:;Y[R73"4P3E]J8/H0&.#_=JI8WTD'Q)@T>VUN2Z1+%WO8KB4L6D
MW#!4=%/.2!@ =J .ZHJ.X1I+=T25XF(X=,;E^F01^E8O@FXFN_!.C7%Q*\LT
MEHC/(YR6)'))H WJ*S+[6HK._2QCMKF[NFB,QBMU!*H#C+%B ,G..<G!QTKF
MO$7B%]5T#1I-%FG6+4M1CMI60;)$7YMZ')!5OE(Z^OM0!W%%8@1?#?A^\N(D
MOKE8P]PL$LOF.O&=@8GIQGDGJ>:YZTU>ZU"P\&ZK?-.)YV>1HX3M68M;R, %
M!YZ#&?ZT =Y17.KXTTIK%;G]\KM=/9^0^U'$R9W*=S!1@#.<XK0T?6[+7;:6
M:RDW>3*T,JDC*.O4'!(]#D$@YH TJ*Y>UO+MOB3?V#74ILX]/BG2 D;0[.P)
MZ9Z <9K8U36+723:I/O::ZE$,$48RSMC)_  $DG@ 4 :%%<_'XPTN6.W,?G/
M-/>/8K J@N)4R6!YP, 9SGH1ZTD'C+2[J"Q> 7#RWL\EO%!LP^^,$N#DX&,'
MO0!T-%<XGC3398X?*BNY)Y8Y9?LRQ#S42-F1BPSQ\RD#GD]*UM)U6UUO2K;4
MK)R]M<)O0D8./<>N: +M%<GI^NZ=8'4)I;S4I?/U46RI=(?EF8#$48QPOUX]
MZW=+U6WU:&:2W$JF&9H)4E0JR.N,@_F.1Q0!?HKA(?$T6B>+_$\>J7-]):Q-
M;-&YA:2.!63)!*C"C+=_Z5T=_P")=.TY[Q9FF864:R7+1PLXB!Z;B!QQS[#G
MI0!L45B2>*M,CU633<W#74<D*.%@8J/-^XV[&-O'7IVZTEKXLTJ[O;:UBDF!
MNBPMI7@=8I]O)V.1AN.1@\CI0!N45YWX/\7)9Z5)%KEQ=R2G4IX'O'B=H4;S
M-JJ7Q@9[=A[5U]KXAT^[_M(1O(K::Q6Y62,H4(&[OC((Y!Z&@#5HJM!?0W&F
M1ZA'O\F2$3+\OS;2N[IZX[5BVWC?1+NU%U#-,T#1)+&_DL!)N<H%7CEMPQCK
M0!T=%<?K/BK1[SPYK:RWFH6)LE1;HPQE9X=Y&TKUSGU'&.]:-SXKTW3]4DTJ
M7[9)=PVXN&6.W=R8^FX8'(SU(Z4 ;]%8TOB6Q2WL9XEN+A+Z!KF'R8B28@JL
M6.<8X9>.O/2LY?%;R^-(M(BL[EK8V*W)E"*0P=@%;KD* &![Y/3B@#JJ*YVQ
M\9:=J+QK!#>[I[=KFV#P%?M*+U*$]^1P<'D54T'QI#?:'8WE]'-#->NWV=#&
M,R@EF 0 G.U1R>/UH ZVBL-/%6F2V/VF%YI6-RUHL"QGS6F7JFTXYP,\\8YZ
M4GAR]-_/K4WF7)5;[RUCG4J8P(8LJ >@R3]<YH W:*XW7+R;4/&-MH+#4(+3
M['+,S6SF-I7W1JI5@<X7<2>G/K5VQ\1V-E!;6DTU_<1+*+-=1FA)267=MY<#
M'+<;L8)[YH Z6BL2+Q/93ZF-/2&\\[[2ULQ-NP5'5 ^6)Z @\'OVJ/6M=GTW
M7-&L(K.>9+QY3*\:@@*L;' YZ[MOMC- &_17$:3XF73KG6_[3DNY(CK;VZ3>
M66C@4K$JAFZ*,L /K]36SJ'B_2]-N)XYO/:&V=([FYCCW16[-T#MV/(SZ9&<
M4 ;U%8?C"ZN++P=K%U:S/#<0VDDD<B=58*2#46B>)K"[AM;26XD2[-HLY^T1
MM&)5 &YE+ !@#U(H Z&BL>V\3:;=2*BM.A>)YX_-@=/-13\S+D?-VZ=B#WIF
MG^+-(U.>TBMKAS]LC,EL[Q,J2X&2%8C!8#J.HP?0T ;=%8J>*=*>X@B\Z15N
M)FMX)6B81RR X*JV,$Y!^N#BN7AU:ZUK4M>>34M3TV/3;H+&T,&42)44N&4@
M@LVYCD@D8!''! /0J*Y>T\0.]WH-K:1W=Q975A]I:ZFCW/(N$"]/XLN"W&.:
MZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BE
M'[R/\?Y5+44OWX_QH ;:_P#'K%_NBIZ@M?\ CVB_W14] !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !111F@ HK"?Q/#]NG@M[*ZNXK>Y
M2TFEMU#^7*V#@KG.T!ERW;/L<0:IXSM-*CU":33]0FMM/E$-Q/"B%58JK8P7
M#'AUYQCF@#I*Y;Q)%)9^)=!UUHU:QL_/@NGSS"LH4"3_ '05P3V!SVK7T_6/
MMU[<6DEA=VDT"(Y6X"896+ %2K,#]TU?D1)HVCD171P596&0P/4$4 <YK?A9
M-:U_2]3651#&ICNT!_X^(@1(B_02*I^A/T*:[;C6O$FB6,39&GW/V^Y91G9M
M4JBD] 6+YQUPI-=*JJB*B*%51@ #  IJ0Q122/'$B/*P:1E4 N0 ,GU. !]
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MPBWA_P#Z >F_^ L?^% 'G^OWFG^-XM/L]4U#2].TZWN1/.@U&.1I2H^55((
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M%K"9KB5(H@0"[L  2<#D^Y J7- &=%<Z@;2\DN-/Q+'+(L$4<JDS1@_(V20
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M!"J=JIQ@!1GVXR:L/A;7#HGAP3Z'%<2Z#*\+6-Q-&4O(W7:7'4#'! ->J44
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MLD488X!8J0.:YQM%U#6FLHIK!K%+72);5IIBI9I945-HVD_*N"2?7&,UW5%
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MSRVR6K>;*SCRUZ#G\>>^3ZT <AH_B75I=?T$27GVJ#5I+A9F2/%N-B,R>02
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ML\UY;?8Y+AV3>L)ZHH"A1G)R<9]^!C6T^R33=.MK*.222.WC6)&D(+$ 8&<
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ML%&%P0!MP>1@#DD]ZC;PQ;21W9GN[N>XN;7[&US(R>8L7/RKA0.YYP2>YX%
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MS7UN;J*.&X:SVW%XA(7=)&0,[ 0,[1D+G'%=M0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 (3CJ<4 @C(.12.-PP5!!X(-" *H4
M+M X H =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4Q^U/IC]5H CM.+6+_<%3U!;#%M%_NBIZ "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ IK#.*=10!#!_P >\7^Z*FJ"W_X]XO\ =%3T
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ <FN7C\;K):Z3>#1M0^Q:F\:1W'R;8_,<(N_P";(R6!XS0!U=%%% !1110
M445S]IXFDOKQ5M]*NGL6NY+/[4"#ATR"Q4=$RI7<3U[=* .@HK)U/78=/COU
MCADN;FRMA=201X!V$L =QX_@8XSGBK.D:BNK:-8ZDD9C6[MTG"$Y*AE!Q^M
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M#6#IDJ/%,T?FPLV-LRC&[:?521D'U!J>[O+>PM_/NI1''O5-Q_O,P51^)(%
M$]%95IK:77B"^TC[--'+9Q1RL[E=KARP&W!/]T]<?2M6@ HJ)KB%+F.V9P)I
M%9T3N57 )_#<OYU+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!@\<="1R*]!K)7PUHZ263BPBWV*[;8G)\L9R!R><$ C/0BM:@ HHHH ****
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ML$'VE6*12J&PPP&RRDC@D8.#CW[K4K^'2],NK^XSY-M$TKXQDA1G SWK@O\
MA&/$+:%H>A26MN8]+U.*878N.)(8V)!VXR&P>GM78>*M+EUKPKJFFP,!-<6[
MHF>F[' _.@#*TR/4;GPY%JNH:LUH;L_;+MA(-L$&TE40D80 ;=S8R?F.<X(R
MX=5N+OPAY]KK-U<))JZP6]W" \C0^: V_:O V[SG XVUM:%JDK>#]&EL]/FO
ML1)!<11NBO"54JV0Y4$AEVD9[YYJWX<TE]+74Y'ACM_MU\]T((\8C!55Y(X)
M.S<<=VH Y*[-[?>)-+L[F:]+6NKRH(_)(VP>0P242A<]^N[JWMQT_AF_NFN=
M4T:_E::YTV8!9FQF2%QNC8X[X!4G')6NAKE_#BF[\4^)=50?Z-+)#:1MG.\P
MJV]A[;G*_530!5\;ZW<V%YHUA%:ZBT%W=@3/9\-(JJS>6K!@P.0">F1GGK53
MPYJ#:/K/BM-1U*^FL;!+5XQ>2&1X@\98K[G) [DX')-:WB>VU"YUKP])::;/
M<PVEX;B>5'C4(NQTQAF!)RP/ Z?E6+J'AG5-1U/Q;(+5XDNWLY;-VE0+,T Y
M4X)*@D8Y ZT =/#XGL&N+JWN5GLIK:W^U2)<IM_<_P!\8)&..1U'<"FV_BO3
MY[F"!H[J%[J)IK7S8&_TA%&24QDYQSM.&QSBL36M!U#Q=-.\UB^EH--GM$^T
M-&[O)(4(/R,PV#9ZY.3Q2BQUC5+KPZUWI,MI_9#&:=S+$1,XC*!8PK="3GY@
MN!^@!N:)XJTSQ 8_[/:9UDA,RNT152H<H>3WR.G7!%6]1UBVTQX(I5FEGG)\
MN&",R.P R3@=AZ^XK$^'.CW^A>"K33]2M_(NHY)6:/>K8!=B.5)'0BIM8M-2
MM?%-AK=C9M?1+;R6EQ;QLBR*K%6#J78*>5P1D=: *'B/QA;MX*N]0TF2YWL3
M;;XX3OMY=P4JX."C MQGOBMS1M*?37NY/M=_)#<,K);WDYF,&!@A6+,<'KC)
MKCKWPYJ[^'M>>/3;AKS6-4CN5M?.B_<QI(A!8[]N2$/0GJH[$UZ,I+*"5*DC
M.#U% 'F6M>+K_6?"7BV2W6^TTZ?,R6\\:F-L)L#*S=F))X&#BNSLO$^G232V
MDTLEO/;6HN9#<H4!BR09 3P5R#S7(WFA:X?#'B_28](FDEU&^GN+:19H@KJ[
M)MZN". 2<@=.]6-<\+:EKVN7R&VEMK6YT!;);DR)A9A)OP0&+8Z X'K]: .O
MM-<M;N_2Q"3Q7$EM]JC66/;OBR!D>X)&0<$9'%97Q!N;NR\(7%[97TMG-!)$
M?,C(^Z9%4@Y]F-4?".EWD%Y#)<>$=/T4P0&.2XC:)Y)V.!\I09 X).3Z5H^/
M+._U'PI<66G6,EY<32181'1,!75B278#HN/Q% &:=4N;+QKH^G:7J[:I:W:S
M&\MWD20P*JC;(& RO/&"2#GBM>7QEI4&FF_F^T)"+S[$VZ(AEESC!'7KWK,U
M"SU/7?$FAW<>B3Z9]AF,LUY<31;RF,&)1&[9#=\X Q61J^B^()M'UC3(-$:8
MR:Q]NAF%Q$%DC\U'X!;(;&[@X''7M0!O_;H)?$OB*SM=2OQ?1V2,89%/DP':
M<-&#U)R">U0>%O$*Q>"?#[7\]S<W][!\@4&6:4@$LWX#N?4#N*(='U)/&WB3
M5C9/Y%S81PVV73]ZZJ<C[V1S@<C%9NAZ)KN@P^&+PZ6]R]II\EC>6D<T8DBW
M,K!U)8*W* $;N] #]+U%9?!=C-=ZMK"-<:LR1SA&:5\7+*D;\80$!00<#M[5
MN7GCK1+&XU"&9KO.G,JW3+:R%8MW0DXZ=.>ASQFLEK+5HO#,%K)I%QY_]O"Y
M9$>-ML7VPS[^&Z;>/7/:JNM^'M7N+7QW'#8.YU0V_P!CQ(G[W"*I_B^7!'.[
M% '6ZEXET_3)FAE,TDB6YNI%@B+F.(<;VQT'7'<X..E6])U:SUO3TOK!Y)+:
M3[CO"\>X>H#@$CWZ5Y[K2ZE/XCN%M=)U >9I45KJ!M/*D/S[CMPS ;E&<$9Z
M\\8KMO"\UB^@P0:=;3VT%IFV\BX'SQE."IY.3]": &ZCXJTO3;J:WF:=C;A6
MN7BA9TMPW0R,!A>.>>W/2I-2\2Z=I6PS/+(&B\]C;Q-*(XO^>C;0<+UY[X..
MAKE;C3M2TX^+[ :5<WR:PSRVLR%2A+Q[-CY/RX(]",4RQTO5O"LRV[Z3/KEG
M>:7;VDJQ.A$<D2E"A#D#RV#'K[T =??^(M+TW;]HN&.8O./DPO+MC_OML!VK
MP?F.!Q1)XCTN.>[A:X<O:VPNI=L+L/*/1U(7#C@_=STKF FN:/K,DUQH(U.#
M4=.AAF2SV!8I4W QD.0/+._K]>*2^LM4@U"56TN28W'A];(O9JOE),"^5Y(P
MO(QQ0!O7'C/0[861:Y=OMUL;JV"0N3+'@'@8SDY&%Z^U07OB/3K_ $K2+ZQU
M9X8+N_@CCDBA+>:=X!B88^7/(.<8YKG]-ENM(N?!<=WH]V]S!HUQ!)#&$=XB
MOD#=][&#C'7/S<]ZA30M2M=&AE.FW EO/$R:L]N@#-;Q"13AL$\[5S@=SCM0
M!V5WXKT6QEFCN+PJ()$BFD$+M'$[' 5W *J>G4C&1G&15#Q9XFM+#2=5@@O;
MF*]MK8R-):P&3R"5)3>=K!<G'7L<\=:Y9O#UW;:GKMG=>$QJ@O[Z2YM+MIAY
M #G($HSD!2,\ D_E5Y[#5](M?%NFQZ-/?'5'DN+6:W*!#YD84JQ9AC:5]\YX
MH [71999M"T^6>42S/;1L\@.0[%1D_B:K?\ "4Z/_:"V/VIO/:Y-HO[F389@
MNXIOV[<@>_MUJ?0HG@T#3X)()8'BMTC,4I4LNU0.2I([=JX&2VU=M2MYIO#V
MH-+;:Z]TSP+$L/E'>H90'!9B-I+,">O/.* .WMO$VF7=^MG#).SO,\$<GV:0
M1/(@8NH?;M.-K=\<'&:T;R\M]/LYKNZE6*WA0O([=% KA+'3M0@\4V,VG:7?
MV,#WT\VH0SLLEODAP)(R22K'/\..&Q71^,]*O-9\+W5II[*+O='+&KG"N4</
MM/UVXH FMO$^G75U-:I]I6ZBC$WV>2VD21XR<;U4@%A].1W K$\'W=YX@M;'
M6O[4O #+.\]NT)$4J%F5%4D8&W /!)Z@TK"]U3Q/IVNMHUU:1:=:2B1957SI
M7DP/+4 \A<$Y)QSQ5OX>6=UIW@BPL;ZUEMKF#S%>.08/+LP(]1@B@"6]\0NO
MC*UT")945[62::46[L0<JJ;3@@8)))/R]!GM57PUXEA-E966H7<\][-<7$*S
MO$=C,DKA5+@! ^U<[>N!TZ5-=P7EO\1+/4$L9Y[273GM6EBVXB?S%;+9(XP.
MV?I6/;1:C'H>AHVCWWF0ZQ)/*FQ<QQEY&W'GTD'3T- '3/XITI+TVQFD($XM
MC.L3&(3'_EF7 P&Y ],\9SQ6K-/%;023SR)'%&I9W<X"@=23Z5YPGAV\34[_
M $R3PXDS3W[W4.J22;H CR>9\R9SN7) &.H';FNN\9:5<ZWX/U33K-MMS/ 1
M'SC<1SM_'&/QH P9/$_VOX@^'X;#4;HZ?=VD\TL,EL8HV 3*.&906SSW(&!T
MS6W9>,]&U&7RK26>1FB>6#_1W'VA5.&,>1\V#QQ_+FN>8ZWJ_B'PY?)X<NK3
M[#:W22F[>,1^8\:A1PQ8KN&,X[].N*7AW3]5AUCPW=76AZA');1SP73DQK%&
M7"XV1JV%0<\@ GW- '0>&_'%OJ_AR/5;N*6'SKJ2"!$MW8R_.VP*!G<=J\XX
M&#T%=!I6KV>LVK7%G(S*DC0R*Z%&CD4X96!Y!!KS73/#^L:?X,T1/[$DN+C1
MKZ1YK.?9_I*/N!,?)Z;\C<!TKO/#,$D5G<S/H\.DK<3F5+5%0.!M4%I-O!8D
M$_3 /- &;<ZZND>-]16_OKDV*:=#.L"PM((R6D#L%12V,1@DG@9]Q6S/XCTJ
MVBAE>X=TFMS=(8H7D_=  [SM4X'(Y.,UC7EM=2>*=>N%L;@Q/HZ6\4NSB1P9
M&*K_ -]K^1]*YY](O(/["O+OPU=ZG;_V1'87%LLBJ\$B=]I8 ALD=>@'X@'9
M7/C+0+2-9)=0&QK47BLD3N&A+!=P*J<\D9'4=3Q3I/%NB1WGV5KT[_/%L7$+
MF,2GHAD"[ WL37.Z5I%_9^+M$\S3/)MK;3)H7,(S#$SN&6,$G)P!C/0GZUGV
MNB7UO>ZIIEUX8>[^T:HUU;7K2@VX5W+;W7=G<F3@ 9/3CJ0#M9?%&CPWAM9+
MO#"40M)Y3F)9#T0RXV!NG!.>:Q[_ %R:]\5OHUM=ZA9!+4[)(M.D;]\SE0Q+
M(5* +U^Z<GGCC*32+ZQ\):IX7FTZYNYKN[E2&Y1<HZRDL)7;/R[<G.><@8SF
MMZ"5T^($ZFSO5@&GQ0+<-;L8G<,S$!\8Z,.3WR* )O%MS?Z9X&U"[M[UH[ZU
MM3()TC7YF4<G:P( -1VOC31/LDPDU!I9+*W66X9;>4[ESM,B?+\ZY_B7([]*
MF\;Z;>:OX+U6PT\;KJ:';&N[;NY!(S[@$?C6?9Z;/>^(M)O9+.2&WL=,>WE>
M<8\QWV?(%]%VG)Z'(QF@#?36]/E@TZ>.9GCU+:;4K$Y\P%=X.,94;1G)QCO6
MA7!^!-,FAO[Z%Y%DT[1KB:RTX8R0&;<Q)]5!5/P;Z5WE !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 10?ZM/\ =%2U%""(
MTSZ 5+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %8]Y<Z/9Z[ \L>_59(2J>5$TDHB
MR,G"@D)G'/3.*V*XWQ'HU[/XC36O#MY&FO6=JL3VUP#Y,UNSL0#QP2RMR#_"
M,XZT =-INJ6>KVSW%E(SQI(T3;HV0AE.&!# $8-,U;6+/18();QG"SSI;IL0
MMEW.!G'0>YKC;+71>6-C96<;Z)=7^K3V^H#<)#%,JL\BHQRNYCC!Z<G'(Q5?
MQ']LM]*73K_4A?36^NV;1,0-ZP,XV!R  6R&Z#TH ])HKSN?Q%J^B0>,HI+X
M7CZ7]G-M-=(J[3*@SNV  JI.>E:TLNK:5XFT[3&U::[@U.WG4231Q[X)8U#!
ME"J,@@G@@]!S0!UU9%]XET[3[Y[28S%XO+\YHXF98?,)";R.F2#].^*Y73-7
MUQ8O"5]=:EYPU*0VUQ;F-=C?*["0$ $-\HR.E4I$OO#VH^,]8@U"ZGFM_LZ+
MYYBV2L80%WX08VEP<C&1U[T >E3SI;6\L\F[9&A=MJEC@#)P!R?H*KZ7J=KK
M.F0:C9.SVTZ[HV9"I(SC." >U<GI5QXEANKFTUA3]DFLG>-KBXA>7S%QG:(P
MORX8=N#CGFLOPKJ%W/I'A#0+6[>S2?37NIIXE4N0A 55W @9+$G@\"@#NM&U
MVQUZ.[DL&D9;6Y>UEWQE")% )&#SW%+>ZW8V-XMG(TSW+1^;Y4$#RL$SC<0H
M.!GBN3^%L;Q6'B.-Y6E=->NE:1@ 7("<G'&3[58UVPU1/$<^L^%;F"34H84A
MO]/N,A)TY9,'L^"V#G'/;N =/9ZSIU_I\-_;W<36LTACBD8[0[;BF!GKEA@>
MM7J\LN+B'5['P?)IKWNF02ZO*DENK*?+D_>,W4$'#@X[8/2MFSO==O/$.OO_
M &O''::3=G;#)&H1T,&0K,.0 Q!S['VH [JF1RQS1B2*170]&4Y!_&N!T+5-
M9N[^*TN-4N9(KW1VO//$*)ME#H"8<J#LP_&]<\ Y-4]%U?4(_#OA+3+>6]DF
MU*U:9Y(?*\Q0@!(4OQR6&<Y. : /3:IZIJ=IHVF3ZC?2&.V@7=(P0L0,XZ $
M]ZXFX\1ZQIVFV<&KW,=HQU;['<W:O&SQ0E2\9<#*J[?*"<8'7C(-0WNOZY8_
M#SQ#K*:B\S0W#Q6$[Q)S$) @DX !)R><8X''J >C1NLD:R*<JP!!]C3JX9;_
M %GQ!?:Q:Z;JAL;K3(X!"C(A25W3>6DRI.T_=^7'0GGMV=M/'=6L-Q$ZO'*@
M='7HP(R"* *:_P!EZ5J2Q((H+O4Y&8*O!F=5RQQZX')K2KR_Q'-+?RW7BRRC
MNI9='ND%B$C;:\,9Q<'.,8;,BGVC&.M=3JFMO>3:!::9="*+6&9_M2%2RQK'
MO^0,""QX'0X&>* -BTU*RU=K^VMWD8VLIMI_D9-KX!(!XSP1R/45,%M=*TXA
M$6&UMHR=J+PJJ.P%< IUK3_#OC2;3+UI-1M=2>19&B3,BB"$G(QC.WTQDCIV
MK6CUJ[U:.^U32M2/V"VTM2@VHX-PRF3)XSD*4R,@?-TH ZNSNX=0L;>\MFW0
M7$2RQL01E6&0<'D<&IZ\_N/$>K0:!HU]<73VEI<:2DTVH"V$J+<LJD>8 "50
MY/0=^HJZM]K&M:AJ5O9:M#:C388&1H4607$CQ[\OD?ZLY &W!.#S0!V=%>=Z
M3XGU_P 27-E#:RVUH+S1Q> ^5GRI1*%/4G((# >F>^*OV6O:A_PF!T[4+MK.
M22\E$-G-$ D]LJ,$>)\<MD*2"<\GB@#J=1U2RTBV-S?SB" '#2LIVK]2!@?C
M4\5S'-;"X02>61N :-E;'^Z1G]*Y;XG_ /).=7_W8_\ T:E=7)+'$H:1U12P
M4%C@9)  ^I) _&@"CIFNZ=K$D\=C,\K6[;)@877RV'53N PP[KU'I5F\O;;3
M[<W%U,L40.,MW)Z #J2?0<URGP^4@^*B00#XANR/?A*4SV^I?%"V#7"306NF
MO):H'ROG^:T<A'.-R@;?;)H Z*TUO3[V\^QQ3,+KRS+Y$L3Q2! 0"VU@#C+
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MT[6-';5(KF%+99)%+M*,!5=E#$]@VW(SZUI6MY;7L GM+B*XA/ DB<.I_$4
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M7@DBMBUFO6U34([@VWV5#&;;RV_>8*_-O';Y@<>U68KF">-I(IXY$4D,R."
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MU [5CZIXOA6P\0C1S#<7VCP>9()&Q&3L+<$9S@ Y''/&1716\ZS1(=RERH+
M'ID4 8=];V_AZ2]\1RQ7^IW9CCA*QQK)(L>X#"*H'&6+'U_ 4OA'15TJSO;E
MH##/J5Y+>/&P&Y [953]!C(]2:W(KB"=Y$BFCD>,[75&!*GT/I56_P!8L].N
MK*VN) );R7RHER,YVLV3STPIY]2* (/$6@P>)=);3;FYN8(6D1V-N5#-M.X
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M,20/-YBE$!)((KFO#?B'5M=^Q7_V2U.EWL<D@\MCYMM@_('R<-N&>@&#Z]:
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M$\$-M;[DN%V)Y8$H1MI#+CD@+^=>I44 >4:[,D5CX\LK^"4ZG=,6M6,#MYL
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M=@8KV%%:6,K+&CEEY&" V 3]<"N?T;0]5T'0)-%A>TO+:(.EI++(T3A&SA7
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MS;T4Y!#CTZ5BP^"+NPN=)MH/LU]IEG9O&(KQV")<,Y9IO+ (?(8X4XQCJ.M
M#]8U.#5]2\#:A:,_V>ZO&E3<,'!A;&1ZUW-</8>%-6ATOPE%*;-9M%DS,HE8
MAUV%/E.WKSG&/QK9\.:S>ZM=:K'<QVS06UQLM[FUW&.5",XR>K+T)'&?I0!B
M+IEI'\8693LSI0N?)W'#2F4@N!GK@#IZT_XK!$\#7-T'FCGADC$4D+E""SA2
M#@]""015RXT75_\ A.F\0Q6]A(BV/V*)'NG1L;RY8XC([XQ^M9OB?P]XG\1^
M&M0LY/L*3W5Q$\4'VEBD$:;3C=L^8D@D\#J* .WQ%966$3;#!'PJ]E Z#\!7
M(>$[.+Q5X>CUS6DDN)]0+R+'(S!((]Q55C&>. #GJ2<YK65/$&HW-JMY:VNG
MVL4OF2^1>&9IEVL-A!C48)()Y[?C4&C:-JWAJR.EZ>+.ZT^-F-J;B9HY(E)S
MM.$8/@DX/'% %C3EO-$73=):*>^CEEN-]X7)\E 6=-Y.2200N?4'\=ZN;N+_
M %?3;S1+(S6=Y-=3.+M2"L@3KNC XVIG!+=MO<UTE !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !2$XI:0C- "T444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 FT9S@9]:6BB@ HHHH **** $"JIX %+110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #/)C\[
MSO+7S=NW?@;L>F?2GT44 %%%% !44]K;W2@7$$4H'($B!L?G4M% #418U"HH
M50,  8 IU%% !1110 4444 %%%% !2  =*6B@ HHHH **** $P,YI:** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHK%\4:Q+HVDK):I&][<3QVMJDA(5I9&"C..PY/X4 ;5%<I>^']7N%-N/$-W9
M64$7F+<0N#/+,22QD+# 0<85<=3T  JC%J^IQ^#=(\53S;I8H5-Y%]V.:%F
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M]3MX+K:J3JJJ" 03@D@GG':NWFUG3X-5M-,DN5%[=JSPPX.65023[# /6K]
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MY8W"7%M)G9+&<JV"0<'Z@U:H X/1'UNSTO0KC4]*GFN1-<"5;:%58!B2KNO
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MQ7$FUN;7X(V27-O-$]FL,UQ;RQE6*),&92",] 37I44D<T22Q.KQNH964Y#
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M<L#M<VCQ!&WH0OS 5W=%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGGUJA_PAPBL8+>TU&:)TNS?R3R1K(\UQ_>;H,>H ';!&*V-:TP:QH]UI[3/
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M)N18D !6+;MH<<A,\[?UY(*0>$9;6RURSAU5Q;ZI)-((W@4B(R_?.>"QZXY
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MU>F58=,;39(A%M$B,""V<\'FFVW@VXCU/0KRYUN:Y_L<2K"K0("RN@3#$=2
M.O?V[@'64444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1RQ&0QX
M=DVMN.._!XIXS2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQK973WUFOEV8C43_ #P'82"A!('/S<<<\CM75^%=4GU310;QE-[:S26ER5&
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MWBJ5.2O8$#G)H UZ*Y4:]>VWC.ST"'3YY;(:>9O/$D99SN10QRP(503GN2>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA)+0)\7+J42
M73E=$2<(LS#<?/?Y>OW>.G2N[J@NBV":PVK")_MS1^493*Y^3.=N,XQGG&*
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M3DCMUF6X"H[*?,'1BP.21VR>*LOX<TF2YU"XDLU>348Q%=EF8B50, $$XX'
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MV]4A*KD$XS@ 9ZU<\)W4-E\/-%N;B01PQZ; SL>P\L5LZAI]MJEF]I=J[P2
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5PGBW4O$?A_29=0_M&'=+J20P1+ I5(&; R2,EN_I7=UQ?Q+M;N_\
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MFI:78W4T227\K*#)($$:JC,6)/'4!>V=WM5YM6TY+L6CZA:K<DA1"9E#DD9
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M636]+DD1$U&U9G5W7$HP50@.<^@SS6)KHM[;Q'X21HV+1W,H$OED[4\ATP6
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M07V[=[A=W3FMK(! R,GH* .8A\&0P:[I>J)?3/)8+*/WH#-,TN=[,W')SQ@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYP"<#DGI6_;Z-I=I:2VEMIUI#;2@K)%'"JJX/8@#!ZFI;'3K+3+<6]A:06L
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M5( 7 P !TYSDUT0&!US[TR6XA@*B66.,M]W>P&?I2O-%&Z(\B*S\*K, 6^E
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MM:* ./UTLGQ$\-SB*1XXK:[5BJD@,RKM&>F3M;'K@UQFDSH=8\+NLKS0"QO
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MX97M)(!I-OLBE "A09LG:W3 9?H&'K5!;BR>T^&LIEA:<&--V06'^CE6&?\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !28!.<<TM% !1110
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M3,/M+,),(#EE)P6!.,XSGBLV^TRVN(W:Z9BDGB_(VRM'MSM7^$CGY>#U&>*
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M5=HX(VD8(,L0!DX%1Z5J,6KZ3::E KK#=0K,BN & 89&<=^:CUS_ )%[4O\
MKUE_] -<#H,M_I&G>!)(=3N9X]1C2WFM) I01^3N!4  C;M'//7F@#T#3M0:
M_:[5K*ZMOLUPT -Q'M\W !WISRASP?8U>KS&XUS5[/PYXENDU.=YK#7U@B9P
MI_=%X1L/'3YCTQ4^J:_J7AN7Q+!'?R7"6WV(PRWF'\DSLRNW '  ! Z ^W%
M'90ZM91^(#X?B@>.X2V-W\J!8]A?''N23V[&M6N(L+7[)\66C^U3W .@@AIW
M#'_7^N/Q_'TXKMZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M0TM% !1110 4&B@T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5FR^']&F\SS-
M*LF\V4329@7]XXSAFXY/)Y/K6E7"ZQX@7P]9^*]5M?[1NKBWDC1XK@@10L5
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M.(K=F"QMGYL], #GGZ9YJ>^U^SCC$42W5S++:FY6.UC)?RNF\9P!UX'4]@:
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MVS/YLO=R21G'8<#\*H376L6GC'1M!?79Y!<64LUPXMX@2ZX *_)P"<\<].M
M'4ZGI-AK%ND&H6R3QI()4#9!1QT92.01GJ*B?P_I4FFG3GLHVLV<N\))Q(Q.
M26Y^8DG/.>>:I6>J2:391VNNW9N=1_>2$VUNTA\H.=K,L:G;\NT9P!G-2W7B
M[0[.&*62^5EFM3=Q>6C/YD0QEA@'/4<=>I[&@#4MK2"SLX[2!/+@C38B!C\J
M]@#UX_2L^+POHL$,T,6GQK'.VZ903B5O5N?F/N>:J/XY\.Q"Z:2_*I:2K%._
MD2%8V8#&XA<*.<9.!G-7K'Q%I6HWC6EK=;KA81<>6T;(6B)P'7<!N7/\0R*
M()_"'A^ZFAEGTBU=H8!;Q@KP(QT7'0@=LT^V\+:-9O;O;60B:W@:VA*2,/+C
M8DD#GC)/7K[U?T_4+75;"&^LI?-MIEW1OM(W#Z'!JB/$VD&>*+[4?WTWD12^
M2_E/)DC:LF-A.01@'L: (W\):')I<>FOIZO:13>?'&SL=CYR2"3D9.<\\Y/J
M:%\(Z"EA<6*:;$EM<2>;-&I($C Y!.#S@\@=C5B#Q!I=U?-9P70DN$N&MF14
M;Y9%7>5)Q@<?AP1U%9MWJUS?>,8_#]FYBAM[<7=[.OWN6PD8],X))].F,YH
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M,L#0 M%%% !0:*:6 ('K0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMY:2!C@'!(QUP>#Z5<XSCO0!P^OZ7=1>-4U4Z&^K6%Q9+;2"%P)(71F8'!8
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M4K++*8_,8L#_  G@8&,<U1C\8WB7OAS5+N<0Z-JEA)+-$8AB*9$WX#]<$;L
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M+.I P1@KZ'KTJ/7-9O-;\/\ C:.*6&&UL;1H54+O9V\K>YSGH0=H_/VK>O\
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M8 9+ Y)/ Z<\*^O^)'G\.V,AM[&\OI;J"X#PK)ADC9HVP'( ^Z2N<]LUH?\
M" V']BZ9IZZAJ"3:9N^R7T<BK/&#U7(7!&.,8[593P=:1WFDW*WEYYFG223
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M"VN-1O);QX<@F(.V50D=PN/Q)H M>)];?1+*T\B,/<WUY%90%AE49R?F;D9
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7[:ZM[VVCN+6:.>"0;DDB8,K#U!'6H#K&F+J*Z<=0M1?-]VV\Y?,/!/W<YZ
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MGOY5U._)DE*AMB8/&T,I)/T [BIH&OW_ (A<WELFFG2'+B*6.Y9YN"0NY-H
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M6]K)/<+YL$TAW10GW[R=..G..<9-74-;U9M6OK'1[2UG>S@BE*S2;3,SLPV
MY^7 0G)SVJOXS-FMSX9GN# &75X@CR8XRC]"?<+^E,TJ#2&^(.N>5%8FXCAM
MB-JIO60^:6]PW3/?I0!UI<* 6(7ZFD,L:[<NHW?=R>O?C\JX?QM<V*^*?#5M
M>"*,LTS)<73XMX_E .5X#N>B@D8)[]*Y#0;?29="\"G4?LSV\5_>VD[2,  6
M\TI&WL3M^4\$$9X- 'LYEC50S.H4G )/&:I:Q>SV>BWMY9+#+/!"TBK(Q"G
MSR1D]*\KU2SL4TV\\J*V70QXFMC:E,"-1A5EVD=%SD<<=:VO)TS3KWQ?=:(E
MO'HRZ,//^R!1%]H"R'"XXSL*YQ_>&>: .QL]1U"\31+A(K46UW;^;<[G(=6*
M!E"#N,[L_2M?>N[;D9],UYS \/\ PDGP]>-XO-;2IQNR,D>5'MS[9S^M4O"-
MYI<EEI\5['+)XLM-1E,\*_+.SLS!F;/6,(V2>GR@=<"@#U/>N[;N&?3-8GAK
M6KG5H=0-['!%+;7\MHJQ$D$)@9R>I/->8VVH6EQ=Z#J OK:V+^()998KAO\
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M9/L+0-;PPK&8E!!S, <Y!& 2.<YYZUZ/0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %,CFBE9Q'(CE#M8*P.T^A]*?7FF@:I+H[^.+V&S>[D362!$AQ]XJ,DX.%
M&<DXX - 'I=%<6WCORM-UN=[2&:32YHXF>UG\R%_, (?=C( S\W!Q@]:JZSX
MDUN2Q"VRV,*-J5K;I>17!>.9'92=I XYRI^M '?55O8;6^MIM/N6!6XB9&C#
M[692,'&.>_453UC6?[!\/3ZG>1>9)"@_<PDGS') 55XSRQ Z=ZYJ.:=?B9'/
M?:;!'=1Z#+*QMV\QG_>I\OW0<C!'?K0!M1>%\V-KI]UJ=S<6-JT9CAV(FX1D
M% Y502!A>F,XYS70UQ>C>-;O5M0CT_[!:QW<]@]Y&@NBQB8$#RY1MRI^89]/
M2IK/QA/?Z):7,5@B:A/J'V&2RDD.87!)8,P7J$&[IC]* .NHK'UO6SI<MA:0
M0">]U";R8$9MJC"EF9C@X  /0$G@5SFN^)]2/A[Q39K;PVNJZ9;[B1,2K1.I
M(D0[<YX/&.".M ';QSPS.Z12QNR'#A6!*GW]*<\B1@%W502%&XXR3T%<;X-T
MIK;PO8ZJFFV$>J-IL443QRL%EBV*R^8=O#9SG ./4UR*:M?ZSX%\+ZUJ4,<\
MY\01/$Z$M(1Y[Y4 CY>@4 $\ ?2@#V*BN0;QO]DM=9.HV*Q7>FW$5OY44X99
M6E"E K$ _P 7/'&">:O>'?$-QJ]U>VEU9K%+;;&$T#,T,JL#]UF53D8.1CTH
M Z&F^8AD,>]=X&XKGG'KBN-U+QX;:\U%+&RCNH-+<)=9E*RN>-PB4*0VT'G)
M&<''2K_]I6-MXKU*1['RY(M,CN9+L-DR1!GPNWV(;WH Z6@$$<5R]GXFNKZ\
MTFTETE FJ6ANE9;C?LC&W(8%1SAU_,CZ\UX#U^32?"_AVR?3R;2\O)[5;@28
M*N996'R8Y7C&<^OI0!Z6[+&C.[!549+$X %.KR?Q%J&H:OX-\=+J4,!CM+OR
MX0LI?RBHCP%!4<<DYSU)XKM])U^YN=>DT>\TMK1EM5NH9?.#B2,MMY&!M8<<
M<_7U .A.!UI"1G&1GTKE[EUUKQX--E >STJW2[9" 0UP[$(3_NJI(]R#V%<+
MK*!O'%Q8NB6VHRZO%+;ZVSDK&@CR+?=_"^,C9P#N^F0#T!QIMOXJAO+6\,=U
M=R&TNH8D+K,Z1EU#X^XZKSD]5X],= V2K!& ;'!(S@_2O-KGPYJLMS>VZZ=<
M&*?5[R[:3>@!#VS1QD$-G&2,YYR:T[.SO-&M/#&IW.^*]*0Z?J2.V3,6 12Q
M!(8J^,$]F;D4 =-HNCQZ-9O$LC33S2-/<W# !II6^\Q X'8 =@ *K1Z#.WB&
M74KS5)KJV#B2ULF10EN^S:6SU8\G'3&3U/-8_P 2+2"72M-F>)3*NIVR!^AV
MM( 5)[@@GCI73:IJ%KH6BW-_,NVVM(2Y5 !PHX4=O84 7J3:I() R.AQ7'V7
MCM+BXG@>R61XM/-]BPN!<YQUB)  #],#)S3H/' %MJ4MWIY1[&RCO6CMIO.8
MJX/R$8!5AMY!'OTH ZX*HQ@ 8]J& 88(!'H:Y27QFUGI$NH7ME D>+<VSPW8
M>.<RDJ!O*J!@CGK@<U=T#Q+'K=_?V0CA\RS\MC+;7'GPNK@D;7P.0001CB@#
M="*%VA0!Z8HV+@#:..G'2N$\36D?A;Q3:>,8XM]DW^C:C&%R(@YXG '<'@]R
M#[U:LI8-,L-8\;:C!L,Z&:*(IM=(57"#GH[]3_O 'I0!V.U3G*CGKQ2E5(P5
M&/I7(6?CN.>XN;>2R62:*Q-ZJZ?.+H,!UC)  $G3@9!SUJ>S\73SS:C:RZ;&
M+RSLTN_*M[M90P;/R%B%VL,=#]: .H(!%&!G..:Q- UVYUO,KZ5-:6K6T,\,
M\CY$N]<E0, C:>.>O6LZ7QL%LI]5AT_SM$M[DV\MVEP"P"G:T@3&"@/?=GOB
M@#JL(O.%'.?QIRJJ_=4#/7 KSZ^A;Q#\2;G2[VSM;O3UTE<))*1L5Y"&=?E/
MSD >G3K6W<7FI6_C'2M&M8X?L*V4LK[YCN=5,:#/RG!!;UYSVQ0!TQ57&" P
M]^:-H"X &/2O-?"?B!-%T=ECL"UBVO36;RF8#R"\I"G&.0-RYZ5N:AX_L;&Z
MOD,:-'8W*6\H-PJS.3MR8X^K*N[D\=#C.* .LV+@#:,#IQTI2BDY*@GUQ7+_
M !&@CF\ ZNSK\\4!EC8<%&'((/;_ .O6%H$EM<>*]*C\-I-';6EL?[7SNC0E
MT_=@HV"7R,[L=#U.> #T3RTX^1>.G'2F7EI!?6<UI<QB2"9#'(AZ,I&"*YBY
M\?:7;37(+Q-';7@LY/WZB7.0K.(SR54G!/\ LD]!3+KQRUHVL,^C7/V?2KE(
M)Y_-3!#!?F SG^('&.G?/% &_I&FOIFGK8R7!N8H3M@:09=8\#"L?XB.1GN,
M=ZOA$#;@J[O7%<SK7C:PT>\OK8B.66R@6::,SJCMNY"HIY=L#./H,Y-+'XPC
MGOS9P64C.^FKJ-L7D"><A_AYZ,.^>!ZT =,54XR <=,BN?U;0;F]U[1;ZUEM
M88-/FDE>-XB3)O4JW0@ X8G/K46G^,;?4;+2;B&V=O[0BDG*1N',,:#YF;'N
M57 [M2:3XGBU^]72Y].DMS=:>+Q0TJMF)CMPP!RK<CC]>* )/%>@7>OVNGP6
M=U!;+:WD=TXDC+!]AR%X(P,]?I70!$"E0HP>V*Y#X<QM<?#+3X_-96DCF7S
M>03(_/UK-NO#NGZ)XS\&V=HCJK1W23.)&#3;8A@L0>3G)_&@#T+8G'RKQTXZ
M4NU=V[:,^N*XN[\1V/@V].CR77GS2K+>@WMZ(Q&A; 0/(26.<X'H#4L7CV"[
M.E+8Z9=7!U*RENX,%1DH#F/K][(QDX'(Y/2@#K=B9^XO7/3O2E%W;MHW>N.:
MY"Z\=F&;588M$O)9=*ACGNT,D:%(VC+D\GG &,=<UJZ?XA>\U:.RFTVXM!/
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !323N%.HH **** "BBB@
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MQ+#$EI/8Q0*1)E@ZDL<C'3YB/P]ZZ2BB@ HHHH **** "BBB@ HHHH ****
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M ,##G.<YXK2N_">B7TEY)<698WH(N LTBA\A0> P )"J"1R0*LIH>GIJ-MJ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBB:#RL,-Z1[#$P/W0>N>G)R169I_AS4M*G\#QM:O(FFBX-V\9!6$RH0%'.2
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M1N3]ZH6,$_>X^X>N.U/?3=8L[_Q@YTRYNX]9A4VLD;QY4^44V.&88P2/48H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC3);\V$>H6KW@R# LREQCK\N<\5Q>G6VI:OXI\7VERVGS0"6&,QSP,PP(PR
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M8S")H@&#QDY*LK @C//UJA<>"X7T+^RK?4+F%7N_MEQ,0KO/)O#Y;(Q]X \
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *0]<4M(<=* %HI!TI: "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***,T %%&:,T %%)D9QD9]*6@ HI-RG.".
M/>ER/6@ HI,CU% (/0@T +1110 4449H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH/2@ HJ-)-SL"C CN1
MP:D'2@ HHHH **** "BBB@ IC%-X#'!["GTA4$Y(&: %HHHH **** "BBB@
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M<@CU%<G\0O\ D%Z1_P!AFS_]&"@#=OM8BL)((C!<33S(\BQ0J"VU "Q.2!W
M^I%6[2ZBO;.&ZAW^5,@=-Z%3@C(R#R*X^[L&NOBM$'O+M$&D-*HBF"8_?(-N
M ,[>_.<GZ5J^+9YX[?3H+>[GMVN;U(V6W ,LR;6)1"?NDX&6R, 'D4 ;TLT4
M$1DFD6-%ZLQP!3Z\A:[N_$/A>:UU.\O4-KXG33H_+D =D\V/'F$9W,H)P?4
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MWUS_ +#=Y_Z,JK)>:UJ]YX@%AJT=C)IERD,,+HIB90B.S2DJ6P<L/E(P!^-
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MV,5W_P"R5@Z%<&ZN;2[EUV/^U(]5,4UK#:G[229&#1R$R<Q[3G(7"A<@<8H
M]7HKRC3_ #;#1_#VIK/*]Q/XB>WWO.[#R7EE0K@G Z9^N#3KN^?_ (2#3[ZS
MG013>)/LS3-*?/=<.KQE?X8@5P!WX.!W /5:S6UF![G4K2U#7-Y81+))"A&2
M6#%5ST!.WOZBN&O8H5MM:O$O9DN;7Q!$(\3D>7N>$%0,\;@S5I>&[>QD\=>+
MFFC@:Y-S$BEL;RI@7('?'6@#I/#VM?V]H\=\;62TDWO%)!(P8HZ,589'!Y!Y
MK5KE/%=GBRTG3]-CLQ(MSNAL9\I#<*L;YC^48'7<,C&5%6?!$]O<>$[9[:&X
M@C\R8&&X<.T;>:VY PZJK94'T H Z*D->2V-U>:;%%+$OVV]NK6[ETO4K<\W
M9VERMPC<AEP,=1GBM*"0P:-X*U;3KUS?7LUO%=#?N^UJZ_O=_/)7!(/;&* .
ML\.^(O[>GU:+[-Y!TZ]:S/S[MY4#)Z#C)K=KQV.\:RT[Q5(TS06C>*BEW*JD
M[82PW9P0<$X!P>A-=UX72RAU+5(].O%NK9_*EQ;@>1"Q!&U/F/) #$=!D>M
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MXN$'*,<#!4D%MW&.N:C_ .$UL8IKV*_LK_3WM+,7KBYC7YHS_=*L<D'C''-
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M5E874EM*)Y'@1))S#$76$,2%+8Z9P?RR:NW]_;Z=;?:+EB$WK& JDEF9@JJ
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M_:I8#.%V' 0$#)/0<D<5=H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ I"H)!(Y%+2$C.,T +1110 4444 %%%% !1110 4444 %%%% !1110
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M9E@ C)!*J6.6Q@< U=% 'G_BG3(]7U?0;>WU")]2<R6%^T1&YK<QDS9 ^[R
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MEP9%$<Y5D94('(^Z1DC&0.M='96MYJ/BJ+6KFPEL8X+)K=(YI$9W9W#'A"0
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MJVYU"YF2U\I?LM[&%N+9SNWAR% 8'C!!/3\].Y\*:3=W5[<2QSE[SRS/MN9
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M:UDZ5H*:7J.H7PO+F>6_<23"79C< %7&%&,* /P]:UJ "BBB@ HHHH ****
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M]Y?,(%*R/(JL-QEFWDE 6#'G&,KD9S0!T=%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%(<XXZTT%]YSC;VH ?1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1124 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4TC)!IU,8D,!0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "LJUT*.TU^\U@7MY+-=QK$\4CJ8U522H4!01C+=
M_P"(YS6K10!ES:'%/XBM=::ZNA-;1/"D(9?+VMC=D;<]0IZ_PBM2BB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHQSFBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF%B/0>O>C?0 ^BF@GCCK3J "FEU#A,_,>@JOJ6H0:5IMSJ%TQ6"VB:60@9.
M,G%9,'B*234].MKG1;RU:^W>3+(T;* J%R#M8X.!T^OI0!T'6BBB@ HK(U#7
M?(TJYO--LIM4D@F\EH+8C<6! ;&?3//TK64Y )&/:@!:*** "BL'5_%=KHSW
M/G65_-!:JK7-Q!"&CA!]22"<#D[0<#K6Q=74-E9S7=PX2"&-I)'/\*@9)_(4
M 345S>F>,8+_ %.VLI],U"P-W&9+22[C55G &2!AB0V.<'!Q724 %%%<^OB6
M2;4?)M=+N+FT%Z;*2YB.=CJ/F8KC[@.5)SU!H Z"BJUU?VUD]NEQ*(VN91#"
M"#\[D$X_('\JHZ/KR:O>ZI:BVE@?3[@0/YA4[LJ&R,$^M &O1110 45@:-XF
M_MC6]3TO^S;JVETXJLSRE-I+<KMP<G(R<XK?H **** "BBB@ HK/L=1GN]2U
M&UDT^XMX[1T6.>0?+<97)*^PZ5H4 %%93:["OBA-!-O,)GM6NEE^785#!2.N
M<Y/I6K0 4444 %%946NPR^)Y]!\B99X;5;HR,!L96;;QSGJ/2M6@ HHHH **
M*IV][)-J5Y:-9S11VXC*3N/DFW D[?IC!^M %RBBFR2)%$\DC!40%F8] !U-
M #J*BMKF&\M8;JWD62"9%DC=>C*1D$?A22W4$,\$$DJK+.2L2GJY )./P!-
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M">$6F5GC\F0M(Q9H_P"YN)SMY/&<<GUJY8V-MIME#9V<0BMX5VQQ@DA1Z<T
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M_P!'C.""><;N"<\?2NPK-T_0M/TNYEN;2.1)9A^]9IG?S#Q\S9)R> ,]:TJ
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MD+P*R\A=XWRD#DL.,8R*ZW04G&O^(I)[&>!)[N.2*251B15A2,D$$]T/X$4
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MRU8:? L2^09(;KE@89T&4&,YR2,!_;%6=1M[NP\2:R+KP]?ZM::O%&5:T?"
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M4%C:R-,\&Y798Y3@+N^4$]^<#UZU8M+C4]5\5:+>B\BBBFT8W/D&#<$+-%O
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M4A'*[MI[''>O-O"7B+4[;PEX?M;B9)-5U:\N(P\R$^65ED:5FPPW8[ 8Y(H
M],JM>:A:Z>(S=3",ROY<:X)9VQG"@<DX!X%96D:K?-K^HZ+J/D/+;1QW$,T*
ME1)&Y8?,ISA@5/0\@BL#Q.U^_P 3?"EM%=1(CK=21[H-VPB+!SR,YS[8H [/
M3M3L]7L(K[3[A+BUE!*2(>#@X/Z@BK5<*-;U#3M.\3_8K?38(-&N0((T@*JZ
ME0[AE##!._J#USQ5J7Q!KMUXRU/1--CL0EDMM+NG#9:-\^9T/7!&/I[\ '2W
MVJ6&F& 7MW% UQ(L4*NV#(Y( "CJ3DCI5S%>3&74Y?!%M=336]U._B)"B[#$
M6D%V1\S9;@X &%X'K707GC'4M'@\1)>16]U<:=/;QVYB1D5_. VAADGY2W;K
MCM0!W.*,5Q%[K_B>PTW6;EK* Q6UB;JVN)H_*W,GWT,?F%L8Y!X]^U=/I$U[
M<VC7%XT!68B2 1*05C**<-GJP.[D=1CITH T**X!O%^N10:[J;06+Z=H]]<P
M2Q@,LDB)&I3:<D [CR?0\#CFQ;>(_$?E3R3Z<OD?V<UTMP\+1I',!DQXW$L,
M=#Q0!V^*,5Q6D^)=;;^QKG5(K/[+J.G-<[+<-OC9$5\Y)P0P/3 QTR>I71_$
M7B#59+*7["$M+^!W#FW*BT;&8R6+?O0>^ M ':48KSQ_'>IVUAI4UU%9QW)U
M![34X!&Y,2+(%,B$-T 9.N>7%=;HVHSZE<ZI(P46D-VUO;G806V !R3W^?>!
M]* +]W=VUA:R75W/'!;QC+RRL%51[DU)#+'/#'-$X>.10R,.A!Y!K@-2CU*0
M>/7GOHI+6.V:,0F Y"_9MRA3OPN"_/!R>>*N6VMZCX>-K;ZE' VFKHK72&-<
M.C0JF]2=Q#9##G _&@#ML51O]8TO2C&-1U*TLS)DH+B=8]V.N,D9ZBL72]9U
MZ>^TTWFG(;&_A9S+$FW[,^W<JL2Y+ C(SM7G''-=!+:PF<W9C'GK$T0?N%)!
M(_,#\J *EMXAT2\N(;>UUBPGGF!,4<5RC-(!G)4 Y/0]/0UI5P'A^YL]*^$V
MCZU<VOGOIMH9X0O7>0R<?7<1^-7T\1:_;QWLMWIJ&&'3I+I9O):%5E49\H@L
MQ8$?Q#'3I0!TMEIMMIYF:%299W\R:5SN>0]!D^PP .P%7*X/4O%OB#3X-$N_
ML>FR6VK7%I!$-[JRM*A+YZX (X//!Z&H;WQGXAL;7Q SVFF,^A.AG<%P)U90
MRA5S\IP>22?I0!Z%BDJ+[0JV?VE_E41^8W? QFN4;Q3J=O8Z)JMQ!;&PU6XC
MA\I582P"7_5$MG#=MPP.O'2@#H+K7=*LK^*QNM0MX;J7&R)W )R2%_,@@>O:
MM&N,T/3)[S7O$8U-[&ZC%_%O7[(RDLL$3(5)<[0I/3!YR<C/'9T %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <Q>^ ]$OVNFE6[3[
M3<"ZD$=W(J^:,?.%SC/ [5;D\*:9*=6+K.1JJ!+L><WS@+M'?CY>..O?-8][
MX[M+FW\16^E74*WVF0.\1<;Q*43>V%XX&-O7K6[HVMV=]!!;?VC;W%^MM'+.
ML;KNY')P.G/;MD>HH 6+P]8PZG::@OGFYM;;[+&[2LW[OC@YZDX&2>>*J6'@
MG0=,U#[9:V;*XD,J1M,[11N>K*A.T'W XIFD>(+:/29KG4-;M+L"]EA2:$<?
M>.V, #YB%QG&>A.2.:VK*_M=3LQ=6-S'/"^0LD9R,@X/Y$4 9$7@S1H=/M;&
M.*=8+6\%]"OGL=DH)(/7IDDXZ9JOJ/@'1]2>^+27]NE\XDN(K:Y9(W<$'?MZ
M9..?SZ\T>%=5U?4-5UVVU.:U=-/NA;Q>1"4+#:&W'+'L1Q]:W[W4K'3@AO+J
M& /G;YC@9QU_+OZ4 8U[X)T>^U9-2D6Y2;RQ',L4[(MRHZ"4#[_X]>^:CU+P
M-IFI37K_ &B^M(KV 07%O:3^7%)@ !BN/O  #T(&""*V9]9TNUBCEN-2LX8Y
M4\R-Y)U4.O'S D\CD<^XI+K6])LA&;O4[*W$J[XS+.B;U]1D\CWH GBLXHK!
M+++O$L8B_>.69EQCDGDGWK"M_!&EVVE16"2WI6"19+>5IR9("OW0AZ* #C&.
M1USFMBYU?3;*58KK4+2"1@"$EF5203@'!/<\5;9U1&=V"JHR23@ 4 4M.TFW
MTZ:ZGC:22XNW$DTTK99R!@#L  .  *Y5?#LM_P"._$%Q<?VA:V]W:Q0QRPD*
MDR!<."<'!R1CH>N*Z"[\5:):Z/=ZH-2M9[6U3=(T$ROSV7@]3V'>K5CK%E?:
M-'JJ7$0M6B\UG\P%8QC)!/08[_2@"I;^&;"TUR'5;=IHI(+3[''"K 1+%D':
M%QZ@'.<\5%)X2L'N+EA-=+;W4ZW$]HL@\EW!!R5(X!(!(! />LJ3QHNHZ7I.
MIZ3<6PMKC44MKE9"&=8R[ 'K\I(7/(Z&NH@U73KJSDO+>_M9K6/.^>.961<=
M<L#@8H K:CX?L-5U73-1ND9I].=G@P<#+#'/KC (]Q3+KPY9W?B&#6Y7F-S#
M UNJ9'EE&SD$$<YS6A9W]GJ$1ELKN"YC5MI>&0. ?3(/7D4ESJ5C9RI%<WMO
M!(_W4EE52WT!/- '-1^ +*%[)8M4U1;6RNQ=V]J9E,<1'15RN=OL2<#.,9JW
M<^"M*NM4N+UI+U%NF#W-K'<LL$Y QET'!R,9'0]^]:UUJ^FV/F?:]0M+?R]I
M?S9E3;NR%SD\9P<>N#4EW?6ME;^?<W<%O&>%DF<*N3TY)% $6L:3:ZYI-SIE
MZK-;7";'"M@^O!^H%4H/#%K;ZC8WPN;MY[.!H(S(X.48Y.>/8?0 8J#P9K5S
MKNCW%U=2VTS)>S0));#$;HC8!7DY!'.<]ZV)]3L+6X2WN+VVBF?[L<DJJS?0
M$Y- &+!X+L;6.!;>[OHG@GEGBD21=RM*#O\ X<$')ZCCM4$?@+3H=-:QCOM1
M"?;?MT4AE5I(I<DDJQ7/.3UR?>I-<\1M;Z_::'9WEE:W,L,D\DUU\RJ!@*N-
MPY+,#UZ ^HI^H^)7\,^&K2]\0?9Q?2/'$\=N^$9V.#M+<X R3]* -'4M&BU+
MPW<Z*\C^7-;&W$CG>P^7 8D]2.#D]ZQK?1)]9MM-_M1[NRU719-JW5K@+*2@
M!9=RD%64\\9!R*6U\4E_&-]8W%Y8+I:6<5Q;3*X&[>2.6)P?NG&.U=)/>VEL
MB//<PQ(_W6DD"AN_&>M '+2^'I-'T:]T;1GO)'U661C-.VY;8. )'+<$GDD
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MT44BQPX$B+$$8H[#&<[E)'3 ]J[A[J"* 3RRI%&0#ND8*.>G6GM-$NW=(@W
MD98<B@##MO"MK8:O!?:?/-:)':I:&",*5=$)V E@2,9/0C-5;7P-865B(+>[
MNQ(E^=0BG<H7CE/7'R@;2,@CT/6NDDN(8H&GDFC2%1N:1F 4#U)Z4HGA;;B5
M#O\ NX8<_2@#G;WP;;:G:W:7M[<M<7<L,DMQ$J(Q$1RB@%2  >?4Y/-+J'AF
M)+G5]5MKG4%O[^T6V8P,FY0O *9 PWN3CZ5T7G1X8^8N%^\<CCZT&:(.$,B;
MST7<,T 4M$COX="L8M4D$E^D"+.X_B<#D^YK!MO L45E]EDU&X86UZUWITJ!
M5>U+$L1G&&RS/G.01@8XK2TW5KN[\5ZYIDT4:6]BENT++G<_F*Y)/XKC\#5+
MQ+XAUG18-1O+;2;:6PL(1(\D]PT;2G&2$ 0@XXZD<T :^FZ0ME=W-[-.]U>W
M.U7F=57"+G:B@#A1DGOR3S574_#4>HZ_I^M"]N(;NP5UA50ACPXPV05R<CWX
MIFEZIK<]_!%J.E6\=M<6YF2XM;AI50C;\K[D7!(;C&>AK<$T11G$BE%ZL&&!
M0!S.H^#/MLNLK'JEQ;VNK(#- B*<2@*-X8\]% V]/Y5<LO#:V7BN_P!>%Y*\
ME["D3Q,J[0$  ((Y]?SK8-U;@D&>($,$/SCACT'U.1Q[TQ+^SDB65+N!HV;8
MKK(""V<8!]<]J .8;P.W]F_8(]9N$MTU#[?"ODH?+;S#(%SCD;CGGTJ>Z\$V
MNH7>M/?W<T]OJPC\V *JB,QXV,K#G(Q72O+'&0'=5)Z;CC-/S0!S#^"XI[&Z
MMKK6=5N6N+4V9GF>,R)"?O*/DQ\V!EB"?>N@M+86=E!:J[NL,:QAWQN8 8R<
M #/T%/$\3*661"HZD,,"N;T/7-7UJ>VO88+)]'N6E'R.?.A520C-R0V[;T &
M,CDX- %JU\*V,%KK-I+)-<VNK3/-<1RXX9QAMI4# P!CN,=:IV?@QK;3WLYM
M;O[M%@:WM?/"$6Z,-IP !N;;QELX&<8R:GU'6]0.NR:7I*6+RP6\=Q(+F0CS
M=SLNQ2/NGY&))!QD<5I:5>74M@CZH+2&Z9W!2";>N Q &2!SC@^^: ,RS\*?
M9?['1K]Y8--MVMUB:% )%8;26Q[ #CT]ZAT/P4FB26T8U:^N;&S9GM+2;;MB
M)SW RV QQD\5U'FQ@L-ZY7EN>GUH1UD7<C!AZ@YH YJ7P583WGB&YD<L=:B6
M)@5'[G";25]R0I/NH]*W-+L(]+TNUL(?N6\2Q@XQNP.2?<]?QJF=:$OB,:/9
MPB9X4$M[(7P(%8'8/=F(Z>@)STS!8:_=:IJEQ'9Z?&^GV]P]L]TUSAMR<-B/
M;T#9'7G&: ([SPQ+=7&ML-4DCMM6B"20")3M/EB,L&//W1T]>?:I9/#IN+RR
MFN;PS);V<EHT1B $BOM#DXZ$[%]O:I].UG[5J=WI=U$L%_; 2&-7W+)$WW74
MD D<8/'!&/0G4\Q-^S>N_&=N>: .;TGP<NFRVHGU?4+^VLCNL[>Y*%83@J#D
M*&8@$@9.!GITQT%U'+-:R1PS>3(RX63:&V^^#Q4GF1[6;>N%."<]#[TC2QJ@
M=G4*>C$\4 8>G>%K:T\)#PW=R->6(B,/SKM8H>QQW'K5./P6PLGM[G6KV\(M
M)+.![@*?*C< ,> -S8 &XY_G74-+&H!9U ;H2>O&?Y"D-Q )!&9H_,8!@NX9
M(/0XH YV^\()?:;H5E)?RA-'GAN(W"+ND:(87/;&.N*BNO!27D7B&.74)"NM
ME#-B,9CV@* OX #G-=42 ,G@"DWKLW[AMQG=GC% $4-N4L8[:9_.VQA&8KC?
MQ@DCWK!M?"$4%K86,EY+/I]A<>?;0.@RI!_=J6ZD)V[],DUT@8, 0<@\@BL/
MQ5KDVA^'9M3LXH+AHY(U(DDVJ SA<Y'ID4 6=,TJ33[[4;EKOSA?3^>ZF,#:
M0BH "#T"H.O/O6I110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS\PRH!'3KBMSPMIVHZ3X>L]/U*6VDEMHDA0VZL%"(H49)Y).,GIUQVH J_\
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M4NI0VR^;*"45Y=Q3)[$94>@^E%KX/NM-OO"PM)89+318IHW:5RKR&10"0 I
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M?Q)HVGK926NK71NHI99F5HB[!I P"G/(XQZ\T =)KNJ3>&O!<]^ )[BVMU5
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MV:F [MCPM'&V<;0 ,G!X]ZYN9[X^#?">JZ3+/<:\MI"8[;S&*78$>9!( 0.
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M(O-7O(=<T_4;2\NYH)_$HLFF>X9%:-LJ8A#RNU<8W'!)&<<YK7N/^0[\2/\
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MUL9%$-NFYVW,%X'MG)]@:YK4)-3TW0(Q?7K#4;C4O+1K6,;[A/,9EB3+?+E
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ME1&7*>4L?E<.#MP=Q)/7@X%*'5]?;1+G5%URX$UOKYLDC>-&C:-I5C^88!.
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M2#_2$/5E(]NE4M+\5:UK-AX8M8U9Y;VQEN)Y895B:1HV"8!8$#^\0.<^@R"
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M,Q2["IS!$X.0H(QO( ! QV)YKK: "BBB@ HHHH **** "BBB@ HHHH ****
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M>5H(9C"XBD=>JJY&T]#CGG!QFH_^$RT++8O&*I=?8Y'$#[8Y<@;7.,+R0,G
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M//-:3HDD;(ZAD8$,K#((]#7-Z7XQMM1\2:KIGES11V6Q5ED@D4,VUF?)(PH
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MYX,\/ZA':+=:<LIM(Q%"YD?>J#HN[.2/8DUK16D-O9+9VZ""!(_+18OEV+C
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M?J&HZEX@U6VM+HV[Z VFQ0F(AYIG+,"JGG W $GN3Z5WTDBQ1M([!40%F)[
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M;B.XMW)"2QG*M@D'![\@U8H Y"<W6@^-;[4YK.[O+/4K>&*-K6%I6@>/=\K
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M\G''K26_@;3;;2K2P2YOC]BF$UI.TH:2 CH%R,;<<$$'/?- '/ZUXNUS3O\
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M7,IEQN.. I& !@8  &"*@MO XB718[C43=1:6\Y5)8!^]212NUN>P)Y[G\J
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M:3!'&D&^$H8G  9-Q.9!QNW8[XR:WATH **** "BBB@ HHHH **** "BBB@
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MTH ]46>)Y6B65&D7[R!@2/J*SM4\1:9I.D7FI3W<+06BGS DBDEL9"#G[QZ
M>]<+K@EU+4O%S:5%)/+<:7:&/R0RF50[[U# =2O&.II=;GT36?#'B"_T2RN"
M\VE>7,PA*1H4/R1E2,%QD],X"XSTH [>?4)Y+_219W-C]EN&?SEED_>. F0(
MP.I!QGVJ\-0LC>_8A>6_VO&?(\U=^.OW<YKC-1N+.\\3>![RT*/$'GS*JX 7
MRF49..A;@=CVK$D$LOP\ATMI-OC"*\WQIPLPN3.29!_LE2Q+=-I- 'J+7=LC
ME&N(E8.(\%P#N/(7ZGTJIKNM6?A[1[G4[Z3;! A;&1ESV5<]2>@KRSQ3#ILO
MA_Q\]M%;M/;:C#+"RH"T;D1!V7N"6#@D=<&NI^)B/??">_>(><QB@E#+SD!T
M);\LF@#JFNYY-1L_L\EFUC+'(9"7_>%AC;LQP1][/X59COK.4@1W4#DJS +(
M#D*<$_0'@UPU]>:-/XO\/3P26GV2;3KV/=@*KK\G'/4</CMUKE/"FDZ+/X6\
M#?:K*S:ZN+^>.X+(HDE3]_A7[E<[.#QR/6@#V@3PM"9EEC,0Y+AAM_.B*:*=
M-\4B2+TRC BO+T%I'X5\0VVGD_8K77?,F@LU5RMOO0MM3!!7AN,8(!&.U;.B
MZYX=TF'5M8BU*\FT[]SY]T]N!$).5 54C7YL;=QP>"OI0!W>0!S445S!,K-%
M-'(J]2K XK!\:M=S>#KJ33 TQ(C=UA;YI(=P,@4@]TS]1TKF;C4_"=SI&NZA
MHME-<0R:8T=X;-&A 5>%3!  ;#MR!P%Y[4 >BQ3PSJ3#+'(!P2C X_*L#QKX
M@N_#OA"ZUG3H[>=X=AQ*QVE68+D8Z]1W%<':/9Q7'BY)KV".WN])A*3:? 43
M: Z,T:YRX7(!.<G'X51UJ0KX)\5VT\-G)=K;V4?VZPX@NE$F5PO0. 3D#V]*
M /9[:YCN8@RNA?:"ZJV=I(Z&GO+'$5$DB(6.%W,!D^@KA-(AL;'XGB.RCM[=
M+G0DD=855!+)YI.X@?>;'.>N*SO'LEG/KVIVV1%?+H<F&NEWHZDDA(4R/WA(
MY;L%&!W !V.I:W=V7B[1-)2"$VVH+.7E+$N#&F[ '0=1SD]^!1X9UVXUFWU6
M2\B@@-EJ$]H!&Q(VQX&23U[\X'TKD;/4+6?7/AN%N8W<:?-O.[/)A11D^I96
M'U!JM:7$0TC57D;?I_\ PEDIO=IRI@+]6_V,[<]B/:@#U%)XI$5TE1E8X#*P
M()H\^'SO)\U/-QG9N&[\J\\?0M/U[Q7KMA9Q))HM[ID?G208,*W88[2,<;PF
MT\?CUK"AN]7C.E>+5TXFYL571IXMHWW$A#1E\^@EV <9^]0![!]H@\M7\Z/8
MYVJVX8)]!2O+'']^15X)^8XX'4UY3K^DZ1I36WAP+;13PZ+,1<78W1MO;YO+
M08+2EE)SD;0>AZ5+8C3=8UOP.]TUO>!]#D6Y,C!PY")P_KSOX/<'N* /4//B
M\GSO-3RL9W[AMQ]:5IHEA\TR((\9WEAC'KFO*H;BVM-.\,238E\.V>H7L5T%
M_>1Q-YC"W+CGY1GC/ RI]*EU,Z)9QZ5=0+.GAA-5GDN)6C\R+>T?RN%8'Y!(
M< XP#R.QH ]/\^(0^<94\K&=^X;<?6GJP90RD%2,@@\&O+KN'3);"UCTO5VA
MC&KFYL9M1C!M9Y=A9D  7"9)P1_%G%='X4\1:5'I>EZ>XCL;F[DN%M[8,71R
MDC;O+;&-F3\O3C@=* -C7M9728;=4,1N;J=8(A*^U03G+-[  GWZ=ZDTN^NY
M(GCU5+6WNEDVJ(9]PD0_<< \C=@\'/0\UA>.$T:2Z\/QZHEBYDU!1MNE0[D"
M/D?-VR5_$BLC3;&QO?B/XIBCCMVFM8K.2S7.!%(D3*" .PS@CWH ]$$L;2-$
MLB&1>64-R/J*>*\H\)?8KN'3)X-0ED\20P3126ZQ+$R2&/Y_M'&YEWA<$G[Q
M'O47@?[ ]SH-W9Z@TNK%6BOK>WM463E09&N&^\0& PQY)(QWH ]9>1(^7=5&
M"?F..!UIP((!!!!KBO%-IIM[XZ\.VUZT6V>"[CEB9\><I0 *1GD99B/<5Q<]
MK8C5-<L]2OY=/U*SN5.FHL"M<- F!"+=V.>=N"!ZG/>@#V@,"2 1D=1GI5%-
M8LY-=DT9'+7D=N+AU'15)P,^_MZ5Y1XDL]/_ +,^($^U#<V]Q;RQ,SY:*1DC
M+,O/#;BPR/I[5OZ8;"W^)4M[=R0;KK0H+G?(!EG4G+#U.%SQS0!Z14:31222
M(DB,\9PZJP)4XS@^G!!K)O=0;5?!][?:!<":2:TE-I+'W?:0N,]]PKE-/;3'
M@\)2:1Y0U1RJ7"J/G,6PF<3#/KSEL_-C')H ]#+J'5"P#-G SR<4-(B%0[JI
M8X7)QD^@KB? .EZ7)9R:A"J23VU]>PPR*^1'&TQ.T8XP1M/X^]5]0;1Y];\3
MVOB46_FM"IM!.W!MA&"/+S_$)-Y..<X]!0!V$VKV\>L1Z3&RO?26\EPL>[&%
M4J/FZD9+<<=CZ54\+ZW)KFB17MS'%!-)-.@B1LC"2LG!/)X49.!]!7"^'[>)
M-?\ #%SXI2W&K2:4X'VJ(&6242KY9R1G>$'U&34.DVNG#0_#6K++ EXFO2)Y
MQ8%FC::4% 2>%(8' XYSWS0!ZW3/-C#A#(N\G 7/).,_RKQ^"&&ZU'4X-3U*
M:'6XM8:XALUMU^T2A6S'Y;]=A7CC@#.>*Z7P98:;>ZOKTKI$UQ9:]/-;[6P4
MW1HN< ]#R/3CVH ZB[U.Y@\2Z=IRPQFVNH9I&D+'<&3;P!TQ\W6M:N6UJ\C3
MQUH=KO59FM+MD&X D_N\ #UX/Y&N&\*?V>7T:Y.K7#:W LJ7EG# L=P-P+2^
M<QY(!&<GG.,<F@#U])8Y&=4D1F0X8!@2OU]*5)$DW;'5MIVM@YP?0UX]X5OM
M/B\3>%Y;*>W2"6TND,:R!YSDAE69^-SDDD+C@YQGK3[9);2TO+723:W5^FAR
MM9:AIY\N1XMZ';*G:3N#G/WN,T >P4FX;@N1N(R!7G7@@:$VL6]UHNH)</+:
M&.>&UM$B6,<$&;'\600">3D]JMZ[IGA^7QT1J_EI#<Z6[2K+,R)(5D3&1D X
MX(^@/:@#NB0H)8@ <DGM2>8@*C>N6^Z,]?I7D^DV,.I-X.MM0E9XKBUU" I)
M*<SV^<1#KG[A!!Z\5*]AHDEOXILM;BA34+-C'8&X;]Y';J@\CR6//4'[O4]<
MT >JTT,"2 02#@\]*\GC:RFOC:?$%A%<7&D6ZVLDYP%.#YNT]!+OP>F>!VXJ
MU<S6D7BC41=@V_VWPTJ1I>D"2=@SC#9^\^ ,CK0!Z<SJ@RS!1ZDXI<YY%>-Z
M+:6>J0?#NSO'\R&YL;V*6/S2 X"X X/NWO\ E1>:=I[ZOKFFZAK"Z9<V)B33
M$,.^6.WC13%Y#,=V[(.0IR3]: /8]P+%<C(Y(I<@DC/2O(?$=I:30^/;J19!
M+"EK<0B21@8Y#'G.,X# D_3) K3C\S3?B T>F%VFO/#C3DM*SF68/\K').3T
M'TH ]+R#G!Z=:0,&&5((Z<5Y%X,2TN3I=^VO_:;Z6.5+VTA@V3'<A\PW#%]V
M%;!#G'0 =>*GAORXO"GP^U1I&6]?5&M&F+G+1L\PV=>A.* /7-/U>SU.>^AM
M)?,-E-Y$Q'0/M#$ ]\9 /OFKU<1X*M-$M=;\0Q6MO80ZA'J$@"1HBRK#MCQ@
M#D)G\,UF:C-H4^L^(5\53K:7\$J&PE5MLRVX560P'J6+[\[<Y)QS0!Z529&0
M,]:\^\NTUC6_%">(E8&VCBDM(YR ;:$QYWQD'Y6W;LE?[HYK%U.[NKG1;34-
M2%O?7-IHR-J%A,_E3QK)G,\+XP'('('/ 'H" >I)J-K)JDNG)*INHHEE=!_"
MK$@9_(U9#*PRI!'J*\T=-&C\4^()YREB9=#AE6?RAY\>5EWR  ;BX&"<<\"K
M?A&YMM$O]0L[NSL[=[;3XYY;ZQ?,$T*EL.5 ^5SEB>N>O- 'H-<]/XAO%\4R
MZ%;Z8DLJ6HNQ*USL4H6*_P!TG.0>/UK=@FCN;>.>%@\4BAT8=P1D&N!OY[=/
MC,!-J36:_P!AJ<B15#D3M\I+?R^M '8Z5?W%\+M;JR-K+;S^3C?O5QL5MRG
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #%%%% !1BBB@
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M&%4+?7 YJW10!5NM,L+V:*6[LK:>2(YC>6)7*=^"1QTILFDZ=,UPTNGVKFY
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !112$\XH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *8?]:#[4^FD?,* '"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH  ,"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "D(R,4M% "!0.E+110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4QF(< #@T^FD$L#0 ZBBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HINP;]W>G4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>stamfordsecondleasemodif004.jpg
<TEXT>
begin 644 stamfordsecondleasemodif004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TJA=?\?<7T-7STJA=#_3
M(OH: +]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 =JHW S>
M1?0U>/2J4_\ Q^1?[IH NT444 %%%% !1110 44R:010O(1D(I8@>U<I:>-9
MFTVQU._T2>TTZ\\LK=">-UC$F A<9! Y&>.,T ==150:II[7YL1?VIO!UMQ,
MOF=,_=SGI3/[9TOSYX/[2L_.@5GFC\]=T:CJ6&<@#OF@"]169JVOZ=HUC=75
MU.I^S0&X>*,AI#'G&0N>A/&>F:SV\6- EQ]MT:^M)$MGN8EE:,K*J]0'#%5;
MGH2..: .CHJB^LZ="8UN+ZVMY70.(IIE5L' '&?4@?4TB:WI,M\;&/5+)[L,
M4,"W"F3<.HVYSD8/'M0!?HK+U35Y+"]LK*"R>ZN+L2% )%0*$ )R3]144>O+
M:PJVO);:0[R%(EFNT99,#.0W'Y&@#9HJM!?V=V(S;7<$WF(73RY VY0<$C'4
M9XS4(UK2M\"?VG9[[@9A7SUS)SCY>>>?2@"_16)8^*-/NH-0GGE2RALKZ2R>
M2YD5%9TQR"3T.>*N7.N:19I$]UJEE LR[XFEN$4.OJN3R/I0!?HJI<:II]HT
M*W-];0M/Q"))57S.GW<GGJ.GK57Q#K:>']*^W20M,/.BBV*V.7<+G/MG- &K
M17,'Q;<M-J'V7P]?W=O8W#02RPO%EBN"=J%@3UK:L=6L-2CA>TNXI?.A$Z*&
M&XQG@-MZXSQ]: +M%<UJ/C&#3]4NK3^SKV>&R\L7EU&%\N'?@CJV3@$$X' .
M:>_BR./639-IE\+872V?VTJHC\XC(&"=Q'(&[&,F@#HJ*Q;/Q3IU_P")+G1+
M1S+/;0F6:1?N*0VTIGNP/7TK.L/'=I? N=/OK>&2VENK26=54721_>V\YSC!
M&>HYH ZNBL/3-<U#4#;R2:#<VUI,F_[1)<0D*I7() 8GT[=ZI+XUCD\JYATC
M4)=*EN! NH($*')VAPN[=LS_ !8H ZFBN;OO%ZZ?J$=I/H6KXEN1;13+'$4D
M8G@K^\R1@$].@)J6V\66MSK,>G"QU",2S200W4D($,KH&+!3G/16P2 #CB@#
M<D!9<*2#GM3QP *S-:URVT2WBDFCFFFGD$-O;P+NDE<@G:!] >3@"LN7QC]F
MM=0:ZT>^@N[+RMULVP^:)&"KL<$J>3SSQ0!T]%<W?^*;G2-%O-3U/0KJVBM_
M+"KYT3F0NX0 ;6..6'6I++Q9;S:A/I^H65UIEW!;FZ9;K9L:)3AF5U8@@<9S
MCK0!T%%9'A_Q%9^)+:ZN;$/Y,%R]MN<8WE0"2!Z<]Z77/$6G^'UL_MKGS+RX
M2WAC3!9V8@9P3T&<DT :U%8%UXNLK36!I\EI?[/M"6K78A_<+*X&U"V<Y.Y>
M<8Y'-$/BZRN-8%A#:7TD9G:V^VK"#!YJC)3<#G/&,XQGC- &_17.:7XSL-5U
M:/3TM;^!ITD>VFN(0D=PJ'#%#G..0>0.*MZ[XB@T$0B2TO+N28.RQVJ*S!4
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MK.:%1$P+$H[29PGS#!7T/'2NT\4:-?7G@JUT^UA::YBDM"R^8&.$="QW'&<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ /2J-P#]LBQC[IZU>JG<?\ 'W%_NF@"Y1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !2$9I:* "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ JE/_Q^1_0U=JA=?\?D7T- %^BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH #TJA=?\ 'Y%]#5^J-P,WD?L#
M0!>HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  \54G'^E1GZ
M_P JMU3G)^UI]#_*@"Y1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %4;K/VR+'H:O52G_P"/R/Z'^5 %VBBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'$51)41X9$4KA]QQM/JI)'H:Q=&\'ZEI/B#PY.RI)!86,T5PZL.))&+8 ZD
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MC@[20#T8#)_BSSC!Y_6_$'B31+.%9S"K2:O!;1RNB^8]NYSDJK$*<JRY[CG
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M110 E%+10 E+110 4444 %%%% !1110 4444 %%%% !24M% !1110 4E+10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %.;2M/N+Z*^GL+66[B
MP(YWA5I$QZ,1D=33KC3+"[N8+FYL;::X@.899(E9XSU^4D9'X5:HH *BCMH(
M99)8X8TDE(,CJH!?'3)[U+10 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 AZ54G;_ $N,8/0]O:K9Z55G#_:H\'@
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MKBYE+6']GRHQ4+)#SP<*"#DDY!%6=!T6'P_I4>GP7%Q/#'@(9V!*J  %&
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MV&F6:>++,PZ5?M>08M';*D\!VS_*NBL=9T>R\?ZAXB37XA:WT:)) ]J^_*C
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MRYQOVR9RH8  \'OC%32>%KR[U6SNK[4()TLK^2[@86Y$RHQ8K%OW'Y1NQTY
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M/?VHD([[8V=5..>65?RI-5$MU\0;G3VN[Q+5]!:;RX;EXP'$P 8;2,' QD4
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MVZLT<>"%$FYG;!?/3OM)[4 =!?W4UK>6$,.F/=1W,Q265" (%"D[FSVR,?Y
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M[+937H%S%)%$\:QLQ#R9V+P#R<&L[1?'>EZKI1OV,L0:Y>"*/R)"\GS,%VJ
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M-%U"SN/#ES8S1"QALKF*_P!XW&/(64%>^#T_G7:>?";@VXE3S@H<Q[AN"DD
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MY:6]TL37%L+@P/YL:''W\$ X)P>">OU[5QWAZS.H>%_$6F6$DFEZC)?7 G!
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M(M+NVNX"VPEG9F.&^7D?._3'4>E &=\/9KZXO?%+7EV;@QZQ-#DI@G:%4=^
M ,8K3\3:OJ6GZA9VUE+!"DT,K@M T\DDBXVHL:L&Q@DEL8&.HS5O1O#4.B:E
MJ=W;7=PR7]P]R]NY78LC8W$<9[>O%.O_  Y'?:[#JZWMU;3QVSVK"$KAXV(;
M'()!R.HP: ,JR\37NMG1[.S\FUN[W2QJ4TCH9%C4[0%5<C.6;J3T!]:PO$FK
MW.F-X7UW7;14O[(7;RP6HW@MLV@;@3M4Y!))P.];@\ 01V6GI!J^H0WUA'Y$
M%]&4$@BP!Y9&W:5X!Y&<\YJX/!]NK6(^V3O%;"42),J/]I,I_>,YQU;GIZT
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MA8W3LZ3 YWJQ)()/4]\U8N/!>B7.H+?2P3&?REBD(N9 )E7H) &Q)[[LY[T
M:-Q?^1HDNHA%;9;&<(&R#A=V,_UKDH;S5(=-\-ZR=8FN?[1GA2Y@_=B+$RG[
MF%##:2,<G@'-=R% 4*  H& !TK+MO#>F6DENT44FRV=I((FE9HXF.>54G ZG
M'IDXH P/"MB\7C#Q0YOKIQ'=Q*4=EVOF!.6^7.1]12^)CCX@^$1<DBRW7&W<
M?D\_8-G_  +[V/QKH--T"QTJ]N[NU-QYUVV^<R3NX=L8S@DCH ..U3ZKI-CK
M5D;34+=9H20PR2"K#HRD<J1ZCF@"#6FLX((KZXC$D]H7FM4W89I!&_RKZDKN
MX_'M7-0:IJ)T7PSKPU&6;[=/$MS;JJF-A/QM'&1Y9( YYVG.:Z6T\/V5G=)<
MAKF>9 1&UU<R3>7D8.W>3C(.,BH+/PII-C<I-!#*JQRM-' 9W,,;G.66,G:#
MR>@XS0!Q4VMZY!IFJZC_ &Q.SZ?K_P!ACC,<>R2+S$!#X7GAR.,5=\07^L6=
MKXRN8M5N83IQBEM FP@ Q E2"IXW$^]=%_PA>CMI]Q92+<O#<78O9=UPV7F&
M/F)!]0#CID=*L3^%]*N5U19XII!JBJMT&G<A@HP,<_+QZ8H Y276/$FM:[JM
MCIC1Q&'3K=X0T_E!))%+>;]QMX!P,=./>K%G>:IXCNM1LUU@6]S:Z=;/;O:\
M(9I$8F4\?,N0,#ICMGFMV[\%Z#?M9O<V1DDM$$<<AE8.4'168'+CV;-2:AX2
MT/4[J"YNM/C,L"A%*$IE!T1@N R_[)R* ,;0+?[5XRU"_P#[0EG\S3+)MZ,=
MC%O-Y4'HORY ]ZP/!_B#4]9M?#]C?ZK.OVW[9)+,I DF,<@"QAL?*,$GC!^7
MC%=\_A[3VU(7Z)+#<" 6X\F9XUV#.WY00N1N.#CC/%4W\$>'WT>/2C8#[+$Y
MEB D;=$Y'+*V<@]_K0!BOJ.J66I^'+%]:^V,=1GM+QTA""0",NJMQ]X#;R,=
MZQ[^2XO/#6H1W%_=RB#Q,MK&#,05B$Z *2.3Z\YKN[CPOH]SIUO8-9B.WMYA
M/"L+M&4D&?F#*0<\G)SSDTP>$M%73[RQCLQ%;W<PN)5C=E)D!4A@0<@Y4=*
M--\6.GN4WR>3&2-[EF; [DY)K@AJVJQ>#]#\3Q:A+-<W-Q";FVZQ2K*X38%Z
MKMW#&.XYS7H%O;Q6MND$*[8T&%&2?U/6LVW\,:/:SB2&S"JLOGI%O;RHY.?G
M5,[5/)Y H QO#2ZC>:WK#7&K7,D-AJLD:1-C#H85PC8'12P(QW'.<UV%4=/T
MBRTQYWM(F1[A_,F8R,QD?&-QR3SP.?:KU !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4T@FG44 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% &1XGU^'PQX=N]8N(FE2W4?NU."Q+!0,
M]N2*DTR\U!Q,FJVD-LZ-^[>*8.DJX'(S@C!.#D?SKG_B?!8R>#GFO8H&\JYM
MRKRJ#L!F0-@GIE<Y]JS-0\/Z!=_$.STGR(XK:71Y6:WA;8CCSD*A0" #D,W'
MIF@#T7-)N!8KD9 R17E%\ED_A77K^YD\OQ7#>R*DQ(-PD@D'DK'SD*5*# X^
M8]:9K5ND[?$)KU5^T06=G.H#$!)1"W*\]B>/K0!ZY17G/AT10^*?#=RLI:YU
M'0FDNI'D+-,_[H@G)ZY+?K6GXV>VFU70-/N-A^T2RLJW6/LIVIUE4D;R,@JO
M<]QUH [*F/-'$5$DB(6X7<P&:\PT^*PU'PYX*CGO/M+K?R6VY9V7>FR7((#>
MR#'8$#O4Z^&+#5-%U^RT^.!KG3-6>XT]<*XB<+&^P#LC,"I'3\J /2\TCR+&
M,NRJ,XR3BN5\(W \17%QXK>W:);F)+:T5Q\RQ)DMGZR,X^B+5;4/L+^/YX/$
M!M6LY-.46*W.-G+-YP^;C=POOM_&@#I;O6+2SU.QTV23-W>E_)C&,X52Q8^W
M&/J1[UG^%M=N]:CU-KV&W@:VU&:SC2)RV1'@$DG&3G/8<=J\^M%M;#6O!MSK
M+0+;[M1CMYKI<,8 0( Q89/!^7V8>M(;?3&T+7=1E\G[7:>+&>.8L-T8-S&#
M@]@5R>/3- 'L--,L:N%9U#$@ $\UY+JT-M>:_P"(K;5M7-I?_:DDM(OLRM-+
M$J@Q"!CWW;AA>_UK9T*PL]0^)OBHSHCB"6RNH55\^5*(V#'COG(/UH ]">1(
MD+R,JJ.I8X I0P90RD%2,@CO7#_$+4H=+O\ PW/=8FM!=R&:U:1$60>4V&.\
MA3M)! )Z_A6':QV%MX=M[DW%K<64^M>;>_9)%D%O;.69(Y"N<(K>7D=/PH ]
M1,\0B$IE01G^/<,?G2B1&VD.IWC*X/7Z5Y[_ &/9:SXQUW2K3RY-$NM+47*1
M(##'=;OD8=M^SGCT&><4SPT^IZCHDI%J8;S0;&;3X-B *]T,J2H]E2/VRY':
M@#T1)HI&94D1F4X8*P)'UI&N(4!+31J%&22P&.<?SKR_PK!X;N7T6ZDU"[GU
M!+:2*\MI5B58\H?--S\@8KO'!<GYB/4U62RTU?@[I^H3;([N:.UM_.\S:Q"W
M.[ YZC+GUZ^E 'K?FIM9MZ[5SN.>!]:;]HAPQ\V/"8W'</ESZUY7XBATVUOO
M&]I&MK%:2Z*EUY:[0IG^?#C_ &B2OU)'K5B+3=$N?'-I!-;V;P7'A\3S1G&R
M:4.NUG7HQVDD9SZT >G-+&L?F,ZA,9W$\8^M"RHZ!U=65NA!R#7CFAWP_P"$
M \#W6HW,XTVWNY5NI5 =8B&=8?,!! 4';C(XX/'%:=U#HT46C_V?<RSV[>)(
MVMY9G7:P<;I!#@#]WDX/OF@#T#5]>T_1='GU2[F4VT(Y*$$L<XP.>3S5T7-N
M=F)XOG^[\X^;MQZUY+J-OI7]D>-;9X;/R;/5898HRJXA!\I78#MW!/UJUXCG
MTF\N-;%E=V4$;:9'+&S#S&E5-SJ8%& B@@DOSSS@8S0!W$FMW*^.H-!^S*+6
M33GN_/).2XD"[1VX!R?J.G?:DECA7=+(B*3C+,!7%I>VUU\7+!H)FE1M!=D?
M?E'!F&-OO\IS[ >E1>,WBA\6Z+)JUU+:Z/Y,JI.L:-''<'&"^]6493< 2/7I
MS0!W+3Q+LW2H-_W,L/FXSQZ\<UFZMXCTW1[&"[N+B-H[B5(H=C@F0NP4;>>0
M,Y/L#7G#V&ECQ7X'LH ]S8DW\0-VJ$S0E,KP  8\EMH(QCIQ3(?[-B\*3&9;
M?^S]/\5F-25#)#!YZG'^[@_E0!Z9+>W%MJ5Q-<SV<>D1VJR!R_[P/EMQ/;;M
MQCWS2Z7KEAJVFVE[!.BI=(KQH[ -\W0$9ZUR=RNFS>+O$=M"MN[S:) PA4 E
MV'FX^7U"F/\ #%9%KI=G=?#C0/$&F) =0T.%+EC&@S)L4>;&WO@?F!0!ZC'<
MP2S2PQS1O+%@2(K LF>F1VS5"QU^QU'5]0TVVE#SV)192""-S G YZC'/I53
MPI9E;"?59DVW6K2_:Y 5 *J0!&A_W4"@^^:XF[AD7_A/[/3XD76)9?-@C5/W
MK1%$W%>^"-P^IH ]-M[ZTNVD6VNH)C&<.(Y VT^AQTJEJ7B+3-*U*PL+RY2.
MXO798E+ 8PI;+9/ XQ]2!7.VTND7OC'0KC0?+;;92"X^S@!4@VCRU<=CNZ#K
M]ZIO$=M8IXZ\-7M[';^5LN8M\J YD(38.G7AL?C0!<\/>)6OY-4BU.2SMY;;
M5)+& *VWS0JH1]X\M\W:MV6^M8+B.WFN88YI?]7&\@#/] >37C>O&WB\)>.;
MV QC4(M?_=2*1YB#?"1CN.5/_?/M6WJATE]8\2VGB"6Y#7OERV1@7YKF!50J
ML3 $Y5U/ Q]XG'/ !ZB3@9/2J8U73C;/<B_M3 C;7E\Y=JGT)S@'FL#Q=%?S
M?#NX2TCN#<^1$7B'S2,@93(IQC)*[@?7FLF.^\(2S:AJT2R2:;-IS+>D1[+=
M0&7;&5VC,IW-CJ1C'<4 =K-JNGVZAIKZVC!B,PW2J,H!DL.>1CO5;3/$6EZK
MI(U.WO(1:XRSO(HV<\;N>,^]>?\ AFXL['4+O1-4,,E])IRC369Q(?LK!BL&
M1P6'&<$[N.3@5!IUY!:^&/!-]/YITZP\R._>) PMY3'M4R+@_=)/;@T >IF^
MM!#%,;J#RIB%B?S!AR>@![U0U7Q+I>DZ6NH37D#0/(L4;+("'<MC (].<^F#
MFN O;;1-NDK;6\HT^3Q")T:[X5T9&,C(I *Q;F4>A./6J^J"U@TGQ#'#Y:V\
M'B.WG"K]V-"8P6'H-P<9Z9!% 'JD^IV-MIS:A-=P+9JN\SEQLQ['O7*R^-)+
MG5?"HTUK9K#5A(UQN.YX=L0?:2#@$;AGZ5O>(%%UX1U1;=?,\RQE\L*,[LH<
M8%>>+<6=W=?#*-&CD187BE4C@G[/&"#GKR<?7CK0!ZD]]:1V@NWNH%MB 1,9
M $(/0[NE4-4\2:;I-M9SSW412\N(X("L@PY9@,@], $DGT%>;V&I6T$(LTFM
MXX(O$MU]FNIB6AMP%)7*C&[.]]H) SCKC%5-,D$7A73_ #RXCM/%RM(9$*B)
M-QY(Q\HR?UH ]E%S UL+E9HS 5WB4,-I7KG/3'O4$>JZ?,L;1W]JZROLC*S*
M0[>@YY/M65XN>S?PM)'=2RP07+Q1+*D8)C9G7:Q5L?*#C(],UP>I274]KI^H
M7<=N8[#Q);RW-]:;C!-&% \Y1SM &T-@XW T >K17EM,9A%<0R>2Q678X.PC
MJ&]#]:P/%_B*?2O!UWK.C2VD[PE/F8[T(+!3C:>O-<9JT<DK>+W2TGN;7^U+
M&YGBBC)\ZW"H7P/XAA3D"K_B*32+_0->;3K:80WGV,RRF-T25A(%*HI Y5$R
M2/7VH ]$@NK>Y,@@GBE,;%'\MPVUAV..A]JIWD]]'K6FQPS626<@E^T),3YK
MD*"HC[>I/L*Y[3(88/BGJIMXT2*;3(7)C&%=][9/'!."/SJWK*V2^-M#FF6$
M/Y%S&[L!]PA< GT/.,^] &^-0LVECB6[@,DH)C02#+XZX&><8/Y4?;[/[9]C
M^UP?:L9\GS!OZ9^[G/2O/-/L=,M/#7AUX88898]8WDK\I7]XX.?0;6^F"*=8
M74-L-3L=0TZYN=:CUI[JVC6)T\\E_P!VX<#&P+P<] I&.U 'H1O[-;P6;7<
MNF&1"9!O/?[N<TQM4T]7VM?6P;S/)P95!WX!V]>N"..O(KSJ(6TDVI:;J%OJ
M3:FNMM=00Q1;?.S)F.02;/NJF,\\!:S=;MP?"/BJ6S@W7)U\21M$F6*;XR",
M=1D'VZT >DQ>)]+N==O-&AO(!>VL:LP9Q]YMWR@9R2H7)';(I=&U3S-/M(]1
MU'39=0E#?\>LHV288CY 3D],'W!KGK9;>V\?>*A?(T4-Y:VVQS&<.JQR!R#C
M''<_0=ZP+2S%E\*-%UJ&'=>Z%*UP@9/F*>:P=#W&4.?P% 'I[:A9KYVZ[@'D
M$"7,@_=D] W/'XTUM5T]+-KQKZV%JAVM,95V YQ@MG&<UY_JEC=V6@Z7JTT5
MVR3ZK_:6HI;1AY(PZ,$.T@Y"#9D8/3/;-3/:6=QIQDLY]1MXY-36\AU"YMBP
M\X1$EWB9%VQ\8SQEN<^H!WME?6FHVJW-C=0W-NQ(66&0.IP<'!''6J?B*>XM
MM!NI;2_M+"X"CR[B\($2'(^]GVS7.^'?$<&F:=:6VJPM;W%Y?SQ)-%"_DSN7
M_P!:"1\JNS#'.,GCCI<^(]M/>> -6@MH))YF1-L<:%F/[Q>@'- #==U^?_A)
MK'0+#4+:S>6"6>:X=5<IM*A5 )P"23G/IQ6_#<R6>DQ3ZQ/;12I&IN)0VV(-
MWP6Z#/K6!>122?%'394C=HHM-G61PI*H6=" 3T!.#Q[5!\2IO(T'3Y45I+A-
M4MV@B",RR,&)PP4$D;0QX!.0.* .C37=)D29TU2R9803*1.IV '!W<\<\<TD
MFO:1"K-+J=G&%D>(EYE7#H,NO)Z@<GTKS>2"&^\.^-IP'EU;4XA*UBEM,#&%
M4*FT21JS')SD#TKH->C6WU72PMG-!&UI<//>6]JTK_,J*4  (#MA?F8'A,=Z
M .JEUO2X$@>74K1%G0R1,TR@2(%W%ASR !G-9VK^,M&TFQLKMKR">*]N$MX6
MBE4ALL%9LYQA>I/:N0T."8M\/"+*\2.S6YAG\VV=3$3#M&[(XR3C/0UGWEC?
M+X?M6-C>,+3Q@;J15MW9EAWN=X4#)7D= >M 'J$NN:5 \:2ZG9QO(%*!IU!;
M=]W'/.>WK67XP\11Z)X>U*6VO[2'4;>W\Z..9@2>N/ER#\V"![^N*Y:ZM[>;
M4?$%GJ6FZS<_VA*MQ:K%YPAN5,:!%) Q&05P=^,8J'5!<6EEXXT^YTV\-Y?Q
M![::*"259U,*HJ!@#RK ]<9SGB@#TC3IWN=+M)Y"#))"CL0,<E0322:G8PW\
M=A)>VZ7DJEH[=I )' SDA<Y(X/Y5CZ-K]KY^G:&\-W%=-8)*K36[1HVT ,H+
M ?,,@D8[U!XSM+F+^S-=TZV>XU#3;D!8DSF2*7"2+^H.>VW- &PGB#2)+474
M>HVSV[3"W$J2!E,AX"Y'&>:E.KZ:+C[.;^U$WF>5Y?G+NWXSMQG[V.W6N,T/
M0]2T_P 7R:=-YDFG))_:YN<;4DN'4HR 8Z;MSXSQQ]3GR:7>M\/V\/207)U=
M-3^1@C8R;CS!+NQR@4Y)]B* /09-;TN%+IY-2M$2T8+<,TR@0D] _/RGZUB'
M7+X?$V+1!+&VGR:4;L*$^;?YFW[W<8'ZUR?B:*ZC_P"$^M5L+V6;41;FU$-L
M[B0")0Q# 8XP>,Y]JO:E9:A<^.UFM8;B$S>%WMXIS&P"3%B54G'##KCK0!OZ
MAXD0^)O#]I8:I:R6]Y-,DT46V1GVQL1SG@!AS@=<<]COW>I65@\"7=U# UQ(
M(H5D< R.3@*H[GFO/]/E:YN/ 5I'I=[%-8!Q=;[1T6#; R$%B .6Z8ZX^E;?
MCP.X\/".&:4QZS;3/Y43/L12=S' . ,CK0!N1^(=&DMH[A=4L_)D0R(YF4 H
M#@MR>@/&:BU_7+;2]+O'%[;Q7:6KS1*Y!/ .&(_NYXSTKD]1M8].\6ZQ%J.C
MZA>:7J]K$D LD<H"BL&C<(1C<6R">.3SUJI!97FC7NK6]UIEP'U'1((+9;6&
M2=$D1'4Q%P#@C(Y)QCG- '9^&M8%]X?T5KR[B?4;NPCN&0E5>3*KN8*.V3V&
M.:O#6=--O'<+?VS0R2>3&ZR@AWR1M7'5L@\#GBN$TB*XTVZ\%WLUC?E$T9[*
M94M7)BD"QD!AC(SM8 ],BLWPS9ZIH'A_P_J<^DW\WV"YNXKFTCC_ 'B+(QQ(
MJX^;&.QZ&@#TM-<TN6UAN8]0MGAG8K$RR ^8PSE5]2,'@<\5:M[NWN[9;BVG
MBF@;.)(W#*<'!Y'N#7F]]:SPW&D:W!X?U"WTN&:YW6MH66YC$NW]\R YY(?*
M@\ CZ5V/A2QBL='=8+&XLX99WE2.YD9I3N/+/N)().3CW'?- '/:WXXENM \
M2MH<BPW>E3+!%*VU_-8E0Q (P "V,\] :["WU?3[IKA(+ZWD:V :?;(#Y8(.
M"?0<'GV/I7FFJV]X_AKQYIB:=?/=76HO- %M7(D4^4 5.,'[K=/3FM3Q!87V
ML^(O$%A9K.B7F@QQ)(T3+&TJN[!=V,9P_K_%0!V]GK&GW\[06MW%+,J[RBGD
MKG&X#NN>XXJ]7!>%+19=8M+Q-'UNVN(K5H[B;5II6V@X^2/<Q!RPSD#&!ZFN
M]H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @N;*T
MO-GVJVAGV'*^;&&VGVSTI([&SBD22.U@1XU"(RQ@%5 P #V&.,5RWQ-:>#P5
M<75K?W-C/%+"%G@E9-H:14.=IY&&/%9UEK+V7BV]DTN[O=3T"+3O/N?WK7 C
MF!X$;N<Y*@DKGWH [B73;">\CO);*VDNHQA)GB4NOT;&10^F:?(\CO8VS-*,
M2,8E)?D'GCGD _@*QH/&5G<1+(EG>@3"W^R[HP/M)F3>H0DXX .[.,8-1WWC
M>RL--U6XFL[H7.F;?M%H0N\!ON-D$@J?4$X].U &Y'I6G0M"T5A:HT/^J*PJ
M#'U^[QQU/3U-336UO<-$T\$4IB</&70-L;U&>A]ZPQXQT^.\O8+V"[L1:VWV
MOS+J+:LL(."RC)/!P,$ \CBJC_$#38%O!<V=Y!+;VAO5B81LTT(."R[7('T8
M@^U '1#3;$;,65L/+8LG[I?E8G)(XX)/-9NJ:->2+&NB7=OI6]C]I=+56=UQ
M_">,$'OSU_/(U#QK<;=-;3]*O-EU>P0[Y51=Z2)Y@V9;N,C)Q@@^U:EMXJMY
MKK5;:YL[BRETR$33"X9.4*EMR[6.1@'G\* ->PLH--L+>RMEV001B-!G. !B
MI)K>&X"B:&.4*VY0ZAL'U&>]45,FM>'L[9K&2\MC@$@O"67KP>HSZU@"S2#X
M@6^EQ3WB67]DRS&%;N4 N)47=][K@F@#K7@BE='DB1VC.4+*"5/J/2F"SM5W
M;;:$;CEL(.3C'/X$BN6N_$:>$;,6DMO>7MIIT<:75XSKN4.<)P3ESZ_GS5C4
MO&<6DZA>6%Y831W4=N]Q:+YBE;P X"H0<[R?X<4 =,8T+JY12RY"L1R,]<4B
MQ1HVY44'GD#U.3^O-<]J?BJ33_(MTTTRZBT N);5KE(_*3I]\\,<@@ =<'I3
MAXOMI[*UN;&PO+O[3:M=+'&$5PJX!&UV&3DXP,T 3ZYHMUJ%]97UE=6T4]JL
MJ!+JV\Z-ED !X#*0>,9!Z$CO2Z)H(TJXNKN62%[NZ"+)]G@$,2JN<!4!)_B/
M))//H *U;6=;JTAN%1T65%<*XPPR,X([&I: &111P1K'%&D<:]%10 /PH6-(
MP0B*H)+':,9)ZFGT4 %-5%52JJ "22 .YY-.HH @EL[6= DMM#(H7: \8( X
MX^G _(4\V\)5%,,95!A!M&%&,8'IQQ4E% $"65I';M;I;0K"WWHUC 4_4=*5
M[2VD\KS+>)_*.8]R [/IZ5-10!"UI;/OW6\1W@ALH/F!.2#Z\\TXP0DDF)"2
MFPG:.5]/I[5)10 8P,"BBB@!&56QN4'!R,CH:1T61=KJ&7K@C(IU% !6+K&A
M3ZQ<QJ^J3PZ<8S'<V4<:$7 )SAF() (X..Q/(K:HH 15"J%4  #  [4!5#%@
MH!;J<=:6B@ HHHH **** "BBB@ HHHH **** "DI:* "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH I7NEVNHS6SW2O(MO()4CWD(7'(9E'#$8R,
M\ \]<5=HHH *R=<T0:REJ4O)[.YM)O/@GA"L5;:5Y5@01ACVK6HH S+#26M;
MM[RYOKF]NF3RP\VU51<Y(55  R>YR>!SQ6E2T4 )12T4 )12T4 53I]LVI+J
M#1EKE(S&CLQ(13UV@G S@9(&3@9JU110 4E+10 E+110 "DI:* "BBB@ HHH
MH **** $HI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#F_'.EZIK7AF73](6'[5)+$ZO,^U4V2*^>AS]VM75(KJXT*[A@
MB1KJ6W9$1GPNXC')QTY]*OT4 <I%H&HP>'?#,<7D?VAHPBW1R.?+DQ$8G&X#
M(X8D''4#-8/C'2;J/P]XKURZ58I;RVAACMPV[8L;]6/<DMVZ"O2:JZAIUIJE
MFUI?0)/;O]Z-QD'ZT <IJOAF_P#%<ES+J,::>3ILEG"B2"0[Y""S-@8V@JN
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDR/6@!:*3(/<4M !1
M110 444FX>HH 6BDR#WI<B@ HI,CUH!!Z&@!:*** "BBB@ HI,C&<TM !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %8=GK$NHZS?K$T46FZ:Y@
MEE;DRR[06&>BJN1GKD^F.=RN1\%$6L/B*"Y"I-#J]P\S$$;P^'5L=LJPZ>E
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M.Z*0SA0><<#'TJ[K>B7NN>#]9N-%L=56XNA#)<1W@(\UDQE53'H.O>@#U/\
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M?B]7[.LIA.48.)!U381NW?[.,^U>??\ ".ZI;:%:S&ROM0T^QU>2:VL)'87
MM"I10.A!!)8 G.,9QR*OBUO+6.WUS2O#%Q#;6]\)VL7_ ./J=6B>-I""QY&X
M8'7 - '0ZEXVTVVMM-GM':Y2]O!:_)$Y*$9W@J!D, /NGGVX-3V%]#-XHU(#
M67E"6T+MI[Q%!;9!.XL?[PQP>1BN=U6VO;Q=+U6UT&2WA36H[Q[=(@MPR^6R
ML\B@XSDCOG'7FF:MHVIZWKGBB*"VGMOMNE0P132J0AD&2R;AP?O 9&1UZXH
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M(6?",^'*D*1OP& 4\Y[<5LZ0D^FZ9<7-WJ=W?VS.9H/-M6$T49_@*@;F(Y[
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M>^D,< 6,D$A2QR>@X'UK1KS6Y74+C6/ 6HWFIR7)NI7D:$Q1JB,T+,-NT X
M.WDGH.^<]1XOU"\L;2P6SO%M&N+Q(I'5 \Q0YR(D((9B0!T.!D]L@ Z*BO+X
M/%.OW?AZ8+>>3>6OB5-,\Z6%&:2+S%&'5<+GYN=N,XXQG-7+[Q!K.B'Q%8'4
M!=SPR68M;FXC5?*-PQ3D* "%(R.._- '9)J-BOB-]+2%EOI+;[2\@BPK(&"C
M+=SD^^/:M*N0L+:ZM/B-Y=U?R7V_1\H\L:(R;9%#?<4 AC@^WTKKZ "BBB@
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MOK:65UWHB3*S,OJ #R/>LOQEJ>H:)X8O=4TYK7S;5/,*7$3.K@=OE9<'WYH
M>?"NG)=:?/:>=9FQA-O&ENP56B)4E&R#D94'L>O/-5[7P5IUE+HKV\]Y&NCJ
MZVR"12"'^]NRN3D<=:JWNL^(?#MFNI:RFG7FG*P^T/91O%) IXW[69@X!(R
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MDKGD9':@#RW0+)+2P^'Q:T\JY264S$Q8908Y%&XXR,DJ.?:NL^(KC_A ]6A
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MDNDDLH8[)DG6*)&4#>/+]2<[<Y SC(JUK^D:]?71N=.TU[/5 L'V2_@G10H
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M\52\->#WTE=6AN)0T,A>VLL 9BMF)?&?7<[#'HJU'H.@>(+$6MO?#3%AT_\
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M2*1]JL2,8)["N5TBP\5V?A>PT..TTZS:&W6"2\:Y:0J!P62,*,MC!Y8#/K0
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M<ET=K1(;-9VN"^Z26;R8HE52Q+O@XSC R*PCX]FN'\-_8-+#IK0EVF:<+L9
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M-N(3;[W1R,,T3[@%)&.JMC%)=>$+P0:];Z=JJ1VVK1MOBG@,AC<Q["P?<."
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MWUMJ5C#>V<RS6\R[D=>X_P >V.U>9^ TN?[1\(_VCPRZ%/\ 9P0<Y\Y<=?\
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MQ8+D_(#SPN,9S6C<ZI/IUBNG"^NOLZ^(192W,MRS2)$5WA6D)W 9(7.<X[T
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M<#!;.W!X'49XAU/7]2F\33Z%HRP+/:V7VR66="RN2<+$ ",9ZEN<>AH 6_\
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M9)'99=H !()P" !R,&B\\3Z'I]U);7FJVD$\2AI$>4 J#TSZ=#5F+5].GO\
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M6. S-J$942O#A06;>GWP% R<=SC%32Z[ID>GV]Y]NB,%S_J)$R_F9&?E Y/
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MM!JPGE"6CR!E-QO$F\ @Y4XZYXKV.B@##\5F%O#DHG6]\MWB&^S0F6$[U(D
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MS@!_NKG;R?O8QTYH R_A]83C3FU&]G^TS &QMISG+6T3L$;GNW4GO\M=G4<
MBCBCCA"+&J (B\ +VP/2I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** .8\6WMP;G1M%M9I(9-4N]DDD9PPA12\F#U!( &1TS67X\
ML=-TSPS<7#M=0F.-8K)H?,$=D?NAQL&% SDD\D<#TK0\80M:7^A>( ,PZ7<M
M]IX)V0RH4=^/[O!/MFI=9AU[5XKJQLX]*.E7D/EK=O*S.JLN&;R]I5NO'S 4
M 5KF[>^\5Z!I+W FM38R7LLB$A;@@*B]#T^<MW[>E8=JUW)X U&\AGE.H:#>
M7?V6X9MSLD3D[&)ZJ5&T@^@]!74R>'/LEWI%[INPS:;:M:+'(VQ98BH !(4X
MPRJ>GK6/?6$GA[P'<Z0'2YUC5VF1448$L\Q); [*H/7T7- '0)XELQX0C\23
M[H[0VBW3*.2 5SM'3)[>]8*W\]SX[T6[N=/>UWZ5<R@>;OW+F(@$< ,.X&>H
MY-:<_A*.X^'X\+/<$*+-;?SMN<,H&&QQW&<50CT#Q'<W=A->75C UKI]Q9^;
M;ER^YP@609  .4!QV]3V )+'QQ+>ZC;:>-(:*[O+,WEM&\X!VCHLG'R,1SWJ
M73/&9U30M-U&+3766^O3:"V:7YHR"VXMQV"$XQTK%T[P[JFA7VC:SJDFDV]O
MIUM-'?2(SEGW!<REB/F8E1G.,>I[:/AC3;.Y\3ZOK=C<>?ISRYM-C[HO-95\
MYTQZD ?7=[T 7M*\5R:Q=(+33B]H;J2UDD$V9(&0-S(@'R@E<#G^(>M-\2:G
MJ]KXD\/6.GPQFWNII3*S3;-Y2)F"'Y3@'KD#^''%4-,\+:LFNZ?J-^;!;BT,
MGGWML662^5E(59$  X)!R2WW1C&:V-=TB^O=8T/4;"2$/I\[M(DQ;:R.A1B
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M$14,),$E>3C&U1SU'>@"O_PEUW%I^FZS<Z:D>CWTB+O$V9(%D.(Y'&,8;*Y
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M';X2"(?>"J6)).2<D]<>E7[;PW+%KVFZK)?*S6>G_8FC6' DS@ELYXY4<8H
MI>(K[5(?'/AFRM9X4M+@7,CHP/S,D?<CMAN!Z]>@J'_A,[N71$\36UK;R:!Y
MI1P6(G$8D*-+_=P",[?0=>PU];T"75-7TG4K:]%M/IYE W1"0,DBA6XR,'@8
M/(]0:S(?!$EOI3Z#'J6W06G,HMQ#^]"%MYBWYQL+9[9P2,]Z -?Q6J2^#]9W
M*K+]AG(R,_\ +-J\^LH5U;6/!%C9*NGW>F6-O>2W#C8;F$HNZ./'WP>0V2,9
M/7FO2=;T^;5=&NM/@N$MC<Q-$TC1;\*PP<#(YP:PKGP3]HT32K==1\C5=*5$
MM-2AAVNBK@8*[B""HP03@^G:@!]]XHOSJ6JV>DV"W+Z:J!T99,S2,N[8I VC
MY<<D]34;^)]6EUZ_L;>R@B2UTZ.\_P!(8[MS9)5@.AX(XST_"I+CPE>G6)=3
MT_79-/N+N)8[X0VZLLY48#J&)V,!QGGM4T/A-;;4[ZZM[S9'<:<EA'$8]WEA
M 0K;B?FZGCB@#+L-9U77=?\ #UW;RPPV5SIDEVT#*V<[HE;.#R1NX_&NYKE=
M-\)7&EKHH@U7!TVV:T8_9A^^B+(V.6.T_NP,\]3TK=TVTN;.&5+J^>\=YGD5
MW0+L4G(08[ <9- '/?%!%?X;ZT&4$")3R.X=<4FL6=RNM>$K:*YC6&&9R-T9
M.66W< GYAG@GZ5K>*-"/B709])-T;:&XP)75-S8!!P,G Y ]>,_41WFB7MWJ
M&DWG]IA6T_G9]G!69BI5RWS9&03@ \'KF@##\?VTNG^#(;'2GALHIKV&*18X
M>"))<M@ \98Y/XBJE_)JEC\1;Z>S%E)>1^'UDD>161&(E?HH)/8#D]._:NL\
M2Z$OB+2/L)NGMG6:.:.5%#%61@PX/7I5!O"UT^LW6I2:L)99]-_L_P">V' R
M6WG:P!Y8\8'&/J0"D/&%]J$>E#3;10]YIXOI&,#SA,X 0*I7OGDGMT/;H]+N
M;R^T*WN-0M_L-W+#F:+=GRF[\USMMX %E8Z.EGK-U:WVF0M MW"B_O8V.2K(
MV01GI72V>FQV.DKI\<LLBA&4RRMN=V;)9F/<DDD_6@#SK3K== @TGP[XBLPL
M4%_'+INLP1AHYG\S<JMCE&8$@D]<DY[UT5QXGUE]2N!IVG"XM+>\6V9?);<P
M! D?S-P5=N3Q@YQUYJZGA>9M/T_3;O5'NK*R>*0!X5$LC1G*AG'&W('10>.6
M/.8Y_!B2:M=W,6K7L%E>R++=Z>FTQ2L,9ZC*[L#=@\\T *-5UN]-Q=V*6@M+
M6_\ LYA<'?)&C[)6+D@+CEAP>%]\#,U+QGJ5CI?BRY6*T>31IHTARC;9%8*?
MF^;K\W4>E:5QX*@FU2YN(]4OX+&[?S;K3XW AF;N>F0&_B (S46K> X-5;5T
M_M*ZM[752C7$$2I@LH"@@D9QA1QZ^W% #9==UBZ\:WF@V(M8TMX;:Y\R0$DQ
ME_WJ_4J>/3'OD8VOZCJ?]BWGE26ML5U^&VE\F CS%+1<DYZDGD]QQQ75VGAI
M+3Q5<:\+N626>U2V:-U&,+C!R.^1^M5+GP<MYI^H6L^I39NKU+Y)$C4&&52I
M& <@CY1P<]Z &7?B6]T;Q!=6>JK ;/["UU:2PQ,&E9/OIRQ^8<$ =0?:MO0V
MU%]"LGU?R_[0>(-.(UVA6/.,>W3\*YS4-/&N:SI6FR07[G1[H7$U]=0[5F C
M/"L %;<S#( _A/'3/7SI)) Z12^5(1A7V[MI]<=Z .2\#6-KJ'PYM;2[@CFM
MY3.KQNN009GKF_"GBG5#I^D^'[8M+/*]T%O),2L((F(0@$J&R<+UZ*:Z^R\'
M?8M#ATA-<U,6B;MZIY2F0,VY@6";@,D_=(//6G7?@G2Y8],%C)<Z7)IJLEM+
M9.JLJL,,IW!@0>IR,YYS0!F?\)%XEDN-!L7MK&TOKXW27*/EA$8Q\K#!.<@J
MVW\,C.:@MO&>IHS:+>1V_P#;*:FFGF=5(C*LI<2A?]T?=SUQSBDU;0VLO%'A
M>*Q?4ODDN9)[U(C*3(ZJ TK;=N&(P1QQTQ6W)X,L9;.93/<"^ENA>F^5@)5G
M P&'&, <;<8Q^= %*]UKQ#IHU2Q\F&_NX+>.YM9+>(AY(V<J^8R<%D R "-W
M XS67?>*KT^"-;U2WO+'44MIXDA:2WV\$H&5X\Y5@S'@^@KIY_#"W:7$EQJ5
MX+Z80@W<.Q'C$3[U5!M( W9)R#G)]L5+GP-8WFF:I9SWEUNU2=9KJ>,1JS;2
M-J@;2 !@=LGN: *]A;ZB_P 3M6E?4M\$-G;[8#",!':3Y0<\8*9SSG/H*[&L
MA-!$?B4ZTE_=*[VZ030#;LEV[MK-QG(WMT([5KT %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 444TD[@* '4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!1U._-C';XLKB[^T7"0%8$W>
M6&."[>BCN:N(BQH$10JJ,  8 %<]XNGEMH-*DCNIX%.J6T;B%L;U9P-I]JQW
MU'4;/Q*ZWMQ.;"ZU...SNX)0\2X&TV\B#E3N##.#SCGB@#NZ88D:19"BEU!"
ML1R >N#^ _*L/Q;=SVNG6OV>6999;R%!' /WDPW9:-3V) (SD =<U#X.NK^X
MCUF/4)"SV^IO%&AE\SRT\N-@F[OC<>M %]]?@7Q*NA?9;HW+0_:!($7R_+S@
MMG/J<=,UK5Q]Q*R?%^R13\KZ+(&_"4&K/BK6FM%MK2TGC69[N".??*8@J/O(
M'F ':24QP,\]L@T ;U_-9PVC&^:(6[LL3"4 JQ8A0I!ZY) _&D@N;)+I]-@:
M-9H(ED:%%QL1B0I].2K?E7"W5M>B2"QU&^9S#K%J\4,-Q(YAC8'"-(0I<Y4G
MG)''M45V9-,\5>-K^S$[75KID$T(\UV^?RY "03A@.N#Q^- 'I-%>=:?+>>3
M9ZC'KH>UO;*5?+CNY+AIY0A;S064"/;C!   )QU(%;7@**ZN?#6F:M>ZC=W-
MS<V2"19),IU8A@.S8.">^!0!U=9>KZQ_9CVD$5K)=WEV[)! C!=VU2S$L>
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M25!)=P#3WO!(&@\HRB2,YRN,Y'KQ7DOA/4+&TUKPS=Q3PV\5U;W22[[C=/.
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M"0[25\LGG&,''I7G-G::?I_P[T'6&5TANVM8=5E0&0&! ^-RGC;NV@\=.H-
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MBB@ HHHH **** "BBD) H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7<@4QRL1E>A) 8#@D#-+IOBI=5U+[+;:9>&)+F:UGG8 +#)& <-SWSP?IZT
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MU@/H%[;:MX@LI?#\>H+JER;FUO)"K0Q;]H(D4D$;"N[C)/08KT;(XY'/2EH
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M, GGO[&L^?1M8M-'U_1K73UNDU.XFDAN&D01QK-R^\$[CM);& <C'3MW-(6
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M[ X VG'7.>U7KOPW?:IXFDOKT6T=G/HSZ;*L4S%P78,Q7*@8&,<X]?:NMHH
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M;L6'J%P1V.#GV]*J0>![&V325CO;]3IB210,L@5C$XP4) Z<#D8/'6@!OQ'
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M>E2Q0'3TA\D,Z!=SQ;\R;D8D9./EV\#KS6[+X,T:8:H&CG U3;]L G<>8%&
M.O QQQ3KWP=HM_J(OY;:1;@QB&1HIWC\Z,8PKA2 XX'!H =K-]<)X)O-2M9X
M1<1V+7,<L>)(]RIO!7/!''!KFUU'7XK'0G.KF8ZP(F4,D4318@+,JL5()9L'
ME3Z#K7:7VF6VH:5+ILRLMK+'Y3)$Q3Y.FT$=!CCCM5&^\*:1J6AVVCW=N\EG
M:[# /-8-&4&%(8'.0.* .>BU;7[>XTS1M2OH([JZU.2(W,)1W6%8S*J-E H=
MOE7(7H<@9-8-[?:IX?L?B#>6-[(]_!>VI2X:)"VTB,'*[=O"DC..V:[Y_">C
M/I2:<UJ?)2;[0K^8WFB;.?,\S.[?G^+.::GA#1$LM1M/LKM%J6/M>^=V,I Q
MDDG.??K0!@>)_$NIZ)K&M""Y!@@TJ&YB22(,L3M,T;-P-Q  S@GM4NN:EJGA
M33M1OQJ\>H0FQ::VBN57S/.##+ H #'A@<?3!K<A\):-%--,UL\TD]L+29IY
M7D\V,$G#[B=QYQD\X ':DTSPAH6DPS16MBI2:,Q.)G:7]V?X!O)PO/0<4 <K
M?:UXFT'3'U*:ZLY;22R78UQ<*S&<L!YBA47*8;)'MQCOH/:75K\2]$^T:C->
M Z;< >;'&N&#1[C\BCKD<=L5KV'@KP_IMM/;6]@##-&T+)+(\@$;?>1=Q.T'
MT&*?8^$])T_4(+^)+A[J"-HHY9KF20JAQ\OS,>..!VYH I>*M3U"VU;2K+3;
MJ19+A9BUO!$KRR84!6RX*HBDY)..P&>E9%KK&K7%OX)FN=2F0ZBLD-VL2(/,
M<PL5;IP0PSQQ[5U>J^'-,UF[MKJ\AD,]NKI&\4SQ':XPRDH02#Z5!9^$-%L1
MI_DVTA_LYF:T\RXD?R2W7 +8QCM0!RT5]K-O8&[?6KB8VNOK8*CHFUX3.(R&
MP,DX;KG^$>^=2XNM0U/5O$T,.I3V9TM(UMA'MV[FB$F]@1\W)Q@G&!]:V#X5
MT<VTMN;>;RI;D7;C[5+S-G._.[.<@'Z@&I+OPYI5]=S74]L?/GA$$KI*Z&2,
M'.UMI&X?7MQTH X[1_%.K:S,[33^5#-X<6^$<:@!)R[*65L;OX1P2:KZ9K.K
MW^I>!;>?5)RFHZ=/+<^7M7>XCR#P.HS^8SUKN;GPWI5W-;R26NW[/"UNBQ.T
M:F(XS&RJ0&7Y1\IR/:HK3PGHMB=/:WM"C:>GEVK>:^8U.<XY[Y.<]: .!+7.
MN6OAMK^^N9'A\0RVJN'VDA/-VL<#!8;1S_B:]60!5";BQ4 $DY/XUB'P=H36
M(LC9,;<7!N@IN),B4@@L#NR,Y.><')K2M]-M+6^NKR&+;/=;!,VXG=L&%XZ#
M ]* +=%%% !1110 4444 %%13S-#"9%C,A ^Z.IIZ,64$J5R,X/44 .HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6B@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH 8[E2."<G%/HHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *,444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 &****
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M+C'W>/?VJ30-(/@K3-7L_$-Q9'2+V]?RW^8M*9MJ[6&.!QCO^ %=]&XEB20
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M1"*=HU,D8;=L;'(SWP:FH Y6Y\'2MK%U=V6N7EC9WS![RRB52LK8PQ#$90L
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MESWTEY.YN(UN',SEEBQ&H.WT'&?J37 M)=P>'?$-CJL=['J?]@RN[O=-/!=
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M9+J]4) 'V1S;59MLC8/R< D#DX KD;>::70-(@DOG:2#Q)]D_P!'N7V^5YK
M*#G)7 P"><"O3;W3[/48TCO;6&Y1'#JLR!@&'0@'OS4,>BZ7%(\B:;:*[R^<
MS"%<F3^]TZ^] 'G=S(ND6OB#3899H-(AUFUCEVRMF*"18S+\Y.0"2<G/<^M;
M?AN.TC^)/B@67E>6;:TR(B"H.'';IVKL!8V:F8BU@!GSYV(Q^\S_ 'O7\:6V
MLK2S!%K;0P @ ^5&%R!TZ?4_G0!YEXQOME[KMS;S>3/8W=F/.EN2&5_D(6)
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M-OXCT;5Y);?1[;4+?4+.))4AD6-8)T3;C#?\LC[9(].Q;;Z=K&G_ !*34)+
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MT %%%% !1110 4444 %%%% !1110 4UERRGTIU(3B@!:*** "C-%)0 M%%%
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MGW*O&2,8)RI]<5AP:QJ/AR#Q3J=C'9O;0^(2MQ%*K;G5_)7Y"#A3\V<D'Z4
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MM[Z.SMXPK&.3S=OEN1G.T@DG!X"GTH ZN]FM8+.:2]EBBME0^:\K!4"]\D\
M5RUCH7ANWGTL0:A>-#<CS["S>^E,+!0'&U"<8 ((!K:\2Y_X1'6-V"?L,V?^
M_9KF-(U*:U/P_L1;6DD-YIQ_>R(3+$4MPWR'.!G@&@#O"0 23@"JFGZI8ZM
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MOKF.WAW!-\AP"Q. !ZFK5>/:E/JMSX#\4S7EW!<;-<$2J(2A+)<1*/FW$!<
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M1FQ0 #@<TM .110 4E+24 +1110 4444 %%%% !1110 4444 %%%% !1110
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M/J"!+RY9QYLZA=H!(& ,<< 5N44 5=.L4TW3K>QBDDDC@01HTA!;:.@X Z#
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MB.>^:Z2B@#+L/#^GZ=JU]JEND@O+['VB1I6(<#[HVYP,#@8'2M2BB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "HI5+,F#CFI::PRRGTH <**
M!THH *2E-,+@/M- #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(-_&\"!@S#\>"?6DT 6%NO@%K3[/#=3:?(KN@ 9B81C<>_S*>O<>U>HXHP*
M/(O \5JKZ1:RW.HOKUE<OY]D\2*L.=PD9G$62A!+8+<G SWKIOB4;:6PT6UF
M?!?5[9B%8AP@;YF!'( !^]VR*[?%% '%6]SHVB^,/+LKQ[F;4XPMPDEPTHA2
M%7;S"[$\?,!C/?/8UQ]N0OPB\6+'@22W\_EJ!\S*SKC [@C.*]EQ1B@#RK7G
MAM]8\.7]Y<:C;:6VEF-;FQA$HCERI(92C8W# R!GC'3-&G30:!?:'>W5C>Q^
M'/L=Q:VS7*&5HF:4NKLH&5WH  ,<# KU6B@#R:5+'3O$O@:YBL'LM(BDOHX/
M-W,Q5D_=D@C<"Q)(7J,CZ5OV&G:;K.J>.=**(L5W,BML3'6%5+#C!(<,<^M=
MUBB@#S+1;?4_$GA35+B2'R]4MM/?1X&+88RH&$C!AT#-L'_ :D\%_P!G7>HZ
M5-:1ZM)>VEJT%PMQ&(8[1<<J1M&[+ 8 )[GM7I-% '%>-;N"T\1>%)IY-L<5
MZ[R'!.Q3&RY..@R0,T:Y(_BC6-"M-+AEDMK._COKJ[>)D1%0$JJE@-Q8G^'.
M*[6B@#R2VNK0W^G71AGMQ:Z],SV\5K(PCW^8NZ1R"69B%QC  .,<9JN([@:#
MXBM&M[R6:W\2->SPP1G>T&],,F5(8Y ('^S7L=% '!Z!J&FV7]M>([5-5N;.
M2*-I[JY3#RNF1A(]JDX!&6[\ 9Q7=@Y ([TM% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %&**0T +10.E%  :B>(.ZN201Z5+24 +1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %)2TE "T444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 51&KV3:R=)6;?>K%YSQJI.
MQ<X!8]!GL#UJ]7)^&[2:[T#4;N*Z-I?ZA>7#M=Q(K,NV5D3AP00%0#'I[\T
M=96+8^*=-O[>WGC:5(9YWMD>6,H/,4XVG/3)!QZ].O%8G@S6-3UV=OMNHXDT
M^,07%ND:8N7R<7 .W.QA@KMP.#VK,L+Z[\2_"779M4G6><"[VR,%0*8\E#Q@
M#! .?:@#TBBLGPO?3ZEX4TF^N6#3W%I%+(0,98J"36M0 4444 %8FK^+M$T&
M^AM-5O#:238\HR1/L?G'# 8XXSSQD5MUQ?C+0+/Q-KNF:7>J/+ELKS:^T$QM
MF'#+GN* .@O/$%E8ZK::;,MR;B[_ -3Y=N[HWK\P! QU/H.:U*\?\'3ZY;>.
M-,\+:TC23Z.EP\=R6R'@9%5,>O/X\X[4'X@ZW%X2M_%!G,@DUHVK60B388<$
M[0<;MW'7=U- 'L%%>7:MX@\1CQ=XQM+76&@L])TW[7 @MXF(?RE<#)7D9W=?
M:HM4\=ZQ#X=T/50\R6USIY:]DLXXW>"8D!)&5E.$)5_3//.0* /4I)XHI(HY
M)%5YF*1J3@NP!; ]3A2?P-25Y5=2WU]\0_!"-K<\@GTUY_.A5 I<PG+JK)CY
MNO(XSQBH==\<:]ID-_=17+2M::S]F988XS;K#VC9F7<7(SG:3COCI0!ZW2$X
M4G!.!T%>7^*];UZ+QEJVEVNNS6=E;Z)+?A5AB)#@$ ;BFX#H>N?>H[+Q=J^I
MZ=X%LY;IXY=7:8W5Q$ KL(\@ =AG@GCG'I0!WVB>)M,\0R7D>GRR/)92>5.K
MQ,A1N>.0/0UKUXYHM[>:/!\1KF'4K>"\AOU"WETH"@[F&2 #SC. !UQQ6QX,
MU[5M0\9:YHTVH73V:VL=Q;O.B>;&75?F&1QG=D*PXXX'(H ]+K)U#Q'INEZM
M8Z9=R2QW-\VRW_=,5=O3<!CN/SKSKP]X@\4ZCX3C\4W6JK+%IDEV;B 1 &Y4
M(-@(50.&S^'-9JW-_J5]\.-5O[Z2XEO;R:5E<#"-N7A<=%Q@8[8]Z /;:P;O
MQAI%EKD6BSR3KJ,Q'E0?9WS(.?F!QC'RGG/:MZO,-<17_:"\.!E! TUB,^H$
M^* /3Z*\2O?$GB1;#QNZ:Y=I'H5[&MIA4R0TS*59MN6 ';/I72>'=7UB3XAK
MIM[JDUU;W6BI>,A545)&8?< '  ..Y]230!Z317A<'BGQ(G@;6-9;7;MY])U
M-(8$8)M=-P!#_+N;.[N>U=CJ<FM7?C^/3++5[BVM]2T:2:1=V1 ^-H:,=0<[
M3U[F@#T.BO*YKW6)KS7]-FU6]C?PYH\9CFB<H9Y_*W&5^?F!VXPV1R3UYJM>
M>*-4M5\'^++W4+B'2[X+%?VR,0GF8.'"]E.,D9[4 >NT5Y;<ZMK.FW/AG1[F
MYOB^L22W-PPG42 8)C@1VP%Q\H.#D]NM0:WJ/BC3M$\+K<ZI):ZH^I+87#P2
MI*'4G@L""I?&.M 'K-%>)7FO:_';>.X$UZ^"Z/.C6S93=\SE2"VW.,#H,5NZ
MCXFUC5O%&@:#!<RVR7NDB\D:!@CO*R,1\Q' !7.!U]Z /4*CN)XK6WEN)Y%C
MAB4N[L<!5 R2?;%>8/>:^WCGPOI=UK4T3WEC,M[]CE#1M)&L@++D8!R.>."/
M:N?O]8U36?@++?7NI7+W"7?ELP8#S4+@;7P.1AOY4 >Y*P= RG*D9!]:6O'_
M !9>:SH0B6/4=3FTF*P\I[JVN,RVD[Y8/,JXRN-H&<<=#GKZQ8S)/8V\B2^8
M'B1PW=@1P?QH L4444 9^I:S::3-8173$-?7(MH<8^^02,Y/3C'&>2*T*\T\
M26=[XHN=;FM]-DF6Q06VFW"/'F.>-M\CX8Y^\J+QV5AWK5FUJZ\2^$=$OM-;
M#WCK)/:PW7V>:95!\R.)\@@AAZC@'D9H [:BL'P?<Q7/AR(Q7-W/LEE1C>EC
M,A#M\CDDDLN0N?:J?C9[Q&\/BSU":S,NKPQ2&.0*'0AB0<CG[O Z'.,&@#JJ
M,UYEJ%UJ]@_B;2(-4O#'8O:7%I<22[Y!YK8:-FQDKG)QG..,XK;-C.?%8T6Y
MU74GLY(9M0&+AXW=C(%\L.I!"(#D*"/O#/% '99JGJ=^=-L)+L6=U=["/W-J
M@>1LD#@$C.,Y/M7G$]]JD.CW.J/J%\Z>'-:>%RDS8NK177<'&<.R@\D_W2*G
MUN[U _#OQ!K\-]>P&[N5EL]LSC9!YBHNT$_*'&6XQPPH ]$O[Q-/T^XO)(Y)
M$@C:1EC +$ 9.,D"F:9J$6K:5::C KK#=0I,@< ,%8 C.,\\UQVLRRZQ>>+[
M.2_N8$TZR5888)=F=T1<N1_%G.WGC@]ZP])NM2U--&T.RG$:P^';:9$-]):D
MR,,;P8U)?:%7@X')SGL >K,Q5&8*6(&0HQD^W-4=$UB#7M(AU*VCECBE+@)*
M &!5BIS@D=5/>N0TZ:[UK6;#1M1U:61(=)^T/+8SO!]IF\QHRVY=K$#;GT.[
M/I6S\/=G_""Z:L>[""1"6ZL1(P)/N2"?QH VM2OSIMJ)Q9W=WEU3R[6,.XR<
M9P2.!WJY7*_$2XN;3PA+<6EU/;3)<V^'A<J2#*JD$CG!!-<[K']H76I>/-NL
MZC;QZ9;0W%M'#.4"/Y#/VYQD<CH<\YP, 'IE8^N>($T*2S633[RY%W.MO&UO
MY>/,;.%.YUQT//2M2W9GMHG8Y9D!)]\5S7C7[WAS_L-V_P#)Z .G1BR*Q0H2
M 2K8R/8XXIU8WB35[;2M)G\Z]%I++!+Y4F,E"L98MCOC _$@=Q7):5/>MJMS
MI<]WJ,2S>'DN$\R[+R*X)4R9R=C'@X!(H ]&S65K6MIHHL3);33"[O(K16C*
MX1I&"@MDYQSV!KA=$-W97G@*Y&HWLTFJ6;B[$T[,DBBWWH-IX&#W !/.2<FF
M/*=4\(^%-7N+VXGO)]:M7E#3,%5S-ADV9P I& ,<8H [ZQUM+W7=3TH6TL<E
M@L3,[E</YFXC&">/E[XZ]*U,UYKK^JWNB7WCW4=/ ^U0V=B4)&=N=X+?@"3^
M%:LBRZ9XC\-Q:?<7,L&HQ2QW0>X:0,JQ[A+R3ALX^8=<X]* .US6$?$\/_"3
M7FABSN6GM;/[864*1(N0 $ .2>HYQR*XH7M[8>!=.U:75KTRW<XT^>XDF)$$
M+7# R<YPX7C=]/05?TVQB@^,FJPB6XDCET9"?,G9R,N!@,3D#C/7J30!V>BZ
MM#K>EQ7\$4\*N64Q3ILDC96*LK#G!!!%:%<MKNGR6=KI%EHZ1B*&8L=.$Y@^
MTH$;(#CN"=^#U(Y-6_!]S'=^'DFBFO95::8'[:298R)&!0DD_=/RCGH* +.O
M:]#X?LH[JXMKB=))D@ @"DAG.%^\PXR:=!K#O?PVEQI=[:-,K&-YC$RDK@D?
M([$'!SR.QK"^) +>'+4*Q4G4K4!AV_>KS4^IRR:+>7%S?ZU(8;RW,%N&4 PN
M [LP"@<!1DDY(VT =+//%;6\D\SK'%$I=W8\*H&2326]Q%=6T5Q V^*5 Z-T
MRI&0?RKR343<0>$M9TK4DN%OTT8S&1+IIX+M0P'G DY#9Z@@9SW%;NC21MJ_
MAG2&D=+$Z.;E$28@37&$!5L'G:I+8Z<Y["@#T/-&:\RMH[FXALK*>_U 16_B
M2:RBF6\</+ (W;:6!YP1MSU&W@BF7T5XC:[I=O>WL.GV6KV+13BY8&))2GFK
MN)P57=G:<@9Z=* /4,UGZWJB:)H=[J<D;2):PM*44X+8&<5YYJ\UYX=U3Q)9
MZ;J%T+!;&WGD:2:69K5FE"N0S-D$H7;@YX'3 J;6]D7ASQ*L6M07L=QI)F^S
MVT;>5'C(#@M(^"P[#&=N>N<@'H6EWO\ :6DV=]Y?E_:8$FV9SMW*#C/?K4&K
MZW:Z,EOYZRR37,P@MX(5!>5SV&2 .Y)) 'K4?A?_ )%+1O\ KQ@_]%K6/XGD
MCLO&7A34+H!;1'N;<S-]V.21%"9],X89]_>@#7CUMTU&TL;[3Y;66[+B%_,1
MT8J-V,@YW8R<8['FM?-9.LWUO;+'$$\V_99&M56/>RL(V^;V&,C/^UCO7$^$
M;NUN[3PSJ']M22WTD4D,UM$SLTK[27,VYB?E(SN(')&."* /0M0U&UTJPEO;
MR416\0R[$9QS@?J:C-U>?VT+3[ WV+[/YGVWS1@2;L>7LZ].<]*\L@M+.;X.
M66MWC33S;+:*5IG+#8EV/X<XZ$C/I7;)%#_PL951MT+Z,=L>_* >:!\HZ#(Q
MG'6@!L'BK5-1076E:";RP:X:W65;M XV/M9V4C 7AB,$DX' S765Y+X;B1/A
M5>2IF-O[3(9D8KE?M"@@XZC!(P>.:V[C4(9_&7BC3-:U$V,*6D#6#^9L:--K
M&22//&X,1R/0>E 'H&:J_P!H6_\ :@TW?_I/D^>5QT3=MS^?\J\U\4:X+NPU
M9K6:ZBN;;1X9&-XQB:(MN96C4?\ +4Y&[&,8 Y.0)V"?\)I=7L<,,M__ ,(W
M%-;,RJ6>?<^"I(^\3@4 >FT5Y_X8N-/OY_#U]::LDET87AN((D;S)/D);SMS
M$C:Z_>(ZD#^*O0* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BL?7KJ>V73Q;ZG9V3O>1*XN<?OXR<-&G^T<C'^35[^TK 70M3>V
MPN2^P0^:N_=MW8QG.<#./3F@"U16>==TCS6B&IV;2*KL8UG4MA/O< YX[^E/
M75].<V@2^MW^V FV*R B; R=I'!X]* +M<JOAN=TUC1;C<-%U"1IXGMI=DD.
MXAI(SQT9MQ!&>"0<<5N1ZSIDU\;&._MGN@2/)$H+9'48]1W';O61KWB%+6YT
MZWL=2M5GDU&&WFA.&9U9]K*O/!'?J1[=: +D7A?38=8MM503K=V]NMM&RRE0
M8P#@,!PW7/.>:R;WPHUKX9E\.:&K16]\SBXN)9-WE(V/,QW+,,X[ D]!@5UK
MNL<;.[!%4$EF. !ZFN?T/7K6/0;%]3\0Z==SS>8%NHV6-)MA;)49[ <GIP:
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M%O!D#V%\DMGK#W%PGD,&CC\R3YFR.GSK[D$XZ''JE,FFBMX7FFD6.) 69W.
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M6DV>BV2VEE&R1CDEW+LQP!DL22> !] * *?BW3+K6/"FHV%E)LN98OW7. S
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M_P!)T][.U>Z>TU*WNGA0X9T5N<<CUKJJ* ."N+&_N]<\47$FF7<<=[HR0QJ
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M\R*XD-XKE\QA=ZA1T)YQUKMZ0LH8*2,GH,]:6@ HHHH **** "BBB@ HHHH
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M%(I(E*%,HFQ6&Y2<@>^/4&@#E=)\2:]>Z5X-\F>T1]6$RSE[?A=B.PV@$
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MWV23RS$05QM/3':O/] M4L[3P#<:9//]MND"W2"9F$D BR^X$X 4[0.F,@4
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M<#?)$74Q(XZ\)D@=BI[BNN\:VUS_ ,(+J,&FQRF185"QP'YB@8;E7KU4$=Z
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M:.12K(ZC!4@^E<9<+]C\'^(="U1)I-;O;R:2W01G?<L7'E2*<$8!V_3&.,4
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MY)[6"4R65ND6WRR4VDL<_,>6QQQG\MFB@ J%K6W:4RM!$9#C+E!DXZ<U-10
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444UFPRCU-
M#J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH **** "D(!/2EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ,T4Q$V$\DY]:?0 4444 %%%% !1110
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M+XIDVZXK1BP$ATXQ;3&-P/FLQY'!Q@U;M/$6E7T\4%O=@O,I:'<C()E'4H2
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M(R_7:-PVDYZ'UK6CU"X\,Z%J.OMX;%G;DQM)9K*OG8!(>5FS@\$ +U^7KS@
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MBBB@ HHHH **** "BBB@ HHHH **** "F. S*#VYI]% !1110 4444 %%%%
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MNN&)SL51R,*,EB,<B@#M:*Y:]\1:HGB&33;2UM/*&F&_625VSD,!@@#Z]_\
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MK7C7*E-VR('9P3C)X3T%:W]BZA9ZYJ&JZ=);!]1MT6>*4G"3(-JN"!R-O!!
MZ"I/$WB>/PS'9/+875TMY<+;1^04XD;[JG<PZX//M6W"[R01O)&8G906C)!*
MG'3(XX]J .9TSPD=*U#19H)8VCT^TEMI"5PTID*L6XX'S*3C_:/IS2U+P?JL
MUEXATVQO;466L.TX,ZL7AD8 .!C@J< CTYX-=M10!CWMAJ;>'(K2RNH$OXUB
M'F.G[M]I7>"O)VL P_'K7,W/@6]-M,MB;&U$VI07QM59_*C\ODA3CJQ S\H
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M1H8YG14AD!B;<(@./+#9'  W;JLW4EK8V?B*SMBL>DVNN6QNHH"0L5LR1F3
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M5$FN4P#LC'F98X)X^<<=>O% '82>-= AGDBDOB#'<"V=A"[*LAVX#, 0H.X
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MY;B*:6=9 %."K9W$Y4J&.<?4UK^!;6Z7PY;ZCJ,HFU#4(TGFD'<; $'_ 'R
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M#ZT\9@W2L @4!?F^7KA0<#/7';);X@\*:[JTFJ%(M-F%U9);VK74[_Z(=N)
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M*** "BBB@ HHHH **** "BBB@ /(J(0(+@S;5W[=N['.*EHH **** "BBB@
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MW223RS% Q6- .%!XR21ZX /'H ;Y(49) 'J:IV^JV=WJ5WI\,C-<V80SJ8V
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MO18]OW-I5@>N1UYYI]O>:G'I?AK6TU6:0ZI+ MW!(5,>)ER?+&/E*G@>W7-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8#;@9QR.G\ZZ5G5!EF"CU)Q6/XF\0P>'=#EU!O+D<;5BC+X\QF8*/P^;)]J
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M=47P_K-AIU_-K6@VLUK+!*@$C^4)-TD(8@B3:J@]#QQWQ7KN!G..::%50%4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4UCCMFG4AH  <CIBEH'2B@ HHHH **** "BBB@ HS14<<0BW8).XYYH
MDHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ I"0.M+3'&<4 /HH'2B@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YYO&NAIKE
MOI$EQ(D]UQ;R-"XBF;.,(^,'Z]/>NAKS3QOYD.L>%_$MD;+4+"UNQ;0VL4>X
MDR<;E(;!(V<=,$4 >EU#=W'V2U>?R9IMF/W<*[G/..!20WMI<7$]O!=0RS0$
M":-) S1D\@,!R/QJ>@#C[;XE:!=VKWD2Z@;&([9KO['(8H6P"58@<$9 _'TY
MKJ;2[M[^TBNK65)K>90\<B'(8'N*^?M%U#5+#X3:ZMM;)+8W.I207,JY+P(R
M(&;'0C&!^->AR3+H7AKPE9Z#J\;:;+(L;%?]?=@\XC]"6R#TVY&2 #0!Z%--
M';PO-,ZQQ1J6=V. H'4DUG7/B#3[74=,L7E9I=3W&V**65@J[B2W0<5X_J>O
MZSJGPI\1B_O;DRV6I_906*J[1EE!20KP>IZ<?45UVIW-]I'C#P180:A<R6]T
MLHF6;:Q;"+CG&>] '1:KX[T#1KR6UO+IU>!@DS+$S+$[*656.,98*<?3G%;>
MGW\&IZ=;7]L6,%Q&LL99=IVD9&1VKRFPFN=.C^)-Q;ZK?&[LY6="[ @':2K=
M.3\NWTP!5VQ\2ZEJU]X5T:35)[22]T@W4DZH ;B8H=HSC&!AF./3% 'J50W5
MU!96SW%S,D,*#+2.V OU-<#J][K-K+H^G7NKK/=&QE,]KIQ9);B50<.'P-J@
MCDEE!(/':N2UG6=4U[X3>'+^[U"=9Y=36VF\HA1* S89ACDC8".V<\=, 'L#
MZU9)K\>B,[?;9+<W*KM.-@;;U]<UHUYU)JFH:1\3#IOVVXO+2#0VN"LP4O(X
M8\D@#DXZ#CVJAH_BG5QI/A'6)]0DGDUK47M[BW<*(PC.ZC:,9&W _K0!ZI17
MBFL^)/$T$7C:Z@UZYCCT>_B6VC"1GAY"NTDKG:!T'MWKUFYU)[;PU+JACWR1
MVAN-B*3DA-V .M &E7/3>--'BUX:.))I+GSDMW:.,LB2N&*HS=CA2?;%<;8>
M)-9L8O!FHW6H27G]NS&&Z@=5$:[V^4H ,@KD#KR!1\.K-H/B+XS0S7$T<,Z
M/,V[+$OR3C[V,CZ$T =IK'C#3="OX;*_CNUGN6"6H2$O]H8E1M0CN-PZXK;@
MF,\$<IBDBW@'9(,,OL1ZUYM\3?\ D=/ '_82_P#:D-=?XK\1Q>'=*FE4*]X;
M>:6",G@F-"Q)]NGYB@#>HKR[P[K7B>[TRTU674($LKK3IMTUW<1G%R%9@ZJJ
M\ 8.5[ $D<57\/>+-2?QGH]M-JDMQIT^EO-<2R ".9TW;I4R RKE>X'0\8H
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MWNTM;:\@>U$3.MS&%)61=R$8)ZCGUKSK4=6O-1T#XA:3>75P;;2Y2;64RD$
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M#ZE;S6:WLDC+<S%U,[/);N&\TCDGS" 2>A->JT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4R0D#(&:?01F@!!T%+110 4444 %%%% !1110
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M8HHM4LWDEC\V-1,N73&=PYY&.:J>&?%%EXFM[F6U=?W4\D83/S;5; 8CWZT
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MMY=8E!+>N<=:LU4TO4K;6-*M=2M&+6]S$LJ$]0".A]QT/O5N@ HHHH ****
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M?3TU'5OMEMIK[[5!;[&+!2J-(VX[RH)Z!<GF@#GK/QWKKZ7:ZG=65BD#:O\
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M@#U^=VCMY)$0.ZJ2JDXW$#IGM7&+XZN'T'POJ*Z>F[6[N*V8>82(=S8)''/
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M &L2PQ!F:-7DVB0 '<H)7A@>HXK8U"32[6Q>2RFO+SPV=4BDU%P%-ML97W!
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MHH **** "H+K_5?B*GIDF,<C- #E^Z*6D'04M !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 4[O2=/OKJVNKJSAFN+9MT$C
MKEHSZ@]NE1:AH.E:K<0W%_86]S-!_JGE0$ISG@]J-0UFUTV\LK27S'N;TN((
MHUR7V+N;Z8%9Q\::3Y>E2*+IUU3>+;9;L22H)((Z@\=.OZT 7U\.Z,D5Q$-+
MLS'<2>=,K0J1(_\ >((Y/O5B+2[""]>]BLX$NW4(\ZQC>R@  %NN/E''M68O
MB[2GT[[8C3L/M9LO)$+>;YX."FWU[^F*SO#5[<W7CCQ6DS7*QQBS\N"=\^5F
M-B0 "0,GGB@#HX])TV%)DBT^U19\^:%A4"3/7=QS^-1IH6DQM R:;:J;?'DD
M1*/+P21MXXY8]/6HM2U^WTVY-K]GN+FX6!KEHH NY8P<%OF89Y[#)]JYM=?6
MV\5ZKJ.+R>Q&D6UT(D.=BDR%F"L0%^51GUQW- '3?\([HOV][[^RK,W;N)&G
M,*ERPZ'.,YI3X>T4QRQG2+ QS.))$-NFUV&<,1C!/)Y]ZH3>,=-2".:!+BZ2
M2Q.H PH.(!U8[B.?;K[56N]1:^\2>$KFRG=M/NX[B7@D*^8@4)'T+=: .@73
M+!+Q+M+*W6Y1/+698P'"?W<]<>W2HTT;2XVN"FFV:FY!6<K H\T'J&X^;\:R
MO";7+7'B'[1-+(BZM(L/F.6VH(X^!Z '/%6;WQ);V6L?V4+2]N+LVS7*I!%N
M#(& ."2!GGOZ8ZD @%I-"T>,VY32K%?LQW08MT'E'.<KQ\ISSQ535/"^FZE9
MW-LMM;P+=RB2Z=(%+R>ISV8_WN2.<8."&1>+=-N;;2I;43W#ZHI>VAC3YRH'
MS%LD!0.Y)_.LG6O&LJZ7;RZ-9SS7#ZI'ITR.H!@?< RG)QDYP#G&3G- '9-&
MCQE'4,C#!5AD$>AK/A\/Z/;PS0Q:79I%,H62,0KM90<X(QC&3G%/U1W;P_>2
M#S8)#:NPPV'C.TGJ#U'L:YCP?XJMQH7AVQO_ +6ES>6@\JYG0[9W5 6&XG.>
M^2 #C@F@#J$T72HYH)DTRS66!-D+B!0T:\\*<<#D\#U-,AT#1K=HF@TFQB:)
MF>,QVZ+M9@ 2,#@D #\!6?:^,M*NKJSA7SD2]D:.TF91LF89Z8)(S@XW 9[5
MJZEJ=II5LMQ>2^6C2+$F 26=CA5 '<DT 1'0-&:U^RG2;$VQ??Y)MDV;O7&,
M9Y/-:"JJJ%4 *!@ = *PAXNTQ$O?M)EM9[*2..:WE4&0-)CRP-I(.[(Q@_E0
MGBJT5KV&\MKNSN[.V-W+;2H"YA&1O4J2IZ'H<T :EOIMC:7,US;65O#/.<RR
MQQ*K2'.?F(&3^-)#I6G6]])>PV%K'=R9WSI"HD;/7+ 9-9FF>*['5+NSMXX;
MJ$WMK]JMFGC""5!MSCG.1N'4=.1D<U7D\8(;:22#2KYRUG)>VV[RPMQ$NWY@
M=_'WU.&P<=L\4 :SZ#H[PR0OI-@T4DGFNAMD*L_]XC')Y/-2R:7ITMPUQ)86
MKS-&83(T*EC&>JYQG;[=*PM+\59T+09+V"X>^U*U$B)&BGS66#S6(P>,\@9Q
MS4H\8V>S4-UG?I)86B7<\3QJKB-@3T+#D;3D'TXS0!L'2M.,EO(;"U+V^3 Q
MA7,6>NTXX_"F+HNE+;SVZZ99""X;=-&(%VR'KEAC!/UK)D\:Z8D$,B1W,K26
M:WS1JJAHH6&0S;F SP> 23C@5.OB33]1A@2Q6XO3=VGVE5MOE81'@$DLNTDY
M YSD'TH TXM,L(&=H;&VC,B"-RD2C<H& IP.0!QBELM.LM-A,-C9V]K$6W%(
M(E0$^N .M<G\*;B:Z\ 6DUQ+)+*\TY9Y&+,?WC=2:MV?C &X\02:C:2VEEI<
MYC,[%",!%/(#$EF+<  ]0.O% '0W.GV=Y)$]S:PS/$<QM(@)0Y!R">G*@_@*
M/[.L=CI]BM]LAW.OE+ACZGCFJ%IXBM[C4H-/FMKJTNKB SPI<(!YB#&<8)P1
MD9!P:V* &B-!%Y011'C;MQQCTQZ5#%86<$<D<5I!&D@PZI& &'N.]8EWXTTJ
MRDN?-\[[/:W MI[D;=D<A(&""VXXW#)"D?D:RKM+K7?&NHZ==6^H+806,8C:
MWN%C,4CESOX<<G: #@XQR!DY .MM]+T^T.;:QMH3Y8A_=Q*OR DA>!TR2<>]
M._LZQ"QK]CM]L9W(/*7"'U''%><Z)K5O>V=QXCU>34[=XM4<0.DX"R@'8EOL
MW$'WX SSNKK(?&FFNUW#*D\-W:R11/;$*S,\O^K"E6*DGZ\=\4 =#)&DL;1R
M(KHPPRL,@CW%0KI]DD#P):0+"_+1B,!6^HQS7%>)_'<UGX5UZ:TT^\M-2T\1
MQNDXC/E>;@))D,RL.>@SR.0*[:UF>:TCEEA>%RN61RI(_P"^210!&FEZ?':"
MT2QMEME;<(5A4(#Z[<8SS4MQ:6UY 8+FWBGB."8Y4#+Q[&L33?%MIJ5[96ZV
MMW M_"T]G+,JA9D7&< $D<$'D#@U9\0>(K7PY#9RW<4\BW=TEJGDJ&(=\XR,
MCC@],T :DT$5Q$8IXDEC/5'4,#^!IX4*  , < "N>C\86!35S<07=L^ELBSQ
M2("[;P"FT*3G=D #KGKBG/XI2'4$T^?3+Z*\EMVN+>$^63.%QN52&QN&>02/
M;- &L^FV,K3-)96[M/CSBT2DR8Z;N.<8&,^E.?3[*5I&DM(':3&\M&"6QTSQ
MS6+8^,++4K#2;NUM[EQJ=R]O%&=BNFS=N9@6Z (2<9/3BBS\6P7LMLL-A>[+
MLS+;2,$ E:/.1][(SM.,@#B@#8DTVQF:W:2SMW-L<P%HE/E'U7CY>@Z>E3Q1
M1P1+%#&D<:#"H@  'H *X&WU^ZU7PEKEWKEA<BWCO71$MY4!54D"A-P.>&7D
MXY!/7I74WNOK:W=Q;06-U>R6L2RS_9]G[L-G ^9ADX!.!V^HR :C6\+3K.T4
M9F0860J-P'H#40T^R$DD@L[??("';RQEP>N3CG-8?_"9V<UU80:?:W5]]NM'
MN[=H=BAU4@%?G88;GOBM30M9MO$&C0:G:+(D,VX!9  RE6*L#@D<$'H: +45
MC:01O'#:PQH_#JD8 ;Z@=:<MM EO]G6&,0X*^6%&W!ZC'3%0:KJ,6DZ;-?3)
M(Z1 ?+&N68D@ #\2*YZ^\>6MCINM7,FGW?G:08Q<6Y,><N,J0P8C'(SW'I0!
MU#6MN]O]G:"-H, >64!7 Z#'2G"*,2>8$4/M"[L<X';/I6!'XNMH[C58]2MI
MM.73XDN"T[*?,A;(#@*3CE2,'GIZXK&BU74+SXBZ+Y]E<:?')8W+".6=7$JY
M3;PI(##J1^IH [B6*.>-HY8UDC;JKC(/X5%#8VENI6&UAB4D,0D84$CH>/2K
M%<M>>-[6UNYU2W,UG;7(M;B=95W*YP#MC^\P4D GCOC.* .G2-(UVHJJO)PH
MP* BJ6(4 L<L0.IQC^@KDIO&MS!J&HZ8^ASG4K=HOLULLP/VM';;O5L8 '4Y
MZ59O_%KVLEY]FTN:]CT\+]M:"12T;$ [47JY .3TH Z:D"@9P,9Y-<?K?Q!L
M=(NKJW6#SGLU1IU:41N=P5@J*>7(5@3T';)/ ?>^-+B.]U&ST_0[B]FL[>.Y
M_P!<B"2-@QW G./NC ZDD\#&2 ==BC%<5'XFU/5/%&A#3H(QI%Y9/='S)@KR
M*?+Y(V\%=QX!YYYKH]:U.32K$30V<EW-)*D4<2' W,< LW.U1W/:@#2Q17'Q
M>/(CH5Q?S6L:3V^H#3I(Q<@Q"4E>?,P/EPP.<?A71Z7>7-[;/)=V1M)5D*;/
M,WA@.C!L#(- %VBN+UCXC6&EZA=VZPK/'92I%<,LZB3<2-VR/DMM!&>G?'2K
M6H>,7T_4+FQDTQVN6@\[3D67/V[KE5PORD<9!]<]* .JHKG+KQ1<6^MQZ.FC
M7$]Z^GF]VQRH%R&"[,DCN>OY UGQ_$"*ZBT9[32[F0ZD\T.UF"F*6-22A'))
MW#&>@'.>,4 =G17"W'Q(AM6DBGT[RKBVACDN[>6Y59(V8;BB#^-@.>W4#KG&
MA?\ C"6'4+BRT[29+V>WM4NFB,HCDD5LXV(02V,<].>* .JQ1D5S">+9+G7;
MK3K+3'G%G=1VURWG!73=C]X$P24&X<Y'>N4TC6+CPZ?'.I6VFM?+;ZLS211R
M;"J;>6'!R!W]J /4J*QH->2ZUV#38(UE#67VN657.(PQ 08(YW?,>WW>G-0Z
M]XBFT?5-)L(-.>[DU"21%VR*@&U"W<^P_#/? (!OT8KCT\='*12:1/'<IJD>
MFW4?F!A"7^Z^0/F!!&.![XJVOB#59IHK"'1HQJ@M_M-U#-=;8X%+,J#S%5MS
M-M.!C& <D=P#I:9)+'"F^5U1<@98X&2< ?B2!7(CQRTJ:+<0Z;BSU"Z^QS2S
M3[6MI@2I0J%.XY4@$'![D=:;XAUXOHVI27.BQW6G6VH0VREK@KYI$B@OC;P%
MDP,9.<'MU .R)P,G@4B.LB*Z,&1@"K*<@CU%<+XUUNXOM"\3Z=I^FPWD%C9L
MEW-+/LV,R%OD7:=Q52&/(]!S2#QBVC:3I>GVE@;NXCTN"XD#.R#!7"JI"-EC
MM;K@<=: .\--CD25-\;JZY(RIR..#7-_\).-4<66GZ8]U,]@+R:"X;RMBMPL
M9R#\QYXZ<<FH/AC_ ,DWT7_KDW_H;4 =4D\4DLD22HTD9 D56!*$C(R.W%25
MP]UXGAT>3QC?6^CH9]->$S$3;3<YC&"3@XPIP.M:^DZ[J%WK\VG7^G1VJM:)
M=V[)+O)0L5(?@ -T.!D<]30!T-1I-%*\J1RH[Q-MD56!*' .#Z'!!^A%<CXR
MO=?AUSP]::2]K'%<W1W&25U,A5'8HVT'Y"!]<@=JIOJE]H%WXHNK'3K>:"'4
MH7N0TGE_*UO!NV  Y/))SC\<T =Q]IM_M9M?/C^TA/,\G>-^S.-V.N,\9J;%
M<G?ZQ%8^,=0"Z;')/:Z(;LS+_K9%#MB+Z94GOR?SN>&?$,OB"'SQ':M;&&.1
M+BVG,BEVW;HR" 59<#ZY'2@#?)"C)./K0.:XOQE:WL6L:=K"Z9_:^F6L<B7=
MCPS+NQB5$/#,,$>N/KQ4TW7-)T/P_<:CHCF[@U+5=L5NZM&+9V10Z,,$@*$9
ML =P .AH ] Q17&VWC:>:'R?[.#7[7R6<(W.D,NY"XD#,F0 %;(P2",=Q5B;
MQ5?V<$D-UH[C4#?+96R>9MBN2PR'5B,A< D\'&,<T =51BN.U3Q?J&C1:Q#=
M:;;M>6%D+V/RYSY<T1)7/*Y4@CIW]:EL_%=ZFIK#K%G:V=K+IKZC')'<%V14
M*[E<;0,X;/!.,'KUH V]1@TV2[L)+^2,21S9M4EDP&E(."%S\S 9QUQR16C7
MG&M7]QK%_P"!M4?3[>*"YOTEBE$NZ159&95(VC&5P3@G!&.>M>CT %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4R0J%^8\4^H;G_5?B/YT 2CH
M*6D'04M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 <WXDLK^[U31VM[-KFTB:4W'ERK$P)4;/F)#;2<[@O4=0>AY[P[HFL
MZ;!X7BN-(=!I]U=B?RY8V5%D+;6'S D?/Z9P#Q7HM5K._M=069K2995AE:&0
MK_"ZG##\* .!M_#NNQ0W%TFGXNK;Q#-JD$$DR 7$3[AM!!.UL,>N!FMSP[8:
MM%XM\1:G?V*VMO?_ &<0CSE=CY:%3D#ZUU>:,T <CXLT&YUFZWQ6;-+#:M]B
MO(+CR98)R3WSRI&W/7IT.:I'0-<:;5?M,8N);O0H['[0KJ!).JON8C((!+^G
M8^U=WFB@#R\>%?$4ND:?I=Q9J]I'HK6AB^TJJ1W.2-[XY==NTJ.<'L#S6OI&
MG:U:P>#H+C2'7^SH&CNF2>-A&?+\L?Q#/J<9P/6NMO\ 4K?3FM1<%P;F=8(]
MJ$C>W3)'3\:MT 8N@07=O=ZRMQ8/;12WIFA<R*PE5E4$\$D'*DX/J*@GL+T>
M/8=56V:2S739+4LKKG>75QP2.,+CZD=LD=%FC- '":;H&M::FA:BMLC7=C#/
M;75IYB_O(Y&W QMT!#!>N,C/3O!JGAS6[BT?5(+%&U&37(-1-GYX \N)0BKN
MSMW84$\_TKT+-,CFBF#&*1'"L4;:P.&'4'W% %>\ADO-+G@P$DFA9,$Y"DKC
MK7$V'AK5KS3O#&EW]G]DM]' >>4RHQE=4**(]I/R\Y);!Z<5Z#4;SQ)((V=1
M(REE3/S,!C) ZG&1^8H X/PSX?UW24L]*FTK2TALIP1J:[6>6$$D +C(<\ G
MC /'-=%XLTV_U'1E_LMHQ?VUQ%<P"7A&9&SM;V(R*T=+U.UUC3HK^R<O;RE@
MC%2I.&*G@\]0:N4 <7J6E>(_$.G"YN(+6PNK6>"ZM+)I!(K2Q-N)=U[-T '0
M &G:GI>IZQ<WVH-IKV\ATF2P@A>9"[O*1N)P2H5<#ODY/'8]E6>^MZ?'K*Z0
MTS?;VC\T0B)S\F<;LXQC/&<T <S9>'M6M[[PI-Y42G3-*>UF8N&"RE$4<9!(
MRG;UJ+2O#>JPW-P(K<Z;9W.GO'<6GFJ\!N6  :)0247EL],\<=Z[NB@#B-.T
M/6HW\'"XLXD71T:*8K,"<?9Q'GWRV3CTQ3M8T'5I-9\17%K;1SPZKI8M4/G!
M2CJD@P01W+"NUHH \]A\,:YI]QIE['INEW[?V;%97=O<N/W;1@[71RIX.3D8
M_.M*UT;7=)UJVU*"*SNVN+-+:]C5O(6-E9F4IA3\HWD8QG@&NQK-UW7++PYH
M\^J:@TBVT.-QC0L<DX _$D#F@#+\ Z%>>'/"-MIM_P"7]H1Y';RVW ;G+#G'
MH:RM2\)ZG?V_BG30L*P:I.MW;W)EZ.JQ[59<$XW1\GTKNE8,H8=",TN: .5G
ML=3U+5M)U2]M(K5M+@FD(,P(>9TVX&/X -Q).#TXZUH^%]5N-;\/V]_=PQ13
MNTBLL+;HSM=ERI[@XR#[UL,%92K %2,$$<&@ *    . !0!P)\+:U9:OJL5E
M::5/9ZE=-=+?7*@S6K/C<-I4A\8RO(]ZV[#3[^+QGJ.IS6B+;3VL<$<GFY?,
M;-U X ;=GOT[5TE)0!YS:^!M5'@NXTF7[(M[%J/]H6S,Q>&0[]P5^ <=0>._
M>K\_AW6M4TEY#;Z9H^H0S17-G':_.HECW?ZQ@HR"&Q@ XZ\YQ79I<0R3R0)-
M&TT04R1A@60'.,CMG!Q]*=*XBB>0JS!%+$(I8G'H!U- '$>(-#\2^*/!>JV5
M\MG;7=S'$L-M#(60,D@<L7(!^;  '0>]=A$+LZ<!((HKK81A6+JK=N<#/;M4
M.BZO;Z[I,.I6BR+!-NVB1<-PQ4Y'U!J_0!Y[HGA?6K75O#^HW5A9K<VJ3)?W
M!NB\L[.H&\G;R.#A<\=.!6WXWT2^UNRTI;!(WDM-3@NW5WVY1-V<'UY%=/2Y
MH X2^\*:GJ.J>*SMBABU$VDMG,SYQ)"!C<HYQN4?A6G_ &)J.J>)='UC54MK
M<Z7%-LCMY6D\R20*I))484 ' YZUU%% '(Z#X4DTWQ1J5[*<V:RN^G1[@1'Y
MP5ICCM\PP/0$^M9FC>'/$=G?Z1=WUKI\UU!=2M>W2W#&28.K*&&5X !&%_+%
M>@44 <*/#VNQ>&M=TA(;.3[1=R36LAF*[UDD+G=\IP1G'N?:M5[75].UF_U#
M3["*Y&HPQL\;SA#%.B[0">ZD8Z<C:?6MK4]0ATG2[K4;D.8+:)I9-BY.T#)P
M*JP:XEQ=Z?!'8WICO;;[0MP(LQ1C (5VSPQSTH Y_2?"%]I&J^'722"6UTVP
MEMYF+D.TCD$E1C&W(]<\U6T=/$/A'2M T=H=.G:2]D6Z2.1W?RI)-V].!@+O
M.XD8X'<ULWOC6RM+JXBCT_4[Q+>4V\DUG;^:HF"AO+P#NS@CG&,\9KI(W\R-
M7VLNX [6&"/8T 97B:QO]1\/75IIDB1W<FP*7D9%*AP64LO(RH89'/-<5<^!
M];N--\46J0Z5;_VO';>3'!(RQQ&/ *_=]!UQR3T';T:[N5M+.:Y=798D9RJ#
M+$ 9X]ZJ:#K$'B#0[35;9'2&Y3>JO]X<XP?RH Y[5O"EYKFK:PUR8H;+4-,C
ML]\<I:1'5F;."N",MCKV]ZCM='\32^(-(U755TJ)=.M9X7,$SMO+*N&P5&!E
M>F>!W-=M1F@#"\(ZEJ&J^'XKK4U@^TEW7S+<'RI5#$!TSSM(_/KT-8\?AWQ'
MIFHZC;:1>6$6D:C<-</(ZM]HMV?&_9C@Y[9Z>]=KFC- '":CX;\1W-Y)K,,E
ME_;-M=A=/9YG$:V@&"LF%R6;+9]\8/ JP= \1V.N75[HUS80PZHJO>QW&YS;
MS!0"\6 -PQV..@^E=GFC- '&S^'_ !)8:]/<Z'JEK]COEC%VE\C.Z.B*GF(5
MQEBJCKQD5FV\>K0?$+6K73?*EE32[6+S[R4[B?FQ(=JG<>N1QDUV&K:[;Z1=
MZ9;SPS.VH7'V:-D4%5;!/S$GVJY'8VD5V]W':P)<R##S+& [#T+=3T% ')P^
M$=0T[4/"TEA<VSQ:3:M:W!G#;G5MF2H'?Y3C)XR.M:_BK1[S6M*BMK.2%72Y
MCF>.XSY<RJ<E'QR0?Z5/K^OP>'K."YN()I4FN8[<>4!\I<X!.2.*UJ .*TWP
MOJ^GV^IQ/_95Q'>ZB+QX'C/ENC( Z$$'&"!M//3GKBMGPGHLN@Z*;*41H/.D
MD2&*1G2%6.0@9@"0/H*W*,T <:_A[Q%8ZS?+HVH64.D:E*T\XFC8SP2, ',1
M'!)ZC=P#VIFL^$]5U>2ZG>[@%S:B+^QI=[;K=E.6=\@@LV!G@Y QQUKM<T9H
M \[DDUN/XFZ?F/3Y-0&AR"9/.=48><.5.W(.<'!'3/UK0LO"6J:9'H0MKFTE
M:TOIKV\,H9=S2JRL(\= !(^,^@]ZZQ[&TDO$O'M8&ND7:DQC!=1SP&Z@<G\Z
ML4 <A=^'=?M/$%_J&@:C9Q0ZGL-TEY$SF)U7:'CVD<X[-QD5G^(?!NM:I%':
M0SV4BPK"+34IG=;RU* !FW*OS[B">HY8^V.ET3Q)!KE]JEK%;3PMITX@D\W
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M-/+I<#O-)YK[LE2_]\+G ;W S4FE:-]@UG5=1(@0WS)^[A4C[F[YV)ZL=W.
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MC\*Z18)<2:?IMNEQ);-;%F9AO0_PL>3CI[\#TJ;PWHD?AW0K?3(I3(L6XY/
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MJ5SIDCQ11QZ?<BZC6.(*WF#G[PZ GDC'.!S6U0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !44Y8(=OM_.I::XR,&@!5Z<TM(.E+0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $,]U;VH!N+
MB*$-T,CA<_G2)>VLC;4N86;9YF%D!.S^]]/>N8\7HC:GI4B7T%E>PI.\,EY&
M&MI%(57C?D$$@@C'8&L;0;B*/Q+X<U*:T_LVVN]!>UBA8$+&XE0A 3ZCH.M
M'=/J^FQF -?VP\_=Y7[U?GV@DX^@4_E3H]5TZ6P-]'?VKV:];A9E,8_X%G%>
M4Z.]G8:9X#?5$2*&.]OP_GQ\+GS2N01TR5.?QIU[:3V_]IZS!;W;:'_;\-RL
M5K&0_EK"RR3*.ZEF4_\  <\4 >K?VC9"-9/MEOL:3R5;S5P7SC:#G[V>,=:8
M=6TY45VO[948L 6E4 E20<<]B"/PKRKQ$MC+I,%_IT-[]FNM:M)OM-VSYG*A
MM[!& *A1@$XY_"MOQHD5G=7DFGR6\=PMAM?3KB -#J$;N[%4VD-OW;N1U+#U
MS0!WLVHV-O<1P3WEO%-)]R-Y55F^@)R:H^(M832=(O98KFT2^CMWF@AG<#S"
MH) QD'G&*\ZU""/^U]=M=>378DU+RI;:WLXBZSCRU'E[MAPRD'J0!UJ_J4R6
M<7C&UOK2:'4+[3%-MD&4R(+8)L5@.=LF_/3J3TH [+0-;2Z\+Z1?ZC<V\5Q=
MVD<S;F"!B5!; /;FM.6]M8H4D:Z@1)!F-W<;6XSD<\UY+9))IIT*[U0ZK;Z=
M<Z##8++:V^\Q2#[Z,I1F&[(P0.<5KZ5''X;UW1WO;"[@TPZ9);69E!E:%O,9
M\/@95VCV< =1M[4 ==X/U:XUSPS;:C=&(S2R3 F(87"RNHQR>RCO6E)J>GQ7
MBV<M];)=-C;"TRASGIA<YKG/AHRGP-9HL4D026<;'B*;09788! XP1TKGI8X
MCX5\4:)J5K-+JLE]/+%&D9WS-(^898_8?+R/N[>: /1I-1L8IO)DO+=)=RIL
M:50VYL[1C/4[3CUP?2I9[B"UB,MQ-'#&.KR,% _$UPNAZ?I]W\0?$\5W'%<O
M&;&2(R8)+QH<N/<-C)]3[UH>-/,M]0\.ZC)"\FG65\9+HJN[R\HRJY'7 +=>
MW6@#1USQ7IFC:!+JPN(+F(,$C$4H(D<D84$9]<_3FJK^*$M_&4VG7-S91:8F
MFK>"X=POS&0I@L3C'RUPWBN%+_3/%>H:7#*]@]Y9,75?EDD1L2.GJ.4!([@F
MNECO+.Z^)LEVS+]FDT!"K3+M!Q,[=#T.WGZ4 =C<:E8VELES<WMO# ^-DLDJ
MJK9Y&"3@TDFJZ?$B/)?6RI(K.C&5<%5&2V<]  <FO*=#U"31M"\':K>_:CI\
M5K-:3/!%YCVTC.,,05) VKCCG'Y&_:6.FPZMX0AMK-[2Q%S>M%'>$EY(W0J"
M0PRN]FX4_P#UJ /0VUO24B>5]4LEC10[.;A %4XP2<\ Y'/N*F_M"RW0+]KM
M]TZ&2$>8,R*!DLO/(P<Y%<-KV@/;>*DM]-MUCM-?L?[.N%CPJPB/'S 8Q_JM
MZCT.WI4WA&.0_:KG5&98="CETF,2$;616#&0_5%B'X-Z\ '36FJP6NC6MSJN
MJ6(9Q@W E"12-S]TG&>E6)-9TN&WAN)=2LT@G&8I&G4+(/\ 9.<'\*\VMKFU
M'AWPO<P:@--U"VLIV@GFBWQ8!4/"Z=<G(QCG@XSTIL=S_94]I<:MI5_::7J>
MD1VB06D)?R7!8O"5(+#(;(Z=,<XH ]6$L9A\X2(8MN[?GY<>N?2J<&MZ7=,R
MP:A;2%8S(=L@X0,5+?3<",^U5] MK?3/#%K MJ]G:PQ'$,[[FC3)/S'UQR1V
MZ=J\^72WE^$MI<0:;+-=V\^Z9(HPL[0I<LY49&??'Z4 >E#6=+:TGNUU*T:V
M@.)95F4K&?1B#P>14\-[:W$LT4%S#+)"=LJ)(&,9]& Z?C7DOB=(=8\$:[?Z
M1I^JR?:?LRRS78?S)&24?*J$9(4$Y;\.<'&QKUO=WGB+Q)%I:OON_#ZK;L@(
M65]SG"MT)PP_.@#HY?$HD\:Z9I5E>V5Q;7$$[S+$0TD;(%QDAC@'=Z#[O>MR
M+4]/FNVM(KZVDN5SNA252XQURN<UP*7]IJWB+PO_ &7#<0HFGW4!*VT@%NQ6
M,*I;;@$$'OQQZC,'A>V4+HUC>66J-K.DRL)/M!<6\2C*O*KXVL"IX ).3TQS
M0!Z%%K.ESX\G4;24F-I0$G5LHIP6&#T!!!/K2VFK:=J%NUQ9WUM/"@R[QRA@
MO&><'CCUKSL:6;_X:WITS37%['>RRM$83')+']H,A1<C.&3;P.O2G:O&OB'1
M=7O-#TB_222RB$\ETLJRR[9 Q@57.&^0.#CC+ 9.: .KT_Q!#JWB40Z=JEI=
M6(M7=XHERZ.'4 EL]#DXX'0]:V;[4;/3+<3WMQ'!&6"@N?O$] !U)]A7+6=\
M-2^(]M=6UK<"T.CR(;A[>1 7,J,$)( R #^9JUXD:2R\2^']4>QGN;. SPRO
M"A<V[2! LA4<XPK GMNH 9XK\<6&A^$I]7LKFWN)F4K:KG<KR9 P<>F<D<'B
MM/0;J:YLY+R35+:_LI KP3QH$*C'SAL<<$?4<YKSOQ99W%SX6\:W-G:7 M]3
MNK7[) +=@\K(4\R0+C.#@\D<[<]Z]6AGC^Q)/D^7Y8?.#TQGI0!4MO$&D7=U
M#;6^I6TL\Z,\2+("74$@D>O0_D:>=;TL7_V$W]N+G.WR]X^]_=STW=]O7'.*
M\\LDE7PQX',=K<0NNKF293"RLB_O02XQP/F R?6G2VUX/A_=>%&L[I];:Y:-
M6^SL$D+3%Q.' VA0.<YR",=<4 >BZGJ,&DZ9<WUP<101LY ZG S@>]<CX:\1
M7.HVMMK=QKMHVGR0_P"E6K1 &&9AN"1L "< XYW$X/X=/X@?9X<U'"22,ULZ
MJD:%V9BI   Y))(KA=.BN[:V\#:C+!=_9-,MVM+V!H&#P2M$J!RA&2 <@GL#
MD<$T =Z-<THV:W8U&V-NT@B$@E!!<D +_O9(&.M1?\))HHL3>G4[86^YTW[^
MZ_>&.O'>O/O$&G7,FD^*+R"UN6AU34;1[2%;=MS"(Q^9)M R =K')Z@9[C.]
MJRG0/&G]L2Z9/<Z7<V)M6^R6_F%)3(6)9!R0PZGU SUH ZN35M-A@BGEU"T2
M&92\<C3*%=0,D@YY&.<U9BECGA2:&1)(G4,CH<A@>A!'45YA+9W%AJEEJ%UH
MNJ6NDW-B;..VTT,9+3]XQ"NJ\_,I7D=&R*[GPS8#2_#=M:0V;VT<0;RK=WW,
MJEB5#$_Q8(SZ'CM0!8AU_29[R2TCU&W-Q'NW)O /R_>QGKC'..G>HK/Q-HNH
M36T-IJ4$TERK-"$.=X4D''TVM^5>=^'X;T:UX0NY;6_C@A^UH]L+%TBLRR?*
MBY7<W?+$D<=NE2:78W\/AKP7;MIM^LUOK;RS(;60&*,R2_,W'RC#KU['VH Z
M3QQXH33=*=-.U2.&^2YBB9 F\MN90R9Z*VT[O7 KKY98X(GEE=8XT4L[N<!0
M.I)["O+KJWU.'P?J?A^?2M0GU'^U1*LT=N\B3(UPLGF;\8^[P1G(QT].T\;:
M9=:QX+U:PLL_:98#Y:@X+$$';^.,?C0!++XJTD:3=ZA!=I-';)O8*#GD$KQC
M.#C@]*XN]\6:KI_A;3]7.M!I=3CA7R9[(*MN\A4LZ$ 955; #;LX!R>0;5K%
M'<07VIVN@ZS;2-IDMO,VHM<S3EFP4CC5F8L =Q) ],=Z34X;IOAUX7M5L;YK
MB"6Q\V);20O'Y>W?D;<@#!^O:@#?TS7(-/66'5?$$-X699(96A\MDB? 7S-H
M"C+9 ) [5JW>OZ58W+6]S?11RKLW@GA-QPNX]%R>F<5Q.N6.SQ/K*7^@:SJ-
MIJB1- ;":58F(C"%)@KJHY4<MV--LX-4T*]UG3[_ ,.SZI_:TRW$#P*)+<-L
M4;)&;&Q591@GM[B@#I]/\86.H^++S0X-Q-M&A\PHPW2'<67D= J@Y[Y-=!,9
M!#(8E5I0IV!C@$XXS7'Z.+[3_'?B%[RPN6%[!:R1SPPDPL8XB' ;L=W !YYK
MJK"Z-]I]O=-;S6QFC#F&==KQY'1AV(H Y:>?7[37]"TR;6%)OX9FG9;9/E>-
M5/R^Q+'K6F->AT2VCMM>OE:] DD9H8&;]T'(61@@.P;=N2<#.>>*IZSYTGCS
M0)H[.[>WM$N5FG6%BBF15"C/?IVX'>LG7M(EA\87M]=:#=ZQ8ZA:QQ(+67!B
M9 P*NN5!5MW4YQS0!TUWXOT"RDECGU.'?%$LS*@+G8W1@%!R,'/';GI4LWB;
M1X+"TO6O-T%XN^W\J-Y&D7&XD*H+8 ZG''>L#1[.6PU^!9=(>WBM]'$!,,;2
M1(P;<8T8\MQQ[FL33+74K/2/"=A-H]^K1VD\,TUO%^]B8[?W9+<(K<9;VX(Y
MH [B;Q3HEO%9R2:A'LO8VEMBH+>:H7<<8'IVZGIUK-U7QQ8VFDZ?J%AYEW%>
MWB6RE;>0X'F;7R ,@@!L#J2.AKE_">F7UI8^!(Y]/NHS927OV@-$Q\G<75=Q
MQQDD?SZ5)!:ZA9>'4E.EWTCP>)#=F%(#YC1-(2&4'&>&'T[XQ0!Z++J%K!IS
M:A/+Y-JD?FL\JE-JXSD@C(^A&:KVFNZ;>F<17.UH(UEE69&B*(PR&(<#C //
ML?2J/BL7EWX-O5M-/\^YEA %K*BN<$C<"N<$@9XSC(KC9-"U.[O];M;>UU,'
M5-+B\JZOL;1(C.2CX.$!R!L4=">,<T =3J7BJQO?#VL-I&H%+ZWL)+I T3(^
MW:2KJK@;E./O#(JUI.OVC6^FV,]P\FHRV$5RZB-V^4K]YF P,D'J16#>3ZIK
M>DW\C^%VLK@Z5-;222QJTSR,,+%$5R2F>23QTXX-1^&)+W0]66"73+V6TU&W
MA=K@6LFZWF1%B,;\?=_=D@]LYZ$&@#=MO'7AZ[EL4AOF;[=(8[=O)<*[!BN-
MV,#)4XSZ5<O/%&C6$TT5S>A# ZI,PC9DB9ONAV VK^)'4>M>966C:Q%X!\-V
M#:3?+=6.O+<3Q^2<K&&9BWN,..G?([&NH%OJ.G:5XFTBXTNXO#>37$MI)$N]
M9UFSA6)X4J>#N[8ZT =*_B;24U&ZL&N'^U6L'VF6(02$^5P-RX7YAR/NY_2E
MB\1Z7<VEA<PW+F+47\NU80/F0X)Z%<@8!.2,8&:YK4O#NJ6K>'FTV0F[%F=*
MN[@ !EC* ^9G_99"1[L*7PEX=O='U^_BF,PTK32Z::C;F!28B1L$]=N-O<\F
M@"SX2\2 ^$+*\UF\9[FYNYX$.PLTC"5PJA5!/ 'IP!6V?$>DC3(=1%V&MIG\
MN/9&S.[YQM" ;BW!R,9&#Z5YW9Z7JUOX8T6230KNY%A?W(NK'!CE9)6++(AR
M,X#8Z\Y([5IKI]YI[Z7KEOX<DAM8;Z6:2QBS)<JDD>SS&!)W/NYPN>#WY- %
M[PMXK^T?\)3=:E=R&SL;\B.26,HR1[0 NS (.1TQDD^M;L'BW1II+F-KEH)K
M5/,GBN(FC:-<9R01P".GK7GNHVUZ?"7B]Y=(O+>;4=6BDLQ*JAY<R1A %SG(
M()Q[]>N+%U:7GB'3];L;BTOK?7=8MXRANK400L(&#!%(=\'D\D]Z .^@\4Z/
M<)=E;IT-G$)ITF@DB=4.<-M902.#T!JQIFM66K-<):M*);=@LT<L+1LA(R,A
M@.HYKAX+":\M;RY'@J:%7M3:7$%Q<_OK@,Z\1L6("J-S9.,G&,<FMKP7%J44
MVII<"^;3%:-;"34$Q<$8.]6S\Q . "W;N: -2\\4Z18:DUA<7#B9#&LI6%V2
M(R'"!V PNX],U%J/C+1-+GO;>YNF\^R17GC2)F95()W8 Y  Y(X&1GK7(>+[
M#4[Z\U^/^Q]2N(/,M'MS8A8UE4;-S,0P:1QA@ <A>#@<&MBY-W<:EXED.CWZ
MK=:5#%%NB4[G ERO!()_>KT]#Z4 ;U_K]C;HD:RSR236YN$^R1&5A'Q\^ #Q
MR,9'/O5'X>WMSJ/@+2;N\GDGN)8V+RR-EF.]NIK T*QUS1;FPU&'1+B[CFT:
MWLYX1+'%+!+%D<AV *G/4&NB\!Z9>Z-X*TS3M0@\FZ@1E=-X;'S$]02.] %F
M+Q3I<NJIIPDF$TDTD$;-"X1Y(QEU#XQD8/Y'TJ&7QGHL-Q+$TUPPBN#:-)%:
MR2)YPQF,%5.6YZ5R$&FZY-J^CW5_HEVTUOJ\LER\4J+ H/F!6CCW?=Y5BQ&X
M\\G-4K349+.74IYM'U:31XM;GU$3VL:/&P1CEMY8$KE2V /;.* /0!XKTMKQ
M[8--NCN3:R.T3*J.(S(<DXP-H/-.L_%&EWLT$2RRQ&X@:XA:>)HUDC7JP+ =
M,@_0YZ5C:?H^HWG_  E]O>0300ZJ[?9IY'5LHT0C'R@EAC'0@<5GZ7X>U">T
MBL[CPOI&F3QV\EO-J$:HS/NB*@Q[1N&2P)R>@8=\T =';^,='N)77S98D%LU
MW')+$52:%?O.A[@>G7&#C!J[IFN6VJR-'%'<12+"D^R:/:2CE@K#MSM/N.^*
MXS2M&UI=/2WG\(:3:3V]O)%/.AB_TU=A41H5^9 YVEBV/\-CP?IU]IUY=QK;
M7MIH_E1BWM;Z59'AD!;>J,&8^7C;C)/.<<4 37_B2=?%,NB16ETD:6#3-<K"
M2 Y8!,'H!P^21U'L:ROA]XJ%QX9T&UU.:[EOKU9=MS,C%9&#N=N\]6V@\>U:
M^HV^IQ>*Y;JVTUKJUN=.6W,JS(OENKN>0Q!((;C'<=NHYG1= UW3- \&6LND
M3/-IEW++=JDT/R*WF =7Y^^#QZ&@#J[7QEI-YJB6,33DR2O!#.8CY4LB#+*K
M>HYZXZ'%,\*>)V\2+?N;6:%8+N2%-\9'RK@8)R1NSG@5RL&D^(DO]*O+W1;F
M6ZM]5>21HKB(0B)EE5?+C#  ?,I8L Q/KVZ+P5I]_I']L65Y9O&C:C/<13EE
M*RJY!&,'/3KG% $LGB&2Z\87/AM;>ZAC%D)/M*1D-N9BN5/0* #\WK].:?A+
MQ1;MHWAVQNC>-=7UJ-MQ+&VR20)N<;SU/4^G7'2KEU::G;>/AJMOIYNK*331
M;.ZS(I1ED9\88C.<@#MGJ1638Z9JT&F>"X9-$N/.TN0"Z;SX?W:B%HR?O_,"
M6!XYPI^A -]_%VFI<PQL)Q;S77V..[\O]RTW(V@YSU!7.,9&,UO5PFEZ+KFG
MJ=);2;"6..Z,L6JR,K?NC+NP4(W&3!(STZ')[]W0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !3) 2.#BGTU@3T.* % P *6D&<<G)I: "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :S(.'9
M1GL33JX;XB:78WUUX6:ZM(9F;6886+H"3&5<E2?[I(''3BNOO[RWTC2KB]F&
MRVM86D<(O15&3@#V% %#4]$EU#7])U,7@B73F=UA\K/F%UVG+9X&TGMUY]JV
M:YBS\637%ZEO-I9&^P-XK6TIF&X=8CA -^.G/-58/')?4;BPFTT"Y@TEM2>.
M&X$C*0<&%AM!#\C\Z .QS17(GQMY?A]];DM(I+)H(7@:WN#)YDDC%#&25&"#
M@'Z_A6GHNOMJM_=6KV;1>3'&XE5F:-]V<@$JIR".F.F#0!MT4R:3RH9) C/L
M4MM49+8[#WKEM+\:F^UBWTRXTX6]S-9->&(7 >2'!^Y(FT%6P0?S':@#K**Y
MWPWXG?Q';V=U#9Q"VGA=Y'CN-YMY%*CRG&T8;YC_ -\GV-7-8UB32IK9%M5>
M*42-+<S2^5#;JH!R[8.,D@#C^5 &M17%6'CY]57P\UEI3$:REPR"2<#RS#D$
M'CH3CGWZ5&?B#-'8RWT^C"*VM]2.FW#&[!*OOV[E&WD#C.<=>_6@#N:*Y+4_
M&ZV-_J5M;V#77]G[1*%=@[L0&*HH0Y(!'4@'/6B]\87T%WK4=OH@FATJV6YD
ME>ZV;U9"^T+L)W<8QT]QW .MS3(IHIXQ)#(DB$D!D8$'!P>1[UC2:W)<:D--
ML;.*>;[&+J433[%4,2$7A6R3AOH!7*^#_$<>D^$O#6G&WW2W-O-*6+$)&B/@
M]%))RP &* /1LTU)$D+!'5BAVL <[3UP?S%<M9^,GOH=,2/2Y8[^^N)(?L\[
M% BQC+ON*_,N,8P.=PZ<XB\!>8'\3^;;QV[_ -MS;HXVW*#Y<?(.!G/7H.M
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M22&&4X1P%)(/!XQ7*R^,+BTT[1MO]G6;7FF1W$*W",D,DI4'R5?(5.V,YZT
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MH_%.M:A=>$_&>E:E#;K<6$$962 '9)'(,@X.<'Y6[T >C12)-$DL;!XW4,K
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M:2/;&8]S-GYB02>W-==61J6OQ:7JNG:?):74DFH2&.%X]FT$#<<Y8$8 )Z4
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MIJYX6\0OXCM+Z=[3[-]FO9;0+OW;MF.<X]2?RK=R,XSS0!@V_AR6WDT1UO\
MG2H&@ \G_6J55>>>.%7IW_*LZU\"+'H]YI]SJ!E,]X=0BGCA"/!<$[MZY)&
M1P/3().:O'Q%=+J'B"W-@NW2H(YHSYW,^Y6;T^7[N*=<^(9[?P-_PD0LUDD%
MB+MK=9,#!4,1N([#V[4 0W/A2>_2]DOM3$MY<V)L!*EN%6.,GYB%+'YFSUSC
M@<4^\\)I<Z)I-C'?S6]UI7E_9KR)1N!5=IR#P05X(K9TZ[-]IMK=E0AGA24J
M#G;N4''ZU9!!Z&@#F+OP7'=::L9U2]345NOMBZB&'F"7&WITV[?EVXQBH_\
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M,UQI5Q?+XCG>226TN=(&U9&?)!G*#@9P6WG(Z#M7KN1G&>:,C.,C/I0!QX\
MQ[;B-=8O8H)M2_M+RHUCXEW!@"2I)7< <>PJ_<>%%N/^$@#7KJNMJJ3X09C
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MFOHQI]Q<VTD4QC1F&'R"0,X)%9?A37WUSPA9:U>B&W:X5F8*<(N'(')/H!0
MRW\'6-I-IDMO<WD;6#O(H608FD?[[R9'S,W//N<8I-4\'6>IS:@_V[4+5-10
M)=Q6TH"2X&W)!4X)7 )&,@"NBR",YXK*T2[NWTF.35KFQ>Y,LD9>U;]V<.P
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MLO\ Z":L6UG;6?F_9H4B\Z5II-HQN=NK'W-+=6L-[:R6UPF^&0;77)&1Z<4
M<9X3"GX-VNX @:;)U^C50CFO-)U;PVUG<7,K7>B2M+ TI*2O%$A0A3PIR3T
MZUVL'A_2K;29=*BLT6PE4J\&XE2IZCKP/:FIX;TB.XLITLU$MBGEVK;VS$OH
MO/ QQCTXH Y'P[J,MSIOAS4SXC\YYW\JXB5FE-P[C+(5)PA4\Y X /:M7Q3_
M ,CAX-_Z_)__ $2U;-CX:T33=0EO[+2[6WNY<[Y8XP"<]?IGOCK3M0\/:7JM
MU#=7MJ)IX?\ 5.SL#'_NX/'X4 8?Q"\0R:/X9OH[&5X]1, E1D0GRX_,1'8D
M=,!S@^Q]*YZ]U/4]+M=2GN?$T*QR:8KQ&P22Y$6)%42YD8\L'Q]X9QGJ":]
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M">>P_M"UC6YM+A]UFZLF8I(LA2C'N/\ GIT/%=9)X6T26PEL7TV VLTHFEB
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M:-1_M$:?:B]P1]H$*^9S_M8S0!Y'B*Q\-_VM%)(+Y/$[QPR"0XC5IOF&.A!
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M3)IUE-=1W4MG;O<1#$<K1 N@]CC(ZFJYT#1S"(3I-@8@Q<)]G3:&/4XQUX%
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MDB:SU&VGUB7)/R7EG< ,&Z??CPN.<8!'I7I(15)( !/7 I!$BL6"*&/4@<T
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M #ATI:0=*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0TM%
M.E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$Y+#*KN*J<$\@=S6]8>'=+T[3)].@MMUI<%FFCFD:0.6&&)W$]>_OD]ZU**
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "FN^Q<X)^E.HH !R**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** *][9P:A936=U$);>=#'(A) 92,
M$<5)!"EO D,2[8XU"JOH , 5)10 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4R7_ %3?2GTUP60@=30 )]Q?I3J11A0/:EH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "FNQ5<@9IU%  .E%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 444V090@=<4 .HI%X4#VI: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ I#P,TM-==Z%<XSWH 4'(S2TBC"@>E
M+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
D !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>stamfordsecondleasemodif005.jpg
<TEXT>
begin 644 stamfordsecondleasemodif005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JW?^LA^I_E5JJMW_ *R'
MZG^5 %JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ95 C=MO(7JR@NN3QUZ4 =;1110 4444 %%%% !1110 4444 %%%% !1110
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M/5+QG#,Z@*^YPWW=I&,?Q''>NYHH \T@\'ZQ87&ER7>E:?K_ -GTYK9UN9@
MC&4N-N]&SA<+G K6;3M9M+W1;_3O#UE"+6"YADL4O B1^8Z$%6"8/W2<8[UV
MM% ''?8?$<5OJFJM86$]]>R1JVFM+N0VZ*5*;R -YW,<D$=L4GA[PE)%II%T
ML^E%KN6XBL[&]8+"K[?D)& W*D^@R<5V5% '%1VGBG1+>XT;2-.M)+>6:9[;
M4&N0OV<2,6&^,J2Q4L>G7 K,\1>#=5UG4[JT>V1K:_2W6;4(KIHON ;VDASA
MWX^7 P 1GI7I%% '$ZGH^K:KXFLY;C1K/=9WR2P:K',%*VZG<8ROWBQR5/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %5;LD20XQU/\JM56NAF2'ZG^5 %FBBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *K71Q)#]3_ "JS56[_ -9#]3_*@"U1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %5;O_60_4_RJU5:Z&9(?J?Y
M4 6:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO<?ZR+ZG^
M56*JW9(DAQZG^5 %JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU0 4444 %%%% !129I: "BDS533=6L-7AEFT^ZCN(HI6A=X^0'7J,]^O4<4
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MBB@ HHHH **** "BBB@ HHHH **** "H+@XDB^I_E4]0S?ZR+ZG^5 $U%%%
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MI!X:M;.\CD76+37HY[T-"[,N9LF3=@_*5V@'// KV!YXHK9KB214A5"[.QP
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M7,<Q=4"LF] , M]Y>2![57L?&AO]2@TY+*-+NZM&NK>-KC+*!C"S#;F,G/\
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M?..2,@_*<#!S[4J>)UU>*TBTK3UO)+NQ%Y)%/,(A'$P^4,<-\S'( QC@Y(H
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M6@P)IOG->W]S; )(%6)]\K =.GRD9QP!GVH ]&M[>&TMX[>WB2*&-0B(@P%
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M^SPQWT2EO,+[5V]?O'&"*DM->2Y\27NB_99HY;2%)C(Y7:X8D#;@GT/7'TH
MY,^"]:;3]=M$.FVZWES;7=LD>X11O&8R5P!POR8R.OH.E:=SH?B:'7EU?3+_
M $])+JW6*^MYT<Q;ESM=,<Y )&"1G'Y=AFLFZUZ&T\1Z?HLEM/YM\DCQ3#;Y
M?R#+ \YSR.W>@#%'AC6+'5)+FPU&">.\LTMK[[8K;V= 0)5([X)^7@5I^$-$
MN/#GA*QTF>6*:>V1@73(5B6+=^>]:E_?VVF6;W=Y+Y4$>-SX)QD@#I[D59S0
M!Y]IW@K5K.RT6U8Z>JV.K/?R>7-(1L;=\B@IDD;SU/8>O'0^&]&O-)NM;FNV
M@(O[]KJ,1,6VJ55<'('/R_K7049H X/5O!VLW5KXHM;.YLUBUB5)4>1G5DP$
M# X!XPI]<Y[5<U7PE>:OK>K3S26Z6>HZ2+ E68O&X+$/C !&6Z9'2NPS1F@#
MG= TWQ#;F ZYJ=O<"VC:)%MD9/.)(P\F>,@#& ,<D\\8COM U"[U_5=05[94
MN-*-A"I=L[LLP9N.!ER.,]!USQTV:,T </;>%?$&E1:+<:7J%DMW9V"6%U!.
MC-#,B\A@PPP(.3T[_GE:TE[9^+-)MI-4T\W=O8S7#W6H2O )'D?&U2K [1T"
M9(  )R<5Z94%U96EZ@2[M8;A0<@2QAP/SH XC0]-NK^QTV>R@L+631+ITMFM
MI&:VNHF3#A6(+#DXW8/*GK4VL^";S6+'6Y6N+>+4=2DMG"@LT42PD%5S@$Y^
M8YP.O3BNW1$B0(BA448"J, "G9H YR[T75;S6K*^:[MXC#8SVS/$I#+))M.]
M0<C *#@FLC0_!FI:9K.C7TKZ8HLK:6"?R(V#S,V/WA8_>8XYSTYY.>.LU;4)
M=-L&N8;"XOF#JODVX!?!8 G'MG-7LT <=-X9UF?0M+T^2ZL'DTZ\@N(I"CC*
MQ-E0>>I&!GZ^O$I\+:A VMVMI>P?V;J[O*Z3(2\#R#$A4CJ#U .,&NLS5+2[
MZ74+1IYK&>S82N@CGQN(5B W'8@9_P YH Q;+PW=:7X@2]LW@-I#I<>G112,
MV_$9)5B0,=\$8JYIF@+!X.M_#]^R3QI9BTE* @.NW;QZ<5MYHS0!RT'AJ^FM
M]&L]3N;>:VTJ=)HWC5A)*T:E8]W.!C()QG)'O5W1-(N].U/6+JX>!EU"X$ZK
M&22F$5,'(Y^[G-:&H7D]FML8+*6Z\VXCB<1D#RE8X+GV'?%7* .3O/#&HR:W
MKEY:WEJL&K6B021RQL64JCJ,$' 'SY/!Z8]ZAT_P?>6)\)?Z5 XT-)4E&TCS
M=Z;,CTP#GFNRHS0!Q*^'->2VNX6&D7$%SJDMU+:3[FCEA<?=)*$A@V""!_\
M7U_#>A3Z)X9_LR296?,A149BD*L2512W)500 3Z5OYHS0!QDOAC6=4T73-+U
MBXT^5;26&22XCC;S'\L@_+G[K'&"1ZGUJ2/PQK5G>:G#8ZS''I>H7)N&4QMY
M\!8YD$; XY]3TSZ]>OHH XQ/"6L:?J-]'HVL16NDZC.;FXC>$M-"Y(W>4P(
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M"&$AEQO3:?X?E4#))^4=ZL2^$[J2\TBZ?5C+/97;W<SS0Y\YF79A0& 0!>@
M/KZYT_#.MCQ'X?MM56 P+.7Q&6W$!79>3_P'-:U '+:YX2EUV:5;J^C>U:XC
MGB5[?,MMMVY$3[OESM/4'[QI;OPM=2+JMG:Z@L6G:LSO<H\1:2,NH5_+;( R
M!W!P?7I749HS0!RUOX3GM+W5I+>]@2VO;&.SBA-N281&I5#NW_-PQR,#/'([
MZ%GH"Q>#X?#UY*+B);(64DB*8]Z;-F<9.#CWK9S7.^(O%<6C^']9U&S@-[-I
M;+'+"#@!B$/)] '!/T- %>S\+7[#2X-7U1+VVTJ436VR#RWD=050R')^Z">F
M,]3Z4S_A$=0&FWVGC6P;:>]-U"C6@_<@S&8KD,"V6[Y'':NK5MR ^HS3J .:
MU/PF-8N-7^V7@^S:C;10&..+#1F-BR.&)/(+,>GIZ<PR>$;Z\T^]M]2\03WD
MMQ9M9H[0*BQHWWFV@\L>.2>U:/BK7I/#6AOJBV?VI(W19$\W80&8*".#GDCB
MHD\2/;:Q9Z7JU@UG<7N[[,\<GFQ.5&2I; (;'/(Q[]J -JW69+>-;B19)@H#
MNB;0Q[D#)Q^=<4?A_=?V!INC+J\7V?3]0%["QM#N(#LP5COP>6/( ^E=SD9Q
MWILK.L+M$@DD"DJA;;N/89[4 <;J_@.?5I-?D;55B.J2VTBA;<XC\G@!OG^<
M$=>G--/@.Z==:#ZRH.JW$%Q(RVH^5HR#@ MT) ]P.YKH/#&LOX@\.VFJ20"!
M[@,3$&W!<,1C/?I6OF@#*MM'DM_$M[JYNPRW4$<)@$6-NPL0=V>OSMVK5HHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H)P3)
M%]3_ "J>HY!ET_&@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT?5KY;R]L_,G">6661TWKUVN%(#CV;-33Z%IMSJL6IRVP-[%'Y22AV!"<Y7
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MVBVMI"(H5)(49/)))))Y))).:HWGAC1+_5(]3NM,MY;U,8F9>3CD9]<8&,T
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MKTK3].L]*M!:V%M%;6ZDD1Q+M4$]>*P-)\,>3KVKZAJ5EI\INKL7%O("9'C
M55 .4&/NYX)Y/XT <'XCU6]FT_6KD7ACO[33[0RM-*8FM92FXK"H.2S;CN)Q
MV'.*Z#7)[OPOX@M=<LHIKF/5;4VKP+N<&ZVYB('0;B-I/X^M=M=:)I5[/)/=
M:=:S321>2\DD0+,G/RY].36<FCZC-K:/=7%HND6<@DLK2"$JV0FT%VSC RV
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M"0COYC>:K@]9!\N.V.G.:/#]W%>$3WNJN->@U:19+6 9N7^8IL(9L&/9@Y
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M7(/!P3T/:N#N="UVZTN_-M'?7=O9W-I=V::@@CN)_+R7A9AAF R,$]\XSUH
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MI8H<%RB[@=H) )Y'>L^XM[YKWQI*-,O"+^TABMAL'[QQ&R$#G'#,.>F.<XH
MZ:^\1:;I\PAEEDDD\L2N((7E\N/^^VT':ON>N#CH:MW3&YTJ5[.=LR0EHI82
M&)XR"O!!KA+C1[ZTUT7LOAIM5M;W3H(F59$5X)4!!5@6 *G/49Z5V5FMSI_A
MJ!3:1BZAME'V>W'RAPOW5&>@/'7I0!P1\6:A:>!+/6!XBBN-;=4<Z=(L1\YB
MVWRPB@.#UZ=Q7:7GBS2=*C U2=K686HNI(S$[;$RJD\+V9@/6N/ET>]N_AG'
MHC>&)CJWD;5++$BQRELEP^[C!Y]3716UA?P^*](:YAEGCM](>VGNS@JTI:(^
MN>=C'..XH U)O$VD02,DEY@+(L32>6YC5SC"L^-H;D<$YYK$L]?-AXN\41ZI
MJ#FRMC9K;(RY*M(K':BJ,L2<<8)XK/DTB^B\)ZUX9;3I9;BZN93!.J?NV263
M<)"V< IN)P3GY!52_P! UI/&NJ>(;/3I)I+66VDM8I& 2Z"Q/%(!\W##?E2?
M2@#N+_Q'I>FB0W5PZ^5&))0D+N8E/0OM4[!_O8Z&J]WXPT.RF\J6\);9'(/+
MC9PRN0JL,#E<D<CBN9U'2KY/$U]J3>&I-8LM6MXLQ/,B/;.J%?+8%L;3P203
MC)Z]]71-/OK;Q.INM/CC@BTB"U66% (A(K,SJHSD+RN..U '75D^)YI[7PMJ
MMU;3/#/;VDLT;IC(94)'4$=14^F7ES>QW+7-D]H8[F2) YSYB*<*X]B.:@\4
M137/A75;6V@DFGN+26&.- ,EF0@=>G)H A\'7%S>>$=+O+RYDN+BYMHYI'<*
M.64$@!0!BI7\2Z8E[]E\UR1<"T:01-Y:S$ A"V,9Y'X\=:P]&N=9TWP7INF0
M:+=KJ4-M%;YE">6C<*6)#<@<GWQBL+4-%URYOKB631[N22/6XKF-HIT2$P+(
MN&6,, SD EBPS[T =C<>,]"MOM'F7;_Z+,(+@B"3$#'&-YV_*.1R>#^!HU[7
MK.TM[ZR%Q<)=I:M*[VT+2&!<'#D@$#GMU]L5R^M:1JMWX6\764.EW#3WNI++
M;KE/WB?NN1\W_3-NOM6O>+K5CKNKR6VCO>6VIVJF)XY$!CE5-NV0,PP#UR,_
MC0!B)J>IHOPW/]I73+?1@W2L^?./E!LL>IY8]_3N*[%_%&EI<F(RR^6)_LS7
M'DMY(ESC87QC.>/3/&<\5RJ>']9:'P"3ISJ=(4+> RQ_N_W83/WN>F>.U/DT
M#5#X.N_";6+.TUT^R\#+Y7E/-YAD/S AE#'Y?51V- '1MXNTP:H^GJMV\T=T
MMK*5MVVQN5W L<<*1WZ=^G-9-QKT6J>*?#0LKB_2VFFG/W"D-PJQ/AL_Q#(!
M'8@YYJ73-&OVU;Q>]U:O;0:FZBWD,B-N41>63\I)'3//K5*PM?$@/A2&YT-(
MQI;%+F47,>TCRFB#(!V(.<<>F.] '6ZKJ]IH\$4MV[CSI5@B1$+-)(W10!U/
M7\JH-XOTE+%;MGG5#>?82I@;<DVX+M;CCD]3Q47B^SU2]M].CTZ!IHUO$>Z6
M.18Y?* .=C$C:>V00>>#7+C0=<30]1LCH[AFUU+Z/9<(X:+S%<G)(/ 7'/))
MZ4 =E'XHTIDU)I)G@.FX^U+/&R&,$94\CG(Z8ZUBVFJ7%S\4Q:A[Z*U.C-,;
M:?*IO\U &"],X./;D<<UEZOX3UO5-3\8R0Q""._2T-FTDJ[9'AP3D D@';CG
M'!K5TZUUV[\>6^M7^CBRMQI;6K@W*2$.9 _\/;B@#4UO3;Z\GDG75;FULXK8
ME8K9@C-+DG<S8/&,#'UK'\+W.I2^&=&U^^UMVMS;M+?K<A NW:<,I"@@@@=3
MTS[5U.K2R0Z7<&*UFN9"A58H0-Q)&.Y _6N3TW0+^^^$O_"/SV\EG?"S,&V4
MC[XY'()^4G _.@#;D\6Z7 MV;C[5 ;6V%W(DMLX8PG^,#&2!W].^*32?%^E:
MS-%%;M<1M-;_ &F+SX&C61!C<58C!QN&<&N9&FZO=^&]85O"5AI-U)ITUJ$M
M/+:2YD==HP1C8F><$G.1Z<VX;36([[PX8]*E5K/1987=RAC29DCVHWS9ZQD'
M'J* -JS\8Z1>R%(GN,_93>(3;O\ O(0<%DP#N[<#GGI4>F>-=,U:XM8K>&]
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M9RA=&8$K['@U)X\O]3U;PCXGDCEMX-,LW^R^2T6^29E9,ON##8,G &#TSWH
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MVJ&/4 9/3I^%<7_PFNIP>)]-L[A;9X+V^EM'AAC+>2%)V'S@=I<\$KC(![4
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M-QL+ 8/7KQBNJ9E099@!ZDT%U5=S, /4F@".VMH;.TAM;>,1P0HL<:#HJ@8
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MJ<A@1D8-:4=S;S6ZW$4\3PL,K(K@J?H>E.26.1G5'5BAVN <[3C.#Z'!'YT
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MOWCTJM:>"IK/4M*OTU=GGT^P%BI>W&'3YN2 1@_=Q_N\YSD=3*[M#(+<QM,
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M)"@   <GZGK6L'5\[&5B/0UFZ-?7<VF))JYLH;PRM&R6\NY 0Q 7)[],CUH
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MB$6KW$ES;W-I)YEO<VLFR2,GK@X/![C%;-0W-W;64)FNKB*"('!>5PJY^IH
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MV " '>AQO;YN!D=2?:N9GU>QM?!?A.6XN+>[CM;X^9:O*@$@59  6<X4J"K
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MG98T4N<L0H&XXQD^O %."@_,,?6@#DOB@ZK\-]9W,!F-0,GJ=ZUB:_<6UO\
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M;6+^TUR^NHM>CU83PV\,,?F3#>#"4<H3MQ@'Y@  <XKU>."*--D<2(N2=JJ
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MCW43;%=$#' +#YCMYVCJ0.H%>:7KPRP_$0*TDWVBTLY87:W,8D."-R+@8&<
M=SC.3UKVVDQSF@#SRXCM8]>NK+2%CM]0N_#SI%Y \O=*<E.1P&ZGUQ52SO\
M39_$W@C[!;RQK:Q7%O.@M73RI#$@"MQC.0:]/IAD02B+>OF%=P3/)'KCTYH
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MJ* /(;5(Y+>W#6<Q!\727*A[5QB D_-@KPO*_P"14FKKY?A_QR[1S1YU6&2
M&)@LIS&% &/F4LI!QFO6JSM9T>#6K2.":6>$Q3)/%+ P#HZG((R"/S!H Y?P
M?=V5YXHU>^DE":G?QQL;86TT:K'$-N0TJ(6)+<X'''UKN:R;/28(-5-W/J%Q
M>WR1E$-PZ9B1B,A415 R5'.,G'6M:@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *1@3C%+10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 9FJ:RNFW5G:K:3W-Q=E]B1;0%"+EF8L0
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M6%M#JUU<7$2)<%F=6 R "JDL..G<BM[P;IL^G>&K7[:[R:A.BRW4DF-S/M
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M4?(.<L1^&>^ ZX\,>((K+5]-LI-.DL[N^^VP23.ZO&3(LC(5"D$9!P<]^GH
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MBTS3;F^G#F*WB:5PBY8@#. .YKGI?'%O;1:R9M/N/.TJ%+B6&-T8F-@2#G.
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MXDC;<,D@%B6R3P.,#WJ:;PQJ5]J5Q/<R6D4-SHITR41,SLK%G^9<@<88=?\
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MNOR.[)O41@?<V[6'/4#GFN8\)WEWIN@>"I(;J;RKR\GM9;<D>65+3'.,9SD
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MOK>\L[(QSV\+01MYKM\C=0<DY'IGIVIL'@S0K>QLK-+23R;*<7%N#<2920<
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MG>WRPS[#C<G39GT-5;?5+2+QL/$JVVOKBU^R+:_V2P"QY! SGMCTK1\2>(=
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M\47%S=I&K7+Z8P"%,[2$''UYYJ:_\017.J>&[R(>(Y)-.N";@O8,JR1E#NR
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MGPM::8Y0S+NDE*?=WLQ8@>PSC/?&>*WZ "BBB@ HHHH **** "BBB@ HHHH
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ME%+D(^>J#KM[D =\UG);Z;=:'H2W;VEU;P>)98#(<>6L),AP,GY4. 0.G H
M]IVCW_.J=SJ5I:7]E8RR8N+QF6%,9W;5+'Z# HT_4-.N_-M]/NK>7[+M1TA<
M'R\C*@XZ<=*XKQ;;63_%'PC+>Q0F(Q70=I0-ORIE<Y]"<CWH ]!P*1MH!).
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MDU:"!\-MNK23*85"<AXC@?+QP3]: /3-HS1BL#QNVH)X)U=M+9UO%MV*%/O
M?Q8]]N??TYK'BM])?5O#QT*&T-O=02FZ1" )+8H!EU'#?-L&3WXSUH U+/6]
M3U+4IOL5E!)I]O?O93DRE9%VCF09X(R<8ZUI7FLV=EJ^G:9*S&ZOV<0JI' 1
M"Q)YSC QGGDBL;P19Z9';ZG-96]HD@U&ZC,D**#M\TX7([8Q@?2L[Q6NCQ?$
M/PU+J4%KB2&Z4R3(I#$!-HY')R3CZ\=: .A\.:Q<ZPNIFYMHX3:7\MHFQBP=
M4"_-D^Y/Y5L[%]!^5>3S1V2^&_%&I.UOY\/B%FAN-PW1#S8LX;^'^(_2J^KM
M;3:]XAM]7UNYL[][D26MK!;1NT\853#Y4C(6#9P, C#9]S0![!L7T'Y5A:]K
M?]E7>D6\$<,C7NH1VLH8\QJRLV<#O\O&:TK][P:+<O:+B]%NQB4\_O-IP/?G
M%>36EYHLFG>!Y!+!_;,6JQI?;S^_61@^_P S/S<N!UH ]@$MN9S )(C,!N,8
M(W >N/2L_1]=TW7);Y+":.7['.8'92"&(522/;+8SZ@UY=;W^F'7+"\BN88
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MJ"Z?9S6.I6D.GH8]1MHMDB+D 13 $C?CD=#P<CJ:]!H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH @ELK6:XCN);:&2>+_5R/&"R?
M0]139K"SN9XYY[2"6:/[DCQAF7Z$C(KF/&^L3:1=:1+<27D&BM*XOI[3[R'
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M[S3Y;&))FCN F9$<X0J0Q&2>.2,'@]#0?'.G0+J/VR*2!["&.:0*Z2!@[;5
M*MC=N&,''44 =(88BZN8DW(,*VT9'TI$MH(U94AC57&&"J #]:Y#Q+XRN=-T
M'6V33;FWO[*!77?M*X?Y5<-R#ANH]J["*1I(E9XFB8]48@D?D2* '"-%C\L(
MH3&-H'&/I2&.,Q^647R\8VXXQZ8K%NO$\,+ZFMM:3W:Z8H-V8BHVG;N*KDC<
MP7DCCL.O%<WKNK-K>M>$X[:S-[I&H+-.8690MP!#E0P/3:3G![^XH [\(F"
MJX/!&.M 15.54 X X'8=!52STNULM)33(E<VJ1F,*[ECM/8L3GO7,?#>VB71
M;JYPQF-[<1%V<L=BRL%')["@#LMB>9OVKOQC=CG'I3/LMN0X\B+#G+?(/F^O
MK6)K'BJ'2+F[B:SGE2SM?M5Q*"J(JYP%!8C+'!X_QIMUXJ*:K9Z;9:7<WD]U
M9&\3:RHJ+D !B3QUZ\]NN: .A5510J@*H&  , 4GEH)#)L7>1@MCG'UKF(/&
MT%YIVD2VEC/+>ZJ)/(M&8*08\^9N;H ",9[Y'%<*\AN/!/BB15EC9/% 54\P
MDKAX5V\'D=>.E 'L=(RJXPR@CK@BN?O?$[P7-^EIIDUY!IP_TR59%7:=N\J@
M/WB%()Z=:9-XNC:Z@AL+&:]%S8?;[=D8#S$W*" .N<.#^E '245YE\2]9CU/
MP-J3V]I<O9P720F\20*I9955]HSEAG*YQC/YUV7]EO'XM?6^%A%A]F8"5B9#
MO# E,8&W#8.<G>?2@#;HK"T'Q"^N-&ZV:+:RVXGBN(9_-3DXV,0 %<9Y&3^E
M;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &-J;Z
MI#J<,EK8_;;'[/(L\(E56+%DVX#8!XW]2![URA\$WO\ 8NN16=K9VJ7=]#>6
MFG2X:)-FTLKXR!N(.0,@?2O1** ."G\,ZE>Z7+)I^F:=H%Q'+#/#:I'&1)+$
M^\,[(.AZ <XZ]\5:UG1->U^U,TWV2TGMYK>>VME?>K/$VX[WP#R20..,9[FN
MSJCJ6JVVEK#YXE=YG*110QEW<@%C@#G@ F@#GM3T[5=0EU'45TU4F&F2V,%O
MYREYF<@EBW15!'&>3D\#I68/#VJ7.HZ*EQILL=H-#?3KIUFCS"S@#INYQM[9
MZCWKMM+U.UUC3;?4+&0R6TZ[HV*E21]#S5N@#B-/TSQ +/P[8W6FP*-'ND5[
M@7((EC6*2,.H R,Y'!YS^==M(S)&[*A=@"0@(!8^G/%+2T <18>&&U'P_J,O
MB#3KH:C>R2O<6\=YP_9  K[#A0H&<=.:R+73_%9\$Z-I=]HDTE[IU[;R%EN8
M2KQ1.&'._KM 7\*]-HH XG5]-U>\@\8I#I<A-_;);VF9HQYIV,A;[WR@9!YP
M<56U+P[?S:Y9:U_PCMCJ:2V4=I<65](FZ!@2=X8AEP,X..:[^EH Y*QTW4[#
M7=*=K(2P6VGW$,DEN(HXU9WC=41,@X CVYP.Q/>L.QT3Q%::?X;O%TK_ $S1
MI;A)+-[F,>='+QN5@2,CT..]>BR2QQ%!)(J%VVKN.-Q]!ZG@U4T_6;'5+F^M
M[28O+8R^3<*4*E6QG'(Y^O2@#@[G0/$0@O2NE+(UWK\6H[([A"4B0H3DL5&?
MD&/KVJUK&B:S?2>,HH=,<)JL,$5K(TT8!*KL)(W9 YSTZ ]\"O0:* //+OPM
MJ0N-#OSHNG:IY.FQV-U8WC)^[8<[U8J1P<Y]1TS6K9:9J-GK6E2?V7#';VMK
M=1N+4QK&AE=7547C(41[2<#)8'UQUU)0!Y_IF@ZS8^$_"]JFFG[3I>H&22&2
MX09C*RJ&W D?\M%)QSP>*[]-Q12X ?'S!3D ^Q[TZH+V\AT^RFN[@N(85+N4
M1G( ZG"@DT <-%X9U&;P_+X8FLS%%)?-=2WXE5HRGG^: JYW;B !C&!R<GI4
MFJZ/#JOCNSDL+R%K:[MR=4B3#"589%*9P>NX[?H#Z5V>GWL.I:;:W]ON\BYA
M2:/<,':P!&1]#573- TG1I9Y=.T^"VDN#NE>->7/N: -.N;\1Z9?:AJVA7%K
M"KQZ?=_:)2SA=RE&7"^_/?%=)10!QOBKP]=W6OZ;KEIIMGJ@MHF@GL;K;\RL
MP(9"PVA@1WQQ4$.DZ['XFT.\N-/A,4,EU)-]E:-8[=90JH@SM9R-N2V.<\>E
M=Q5&75[2'6;?27,OVN>-I4 B;;M7J=V,=QQGN/44 <!H_ASQ#::7;6L^FO\
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M3VP#0!Z=/J=A:NZ7%[;PNB!V6255*J3@$Y/ SQFG2WUI# DTEU!'%)CRY'D
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MFT7PQIMA#;*U[>7MX2B122K$J2,6(6-2QY( P.] 'J4TT5O"\T\B1Q(-S.[
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M 1G:6!QW^Z: ,&R\"7.E/I5SIVKK#?6EH+&>8VV4G@#;A\F[AQQSD_3M20>
MKFTT+3+:TUR6VU+3YI98KU8%8$2L6=2A."#G]*[;-5+&XNIS=?:K3[.(YV2'
M]X&\V, 8?CIGGCVH YR3P9</)I4YU56NK6]-]=3R6N3=2;=HX# ( N0!SV].
M>JGB6>"2%B0LBE3CK@C%29HH X^S\&ZA:V.A6C:TDL6DW*S*'LP=RJA15&&&
M/E9LDY.XYXQBF7?@6?4+6_CNM8VS2WPU"TGM[<QM:S!=N>7.X8 XX[\\C'9T
M4 9&AZ+)I8N+B\O6O]1NBOVBZ:,1[PH(4!!PH )_$D]ZS[CP]K+^*FURWUFS
MC86QM4A>P9U$9?=R1*"6R!SP/:NGS1F@#D[WP=<ZK9W8U'67:^EGCGM[JU@\
MG[,4!VA5W-G[S9R>=U)/X-NKJWMY)];EEU2.[BN6O'MT(/EA@$$?15^=CW()
MS70V5Q>37%ZEU:"".*;;;N)-WG)M!W>W)(Q[4S6KZ73-$OK^&%)I+:!Y1&[[
M0VT9/.#V% &)%X4U*SCD%GX@D$C:B][FXME=2K(5:-E4KD$MG/'0<57/@"*/
M3[ 6>HR6>IV,DTL-Y!$H4-*<NOEGC8?[N> .M=7;W ELHKB3";XP[<\#(S4>
MF:E;:OIT-_9N7MY@3&Q&-PR1G]* (M(TI-)M7C$TD\\TAFN)Y3\TLA !8XX'
M   '   KG[KP*UY8:Q9RZH0FK7@N;@K  5 QA5^;C[J9)ST/ SQV%&: ,F#0
MUA\47.N?:7:2XMDMS%M&T!22"#USDG\ZUJYF3Q#JD^NZE8:9I45S'ITD$<K2
M7'ELYD 8[>,?*I!YZ\XKIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** .3UVQGU+Q=:6"ZC=VMO/I5T)1!(5SAX@"/1@7SGVQT-<P
MMYJ5\OB42>(_L<NFWWEHSRR;XHH\%3Y:D!M^&SD'<?H*](ETNQFU*+49+:-K
MR%"D<Y'S*IZ@'TYJ&;0M(N-234IM,M)+U/NW#0J7'ISC- '%-?W-IXG2>YN)
MY]/O-6%O#=P7+_NGY7[-)%D #=GD9YZUF":_B\*ZKK,>LWYOK'6GC@C>Z8I(
MJS!1$5SAMP..<GI7HXT+24O#>)IML+CS#-O6, F0]7_WN>O6L'PCX46QCO+K
M5=-MUOI=1FND.X2%0S94Y]1DB@#%DOKF^N]=G;78K.?3M0/#R2!HHE(VJ(P0
MK!P/0[B?I5I+F&^;5=1NM;NK:\TW5F7RUD<A8D<!8Q$" WF*!S@DE^^,5U\N
M@Z1/J:ZE+I=F]\N,7#0J7!&,'.,Y&!@]J'T#2)-475'TRT:_7D7)A7?G&,YQ
MG.* .8\(VD/_  EGBJ?=.'34%"KY[A3F)<Y7.">>X.*LW[?VKX^.B7LTZ64>
MFBYBBBG>$RR&0@ME2"=H XSCGZ5T::3I\>IR:FEG"+Z1=KW 0;R.!C/X"F:A
MHVG:H8VO;2.5XON.>&7UPPY /<=Z //)8CJ?A_3DOKFYNOLGB);*&Y-PX::(
M3X#$J1N..-W7C@]:]-@MX[>W2"/<408&]RY_$L23^-4;CP[H]W;VUO/IUN\-
MM_J(RGRQ^ZCL:T44(BHHPJC 'H* .8MO^2HZA_V"+?\ ]&RUS]^)-<U?Q*EU
MK#:3=Z>ZBSQ,X,4:JK>;M#JK!CG.0?3-=S'H>F0ZF=2CLHEO2"#.!\Y!ZC/I
MSTIMWX?T?4+^*^O-,M+B[B "32Q!F7'(Y- '"ZP]U=ZQXM*ZIJ,4-OH\5W!'
M'.T8C<*[ @#D<KR/<Y[8B\0:G=7^C0W<5Y<->PZ!]NDBAN&@2W<IN$Q*G+L2
M"H3D=<D9KOI] TJXFO)9;-&DO(Q%</DYD3^Z3GIQT^OK4,GA/0)Q")M)M91#
M"8(_,3=MC/\ #SV]/3MB@#EU@DUOQ+H45YJ%TL=QH1EEBCG:/S&S'R-N,'/)
MQC\N*Q;-QJUS\.)M0GN6DEBNXV=;B168HF%.5(.3W/?O7I-OH&DVLEO)!801
MO;P_9XF"\I'W4>QIA\,Z(;.WLSI=J;:V?S(8C&"L;>H':@!-1LK:UM-6U&*1
M+2[FMF\R\?+>6%0[3UX5>N!CN>IKG_"=U<CQ+=6&IK=VVHQ6,9,#W3W$,R!B
M/.C9CD9/!!YX[\UV5Q;PW5M+;7$:R0RH4D1AD,I&"#[$56LM)T_3I'DM+2*&
M1U5&=1R57[HSZ#L* .4NK*ZO_B/?V,^K7\-BVEQSI%;3F+82Y4D$<C[N>/QS
M61HFM7^KWWAG3=3OYDMY[&XE\R.=HGNY$D*+\R8)^0;L C.<G.!6[)X;NK[X
MAWVHZE913Z5)8+:PL9!D=V!7T)9A70WNA:5J-K#:WFG6TUO"<Q1O&-J<8^4=
MOPH X 3Z@^O^&M"DU^YNHKA-1M+N>%V0N44XY_O(>-WJN:G@MO(^*FL.KW4\
MMKH\4D8-Q)EV!Z$ \@G^'ID]*[I-$TR.XM+A+&!9;-"ELP7'DJ1@A?3(XXI4
MT;3H]3DU)+2-;V0;7G'#,/0GN/:@#B;34+IM!\(Z\NI7$ES>W<4=S$96:.;S
MLAQLY5=G)' P%(JE%%>OX'U7Q!)K&I&YLSJ*Q(L^U<;V"Y]<%<@^^/2N_@\/
MZ1:W(N(--MHY@6962,#:3U(]">>1ZTY-#TN/3I]/2QA6TN&9IH@/ED+?>)]<
M]_6@#DK2RGE\0:+:/JNI^3=:,TUPBW;@22(8@&'.4/SG.W'Y9SG6&H:E?^%O
M"UM<37%W>W,\ZM#YIB-RD9=0[R@Y4*-K'&2>!BN^CT/3(98)8[.-)((C!"RY
M!CC/55/8?2H/^$6T$VD%H=)M#;P.7BC,8*H3U(';..?6@#@XKF_OM"\%>9JE
MX'GU.6":6.X),J*90,M_%PH&[&>_6E@U:YLXY-*DOKB'3O\ A)I+ W!G.^.$
M1AUC\PG<,MQNSD#(R.*[V/PUHL1@\O3+9?L\[7$("<1R$Y+*.QXJ0Z#I+6]W
M;MIULT-Y(9;B-HP5E<]68'J>G/M0!Q?B*=](L#IT6NRRQ3ZS&EU)/*_^BPR(
M6$1DSD#*CG((#CIG)Z3PU!/976IV5QJ!NBLB2JF^23R RXV;W))^Z6QGC=[B
MKZ^']'72WTP:9:"QD.7M_*&QCZD=SP.?:I]/TRQTFW^SZ?:0VT1.XI$@4$^I
M]30!Y^;&"*U^(<@DN-\?G!0US(P.;52<J6PW7N#C\*?ILLVDW_A%K6:X<:EH
M\BRPO,[)NCAC9"%)P.XX ZFNWGT#2+FZN+J;3K9Y[B/RII#&-SIC&"?3  ^E
M-B\/:/!)9R1:= CV2E;9@O,0/4+Z#F@#@_#DEQ.?#VN-KZ>9=/Y5U LLDC7$
MC+\T90MM0H>> , >E4S<7MI\.M)U\:G=+-<"*SNGEF8HL33G<Y/56P<;@<X/
MTKT>'P[HUM=7%U!I=I%<7 (ED2(*S9Z\CU[U+:Z)I=EISZ?;V%O'9.26@" H
M<]<CI0!Y]K-K=6FF:Y;QZR1LA@OX([5Y"+<JP!_>%LX< _+GU(%7?$%Q,OBW
MQ%;P7MRD8\-FY*13LH24.V& !^4X"].WUKL[?0=)M--ETZWTZVBLY01)"D8"
MN",'([\<5#'X8T.*)HTTJT"M;_9F_=#)BSG83Z9.: .(TF6\L-1\*S07-Y=3
M7NA2331S7#,)G6.,H,$X&"<9 SZY/-10+!?:=X$UIIY)KVZU%#.YE8@NT<A<
M;2<### XX'%>A+H6EI+9RK8PB2R3R[9@O,2^B^@IH\/:*MXEXNDV*W22&59E
MMU#ASG+9 SGDT <!;7.H7GV_5YM9CL[JSU9XY$>1W9$$A58/+!VD,I !QDDY
MZUO^%;1KK4-5GEO+MVL=:N5B#3LP*&-!M()Y SD>F..]="^@Z1)J@U1]-M6O
MQC%P8AOXZ'/K[U)I^CZ=I1F-A:16YG;?*8QC>WJ?4T <AXX>6?46MH)+AFAT
MJYN&C2X,*1= LI(.688( QWSD5E:9/=:U?>!6OKVZ<7FF7)N%24H)"%49.W!
M!^;J,&O0[S1M,U&YBN+RPM[B:)2J/)&&*@]1]*9'H&D0M;-'IULK6J>7 PC&
M8EYX4]AR>E 'FOA;6+G49="T2_NIS9M<WR[VG8/.8B-B%LY( ;.,\[173_#F
M-(+3Q! DKR"+7+I=TCEW/(Y8GDGW-=$OAW14M!:C2+'[.'\P1&W4H&P!NQC&
M>!S4]AIEAI4+PZ?9P6L3N9&2&,("QZG H \SO+"",_$J8-,98X=B%YW;@VX)
MR"<'GUZ=!Q6QJ#WV@W^LO!=W+W'_  CTEV[O*9$%PA;#*K9 Z\ #&%Z5UMUX
M?TB]EN9;G3;662Z01SNT8+2*,8!/<<#\AZ5*FDZ?'=0W26D0GAA^SQR <K'_
M '?I[4 <'97%Q#9VU]#X@A>.[TR7$*22/).ZQEA+EC\K+W( Z@>E4([B>P\%
M>&=0_M.>W;5'M(;NXFG;8JJKD#<#E0QP"01_.O1;7P]HUAY_V32;*#[0")?+
M@5=X/4' Y'MTJ;^Q],_L\Z>-.M!9'_EW$*B/_OG&* ,CPPEW!?ZM;W.J"]3S
M$FC12[B ,#E [$Y^[G';/N*Y*:]O+W5_%#76L"QGTZZ#1!G<-# H!4H@.U@X
M!R,$G./2O1[#3;'2[<6]A9P6L(_@AC"#ZX%,N-'TR[O$O+G3K2:ZCQLFD@5G
M7'3#$9% 'G^M3II^OW:QW=T- O)((]4F\YA]ADSE0K$_*'W*&Q]W(Y&1CH+]
MX;3QY9S23.EO#HUS(Q+L50+)%\V,XS@GGJ:WGT/298)H'TRS:&>3S9HS NV5
M\YW,,?,<]S3_ .R--$\<_P#9]IYT:&-)/)7<JGJH..![4 >4ZMY\'A[6]-U*
MWGCO$T8RK/'=-)!=*& \P9.5;YN0?7Z5Z=H=K%%X;L8$#+&ULF<.<\J,X.<B
MIH]%TN%94BT^U1)8Q"ZK$H#(/X<8Z<].E3P6=K:VBVEO;Q16ZKM$2( H'ICI
M0!YSI<\L,O@RYAO+F0W=S<P3.UR[B6,"0J""2#T!S^-&JW)7P5?:Y8:G/)J]
MMJ1PQG8?.)]OD;>FW:0-N,'K7?1Z)I,,<$<6F62) Q>%5MU C8]2HQP3ZBGC
M2M.$[7'V"U\YGWM)Y*[BWKG&<^] &%X]U&?3?";3I*ULKSP17$R'F*)G4.0?
MH2,^^:Y+56.D_$77+K1QF<>%GFBVONPXD&"N<CH <=_QKU.6*.>)HIHTDC<8
M9'&0P]"#56UT;2[*3S+33;.W?9LW10*AV^F0.GM0!PV@&UU#4]*EB\2PW:7-
MHT<UC:JY+C;NWRDRL58'C=@$DX[UE6,XT_X?^&MMPEE9W-Z\=[=,K,H4-)M5
M]K*=I8*#R/?C(/IL&BZ5;";[/IEG%YP(E\N!5\P'J&P.<^]+'HVEQ6+V4>FV
M:6C_ 'H%@41M]5Q@T >=:E$XT6:VLO$ NX&U>S8-IY,4=JKR!2BD.V1T.W/!
M(/I6@\<O]K>,]'AU"2VMQ;VK0O+([B)Y%8$YSD D#./<UV9T72C8BQ_LVT%H
MK;E@$*A%/J!C /O3AI.G?:9KG[!;">9=DLGE+ND7CACCGH.M 'F-[>W&G6M_
M;M9QZ.Z7]BNJ!6\RU6!PR[U"E2%8J PR#SUY-:C6LL4.J6-AK%E<>;<VTD,"
MQE+7><[K?(=R X0$C@?,.S8KO1IMB(98A96XBF_UJ>4N'_WACG\:;)I.FRVG
MV233[5[;=O\ ):%2F[UVXQF@#FO!NJ:?';WT#))87+:F\+VEQ.'V3;%.R-AU
M7:,@=N14_CR^%AI%E)/+-%827\,=])$Q4K"<YR1R%+;03Z$U>U3PU:ZE';6R
M);V]K'<"XE6. !W96##:W\.2HR<9(XXK9DBCFC:.5%=&&&5AD$>XH \ZU1[/
M2H+^'2]0N3ILFHVGVU8\&&UBD^^J,.@( +#L&&.M3:UI\5O?>([&S9DL9-#>
M>6%#E()@6V,HZ*2-QX_NYKO$L[:*W-O';Q) 008E0!2#UXZ4BV=LB2(MO$%D
M&V0!!AQC&#Z\<4 <#:W=O=>,/!OE7*2R2:1+YVV3)8;$*YY]V(_&L32$$.D?
M#^\665KBYO&BFD>5G+HP?*G)/'M7J=KI&F67E_9-.M(/*W>7Y4*ILW?>Q@<9
M[^M+_9&F^6L?]GVGEJQ=5\E<!CU(&.O YH \INULM*\,:O+9"*W+:_+!J#QY
MS':_:"#E58';]U2!C(.,TOB)DL_#?B2[TSQ#'<E3:7$<>FJ8H;5S($R")&Y8
M9ROXUZLNFV$<EPZ65LKW'^O81*#+_O<<_C4)T#1C8_8O[)L/LF_S/(^S)Y>[
M^]MQC/O0!R>K)I.E>++&PU698M(NXKF=%N93Y;7+.I.2>.%+8R>,\=JCG%LF
MG^"XK.ZN+NUBU<1Q7%PP+2JL<P!R.H[ ]P!7;W.G6-];"VN[.WN(%QB*6)74
M8Z<$8HETVPG%N)K*VD%L08-\2GRB.A7(^7\* /.-%O+>7Q5IEY"R*+G4[X-+
M+<?OY5"R?*R= BD #D]%Z9J+4'D3PYK>R>8&+Q2BKB5L[=\0P>>1@GBO1UT7
M2D=G73+-6:7SR1 N3)_?Z?>Y//7FAM#TEXGB?2[)HY)?.=#;H0TG]\C'+>_6
M@#SB_P!/@D\3>-[%C-]E@TY;J.(3/M$IC)+]>6R.M/NY)KK0M)NV2WU1X/#T
M4UU8W$IC<HZ\S1R'(# J<\9Z<\BO1VTK3GN)[AM/M6FN%"S2&%=T@&,!CC)'
M Z^@H_LG3BJK_9]KA5*J/)7@$YP..F23^- &9>WER? DEYHT3O<'3_,MD<_/
MRF1GW_K7,"ULHX_!MYH[MYMZRPW!B)W7,)B)D,F.I! )8\@]\UZ+@ 8%58=+
MT^WE>6&PM8Y),[W2%06SUR0.<T <I\.M-LO[ LM5CEEFN-DULLAF9AY8G<@8
MS@X]>OO4FH:;::KX^N=/N96:";2 TMN)F!)$PPX /RD8ZC'6NM@MX+6/R[>&
M.*/.=L:A1^0J,Z?9&]6]-I ;I00)S&-X!&#\W7IQ0!YW-<S1>'/B#(MR\;1Z
MA(%<R,,#9'\H/49SCVS1%]EO8?%6I6[PP6_]E&.*SCNHY-K"-M[E8W*C/RC)
MY.*Z_5_#%I>:7<VMC#9V4ES*DLS"V4K.58-B11C<#R#SW-4M*\(10WT=Y>6&
MC6[(CIY&GV817W8Y=CRPP.F ,GO0!SUG:VJZSH,?WS?>'I&NXW<MYV!&07!/
M/5N3Z8[54TV*QG\(>$[?1Y],&H*JSO:SCY+F00D,CXZ-\V1GTKTY-/LHS$4L
M[=3$NR,B(#8OH..!3?[*T[REC^P6OEJ=RKY*X!]<8ZT 9'A"=;CPA!):6[P'
M,P6&9MVQA(WR[AU4'@'TQ7'V\:2>#] U'3S_ ,5$;Z)9G/$LDV\^>C]R -^0
M>@%>H)&D4:QQHJ(HPJJ, #T J);*T2X-PMM"LS9S((P&.>O/6@#D_"T=C_PF
MOBX0);[X[J#&P#*?N%!QZ<[A]<UV=5[>PL[61I+>T@A=N&:.,*3]2*L4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 444TD[A0 ZBBB@ HHHH
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M8D2E0<G'4D@?K67KNCWS:IHFMV^E_P!I+;VS6UQ9,ZHZA]IWIN(&X$8()Y%
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M #LJ*HZ1>75_IT=Q>:?)83L6#6\CABN"0#D<<CG\:O4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%-*'S VX\=J=0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4449&<9H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *SGT.Q?7H];9)#?QQ&%7\UL!#R1MSCKSTK1HH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FE S
M!CU%.HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHKGM,\13:]J-RFEVJ_8+28PRWD[$"1E/S+&H
MZ@?WB0,GH: .AHHK+U_5XM"T:\U2=&:*UB:5E4X+8&<?C0!J45QEEXFU2X;1
MYI+6TFLM1D"&6VE+>5E6(W<8Z@#\:ZO^T+/#G[7!A#ACY@^4\C!_(T 6**AE
MN[> *99XD#<@LP&?I1+=VT"AIIXXU/=F % $U%0M=VZJC-/& _W26'/TI)KV
MUM_]=<PQY7=\[@<>OTH GHJNU_:(RJUU"&;&T%QDYZ4K7ELLPA:XB$IZ(6&3
M^% $]%0/>6T9</<1*4!9@7 V@=2::=1LE(#7< ) 8 R#D'H?QH LT4UI$12S
M,%4=23BHDN[:2)I$GB9%X9@P('UH GHJ!;NW=U19XF9AE5#@DCU%<SXX\6GP
MMHLVH01P730;?-A:7:P5C@$"@#K:*KV$YNM/MK@KM,L2OM],C.*YNY\96=GX
M^L?"[%3-<PO*9-P^0\D+^.T_E0!UE%0S7=O;@&:>.,$X&]@,_G4<NH62!=]W
M N\97,@&1ZB@"U16#;:M=3>([^Q>VB2RMXT9+A9 2['J".V!6G'J5BV%6[@)
M/  D!- %NBJXU"S9D5;N ESA0)!R?:AKZT641-<PB0D*$+C))Z#% %BBD!!Z
M'-+0 452U>[NK'2Y[BRLS>7* >7;AMN\D@=<''7/3M6(_B#5_P#A*)="BTVR
M:5+);P2-=N 06*[<>6><@_A0!U%%<MH_BBYN]?U*RU.*VL8K:WMI4#.0P:4,
M2K$X&1C& .QK:N)[I-9LH8WM1:21RF8.Q$I8;=FP=Q][/X4 7Z*JP:E8W,[P
M07MM+-&Q5XXY59E(Z@@'((K+U[7I=/U72M)M5A%WJ1E\N6X)\M!& 6R!R2<@
M <=^>,$ WJ*Q])U*]G741JMO#:-9S^5N1R4=?+1MX) XRQ^F,=JTX[F"6'SH
MYHWBY^=7!7CKS0!+14%O>VMY;?:;:YAG@.?WL4@9>.O(XID>I6$UJ]U%>VTE
MNA(:595**1UR<X% %JBH(KRUN)#'#<PR.!N*HX) ]<"L'5?$,\'BC0]+L9;%
MX[R:6.YW,7D0(A?  (Q]W&3GZ4 =+12%@JEF( '))[5SGA;Q0/$5UJ\6$ M;
MG%OM!'F6Y4;).>H8A\$<8Q0!TE%5WOK2-MDEU K;MF&D .[T^O(_.GQW$,SR
M)'-&[QG#JK E3[^E $M%0QW5O+(\<<\3O']]5<$K]1VJ.#4;&Y*""\MY3(NY
M!'*K;AZC!Y'% %JBN9\4>(9=*>QBL9[)II+V""XBD;,BQR.%R%!]SR:WGO[.
M-RCW<"L&"D-( 02,@=>N* +%%0PW=M<,ZP7$4K(<.$<,5^N.E,@U*QNO,^SW
MMO+Y7^L\N56V?7!XH LT54_M33RTBB^MBT<?FN/.7*I_>// ]^E1:/K%GK=B
M+NSE1XRS ;7#<!B >#WQF@#0HJM_:-D;MK1;RW-T.L/FC>/3Y>M8OA?Q"=0T
MZ)-4N[)=3>>XC$,;!-XCE=,JI.2,+0!T=%53J-B+[[";RW%WC/D>:OF8]=N<
MUR4WBG5(=6\9VH^S-_8]FEQ:@QD YC9SOYR3P!QB@#MZ*S=&NI[_ ,.:?>2,
MOVFXM(Y6..-[(">!VR:R?"GB,ZAID(U>_L%U*:XGC2"-PA8)(R#:I.3]V@#J
M**Q8-3-O>ZS+J&HV L;5T*;9,- NP9$I/0DY(]C5^UU.POI'CM+ZVGD0!G2*
M5690>F0#D4 6Z*Y34/%&WQAX?TS3[ZQGMKUYEN$0AY%V1L0<AN!D8Z=NM=-/
M<P6L8DN)XX4)"AI'"C)Z#)[T 2T52;6-,6"WG.HVODW#B.&3SEVR,3C"G/)S
MQQ3K;5+"]LGO+:]MYK5-VZ9) 47;UR>@Q0!;HKF-/\0O?>.+K2X+RSN;".P6
MX4V^"R.7*D,P8@\#/;J*T-1O9+?6]+@34K*WCE,GFVTW^MG 7(V<\8()/M0!
MKT5F0^(]$N)X88=6LI)9V98D6=27(."!SSS4@US23!-/_:=F(8'V2N9U C;.
M,,<\'V- %^BJ$^MZ5;3^3/J-K'+\GR-*H/SG"\9[D\>M2+JNG/?&R2_M6NP<
M& 3*9!W^[G- %NBL77_$VG^'39+>2H)+NX2%$+A2 3RYS_"HR2?\:MOKFDQR
MQQ2:I9)+*%9$:=0S!OND#.3GMZT 7Z*JW]_:Z78S7M[,D-M"NZ21SP!7)#QP
MEWJ7AF>TN[1=+U&.=KO=RT+)#YF"^<#&1GCM0!V]%9Z:YI3Z9_::ZC;-8YQ]
MH$HV9SC&?7/&*L6=]:ZA!YUG<13QABI:-@0".H/H?:@"Q17(6GBQ;3Q9K^G:
MWJ5C;V]J]N+0N1%D2(S$$D\D8'/\JZ*ZUC3;%T2[O[:!G4NHDE"Y4?Q<]O>@
M"[16?=Z]I%@[)>:G9P.L?FE9)E4A.QP3TJ2XU;3K6*"6>]@1+C_4L7&).,_+
MZ\<T 7**Y;Q'XJM].DTB"VOK93J%RJF8L&"P[68NO8YV@#ZU7T[7+K2HM>N-
M=\0:=?QV(5A':IL:$88X<#.&; XYZ&@#L:*S]%U6#6M*M[V!T(DC5G"-N",5
M!*YXSC-)'KVD37WV&+4K9[HLRB(2#<2OW@/<=_2@#1HKAH?%%WKGBS5])TG4
M;:#[$EO]G\R+>L[,"\F3UP%&.._-=S0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 444@8-G!!P<'% "T444 5M1BEFTR[B@;;,\+
MK&WHQ! /YUXQX8L[FQ;P7#86TUMJL=[<1:HB@AC&'!;S!TQM/!/X5[A1B@#-
MT?7+76Q?&U29?L=V]G)YJ[<NF,D<\CD<U1\87T=AX>NI9[47,!VI+$5)W(Q
M;IUX-;X4+G  R<G ZUDZ[I-UJMJ(K/4Y-/D#*QD2%9,@9XPW^>* /,+32(O#
M7BS1CX)U:6;3KVZ5;W3 ?,$4?5G.<E,=.<$5S^NA++2OB38R(R7$UY'+;P;#
MN9<YW#'U/->HKX1U_<TL7C6=?,YRMA#S^.,_K0?!WB(N6;QM<EF7#$Z?#SZ9
MXH XB^O+9_&FDIKI;^P+G0O)MIL'8DC!2W/4-A3[U->2V5GXPTVVU:.Y?PW/
MHAL[2YGWGYB/FW>C,!@9KLG\'^(G55/C6X(3E-VG0G!]>G\L4-X3\2?+O\<W
M+<\;K"'K[4 <3J8MK7QCI%M>7$T.@2:.]M:RW$1;#$X;/<,1MQGTJAXACEMK
M6$6E\M^+;3$M[RROHPCW<)Y5HNOS\=.O2O1SX2\2,3N\;7##J VGPM@^O(IC
M>#O$,C!Y/&3NZD$,=,@)SZ\]Z .#N=]KXSCGMQ%>V4][;1W.G3 ">WD15*M&
M>ZC@GZ'-9VJI?OX<\403LS>)&UH/:<XE9<J%*?[. ?:O4%\(:\)5G_X2^0S#
M^,Z;!GWP<9&?K3F\)Z^TZS'QA,7'\3:?"2!Z XX% '(7-I;ZE\8X[2]59$ET
M0PW:AB \G&5/.,X(-9^M6:V7BR9=,\N]LTN+6TNM*F'[U @78\1ZD#@FN^_X
M1+Q )%D'C*?S <[CIT!/\NOO[4I\):]N#CQC<>:/XS80$Y^NW- %7XH7EG:^
M#)WN_/96E0!(&VECD<,1SM]<5QVARM!K_CRRN7C6.XM%GCA0%$?Y3RO_ .NN
M\D\*>()4VMXRN2IP<&QA/([C(IK^$=?9F8>,9@Q7;DZ?">/?CF@#S?PM!';/
M\-[B-@LK+.EQ(26/(;"-Z<D#FJNNR_:_ WBV&_0MK_\ :FZ12N7,?R[2!C(7
M QZ9!KU ^$/$ 0*/&4PP<C&G0#![]!Z\TJ>$M>WLX\93ER-K-_9\&2/0G&3U
MH V8M6M--\+P7]U*%ABM5=BO)P%' ]Z\;\3V&I?\(S;>-XVMUU!;[[?&49FD
M8.558\8[*J\>Q]:],/A+Q 1@^-+LKS\K64)!].,5&WA#7V"QOXVNMO54%C !
M^6* ./\ &&I#Q##I>K:=<P^?'ITDYM+M/W-PAR'3)Z.#T&/2LS7()@8=1LE#
M>7IUM#=:/=+E_*/*F%O[W7WKT,>#-=V!&\9W;*&W#-C!D?3CBFMX-U_>&;QQ
M>;R>";*'Z\<?6@#C-32,>*O'CK/]B\S1HP)L]&"_-[$XP#5CP5H]E=>(-)UA
MKW3(TM-*2V^S0SK([28.6P/]DBNHNO FLWMO-;W'C2]>*=&CE'V.$%E(P1G%
M9%K\'/L5U:W-KXA:"XM6W1216$2L.-N"1U&* /-]*MX8O#NE703;.OB9L.&P
M5BZ=^U=9?O,OC@WEK&NH6$VLHLUFXV7%O.N%$B-W3:/IS7;_ /"%:Z1M;QE<
M%?0:=!^O%2IX1U_[7#<2^,9Y"C*6'V"$;@#R,@9&: -CP_K]GKOVY;1)5-C<
MM:R^8FT%UZ[>3D5LU''"D6[8H7<<G QD^OUJ2@ KBK:[MI_B_=B&>-RFCK"V
MU@<.)F)7Z@$$CWKM:8(T4Y"*#DG@=SWH \RUNRTZ_P#$?CK[;' [1Z5$8GD0
M.8V\N0;E!_B!*].>1ZUHJ]J/%W@N?=%YLFE3(SY&YAMC*#/?G?C_ (%[UWA*
M"09VAR,#U(I2H;&0#@Y&1T- 'FOA%H/[?T>*W-K>VRVDSVLL:%+BS0[?W<X!
M()Y"Y.#D?GM^,+G0KS4+;0?$,*)930-<K>/)Y8@D1@!\W\.<GG/MWKL:8\22
M AT5@1@@C.10!Y'<S:M<>&KVW:\NM7T;3M5MV2^2(223VP^9\<$2;#CYCD'%
M6;Z.S$%[>:8-2U/3'N[2?49-H\N55)#JL:(N<*$+8'/&>AKU-=B;8UVK@<*/
M0>U/Q0!YWJ,NGW5EJMSI=O='3YKJREO+B-6,<B"15D")CHJ*-V!SGV-9?BMK
M'4#X@N-(>VGTR31,730E6B>X#GR<$<>8.??[OM7JS,JLJE@"W0$]:1(TC7:B
MJJ^BC H \UDBM;'QC$NA+%'))X9F6U:->7E+ADSW+'!//)YI=+?3KG4? OV&
M$+/;&9+E3$5>-S;-N#Y&<[NN>]>F8I-H)!(&1T- '.>-+\6^A?8(YQ#<ZG(M
ME%)_SS\P[6<^R@D_7'3-<A);7G@7Q=H=]>ZC:RVES -,ECM[4PA(D&4=LLV<
M$@$\<5ZGBC% 'C^I6UD_AOX@A((#.E\S0[5&Y<B/E>_++VZE?:MU4">.+J+2
MC'&\GAE1%Y6 IEWMMZ=3@@_2O0\48H \P\/W6E^5H<EI#>I>VMG)!>0[/(CM
M5\O]XTORC/SJ" 3R3GM5#PS:VEK:?#NXC6**Y:2=9B!AVS&P^8_4*,'V KU[
M%&* /)96M)/#&DP3V\HUBSUR&>\#0-YBR-/\SL0.A!X/<8]*JZ_;6Z>%_B"D
M4$8;^THVA"J,Y/EY*^Y(;IZ&O8R >M+B@#S:XA,.OZAIVD1)#<S>%ML7E84B
M8%M@X[X8'Z5'I3Z;<:/#=&6_>2+2I;6>*[@2&.W3:/D;$:@G<!@9)Y)[FO3<
M48H \VT)%MM:\#^4NQ&T1DE*C@L4C(#'URK8SZ'TKI/ T\3^%;2"/(> ,LB[
M2-K;VX^O'3Z>HKI<48H \PL62R\41BTG34;*;69Y);)TVW-E.2ZM-D'YH^O7
MC##O26D$::)IUPR,TB>)GE)\LEHD,KGTR%*L&],-FO35DC:1XU=2Z8W*#RN>
MF?2G4 >3:LP?6OM$0,$</BJW^T1F,ES@!?-9OX5.0%'H1R<UJ7:M_:WQ%7RW
MW7%A&(3L.)"(&4A3W.X@8'<UZ!(\$;HDC1JTK816(!=@,\>IP,_A4M &3X6_
MY%/1U((9+*%&!&"K! "".Q!%<)_8L<O@Y;2VL?+UYM:,R/Y)$D3?:B?-;C(4
M1=SQC%>G?:(?M/V;SH_/V>9Y6X;MN<;L=<9XS4E 'F^O".2V^(,(B+F:&(1*
ML982/Y04!>.6WX''(-03P.+KR]+BVR3>$Y((/)7 :8_,B@CC=@,0/K7IU% '
MF5I+#-JGP[$-E<QR6D4L4RM:NIA/D;2K<<?-_CTYKHO&$K+J/AY%386O&(N]
MC/Y!$;=%7JS D#.0.N#75T4 >2:?9PW'AFQMKFTDEC3Q0Q*2VY!";V.2N!@8
M(SP ,U9U"UN$D\:?8[:5K47UE.8H4.)8E"><%'1ONL"!Z$5ZGBC% '&:;/;W
MOQ*EOK..1K>;1HQYX@=48^:V/F(QT'Z>U3Z]%(?B#X1F$3M&BWJNZH2%S&N,
MGMGGK76=*B^TP?:1;>='YY0OY6X;MH(!..N,D<^] 'ED.GQ6_A;07M]/>*0^
M)UFFVV[!MHGDPQ&,X";>?2G>(H)EL_B);?9I_-NC#+ !$V)%"("5.,'G->JT
M8H X73--BN/&8CO+'?&NA6@82PG;YJ2,<9(QN'RGU'%9&D0@QV6GS6>L2:U8
MZF91%(66 -O8M-OV[2A5FXZG..^:]1J.*XAG>5(IHY&B;9($8$HV,X/H<$<>
M] '.^+6>&^\.W1#FW@U'=-LC9R 8I #A03C)Q^-8A*Q6GC'3M2M;EKF_FDDM
M_P!R[&>-XE6,*<8R",8SP?2O0L48H YS[%?Q_#EK*[W2Z@-*,4F#N+2>5@\]
MSFN7TK==W?P[5;:XVV=K+#<>9;NH1A:J#G<.F>,],@BO2Z2@#RZX%RVDWD\=
MC?R)8^)Y;F6*V0B5XCN =!CD L#_ ,!-==X5C@,FI75M;:C'%<RHYFO]RO.V
MP L$8 @ !1G SBNCI: /.=0@6'Q!XW6ZTZ><ZA9P1VB+ Q^T$1,"JL!_>QGG
MCKVK.6PDTB\_L_Q!;ZO+;7NDVUKYUBC2*2B%'A8(I(Y)(QZY[UZOBC% 'GMA
MI\5OK]L]S8_9VMO#<<2)(AD,398,HDZ9 X/<Y^M8NF>;I]OX5U"ZM=46S&E&
MQEDM(7,D$H8'#*%+8.,<#TKUS%)0!YD%32X?!5NFGW=G;V]Y+,8)4:22")A(
M$+G!*_>&1VS[58U*RNKC4OB''%9W.;W38DMB8659F6)U8*2,-@LHX]:]!FGB
MMH7FGD2*)!EG=L!1ZDT\D#DD#G'- &/X>N&O/"]KY,<\#I;K$IGB*'<$ W -
MSC/MSBN,MK62]\'^'M"2PN;?5["]M_,#V[ 0-&V7EW8VE2N[!S@[@*]-HQ0!
MPWAC>/B9XPE>"XCCN5M&A>2%T#A(RK8)'8D5W-%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %-+@,%YR:=1@4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 <OJ.IZTOCO3=.M;5#8
M&WEFE8R@&0 HI.,$C;O!QWK"\*ZU%H5BEM'83O:7&MSVCW!D7$<K3.$ 7J1@
M+DGIGO74ZEIVIOXDT[4]/-F8X8);>=;AF!VN\;97 Z_NR.?6N8_X0W7#H*63
MC37F_MLZFP\^0)LW[]F=F<Y)'3TH V;CQYID$MWM626*TNQ9SM&075\X)V?>
M*@\$^QQG%=4.1FN+;PWXCMKR_M-.U:VAT?4)GGD9E;[3;M(<R")A@<DG!/3/
MM79@8 % '.7OBF>'7;W1[+1KB\NK:T6Y7$J(LF20 "3QT(SUSV[U'/XVM8],
MAOTLYWB>Q>]<L501JI *DD_>R< >WTK,D?4E^*VHC38K21CI$087$K)@^8^"
M-JMGW''UI#X)U2*YL2MU8744=E-#*+N-B$FD=G:5(QQR6(P2.!UH T[GQK''
M<Z9#:Z5>71U*R:\@\O:"RA0VW!/WL$=<#T)/%0Z?JM]J&L>)K>]M"UK;)$HM
MUD^8*T.\KV&XEL=1CCGC-0:9X9UNUU3PS<7#:>8M*L7M)_+D?+Y  *@K_L+U
M/<^E:$&BZK:^)-=O8FLFL]16-E5F82!DBV 'C &1G//':@#*T?Q;I.F>&?#]
MO:6\=L+V!GMX+F["I%&IY+2-]1C )/X&KMMX^L=1BTG^SX?,GU)I%2.:01A?
M+^^-W(+<C '7/4#FJ%KX0U[1].T-])OK'^T=-MY+65;A7\F>-F#=N000#Q5_
M5/#^KZI:6\-_'I.I*T<IN([@-&(Y&QM,+A690O//4]>#T .FL+IKW3[>Z:"6
MW:6,.891ATR.A]Q7,>,R8M8\+7")-*Z:B5$4;XWYAD.,$A<Y Y/3GGK6_H5A
M<:7H-C8W=T;J>WA6-YC_ !D#K6?XBTS4-0U/0I[..!HK&\^T3>9(5)&TIA>#
MDX<GG'3WH K+XZL$L+Z>Z@FMI;.]%B\+E26E.-N&!VX.>I(Q@YJFWQ)T_P"S
M7<D=G/,]K<00RK$Z.H$V-CA@3D<XP,G/&*I?\(5J]RVLRM);VMR^L+JFG2AS
M(NY05 <8'&/K][VJ]J>A^*M8T62*]N-+-XUQ!(D,32)#&L4F\G<5+%FP!T '
M\P"2_P#'+6,D=K)I8@OW:1C!>7D<"B)&VA]YR#N[ >_.!DP6OB^[UCQ'H_\
M9=L9=+N;"6Y.)55F8,BD,#TV%L8!Y)]N;^N:/KC:Y;:UH$NGI=BW-K<1WN\H
MZ;@PP5Y!!S]<U770/$%OJNEZA%?6EQ<1V\T5Y)=%S@R.CGRP!]T;2 "1@8H
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M^K3KIQ2UT^6U,:3N"69LKR4Y'RJ">.I..,$ <OCNQ?2=(NL0Q7&J1-)%%<7
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MHHH **** "BBB@#+O_#VF:G=-<7<$CR/$(7VSR(LD8)(5E5@&&2>"#U-,O\
MPOH^IW0N;JS#3" V^0[*#&<_*5!PP&<C(.#6O10!A7?@[0+ZVL[>XTV-H[--
MEOM=E*+_ '<@@D>Q.*DU'PIH>K0VL5YI\;):C;!Y9,9C7&-H*D';CMTK9HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=/%Q']K$0F,.?FV$XW8],\58H **** "BBJ]]?6NFV4MY>3+#;PJ7>1N@ H
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M1D]: *>GQWT7Q,VZG<6\\_\ 8Q,4D$)B!7SAN!!9NAVX.>]=E)(D43R2,%1
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MB-<HPVX4=L?(O7T]Z?J'@F"_FU!AJE_:QZE"([V*V**LQ"[2WS*=I*\'&,T
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M5V%PN.2HST!X&>146HV'A\:EXZMK\PHT<<+6Z-(=Z,8!AD&?O;L<@9.<=\4
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M\\<VIOJ5Q8QVL,X6%DDP43:/]9D\-G/X8KS#1!IEU_PBJ:C>:?!!I;S?-(K
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M@G5[K7?"5CJ5XN)IU9R>,'YCC&.P''X4 ;P55+$* 6.6('4XQS^ %*H55"J
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M-QY VGI&IVD-)@$[<CIUJC>7=Q#\3XKS3=->\EGT'?Y(E6/K,O)+''0 <>U
M'?,Z)C<P7)P,G&3Z4ZO.]3U>'Q _@O5$MY()#JS1/%)]Z)@KAU/XK6BGC^&7
M5X[:"WMY;9KTV3.MWF92&*;_ "@OW-V!G=WSC% '9T4UVV1L^UFV@G"C)/TK
ME-'\:2W^N1Z9?:8EF\MD;U,7/F/&H(&V5=HV-@@XYH ZVBN)MO'MQ</H#?V.
MJP:W(ZV["ZRR*O.6&S XYP"?2I?^$Y=-=M["XTOR(KF^:RA+W \YBN?WGE;>
M(R00#NS[4 =<DL<C.J2*S(=K@')4XS@^G!%/KA!XFMM$L/%6IV^C@&TU013(
MLYS.["-?,R1A?O#@>E:9\6S6\VMV]YI@2XTRT%X(X9_,\U"&(!.T;6^7D#(Y
MZF@#J**\[UKQGK4GA^6YL;&P5&GMXX[N"_:6-Q(^T[6$:\@C!],YYZ'O[=IV
MMT-S'''.1\Z12%U!]F(!/Y"@!TLL<,32RR+'&HRS.< #W-/KR?7+[5]>\(^.
M8M1@M%MK2X9(RL[.8VC6,A54H,@XSNR.6/%=7<>,GTG4=4MM8L5MTM+(WT#0
M2^:9HE;:<\#:Q)7 YZ]>* .MHKE] \6R:OJ_]GRV@7=:BY6:$.8U.<&(EE&6
M'!SWST%=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !360-G(
M/3%.HH 11A0!2T44 %-8&G4A8 @'O0 M%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% '%^*/#.I:Y>7DL<5LLB0H--O$F:&>WD&=VYE
M4DID@XY[].HD&BZNNI^(KQH8)/MUC#;0_O=K,Z*P+$8PH)?/X5V%% 'G5UX2
M\07$4$+I8SPIHRV*17%P[)#,!@R8V_,2,88C(_GM6NC:L=9\/WUU%:H-/LY;
M>98YBV6<+@KE1D#RQ_WU[<]547VF#[2UL)%,Z()&C!^8*20#CT)!_*@#'\*:
M7>Z3I]W#>K$LDU]/<+Y3EAMD<L!D@<C.*J>(-+UN/7;;7?#XLY;E8#:7$%VQ
M57C+;@0PZ$')]Q6YI6H)JNF6]]'!/ DR[A'<)LD7ZCM5V@#D)=%UNWU+3=>6
M2"^U*&"2WNX,^6KH[;@(VQQM8 #(Y&<\U1U'PAJ5UI-X\26W]I:AJ45[<*TS
M".-8V&U =IR=JC)P.2>V!7>UFZ1K5IK:7;V@E"VMRUM)YB%#O4 MP>>,XY]#
M0!S6L>$K_6-;UYY#!'8ZEIB6B.)"72122"1C&W)]>U+%X>\1:Q926'B&;3H+
M?[.\+/8*2UPS(R;GW    AMH_B / &*[:B@#D=$T[Q6HMK76+C3TM+.+8K6C
M.7N2%*C?N& ,<D#J0/2J!\.>(9?#WAO398=/#Z1=VLC.MPV'CA4#^YU/]*[R
MF1S12M(L;JS1-L< _=; .#^!!_&@#E-9\*3:CXULM2C<+8O"JWZ9P9#$XDB'
M_?6<^PQ3;_0=<L_$]]JFB#39HM21!<I?;@8I$7:K)@'(QC(/IUKL:* .<BL;
MG3=;MKZZFA-E;:;]EEN9I=K%MRG<1C&./7O67X0TFS_X2#6-2LKK[1I\=S(E
MFJX\N-I C3;"."-P4#'3#>]=5JXM3I-T+ZV:YM3&1+"L1D+KW&T<G\*R=/\
M%6A?V E_;B>WTJ) $D-G(L80<<?+T'2@#3US2TUO0K[2Y)#&MU"T6\#)7(ZU
MSW]C>(]<T6?2?$#6-O;O:-"SV<C.TSD8#$,HV@8S@9R?;@]C10!QZ:%JU[!H
M$&I16T::0Z7!:WF+-/*D910 5 4$DDYSV'O446C:W;^'-$M?L=L]S97RSR*M
MQP4#,>"5ZX;I[=:[6B@#B8- U%O%,.IBQAL;E+J3[1=P2_)=V_S!0T8ZN1MY
M/0@G/05ER^%?$<?@NYT..VLY&COA/;N)L&0>>926R,*,8&.3G->BRSPP-&LL
MJ(97V1AFQN;!.!ZG /Y57M]2BN=2O;%(YEDM/+WLZ81MXR-I[^_I0!@W&DZG
M<Z_JLOV>-+/5-,CMFD:7YH742<;0/F_U@Z'M6/I7ACQ NL^#Y[V"SAMM"MY;
M=_+G+L^81&&Z <D9QV'Y5Z'10!YU'X1UVWTF"&U6Q%SINIRW=IY[EDG1VDR'
MP/E^5QCKR#78Z%%JB6DCZNMG'<.^1%:9,<:X  R0"2<$_CCM6I10!S>O:=J3
M^)-%U;3[>*X6S2XBEB>7RS^\"X8'!X!3GOSQFLF;PKK4=MI5[ UE-JEMJ,M_
M/$[M'"QD# JK!21C(QD<\UW59,WB"S@\2VV@LLQO+B%IU(3Y J]<D]_IF@#E
MXO#7B"WTC5E6.R:[EUI=4MU$K;7PZ,5/''W< _RKN+8SFVC-TL:SE1YBQDE0
M>X!/)%35FV^N6EUKUWHT8F^U6L22R;HRJX8D#!/7IVXH Y9O#6L6^B:AX7MX
M+:33+J60QW;3%6BBD;<ZE<$EAEL'ITSWJ0>&=4M[[Q,UK%:BWO\ 3XK2T#W#
M%@8T9!O^7H0V<Y)X]ZZ^]NH[&RGNY5=HX4,C!%W-@#)P.]9T7B.WN+72+FWM
M+V>#5,&-XX<B(%<AI.?E':@#F;?PSXATJ'2+G38]+DNX=/BL+V&Z=RCB,?(R
M,%R#R<\>E=GI5K<6>EP07<XGN%7,L@& 6)R<#L,G ]L5<I* /.?$'A#Q!JES
M>R^5I=U(+^.ZM+F=V$J1*5(A'RX0#!Y!.<G(R:SKVQO-0\1Z_<,NF26$EQ"D
M]K-J)@61H44G>NQLC/\ NY &1BO5ZIRZ3IL]VMW-I]I)<J05F>%2X(Z88C/%
M '/:/'J.I^*HO$PMHH=-N]*BA17E/G*=QDR5QC'S$=>P/M4&G:#XEL+A]+6Y
MT]="%P9(YT#"Z$>[<(\8VGTW>F:[6B@#B](T#Q+I<K:4M]9C0UN#+#.N[[4L
M>[<(O[OMN.>,^V&SZ!K<VFRP""S61];2_&;AB!$LBOC.S[WRXQ[]:W8O$EI/
M?_98H+MP+IK1IA%^[655+$$]<<=<8SWK5::*.6.)Y4624D1JS %R!DX'?CF@
M#C=0\(7NJ:KXI\Z2&*UU6WMTMY4<LZ/$"064C&-Q]>@]Z&T7Q5>:+>P:A-IG
MVA[*6TC2UW(DS.-OF2$CC &0 .YKI='UBWUNVFN+:.=$BG>W(F382R'!P/3/
M\J?;ZG'<ZK>Z>L%PKV@0O*\>(WW#("MW([T <]'H6K'Q'H-]+%:K!8Z<]M-M
MF);>P7.T;>0-H].M4-+&O>$-"\.:*4TZ64W0MY45I'=X"XW.@ &"H8DYX '6
MN^K+U/7;72[B"U:.>XNYPS1V]M'O<J,9;'8#(Y.!0!H3-(L+F)%>0 [59MH)
M]"<''Y5Q,/A36(O!D.G,;-M0LM1%_ 5D;RI2)C+M)(ROWB._0&NKTG5K76;>
M2>U$H6.0Q.)8RC*P )!!Y&,XJ_0!Q5WX9UB^_P"$F>5K))-8L8K90KMMC95<
M9SMR1\Y]^/>I9?#5\-?\,:F\MJL&C6LD4X,C98M'L)'RXP,9YQ^%=A2,JLI5
M@"I&"#T- '#Z/INFZMXYO=;TZY6ZTY0DW[M@T)N]K(67'<)C/NWY=I<Q&>UF
MA!P9$*Y],C%%O;P6D"P6T,<,*<+'&H51] *HR:W!%XBM]$,,YN)X'N!(%'EJ
MBD Y)/7)' !H YJR\':BVC^'](U":T%KI$Z3EX&8O,8_]7P0-O)YZU7UCP;K
M6JZ%KVG>;81G4M16[C?S'.Q1LX/R]?W:_F?3GT"LZTUFSO=7O],@DW7-B(S,
M,C W@D=_:@#F-5\#3:QKNO7$]RD=KJ5I#%&4R7CDC8,"1C!&5!ZU;T_2_$3>
M(K?6=573O-@TZ6UV6TCX=RZ,&Y7@';[X]ZZVB@#A=-\(ZK;1^'5F>SSIE]<W
M,VV1CN$K.0%^7MO[XZ5C:MI&H6&ERZ=>M8PRZOXB-W"YE;8B_P"LP7VC8WR
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MQ=2<C@@8!KK:* ,'0M'U>Q,)U76A?"WC,42QP>5D<89^3N; 'IC)ZYK>HHH
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MV1(YX1;I)''Y-PZ':Y!?)!RV2 23DYH L:!,]QH%A-)?)?/) K&Z10HER/O
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M%9TNOZGHDWB*U#7EM'%#8.$FN6N6LXY&Q*^YLG=ANV0#SVKT5?"^BK;W=O\
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M$I$3QM)&#&&RS+\K$NW PP&#7?6,WVFQ@E\J6(L@)CE0JRGT(->::KI>K?\
M"+>-=-32+R2:^U1I[=D0%9$8Q8(Y]$;Z8H ]!M]>TRYEO8X[G#6(#7'F(T80
M'=@Y8 $?*W(R.*+'7]-U*Y6WM;@M,T N%1XG0M&3@,-P&1]*Y#7M)OM9U_Q!
M:P6]U$E_HT=O#<F,B/S%9V*D^X8#TZBK'A'1S!?PWB^%_P"QI(X7AN))IA(T
MAR/ECPQ^7()R0,X&.N: .IO]:LM,GCAN7D\R1'E"QQ,Y"+C<QV@X R.?>J$.
MJ6M_X@TR6UU21H;G3Y)HK94(25=T>)"3T(S@ _WC67XTTV:\N[:YAMM0$]O"
M_P!DO-/?+1RGG9(G\4;87L1P0<9Y;;PZA;>+M"FO;,@0Z3)!<S6\>((I"4;K
M@ #Y#TZ<4 ;0\6:,;F&W-TP>=WC@/DOMF9#A@C8PV#Z5"_CCP\DLD9OB3%<_
M992L+D1R<8#$#"@DX!. 3D=C7GGA^Y>%=$U#6[/5%TS3'>2RE6T!0+,V%9Y
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MI+A_+A5V ,C>@'>K%>;ZK?:CJ\G@S5+FVM8K6YU..2)0I,L2LCE06S@[EY.
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M\0V>H10(UA%%-9;0P-P),A1CG^/"\=ZZ62X-EIKW-XRYAB,DQC! X&3@'Z4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNDB@M8+MHR#I&G^);1[24G*PC='YH4Y.%!+#TZ_2JFOS6+?\+)-O)$%DAL9
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MC%5]1D3_ (0'Q[;1SI+_ ,3&-T$:; VXQ'*KZ'!QUX'>O:6574JP# ]01F@
M D@ $]?>@#/L=3M6GM]-5RUR;-;G 4[?+SM!W=.O:M*@44 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2-!\6Q+J,;EO[.U&(D$-L(.[IN^4D'(SR#S6YX!_Y#?C+_L,/_(4 =Q1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HR,XS132@+!CU% #J
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ IK*"P;)XIU% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %-(.X4ZB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBF.&WKCIWH ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %-8*6&3@]N:=4;Q[I%;TH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "F-C<.OX4^FE<L#0 X=**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ IC2*KJIZMTI]12%1+'GKDX_*@"4<BBD'04M !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4QD#.K'MTI]1N&\Q,#@9S0!)12
M#H*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:6 8#UIU12C,
MT1SW/\J )1THI!T%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%1O_ *Q/K4E(<9H !TI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ IC-B11SS3ZBD9A+$ .">: ):*0=*6@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *8[$.@XYS3ZAE<">)>YS_*@"4=!2T@Z"EH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "HY 3)&0.A/\JDJ-P"X.XC';UH
M>.@I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&6,M-$P;
M3)(QUXJ:FM]\4 . P,4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !3'4ET(/ ZT^FLS!P ./6@!PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "D) ."1FEIC!2X)&30 ^BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *BDW>;'CISFI:AE?;-$N#\Q(^G% $HY I:0< 4M
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444ASVH 6BD'3FEH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D-+3&8A@ ,T /HH'2B@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *8QPXYZT^HW!,B$8P,
MYS0!)12#..>M+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 C="1UID6_:?,()]J?CG-!&: %HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ IK*"P)[4ZFD_,!0 X=**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ I".<TM,=<LI]#0 ^B@44 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !2&EI"><4 +1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !15#4]-?4DB1-0O+,(VXFU<*7&",$D'
MCO\ A3]+L6TW38;-KN>[,0(\^X;=(_)/)[]<4 <1#J"WGC>>WU34=?TN26Z"
MV-N<Q6TZQA3A6(Y+')(!&0<5Z'7&SWEQXNL;6T_L*^LIX[R*:1[V'8(%CD#;
ME8_>+!2HV_WCG Z]5?6@OK&:U:::$2J5,D$A1U]U8=#0!8HK.TG21I$$D2WU
M]=[V#;[R<R,, # /8<?GDUHT %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4UE!(/-.J-PV]"#@9Y% $@Z44"B@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIDCB-"Q!..
MP&30C[U5MK+D9PPY% #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !3&^^*?3&.'7@\T /HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH 3'- &.]+10 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4T@D@@X [8IU% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(:6F.&+J0> >:
M'T4@Z4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4TD9 S3J0J
M"<F@!1THHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>stamfordsecondleasemodif006.jpg
<TEXT>
begin 644 stamfordsecondleasemodif006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 10?Z
ME:EJ*#_4K4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3A,JH7GGJ<]*]5HH \-U9;BPN;WPS ;:ZNKO5+2X9#O6X&-F0J%/G4;<[@<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (H/]2GTJ6HH/
M]4GTJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (H/]2G
MTJ6HH/\ 4I]*EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@"*#_4I]*EJ*#_4I]*EH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@"&W_X]X_I4U10']RA]JEH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@"* ?N(QZ 5+4<'^I3Z5)0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 44E+0 4444 %%%% !1110 4444 %%%% !1110 4444
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M0$13JSEC'NP2H ) X[]!4^J^%-3\9>(](O=<M;>RT[2RTBVR3&62:0D'E@
MORK[\'UI@<5XEOHM&^+%]#/+J#Z5#I[W#6L5Q-@OY9.?E.0,]^@Z\ 5Z=X)T
MN?3-)N#+/)+#=SBZMQ),\K1HT4?R9?)X8/CD\8YS7,2>#/$-W\39?$MW;:8U
MA)"UJUNMTY8QE-A)/EX)Y)QQZ9[UT>M:C?Z)J_AG3=+C@EM;B4P3P,6,OE
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M-:FFG2YDF*?9S,,2!EVDMCDC'XXKJK?1Q9^%H]%@D)$5G]F1W[X3:": .(\
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M4ZYW':3TQCOR*XJYU.ZTSXOZCY%I?7Z-HR2FUMV#$$2 ;E#L .!T'7T)K<\
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M'ILEM)'%=!]KEBRXR!D= ?<F@"T/B3I#:=H]RD-P\VJ!S%;Y1&382'W,[*H
M(QUY[5M>&_$=EXHTD:C8B54$C1.DJ@,CKU!P2#VY!(YKSG3? /B?3-(T6YA@
MTV;4;%[A+BSNB'BGBD</\K8.""/\]#Z'X7TW4--T^8:DUL)YYVF\BU3;% I
M 1> 3@#.2.230!@3_$ZT@34ICHNJ-;:;>"UNY@BXB[%C\W(!],^IQD9O:MX]
ML-)N9U:TN9K:VDABN+F/9M1I0"H + MPRDX'&>]<;I=CJVL#QYH^GVUJ8KW5
MYHI+J>3B$'&?DVG<<=.>OTJUXA\":YJ4NJ0QVMA<QJ+<:9<W$Y5K=(]A,:H%
M(&2I!;()![]  =7<>-!%KE[I4&C:A=36<UO%+Y"AL"4,0_7A!A<DG^+H,&N)
MO/%,FL?#:_OO$FG:A]F&HE%>RG1&3]X0%)ST7A22#G(^H[G1=(U.S\8Z]JEU
M';"UU%+?9Y<S,ZM&NW!!4#!R3G/;WKDI_ _B2X\ ZIX:$5@C2WYFAF:X;#(9
M?,)("''0#'U- &_KGQ(TW1;V^@\B2X73R@O'21%*%NRJQ!<@')QTJ:;Q[;+J
MIMK?3[BYM8Y[>":ZC9?W;3 %#L/S;?F7)QWK/G\,>)-/U_5;S09-,%OJX628
MWFYGMIL8+)@888YP<<_K#J7@O6+O7XK^W6P@NH;F%H]425TF>%44.DD:KAR2
M#U;H<=J +?Q3=8?#EC,6G#KJ5NJ+$Y&[+\@@'#< \'O5_P#X3NRBCUO[98WM
MK/H\237$$@1G97!*E-K$'IZ\9%'CO0=1\0Z78VVG"WWPWT5RYGD*#:F3@84\
MFL?5/"GB2XUCQ3J&GW%I:2ZG:0P6LGFL60H0&W?+QE=W(R10!<C^(1>WU$?V
M%>B^L;=+M[3>A9H6&=P(.,CNO7ZU=A\;6LL>CS&V=(-0L9+]Y#(/]&B15)+#
MO]X#CWK)\)>#K[0O%,UZ^GZ=;64^G);O';3,Y\Q6Y)W*"Q(Y)/ZT[PUX ;3+
M#6[*]EW17"36-D5;<8;1BS ?7+G/^ZOI0!=T3X@V6LZQ9Z?]E:#[?"T]HYGC
M?S%49PP4DHVWG!]_2NPKC/#&C^++&:RMM6N=+^P6*%%DM4;S;G"E5WY "@#D
MXSD@5V= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 06QW6T6/[H-3U7LQ_HL6?[@JQ0 4444 %%%% !1110 4444 %%%%
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M"H.?]GOG-0IK'B?2]%M=9GUVP>&;29WAB^TR327,JQ&02;3& I4CGG Z=3R
M>P45YT]U<Z%9PZQ9^();^*ZTB1XK6X9IOM,Z1M)YBDG$8P.0..@P#BH+R?4=
M(C\'ZCIVKWM\NIW$5K=I+<&19A(I)D53D*5P3\H X&: /3*S=?UF/0-"O-5E
MMYKB.UC,C1P@;B/Q(X]?:O)M,U/7%\*Z)K?]MZE<7<NO"T,,DV8WC9V4J5 ^
M;IQD\=L5HZU<2^(?"GCVZN=3N$>PN9K6&".9DCBCCQP5! ??SG=GK@=* /5H
M)#+;QRLA0NH8H>JY'2L^?Q!8V_B2TT%W;[==0/.B@<!5..3[\X_W35]76*T$
MCL%14W,QZ  5XWJL6JSZ:/'G]D7*ZA#>KJ$4P>+:+$# B^]NP4.3\O4F@#VF
MBN$\3W5QJ.O^#4T[4KFWM=0DF9_)DV[T\DMGZX)QZ'TZUS(NM<@T2YU*/7-4
M;^S/$)LHXY9 4>'SPGSG[TF=X'S'C''J0#V&BO(M9OO$NO\ BGQ'8VFKV^F#
M2MOD[[Z2VV)MW>8552)!ZD\=/6@W.KZ_X@N(E\07J1R>&X[X1VLC1)YW3*Y
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M[J>0<#C)QGVK9\'ZM<>)]0TNXBN+Z.WTNP\J^C>1@'NVPI1\_>*A6;)_O*:
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ME<1*QRVP,Q"$^JX/6MZB@#F1\/O#(TZ/3Q82BTCG^TI&+R;"R_W@=^<T[4/
M7AK5+BYGNM-#2W2!9F$KJ),# 8@'!8?WB,^]=)10!1N]'L;W1SI,T3?83&(O
M*CE:/Y!T7*D''&,9YJ&;P]IL^@C1)(IFT\1^7Y7VB0$I_=+;MQ';!/3CI6I1
M0!ST/@C0+<:<(K295TYR]H/MDQ$)/7 +]/;I^=,'@/PZME/9BTN/(GN1=RK]
MMGR\P_C)WYSW]R >H&.DHH P-3\%>'=9NX+O4=+BN;B!!&LDC,2RCLW/S_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 E+29I: "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** &NZ(,NRJ/4G%-^T0?\]H_^^A6/XE\,VOBB/3H+TJU
MM:7JW3Q,FX3;4=0A]LL#WZ8[UY'X3\):/KGCGQUI$]E D*-)%;%8A_HV78 H
M.Q''Y4 >ZB:(MM$B;O3<,T+-$Y(61&(&>&!KQ;Q/I-KX*^+&AZRMC VF:ABW
MGWQC8LA^1V] <$-[_-ZFL+PUJ^E^&/'FL7T5BD>E:A8W,NG^;CE5+8 S_"QC
M8!?=: /H=75QE&##U!S0KHY(5E8CK@YQ7A>HV]]X>T;P/X/21[2/69Q)J?EJ
M8W<R2)E#W  ?:1_LBMOXH6EOX+MM'\1>'X[?3KJVN1"T<($8N$()VL!][[O?
MU- 'K3,J#+, /<TTS1*Q5I4!'4%A6%XQM+;4O!.JBZMTE5;.69 XSL<(2&![
M$>M>(+/IS_ XQMI%[_: <S?VD+-O++B?:,S8_N';U[8^H!]&I(DF=CJV/0YI
MP(/0YKSOPA?V7A?X066L"TCW_959EB4*T\A;:H)[DD@9-5?A=JNI0:WXA\,Z
MXR_VE#<->_*, B0@OCVRP/\ P*@#TZD+!<9(&3@9/>O"KHZ#I7Q:\5MK=K_Q
M)(+)0(TA9DCD=8B,;1\A/SX/')ZUI:!IVH3_  0UB37(S-"()KK3/M#;WBC$
M>48')VX(R/\ Z] 'LE(S*JEF( '<FOFV*X5?#GA$Z9]ITK59)F$NKSAX8)!N
M;"E^C]!V([9KO[63_A-/B[K&GZJOFZ3I$&R*QD)\MWR!O9#PW5L$_P"S0!ZG
MO79OW#;C.<\4H((!!R#T(KR(M_87QBB\*P#?X?U6T)DTY@6BC^1\[5Z $KD@
M<?,?2N2LY_#^DVGCI=3MV#1WLEOI96-_W;@R;51QPN,*<9' H ^BJ*Y3X<PZ
MU!X(L4U^21[WYB#+)O?83E<GG)Q[],5YKJEMI=I\;+^RGT^2:P-D2MG:P,Y9
MS$#\J*.&SW['O0![K2!E+%0P)'49Z5\_SZEXU\/?#;3])O9KFWO-6OC#;R3,
MRS6\0V_*6ZKECT/(7/MCJ_B+X=T_PGX,CUC0(O[/U'3YH=ES#Q)(,A<2'^/K
MGG/3W- 'JU%>%>*YH]2\9>!+CR5BCUJ.UGO84X68LZG#@?>ZXYI_BW1[_1O&
M6I:]X6585T1;:6>TA.U3&RN7..G11D>AS0![B"#G!!QP:6O(] AT;Q]J&NW.
MF1I:+>6EFTP7AHV,TAF4[2.6$8!/&1@UF)HNFO\ 'R?1C9Q_V;]E_P"/;&$!
M\D'./7/.>N: /;Z3>N2-PR.HSTK(TO3)]#\*PZ:EV)IK6W,:3NNT' .TD9/3
MC\J\1TN[T^PM(_#?BK2KG2==>X!_M67=_I \W<1(PY*$?+GYEZ'C% 'T*S*B
MEF( '<FC<NW=D;<9SGC%>56TQ\9_%W6=(U8O/I&EP@Q6+M^Z=P5&YEZ-R2><
M]O2AC%X;^+T'AJW0OH>M:>?,L&YBB/SCY5Z '8<CI\YXH ]5!!&0<CUH!! (
M((/0BO&_A+IMG/XH\9Q36T<B6MR(8%89\I"TRE5] 0 /PKJ?A_'INB:'X@F2
M,00VFJ7:2R'G]W$QV_@%XP/?UH [RBO)OA_XIU&Y^(6KV6J*T2:M"FHVD3-N
MV+M& /?9C/\ N5G^)$TJR^-D%OJ"!-(DLFN;J$*QC9]DF7*KW[YQ0![317D_
M@JSEUG2_%"2":?PE,[?V6DTK?=5F)V<[E4$+C..GUKDO UOINM^']-T&:T#:
MCJ<UW_ISQMNB$<>4*OD9PVW@'&,YZT ?0M%-C#B)!(P9PHW$#&3WIU !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !11D9QGFB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 0M K3B8CYU&!SQBIAP,444 %%%% !1110 4444 %%%% !1110 4444
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M"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **,TF10 M%)N'K2;Q1<!U%)N'K2;USC- #J*:'!Z4%P.N1^%
M#J*894'4_I2>?%_? ^IH DHI@E0@E6! [CFD2>*0X612?0'F@"2BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 TGK7G&MR2^._$C>'+24KH]BP;4IEY\U^HB!_#FM7QWXBFL+>#1=+;.
ML:G)Y$ !_P!6#U<^P%;'A;P]!X:T6&QA7<_WYI3UED/WF-=%-*G#VKWZ?Y_Y
M$/WG8U+>WCMHD@A14C0;551@ #H*G7O2T5SN[=V6%%%% !1110!YO\7K35]2
MTG3[#2K*6X,MR&D,8X&!QD]AFM7X?^#O^$3T4QS.LE_<MYMTX&!GG"CZ9KLZ
M*W>(FZ*H+:]R.1<W, Z4445@6%%%% !1110 4444 %%&129'K0 M%-SS1^-*
MX#J*;TI"10 ^BL#5?%^B:0QCNKU#+G'E1#>_Y"LB3Q1KNI;!H/AZ5HVZW-\W
ME*H^G4UM"C4DKVLN[T7XDN2.U-4+[5K#38S)>7L,"*.3*X6N87PYXDU0YU7Q
M))"IZP6">7QZ;CS5RS\"Z!:.7EM3=2@Y\R[8RMGZM5^RHQ^.=_1?KH*\NQ#-
M\0--<%=,AO-3E/ 6U@8@_P# CQ6->V>L^))O-/A#3K9R/^/C4'#N!]%%=_ +
M6WC"1"&-1P H Q3VO+9& :XB4GU<41KTZ;YJ<=>[?^5@E%RW/,%^$K7,_FW^
MJ(NX\PV4 11]"3D5MP?"OPW%"(IX[JY YS)<O_('%=<^KZ=']^]MU^L@JJWB
MC0D'S:M9CZRBMY8[&3ZM>A*ITT8,?PUT2W!^PS7MGZ^1<,,T\^"[F-B;;Q-K
M$8[!I X_45L'Q;X?'_,7LS])14+>-/#2L5;6+3(Z_.#4.MBZCO*[]5?\T/EI
MK8S/^$8\2H/W/C&Z]@]I&12C1O&D?3Q3;/[/8C_&K+?$#PL,_P#$WB;']U6/
M]*C/Q$\-9^6\F?\ W()#_2FOK#_Y=_\ DO\ P!-077\2(V_CRVR8[S2KOV,1
MC-0-KGCJS)$_ANUNAU#07.,?@15K_A8FB9PD6HMZ$63\_I2'XAZ=G L-5(]3
M9N/Z5<856M:*^YH5XK[147Q_?6YQJ/A/5;?'5HQYH'Y"K2_$GP]]VXN);23N
ML\++_2E/CJW<9BT;6)0?[MK_ (FJ\OB&:\!5O!5]./26- /UH="/VJ37H_\
M.X<SZ2-^Q\2Z/J17[)JEM(3T42 $_AUK84YKS&?3[F^F66#X=PPR \3-/'$Z
M^X(J+^R/'KZE'<VH>SVC;MEO1*A _O#O2^J0D])I>K7Z!SM;H]5HK/T>/4(]
M+A759(I+T+^]>)<*3[5H5PM6=C5.ZN%%%%(84444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!!<7MK9@&YN880W3S) N?SIMOJ%E=L5MKN"9@,D1R!B/R-<K\46B7P4XD
MA\YFO+4)'@'<?.0XYX&0".?6N>U64S_%'PI+<:3/H#J)E6:01M]J) Q%F-F
M[]3_ !=* /5**X!/&>L_V?KUI/!8Q:]8WL5I;1 -LD\TJ(WQG)!RS<= /:NL
MM3K/]N7"W*VITL6\9B=,B0R\[^/[O3_Z] &G1110 A.*KWEREI;2W$IQ'&I=
MC[ 9JP>M<3\5+^2T\$W$,+E9;R5+5"/]LXJJ4'4FH+J)NRN9_@2WE\1:O>>-
M+U!FY)AL8_\ GE"IQGZG ->C <U1T;3XM+T>SL8$"Q01*B@=@!5ZKKU%.H[;
M+1>@15D+11160PHHI#0 N:*86&*K7&HV=FA:XNH8@.I>0#'YT)-NR"Z+F:3(
MKE[CQ_X8MR0=8MI&'\,3;V/X"J#_ !*L9&VZ?I&KWQ[&*V(!_%L5K&A6EM%_
MUZDN<>YV^X XI-XSC/-<./&'B6\4BQ\'7*'UNIPG\@:07?Q$N_\ 5V&C6BG_
M )Z2.Y%7]5J+XFE\T+G1W6X#O0&%<0-*\>W'^N\0Z=;CT@LR<?B6IR^$-=N.
M;WQA>L.ZP1(G^-)T8K>:_%_H',^B.T\Q?7'UJO-J5E;_ .NNX(_]Z0"N4/PX
ML)?^/O5=6NO:2Z./T J:/X;^%U8%M/\ ,(_YZ2,V?S--0H+>3^2_X(7GV+]S
MXX\,6;E)M;M P[*^[^59TOQ/\*H0$OI)F](H';^E:]MX6T*TQ]GTNU3'0^6#
M6@MG;1<K!$I]D HYL,MDW\T@]]G(/\3-.=L6>EZO<MV"6I&?SIR>.;^X!\GP
MCJ_'=U1?YFNNDEB@C=Y76-$&69C@ ?6N9N?'%FUS]ETJSNM6FYS]D7,8^K]!
M5Q=.>D*;^_\ X%A.ZW97_P"$E\52J/L_A)QGO-<JN/UK+U+Q?XKTU#)=V>BV
M8QE8Y;@M(?H!R:UETWQ7K1/]HW\.E6K=8+%=TOXNW^%:NE^#]&TM_,CMA+/G
M)GG.]R?J>GX5KST*>DHQ;\KO\=B;3>S.'L?$_P 1=;Q]ATVSCB<_+/)$RJ/P
M8Y_2KT_@WQIK08:MXH2*-AS%:1[1^/K7HP3!Z\4]>E9O&+FO3IJ/RO\ F4J>
MGO,\[T_X97FGKB'Q%-#GJT%NBL3]<9/XUH?\()J!'S>+]9/KAU'\AQ7:T5,\
M;6F[R:^Y?Y![*)QC?#\2QA9_$6N28.>;K'\A31\-=/;_ %VJZQ*/1KQJ[6BI
M6*K+9_@A^SB<</AGX? ^9;MS_>:Z?)_6I$^''AI<%M/\PC_GI(S?UKK:*;Q=
M=_;?WA[./8YM/ ?AE/NZ/:Y]US4T?@WP_",)HUCCWA!K>HJ'B*KWD_O'R1[&
M.OA;0U&!I-D/I M21^']+B/[O3K1/=85S_*M2BH=6H_M,.2/8I+IMLGW;6 ?
M\ '^%3"UB7[L4?\ WR*GHJ7*3W8TDMB+RAV51^%.V'U'Y4^BD,CV'T%.VGMB
MG44!83%)@TZBER]0$ XI:**8!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!SW
MB_PY<>)]-ALH=02S5)TG+M;^:2R'*X^88YZ]:IGPE?WNJ65]KVO-?Q:?(+BW
MM8+18$$HZ.W+%B!TZ8KK:* . T!;3Q;XV7Q9;6-U;6MK:>0K7*&-I9B6&=O0
M[4+#/^W[5U]O8WD6M7EY)J#2VLT<:16FS A*YRV<\DY]!T%:%% $%U=1V=LT
M\[A(T&6;'05E_P#"6:(%R;]#_P  ;_"MEP"I)7=CG%9&E^(=.U:]N;"(2PWM
MJ%::VN(BCH#T.#P1[@GJ* &?\)=H9_YB$8^JM_A7.^,[C1?%/ARXL(M5@BG!
M62&1@<+(IRM=/;:U;W6MW.E+9W2S6RAI)'B C .=I#9[X./I6D88F.3&A/NM
M.,G"2G'="//O#7Q0L)H$LM?SIFH1_NV:93Y4I'!*/T-=(GC?PVQ&-=T\CVG%
M:5]HVG:E;M!>V-O<1'^&2,$5SQ^&GA ?=T6*/_==Q_[-6K=*<N9W7IJ*\B\W
MCSPLA^;7K$?20&J-W\3O"MMQ'J8N7[);1/(3^0Q5VV\#>&+;&S1;0D#JZ;OY
MUKP:7I]LH$-E;1@=-L0']*G]TN[#WC@I_BW&[O'I^@WTK+T:?$*G\SFJ[>+O
M$>J%0M[HFDJ1D[I_-<9]AWKTPPQ'_EDG_?(K-_M+0_[872A/:-J# D0* 6
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M="&\EF*PQGV4=1]:Z:VU_P ,VT0@@O[**-0%"(P4#\*V94M(49Y$A1%&YF8
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M_O@4GV&T_P"?6#_OV* (M/U.TU2,R6=Q%<1C@O$P(SZ5=ID<,4*[8HT1?15
M%/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KS[Q#>>*-#AM;N36AF^UA+5;86\;+!
M [D*%;:"6VX.3G_'T&N'^(YGF@T6WM;"^NI(M4M[J0VUJ\BI&C'<20,9]NM
M$NK#4=.:&._\6?9DFU* VSO F^5.-T&$ ZL1SZ=:K7WCR.]M?%-OI<KPW6EV
MKRP2M;L=S+&7;(88&",<]?>KGQ 6>YTG21;6=W<'^U+:9A# SE$5MS,P R,
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MN3#'& ^7(.-W7'%:>J^$Q=:#;:#I[BTT\.//VCYG0<E?J3UKKJ*J6*JRM=[
MJ,4CG=;T:74O#LVE6=P+19%$1=!]U.A _ 8J&\\&:3=6-G9I;BUBMIXYD$"!
M=Q3) ..M=116<:LXJT7YE.G%[HY37-$OYM4L]7TN2(7=JCQB&<?NW5C[=",=
M:@T7P_J@UNXU[5I[<:C) ;>"*($QP)UZ]6.>M=E15*O-1Y5Z?+L2Z47*YP5K
M\-8/^$<6TN[Z4:K]J:\.H0<,)3T//4=/QYXKJ]#M-1L=-6#5-06_N%/$XB\L
ME>, C)R>O-:5%55Q56JK3=];]/P[>@X4H0=XF5HOAZQT'[6;02-)=S&>:25M
MS,Q]_3K^9K@5\%:WIVH74K:)HNN--.THNKQV\P@G.&4\?E7J=%52QE6FY/>^
M]_+TLR9T(226UCCM*T;7)IO^)A8:'IMIY;)Y=C#NE.5*@;CP "0>/0"N=T[X
M37&G2LBWNFS1DY\Z>R,D@Z<!6;9V[@UZG15QS"O"_(TD_+_,3PU-VYM;'"Z_
MX1O[W5[:\AAL;K3K$;K?2R3"CR'JS$ @\]L?US>\$:#J.CC5;G4E@AEU"Z,X
MMK<Y2(>Q]\_H*ZRBHEC*DJ7LGM_3_/KN-48J?.@K-URRU&_L%@TS4SITWF M
M,(1(=G.0 >_3GVK2HKGC)Q:DO\S5JZL<:G@!+B_ANM6UW5=2\F59HX9I0(@X
M/!V@8_+%:.N^&VU[5]+FN+D?V=9LTLEKMR)I.-I/L.:Z&BMGBJSDI-ZK;ROV
M,_8PM:QAZKX0T36KW[9>VCM<&/RF>.=XRR^AVD9_&J=UX!T"ZL[*R%N\-E;3
MFX^SQ-A9GQC+YR6X]ZZBBE'$UHI)3>FVHW2@]TCGM3\#^'=7NQ=7>G@S; FZ
M*5X\J!@#"D#@<5'+X"\.2QV,)L (+-VD2$,=CLV,E\_>Z#K_ "KI:*%BJZ22
MF]/-@Z5-Z\J,F'PSHEMJ5OJ%OIMO!<VZ,D30IL"ANORCC/)YQWJ_/96MU)!)
M/;QRO _F1,Z@E&QC(]#S4]%9NI.3NVRE&*T2$(# @@$'@@URS_#CPH]P9O[*
M4%FW%%FD"9_W0V,>V*ZJBG3K5*5_9R:OV=@E",OB5S,G\.:-=-:M/IEK(+1#
M' K1@K&IXP%Z8X]*2Q\.Z+I4K36.EVEO(>2Z1 $?CVZFM2LCQ1::C?\ AN]L
M]*=4O)U$:.S;0H+ ,<_[NZJA.<VJ;G9/ST%*,4N9+4Y"SB;XA^)Y+^XWGPYI
MLGEV\.?EN9A_&?4<_P AZUZ-5'1]+@T72+73K8 16\80'&-Q[D^Y.3^-7JK$
MUE4E:&D5HE_75[LFE#E5WN]PHHHKG-0IK/M8#'6G44 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 (<XXH&>]+10 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+ 9W)<\<'Y>"=P ]^N*V;SQI>_VUI_AS3]/BFUV:W6>[5Y"(;-2 26.,MR>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F,I+@Y
MX%/HS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "D(^8&EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "F22"/&>]/JO<#,D6?4_RH L4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !116/K^OVN@68GG#N[N(X88QEY7
M/15'K19O83=C6#H20&!(ZX-+N'J*Y.U/C&]A6>0:=IY896!PTKJ/1F&!GZ9J
MP;7Q=_T$-,_[\-_C5<C[HGG\CI,BD#J>AKA?%5OX@_X0G64O9HKAWA41K9Q.
M&'S#/3GIZ5@K<75@+]_#1NH-%FFA629HI',&5;S'1'R3_"..^:35BD[GK&]1
MW%&]>.>M>966O^(9)]'%Z]Q:HRC:D5F6^V?O"IR,83Y,'G'6H+O7-7U/3-0L
M&GO()8[6832Q6KY1A.0N.F<)C.#G!I#/5=Z^O;-)O&2/3VKQVRU+5+'1X)+2
MUD\N"ZN/+9O,,<@$)*NHDY SG@]^E6K#Q'KNI3K;6.J"XC^T^3]K^R@;5^S[
MS\N.N[B@#UG<,9S2>8F<;AFO++'Q3XINM=TNWDMRD$D,;2*T+ 3[E.\Y P""
M!^=7O"6IZMJEWJTVHR32,UA$?+\HQK#*?,WH/4KD#/M0!Z/D4@(/2O%O#/B?
MQ%8>&))#>/=0Z;9P3W$$]H8VMPDH#Q%V!W%H\MGD\< 5W_A34M0O;>UN=2O?
M,DO+<W26RP;1'&S93YN^%P/7F@#JZ*!10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %,=5;&XT^F2=5H ?1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %,<=*?2$ ]: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHH/2@ HKDO$FO:EI&N:+86L$,L.HRM#YDCLIC95+9.![4W3/%4@\2W
M.@ZI!!;7J6HNU>*7=$T><$Y(&#D]_6@#KZXM/^2Q7'_8%C_]'-74G4;)(8YF
MNH1%*X1'+C:S'L#W/!KDK:X@N/C!>&&:.3R](CC?8P.UO-8X/H>16D-I>A,N
MAVIY4UE64+:9;HAB )<ERA+9R3R2>:UA2D9[5FAE<7,)/,G7ID5,LB$<.I^A
MH,:,,,BG\*A-K#DCREQ[9% $V]<'# XXZ]ZQ?M]Q?ZQ/96KF&*VV^=(1DLQ&
M0!^%698["UC8-(L8,F\Y?'S<]_SK-U+19KV1KG3[E[2YD4*9R21M';;T/'>J
MBM29&A.D-N7D)EEE'S; 26/T&:RM/M+R.\N[_49W@LY&W163OOQ_M$]03_='
M I(8].T5_M&J2-#(^(_M-Q/E7]L]JBTY4U746U&T,YMU#+"\A)1CTW 'KS5V
M)N:KW7[D3WC^1"6Q'&IP7/X>OI34EMFF2ZNMB>3DPQ ?,F?7'?%44D$EX(S/
MYTL6-UTX'WO[J+T)P>HJXK6FF:?Y]S(MK%&-SM)RW_US[4GV&C;AE66-77[K
M<BI<USD$MQJR?:)6:QT[.4!(5Y!UW'^Z/:I1XELO[233;9;B>;^(QIE4']YB
M>U3ROH6F;U%113))NVL" <9!R#2K*KLP4@@<<&I&244T.O9@?I2[U]10 M%-
M+CL1^= D7H6&3[T .HIN]?44!U.<,#CK0 ZBBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *:<[A3J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *1CM4GTI:",C% 'G?CRZME\5>$HI9=NR]DDE*M@
MQJ8RH)].35+3;*";XD726A>_TZYT[%Z\Z[U1@P"*)&'0@L<#TKTMK6%V+/&C
ML>"64$D>E5[^R>?3I[:TG^RRR(525%'R'U H \[\,Z5<C5%\+SQ+)8:!=-<1
MR,0=^X;H5/NNYL_2I],FTJT^*=W<6118;N)K60[<9ND8,RY/4[6!KL]!T/\
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MGR0?0@>Q[5Q&JQ3_ -E0&QDM9(0\H\A+>>-5?Y?G'))8<8R<5*8-2_MJ7RY
M^M1WB/L$4@)48R=Q;;M(R,8ZTG-WN.QZ3'IZL/\ 2V-PQ..1\HXY  _K69I7
MA:'3YKFXN;B:[NKB8NTARFU?X4 '4 5P-A#J[6=Z5N':%Q ]^8XY0R/YA\P8
M+<\8R1V!JS<+K*^'KF/1&DETWS-VZ"-XF0K@A8P[9*$\?G24FM0L>F)8VL)(
M2)E]@Q -/6PMP25# DY)!/I7G:17NIZ_JDZ7=K%<:?:D3R6T;Y+R)R"F_&5
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:=110 4U@3C%.IK,%QGO0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M)CG-+10 4444 %,DC$F,DC'I3Z#0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 45'%,)=^%==K;3N7&?I4E !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4A&:6B@  Q1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1SFBF,F6#;B,=@: 'T444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1143N5D5>QH EHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HW(W@$$GUJ2FEOW@7
M:3D=: '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !43*#<H
M><A?6I:C?_6+ZXH DHHHH **** "BBB@ HHHH **** "BBB@!DLT<"%Y75%'
M4L< 4^J]U907L9BN(DDC)&Y67(..1^M6!T&>30 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1/%NF23=]T$
M8J6HG)\Y0#VH D' %+110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %,92958$<#%/J)U!G4EL8'3UH EHH!R** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ IC??%/II!+ T .HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&(523T%(K!U##H:
M<0",'I2  # &!0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !29 -+4;C,BF@"2B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *8P!<'//I3Z:5RP
M/I0 X=**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IC%MX Q
M@]:?3&_U@H ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!
M&:*8RDN"&('IF@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5$SD7*)V*YJ6HV+"5<8QCGUH DHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "HW^^/F ]C4E1O]\<"@"2BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *B8_P"D*,]JEJ"0,;J,@KM .01S0!/12#H.,4M
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5&R_OE;VJ2H7D N4CQ
MR1G- $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "-]T\XJ*(
MS&:3>5,9QY>!S[YJ:B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ J)F43JI')'%2U6F1C>1$$8"-D?E0!9HI!TI: "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ J%V N$!')'6IJC8'SU(4$8ZYZ
M4 /'3FEH'2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *A?_CZ
M3Y2?EZU-49)\Y1GC% $E%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5$R,9U<-A0,$5+36!+#TH <**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ IAD42!#U(S3Z3:"P;'([T +1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %-).X#MWIU-;[XH <.E%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 W>!GK3JKW=
MK]JA:/S&C)(PR]1@YJP.!0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !32
M/F!IU0R$^=&,]<T 34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !4,O^OB^I_E4U0RN!/$N.3G^5 $PZ44#I10 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %1OCS5^3/OZ5)4;NHE52>3TH DHH[44 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !4;Y\Q>>!4E12.!-&O][- $HX%%
M Z44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4;QAI%;TJ2HW9
M@Z@=.] $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4Q\;Q
MDX/I3Z:VW<,]>U #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ J-]GF+D<]JDJ-]OF+E23V- $E%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4QB ZC-/II168,1R* '4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 45S^OW?B6V,9T.QL;I=I\W[3.R;3VQQ
M5N_:\E\-7FY=MXUF_P L1SARIQM/UH S+#Q#J7B&^,FAV]H-'AF,<E[<LQ,Y
M4X;RD7MUPQ/)'3O745XKH>G0Z9X1\$ZKHUU-%J-Q?10RQBY=DG1F82J4)VC'
M)X QCUKUC79M7M],9]#M+>ZO=P CN)-B[>YS0!I45EZ!/K5QIQ?7K2UM;SS"
M!';2%UV8&#D]\YK4H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J-W9944
M+E6SD^E25#*!]HA/U_E0!,.E% Z44 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 9EMX=T:SU%M0M],M8KMBS&98P&RWWB/0GO
MCK6G110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#("9XCEN,\#
MI4U,8_..#0 \=**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "F*7+L&4!1T.>M/I H!!]*
M %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ J-V82HH/#9J2HI%8S1," !G(_"@"6BD'2EH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH * <]*0@,I!Z'BFH@C55484# 'I0 ^BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F
M-]]?:GTQOOB@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5&YQ(HP:DHQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>stamfordsecondleasemodif007.jpg
<TEXT>
begin 644 stamfordsecondleasemodif007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WJW_U*U+4
M4'^I7Z5+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $5O_
M *E?<9J6HK?_ %*?2I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*JJI4*C2,RX!Y P<CV(KJJ0#%+0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !112$XH C@_P!2GTJ6HH/]4GTJ
M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0C-+37[4 ,@_P!2
MGTJ6HH/]2GTJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *;)(D,9>1U1!U9C@"G5'/#'<1-%*@=&Q
ME6Z'G- #PP/3GWI:0+CH  !@4M !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4USTIU-=<D>U #(
M/]4GTJ6HH/\ 5)]*EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"&W_P"/>/Z5-4-N08$(Z8J:@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH ***3('6@!:* 0>E% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK'&*=
M2'% $%F=UI$1T*BK%5K(8LX5]$%6: "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+:+_ '14]06O_'K%_NBIZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ",H92K
M$$8(/>@*%4*H  & !VI:* "DQ2T4 %%%% !1110!'-#%<1[)HTD3(;:Z@C(.
M0>?0@&I*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI"<4 +1110 4444 0
MP?ZI/]T5-44'^J3_ '14M !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 1P?ZE/I4E10\1H/]D5+0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% $<8_=K] *DIB?ZM:?0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% #$!"**?24M !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %-DSMXIU(10 HZ44#I10 4444 &**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ***0Y[4 +10,XYHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D.>
MU+10 #IS1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-9P@R
M>E.I&4,,, ?K0 HY%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%-8%@P/0^G6E48
M'I0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 444V1_+C+[2V.PZT .HIJMN /3(SBG4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%-8;AC.* '44#I10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !01FBB@  Q1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !3))!'C/>GU7N2!)%D9Y/\ *@"Q
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%!..M)GG'>@!:*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HI,\TH.1F@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MFN0,9&:=3)!]V@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 V2-94*-T-*
M !2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!')$LNW=GY3N&#BI*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBF2/L&<$^PH ?130>*=0 4C#-+10 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
MR3?M^09-/HH 0=!FEHHH ***1F"]: %HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "F21"0KDD8]*?10 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 444A% "T4#I10 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%(30 M% HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **:SJN-Q STIU !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 (1G' -+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 444UG"<GI0 ZB@'(S10 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %&,T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4FX9QD9]*6FA
M5#EMO)[T .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBD()Z'% "T4@X')S2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !2,=HS2U',6"C:,G- $E%(.@I: "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ IKD@<4ZD/- "CI1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %,D4NN VWWI]-8 \F@!1T%+2  # I: "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ J*?E/Q%2U'-]V@!XZ4M(OW12T %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%%  >G%1-"'=&).4J6B@ QS1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1RDA<J,GCC\:DI
MDC!!D]* '#I2T@Z"EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"D(!X(I:CF<HF1UR* )**!THH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "HIU+H5'J#^M2TUB!R30 HZ4M(.E+0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%(K!LX[4M !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %1R@LN /2I*9*S* 5&: '+TI:09P,]:6@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH   .E%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1S2>6FX^H%25%.BR
M)M8D#(/'UH E'2BD7I2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !36IU1RQ^8NTG'0T /'2EI!TI: "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ IDC%!G*CIRW2GTR7[O3//>@!PY%+2#H*6@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "D9E099@H]2<4M-= Z[64,/0B@!U%(!B
MEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BG7<F,XY
M'/XU+374.,&@!5Z4M Z44 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 44C'"DXSCM21N73<5*^QH =1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4UVVC.,TZHY4WK@8_&@!XZ4M(!@4M !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %'
M2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *CE*A?FZ9J2HYD9TVJ<'CK0 \=
M!BEI!TI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDK,J_+US
M3ZCESMX&30 \=!2T@Z4M !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !144ZNT>(W*-GJ!4B].3G\* %HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ J*<X0]1TZ?6I:9*6"_*NXYZ4 .7D4M(.E+0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %17!;R\*"3D=/K4M13[MA
MVXSD=?K0!(#D4M(.E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 &:*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *AN%+QX#8Y'-35'*&90%X/O0 \=!2TB_=%+0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %1S/L7=]/YU)3794&6.!0 HZ4M(.E+0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %,E=$3,GW<BGU'*I9<#'XC- $@Z
M44@Z4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C,%Z]*6FLN
M[K0 HY%+2 8&*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0T
MM1RN$7<?I0!(.E%(.E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %13X*8.>2.E2TUO3;F@!0<@&EI!R.F*6@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *:[[%R!FG4AH 4<BB@=** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ ICMM&:?374,,&@!1TI:!10 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3%9B3
ME< =*?10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %(2>PS2T4 (.G-+110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% #&+AAM7([\T^BB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0T +1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D
M)QUI::XR,4 .HH'2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*0J">12TUUW<$G\* % P,4M(.!2T %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !112&@!:*!THH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "F2+N&,FGTR4E0"HR: '+T%+2#H*6@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
/ **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>stamfordsecondleasemodif008.jpg
<TEXT>
begin 644 stamfordsecondleasemodif008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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MA^I_E5JJMW_K(?J?Y4 2P?ZE/I4M10?ZE/I4M !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR\%CY?G/%)&/OQB0!0S DX;\ZU=)U[3]9M+:XM)Q_I$;2)&_ROA2%?*_[+$
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M(WEW0.5@W_=$K ;4/^\10!O4444 %%%% !1110 4444 %%%% !1110 4444
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M325OT.L6UNS1-8LXG;[N?,/$6  &##Z8)KU7%&* &0H8X8T)R54#/X4^BB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "JMV2)(<8ZG^56JK70S)#]3_*@"6#_ %*?2I*9'_JUI] !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 56NCB2'ZG^56:JW?^LA^I_E0!80
M8'-.I*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J7G^M@^K?
MRJW56[7,L/L3_*@"S2TE+0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %5[C_61?4_RJQ5>Y_P!9#]3_ "H GI:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ JI=_ZV#ZG^56ZJ7?^LA^I_E0!;HHHH **** "BBB
M@ HHHH **** "BBF*K"0DD;<<>M #Z*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***2@!:***
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M0S(DIV,5:[#C@XYVD'%%M8WL>O7G@W84T:.Z&HF7 51:L2YA'/3S<@_[.>E
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M#5"D5O%&X;(W*6<XZ*!R3]* )]8U[6K;QGI>B63Z?Y&H122)++ [,FP9(.'
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M@#FY?#-Q/,99KVSFD;[S2:;&2?J:>GARXCBDB2ZLDCDP'5=/0!L=,CO70T4
M<U_PBI[R:>?^X;'4ZZ!<K<"X%U:"<=)!8)N'&.N<].*WJ* .?G\/3W4OFW%S
M9S28QODL$8_F:@D\(K++YLG]FM)N+[VTR,G<>ISZGUKIZ* ,"?0+J[*FZO+2
M<J,*9+!&P/;)H@\/36L@D@ET^.0='73U5A^(85OT4 4+.UO87E:[NH[@-C8$
MA";?U-7Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JM<G$D7
M!/)Z?2K-03;O,BVMCD]O:@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *BD'[R/\:EJ*3[\?XT 2T444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 444T[LC&,4 .HHHH *AE_UD?U/\JFJ)Q\Z'ZT 2T444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !3'ZK3Z8_:@!]%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1124 9T
MOB'1()7BFUC3XY$8JR/<H"I'4$$\&C_A(M$\II?[9T_RU8*7^U)@$YP,YZ\'
M\JY'Q_8V^G:-X?M[9-D?]OV[XSDDLSL3D]>2:M?$NP@C\%^(-052+B:TBA<Y
MX*K)D<>OS'F@#J'UK2H[1+M]3LEMI"528SJ$8^@;.":C?Q#HD:1N^L:>J2#*
M,UR@##...>>017#^*M?$_P ,[VV_LO58]UBJ^9):E4' Y)]*M^-P%7P0   -
M:M0 /H: .TNM5TZQ6-KN_M;=91F,RS*@<>V3SU%2VUU;WD9DMIXYHP2NZ-@P
MR.HR*XK7IM6\+^*[GQ#!I,FJZ?=VT<,RV_\ KK?82<XP<J0Q.!W'..^YX.?3
M9?#L=QI$RR6$\TLT6V/9LWR,Q0CV)(_"@#?J.2:*)XEDD5&E;9&&.-S8)P/4
MX!/X5)7F'CG6GENKJ_L]3BC'AV:*2.U+J#/-G]YQG) C8+T[M0!Z;)(D,;22
MNJ(HRS,< #W-4++Q!HVI3"&QU6RN93G$<4ZLW'7@'-8_B_3I_%O@>2/2)8V>
M=8KF#S/NR@$.%/UP.O%96AZ]!XA\26$6I6$FC^(K!7+VTT.?.B*D'8_]W.#^
M'?K0!VTE_9Q3K!)=P),S!5C:0!B2,X ]<4UM2L%*AKVV!=0ZYE7E3T(YZ'UK
MSJ^OF\,3ZMI/BG37FT#5;N65-3B7>L8D/"R YP5X /L, XK5U&U@M=/\!QL\
M=\(;Z"*.X"[=X^SR88>@R%;'L* .UFNK>V@,\\\44(&3([A5Q]3Q4*:KITIQ
M'?VKG9YGRS*?EX^;KTY'/N*Y:PSK7Q+U=KMBT6AQP1VD.?E#RH6:3']['R@^
ME274^FQ_$:U065P-5EM'B?;&FR:W)4[V8MT4KC'7KQ0!UL4L<\8DBD21#T9&
M!!_&H?[1L<,?MEOA/O?O5X^O-><:-=W/A:XFU<-O\/7^HW$5U"HXT]Q.Z*XQ
MT0X&[TZUK7(MYM+^(+K"G)<,>N[%I&0?US0!W".DJ*\;*Z,,AE.014,U_9VT
MGESW<$4FTOMDD"G:!DG!/0 $_A7&>$KV+PO;:MH.H3[(-)'VJV>1ADVCC(],
MD,&!^HJMX6BN)?'U]<ZG'B^O-)CGGC/*QJTC!8P/9 H/J030!W/]JZ=_S_VO
M_?Y?\:?%?V<SHD5W!(SJ&14D!+ C((]1CFO-=-O]-TG3_$SR>');TV^I7CJR
M60>/ /"EL<#C\*NZ_P"&(K6\\,Z9HI^SWMK'/):W+!2Q,2*%1SC)4[L'IQ0!
MWTU[:VTBQSW,,3L,A7D"DCZ&FKJ%D\QA6[MVE#%2@D!8$=1C/6N*N=4L_$UM
MHS75E%'J%MJL4%Y:RJ&:!\,2N2.5. 0>AI/&VA:;8:%:&*UC:276+=Y)9%#.
MY>8%LL>3UQ],"@#O0Z,Q4,I8 $@'D9Z?R-.K-L]#L-/U.YO[2$0R7$212)&
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ML_&\":>#J/V^XCM5M+5C,!L0HJ%!D#=S@?CQ0!ZT6 ZD"FO-%&"7E10 22S
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M298DNV"@1RL2H1ESN^\I&<8Z<T =317&ZA\2-(L;VZB^26&TF$-S(MQ&'0Y
M+",G<R@D D#UQG%7;WQ>+?4[[3[?2;RZN+2W6X(1D =&SR"6P!A>_/M0!TM&
M17#77C2[OF\+S:-IMS-:ZFS2.P>-6(5'+189AR,9)R!QP3FH+SPKJ,VN7EP'
MN"DNNVEXK[QCRHXQGC/0$E?P'% 'H%%<N)ET+QM::?&Y%IK,<\JPYX2X0AW8
M>@8,21ZC/<UU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4AQ2TUAG% #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HKG3XUT=;J.*1IXXI9)HH[EHCY+-%G?\WMM;GV-6]/
M\26.HZDVG1K/%="W6Y$<T10M$W 8?U'44 :]%)FAF5%+,P51R23@"@!:*SI-
M9M8M>@T9O,^USP-<)A,KM4@')['G_/%:- '.>,/#]WXAM+"*TE@C>TO8[S][
MG#E,X7CH#GKV]#4WC'1KKQ#X5OM)M&A26Y0*'F8A5P0>P/I6[10!S/B#2-5U
M?P/+H\,-C%=W$0A<&X?RHU]5;9EN@X('4\\<TM?T#7M9BT(QQ:;%)IES%>%6
MN782.AQLSY? QSNQUXQWKLZ* ,"/3]9L];U:]MI+2:VO C1VTTC+MD5 I;<%
M. < $8/W0<]JL>'M%_L2RN(V>-I;FZENI/*3:H9SG &3P!@>^*UZ* (YO-\E
M_(V>;CY-^=N??%8NEZ&UEH*V]U:V-U?JK;Y&&%G<DG<QVDC<3D\'&>];U4M3
MU2#2K=)9ED=I)!%%%$,O(YZ*HX&>#U(Z4 <AI_A+Q!:>'--TEKNR4V%Y%<PS
MH[G:@8DQE=HW  X!W#(/;'.TVCW^I:]INHZC'8PC36D:(V[M(\I9"G)*KL&"
M3M^;)QSQSIZ/K%IK=D;JT,@"NT4D<B%7BD7AD8'H0:LW5REI;M/(LC(N,B*-
MI&Y./NJ"3^5 '*+I'B2/1;_1C!I5Q;3R3K#/-=2;EBD9BH9/*(8J&_O#I^-+
M=>'=6MH/#ECIL6GW%IHQ23==SO&\K+$\8X6-@OWMV<GGMQD[^D:W8:[;&YTZ
M226WSA93"Z*_^Z6 W=#TK1H YB\\.WUOXE/B'19H%NIXEBO+2X)$5P!T;> 2
MK =\'/H*@30]:N?&*>(KQ-/A:VL7MH;:&X>02,3G+.8UVCZ*:ZZB@#G=#T2Y
MBTS4++6;2Q:*ZN99C%#(94*R,6*G<B],_CUXK(TWP;J.C>&?$.D6DT-Q]OED
M6U>XF8;(FB6-0QVDY4# 'H!R*[FB@#CM5\'S:WK&B:G=>1#):JT5]%%(S+/%
M]Y4R5&1O ."!P35B'2=:C\<7FMF*P-M+9+:H@N7WY4E@3^[QR3@^G7GI74T4
M <1X:T3Q-X?TJZLI+/1[O[1<RW#,U](H^<_=(\DY_/FI[+0]?35-&OKV6UN'
MM_M#W3-</D--@E8UVGY4Q@9/(':NGO[^UTRSDN[V=(8(QEG8_I[D]AWJMHNO
M:;X@M&N=,N1/&CE'&TJR-Z,K $'ZB@#-U/PP+CQ7IFNVK[)(9,7<6<+.@5@C
M$=V4MP?0FH_&^F:MJ]A9VVEVT$ICNXKAVFGV8\M@P &TYS^&*VK#6=.U2XN8
M;&\BN'MB%F\IMP0G.!D<9XJ]0!' TKP(TT:QRD LBMN"GTS@9I9C(L+M$@DD
M"DJA;;N/89[4^L<>*=#.KC2AJEM]N+%!%NZL.JYZ;O\ 9SGVH S_  SH,T%M
M>S:WIMH=0NKAYII RR[\G@ E1@*N !6+I>A>)K#PWK^B-96CV]TTYL/]+(\E
M).!&1M. H)/'N/>NTU#6+#2C"+RX$;3$K&@4LSX&3A0"< =3VI+O6]-L=-34
M;B]A2TD ,<N[(?(R-N/O9'I0!GW>A'7/"T%CJ2"VO(T5DD@DW&WF4?*Z-@<C
M^N*P;_PWK7_"&^'M(M+6VDN+&6WFN"\^U28B"<':<EC^5=;9:YI>HZ8=2M+^
MWEL@"6F60;5P,G=_=QWSTJ+1_$NB^(#*-*U*"Z:(X=8VY'O@\XYZ]* ,?6=+
MUSQ3;C2KVWMM/TJ0@W;QW)DFE4'.Q?E 4$@9))X[5U,$$=M;QP0H$BB0(BCH
MJ@8 J2HKFZ@LK:2YN9DAAC&7D=L!1[F@#$\8V.IZIH+:?ID:,;B1%G+3>7^Z
MW N <'E@"OT)K/\ $OA&";2(O[!TFSAU*":.6VD&V(1%6!Z@9Q@$8%=-]OMQ
M8?;7<I!Y/G$NA5@F,Y*D9'';&:BTC6+'7M-CU'39O.M9"P23:5S@D'@@'J#0
M!FK_ ,)"-<AO?LD'V.2S2.YM_M/*2AF.8^,-P>^W((],5E#PWJEI;>)+O3H+
M>VO=0NHIK6W23"*(ROS-Q@,Q#%L9_&NVHH Y?4-,O=<U'19Y]+AM7L;D3RSO
M(KL %/RQE>2"3SNQTSBB33M3TOQI=ZS:6OVVSU"WCBGB214DB>/.UAN(# @X
MZ@UNZAJ=GI444MY+Y:33) AVDY=SA1QZFJG_  D^BK;7%Q+J,$,-O<O:RR3-
MY:K*IPRY;% %?3[&]_MN_P!<N[<122P1VT%LD@9A&A9LN>FXESP"0 .IK%OO
M"FHZIH6DKQI^K6$^!/%('Q"Y*R!6QW0YQCJ!]:Z"#Q7H-RR+'JML&DD\I%D?
M878]  V,Y[8ZU-JFOZ9HP)O[H1!4\QL(S[$SC<VT' R<9- &(^CWL7C32[VS
MT]4TRPLWL\&50V&VD%1SD#:!R0>OXR^$].U/3-0UT7UFL<5[?/>PRI,'&&"K
MM(Z@C;GTY_/5G\0Z5;:E#I\UXB7,TGE(I!P9,9V;L8W8(XSGD>M:= &;KXNV
MT.\BL;0W5Q+$T:1^8J#+ C))["L_PO!J6F>#+*SN=/*WUG;K#Y/G*1(5& 0P
MS@'WZ5T1JE?ZM9:9):)>3B)KR=;> $$[Y#G"\=.G>@#BM-\):C>_#P:!?6YT
MR_M9O/M;E95D"R^875QM.1C.#]>*V]2/B+5-#DTV*P2SO)X_)FNWF5HD4C#,
M@4[F..@(7W(Q73T4 <TFDSV&M:!':VDCV.G64EJTNY!C<(@IQNS_ ,LSGCN*
M@N?"I@\;:=K5@72V>9Y+ZW1@$,GE2*LV#W^<J<=<J>QKK*@N[RVL+62ZO)XX
M+>,9>65@JJ.G)- $]<UXHT&YO;S3=:TM8SJNF2%HDD;:LT;##QEL<9'0]C5J
M'QAX:N91%#K^F.YZ*MTF3^M;0.0"#D&@#E/$&EW_ (OLHM)N;&6PTYY5>\>6
M1&=U4[@B!2>I R21C'0YX5K#4$^(T6J1Z:_]GKIQL?,$D8P3('W!=V=H QZ^
MU=5FC- #8H8X(Q'%&L:#HJ# 'X4DSM'"[I$TK*,B-" 6]AD@?F:@NM3L[&>V
MAN;A(I+EF6%6_C*J6/Y $U%;:YIEW):1P7L3O=PF>W /^M0=2OK].M '*^#[
M37/#>@W5G/H4TL[W4T\>RXAVD,<@$E\CWX/XT7VE>()K/PSY]M+>W=E>B^O)
M%DC4#(?,:Y89V[PH[87K7=44 <]+)JL^J03V^DRVD:@M=2.T)DG5 VR(88\;
MG)R2,8/K5+2?"]M<V=Q?:YHROJ<\\DTJR.LF[)^500<%0NU0#Z5T<VI6L&I6
MVGR28NKE'>)-I.X)C<<]!C<.M6Z /.=*TKQ;8^#-4T:*T>UFBE+Z5*MRA(C\
MP$1M@G&!^!!(^NEK.B7OB;4]$GDTLZ=/8W*7$UZSQLVU<DQH58L0S'OCCG':
MNTHH X:)/$EEXSU?5H?#IFMKR*&*,->Q(P\O/)'/7=Z]JW/#T6K&>]N=2MDL
M8795MK&.17$8&2SE@,99F/\ WR*W,TM $5S$9[66$'!D1ESZ9&*P/ <H/A"Q
MLV^6XL%^QSIW62/Y3^> ?QKI*R-+ET74K^[U/2Y(Y9D<VMQ+"Q"LR@'!'W6(
M!'S<D<C/44 ,\6Z9/K/A+5-.M=OVBXMV2,,< MC@9]ZR47Q!>>(=!U"YT9K:
M&WAG2X1;F-_+,@4*>HR1M.<>O&:["B@#S.\\/:]<^%O%6FKI+K-JNHM=6Y:>
M+ 5BAPWS<$;#Z]16MXFTS4-9:</X=$Y-DIL[A+B..:VN.<J6R#C[IR"1QT.:
MZBRUBPU&[O+6TN4FFLV"7"ISL8YP">F>#5Z@"KID-Q;Z39PWDIFNHX$2:0_Q
MN% 8_B<UD^*[>_OK*"PM+)[FWGG3[9MD1?W .77YB,[AQQV)Y%=!10!QOBSP
MW(T=C?\ A_3(CJ]I=I-'(I1,J.&5F)!VE>,#VJCK^G:WK37CRZ T=VL*'2[R
MVN426WD*C<KN&!*A_0$$=NE>@44 >>:YH>NWGGLFF?\ $ZCBA6RUFTF2([MJ
M^8).0=N[?@8((.,#K4NK0WVG:KXCU>^LT;3&T<0;YI!LE=-Q^95)8*=Q'3/Y
MUW%U=065M)<W4T<$$8W/)(P55'J2:@@GT_7M)$L9BO+"Z0CYERDB]#P>HH X
M'P[!?:'9Z#+KFCZ@R6B1VT$INX9%@DE(CSL7#8^?;R6*C\33[SPYK=SX2\6:
M<NG,MQJ>IM=6X::/&QBAY.[@C8?S'OCIHO#?AKP^#J)MXX([<;A)<SNZ0@=U
M#L0F/48]*V[.\@O[.&[M9!);S()(W (W*>0>: .;@@U6/QEJ&K?V3*+>;3XX
M8PTT6XR(S-C ;H=V,Y[5C:=H6N67@KP_ICZ6S7=CJ*7$ZB>/;L64N2#NYX;&
M/8_CZ)10!P5MH>N:1=ZGI]II5G>6=U.\]K?RRHK6YDY8,I4EMK$D>O3Z7(]'
MU2'Q-J]VUO)/#/I<=K',7C!ED0-DD9&,[O0#Z5V&:* /.=*T77-$T+P@ATEY
M[C3)YEN(HYH^CI(H8'.,?,,]_:O1ESM&X ''(!S2TF: .4U*%-2^).A"%]S:
M3;W$]Q@_=\U0B ^YPQQZ"NLJM:6%M9>:;>(*TSF21R2S.Q[ECR?0>@P!P*LT
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UD#,&R>*=10 444
M4 %!HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M ,?Q3JESH_A^>[LXUDNB\<,(<C&^214!.2!P6SU'2LJR'BB74A#=33V]C/;X
M\R4VYGAF5A]W:-K*RYZ@X.>E;VM:19Z]I%QIE\C-;S@!@IP00000?4$ _A6-
M9>$9K*+S/[<OKN_C0I:W5[B7[.#@-M7@$D#J<G]<@'"VD5[;? B^N5U2<HT<
MZB'RX]H4S.C#.W/S9)ZY!Z8KK=2U'5K;6;#P]8W5[<326KWD]RL=OYH0%455
M#;4^\<G()_HZ/P)*/!K^&)-9D:S=CETMU5]I8NPR21RQZ^@Q5K4O"5UJ*:=<
MC6I;;6+'*KJ$$"@NAZJR'@CH?3/;F@#._P"$AU^T_LC1M0CBAU74KR6)+@A6
M"P( V\JI(WE2!C.,\T>*;76+KPS>6NH7JQQG4(84:!5W2P//&JE\CY6&3TZX
M_"M"\\$0WMA!YM_<'5X)A<IJFU?,$N "=HPNW  V],"IIO"C3Z5=P2:E,^H7
M4L,TE\T:DAHG5D 3H%!7[ON3U- $1O\ 48_'EMHSW:O;MI4D^_R5#^9YBKG/
M3H>@ 'KFLZWU[6X=.UBQO;@/K,.H+:69B@4!Q( 8W*GJN-Q;V5L=*V(/#5S%
MXDL]9?5GFD@M&M762$9E#-N)R",<@8P. ,59?P[;OXM7Q S$RK:B 1$<!@20
M_P!0&9?HQ]: ,2ZU;Q%<W^L6>EI)(U@J01.$AP\Q17+2;G!"D,!A1ZG)Z5UE
MA+<3:?;RW<(AN6C4RQJP8(^.0".HS7/W?A"9_$4^KZ;K=YIS7807D,2JZS;1
M@$;@=IQQD5T-G9V^GV<-G:Q"*WA0)&@_A Z4 4/$U[<Z?X>N[JTN+:WF0+B:
MY/R("P!)]2 3@=S@5@:9K6M3CQ)#!]HN9+6UCFTX7L"Q22,Z/@,JA>"R<9 /
MK6_XDT0>(=%DT_[2ULY=)$F50VQD8,#@\'D=*Q[OP7<W4FHR'Q#>A[^WCBD8
MQID.C;E<8 QC)&!@<DG)H B\(:Y=:UJDQ;53+#':KYUA<P"*YMYRW.X!1E<<
M _SZUV=8FG>'VM]:;6;Z[%WJ!MA:K(L0B41[MQR 3DDXY]N,<UMT <8NJ:OK
MDOB*33-16T&ESM:V\9A5DDD10S&0D$X).!MQC&>>E07%Y?>((?!][;:A-8&_
M<S,$CC?RV^SN3MW*?]H<YZUK7'A5_MVH3Z=JD]A%J0_TN)$#9?&-Z$_<8C@]
M>GK27?A><S:1_9FI"QMM*3;!!]G$@)VE,DD@_=./S- '0PQ^7$JEMS8&Y\ %
MCW)Q3S0H(4!CDXY.,9K+UG3+S4&M)++5)K"6WD+G8NY) 01M9<@$=_PH XWP
MI<WMM\+?#GV.Y2V61RD\^P.Z(6D_U:\[G+!0!@]3Q1/XIUZ'PC>W*W"&\M-8
M2R$D]OL:2(E,;EZ*WS\G';IFM^3P9%#I^BV^EWTME)I&[[/+L$@.Y2K%E/!)
MR3GL2:HR> KF73M1LGU^=TO+]+X/);J61EP>2",Y*KZ  8 H F@U;6(_&UQX
M<N[R%_M.G&\MYX8 IMSO*;<$G?V.3Z=*S[/Q9J]QX;\):J\D0EU34%M;F,1?
M*59GY7N" @'7N?:MY/#=R/%T'B"34E:1+,6;PBV #KG<3G)(.[GCMQ66/ 5R
MEEI=DNO3"VTR[2XM5-NI*A2Q )SR<-@$\ 9X[@ ;J'B35+36((TF1LZI':RV
MZ6Y>-('<*K-(/NN=P.,^V*FCO?%%[XGU:RM+NQ6UL[FW&7B.?*92S #/+<CD
MG!QP%HD\$7GV>>"#Q!-%$U^+^%/LR$1R>;YG/=AGMQVZ]*T=.T271-5U?5I-
M0:>*](FEB^S_ #*43:""IR3@=,<GIB@#G[/Q%X@GT>\L[BXABU]-7%B@6$;=
MIPVX*3RNS>V2<_+7H"Y"@$Y('7UKC]"6P\1^*IO%%I'.+>.W6VB,T31[Y,MN
M<!L=%8+G'<CM78T 5KRVBN$1I+=)W@?S8E;LX!P0>QYZUS/A*Z,GB7Q/!=6C
MVNH&XBFDCW!D,90*A4CKPG/N:Z'5+6]NX(UL-0-C*D@=G\E9 Z@'*D'L<CD<
M\56TG1/[/OK[4)[DW5]>[!++L" *@PJJHZ#DGJ>30!C>%T6/QKXQ5%"J+BVP
M , ?N%KL*P-'T"[TSQ!JVIRW\4Z:DR.\0MRA1D7:,-O/&/;\:B\++K*W.K#4
MKN:ZM3<;K22:V\A@#DLH4\[02 "<9P>V* .DKC/%6EV4NBV/A?3[9?/EFC:W
M55S]G1'#-*3U P",]26QW-=G7$Q^$O$T-[>W4?BNW\Z[RK2MI@+HN> I\S@#
M/ Z=\9H =ILLEU\6=<\X8%GI\$,(QU5R78_GQ^%0^ X89[74)KF/ TS5KV&T
M+.=D<98$D#H,9(SV&1W-;,_AVX34XM3T^_6&]6R-G))/#YOFC(*L?F!R#D]>
M<U1O?!EQ)X<MM&L=3C@C$IEO'EMC)]L8\MN =< L22,\\#IP0"+P_H=IJK:W
M?SVBC3-3O4N+>#E1(L8 \Q@.H=E+8/4$9ZU82"'4_B)'?VD8V:9:26UQ<+C#
MRNRXBSWV@,3Z%@*>- \2&"]W>)HEGFA6&W,-CLCM@"=S!/,(+$8 )/&*=HWA
MW6=.DLHI]<A>QM<G[/;61A,K$'EV+L3R23ZGDT =/7*:W*UYXYT'27/^BK'-
M>RIVD9-H0$>Q;=]0/2NKKF=?M)+7Q%I/B%$9H+198+L+DE8G PX&.0K*,X[$
M^E %"R;5'^*FHQR7T+6\5C$PC^SD81G?"@[NN>K<Y]!7/?#_ %34M,\&>&WC
M6T;3;F\:T>,AO-#/(_SALXQD?=QT[UV,V@74WB8Z_IFKQPQW%K'$\?V<2B0*
M692&W#"G<,X&<=",UFV'@6]TWPQI.C0:O 3IU]]K$SV9/F88L%*^9QRQYSZ4
M 0R^+]:N;BYGTJR:XM[>]-L+<6,K&54?8[><#M4YR0,'I7>UQ_\ PAM]!=:A
M'8ZX;;2=0E,L]G]F#,"W^LV2%OEW?0XSQ77(@C144851@#VH R_$&CG6[*W@
M#JC0WD%R&89_U<@8C\0"/QKC/'NCC1OA;XF42!S=WOVMB!C!DN$./P&!^%>D
MU@^,/#TOBGPY<:/'>):)<%=\C0F0@*P88&X=UH S[W4+J_OM"TRYT"Y2RNIM
MTTLY0[#&AD0@QN<'>J]?IWJK!'KEWX]UNTFGT_[-]AA7]Y8LWF1L9MHQOYPQ
M8'L0.U:DNG>);RW%G<WVG16SE5E>UCD678"-P4EN"0",]LY'-20Z=K47B#4-
M1:;3W2XA6&%?+<-&J;RF3GGESG]* .,T'4;G1_#E]>W"VU[OUJ:&UMEM3N^T
M-+@/G<>!SP!GMFMH^,=5TRTU:;4]/D>*WC1K2Y-H]LLKN0@C96)(.YAR.V?2
MG1>!+B7PU?:/>W\1,UT;V"YMXBK03%]^<%CD \#GD$]*L/X1U#6=-NK;Q-K'
MVMI81%']DC,*QD,&WXR=S[E4Y[8('4T +<7'BZWMM2BN'L,QV GAO(H&V+*,
M[TVE\G@ @\?0UB:;JFK:7X-\%L?L-Q%>7-K S/$P>-' QMY(+?>RW'4<5TFG
M:%K36TL>NZVMX3;O;H((/*'S#!=N3N; ]@.:R?\ A#M<'AW0M,_M.QD?2KJ*
MX5V@901%PB\-]<G\J +L'B#4[3Q-JNFZS)916UO:&\M9TC9?,CSR3EC]SH1W
MZ\5!8>)-:EN+'2KH6J:G)8_;KATM9'2-6.U$"ALYSG))QQ[UI^(O"L7B&\TN
MXF<+]DD/G(!_KHV W)GT)53^%0ZYX;U"Y\0VVNZ)J$-E?I ;6;SX?-22(MN
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M-NTR1D$<D>M:7A/1;CP[X9L])N+F.X>V4J)(T*@C)(X)/KUH O:O_P @6_\
M^O>3_P!!-<5HWB#6=(T?PJ;O3[8Z5?1VUFK12,9HF9%",W&"">PZ9')KO+J
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MKJ6TU%@J2*FUW*Q@,VU0>,CI@8'2@#U*BN15]6T75-%\_5I]0M]2F:&X2:)
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MB@ HHHH **** "BBB@ HHHH *1@3C%+10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 4=7TBRUW39-/U"+S;61D9TR1NVL& X[9
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MNBO"[@KRXZ*7;M]>E8'@KPRMCH\']KZ+;V^HP2LVX.L@8DDB08X#<XSUXZT
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M?[3XJU^ZU7142RO!"MN#(I&R--A5E4]#UQ@C YH Q]*E_MV?0M,UZYBN!-I
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M@#,3R$\KC&W)]JKW-G;Z_P".]9^Q:I'!>PP6DME<1N&"RKYH(*YPPPV"/1J
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MU]XEU&(6FHV"6\<6HV4YV2HHCW!X'Y'W7STY(..: /1IKZUMW"3W,,3'D!Y
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "D(R<TM% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !C/6BBB@ H
MHHH **** "D  &  ._%+10 4444 (5!&" 1[TM%% ";5W;MHW8QG'.*6BB@
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M %%%% !1110 4444 %%%% !1110 445&Y^<#- $E%%% !1110 4444 %%%%
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M0 4A.*6D(S0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R7Q._Y)QK7_7)
M?_0UK%#7&N^(O#NC:M$EC%8Q1ZE!Y<OF"\=5P &PI4KDDCG(SV&:Z/Q?8MK&
MDG26BO9+>Z.)C:A<[1SC<P('(%95UI$M]I.GV=W9:L]S8.'MKZ-HEFC(Z8(&
MWI@'CG% $^L->K\2='-C%!))_9USN$\A0;=\?0A3SG';UJAXDFUB'P?XKNKV
M-;>^*M';>4X8?9PJ9VG )'+DY ()/M3YM,UJXUBUU4SZNMU;0O"I$%O@JQR<
MC\!^57(;>Z;47NM0M=3OY#;FW"3I $16^_A5P/FP,YSTH W?#4=O%X7TI+7!
MMQ:1>61W&T5R/C.RM=/@\'6MD +>/Q';A0&SM.YR1^!)%7;&QN=+B%II_P#;
MEMIZYVVWEQ/Y?LC-D@>W.*J:GHRW\.F0P6NLVL.G3+=V\<<:/^_#EM[,^2Q.
MXYYY)S0!K?$%$M_A]KA@58B\)9M@V[B2,DXZY[UTD_V>W#WLRQJ88VW2E>53
MJ>>N. ?PKEM?^T>(=(DTR>PU>""88F,,<8+CTRV<<XZ4S5UU'6O#[Z5+#K$0
MF7RYYHXH0TBD8(QG S[4 <N]Y-;75CXZE^VO(;QUN%:TD4)8R<( 2 ,+A6X[
ML?QZ+X@G-_X/(Z?V[!_6K6J&?5?#[Z/<:=J@CEC$4TB01AF7&#@?=4_0<=JS
M+K1YKZWTR*[_ .$CD.F3+-;.(X-P9>%+$J=Q _/O0!WTKQJNV5E ?( )QG@D
M@?@"?PKS%!?>#M!DM[R+^VO!<R@PSPG$UI$YSEEQ\P^88(Z8[=*Z K=RZI!>
MW,.NW @1Q'#)%"$5F&TM\H!)QD<D]:SH=)OETM-'DDUM]'6)86MFMXMSH  4
M,@YVD CUP<9H [+RKV768+N*\4:;]F96M]G+.2"KYZCC(Q[UHUS*W5P=;MKD
M6^K16ZPFW%J(QY9)((=N>P&/QKI4.4!(QD4 +1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!28!.:6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "DAMQ( QUH Z3<,@9&3T%+7G]O=S2_%6VFN;"YL =(ED(GE5@?G3D;6(7
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MF@#=HK&T_P 1P7NHKI\UG>6-V\/GQ1W2*/,3(!*E6(R,C(.",]*V: "BBB@
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MX)VCZ#FIT=9(U=#E6 (/J#0!S_CC2[S6/"L]KI\0FNA+#*D9<+OV2*Q&3P.
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M %%%% !1110 4444 %%%% !32^'"^M.II'S T .HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#.U72QJ8LP9=@MKJ.X
M^[G=L.<5QOB_1%T+X8Z] LYF\^[^U$E<8\RX5L?ATKT.L/Q7H,WB70I=*CO4
MM(YBOF.T'F' 8,,?,,<@>M &T65%RQ 'J37 #QAKM]!-?Z3IT]U$MXT4=N+0
MX>)7V,?,W<-PQZ8Z#%=!<:)K&H>1#J&L6SVB3)+)';V31-+L.X*6,C8&0"<#
MMBJ2^"[JWEO;>TUV:#2+V=IIK/R%+#><NJ29RH;Z<9XH I>(_%FJZ0NL2QFT
M5[&:$6]KM,C31MMW,Y!RF2W!(&,=\U8UCQ7?VFKWFEJ;2RN3!&]A]K0[;IS]
M]5D+*N1P /7GFDU3P/>WMOK=M;ZRD,&J7 N2K6@9T<;>-^[E?E'&,CL?6S?^
M$[[5=-U6PO\ 6$N(-05/EDM=P@8* QC^?C)&X#L?6@#/UCQGJT-[K%MI.FRW
M+V3+%$%L)IEDDVAG#.A 7A@ ,'U/!J]>>&/[?:\U1Y'M)M2TN.U,$L63"0Q?
MGGDY.,>U/G\+ZK;ZS=WFBZVME!?!3<PR6PEPX4+O0Y&&('?(KI+2U2SLX;6-
MG9(4"*SMN8@#&2>YH Y;QN6L+KP_K$&5F@U**WD93RT,ORNI]1G:?J >U=?7
M)>)HO^$@UG2]$MG.VUNX[Z]<*2J)'RJ$]-S$@@9Z GTSUM '!2>-M0M+O28;
ML69FO=5-E+;10L3 A9@I,@<KOX4XZD-P.*FC\4ZO<ZW)IB?8K>ZCU/ROLD\3
M))+9AP#+&S. WR@G@'Z<<PMX"U1M.TJP_MZ,0:7?+=VQ^R99L$D%R6^9OF/(
MP#GD5HW_ (0NM5>VCOM366WM=2.H0MY)\Y1O9A%N+?=&[&<= !B@#J)O-,$@
M@9%FVG87!*AL<9 (R,^]>=V/C;Q%<^&8->-OIGD?;Q:R08?<X:;9E6SA<94<
MALX)]J]%D#F)_**B3:=I89 /;/M7%6?@2[M?"HT$ZI"46\6[$_V8YR)!)C;O
M]1CKTH L2>(]1T.YUD:Z]G+%:6"7L7V5&CZEU*');/S* #[]*2;Q'J>D+H-W
MJ;6LMGJLJ02"&-E:"21<Q[>3N7@@Y&>_M5^^\,?VEKUS>W<\<EI=:>=/EMQ&
M5.PDMD-NZY)[5%;^%[N0:3%JFI)=V^E2"6%4@V-*RJ50OR1\H)Z#D\^U %&U
MU[Q%)=:JTL=@;;2KUDN-JLI> 1!_DR3\X)'7@Y[5/8>(=;N9='E.G>9;7O\
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M<22F0J3M!'#%>E.LM U9?$4%Y)8Z9:6,FFM8R6]K*?W W;OE^0!NOH .>O<
MIZ/XQET[P?HMQJ4<+7>I9:'?=G##!=F=BN5 '0#=V K1M/',=W:W&VRS>1W:
M6<4239CG=QE2LA4?+@,3QD;3QTK,3PEK]MH>B>0]@FJ:$^+7$KM'/&5VNKDJ
M-I8>@./7GC0U#0_$&LVD5[//:6NI6US%=6EJKM) A0."&; )+!R"0.,#&<4
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M ,2(QY!.,CIV(K#NT\1'7%\-QZK/<^3:&]:=+E;:9]\KJH)V-E5"XX Y(]J
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M110 444S!$C$ME<?=Q0 ^J.HZ/I^KQJE_:I<*I#*'S\I'0CT/O5T<@&EH 0
M 8%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !3&)#CY<^]/HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH R->\/6_B!+1;BYN8?LLZW$1@91B1?NL<@YQZ
M'CVJL?"%C)J][J-Q/<W#7T!M[B&4H8WC[# 4$8R<8/US7044 <UIG@G3](1Q
M9WFI*WE^7"TER9/LZ_\ 3,/E5XXSCI4J^#]+/A<^';CSKG3P,(LS@M&.HVL
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M))Y%N4,%VMG<1E 3"[' +$$C;WR">AJS'XOM9"(A87XNB\JBW>)4?;&VTO\
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M:7%[.Z36\KNF(@-J !3@C9@\?Q%J -JZUJRMM$75B[26KJC1F,9+[R @'U+
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MW=!IXQ:S""6*6%ED#MMVKL(SSO7'KFN4CFMFTCPK;Z1I^J-;:;?KYR2V[>9
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M5YVJ6)L[M9'C9,$!@#PP!YP1@T 6+/6-/U"\N[2TNXYI[0@3HASY9)( /O\
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M)&5MRKEF53G.0I.!SR,#BLG_ (2K663PO(EC:D:T"6CW,&B_=%P.>H'!)]B
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M99VD"E I8#&=W.1QBKPU_4+378])U&RMUDN+9Y[6:*8[)&3&Z,Y&00#G//%
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MHHH **** "BBB@ HHHH R=8TJXU2?3S'>K#!:W"SRPM%O$Y7[H)W# !^;OR
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M,-_8+;1ZDMW;EX69F3SQ-A^<9!SP.N!R,FNYHH Y2W\/:G'J/B*X>2T\O6%
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MI&1 I=NK$#J?>@"2BBB@")(V1G._.YL_2I:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ IK9W 8_&G4AQT[T *.**0# I: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\21!YZ;<*6!;(;L:Z^B@#C-&&IZ?X.T_3)O#UU)?6<"(H,D7E^8GW6W;\XR
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M(!P1GUKA_+U'1O''B.__ ++N;FVOX+<Q20C('EQN"#CG.[:, 9^;/0&NYHH
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M.?2IH+764S:W!D4DL$#<IU .>#GTX%6H?%,UT!=6NER3:<;\6(G$GSGYQ&9
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MBBB@ HHHH **** "BBB@ HHHH **** "DSSBEII^^* '4444 %%%% !1110
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MV>JS#3M/@:%[:1 QGST8MQC&.,#VK?HH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "F-NWC&W'OUI],8#>* 'T444 %)2TE "T444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "F,?G%/J-I,2JGJ,]* )**** "DH-(6 8+GDT
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M6S'_ 'TW^-)_PC&C?\^0_P"^F_QK9HH P_\ A%]'S_QX/_W];_XJ@^%-(/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRZ=;?RFSNA&-K-Z,><BKRLK#*D$>H- "T4@(89!![<4$A022 !U)H 6BBB@
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MR]OC>W-E%)<F'R#*1\WEY)V_3D\=ZJ+H$2^)TU=(;6+RH/)4QQ8D<' PS=E
M' 'K[4 8?B*VLU^)/A:XEA@!>&]\V1U'(5$QDGTR:HVFF:7!>>)]8O)[B---
MU&2:*02,WE9MDW$#J<[NG^R,8KN+_2-/U.:VEOK2*X>U?S(3(,[&]?Y?E3(=
M"TNW:[,5C"GVS=]I 7B;=UW#OG)ZT ><:.)8/&/A2*.,6UG?Z;,75929+@;
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M5SG:)&!7RAQC[X\S':J8VV-]K&BZYX?O[];Z^DN+5HD:6"9';*JQSM0@X'.
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M6&VA7<\C= /ZUP]II/\ PEG@74KN[O+6-=<)N7;&[R0"/*7?NP-H1,C'!W4
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MZ5"X9&7/5=@&/3&*G-UHRZU%+K&HW-C;W>CP0V]TNT1NJ[A)$693@Y[<?RH
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M'.>@Z]?2NWH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ II7+
MYZ=J=32Q\P+C@C.: '4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT4ZMA2Q5\%>3TSD5NZAXFCLKR\MH+&ZO9+&%9[H6^S]VK9P,,P)8A6.!Z>]
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M*2KL"<%?<9K07Q1Y4-E#)INH2W\UNT[6RQHLBJN S$,P'5AP#GVH TM,TO[
MUQ-+<RW5U<,&EED &<#  4<  5H56T^]CU+3;6^A5UBN84F0.,,%8 C(]>:K
MZSK5KH=K#-="1S/,MO#%$N7ED;.% X&>#U('% $M_IT.HB%+AG,44JR^4#A7
M92"N[N0" <?GFKE8<GBFR@L3<3P74,@NELQ;.@\UIF *H,'!R&!SG'O6?JWB
M'2-1\+Z\MZM_!%:(8+V)8_WT>Y0>,9'0]<X]\4 =916%-K]AIEMI]O%%=7$M
MQ"&@MH$WRF, ?,1G@#(R2>IK,^'MU+=V.M/+)<L%UBY1!<LQ=$&W"G/(P.U
M'844V21(HGDD8*B LQ/8"L#2?&.GZQ>06\,%[$+F-I;66>#:EPBXR5.?<=<4
M =#17/:=XQT[4I5$<-W%!)')+#<RQ;8I43&YE;/3GOBH[?QA8W[&W%IJ<+26
MDEU$6MR#)$NWYDP223N&!U]A0!TM%<MHNK:-I'A+1OLT]U);7 6&R68;IIB3
MQQ^O8 >@JP?&.F+9:G<LEX!IBDW2?9FW(1G*],$X /7&"#G% '08!QQTZ4M8
M-AXMTV_O$M56[AED@\^$36[)YR8!)0X^?&1TS^-58O'NB2Q6\VZZ2WGG:W6=
M[=A&KABH#-T4DC@'G!&0* .HHK&L?$VG7T]["?M%M)9()9ENX6A(C.?G&X#*
M_*>:2#Q-837@M62Z@E>)IH1-;LAF1<;B@QDD @XQGGI0!M4A4,"" 0>QKG+7
MQQHMY'I\L+W)AOY?)AF-NPCWY(4%\8!)' SGIP*AT?Q7)JGC+6-(%I<I#9+"
MH9HL;78.S%CG@$!<?0T =5341(U"HH51T"C IU85UXLTVSO);=Q<L(9D@FF2
M!FCBD;& S=OO+[<B@#=I-JABP R>I]:YZ]\::38WE]9M]KEN;$*TT4-L[L P
M)R !R !DGITYYJX?$6GG3[.\BD>=;U-]M'"I:248R<*/0=?2@#6HKCO ]_/?
MW_B0RO=E(]0"1I=9#QKY:\8/3G-=C0 A56QN4'!R,CH:6L%/%VF274,2?:&B
MFN3:QW0B)A:7D;0WU!'IFGW/BBQM;W[,\-XP%U':-,D!,:RN0%!;ZL!GIDXZ
MT ;=<]?Z+JXUN;4](U2V@-Q"D4L5W;&8#83MVE64C[S9!SUIT_B_3(+IX6^T
M-''=+:27"Q$Q1RD@;6;MRP!^M(_B^PCTJ_U%X+T0Z?.T%TOD'?&0H8DK_=PP
M.?>@#0TO3!IXN9'D$MS=2B:>0+M4MM5>%[#"CN3ZDUH5@W/B[2K6^6R<W37+
M6WVE(X[9V+K\N N!\Q.[MG&#G&*KCQYH;6]M<+)<-#,XC>00-MMW+;0LIQA#
MGC!H Z:BL;5/$UAI)G\Y;B;[,@DN#;PF3R%(R"^.G'/KCGI27OBC3K--R"XN
MP(%N6^R0M+MB;.USCL=IQ]#0!M4@4*,* !DGCWJ.UN([RTAN8B3',BR(2,'!
M&15;5-6M=(@BDN3(3-*(8HXT+M(Y!(4 >P)_"@"]17&>)/$4=_X%U^YTNYNK
M6[L49)!@Q2PR#G!_ @\4MU<7*^-?"*"ZG\JYM+AI8MYV,RQK@D>OS&@#LJ**
MS[W6K.PNH[5S)+<R+O\ )@C,CA <%R!R%_R,T 7V4,,, 1Z&EP,YQSZUQWB_
MQ0D'A*.[TN2YD%^Z0Q7-K$6\O<ZJWH0V"P Z[ACK6OX>M/*CGO$NM3>"[(=+
M;4"Q>WQD$#=\P!ZX)^E &N(8@01&G#%Q\H^\>_UYIQ4,I5@"I&"#WH)P,DX%
M<-X<\47=[XTN[>[9EL-2MQ<Z4&)'R1L48>F6QY@QV(H [=HHW;<T:%L;<E1G
M'I]*5XTD!#HK9!4Y&>#U'TK+U#Q%I^FWAM9S.TR0_:)!# \GEQY(WMM!P,@^
M_!JIJ/C/2=.$I8W,X@A2>8P0,XB1_NECVS_2@#<>V@D;<\,;';MR5!X]/I3V
M1'QO4-@Y&1G!]:Q+.XL3XLU-([^[>[6WB,UM)D0Q+SAER!R><D$]*CA\::1/
M-;(INO+NY&CM9A;.T<[*<':5!]"<G P": -XPQEBQC3<2"3CDXZ4^N>NO&>B
MV9NA+--_HLX@N-L#GRC@$LW'" $?-TYK1O-8L[*:&!W>2>8;HX84,CLHZMA?
MX1GK_7B@"ZD4<?W(T7&?NC'4Y-(((5D\Q8D#\_,%&>>M93^*M&6WL9_M@:*^
MG%O P1OFD)QM/'RG/4'!XK)T_7SJ6O/J\,]RF@IICE_-B94$J3,&)R.& 5N/
M3\* .M1%C7:BA5Y. ,"G5E:;X@L]4O)+2**[BG2/S2ES;/$=FXJ"-P&02#6K
M0 4444 %%%% !1110 R1]B%L$_2G*<_E2T4 %%%% !1110 4444 %%%% !3&
M#;P1TQS3Z0@D@Y-  !@8I:!THH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#C_ !)!JTGC#P_?V6BW%W;:<9VF=)H5W>9'
MM 4,X)([YQ]:FU"#6/$OVJPELKC2M-EL)H7:=XG:660!5X1FP%&X]><^U=55
M2]U.QT][=+NZBA>YD$4*.V&D<D !1U/)% '.:'-XMN8(+74M+ATTVT1$ERMP
MDHN6VE1M4<H,D,2?3'>L/2]%UN+5O#VI3^'76ZM"\=]<R7D4DTQ=-I<MG)13
MR%SD X KT6XN(;2WDN+F5(88U+/)(P55 [DGI5%-?TI[6QN5OHO)OW"6K$D>
M:QZ  _2@#C[70-5.HZ?>0:3+I=Y<7#?VQ+'/'Y,\>TC.P.02Q((.W(.<^YH&
MB:WI*6VCMX>L=MI,JQZTSQ$M"K9SLQNW[?E^O.:]#HH Q=$UFYU*^U6TNM/-
MJ]C/Y:L)5D65#DJV1T;&"5/(R/6M>0,8V"$!\':3V-,MK2WLHC';01PH6+E8
MU !8G)/U)J&+5+&?4[C38[E&O;=%>6$'YE5NAH \ZLM \0;=(O;[P[YVL6E\
MDEW>R7<323H X^0YX49'R\=L \D3MI.O2>&_&%E_8-TLVK74LUL&G@Z.JKAL
M2'!&TDUZ510!Y]H]EXET._M;R+0Y+B*XTVWM+J!KJ)7@DAW ,#NP4(8G@Y_E
M6UX%T[4M*T.>VU2U6WG-Y/* LH<,KN6!!';GOS["NGHH KWT\MK8S3P6LEU*
MB%E@C*AG/H-Q _6N0L?#<5[X/G?5K+43?74;R7MNMPR&64]<(K[#V ]@*[>J
ML.H6=Q?7%E#<QR7-L%,T:MDQ[LXSZ9P: .#LHM;O?!>F:?KOAN2Z2"X$%Y%*
MRF5X@IV2H0W# [<\YX..M)%IFJ?V7]CUC2+_ %32GU$F&"X='N8( @*,6#YX
M?(^]NQ^5>CU#=W=O8VDMU=3)#!$I>21S@*!W- 'F6IZ7XDNO"UI:S6>H7<@U
ML7,(F='EBM4;Y1(<\MC/<_6I]=?4Y/&>K-I%AJ,D$MI!;WC6 CR[88X8R'AP
MC+C'(#<]J]*CD2:))8V#(X#*PZ$'H:R;GPOI%WJ$E^\$T=S*5,KP7,L/F8&!
MN", V!QS0!R#Q2ZIJ7@NZT[2;N"STJ:>"XB< FV"J(PI.3NY7J,\4S5]#U76
M?^$B6VTR1)CJ-O?V8NU3RKCRT1"IY/7:W! ZCWQZ+;VT-I L%O&L<2]%4?B3
M]2><U+0!Y_/HU_XIT+4;$>'X/#RS6IB.]8V>23*L,%/X!M/)ZY''%:'AM-0E
MN+0S^%+?1S I%Q/B(F1MN-L>SD DYR>PQWKL*0D 9/ H 6N#TRUU"R\2^-;Z
M73+LPWPA-KM4$R[$*$#GCDCKCBNSL]0L]021[.YBN$C<QNT3!@&&,C([\BK-
M 'E">';^W?0=4G\+?VK#!I*:==6%R(FDB=#D2+OR""21P>E;LEC?>9H;'P_Y
M:0ZB]]);6R1A;>/RW1<D$!I-S*QQGOUQD]U10!Y]K.AW%EXWN]8;PS#K]G?0
M1*%V1&2VECX&-_12.<CN/89GN-/O]+UOP[J;Z7NM[6"YCGBTZ(,(6D(*@(,$
MCC!('7DXS7=44 <99^&$O-$\1-J:/;C6IGG,4C#,"@ (3@X##:&..G [5>\$
M07;:%'J>I>6=1U!$DF9%(^55"H.>3\HR?=C5[7/#>G>(C:C45E=+9RZHDI0,
M2,$-CJ,5K*JHH50%4#  & !0 M>0ZMI_B#4;0>?H&HRZA::PMS-*K)Y+1B0X
M$"[AG*E23M&<$L:]8NKJWLK9[BZGC@@09>21@JK]2:1[VUCNHK5[B);B;/EQ
M%P&? R<#J<"@#C+--;\/>)M9:+0Y[^TU61;F&5)(P8I"H4I(2>%&.HW8'0&A
M$\1>'/$LUVVG3:U!J%I")Y;9D1HYXU*_=8@!6SGVYKM+FZM[*W:XNIXX(4QN
MDD8*HR<#)/N0*5KJ!+A+=IHQ,X)6,L-S =<"@#SO4=)U&VUZTU?6/#D/B".[
MM1!<11PQR/:.'9EVA@ 1A]I.1G;DU9OS+I=YX3_XDD5G&-1N&%K9JO[M#%(!
M\J\%MI+';GD'K7<V]W;7BNUM/%,L;F-S&X8*XX*G'0CTK$UC1+._\1:7=SZU
M=VMW 6:TMHYHU5R =Y"LI+':Q!]CVH YC4="U+5E\::K%831_;[-+6S@<;9)
M@B\N5[9/ !P<#H*T-223Q%?6TMSH6JZ?)':M):ZA"VV>WD)(V$*>X X.>O.,
MUW-% &?H4=[%H&GQZD$%ZENBS!   P STX_+CTK-\8P+=Z;:6LNDR:C;372K
M<"('? FUCYJXYRI Z<\\9/%=%10!YK)!KMOIRQ^1J-Y9#64,<TEN&O%M]G+\
MC<"#\NX_-M]*IM:ZB-.\<VJZ%JJ&_13;B1?-+9B50"P9MQ)Y."<<Y(KU:D9E
M12S$ #J2>!0!Y['%?Z?XIT?Q$NFWUQ9-H_\ 9TT4<)\V"0,&R4."02,9 ]_2
MM/P"E['%KAO=-NK(SZM<7""<*-RNW;!.<8Z]#Q@FNLAGBN84F@D26)QN5T8$
M,/4$5)0!4U3[1_9-Y]EB6:Y\A_*C< J[[3@'/8G%>?Z,;]=:\+32Z'JT>R":
M&YDEC CCD9$X5 ?DC!4@<*,8QFO2ZBGN8+6/S+B:.),@;G8*,DX'6@#SC2;.
M_M'MI-(T>\@M);*X>\TR]B/DP2E<A8RW(#-D87(QU J[H,%QIFO6YTZSU--$
M6P=YK>[@=C:R?+A(F8;SG'W5RO&17?YHH \E=+JP\)^!H6MKY=3M+T9C%N3*
MH5'+CR\@NN" 2.W?/!V)B+GPUXKMDAU&75[^WDE=);%X3(6C\I B\\#:HZGU
M-=7KFAV6L-:R3W%Q:W5JQ:WN+:;RY(\C!QV(/H0:DTK1[?30TBW%Q=W$@P]U
M=2>9(RY) SP !D\  4 <HD=Q'K_@VY:QO?)M-.FCN&%LY\IF1  >,YRA_3U%
M8PL;T?#0::-+O_MIU3SC$+1\[?M'F;NG]W_"O5Z* .#U/3+O4_%GB**.WF6.
M]T06<4\D+",R'?QNQC^(56T.TC5]-FA\'-I5W9B22[=[<E8QL*E8<'YF<D=,
M\ Y[5Z+10!Y=8VM];_#KPM92:;?BZL]1@EGA%JY9%CFW,>!Z'(]>W0UO:)9W
MVG_$;Q)-)93-;:F+:2*X5?D4)&P;)/?.!CKSGL:[.B@ KR[5DU6\BULWNBZF
M9H[]9+>.U3$'E*R?O/EP97('(.X\#  !->H$@#)Z5#]MM?LYN/M,/D@X,GF#
M;GZ]* .,TZ*9/B)X@U&YT^\2RN;&!49K9SO*K\R\ Y//2LBQ@O\ 2U\*:M_9
M>H2V^F036=U;);L)82P&'"$98<#IFO4%8, 5((/((I: .-\%-</K'B6:;3[V
MUCNKT3Q-<0E-R^6H[]^/\FNRHIJ2))NV.K;3M;!S@^A]Z /*(#J<UE8O=>'M
M3BO+;6DGGAMH"EO"@D/W$! ?(.2P#<DDFM2]ANSK#W.FVFHVNHR:F@FM7A9[
M2ZC5U_?,6!12$4'<I!RH]J]%HH \TNH[@:K<7&BV&I6]ZVJ%;JQ>V=K2Z02<
MS_,NT$J VY2#GUXJSK9O8X/&>D)I.H32ZB&FMI8H=T3!K9$QNZ @QGCKTQG-
M>A44 <7;3O\ \)1HT\VF:@D5OI,D;2M:L521FC(7C/.$;\QWKGF6^?X>:Q8O
MIFH+<RZJTL$7V.3<T9G$NX\>@;\@.I&?5:* /.I&?2_$VIS7?AF]UBPUKRIK
M>2"U$C)^["M'*LA&SIW]>?0+JMJXDA"VEYI&L6VFQ?9Y]+MI)(226W6Y"J4*
MJ57@_P![(KT2FJZO]U@V/0YH AT_SO[.M?M$2Q3^4GF1H,!6P,@>P-<_XUFO
M(8=+^SVES- ;Q?M$EI;^;-"NTC<G]TG.TL.0&.*Z9Y$C0N[!549+,< 4[.:
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M'(YKD;CP]XCFTI-(FM]&O-._LV.U,5Q-(-DR;AYBD)D@C:<9!!'!&,FUI_\
M;&CZYH6B)?)?6<5B(KP&,F16"L1*6[ E54 G//?K0!KZ_K;:2+&WMXDEOK^X
M%O;I(Q" X)+,1V !Z<GBN:2[U:P\1^+;LV]E]KM]/MI4 =MDJJ9CD\94D9&.
M>G4UN>*/#]QK#Z;>6%Q%!J&FW(G@:9<HP(PRMCG!'<53B\/:U<WNM3:C>6*C
M4[%;7-M$^Z(A6'&XX(!=CSU]J &0^*]1GN/"H6VM1%KMJ92"S;HI!"9,>ZGY
M1Z\'KGC'T;4=8;PWXKOM1M[/4HDO+K?;LQ48C 4J-V1LPF<=>35RV\*^)EU'
MPU/<7VE^5HH,86.)_G0Q["?]XCZ =>>E6+7PSK=II?B+3DFL9(-1GN9("696
M FZE^#@K\W SG/48H M7?B2:S%CIMI;PK=M8K=2'R9&AACX& $!/7('0 #Z
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M -^Y\3ZT=2UZRLM(MW?2TCD5I;D@2*RLW8$[C@8&,=<GIFR?$DU__9EIIMO
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ME&(Z,.O<>AK*U7PUJ>M:MJTDD<5M;:AIR6BR"7<\3HS.&*XP1EL<'M6KHO\
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MHH **** "BBB@ HHHH **** "BBB@ HHHH ***8RL7!#8 [4 /HHHH ****
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M8;0P$;,%+$  L 0"<C@G/- &Q167?^(](TNX\B]OX8I<9922=@QG+X^Z/=L
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M]EXCTM+^RE1D8G*JX++R0-P[$@9P?6KDVH6=O.L$UW!%,^-L;R!6;/ P">:
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M11367+ Y/% #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[%::EXCT76],U2XFNKR2>TBAEG\J\63D+A"%&W@$G\^*[7_A')O^@[K/_?\
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M:/\ #GQSLNH&W:E=;<2 YW,-N/K@X]:]%\/21R>&=,=75D-I%\P.1]P5IT4
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M2=IGAM9)%0/&47)4$=?RZ]*YFVL6MIM2T*^\)37M\]S-<VLY&ZUD5Y"R,[9
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MSS-NW '/7D\=:[C2KB&?Q?K.;6]3S8X0CSV<B1R>7NR59@ <%A]>HR* +?\
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M#K4\<+WL^CK:KY+ZA R30/NYA#, S@ 9YSC@9IWB^:>+7-$_<70M&\X2W-E
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MO]@57NEN(7C:-6SM.".<X/3-,_X2[1A]K62XEBDM$1YHI+>174.<)@%<G)Z
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M!IL5M:W&FNZSK/N,<AE\O9C .=I+!O44 =OIUOI_AZQT_1TN=JX,-JDTF7?
M+;1ZX _ "M3%<DVHI;W?A&VN].@FN+H,L5QOR8"(221D=Q@?B?QCN_'8@CN[
MB&P>XBMKIK8Q1[VFDVN$9E 4K@'<<9Y SQTH ['%5+^*P")=WXA"6Q\Q9)B
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M3Z* ,KP]H-OX:T:'2K2>>6WASY?GE2P!))&0!W)K5Q110 8HQ110 8HQ110
M8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8K&NO#D<^N'
M5X-0OK.[:$0/Y#(5=021E75AQD],=:V:* *.G:7%IPE833W$\S!I9YWW,Y P
M.@  P.@ 'YU>Q110 8HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M% !1110 4444 %%%% !1110 4444 %%%% !1129H 6BD)Y R.>WK2T %%%%
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M'.!D_F*T8K^&YTQ-0M<W,$D0EC\KDR*1D8SW- &?<:%/<32/_;%_$';.V)U
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M#1_MD=N)IB)+G[(DX@?R6F_N!\;<YXZ]>*S=*\:"^\3:W97%K<6UE8",++-
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M7CI3/[,L#,TWV&V\U@0S^4NX@C!!./3BL4ZE:77BK2MFIWT4DUM*R:<8617
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MU&>]\.Q>(X;Y4G6X$<(>.4(%92'(^4D C'3/2NYTB":VTBUAGCABF6,;XX%
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MX<U>WM9;F&PNW^T)"A=U21"F\*.2!GG'-=710!R%DCR>--3\1"TNXK)+".U
M:WD5[APQ<L(R W (7IZU;\"+)#X*TJVGM[BWG@MU22.>%HV4C_> S^%=)10!
MQD%K=>&O'&I7GV2:XTK6?+<R6\;2-;S(,890"=K#G/0'TJ[KO]HZ]97^DZ?
MT-O/93(]U.C1_O&&U54'!/?)QC!&,UTU% ' ,;C7M(\,Z>;"\M+ZTO()+D/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW'*R1XX!X'MT/<4 =I17F:WUY>_#34?$8U&[BU:"2><,)6 B:.0XC\O.W;M
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M<W3.F49=W"N#DY'% '>T5P_P[M;F\T'3-9NM5U">817%N\<LY9)/W[X<@_Q
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M1R&'I]^MZYN[:RB\VZGCACR%W2,%&3T'-1V^I6%W+)%;7MM-)%_K$CE5BGU
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M0=QDGOQ]<57'A'P\)"XTBUR91-]S@."3D#H.2>E:=Q>VMH8Q<W,,)D;;&))
MN\^@SU-%Q>6MKG[1<PPX0N?,D"X4$ GGMDCGW% $>HZ99ZM9/9WT(FMW^\A8
M@'\C3+[2++4M*;3+M));1D",GG."RCLS [C[Y//>KU<IXE\0W6G:GI$.GW=B
M\<VHPVEW$1NE0.>",-\O /44 7/^$+T$06L*VDRK:JR0E+N9616()7<'SC@<
M9Q4C>$=$)@*6CP^1";=/(N)(L1DDE3M89!))Y]:U)+ZTAN4MI;J%)Y!E(FD
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M(BW;O*3.=V=HZ^M 'E4Z:-<7'B?3-;UN^M+A[UY6LHWB'VI&(:(QY0LQQM&
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M^(WA1HT@L[-_MSN[$*OF.F3R?4GITYKLVT'1GC$;:38,@<R!3;(0&.,MTZG
MY]A4\VG65S%%%/9V\L<)!C22)6"$< @$<8H \N(TF]\.>-U:2V-I_:RNKH1A
M 1& RX_'!'O6I+HNC/\ %N"R%G"8'T7SI(-@\N1A-\K,/XFZ\G/05W$FBZ5+
M')'+IMI(DDGFNKPJP9\8W$$=<<9I%T/24E25=+LA+&H5'\A=R@#  .,\  4
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M+Q81I*Q)-Y).&+EV0X[X"_CQ0!I?\)1IS:18ZC"9ITOP/LL,4>9)6P3M [$
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MS:W+R6UU:73C;*QC<!8RK!<XSACSC/-3^$HS%J/B93-/+MU0JIFE9R%\F)L
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MJ5I)]/\ B!=7;6%Y/#>V$,<#00E@61W+!CP$X8?>(H T!XPT9XM/ECGFD34
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MF>2_E>:>B>9C;N[8SUXZUKUYA8Q+;QW.AZGH=_=ZL+N1H"S3&UN,N9%<OG:
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M[A\RY1=N!CN5(K?\17-FNBZ!=VMN%M7O(B]VMJTCV^Q&"OL R2"-HW @9Z4
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M4G]L:E)\11I7EPBR333<IMF)\S=*%W'Y>H .!SUZ^@!U5%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 9FM:3)J\$$<6I7E@T4PE\RU8
M*S#!!4Y!!!SZ>E7;2UAL;.&TMTV0PH(T7T &!4U% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %&.<]Z** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#3WTHATHWS"YE9045_+;RMV<C&[G)X&,\8H ZHZE8B**4WML(YO]4_FKA_\
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M&"#-KQ!!_P")K(./]Q*WZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *:S$,!MR#WIU(6 8 ]30 O2BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BL2^\5:7I\\L<\DOEP.L=Q<+&3%
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M6LC=0 6[;-I;:&8]AG&:VY/%5C;M!!.EW]K>#SW@2UD+QQ@X+LN,@9X]^V:
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ML7?OVC?C&['./2G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4TXW#UIU-(!(/<4 .%% HH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:U;0VD[WFEVXG:,[0) P8J0=W?:>N#5CPM>7E_X8TVYOT=;J2VC:1FV_O&*
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M8]QVYJIK_C&=?"FIW>D65P;ZVG^QR1R[%:WD) #')P1\RD8SG([9Q3&E7_\
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M10 4444 %%%% !1110 4444 %%%% !1110 4AI:C8_OU&>,4 24444 %%%%
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M\@8.3M'? YY-59/'<S:?X?O&6WTZVU.W:26\N8VEBBD& $^5EQDD_,Q X_(
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MVU68$<*21@C/'..@JK#X\>(ZFU[ILXM;&S-U]K2&6-)"#@QA9%4[N1SD@^U
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MB6Y#"6/<5RVT'8<@<9/6G^ ;_4M2\(65YJ80R3+YBR"8R,X8DY(*C;UP "<
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M9NL?G^9G>Y4,1C'& PSS0!HT5G:UK$6C623-&TTTTJ06\*G!EE8X5<]O4D]
M#56+7W;6KC1IK01:@EO]I@4R9CG3."0VWC!P#D=QC- &I]LM?M8M?M,/VDC/
MD[QOQZXZU/7GO@?3&UB"XU35;&+S?[7N+NWN%F)=6#;-O0': NWD\@#BNQUC
M5&TN*V,=K)<R7%PL"*IPJD@DLS<[5 4G/^- &C16/H&OQZZM_MB$;V5TUJ^R
M42(Q !RK#J,,/<=*V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *:WWA\N?>G4A(SCO0 M%(#D=,4M !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 <0_@[6!%J,-OJ5@D<^I#48F-H2[,)A*
M%E;=RHQ@8P< <@<5SVK2QW/B[6A)JGA^VD40VT\.JR2Q>=M0-D()%#(2YP#N
MZ?GWNI>*+#3;FY@:.XGDM(A/="WCW>1&>C-R,]"<#)P.E:BI;W/E77EQN=H:
M.1DY /(QGD4 <78:;K>MWFD^)H[FSM9EMGM)()+9VCV>8<2Q D%2RA2,]B,Y
MIUKX0UNU\/Z3I8U*R?\ L^]-WYCQ.3)A]RJ?FZDLV6^G'4GN124 <TGA[48?
M$&M:G'=6K#4H$A6-HV'E[ 0I)SS]XYZ=*I6/A;6],T6RTR'4-/NK:"V:VEM[
MJV;RY@3D,1N."!P1R#[5T>GZK'J-S?0QV]U$;.;R6>:(HLAQG*'^(>]7Z .,
MB\$WEC%H1T_5DBN=-MY;9I9(-X*R8)*KG@@C@'(Q7:8K/UK58]$TBXU*:&>>
M.!0S1P*&<C(' )'K2R:M;1:U!I+B07,\+3(=AVE5(!^;UY''O0!RTG@C4CX=
MU708M4MUL;MY#%NMRSJ'?>2QW#)'(&,#N<]*U;[P]=W_ (DTW5)I[5H;6WD@
MDM_+;]X),!SG/ P!@8]>?3HZ* .0TKPOK>GK%I;ZVAT.VE5H%CC*W)C4Y6)G
M!QM' .!D@8R,UUS,%4LQ 4#))[4M,EBCGB>&6-9(W4JZ.,A@>H(/44 >=>$-
M-O=:\"FP\^WCTZ>[N!*P5C(T?G-N0<X&>?F[ ].]:VH>$-3N?[?6WU6W6/57
M60>;;EG3:H 3=N^[D>G )Q74V>G6.GJRV5G;VRN<L(8E0,?? JS0!S=IH&H0
M^,!KT]U:R&6Q2TGC2-EP5);<N2>K=CV[U#'H>M6]WX@6&XLC9ZA(TT0=6W[V
MC5"&/0* F> 2<]JU[C7;6V\06>BND_VJ[C>2-@GR809/S>O3@9ZBM.@#AAX+
MU2WL]!N;"^M;;6=)MQ:>8R,\5Q"  5<<$=,\=,GZC0N-+\2O91.]]8W=R9G>
MYM)(REM+&4VB(9#,!D!LG/)/;BNIIGG1&<P>:GG!0YCW#<%)QG'ID'F@##\)
M:#)X?TRX@E:-3<7+W(MX23%;!L?NTSCY1C/0<D\"F:WHNHZCXET/4;>2U6WT
MV1Y&20MOD+J4.,# P#GZUT5% '$W7@W4=0EUQY;V&V>^N8;NVFMR2T$D2J$R
M",$?+DU=O-&\0:EI5[%>WME]IGLY+1$A#K"-X :1@2<MQP.W//-=35%-6M9-
M<ET@>9]JB@6X;*$+M)(&#W.10!B:QX:O]4L]'N(;FWM-8TJ020R[3)&WR[64
MC@[6XSW%1:YX<UG7/#6I6ES?VQO;H0^5&BLL$?ER!^^3EL<GZ>E==10!RLVB
MZW'K=GK]N]E-?BV:UN[=RT<;QE]ZA&P2"I)Y(Y]!2QZ-KFF:=<RZ;<63ZK?7
M_P!JN6G4^6J' *+CGA54 GK@GO6E%XETR:+494DF*Z=)Y=R!;R;D; /W=N3P
M>H'OTJ_8WD6H6%O>P;O)N(UE3>NT[6&1D=NM %BBBB@#B-%T_P 6Z3?ZO<-I
MVDS+J%VUSM%\ZE/E"A?]4<]!S4S:'K]_#;V>I&T^P7%RTE_;PSL D07;'#'\
MO*':I;IG+#H:[&B@#AX_">KS^&;O0I[B&U@2;S=-FBF:22WVN&C5LJ-P!'7L
M,"KTWAW5M<TZ>T\0ZC 8Y+5[<)8HZ LP'[QLM@D8X&,#)ZUU5% '-Z/I/B&"
M2P&J:O!)!8J5"6T14W/R[0TA)[#G XSSV%8TO@S6AH5EH\%[8"VL-0CN;<M&
M^XQK(6PW/49'3KCJ*[VLN?7[&W\06NB.9OMMRC.@$3;-JC).[&/R)ZB@#.?2
M]:BUK5+JW:R>WO($X<L&:18V4+W"J25.[G@$8YS6-;>#-6M=%T#RI;--6T%W
M%NQ+-%<1LN&#< H2/3.,?EWU4-8UBST+3I+^_=TMXQEF2)GQ_P!\@XH Q9]#
MU.Y;5M0?[(-0OK1;**/>3';Q@-G+;07.YV/0=A[U$GAW4VD\+2N;56T56611
M(Q\W,9CR/EXXPWZ>]==10!#=1//9S0Q2F&22-E611DH2, _A7G]KX,UR*7PW
M<-!I4+Z3*[RI%(Y,Y9<-(SE<EB><$=SSVKT:B@#B)_#6MWOA34])G&GI/>71
MNED$K,@W2B0J05YP1M]^O'2K5MH6N:?K-WJ5A-9*-32)KNWFW,MO*J[2T9 &
M\8&-IV^N1TKK:* ,/P?H]YH/A>STR]EAEE@4KNA! P3GOUY)YXJIJVA:A'XI
MM_$>C?9WNOLYL[BWN7*))'G<"& )!#8[<CTKIZJ76HVUG/;0328FN7V11@99
MCW.!S@=ST% ')#P7J3Z?/F^MHM035GU2TF2,E5=CRK G)4@L.#W'I3]:T7Q1
MK'AS4K>9]/-[>Q?9EA2618(8\DE^02SGCL,#'7!ST^EZK::O!+-9L[1QS/"Q
M9"OS*<'@CUJ]0!QK:-KLWB3PW?R6UBEOID$D4P6Y8L3(JJ2OR#.-H],Y[5:N
M_"[S>.;;68Y2MF8@UU#NXDFCXB;'L';_ +Y6NED=8T9W.%4$D^PJII.K6>MZ
M>M]8N[V[LRJ[(R9*L5/! /4&@# GTKQ+IWB"]NM#ET^2QU!UEFCO"X,$@4(6
M7;]X$*#@D=*+?1-8A\:6FJ3"VNK>'3A9-</,5E<E@S2; F!R",9]\]JZRLZZ
MUS3[+5[/2IYF6\O,^0GEL0V 2?FQ@<*>] '+3Q:?XB^(EG<:;>F5+*)AJ0MS
MF-F1P84<CN'#-_P&N[K+T=M+87RZ9;Q0^7=/'<".()NE&"Q..O7K6I0!RKZ1
MK&G:CK+Z8EG/;:F#-BXD9&BGV!.RG<F%!['.:S9?"&I:;9>%K'2([6XAT:7S
MI'N)VC,K$,&  5L9+$^W2N\HH :A8HI=0KD#< <@'Z]ZY1-(UFP\1Z]=6<%K
M/:ZDL<@,LQ1@ZILV< XZ;MWX8[CK:* /.Y/">O'0?"5DL-B9=%N8YYB;E@'"
M< +\G?/?I[U=.D>(H-0\3ZA#:632ZD+<P1--O4^6 K(^5'#+FNWHH Y/PKH-
MWI6L:G="UBT[3KE8_*T^*;>JR#.Y\?=7/ POI6AXKM]7OM#ELM%\I+BX_=O-
M)*4\M#]XC )R1D#TSGM5_5=6L-$L'OM1N5M[9/O.P)_0<FDOM6LM.MHI[F8J
MDK!8@J,[R$\@*J@L3CL!0!S'B3P/9:AX3DL-+T;3K>_94$,BA4,+ @[MX7)Z
M>G.:EO-/US4-.TVUU;2].U"$1.E_ 900[_*$D1F48/WR>F,GD\5TNFZG9:O8
MI>6%PL]N^0&7(Y'!!!Y!'H>:CU+6+'21&;R5E,N[8B1M(S;1EB%4$X ZG% '
M)P>&M4M=%L=(N=/M-3TQ4N//M99LF/+AH0CLN254D9X_E47_  C6O0:#X:ME
MCBN9M+OOM<JR71W;<OB-6(.=JN!DD?=KH[;QCH%YIU[J%OJ*26=GM\^958JN
MX CMSU&?3G-:>G7]OJFG6]_:.7M[B,21L01E2,C@T >;W=GK6J>(_$CV&F1W
M5A-,EM<1_;Q LFR--RLNPD\D@L""1QTJ]!'JNOZ[X8\1V>EP16NG_:+>:#[2
M/ESF,E#MPRC;D$=:Z/5=*\*-JUL=4TS3WO;QB(I)K4,9&49P7(QGT!.3VZ5O
MHBHBHBA548"@8 % 'F^J^'O$ES#K,4>F6Y:]U.&]C878VA8Q'\IR <G9Z=ZW
MOLVM'QQ_:YTM!;?V;]F_X^5SOW>9TQTS\OZUKW?B+2[+6K31Y[H+?W?^JA"D
MDC!.>F /E-:M 'G%GX7\01:/8W,<%O;ZSI5[<7%O&\P>*=)F8NC$#(.&P#[>
M_%W6;'Q=JV@70EM+3[3<2P!+)+CY(4C?>6+D?,S$ >@ 'O7=44 <=+IVL3^.
MCJC:>B6<NEBQ9_M"ED8MO+8[@9(]\9JWX(T[6-(\/6^G:K':QBUC6*(0N7+8
MSEF/ YXP .,'DYXW-2U"VTG3KB_O)#';6Z%Y&"DX ]AS5A&61%=&#*P!!'0B
M@#G?%&E:A>7NBZEIT<4TNFW)E:"1]GF*RE3ANQ&<\U!;VR65[J&O^);BTLC>
MHEJ())E$<<2[BJECC+'<Q/:NKJK?Z98ZK;BWU"S@NH0P;RYD#KD=#@T <Y\/
MM,-GH N97:5IV*V\K@;OLJ';"O';: W_  *MKQ#I7]N>'[[3!)Y37$117_NM
MU!_/%:2J%4*H 4#  [4M '%)8>)]1U#0[G5+&P0V9ECN3'<DB16CVEP-O&>P
M_44:+I7BG24304:S32('_<:@C9G$(;(0H1@MVW=,<X)KM:* .)T_2];MG\5!
M]-3&ISM);-]H7&"H3YO3@;N_I5G4-#O]1^'\>GR01QZK:1(UN$D#+Y\6"A#'
M'!*CKCAC76T4 <K?^&[^3PM!;65S"FK0SK>F61/W<L^XL^X#^%BS#V&/2L[5
M[#Q;K/AF_AN+2SBGN(/LT5E!/\BY(+2LY'7C 4=,\DYX[NB@#E/%]Q8S^";Z
M#6GCLIIK5Y%@,P+ATP04Q][#;>@[BM'PGI\^G>&[1+MV>]F!N+IVQEI7^9^G
MH3CZ"KMYH^G:A=VEU>6<,\]HQ:W>1<F,G&2/R'Y5<H PO%6C7&KV=G)9L@O+
M"\CO(%<X5V3.5)[ @D9JO!9:E=>)#KMU9BW^S63VT%L)5=I2S!B2W1?N@#ZF
MM.+Q!I4]^ME'?1-<,S(J@\,R_> /0D9Y /%:= '+^!['5M+TNXL=5M4AVW,L
MT+)('#+([/@X[@G]14WB_3M2U&TL5T^.*XCANEDN;223RQ<1@$;2V",9(.".
M<5JG5K!=7723=1_;VB\X09^;9TS]*NT <UX:TS4],U/6/M-K8P6=U.L\/V5S
MP?+1"NW P!LZ]R>@KI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *C8'S0W& M24PHID#_Q 8ZT .&<<TM%% !1110 4444 %%%% !1110
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M5&8HHT'0*N3SDDDDY_ 5KT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 8HHHH **** "BBB@ HHHH **** "BBB@ Q1110 4444 &**** "BBB@ HH
MHH **** &F-&D60JI=00&(Y /7^0IU%% !1110 4444 %%%% #9(TEC:.1%=
M&&"K#(-$<:11B.-%1%& JC 'X4ZB@ HHHH **** "H(K.UAE,L5M"DASEUC
M)_&IZ* &^6OF;]HWXQNQSCTIU%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !32V& QUIU-/W@* '4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1@9S133]\4 .HHHH *2EHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *:1\P-.I"?F H 6BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%)CG-+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4C*'0JPRI&"#WI:* ,*V\)Z9;0V$"B=[;3Y3-:0/)E(GYP?4XW'&2<5
MN4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !33]X4ZFD?,#0 Z
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0TM-)^8"@!U%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UF < CDTZD)YH 6
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:?OBG4A&3F@!:
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>stamfordsecondleasemodif009.jpg
<TEXT>
begin 644 stamfordsecondleasemodif009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JW?^LA^I_E5JJEW_ *V#
MZG^5 %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%9<?B#3IO$4FA13B2_C@,\J)@B-05&&]"=P./2K]Q<0VEM+<7$BQPQ*7=V.
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M1^="RHS@Q_WCM!VK[G IM_XTT#3;AX+F]?<B)([16TLJ(K\J6=%*C(&>3TH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J
MI=DB6#&.I_E5NJEWS+!]3_*@"W1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %5+O_60_4_RJW56[_P!9#]3_ "H M4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !52\_UL'U/\JMU6NAF2'ZG^5 %FBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K7'^LB^I_E5FJUQ_K(O
MJ?Y4 6:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JI=_P"M
M@^I_E5NJMU_K(?J?Y4 6J*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/#]]%K%AK=E%8WT,<T2!!)O^5DR58KM.Y>_IBNCU;Q9;:5J,EBMA?7L\-O\
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MTJ1I&#L15SUVC%*RJZ[64,#V(S7"GXBQW.MZ7;6&FZE+!<1SO*OV8"0E#MP
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M>1N )Z#'4=*MZGX_T'2[R[M)I;AY[2,2S)' QVJ65<C@9^\#D9&,T =.
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M3<NEPCP_/!LC:/8P)Y;+ \?_ %JKZK#JLT/CF*/1-4E;5BBVC>0 & 0(<\\
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M4>I)Z"GJP90RD$$9!'>@#R>&SU6T\.>)]/B35KS3;FT%KIBW=FPN2[1O\A)
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M-PO1(PF\GS?,V^7MQNSQG=BM35/#>O)XGU2_T?\ L[[/JEFEO,UPSAXR@89
M PW!'<=* *S?$'5/(\,&'0%FFUV*1T1;D+M91D#D=,%22>V>">*H:]XPUZ^\
M#:S-!9PZ?>6%Y]AO"+AMRDNBAHB .N_J<8ZC-367@WQ%8MX+#+8SC0Q*)R)V
M7<)!MPN5.<#Z9Z<4V;P=XCOM#\3V-S#8)+J5^+ZV=;AF"D.A",-@_A3K[]*
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MEKFYL/M1$4WF>4<X:*0$#YAGG^5<7:V=K_PJ'5?W<3^7K)*J8Q^Z/VE%P/\
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MTC[*C1R^9F3SLG<I [8[^W?/&M0 4444 %%%% !1110 4444 %%%% !1110
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M62/$^AMJ2:<NJ6K7CN46)9 26'4#W%9_AO4DD36KF?Q%;ZC;Q7CD2(H6.U3
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-^'.KV-WH=S)<"2=OLDJ$?:$D/08]02/4573P[?B+Q+9:7;WZ:1<:,T=M!?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %(2>PI:9(K,N%.#0 \=.:*0=!2T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ IK' S3J9(K,N%.#F@!]% Z44 %%%% !1110 4444
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MBCL_LK1JI "Q@+\I'IC .?:O/-+U6[O/!GP]O[B.6\N5U!H]L>W>X1)D7[Q
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !11G-% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4U\XXIU%  .E%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 -5MV>,4V>9+>(R29VC'09J2D(##!&10 *P89%+2
M $FEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **0YQQ4:3JTIBW+O W$9&<9]* ):*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ I" 1@TM% "*H1<#I2T44 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML1J-C?2+$K>?Y3(S' !&T]\@^F* .QHKEO\ A++E-7FT2;2?+U@6WVFWA^T
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M,E8Y Q ^@->=Z8^E16'BUM:40:_&)3J-PB@N(F0B-XO]GRR,#KG.:C\'6_\
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M1]#WH ]C:]M4B>5[F%8T;8S%P K>A/8^U4M:U^QT*&W>\F0-<3)##'O +EF
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M[CI6TVBZ1?\ Q \:>?:V\D(TZ.9,@%0SQDEP.F[G.[J,^] 'J#7UHER+9KJ
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M+X<T.>X-Q+H]@\Y3RS(ULA;9C&W..F.,>E0GPCX;-NMN= TLPJQ=8S:)M#$
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M4 5-*M_LNDV=O]G%MY4*)Y E,@CP -NX\MCID]:MT44 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX2+1?^@M9#ZSJ/ZT :=%9G_"1Z( 3_:]AP,G_24_QH_X2+1?^@O8?^!*?XT
M:=%9B^(M&>:.)-4LFDD(5%%PA+$] .:TZ "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HSBBF2@,N"">>U #Z*0=!2T %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %(2 >:6FL >#0 X=**0=*6@ HHHH **** "BBB@ HHHH
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MUH.H:M<ZC(+R)[O_ (^H8+EXX[@^KJ.O&1Z<GO75K(C.R!U+KC<H/(STS3J
M,A?#>GIXA@UI!(EQ!9_8XXE;$2QYSPOKV^E:]%% !BC%%% #0BKG"@9.3@=3
M3L#THHH **** #%&*** # ]**** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ I*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** (YH_-CV[BON*D' %%% !1110 4444 %%
M%% !373>N,D?2G4C-M&: %'2BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBDR,XSSZ4 +12,RHI9B !U)- 93T(/T
M- "T4P2QDD!UR#@\]#Z4^@ HI-P&,D#)P,]Z-RYQD9],T +111GG% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *,@45#<#(4X8X.?EH FHH'(%% !3&(R!3ZC8?.#0!)1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4C!]O2FZ=X6DL/$-]K#ZI+<27Z(EQ$\*!&" A<8&1C/XT 7=.GT9O#22Z9+
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5[P Q+
MNW8WK]WZU8J&X<(BD]V H E P*6@44 !J-X@[AB2"/2I*:QQ0 ZBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1SA&/H*6FR
M?ZMOH: ./^&8\WPBEXX_?W5Q--*W=R9&Y-=E7&_##_D1+'_?E_\ 1C5UMQ<1
M6L#33.$C7JQZ"@"7(SBFEE!Y8 _6J,4]S=;7B15A89$IZX^E/BTV&.0RG<\I
MZNQYH E$Z%BJY;G'3BB3SSQ&J ?[53!<=,?E3B< DT 1(LH&&9<^PJ*2RCG!
M6X F3.=KKP*LA@>F:B-U"&9?,7*\-ST- "K$%4+G@=!5+47:V@>=+D0[!DE\
M%3[5;EF58V(R6QP!U)K%EMC<^7=:E(XBMSN$(^Z?0$=S0!L64YN+2*5EPS+G
MIUJ5H(6G2=HHS,@(60J-R@]0#VJCI^JVU]/)!$CI)$J[E92N >E:5 !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)<;>
M?6GU'*"1^7\Z )!THHHH ***2@!:*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***",C% #2X!'OQ0'ST7Z&N'^*Z^1X&N;R.>:&>&2/9+%
M,T;*"X!Y4CM63JE[:6'BGP]!X;U"62[FN2EW:K=-(K0[?F9@YX(.,8]3UH ]
M0!S39/\ 5M]#7-1>+TDUW5-)>PN(9-.@\]W? 5U[%>>0?6FIXO,NFZ7<G2;X
M?VFYCC58]WDC'WI"/NB@"M\,!_Q0>G_[TA_\?:NHU"T%[;B)MI4.&(;H<5S'
MPP_Y$+3_ /@?_H;5V- %..Y*&3S(G49X.,TY=0MV.-Q!]QBK6*85&[D#'TH
M8;N$=9%'U--:YC,3MU"Y./7%.DBB=?WB(R^XZ53^TV4DYMX-DDH&"N>BT 5+
M%'OXVNY[QGCDSB)3A4'H?>F7)BEL)(=,LH+K<?*ER^U%YY.>^#VK,NO"$<EZ
MLZW!CMPQ+V:N5CE]-QI;S6]*TN&2RGMQ'=%0J)&"4<]@".M %FW"Z-&MG%-]
MNU)N69VXC!/4^@':M"0F)RR%9;D#]Y(QPJ"LVSTR+3]/GN[F4V[R[99RK!F]
M ,]QVQ5J%A>LR/$6P<B!>BCMN- $MG<P6H0!I+B:5LO(J?>..?PK9$@. ,9]
M,_RK"NM9AM9H[.W5KJ]FSY,04 #'8GL*9;(UC<+>:G=">\8$80':@_NH!V'J
M: .B!S2U@Z1XCBU,S.B^7;*=J23,JEV[@#-; N8R<"6/\&% $U%0?:X>GG1Y
M_P!ZE^T1E0XE3:3C(88H FHJ#[5%@_O8^#C[PH:YC'26+KW:@">BH?M$?_/6
M/_OH4@NX2N?.C'..6'6@">BHEN(VD$8D4L1G"G-2T %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !2,NX8S2U'-*(5#$9!(% $E%%% !1110 4444 %%%% !1
M110 4444 %%%% !11THH **** "BBB@ HHHH *#TXHHH XGXF07VI>$Y=-T^
MPN+J>=T($:\*%8$Y.?:J/B>QO_%-I9VEAI$MC<PW<4QO)P%\I5Y.TCKD9'XU
MZ)367=^7?I0!Y]XTT@W/B#1C;2;9[YGL;O'5[4@LY_ #]:Z?4;RYTTV-K9::
M]U#-*(9"C!1;)M^\?:DL_#&GV.MW6KQ0NU[<OEY';<0",$+G[O3M6XN=HS0!
MQGPY86V@R:.YVW6F7$D$R$\_?)#?0A@179BN2U/0[36-0EN]'U3[%JL8\N:>
MT=7)'3;(N>>AQGI6(^F^(X+I;.7Q?IXFR $DE9')/3*[NI]J /2:KW%U!;M&
MLTT<9D;8@=MNX^WK7%#PWXS4_P#(>MB,'C]Z>?Q-4-=\+:G+I]O&PN[K4PGR
MW,;!T!W [,,24!Q]X4 =),;F>]OVN]6MDM;=@R6Z,%*+M_Y:'MD\UD17MX]J
M+O[99V<\@"B62Z3R202#M]>,?G6<OAO48]=OITL[LQ!;EG^51YY;&Q=V3OY!
M.2.*E/@2Y>+2HHY7ME2*2>[/EK)ND<@L@!&!SZ4 =2+2[GN(1+J44WRAFCV8
M#C^\N&Z5G7FEW>H.[QZO8(+9F\IH801$3P=^2>V?QK&F\.:]_;QU.W\U%BD^
MRHQD/F-#MZX QM,A#?\  :S;3PCK"VTEM;V]RHN4AM[@3MY:.%!\W.T<JPR
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MG Q_:%[_ -]K2?V5/_T$;W_OM: -:BLG^RI_^@C>_P#?:TC:1.W_ #$KX?\
M UH UZ*QQH\XZ:G??]]K2?V-.5;_ (F=_DG/WUH V:*Q_P"R+C>6_M._Y&,;
MUQ33HMQQG5K_  #G[XY_2@#:HID:E5YZ^I.<T^@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!]35/_A#=*+,Q\\EYIYFS)U:9-C_ *?K6OIUA#I>F6NGV^[R+6%(8]QR=J@
M9/T% %FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;2T>]6W("";>0A('&XJ/KBNYJK9:;8Z:C)8V=O:HQRRP1*@)]2 *M4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,D.!
MG=M]Z?4<SE%! SS0 ]>@I:0<@&EH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "@@'K14<C%1P?3^= $E%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5%-G;QCM_.I:CE4L.!Z?SH >,XYI:** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **JBYD-^8/L[>2$W";<,%L
M_=QZU:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FLP498
MX%.IDJ[@!@'GO0 \=**0=*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** $VKZ4M%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4449YQWH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ J&Y5FB^4X((-35%."8^ 2<CI]: )!TI:!THH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "FL0.OX4ZD().<\>E $=O*9H0YC:,Y(V
MMUX.*EI ,"EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "D-+3795&6.!0 X44@Z4M !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5'*<+T!Z=:DIK@'@T *.E+2#I2T %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !3) Y7Y" :?3)'"#)!_"@!PZ"EI!T%+0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%-D?8N<$_2@!U% Y%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 445'(,[<>M $E%(.E+0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %13;24W-M^:I:BF )3(!&Z@
M"44444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<HSMQU!S4E
M0W!(52"0=PZ4 344"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **9)*L2,[G"J,D^E.5@ZAE.01D4 +1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %-==PIU(S!1DG H 4# Q1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 (RAN#T]*7I110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !3) "OS#(S3ZBF#-M"OMYY
MXH E'2B@=** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.4,=N
MT G/>I*BF4L4 ;;S0!(.E+110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %07!8>7MZ[JGJ&XD$05B,_,!0!-10** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ J"Z#LB["N=P^]4]0S_=7/\ >'\Z )1TI:0=*6@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AN.44?[0_G4U0W!(5<
M#/S#^= $PHI!TI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&
MX8H%( /S <_6IJ@NL;%X/WAT^M $PZ?C2T"B@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *@NB@1=XR-XP/?-3U4OCA(S_TT3^= %L=**0=!2T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5:\.!'\N[]XOX<U9J&
M<A0&/]X#]: )1T%+2#I2T %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !4<RJR@, 1GO4E0714(NY=PW#C\: )QT%% HH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "H;@;@@']X5-4,Y"A#Z,* )A1110 4444 %%%%
M !1110 4444 %%%1SJ[1,L3[)"#M8C(!H DHJ. .L$8E</(%&YAW-24 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M44'I0 44U05XR33J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "J]VI9%V]=P_G5BH+G.Q<?WA_.@"8=*6D'2EH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "HY2  ">I J2JUVN[R@<_?4\>U %
M@=!2T@X%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0SL4"L%
M#'<!@U-4-P2JKC^\/YT 344"B@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *BG;:4.,Y:I:BF^]'_O4 2BBBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *BFZQ_[U2U%,?FC_P!Z@"6BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *CE&2OL:DIK$#DD >] #J*0=*6@ I*6B@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ IDF< *P4D]QFGU%-C*<9^:@"0
M=*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !36QQGM3JBF^Y^7\Z )1THI!TI:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *0X(P:6D(S0 R*195)48 .*DI ,4M !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 9T6C6RZH=2E:6XN@"L;3/D0@]0B]%S@9(&36C110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5%-P4/8-4M-?.. "?>@!U%
MZ44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%)2T %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %(:6F2$  >IH ?10.E% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5%+U3_>J6FLFXKST.: '
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
E110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>stamfordsecondleasemodif010.jpg
<TEXT>
begin 644 stamfordsecondleasemodif010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV0$0PY(W')&>AX'/% '1T5R[>,6GU*[L]*T>ZU(6L4,KRPRQJ"LJ[DP&8$\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 10?ZE/I4M10?ZI/I4M !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 10?ZI/I4M1P?ZE/I4E !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 1P\1H/:I*CCY1".F*DH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@"&#_5)_NBIJB@/[I/I4M !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 10C$:?[HJ6HXN(USUZ5
M)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M///(S.P12N5C&>I'?\\34]+O]'CTWQ=:6]U?>(I)=]Y###(1-&X&8L%<H$
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MJ" 10!/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $4)!B0]L5+44"X
M@C'H!4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 C E<#O6$?"E@79B;LEB23]
MMF_D& K>HH P?^$2TP_>^U_^!LW_ ,52?\(?I)ZB\_\  V;_ .*K?HH P?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK@'J 1FN=\6_\DTU7_L&O_Z!7-2:AJWAB^T)DU&YU%+[3)WEM9 NU7BA#JR
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M9H+=;ZU>$0A1)M("MQT(PW'H:M6FM:QX5T_0[BYODO\ 3KC2))OLODK&8C%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:U*\TX@+]DF,>UE'\+,$#D?CST.15OQ+HAUS0)K"&403@K);RXXCD1@R'Z9
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MQP^?PJCGG'? ^F:]0HH XV!+[1_&OB*]?2;NXLKV&W:*6W"L/W<; KC.<DD
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M:597=_;WUQ );BVSY+.Q(C)ZD+G ;WQGWH Y3XI)-<>%%M;:UNKF=[F)PEO
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBHTF23=L(;:2IP<X([&@"2BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "FL"5(![4ZD)QVH %!"@$Y-+0#D44 %%%% !1110
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MCYG^8D]R?YUHV-AI]KXX\)3V4AE-SIL[O,9&8R_*AW\D\G)_R* .K\*^)/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;3R-++$5^61V.2S#N2>>:T** &0PQV\*0Q*%C0;54=AZ4^BB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***,T %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1163XEU@:%H-S>J-\^/+MXP,F25N$4#(S
MR1^&: -:BN?\(>(1K_A.UU.X9$G"%+K/RA)$X?/H.,_0U:M_$NC7,,\L>H0A
M($$DA<E-JDD!OFQP2#@]Z -:BN?U77+:X\.7]UINMVEHT!"-=R@,D+#!(8'J
M<'I[BKFI>(=*T>2./4+Z*!W4N V3A1U8X^Z/<X% &I169_PD>BE(7&K6)CF#
MF-UG4JP7[V#G'&1FI/[:TS[-#<C4+5H)W*12K*&5V&<@$<<8/Y4 7Z*S$\1:
M*ZH5U>P(D<QI_I"?,P.-HYY.2./>GW^NZ5I<R17^I6MK(XRJS2JI(]>3T]Z
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M11CA5QDG\Z +U%5-/N+JXAE:[M/LSK-(B+OW;D#$*V?<8./>K>1G&>10 44
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M=N&( _ 8J/X@973M*EGB,FFQ:E"^H#9N40#.2P_NAMI-=8B)&NU%51Z*,4I
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M<^E:=);PP/86K0PKMBC,*E4'HHQ@#Z4 >;--I?\ :ME:>*;S=ITFB(+&>_\
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M71W^CZ=JDL$M[:1SO V^(O\ P-ZCWJ2^TRQU)46]M(9Q&=R>8@)4^H/;TXH
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M@_4-3U@V&DWK7(N=%FE.HRF9R9'7*QJ2?O!MQ?&<?(/:NIN=*?2-,NYO#UE
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M%K-'>KILTDELBQ,9'0V4XSNDC8(6()(X)'W1ZUV5M";>UAA:5Y6C0*9'.6;
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M0,YRZYVD,I)R.F/>N6\5Z!<:5X#\1ZE=212ZMJ=S;2S%,^6FV:,(@[D =^]
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MW+-#>B4#RTE.6#+U)';'7/:@#:U'QM9:;<:C";&_N&TZ-9KCR(U(6-@3OR6
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MLHK[[+Y"-(KDA$8'..AY&?YFNLHH Y34M*O=.\8#Q/I]NUXLMI]DNK2,J)"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIK
ML41F"EB!G [T .HI%)*@D8)'3TI: "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ I",]Z6B@ ' HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **K7%Y';-$)6V
MB1]@;'&?2K'.?:@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@".2&*90LB*P!! ([@Y%2=*** "BBB@ HHHH ***K3VBS7EO<[G#PAPH#84
M[L=1WZ4 6:*100.>M+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !3'D",H/\ %3ZKW) DAR.Y
M_E0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HY2H*[ES
MZ5)4<HR5H DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FN
M.E.IK]J '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4S:
M0Y;=P>U/HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "FOVIU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% "9I:3%+0 4444 %%%% !1110 4444 %%%% !111D"@ H
MHHH ***#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A4'K2TAH 4# P
M**!THH *#136[4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&!/0XI:
M* $ P.N:6BB@ IK@DC%.I"P! />@!:*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ J*5 Q0Y(VYZ5+37[4 .HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "@T44 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-<
MA>2<"@!U%(.E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-?.
M. "?>G4AH 4=**!THH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHI&Z<4 +10.E% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !2$@=:6HY?N@T /'(XI:1?NBEH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "FN@<8-.I&8(,L<"@!:*!R** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ J.4 J-PR,U)36&>M "CH*6@=** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ IDFX#Y:?3)7*+PNX^E #AG S2T@.0#2
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2'%+3)"RKE0"?>@!
M]%(.@I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ID@<K\AP:?
M2&@ '04M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1129Z^U "T444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A%
M+10 #I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5#+$TA&'9,,&^7OCL?:IJ* "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBD- "T4#I10 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %-9L'&*=32"6!H 4<BEHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBD)H 6B@=** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ J.601E,_P 1Q4E-(.X4 .HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "C-%(1F@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M 1F"BE'(!I" >H%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !113=OSEMQ^F>* '4444 %%%1REP4V=<\_2@"2BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *AGR-F&V_-UJ:HY<93(SS0!)1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1RD IGUJ2D(!QD=*
M%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** $;I3(V<R2!DVJ"-IS]ZI** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *:_3BG5')ORFP9YY^E $@Z4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !37=4QN.,G%.ICJ&901G'- #Z*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ J.0D,F.YQ4E,<$NGRYYH ?12#I2T %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !2$@$#UI:8PRZ^U #Z*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ II'(-.ICMAE'J: 'BB@44
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<GWTX'7O4E1RC+)]:
M 'CI2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<A(D3CO4
ME12DADQZT 2#I2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M44W6/_>J6HI?O1_[U $M%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5%*H:2/G&":EJ&8@2PC&=S8^E $JC  I:!Q10 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %12J#+$3V/%2U#,X22)3U8D#\J )A12+]T4
MM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% $8$OGL25\K P.^:D'3FBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M J"?_70?(&.X\_W>.M3U#*V)H1ZDC]* )1T%+0.E% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5%(@:6,Y^Z<U+3'^^GUH ?10** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ J-WPZ#'4U)3&8!U!&<]* 'BB@<B
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *C<9D0^F:DI",D&@
M!1P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6B@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F.'+H5. #
MS[T^B@ %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
'!1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868184830024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SPRINGWORKS THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-4066827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Street</a></td>
<td class="text">100 Washington Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City</a></td>
<td class="text">Stamford<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State</a></td>
<td class="text">CT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Zip Code</a></td>
<td class="text">06902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">883-9490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol(s)</a></td>
<td class="text">SWTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,413,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001773427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868185126040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 81,933<span></span>
</td>
<td class="nump">$ 103,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">266,338<span></span>
</td>
<td class="nump">269,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,680<span></span>
</td>
<td class="nump">9,409<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">355,951<span></span>
</td>
<td class="nump">382,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable securities</a></td>
<td class="nump">32,475<span></span>
</td>
<td class="nump">59,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">6,035<span></span>
</td>
<td class="nump">3,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">5,356<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investment</a></td>
<td class="nump">2,546<span></span>
</td>
<td class="nump">2,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">590<span></span>
</td>
<td class="nump">565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,627<span></span>
</td>
<td class="nump">2,709<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">405,580<span></span>
</td>
<td class="nump">452,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,654<span></span>
</td>
<td class="nump">3,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">21,257<span></span>
</td>
<td class="nump">25,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">327<span></span>
</td>
<td class="nump">1,162<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">23,238<span></span>
</td>
<td class="nump">29,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, long-term</a></td>
<td class="nump">5,538<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">28,776<span></span>
</td>
<td class="nump">30,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, Value, Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">733,477<span></span>
</td>
<td class="nump">715,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(354,314)<span></span>
</td>
<td class="num">(292,513)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock, Value</a></td>
<td class="num">(906)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,458)<span></span>
</td>
<td class="num">(312)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">376,804<span></span>
</td>
<td class="nump">422,396<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 405,580<span></span>
</td>
<td class="nump">$ 452,494<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868186595832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (shares)</a></td>
<td class="nump">49,423,827<span></span>
</td>
<td class="nump">49,247,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (shares)</a></td>
<td class="nump">49,407,617<span></span>
</td>
<td class="nump">49,247,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock (shares)</a></td>
<td class="nump">16,210<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868185098088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited)&#8203; - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 34,103<span></span>
</td>
<td class="nump">$ 17,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">27,366<span></span>
</td>
<td class="nump">12,381<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">61,469<span></span>
</td>
<td class="nump">29,756<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(61,469)<span></span>
</td>
<td class="num">(29,756)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Interest and other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="num">(193)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income, net</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total interest and other income</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity investment loss</a></td>
<td class="num">(337)<span></span>
</td>
<td class="num">(261)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (61,801)<span></span>
</td>
<td class="num">$ (29,787)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Net loss per share, basic (usd per share)</a></td>
<td class="num">$ (1.26)<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Net loss per share, diluted (usd per share)</a></td>
<td class="num">$ (1.26)<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding, basic (in shares)</a></td>
<td class="nump">48,937,756<span></span>
</td>
<td class="nump">48,229,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding, diluted (in shares)</a></td>
<td class="nump">48,937,756<span></span>
</td>
<td class="nump">48,229,539<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868188465640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss (Unaudited)&#8203; - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (61,801)<span></span>
</td>
<td class="num">$ (29,787)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Changes in other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities, net</a></td>
<td class="num">(1,146)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total changes in other comprehensive income</a></td>
<td class="num">(1,146)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (62,947)<span></span>
</td>
<td class="num">$ (29,775)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868187374200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited)&#8203; - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common</div></th>
<th class="th"><div>Treasury</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,819,591<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 557,058<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 675,615<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="num">$ (118,603)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">7,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(29,787)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,787)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,024,152<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">534,697<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">683,029<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="num">(148,390)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,024,152<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,247,985<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">422,396<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">715,216<span></span>
</td>
<td class="num">(312)<span></span>
</td>
<td class="num">(292,513)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">17,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeiture of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,440)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares of common stock used to satisfy tax withholding obligations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares of common stock used to satisfy tax withholding obligations</a></td>
<td class="num">(906)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (906)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(1,146)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,146)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(61,801)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61,801)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,423,827<span></span>
</td>
<td class="nump">16,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 376,804<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">$ (906)<span></span>
</td>
<td class="nump">$ 733,477<span></span>
</td>
<td class="num">$ (1,458)<span></span>
</td>
<td class="num">$ (354,314)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,423,827<span></span>
</td>
<td class="nump">16,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868184840872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited)&#8203; - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (61,801)<span></span>
</td>
<td class="num">$ (29,787)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_swtx_NonCashOperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">272<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="nump">17,094<span></span>
</td>
<td class="nump">7,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity investment loss</a></td>
<td class="nump">337<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,729<span></span>
</td>
<td class="nump">697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other assets</a></td>
<td class="nump">82<span></span>
</td>
<td class="num">(545)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,770)<span></span>
</td>
<td class="nump">879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(4,695)<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_swtx_IncreaseDecreaseInLeaseLiability', window );">Lease liability</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(355)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(48,688)<span></span>
</td>
<td class="num">(21,104)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(2,387)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(23,242)<span></span>
</td>
<td class="num">(86,373)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sale and maturity of debt securities</a></td>
<td class="nump">52,053<span></span>
</td>
<td class="nump">55,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">26,424<span></span>
</td>
<td class="num">(30,918)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares of common stock repurchased to satisfy tax withholding obligations</a></td>
<td class="num">(906)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">1,167<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(22,003)<span></span>
</td>
<td class="num">(51,663)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents including Restricted cash, beginning of period</a></td>
<td class="nump">104,526<span></span>
</td>
<td class="nump">147,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents including Restricted cash, end of period</a></td>
<td class="nump">82,523<span></span>
</td>
<td class="nump">95,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease obligations</a></td>
<td class="nump">$ 5,580<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_swtx_IncreaseDecreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">swtx_IncreaseDecreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>swtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_swtx_NonCashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non cash operating lease expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">swtx_NonCashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>swtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868189942552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations</a></td>
<td class="text">Nature of Operations<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SpringWorks Therapeutics, Inc., together with its wholly-owned subsidiaries, collectively, the Company, is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The Company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. Two of the programs are late-stage clinical product candidates: nirogacestat and mirdametinib.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred losses and negative operating cash flows since inception and had an accumulated deficit of $354.3 million and $292.5 million, and working capital of $332.7 million and $352.9 million, as of March&#160;31, 2022 and December&#160;31, 2021, respectively. The Company is subject to those risks associated with any biopharmaceutical company that has substantial expenditures for development. There can be no assurance that the Company&#8217;s development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees, advisors, consultants and vendors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had cash, cash equivalents and marketable securities of $380.7 million and $432.7 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively. Based on the Company's cash, cash equivalents and marketable securities as of March&#160;31, 2022, management estimates that its current liquidity will enable it to meet operating expenses through at least twelve&#160;months after the date that these financial statements are issued.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 11, 2020, the World Health Organization designated the outbreak of the disease associated with the novel strain of coronavirus known as COVID-19 as a global pandemic. This disease continues to spread, including recent acceleration of the spread of the Delta and Omicron variants of COVID-19 in the areas in which the Company operates. Governments and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including, but not limited to, shelter-in-place orders, quarantines, significant restrictions on travel, as well as restrictions that prohibit many employees from going to work. Uncertainty with respect to the economic impacts of the pandemic has introduced significant volatility in the financial markets. The global pandemic caused by COVID-19 (including the impact of emerging variant strains of the COVID-19 virus and stagnant vaccination rates) did not have significant impacts on the Company's financial condition, results of operations or cash flows during the periods presented. While the extent to which the ongoing COVID-19 pandemic impacts the Company&#8217;s future results will depend on future developments, the pandemic and associated impacts, including the duration, spread and intensity of the pandemic (including any resurgences), the impact of emerging variant strains of the COVID-19 virus and the rollout of COVID-19 vaccines, all of which remain uncertain and difficult to predict, could result in a material impact to the Company&#8217;s future financial condition, results of operations and cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868185945944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the pet States, or U.S. GAAP, for interim financial information and Article 10 of Regulation S-X of the Securities and Exchange Commission, or SEC, and should be read in conjunction with the Company's consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February 24, 2022. The condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q are unaudited; however, in the opinion of management, such financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses and the valuation of stock-based compensation awards. Management bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results may differ from those estimates or assumptions. On an ongoing basis, management evaluates its estimates, and adjusts those estimates and assumptions when facts or circumstances change. Changes in estimates are recorded in the period in which they become known. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 730, &#8220;Research and Development&#8221;, expenditures for clinical development, including upfront licensing fees and milestone payments associated with products that have not yet been approved by the U.S. Food and Drug Administration, are charged to research and development expense as incurred. These expenses consist of expenses incurred in performing development activities, including salaries and benefits, stock-based compensation expense, preclinical expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. Expenses incurred for certain research and development activities, including expenses associated with particular activities performed by contract research organizations, investigative sites in connection with clinical trials and contract manufacturing organizations, are recognized based on an evaluation of the progress or completion of specific tasks using either time-based measures or data such as information provided to the Company by its vendors on actual activities completed or costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of expense recognition. Expenses for research and development activities incurred that have yet to be invoiced by the vendors that perform the related activities are reflected in the consolidated financial statements as accrued research and development expenses. Advance payments for goods or services to be received in the future for research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no recently adopted accounting pronouncements that had a material impact on the Company's financial statements, and no recently issued accounting pronouncements that are expected to have a material impact on the Company's financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868189944872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s available-for-sale marketable securities as of March&#160;31, 2022 and December&#160;31, 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:23.740%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.212%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.212%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.212%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.216%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash Equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(515)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311,364&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,460)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">309,906&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:23.740%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.212%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.212%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.212%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.216%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Government securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,729&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,677&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,668&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(131)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,540&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketable securities are available-for-sale securities and consist of high-quality, highly liquid debt securities including corporate debt securities, U.S. government securities and commercial paper.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s available-for-sale securities classified as short-term marketable securities in the condensed consolidated balance sheets mature within one year or less of the balance sheet date. Marketable securities that mature greater than one year from the balance sheet date are classified as long-term. As of March&#160;31, 2022, the Company did not hold any investments with maturity dates greater than five years. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of, and for the three months ended March&#160;31, 2022, the Company did not have any allowance for credit losses or impairments of its marketable securities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868189967640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s financial assets measured on a recurring basis are classified based upon a fair value hierarchy consisting of the following three levels:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#160;&#8212; Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets, or liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#160;&#8212; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the instrument.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#160;&#8212; Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy is based on inputs to valuation techniques used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources while unobservable inputs reflect a reporting entity's pricing based upon their own market assumptions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, the Company's financial assets and liabilities recognized at fair value on a recurring basis consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Hierarchy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">117,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">117,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">336,641&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">176,459&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">160,182&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Hierarchy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">418,675&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">254,102&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">164,573&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, the Company&#8217;s financial assets measured at fair value on a recurring basis using a market approach included cash equivalents, which consist of money market funds, and marketable securities, which consist of high-quality, highly liquid available-for-sale debt securities including corporate debt securities, U.S. government securities and commercial paper.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s money market funds are readily convertible into cash and the net asset value of each fund on the last day of the quarter is used to determine fair value. The U.S. Government securities are classified as Level 1 and valued utilizing quoted market prices. The Company&#8217;s corporate debt securities and commercial paper are classified as Level 2 and valued utilizing various market and industry inputs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid instruments that have maturities of three months or less when acquired to be cash equivalents. The carrying amounts reflected in the Company&#8217;s condensed consolidated balance sheets for cash equivalents, accounts payable, and accrued expenses approximate fair value due to their short-term maturities.</span><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"/><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868185966936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment and Variable Interest Entity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Investment and Variable Interest Entity</a></td>
<td class="text">Investment and Variable Interest Entity<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MapKure</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June&#160;2019, the Company announced the formation of MapKure LLC., or MapKure, an entity jointly owned by the Company and BeiGene Ltd., or BeiGene. BeiGene licensed to MapKure exclusive rights to BGB-3245, an oral, small molecule selective inhibitor of specific BRAF driver mutations and genetic fusions. MapKure is advancing BGB-3245 through clinical development for solid tumor patients harboring BRAF driver mutations and genetic fusions that were observed to be sensitive to the compound in preclinical studies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company&#8217;s ownership interest in MapKure was 38.9%. In addition to the Company&#8217;s equity ownership in MapKure, the Company has appointed a member to each of MapKure&#8217;s joint steering committee and board of </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">directors. The Company also contributes to clinical development and other operational activities for BGB-3245 through a service agreement with MapKure.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that MapKure is a variable interest entity. The Company is not the primary beneficiary, as the Company does not have the power to direct the activities that most significantly impact the economic performance of MapKure. Accordingly, the Company does not consolidate the financial statements of this entity and accounts for this investment using the equity method of accounting.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 323-10-35-6, the Company records MapKure&#8217;s earnings or losses based on a one quarter lag.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized an equity loss of $0.3 million for each of the three month periods ended March&#160;31, 2022 and March&#160;31, 2021. The Company&#8217;s ownership interest in MapKure is included in &#8220;Equity method investments&#8221; in the condensed consolidated balance sheets. The balance of the Company&#8217;s investment was $2.5 million as of March&#160;31, 2022, representing the maximum exposure to loss as a result of the Company&#8217;s involvement with MapKure.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868185951336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consists of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,257&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868189927256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into contracts in the normal course of business for clinical trials, preclinical studies, manufacturing and other services and products for operating purposes. These contracts generally provide for termination following a certain period after notice and therefore the Company believes that non-cancelable obligations under these agreements are not material.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company has excluded milestone or royalty payments or other contractual payment obligations as the timing and amounts of such obligations are unknown or uncertain.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into a lease for its corporate headquarters in Stamford, CT. In January 2022, the Company amended this lease agreement to extend the lease term through April 2028, with two five-year renewal options or one ten-year renewal option. Pursuant to the amendment, the Company is entitled to $0.5&#160;million in tenant allowances, which may be used to offset certain future capital expenditures, and the lease payments increase by 2.5% in each year commencing December 1, 2022. The amendment was treated as a modification and the lease liability and Operating lease right-of-use asset were updated to reflect minimum lease payments and any other adjustments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, future lease payments under non-cancelable leases with terms greater than one year are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.116%"><tr><td style="width:1.0%"/><td style="width:74.629%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.442%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,739&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(874)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,865&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in disputes or regulatory inquiries that arise in the ordinary course of business. When the Company determines that a loss is both probable and reasonably estimable, a liability is recorded and disclosed if the amount is material to the financial statements taken as a whole. When a material loss contingency is only reasonably possible, the Company does not record a liability, but instead discloses the nature and the amount of the claim, and an estimate of the loss or range of loss, if such an estimate can reasonably be made.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, there was no litigation or contingency with at least a reasonable possibility of a material loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868189835272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019 Equity Incentive Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2019 Equity Incentive Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards and dividend equivalent rights to the Company&#8217;s officers, employees, directors and other key persons (including consultants). The number of shares reserved for issuance under the 2019 Equity Incentive Plan is cumulatively increased each January 1, through and including January 1, 2030, by 5% of the number of shares of the Company&#8217;s common stock outstanding on the immediately preceding December&#160;31 or such lesser number of shares determined by the Company&#8217;s compensation committee.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The terms of stock options and restricted stock units and awards, including vesting requirements, are determined by the Board of Directors or its delegates, subject to the provisions of the 2019 Equity Incentive Plan. Restricted stock units and awards granted by the Company to employees generally vest over three years, and stock options granted by the Company to employees generally vest over four years. Restricted stock units and awards and stock options granted by the Company to directors generally vest over one year.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, there were 4,785,168 shares available for issuance in connection with future awards under the 2019 Equity Incentive Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Awards</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, the Company granted 1,350,479 stock option awards, 464,513 restricted stock units and 36,625 restricted stock awards to its officers, employees and directors under the 2019 Equity Incentive Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, 104,985 restricted stock awards previously issued to employees of the Company vested, and 142,657 stock options were exercised.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, there were 2,991,905 stock options vested and exercisable. In June 2019, the Company&#8217;s CEO received an award of 176,411 stock options, or the 2019 CEO Performance Award. During the quarter ended March&#160;31, 2022, 11,026 options of the CEO Performance Award became exercisable upon the satisfaction of the market condition applicable to this award.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense included in the condensed consolidated statements of operations for each of the periods presented is as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"/><td style="width:66.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.431%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.700%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,094&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the unrecognized compensation expense related to unvested stock options, restricted stock units and restricted stock awards was $153.9 million, $25.3 million and $18.4 million, respectively, which is expected to be recognized over a weighted-average remaining period of approximately 2.78, 2.77 years and 1.78 years, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company had 7,832,865 stock options outstanding, 459,614 unvested restricted stock units and 398,510 unvested restricted stock awards.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868185979720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per Share<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Company had a net loss in each of the periods presented, basic and diluted net loss per share are the same. The table below provides potentially dilutive securities not included in the computation of the diluted net loss per share for the periods ended March&#160;31, 2022 and March&#160;31, 2021, because to do so would be anti-dilutive:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock options issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,832,865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,692,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units subject to future vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">459,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock awards subject to future vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">398,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total potentially dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,690,989&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,378,341&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868184816168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationThe Company&#8217;s unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the pet States, or U.S. GAAP, for interim financial information and Article 10 of Regulation S-X of the Securities and Exchange Commission, or SEC, and should be read in conjunction with the Company's consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February 24, 2022. The condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q are unaudited; however, in the opinion of management, such financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses and the valuation of stock-based compensation awards. Management bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. </span></div>Actual results may differ from those estimates or assumptions. On an ongoing basis, management evaluates its estimates, and adjusts those estimates and assumptions when facts or circumstances change. Changes in estimates are recorded in the period in which they become known.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 730, &#8220;Research and Development&#8221;, expenditures for clinical development, including upfront licensing fees and milestone payments associated with products that have not yet been approved by the U.S. Food and Drug Administration, are charged to research and development expense as incurred. These expenses consist of expenses incurred in performing development activities, including salaries and benefits, stock-based compensation expense, preclinical expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. Expenses incurred for certain research and development activities, including expenses associated with particular activities performed by contract research organizations, investigative sites in connection with clinical trials and contract manufacturing organizations, are recognized based on an evaluation of the progress or completion of specific tasks using either time-based measures or data such as information provided to the Company by its vendors on actual activities completed or costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of expense recognition. Expenses for research and development activities incurred that have yet to be invoiced by the vendors that perform the related activities are reflected in the consolidated financial statements as accrued research and development expenses. Advance payments for goods or services to be received in the future for research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no recently adopted accounting pronouncements that had a material impact on the Company's financial statements, and no recently issued accounting pronouncements that are expected to have a material impact on the Company's financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868189939224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Summary of available-for-sale marketable securities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s available-for-sale marketable securities as of March&#160;31, 2022 and December&#160;31, 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:23.740%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.212%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.212%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.212%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.216%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash Equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(515)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311,364&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,460)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">309,906&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:23.740%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.212%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.212%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.212%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.216%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Government securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,729&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,677&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,668&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(131)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,540&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868189816104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of financial assets subject to fair value measurements</a></td>
<td class="text">As of March&#160;31, 2022 and December&#160;31, 2021, the Company's financial assets and liabilities recognized at fair value on a recurring basis consisted of the following:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Hierarchy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">117,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">117,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">336,641&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">176,459&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">160,182&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Hierarchy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">418,675&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">254,102&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">164,573&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868189928376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consists of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,257&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868186663064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum lease obligations</a></td>
<td class="text">As of March&#160;31, 2022, future lease payments under non-cancelable leases with terms greater than one year are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.116%"><tr><td style="width:1.0%"/><td style="width:74.629%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.442%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,739&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(874)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,865&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868186665320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of equity-based compensation expense related to restricted stock and stock options</a></td>
<td class="text">Stock-based compensation expense included in the condensed consolidated statements of operations for each of the periods presented is as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"/><td style="width:66.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.431%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.700%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,094&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868186663064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potential common shares not included in the calculation of the diluted net loss per share</a></td>
<td class="text">The table below provides potentially dilutive securities not included in the computation of the diluted net loss per share for the periods ended March&#160;31, 2022 and March&#160;31, 2021, because to do so would be anti-dilutive:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock options issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,832,865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,692,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units subject to future vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">459,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock awards subject to future vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">398,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total potentially dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,690,989&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,378,341&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868187358888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of Operations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>trial</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_swtx_NumberOfClinicalTrials', window );">Number of clinical trials (trials) | trial</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (354,314)<span></span>
</td>
<td class="num">$ (292,513)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_swtx_WorkingCapital', window );">Working capital</a></td>
<td class="nump">332,700<span></span>
</td>
<td class="nump">352,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="nump">$ 380,700<span></span>
</td>
<td class="nump">$ 432,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_swtx_NumberOfClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of clinical trials reported by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">swtx_NumberOfClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>swtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_swtx_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The capital of a business which is used in its day-to-day trading operations, calculated as the current assets minus the current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">swtx_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>swtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868185975752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868187497384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Corporate debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 311,364<span></span>
</td>
<td class="nump">$ 269,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,460)<span></span>
</td>
<td class="num">(131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">309,906<span></span>
</td>
<td class="nump">269,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. Government securities | Short-term investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Corporate debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">117,894<span></span>
</td>
<td class="nump">105,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(645)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">117,249<span></span>
</td>
<td class="nump">104,967<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. Government securities | Long-term investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Corporate debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">32,990<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(515)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">32,475<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Cash Equivalents:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Corporate debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">11,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">11,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Short-term investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Corporate debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">73,451<span></span>
</td>
<td class="nump">78,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(300)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">73,151<span></span>
</td>
<td class="nump">78,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Short-term investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Corporate debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">75,938<span></span>
</td>
<td class="nump">85,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 75,938<span></span>
</td>
<td class="nump">$ 85,896<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=swtx_LongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=swtx_LongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868186938888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 336,641<span></span>
</td>
<td class="nump">$ 418,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">117,249<span></span>
</td>
<td class="nump">104,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_swtx_LongTermInvestmentsFairValueDisclosure', window );">Long term investments</a></td>
<td class="nump">32,475<span></span>
</td>
<td class="nump">59,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">73,151<span></span>
</td>
<td class="nump">78,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">75,938<span></span>
</td>
<td class="nump">85,896<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">26,735<span></span>
</td>
<td class="nump">89,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">11,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">176,459<span></span>
</td>
<td class="nump">254,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">117,249<span></span>
</td>
<td class="nump">104,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_swtx_LongTermInvestmentsFairValueDisclosure', window );">Long term investments</a></td>
<td class="nump">32,475<span></span>
</td>
<td class="nump">59,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">26,735<span></span>
</td>
<td class="nump">89,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">160,182<span></span>
</td>
<td class="nump">164,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_swtx_LongTermInvestmentsFairValueDisclosure', window );">Long term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">73,151<span></span>
</td>
<td class="nump">78,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">75,938<span></span>
</td>
<td class="nump">85,896<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">11,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_swtx_LongTermInvestmentsFairValueDisclosure', window );">Long term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_swtx_LongTermInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of long-term investment securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">swtx_LongTermInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>swtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868187466936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment and Variable Interest Entity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity investment loss</a></td>
<td class="num">$ (337)<span></span>
</td>
<td class="num">$ (261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Mapkure</a></td>
<td class="nump">2,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,883<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=swtx_MapkureMember', window );">MapKure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity investment loss</a></td>
<td class="num">(300)<span></span>
</td>
<td class="num">$ (300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Mapkure</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=swtx_MapkureMember', window );">MapKure | Series A Preferred units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest (in percent)</a></td>
<td class="nump">38.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=swtx_MapkureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=swtx_MapkureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868185102984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">$ 975<span></span>
</td>
<td class="nump">$ 1,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">4,528<span></span>
</td>
<td class="nump">12,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_swtx_AccruedResearchAndDevelopmentExpenses', window );">Accrued research and development</a></td>
<td class="nump">12,235<span></span>
</td>
<td class="nump">10,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">3,519<span></span>
</td>
<td class="nump">2,120<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 21,257<span></span>
</td>
<td class="nump">$ 25,378<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_swtx_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">swtx_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>swtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868182020904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($) </div>
<div>option</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation or contingency expense | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=swtx_StamfordConnecticutMember', window );">Stamford, CT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_swtx_LesseeOperatingLeaseEntitledTenantAllowance', window );">Tenant allowance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_swtx_AnnualIncreaseInLeasePaymentsPercentage', window );">Annual increase in lease payments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=swtx_StamfordConnecticutMember', window );">Stamford, CT | Option One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_swtx_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of renewal options | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=swtx_StamfordConnecticutMember', window );">Stamford, CT | Option Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_swtx_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of renewal options | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_swtx_AnnualIncreaseInLeasePaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Increase In Lease Payments, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">swtx_AnnualIncreaseInLeasePaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>swtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_swtx_LesseeOperatingLeaseEntitledTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Entitled Tenant Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">swtx_LesseeOperatingLeaseEntitledTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>swtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_swtx_LesseeOperatingLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">swtx_LesseeOperatingLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>swtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=swtx_StamfordConnecticutMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=swtx_StamfordConnecticutMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_swtx_LesseeOperatingLeaseRenewalTermAxisAxis=swtx_LesseeOperatingLeaseRenewalOptionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">swtx_LesseeOperatingLeaseRenewalTermAxisAxis=swtx_LesseeOperatingLeaseRenewalOptionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_swtx_LesseeOperatingLeaseRenewalTermAxisAxis=swtx_LesseeOperatingLeaseRenewalOptionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">swtx_LesseeOperatingLeaseRenewalTermAxisAxis=swtx_LesseeOperatingLeaseRenewalOptionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868187460728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Maturities of operating lease liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">1,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">1,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">1,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_swtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear', window );">2026 and thereafter</a></td>
<td class="nump">2,881<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">6,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(874)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 5,865<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_swtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Liability Payments Due After Three Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">swtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>swtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868181901912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - 2019 Equity Incentive Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,094<span></span>
</td>
<td class="nump">$ 7,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=swtx_ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember', window );">Employee and Non Employee | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=swtx_ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember', window );">Employee and Non Employee | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,022<span></span>
</td>
<td class="nump">4,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,072<span></span>
</td>
<td class="nump">$ 2,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=swtx_EquityIncentivePlan2019Member', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_swtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock', window );">Percentage of annual increase in the shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,785,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=swtx_EquityIncentivePlan2019Member', window );">2019 Equity Incentive Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense related to restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense expected to be recognized over a weighted-average remaining period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock award outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">459,614,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=swtx_EquityIncentivePlan2019Member', window );">2019 Equity Incentive Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Stock options vested and exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,991,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense expected to be recognized over a weighted-average remaining period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,832,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=swtx_EquityIncentivePlan2019Member', window );">2019 Equity Incentive Plan | Restricted stock awards subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense related to restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense expected to be recognized over a weighted-average remaining period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock award outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=swtx_EquityIncentivePlan2019Member', window );">2019 Equity Incentive Plan | Restricted stock awards subject to future vesting | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock awards vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=swtx_EquityIncentivePlan2019Member', window );">2019 Equity Incentive Plan | Executive officers and employees | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock awards vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">464,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=swtx_EquityIncentivePlan2019Member', window );">2019 Equity Incentive Plan | Executive officers and employees | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=swtx_EquityIncentivePlan2019Member', window );">2019 Equity Incentive Plan | Executive officers and employees | Restricted stock awards subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock awards vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=swtx_CeoPerformanceAwardMember', window );">CEO Performance Award | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Stock options vested and exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=swtx_CeoPerformanceAwardMember', window );">CEO Performance Award | CEO | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">176,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_swtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of annual increase in the shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">swtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>swtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=swtx_ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=swtx_ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=swtx_EquityIncentivePlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=swtx_EquityIncentivePlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=swtx_ExecutiveOfficersAndEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=swtx_ExecutiveOfficersAndEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=swtx_CeoPerformanceAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=swtx_CeoPerformanceAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868182019144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Equity-based compensation expense related to restricted stock and stock options (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 17,094<span></span>
</td>
<td class="nump">$ 7,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">7,072<span></span>
</td>
<td class="nump">2,282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 10,022<span></span>
</td>
<td class="nump">$ 4,773<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139868190146952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities (in shares)</a></td>
<td class="nump">8,690,989<span></span>
</td>
<td class="nump">6,378,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonStockMember', window );">Common stock options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities (in shares)</a></td>
<td class="nump">7,832,865<span></span>
</td>
<td class="nump">5,692,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities (in shares)</a></td>
<td class="nump">459,614<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities (in shares)</a></td>
<td class="nump">398,510<span></span>
</td>
<td class="nump">686,241<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>swtx-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:swtx="http://www.springworkstx.com/20220331"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="swtx-20220331.xsd" xlink:type="simple"/>
    <context id="i9ccede58414f4148821842e315a905d7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i48bbb6301e904262900e93986ab7878d_I20220429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="i4858197abb9f421195cb86f9528f4108_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id73789b2c218404991bfa981f4cb6592_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i658acb93480c4b5393f0f53a36eab567_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic0990f9597e64307b0c20baeb0374ba3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3287fd7612614db4b178dca62d93314c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8966326533744dcb83a31d655df247a5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7145ff8fbb7347739deda6cecec6c32c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6aca392105844fb988854fc2a1e19f5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9db5cd8bf9aa4652801e6be37eb56232_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5b30664e42c44ea2bdfe57102b7f8793_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if7752062fa254d488520f76b3b98be23_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia179ee44b4324835983690644a8c2d55_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5aeb1d4fe3aa413287784b210d8cb0c7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4d19dcca70de49e18de075013224639e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1e1848bac6dd4d3395a865c973884624_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib131c00375dd4d01a1d5a8ca99a78357_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5a27a2ad8f5b4adabc882295f434ad85_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id7c72970af33479486aedd56f27b30d3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib34b57b88c524fb2a5cfb417de744b4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia0c1b343064f4976a0430d48302ee8dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5cea465f2f2844ecbd14a5a3b0ba249c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic68434afffb54cf0b8787b66026e3164_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifee6028d47d94c659487fe06b58c5d96_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic2b735c9c0ea4731a01282de2dda1e04_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5310686134dd466eb22c5118bf07c60a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if3b4361b2bc8468a8261a967f49bda37_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i17d85f9a1e034f45ac98309a4aa39e2b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie552d9ac6bf047888c1a1153ddd4b5f3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic22dfb0a26f1485a97ca52722464d5ad_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0538532efa4c481fb6287237941a7a83_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i76cd6147b1f74623a56a60a92568ed2a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9e643f8a8bad4d0685bb17341335398d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i774d25c476d6488093d122507b7e32fa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic96e90b96953469abcc2db764348a6e1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic8b06dfad0e4445b9def4cf77df1caf8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i67ce1d0e7f26429d9c2e120dd4006a6d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie516370bcc604882a6b3b1072c5423ed_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i65431ed7c312413eb40bd20210448df7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">swtx:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i300f6154df4c49c19cae97a30ab27fca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i150fe21584a54235b4ee8a7eab45b761_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id08a9791d8bf499dbcb446a78165cc74_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7fe7159edfa24359996120ecad894ca9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">swtx:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic4afc949d12f47acb07e3840b1a868ac_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ieaa89fe2a4c24ac598f43e035f41aa5b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib7e42a60b7564e79bc3c7c48d5590c00_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icb7ddd9a5fdb4cf3abb770f8dbe58b35_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5a06e303f7d247fe94023b4d619218aa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifd4bd8059ca34abfb81ea2cc6436bce6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i26bf9156508046f3a787efd142360d06_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if81ad8f0dc3845e892842d063335a2c0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia50bc0b54e7b411cbc0c32ee73246291_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i83db6194bc09401ea9d4f8dbf3dd05ef_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8d2ba195827a4b65a9c8591347ec440e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iac009ae2fcd34d3cad26b302a0e27bc8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i60cfe3f50c6b4c5892a4f8065819a89a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id10a160829dd4d6988d22ab73639351d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib1994ec146e34e20b804657cf2ba88e0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i35144578669449479c826d121a4a39af_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i07d72b0a1c1041edbe9b872760e69623_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2b0faab11338417da46a57af69648a69_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i96e7836def764eae8d4fccf746bff3ed_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i52195f7f2e1149f0bfc9825b28eb3e9d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6c5e5caf0cc0466db2575b43a6561e92_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i34e57c62cb4b46b18943ea2ade2bb811_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if853b5ddc3f24be599e3d8610e8928e9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i685d1982ea314317b0b57e4839162cc6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i16725e0ada024661899310a4ee93bfcc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i25f5c527da6b4872a8eeb9f36a3e424e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i582a7aa81bf94063ad30c2ae9cd74ef1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4381bd10810f415e80d931113c9f98aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d343dab4b5444209fd3ed76c2203491_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iafd101aebef746019f6ce6cfeb3ee12b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iffe9941ac0af4829ae1f8653c196fcf8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b0bf57bc62646ee88f4c37260c3618a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if240cefa329a43f5985a94cbabaaf6bf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iadafdf4d3eea47f18794b5f1ab930fc6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib9fd763563b24d6aa1f44bd42f945197_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b14ef11391b4c02b03d75aee65c957f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia01bf0d0d0004d6da16a34e81942ea85_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i310af46a88e3405dae093107956ce302_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3757e607d7cc45e0ae3411908f9b244f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5e9ce2dfe7e45279052b07d7cd8b812_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i31f65ade5edf48fc9494eade358d77e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i03111218aab744f3a7bce0157ba6e7fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i075a5d5199b1444fb36eab85ce242914_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i863575ed748a4e7b919599b8c6e813af_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7eba2f99c15b49c2a91337a9f21c9f15_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">swtx:MapkureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i60df7d63a68a48d59113cc28df86b1f4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">swtx:MapkureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic15d05a5ead7496488cbe289375b0b77_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">swtx:MapkureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9c3264a753fa40f19ce07bcf42665c50_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">swtx:MapkureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i65b72505f5de4b88b1745e53289c8346_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">swtx:StamfordConnecticutMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="swtx:LesseeOperatingLeaseRenewalTermAxisAxis">swtx:LesseeOperatingLeaseRenewalOptionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="i7f3b13792a2240b6bb59248690c98652_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">swtx:StamfordConnecticutMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="swtx:LesseeOperatingLeaseRenewalTermAxisAxis">swtx:LesseeOperatingLeaseRenewalOptionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="i37565722b4fa4a69ba807d2fba2e932f_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">swtx:StamfordConnecticutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="ia34d861b8e7c40f69f8da029b428f1a0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i74cc340c1aa4424ba3726c91ee26d876_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">swtx:ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i022436fef9574100a67fd5ee74396304_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">swtx:ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3948092549294997927bcdcb9f543aa4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i09e3d5011a2c4255b31c3514190f2c5b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id21cc7dd1c9e49d7b59a05c489a69c95_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">swtx:ExecutiveOfficersAndEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaf02bd13545f44a9bb747e767c85e226_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">swtx:ExecutiveOfficersAndEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia76c9558fc764171b39ba192df90d64a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">swtx:ExecutiveOfficersAndEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i147d6c8ff5e4443d9e538dcf1cb66057_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i05cb736fa4db484e8bc7a1b84df8778d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2e392b95e3564143b67b20dfaa88de74_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idd87f05bb1d645db8de68c02ff92440f_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:CeoPerformanceAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i2db6208a117f44e39e09d534da69e196_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:CeoPerformanceAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i75b5d0e6891445328c454b9d1ec87a5a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1c5e6b459a3f46278653aaa6c0dccad1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i61eb5ddf4b7047d8bf7f1bfb229fd7ab_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8f25ec114c634fc4865cc49981bd981f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1807ff5c5c8841e9b42432e38c96459d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifc237dbb79e949169c0b49053a2a8980_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia3e71bacda9e4305913d6ceeac24be0d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6d1841e76bd84918b42a921397d98d2e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">swtx:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4e6ea28cc5b746708a2447e6c1e2b5d9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i074022392378431ca43171749ce67e70_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i701fc5f7822543f5afa349b588446470_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8962a5ad7a90438bac9fc74322fc41db_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie455f786f4cb4de6b10f9237538eb2b1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6723bcf58742472287b2d9590f8e52df_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001773427</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="trial">
        <measure>swtx:trial</measure>
    </unit>
    <unit id="segment">
        <measure>swtx:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="option">
        <measure>swtx:option</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180L2ZyYWc6MTIzZGE5MzhmZmQzNGY3ZmFjNGQ1NTgxMTQ5MzE5OGQvdGFibGU6YTkxOWJhZTE0ZmE4NDhlMjkwNmY1ZWI1NzgyZmM3YTAvdGFibGVyYW5nZTphOTE5YmFlMTRmYTg0OGUyOTA2ZjVlYjU3ODJmYzdhMF8zLTEtMS0xLTE1NTIz_ff8ba708-378b-4ba9-95be-e69560685406">0001773427</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180L2ZyYWc6MTIzZGE5MzhmZmQzNGY3ZmFjNGQ1NTgxMTQ5MzE5OGQvdGFibGU6YTkxOWJhZTE0ZmE4NDhlMjkwNmY1ZWI1NzgyZmM3YTAvdGFibGVyYW5nZTphOTE5YmFlMTRmYTg0OGUyOTA2ZjVlYjU3ODJmYzdhMF85LTEtMS0xLTE1NTIz_3767b6e0-e34f-4b8a-8a14-a8fbd3f1f367">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180L2ZyYWc6MTIzZGE5MzhmZmQzNGY3ZmFjNGQ1NTgxMTQ5MzE5OGQvdGFibGU6YTkxOWJhZTE0ZmE4NDhlMjkwNmY1ZWI1NzgyZmM3YTAvdGFibGVyYW5nZTphOTE5YmFlMTRmYTg0OGUyOTA2ZjVlYjU3ODJmYzdhMF8xMC0xLTEtMS0xNTUyMw_43336016-4f39-45b4-b565-8cd4af6cf14a">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180L2ZyYWc6MTIzZGE5MzhmZmQzNGY3ZmFjNGQ1NTgxMTQ5MzE5OGQvdGFibGU6YTkxOWJhZTE0ZmE4NDhlMjkwNmY1ZWI1NzgyZmM3YTAvdGFibGVyYW5nZTphOTE5YmFlMTRmYTg0OGUyOTA2ZjVlYjU3ODJmYzdhMF8xOS0xLTEtMS0xNTUyMw_fc705efa-c086-440b-88b1-a6901b67fe43">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180L2ZyYWc6MTIzZGE5MzhmZmQzNGY3ZmFjNGQ1NTgxMTQ5MzE5OGQvdGFibGU6YTkxOWJhZTE0ZmE4NDhlMjkwNmY1ZWI1NzgyZmM3YTAvdGFibGVyYW5nZTphOTE5YmFlMTRmYTg0OGUyOTA2ZjVlYjU3ODJmYzdhMF8yMC0xLTEtMS0xNTUyMw_2b13f03c-a5dc-4d81-9666-da0d4be211c1">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGV4dHJlZ2lvbjo0MzU4NzJhNzIzYjA0MDlkOTA0NjA3YTg1OGFjMjc4YV8yMTM2_28e509dd-e18e-4856-b3ae-14c9f5320997">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6YjA4YmY0MGNhYzg1NDFmZThhNDlkNDY0NDM0MDI4NWEvdGFibGVyYW5nZTpiMDhiZjQwY2FjODU0MWZlOGE0OWQ0NjQ0MzQwMjg1YV8wLTAtMS0xLTE1NTIz_41018154-50a4-44ac-ba6e-39d52b16b21b">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGV4dHJlZ2lvbjo0MzU4NzJhNzIzYjA0MDlkOTA0NjA3YTg1OGFjMjc4YV8xMDk5NTExNjI3OTkyMQ_5fbe7ada-7b0a-4233-b419-523e92e75ce3">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6YzFjNTUxMzJhNDgwNDdkYWIyNjVkNjQ4MDk4NjM4OGEvdGFibGVyYW5nZTpjMWM1NTEzMmE0ODA0N2RhYjI2NWQ2NDgwOTg2Mzg4YV8wLTAtMS0xLTE1NTIz_037f954b-80b8-4d0f-8167-9f0f783bd2b6">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGV4dHJlZ2lvbjo0MzU4NzJhNzIzYjA0MDlkOTA0NjA3YTg1OGFjMjc4YV8yMTMz_5336dc5b-7aa0-4eb5-af9c-185fd1f41ebf">001-39044</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGV4dHJlZ2lvbjo0MzU4NzJhNzIzYjA0MDlkOTA0NjA3YTg1OGFjMjc4YV8yMTM3_36906313-38c4-4c27-b5bb-5a5b3f8dc96f">SPRINGWORKS THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6MWE5ODY2Mjk0MWUxNGExNzg1ZWY4MDhmMDljODMxNWQvdGFibGVyYW5nZToxYTk4NjYyOTQxZTE0YTE3ODVlZjgwOGYwOWM4MzE1ZF8wLTAtMS0xLTE1NTIz_fc2858f8-ac5f-4e61-b641-a3cf011a07c3">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6MWE5ODY2Mjk0MWUxNGExNzg1ZWY4MDhmMDljODMxNWQvdGFibGVyYW5nZToxYTk4NjYyOTQxZTE0YTE3ODVlZjgwOGYwOWM4MzE1ZF8wLTItMS0xLTE1NTIz_c1aac0b2-1118-422d-8858-c23c1f1de195">83-4066827</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6MWE5ODY2Mjk0MWUxNGExNzg1ZWY4MDhmMDljODMxNWQvdGFibGVyYW5nZToxYTk4NjYyOTQxZTE0YTE3ODVlZjgwOGYwOWM4MzE1ZF8zLTAtMS0xLTE1NTIzL3RleHRyZWdpb246OTc2ZGVkNGQ5NTBmNGY3ZGJlY2IwZDYwNWM2NGE0YmFfNA_7289aa20-f990-4a01-8380-ef05c40123b1">100 Washington Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6MWE5ODY2Mjk0MWUxNGExNzg1ZWY4MDhmMDljODMxNWQvdGFibGVyYW5nZToxYTk4NjYyOTQxZTE0YTE3ODVlZjgwOGYwOWM4MzE1ZF8zLTAtMS0xLTE1NTIzL3RleHRyZWdpb246OTc2ZGVkNGQ5NTBmNGY3ZGJlY2IwZDYwNWM2NGE0YmFfNw_5811d20d-fc25-43e2-bdae-31523856177e">Stamford</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6MWE5ODY2Mjk0MWUxNGExNzg1ZWY4MDhmMDljODMxNWQvdGFibGVyYW5nZToxYTk4NjYyOTQxZTE0YTE3ODVlZjgwOGYwOWM4MzE1ZF8zLTAtMS0xLTE1NTIzL3RleHRyZWdpb246OTc2ZGVkNGQ5NTBmNGY3ZGJlY2IwZDYwNWM2NGE0YmFfMTE_7db26e90-d531-442b-ab9e-bb932d901877">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6MWE5ODY2Mjk0MWUxNGExNzg1ZWY4MDhmMDljODMxNWQvdGFibGVyYW5nZToxYTk4NjYyOTQxZTE0YTE3ODVlZjgwOGYwOWM4MzE1ZF8zLTItMS0xLTE1NTIz_45ae062c-4f1b-425d-b809-d4e9c20f4e0a">06902</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGV4dHJlZ2lvbjo0MzU4NzJhNzIzYjA0MDlkOTA0NjA3YTg1OGFjMjc4YV8yMTM0_586660d3-98bf-4b69-b280-297b12249f2f">203</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGV4dHJlZ2lvbjo0MzU4NzJhNzIzYjA0MDlkOTA0NjA3YTg1OGFjMjc4YV8yMTM1_375ff953-4099-4fd9-a657-c69232d727f0">883-9490</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6MGExYTNlMjJhMDE1NGM1M2EwMDEwYTNlMWE1ZjViNmEvdGFibGVyYW5nZTowYTFhM2UyMmEwMTU0YzUzYTAwMTBhM2UxYTVmNWI2YV8xLTAtMS0xLTE1NTIz_20edac4b-71b0-4852-9587-7143e08c6387">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6MGExYTNlMjJhMDE1NGM1M2EwMDEwYTNlMWE1ZjViNmEvdGFibGVyYW5nZTowYTFhM2UyMmEwMTU0YzUzYTAwMTBhM2UxYTVmNWI2YV8xLTEtMS0xLTE1NTIz_83f3298f-f3e9-4e10-b3c3-e6e649b4f066">SWTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6MGExYTNlMjJhMDE1NGM1M2EwMDEwYTNlMWE1ZjViNmEvdGFibGVyYW5nZTowYTFhM2UyMmEwMTU0YzUzYTAwMTBhM2UxYTVmNWI2YV8xLTItMS0xLTE1NTIz_eb5b4ca1-a8ad-47f2-a304-c239d3c2e596">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGV4dHJlZ2lvbjo0MzU4NzJhNzIzYjA0MDlkOTA0NjA3YTg1OGFjMjc4YV8yMTM4_8d56a840-382a-4017-be02-088a88e23fdc">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGV4dHJlZ2lvbjo0MzU4NzJhNzIzYjA0MDlkOTA0NjA3YTg1OGFjMjc4YV8yMTM5_29dff919-1069-4b06-9c3e-9c15ead55f8b">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6MWFlMTcxNGM5ZWVjNDQ1NThmMTNjMDM5MDA0NmEzYjkvdGFibGVyYW5nZToxYWUxNzE0YzllZWM0NDU1OGYxM2MwMzkwMDQ2YTNiOV8wLTAtMS0xLTE1NTIz_ab7496ab-0ca7-45a1-ba2e-5944dbb20174">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6MWFlMTcxNGM5ZWVjNDQ1NThmMTNjMDM5MDA0NmEzYjkvdGFibGVyYW5nZToxYWUxNzE0YzllZWM0NDU1OGYxM2MwMzkwMDQ2YTNiOV8xLTMtMS0xLTE1NTIz_bf3cbd35-83c9-4f5d-993c-e7fae9df9d9d">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGFibGU6MWFlMTcxNGM5ZWVjNDQ1NThmMTNjMDM5MDA0NmEzYjkvdGFibGVyYW5nZToxYWUxNzE0YzllZWM0NDU1OGYxM2MwMzkwMDQ2YTNiOV8yLTMtMS0xLTE1NTIz_963b2e78-40aa-4193-9829-e8a9d940f0b4">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGV4dHJlZ2lvbjo0MzU4NzJhNzIzYjA0MDlkOTA0NjA3YTg1OGFjMjc4YV8yMTQw_26a2a64a-9ec4-4fb3-b772-44cda005b285">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i48bbb6301e904262900e93986ab7878d_I20220429"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xL2ZyYWc6NDM1ODcyYTcyM2IwNDA5ZDkwNDYwN2E4NThhYzI3OGEvdGV4dHJlZ2lvbjo0MzU4NzJhNzIzYjA0MDlkOTA0NjA3YTg1OGFjMjc4YV8yMTI4_5a5736f3-5ece-4f15-aaec-e9020b5cbb2b"
      unitRef="shares">49413760</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfNC0xLTEtMS0xNTUyMw_242430e4-734a-446b-9bf6-e9c13b9e9c4d"
      unitRef="usd">81933000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfNC0zLTEtMS0xNTUyMw_8ff7f0cc-94bc-48f4-9d5b-e74b8e651539"
      unitRef="usd">103961000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfNS0xLTEtMS0xNTUyMw_f55e82a9-b04b-4ed6-b595-d8848732230d"
      unitRef="usd">266338000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfNS0zLTEtMS0xNTUyMw_6ce6eb37-c054-4b0d-8182-efac84d3d997"
      unitRef="usd">269540000</us-gaap:MarketableSecurities>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfNi0xLTEtMS0xNTUyMw_396e8a73-6b9a-43c2-8e69-e29a08a6464f"
      unitRef="usd">7680000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfNi0zLTEtMS0xNTUyMw_ca0f37f9-0110-4b25-920b-5185876f5b30"
      unitRef="usd">9409000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:AssetsCurrent
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfNy0xLTEtMS0xNTUyMw_090fb400-3719-4cd5-999d-e281c562de85"
      unitRef="usd">355951000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfNy0zLTEtMS0xNTUyMw_e4b0988f-c11a-4dd9-b3bf-0e302c1fd9c2"
      unitRef="usd">382910000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfOC0xLTEtMS0xNTUyMw_30d00836-d56a-4b9b-8e0b-01760552e5ad"
      unitRef="usd">32475000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfOC0zLTEtMS0xNTUyMw_d1a510c6-3766-4153-af5d-529e4701b015"
      unitRef="usd">59230000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfOS0xLTEtMS0xNTUyMw_7dd86eae-3fe3-423f-88d2-3eca93e14c5e"
      unitRef="usd">6035000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfOS0zLTEtMS0xNTUyMw_efc1c42a-aff2-4480-96fb-445ab9a6ba54"
      unitRef="usd">3187000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTAtMS0xLTEtMTU1MjM_efc270fd-4b50-45b4-8a40-f6689804d706"
      unitRef="usd">5356000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTAtMy0xLTEtMTU1MjM_23b582a1-4cfd-4f7a-9e1f-e1f83d75de50"
      unitRef="usd">1010000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:EquityMethodInvestments
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTEtMS0xLTEtMTU1MjM_434b9691-24b4-4824-a13c-7cd7bdac7dda"
      unitRef="usd">2546000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTEtMy0xLTEtMTU1MjM_d48418b9-58b3-4fb1-9b9e-4ee108054fad"
      unitRef="usd">2883000</us-gaap:EquityMethodInvestments>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTItMS0xLTEtMTU1MjM_e1e6b146-1521-4044-a943-d12653d2bf93"
      unitRef="usd">590000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTItMy0xLTEtMTU1MjM_9418763c-12b7-4afa-ac78-f823a9812631"
      unitRef="usd">565000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTMtMS0xLTEtMTU1MjM_20b863be-0211-4436-b74a-8eebc5451fd2"
      unitRef="usd">2627000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTMtMy0xLTEtMTU1MjM_84dc1485-0e7f-4e9d-9143-dd2bf1a567e5"
      unitRef="usd">2709000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTQtMS0xLTEtMTU1MjM_ec7f937a-4a43-48c0-91dc-d4e2ec815c1f"
      unitRef="usd">405580000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTQtMy0xLTEtMTU1MjM_09720be6-ada0-49d5-82f1-8e972669dd96"
      unitRef="usd">452494000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTctMS0xLTEtMTU1MjM_099810cb-358d-41f4-a9fb-1fc1511d3657"
      unitRef="usd">1654000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTctMy0xLTEtMTU1MjM_e3a02afd-f581-4b73-b373-0095d9413860"
      unitRef="usd">3429000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTgtMS0xLTEtMTU1MjM_99698a61-97ed-48c2-b29e-74542920fa0c"
      unitRef="usd">21257000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTgtMy0xLTEtMTU1MjM_5f5d5f19-acaf-4a7b-8041-242d0365f663"
      unitRef="usd">25378000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTktMS0xLTEtMTU1MjM_99f22738-47f2-4bf5-931e-dc0ff0d2fb6f"
      unitRef="usd">327000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMTktMy0xLTEtMTU1MjM_eaf7ae92-aa5a-4cfb-8a97-cb3db6a67104"
      unitRef="usd">1162000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjEtMS0xLTEtMTU1MjM_474f65ac-5ddf-493e-a012-bf78cf4cb64d"
      unitRef="usd">23238000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjEtMy0xLTEtMTU1MjM_b5976b32-0d76-4647-9dc1-2b1f844f5fd7"
      unitRef="usd">29969000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjItMS0xLTEtMTU1MjM_3bee008e-2cbc-44ca-96b0-1272c45c8239"
      unitRef="usd">5538000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjItMy0xLTEtMTU1MjM_5294f4f4-8a67-4a04-a712-7d7bc116a12b"
      unitRef="usd">129000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjUtMS0xLTEtMTU1MjM_48b2ff7f-aa7d-4ca2-80e1-529b7db05caa"
      unitRef="usd">28776000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjUtMy0xLTEtMTU1MjM_b3927548-df83-4425-9043-0de09c4bcaad"
      unitRef="usd">30098000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjYtMS0xLTEtMTU1MjM_44d3ccfd-8fe5-4b7b-907f-37355b91757e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjYtMy0xLTEtMTU1MjM_bad65b7a-0915-4d1f-95a4-cf246d68013e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjgtMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjpiMDlkMDA1YTU0ZDY0ZDE0YmY5ODRhMmZlOThhOTkxYl8xMDk5NTExNjI3NzkxMw_452eca01-41b5-4323-be80-af60d3684dc5"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjgtMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjpiMDlkMDA1YTU0ZDY0ZDE0YmY5ODRhMmZlOThhOTkxYl8xMDk5NTExNjI3NzkxMw_8977bda2-a724-4cbb-8306-6ca503693561"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjgtMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjpiMDlkMDA1YTU0ZDY0ZDE0YmY5ODRhMmZlOThhOTkxYl8xMjA5NDYyNzkwNTcwMg_9e6dbe48-533a-4429-a65d-277d4af0d9bf"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjgtMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjpiMDlkMDA1YTU0ZDY0ZDE0YmY5ODRhMmZlOThhOTkxYl8xMjA5NDYyNzkwNTcwMg_dbc8168d-f3cc-4997-8489-02cabe2b7663"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjgtMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjpiMDlkMDA1YTU0ZDY0ZDE0YmY5ODRhMmZlOThhOTkxYl8xMjA5NDYyNzkwNTcwNw_0eceeaa3-fb96-497e-8e27-95214d9d840b"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjgtMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjpiMDlkMDA1YTU0ZDY0ZDE0YmY5ODRhMmZlOThhOTkxYl8xMjA5NDYyNzkwNTcwNw_444fcd09-26ec-4c17-933e-c25863f1e3d1"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjgtMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjpiMDlkMDA1YTU0ZDY0ZDE0YmY5ODRhMmZlOThhOTkxYl8xMjA5NDYyNzkwNTcwNw_a2f20e48-6996-463a-8c54-026593f45dd5"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjgtMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjpiMDlkMDA1YTU0ZDY0ZDE0YmY5ODRhMmZlOThhOTkxYl8xMjA5NDYyNzkwNTcwNw_c0fd858c-5c4d-4548-bd07-7ea6f5495c60"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjgtMS0xLTEtMTU1MjM_0336deca-188d-4dd5-a477-ebf78ff7610e"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjgtMy0xLTEtMTU1MjM_7b64f527-7dd1-4ddd-9afe-ce9731db5feb"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjktMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjozYmFmMDU1OTYxNWM0YzBjOWI1OGJkNzZlNzc2MzFmOV8xMjA5NDYyNzkwNTc1NQ_4a6154e8-2a60-41d7-a3cb-99661ad25265"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjktMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjozYmFmMDU1OTYxNWM0YzBjOWI1OGJkNzZlNzc2MzFmOV8xMjA5NDYyNzkwNTc1NQ_ca056256-938d-426f-995a-dd61e7ce4df3"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjktMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjozYmFmMDU1OTYxNWM0YzBjOWI1OGJkNzZlNzc2MzFmOV8xMjA5NDYyNzkwNTc2OQ_5f84bb25-892c-4ea4-896a-81956dcf9ac3"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjktMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjozYmFmMDU1OTYxNWM0YzBjOWI1OGJkNzZlNzc2MzFmOV8xMjA5NDYyNzkwNTc2OQ_9c6a9b65-7529-434b-b375-e8f36e2c73ed"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjktMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjozYmFmMDU1OTYxNWM0YzBjOWI1OGJkNzZlNzc2MzFmOV8xMjA5NDYyNzkwNTc4Mg_132eae24-c7d0-41c2-a6a9-669cd2af81d9"
      unitRef="shares">49423827</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjktMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjozYmFmMDU1OTYxNWM0YzBjOWI1OGJkNzZlNzc2MzFmOV8xMjA5NDYyNzkwNTc5NQ_ea18339f-1a86-480d-9db5-eef297f71e4d"
      unitRef="shares">49247985</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjktMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjozYmFmMDU1OTYxNWM0YzBjOWI1OGJkNzZlNzc2MzFmOV8xMjA5NDYyNzkwNTgwOA_2928ddf2-31db-4a2c-b6b1-b42d579b8324"
      unitRef="shares">49407617</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjktMC0xLTEtMTU1MjMvdGV4dHJlZ2lvbjozYmFmMDU1OTYxNWM0YzBjOWI1OGJkNzZlNzc2MzFmOV8xMjA5NDYyNzkwNTgyMQ_1703de10-602c-4a68-862e-35bf4b82b8de"
      unitRef="shares">49247985</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjktMS0xLTEtMTU1MjM_e1426987-6a13-4185-b21c-e108dcb9db89"
      unitRef="usd">5000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMjktMy0xLTEtMTU1MjM_9b6d5194-2084-44f8-85e5-f620bcdf7455"
      unitRef="usd">5000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzAtMS0xLTEtMTU1MjM_6484ca5a-7371-4eda-aa62-cb3cc68d6055"
      unitRef="usd">733477000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzAtMy0xLTEtMTU1MjM_84097ae3-3508-4741-b54d-a43ef6ef1f27"
      unitRef="usd">715216000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzEtMS0xLTEtMTYwNjA_67f62757-c1e5-4979-a435-8fde911bb2a6"
      unitRef="usd">-354314000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzEtMy0xLTEtMTYwNjA_c30e694d-8ffd-48f3-a9af-264556336d62"
      unitRef="usd">-292513000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockShares
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzItMC0xLTEtMTYwNjcvdGV4dHJlZ2lvbjpkMWZiZmJkZGE4NDM0YjFjODFlMjJkYmY4MWI5MmZhMF8xMjA5NDYyNzkwNTY2Mg_f9d0d27c-de43-4a68-a96a-01473ee22927"
      unitRef="shares">16210</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzItMC0xLTEtMTYwNjcvdGV4dHJlZ2lvbjpkMWZiZmJkZGE4NDM0YjFjODFlMjJkYmY4MWI5MmZhMF8xMjA5NDYyNzkwNTY2Ng_33a67f99-eef3-4369-8676-98d20d4e63ed"
      unitRef="shares">0</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzItMS0xLTEtMTYwNjc_9e973ef1-4b44-4840-9a1b-0d428089972b"
      unitRef="usd">906000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzItMy0xLTEtMTYwNjc_d3711ce9-af75-443a-bdb5-1ba6fcca5f3a"
      unitRef="usd">0</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzEtMS0xLTEtMTU1MjM_36c56be9-445a-4bc6-9b8e-bf7333b06542"
      unitRef="usd">-1458000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzEtMy0xLTEtMTU1MjM_c85a0ede-df69-4f16-8fc1-930bbe60111f"
      unitRef="usd">-312000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzMtMS0xLTEtMTU1MjM_0eb89216-cf8b-42c9-9d2b-ad34fae4509d"
      unitRef="usd">376804000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzMtMy0xLTEtMTU1MjM_738e1ffb-8825-4198-b555-1d1e50b748cd"
      unitRef="usd">422396000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzQtMS0xLTEtMTU1MjM_3702044e-32fc-494b-b87e-4915809acc61"
      unitRef="usd">405580000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18xOS9mcmFnOmM1OTk1YmFhMjg2MTRiNTBhYWU4YTYyZjI3Y2FkYWM5L3RhYmxlOmU4MTk4MzE0OGI1NTQxNDhiYWI5NDYyNTE4ZDkxMWEyL3RhYmxlcmFuZ2U6ZTgxOTgzMTQ4YjU1NDE0OGJhYjk0NjI1MThkOTExYTJfMzQtMy0xLTEtMTU1MjM_24e72145-7c3e-4dab-8452-e0d9b5b38ce0"
      unitRef="usd">452494000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMy0xLTEtMS0xNTUyMw_f1111dc0-abe9-4836-b20d-da0f8c4de1c0"
      unitRef="usd">34103000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMy0zLTEtMS0xNTUyMw_b4069584-7ba2-4b93-bfc1-da0b282d51a4"
      unitRef="usd">17375000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfNC0xLTEtMS0xNTUyMw_222eb09e-3ba4-4244-92eb-3f13cfe94796"
      unitRef="usd">27366000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfNC0zLTEtMS0xNTUyMw_8e758b29-6b36-469b-a473-6b2ff92426b7"
      unitRef="usd">12381000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfNS0xLTEtMS0xNTUyMw_7d2cd436-a2b5-487a-ae50-b833e0a0e513"
      unitRef="usd">61469000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfNS0zLTEtMS0xNTUyMw_cb6af7bd-0851-4d55-a0c0-fa31bcc9909f"
      unitRef="usd">29756000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfNy0xLTEtMS0xNTUyMw_f570037a-5c49-4792-b333-dcdaf9bd5bd6"
      unitRef="usd">-61469000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfNy0zLTEtMS0xNTUyMw_5e23ed47-a784-455a-8c1c-f200f964396e"
      unitRef="usd">-29756000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfOS0xLTEtMS0xNTUyMw_04688301-0d48-4b20-9ce6-018ae92682a9"
      unitRef="usd">-193000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfOS0zLTEtMS0xNTUyMw_0ea28b2e-70f8-4a9f-9f59-28b3a6fcc835"
      unitRef="usd">3000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InvestmentIncomeNet
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMTAtMS0xLTEtMTU1MjM_78678581-9c3e-4797-94c5-c9cb41ca92a6"
      unitRef="usd">198000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMTAtMy0xLTEtMTU1MjM_80c4ead0-cff9-495d-afcd-9ae5858ce59b"
      unitRef="usd">227000</us-gaap:InvestmentIncomeNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMTEtMS0xLTEtMTU1MjM_e79aa78e-4b52-4ae7-bea5-4084ac567ddc"
      unitRef="usd">5000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMTEtMy0xLTEtMTU1MjM_0314e1bc-c569-4b84-bb42-b17bf5531724"
      unitRef="usd">230000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMTItMS0xLTEtMTU1MjM_bec46ad5-56d2-4bd7-aa60-2d547b14653e"
      unitRef="usd">-337000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMTItMy0xLTEtMTU1MjM_926d263b-cc0c-407a-9c69-172775d42513"
      unitRef="usd">-261000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMTMtMS0xLTEtMTU1MjM_4cfaa1ee-de5b-40af-97bf-a7675c08b958"
      unitRef="usd">-61801000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMTMtMy0xLTEtMTU1MjM_2e35236d-ea2e-4636-9eea-292561b2a4eb"
      unitRef="usd">-29787000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMjAtMS0xLTEtMTU1MjM_a9d5b808-bd93-4011-91ff-85ec4addfef8"
      unitRef="usdPerShare">-1.26</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMjAtMS0xLTEtMTU1MjM_ddf7f94d-7ebf-4c22-9b46-81be15a3a2f6"
      unitRef="usdPerShare">-1.26</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMjAtMy0xLTEtMTU1MjM_420a340f-8607-454f-b137-bbd51fd18e8c"
      unitRef="usdPerShare">-0.62</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMjAtMy0xLTEtMTU1MjM_b11eac6f-894f-43b9-9810-147d7f624309"
      unitRef="usdPerShare">-0.62</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMjEtMS0xLTEtMTU1MjM_c9916e07-4bde-4f66-a92f-b05e2c5da9d2"
      unitRef="shares">48937756</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMjEtMS0xLTEtMTU1MjM_decb64d6-8cd0-4458-84df-7b131ee015a2"
      unitRef="shares">48937756</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMjEtMy0xLTEtMTU1MjM_133ffbe0-17b7-4ca7-a526-1b7f224e1b5d"
      unitRef="shares">48229539</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yMi9mcmFnOjZkMGE3OGJmMWNjMzRhYzVhZTdhZjNlYmE3OGY0NjU0L3RhYmxlOjQ3ZDhiZjEwMmNlMjQzZDNiYmJkMDRkZTAxM2I4MDBjL3RhYmxlcmFuZ2U6NDdkOGJmMTAyY2UyNDNkM2JiYmQwNGRlMDEzYjgwMGNfMjEtMy0xLTEtMTU1MjM_c273db81-6304-4145-932e-93b2eb1d8724"
      unitRef="shares">48229539</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yNS9mcmFnOmFlOWIyNjdlOGI2MDQ1OWQ5MWRlN2ZhNTBjM2RjMGY0L3RhYmxlOmE2ZDk5MGVmZjBkNDRhMjRhYjM2ZTI0MTNiMTAyNjY0L3RhYmxlcmFuZ2U6YTZkOTkwZWZmMGQ0NGEyNGFiMzZlMjQxM2IxMDI2NjRfMi0xLTEtMS0xNTUyMw_42c5a8fa-cf6b-45c2-b792-af4154145889"
      unitRef="usd">-61801000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yNS9mcmFnOmFlOWIyNjdlOGI2MDQ1OWQ5MWRlN2ZhNTBjM2RjMGY0L3RhYmxlOmE2ZDk5MGVmZjBkNDRhMjRhYjM2ZTI0MTNiMTAyNjY0L3RhYmxlcmFuZ2U6YTZkOTkwZWZmMGQ0NGEyNGFiMzZlMjQxM2IxMDI2NjRfMi0zLTEtMS0xNTUyMw_5e001efe-842c-4b4f-a651-c8356ab5de26"
      unitRef="usd">-29787000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yNS9mcmFnOmFlOWIyNjdlOGI2MDQ1OWQ5MWRlN2ZhNTBjM2RjMGY0L3RhYmxlOmE2ZDk5MGVmZjBkNDRhMjRhYjM2ZTI0MTNiMTAyNjY0L3RhYmxlcmFuZ2U6YTZkOTkwZWZmMGQ0NGEyNGFiMzZlMjQxM2IxMDI2NjRfNC0xLTEtMS0xNTUyMw_e9aab7ee-9722-4364-bd73-7124c2f74046"
      unitRef="usd">-1146000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yNS9mcmFnOmFlOWIyNjdlOGI2MDQ1OWQ5MWRlN2ZhNTBjM2RjMGY0L3RhYmxlOmE2ZDk5MGVmZjBkNDRhMjRhYjM2ZTI0MTNiMTAyNjY0L3RhYmxlcmFuZ2U6YTZkOTkwZWZmMGQ0NGEyNGFiMzZlMjQxM2IxMDI2NjRfNC0zLTEtMS0xNTUyMw_263f389a-9a6a-4cc1-a8e7-a0f9158a25a7"
      unitRef="usd">12000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yNS9mcmFnOmFlOWIyNjdlOGI2MDQ1OWQ5MWRlN2ZhNTBjM2RjMGY0L3RhYmxlOmE2ZDk5MGVmZjBkNDRhMjRhYjM2ZTI0MTNiMTAyNjY0L3RhYmxlcmFuZ2U6YTZkOTkwZWZmMGQ0NGEyNGFiMzZlMjQxM2IxMDI2NjRfNS0xLTEtMS0xNTUyMw_09026b1f-a8da-4a9a-a928-06d826afe910"
      unitRef="usd">-1146000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yNS9mcmFnOmFlOWIyNjdlOGI2MDQ1OWQ5MWRlN2ZhNTBjM2RjMGY0L3RhYmxlOmE2ZDk5MGVmZjBkNDRhMjRhYjM2ZTI0MTNiMTAyNjY0L3RhYmxlcmFuZ2U6YTZkOTkwZWZmMGQ0NGEyNGFiMzZlMjQxM2IxMDI2NjRfNS0zLTEtMS0xNTUyMw_feaa266e-bd07-49cc-afa0-5ac723927eb1"
      unitRef="usd">12000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yNS9mcmFnOmFlOWIyNjdlOGI2MDQ1OWQ5MWRlN2ZhNTBjM2RjMGY0L3RhYmxlOmE2ZDk5MGVmZjBkNDRhMjRhYjM2ZTI0MTNiMTAyNjY0L3RhYmxlcmFuZ2U6YTZkOTkwZWZmMGQ0NGEyNGFiMzZlMjQxM2IxMDI2NjRfNi0xLTEtMS0xNTUyMw_211917cb-201c-4d26-abe0-f743d7d88151"
      unitRef="usd">-62947000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yNS9mcmFnOmFlOWIyNjdlOGI2MDQ1OWQ5MWRlN2ZhNTBjM2RjMGY0L3RhYmxlOmE2ZDk5MGVmZjBkNDRhMjRhYjM2ZTI0MTNiMTAyNjY0L3RhYmxlcmFuZ2U6YTZkOTkwZWZmMGQ0NGEyNGFiMzZlMjQxM2IxMDI2NjRfNi0zLTEtMS0xNTUyMw_e63f19d5-9e0d-4f89-a625-098e45adaa0a"
      unitRef="usd">-29775000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="i658acb93480c4b5393f0f53a36eab567_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMy0xMC0xLTEtMTczMjE_777ba6f2-412a-41be-be3e-e7fee59d0fc7"
      unitRef="shares">48819591</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i658acb93480c4b5393f0f53a36eab567_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMy0xMi0xLTEtMTczMjE_3795dd47-9112-41a6-8699-6e318b067757"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="ic0990f9597e64307b0c20baeb0374ba3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMy0xNC0xLTEtMTczMjE_91d4e25a-63d1-4f8c-bc7a-d4cf3d43f51f"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ic0990f9597e64307b0c20baeb0374ba3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMy0xNi0xLTEtMTczMjE_dc3e6a6a-0b0a-4d7b-869a-fd2d8ab8c776"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3287fd7612614db4b178dca62d93314c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMy0xOC0xLTEtMTczMjE_eafbfa65-6d95-4b4a-bfa9-9cf03753db68"
      unitRef="usd">675615000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8966326533744dcb83a31d655df247a5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMy0yMC0xLTEtMTczMjE_d4a27611-5412-4db8-acc4-fd92889c68e6"
      unitRef="usd">41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7145ff8fbb7347739deda6cecec6c32c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMy0yMi0xLTEtMTczMjE_4194484a-2693-413f-9cb4-2b4db6e927d2"
      unitRef="usd">-118603000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie6aca392105844fb988854fc2a1e19f5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMy0yNC0xLTEtMTczMjE_1fa9a939-a776-44d5-82b1-fe9dde392ea9"
      unitRef="usd">557058000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9db5cd8bf9aa4652801e6be37eb56232_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfNC0xOC0xLTEtMTczMjE_49272a11-6a9f-4e52-97fd-c2ba10c40bce"
      unitRef="usd">7055000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfNC0yNC0xLTEtMTczMjE_6aaca822-f489-4d9f-aaa7-29d433a0e17c"
      unitRef="usd">7055000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i5b30664e42c44ea2bdfe57102b7f8793_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfNS0xMC0xLTEtMTczMjE_71ad16c9-c549-4180-ad6e-af37bd517cc0"
      unitRef="shares">145535</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i5b30664e42c44ea2bdfe57102b7f8793_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfNy0xMC0xLTEtMTczMjE_59466e89-d1df-4943-810b-4630676f5864"
      unitRef="shares">59026</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9db5cd8bf9aa4652801e6be37eb56232_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfNy0xOC0xLTEtMTczMjE_45a8fadd-9b33-4653-b699-504a0bae9363"
      unitRef="usd">359000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfNy0yNC0xLTEtMTczMjE_7019f9b5-973d-40bb-99d9-7b2181e8a533"
      unitRef="usd">359000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if7752062fa254d488520f76b3b98be23_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfOC0yMC0xLTEtMTczMjE_3f38a61a-b2bc-42d9-adcf-39d5fc0ea7e6"
      unitRef="usd">12000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfOC0yNC0xLTEtMTczMjE_01ed6b2f-cc88-4b24-84e6-d4cf6151acbb"
      unitRef="usd">12000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="ia179ee44b4324835983690644a8c2d55_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfOS0yMi0xLTEtMTczMjE_fab149f6-560e-45a4-af0d-7d3f7d874636"
      unitRef="usd">-29787000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfOS0yNC0xLTEtMTczMjE_2f2a7758-87bb-4e0b-a987-43a2d0cf5ab8"
      unitRef="usd">-29787000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i5aeb1d4fe3aa413287784b210d8cb0c7_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTAtMTAtMS0xLTE3MzIx_bf2971c3-28a1-4bc7-9c08-8d6bce23d5ea"
      unitRef="shares">49024152</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i5aeb1d4fe3aa413287784b210d8cb0c7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTAtMTItMS0xLTE3MzIx_fa9a684e-6892-4080-a937-3b6cc622c3e6"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i4d19dcca70de49e18de075013224639e_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTAtMTQtMS0xLTE3MzIx_d1068638-945b-4825-84ab-9ba7ccd1e24c"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i4d19dcca70de49e18de075013224639e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTAtMTYtMS0xLTE3MzIx_85217009-79b0-449b-9118-f7f2d000030c"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1e1848bac6dd4d3395a865c973884624_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTAtMTgtMS0xLTE3MzIx_627d44cc-dd0d-4095-904a-53b0d16fc1b0"
      unitRef="usd">683029000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib131c00375dd4d01a1d5a8ca99a78357_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTAtMjAtMS0xLTE3MzIx_3bbeb96b-b22f-44b9-91a7-39767f6b3ada"
      unitRef="usd">53000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5a27a2ad8f5b4adabc882295f434ad85_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTAtMjItMS0xLTE3MzIx_330d5028-67df-42c3-881b-039c8ceea054"
      unitRef="usd">-148390000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id7c72970af33479486aedd56f27b30d3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTAtMjQtMS0xLTE3MzIx_b8df626f-a2cb-4d5d-83b3-4ef553efbd42"
      unitRef="usd">534697000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="ib34b57b88c524fb2a5cfb417de744b4e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTItMTAtMS0xLTE3MzIx_c8a16949-752f-4ee8-9293-0e2e958ef627"
      unitRef="shares">49247985</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ib34b57b88c524fb2a5cfb417de744b4e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTItMTItMS0xLTE3MzIx_18b36607-4fbb-4e18-8076-8247ec4dff51"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="ia0c1b343064f4976a0430d48302ee8dc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTItMTQtMS0xLTE3MzIx_c3e3cef9-43f5-4540-8701-f9b44b0120c8"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ia0c1b343064f4976a0430d48302ee8dc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTItMTYtMS0xLTE3MzIx_ee0cc5ce-6f79-40c2-be83-4fe78f55bfaf"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5cea465f2f2844ecbd14a5a3b0ba249c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTItMTgtMS0xLTE3MzIx_ea1a5fe3-c532-454f-bbb4-a0279884ea46"
      unitRef="usd">715216000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic68434afffb54cf0b8787b66026e3164_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTItMjAtMS0xLTE3MzIx_bee41392-cd5a-4ffc-81fc-4034889209a2"
      unitRef="usd">-312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifee6028d47d94c659487fe06b58c5d96_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTItMjItMS0xLTE3MzIx_a340bac6-2ec2-415d-912a-b5700907240a"
      unitRef="usd">-292513000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTItMjQtMS0xLTE3MzIx_e95ed9ae-ba7a-4cc0-a7b9-52a4868e0344"
      unitRef="usd">422396000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic2b735c9c0ea4731a01282de2dda1e04_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTMtMTgtMS0xLTE3MzIx_50d68152-4961-4e2e-81bc-a0bda09cc1eb"
      unitRef="usd">17094000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTMtMjQtMS0xLTE3MzIx_3d61e9ba-d967-44c0-bd70-35949f2963a1"
      unitRef="usd">17094000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i5310686134dd466eb22c5118bf07c60a_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTQtMTAtMS0xLTE3MzIx_32c1925c-b9d5-4a5d-97dd-b56b03320558"
      unitRef="shares">36625</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i5310686134dd466eb22c5118bf07c60a_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTUtMTAtMS0xLTE3MzIx_298b0c5c-a467-45c0-a0e3-3caa012f4d0b"
      unitRef="shares">142657</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic2b735c9c0ea4731a01282de2dda1e04_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTUtMTgtMS0xLTE3MzIx_c0042f57-22a6-4d47-afab-fd593d696113"
      unitRef="usd">1167000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTUtMjQtMS0xLTE3MzIx_e8a0cf6d-6c88-4517-ad53-eda76c19a55f"
      unitRef="usd">1167000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="i5310686134dd466eb22c5118bf07c60a_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTctMTAtMS0xLTE3MzIx_5d680ca6-2fdd-49f4-a7b2-55e63decac3b"
      unitRef="shares">3440</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="if3b4361b2bc8468a8261a967f49bda37_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTgtMTQtMS0xLTE3MzIx_5889cdea-b780-4d3c-a79d-2f195aa8b19c"
      unitRef="shares">16210</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if3b4361b2bc8468a8261a967f49bda37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTgtMTYtMS0xLTE3MzIx_63b4e201-5298-4392-a2db-3dfdd4c3b978"
      unitRef="usd">906000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTgtMjQtMS0xLTE4MzY3_91add851-5501-420c-a309-ff6cee42f42d"
      unitRef="usd">906000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i17d85f9a1e034f45ac98309a4aa39e2b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTktMjAtMS0xLTE3MzIx_655b1268-2953-4b5a-818e-536be534c26c"
      unitRef="usd">-1146000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMTktMjQtMS0xLTE3MzIx_58f218af-c5f8-4649-8463-0d86a34bc179"
      unitRef="usd">-1146000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="ie552d9ac6bf047888c1a1153ddd4b5f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMjAtMjItMS0xLTE3MzIx_af338377-884b-422f-983e-59bd0279f646"
      unitRef="usd">-61801000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMjAtMjQtMS0xLTE3MzIx_e95189b2-01d4-4416-b97b-ebe7cc55f490"
      unitRef="usd">-61801000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="ic22dfb0a26f1485a97ca52722464d5ad_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMjEtMTAtMS0xLTE3MzIx_7a3c0ecf-718e-4056-ae80-434e5da554cc"
      unitRef="shares">49423827</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ic22dfb0a26f1485a97ca52722464d5ad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMjEtMTItMS0xLTE3MzIx_60416e71-72ba-42cb-8c5d-72bbe3298a71"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i0538532efa4c481fb6287237941a7a83_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMjEtMTQtMS0xLTE3MzIx_e1bff807-9d59-4c98-ac49-deb5d6bf7c09"
      unitRef="shares">16210</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i0538532efa4c481fb6287237941a7a83_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMjEtMTYtMS0xLTE3MzIx_782f4960-8490-4ec5-98bb-8bab4159405e"
      unitRef="usd">-906000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i76cd6147b1f74623a56a60a92568ed2a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMjEtMTgtMS0xLTE3MzIx_f24ec4be-49f5-4c65-8644-749c96381918"
      unitRef="usd">733477000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9e643f8a8bad4d0685bb17341335398d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMjEtMjAtMS0xLTE3MzIx_f15a6f3e-30b0-4520-a0a4-ffa044bb80f5"
      unitRef="usd">-1458000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i774d25c476d6488093d122507b7e32fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMjEtMjItMS0xLTE3MzIx_f69a2d2e-6c0a-4436-95ba-bc8385ce5faf"
      unitRef="usd">-354314000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18yOC9mcmFnOmUyNjA3ZjVmZDdmODRhMzVhMDZmMjI5MzlmOTU4YWQxL3RhYmxlOmQ1Nzg1NGQzYWQ0ODRkNmI4NTg2MzI0ZDcxNDc4ZjU1L3RhYmxlcmFuZ2U6ZDU3ODU0ZDNhZDQ4NGQ2Yjg1ODYzMjRkNzE0NzhmNTVfMjEtMjQtMS0xLTE3MzIx_33cc0d31-2bf3-48b4-8615-7967e2c17734"
      unitRef="usd">376804000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMy0xLTEtMS0xNTUyMw_8a776bb9-86d8-41d8-891c-774f1ec8d86c"
      unitRef="usd">-61801000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMy0zLTEtMS0xNTUyMw_e02c6d88-087b-4812-88dd-72fe608502b7"
      unitRef="usd">-29787000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfNS0xLTEtMS0xNTUyMw_f70ae803-b3d7-400a-a441-922bdae7dd16"
      unitRef="usd">108000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfNS0zLTEtMS0xNTUyMw_a4e41718-b70c-4bf0-8293-fa5ed4433ddb"
      unitRef="usd">110000</us-gaap:Depreciation>
    <swtx:NonCashOperatingLeaseExpense
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfNi0xLTEtMS0xNTUyMw_f43e1880-b985-4750-af03-1ee1475906a4"
      unitRef="usd">272000</swtx:NonCashOperatingLeaseExpense>
    <swtx:NonCashOperatingLeaseExpense
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfNi0zLTEtMS0xNTUyMw_dd2f590e-6bc9-4149-8a6e-2c2afab24a1a"
      unitRef="usd">257000</swtx:NonCashOperatingLeaseExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfNy0xLTEtMS0xNTUyMw_43ad980f-682d-48b8-9855-c6ef7183b32a"
      unitRef="usd">17094000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfNy0zLTEtMS0xNTUyMw_b5ddd4d9-9a26-4640-8054-28c3e58fe604"
      unitRef="usd">7055000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfOC0xLTEtMS0xNTUyMw_0da24ab7-1731-412e-8208-f8a3e62bafd2"
      unitRef="usd">-337000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfOC0zLTEtMS0xNTUyMw_ef581b01-516b-46fe-9c4f-5f089ae8e867"
      unitRef="usd">-261000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTAtMS0xLTEtMTU1MjM_b45af3d3-95e4-4e23-b0fd-c929b7e0c33d"
      unitRef="usd">-1729000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTAtMy0xLTEtMTU1MjM_2f940f67-5a4f-4c8e-91eb-5c75707b342b"
      unitRef="usd">-697000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTEtMS0xLTEtMTU1MjM_1d65e30b-7f14-43a0-89f5-cf09f4a7d1cb"
      unitRef="usd">-82000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTEtMy0xLTEtMTU1MjM_3bcab435-0ce3-4adb-8d53-661700b79963"
      unitRef="usd">545000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTItMS0xLTEtMTU1MjM_1be2e0e9-ea00-4714-bf55-0392a1f2f1c4"
      unitRef="usd">-1770000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTItMy0xLTEtMTU1MjM_cf61d89f-87a4-41d3-89a2-2feb06dead41"
      unitRef="usd">879000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTMtMS0xLTEtMTU1MjM_e49a6f3f-add8-4b6f-b667-314e9173f229"
      unitRef="usd">-4695000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTMtMy0xLTEtMTU1MjM_f59ee2e8-dd5b-4887-a81a-0ce7471269ed"
      unitRef="usd">357000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <swtx:IncreaseDecreaseInLeaseLiability
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTUtMS0xLTEtMTU1MjM_38a64443-e469-43a4-92a0-fdf774cbe11c"
      unitRef="usd">-44000</swtx:IncreaseDecreaseInLeaseLiability>
    <swtx:IncreaseDecreaseInLeaseLiability
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTUtMy0xLTEtMTU1MjM_5ab44fef-74a9-40cb-a9a6-c43c644b5924"
      unitRef="usd">-355000</swtx:IncreaseDecreaseInLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTYtMS0xLTEtMTU1MjM_2f22c8a6-8dfa-4889-aafc-ae38dd225137"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTYtMy0xLTEtMTU1MjM_050a22ad-a1de-4767-a5e1-cfbc9687800a"
      unitRef="usd">-33000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTctMS0xLTEtMTU1MjM_830f7b18-cabb-40fc-ace2-05179a584ee3"
      unitRef="usd">-48688000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTctMy0xLTEtMTU1MjM_3f93e5c0-7e15-4928-b7a9-78827f7d92e8"
      unitRef="usd">-21104000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTktMS0xLTEtMTU1MjM_7af9fdbc-4c8f-461a-a29f-2bc8bb13b0c8"
      unitRef="usd">2387000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMTktMy0xLTEtMTU1MjM_f29df5eb-85ca-4b50-a2ec-a642868483f6"
      unitRef="usd">45000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMjEtMS0xLTEtMTU1MjM_635e2144-9c99-4239-aa47-8fcdc076883c"
      unitRef="usd">23242000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMjEtMy0xLTEtMTU1MjM_7dd7fecd-b75f-4d08-ab7c-6ff2a9979b31"
      unitRef="usd">86373000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMjItMS0xLTEtMTU1MjM_1cdded7d-a3ed-4265-9943-8235a880b2c4"
      unitRef="usd">52053000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMjItMy0xLTEtMTU1MjM_ce694c0f-3931-472d-9c5e-25b8015f9483"
      unitRef="usd">55500000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMjMtMS0xLTEtMTU1MjM_e2cdf9d1-8e44-456e-b546-3387a75a800d"
      unitRef="usd">26424000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMjMtMy0xLTEtMTU1MjM_bd85f0f6-1f61-4ab2-849b-b1bd4a6599f0"
      unitRef="usd">-30918000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMjgtMS0xLTEtMTg5NzQ_cf4dc284-793b-41fb-953f-ac0543b24a19"
      unitRef="usd">906000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMjgtMy0xLTEtMTg5NzQ_f7733fc8-4552-491f-bcf2-860d4332003a"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMjgtMS0xLTEtMTU1MjM_fc2aff8d-2b06-40e8-9357-bc0e9da995b2"
      unitRef="usd">1167000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMjgtMy0xLTEtMTU1MjM_2b22cbbb-9a32-41a9-baa1-87b56dd82f51"
      unitRef="usd">359000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMjktMS0xLTEtMTU1MjM_fb64bfe2-bff5-4c0b-ab06-871fb8f4db41"
      unitRef="usd">261000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMjktMy0xLTEtMTU1MjM_ce740e13-70ef-41ad-8ff7-dc25e13b3e27"
      unitRef="usd">359000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMzAtMS0xLTEtMTU1MjM_363f1f48-e4ef-46aa-b0ff-aa7654d61d77"
      unitRef="usd">-22003000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMzAtMy0xLTEtMTU1MjM_3a5df25f-67da-4d5c-84ee-55eae91c9af1"
      unitRef="usd">-51663000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMzEtMS0xLTEtMTU1MjM_1a0001fe-3b39-49ed-849c-75efa1b1975e"
      unitRef="usd">104526000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie6aca392105844fb988854fc2a1e19f5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMzEtMy0xLTEtMTU1MjM_73c1a603-5eef-4847-9a5e-cba1e3a2a0e7"
      unitRef="usd">147654000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMzItMS0xLTEtMTU1MjM_8a24573d-e076-412f-8e77-bdbd4e7a6360"
      unitRef="usd">82523000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id7c72970af33479486aedd56f27b30d3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOmQ1OWNmOTliOGI4YzQxYmJhYTMzZDdmOTYzZTNjZWIyL3RhYmxlcmFuZ2U6ZDU5Y2Y5OWI4YjhjNDFiYmFhMzNkN2Y5NjNlM2NlYjJfMzItMy0xLTEtMTU1MjM_586c3440-e4f6-4602-9def-91fd89197aab"
      unitRef="usd">95991000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOjA2NTkxZTE5OTE3MTRhMTNhOTIyOTI5ODhlNTAxNjcxL3RhYmxlcmFuZ2U6MDY1OTFlMTk5MTcxNGExM2E5MjI5Mjk4OGU1MDE2NzFfMS0xLTEtMS0xNzQ3NA_ed363e33-297c-4fdc-aba1-d24220f537b5"
      unitRef="usd">5580000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zMS9mcmFnOmYwNzExZWQzMjIzNDRjZGNiMTg4Yzc5MTQ4MWVjMTVhL3RhYmxlOjA2NTkxZTE5OTE3MTRhMTNhOTIyOTI5ODhlNTAxNjcxL3RhYmxlcmFuZ2U6MDY1OTFlMTk5MTcxNGExM2E5MjI5Mjk4OGU1MDE2NzFfMS0zLTEtMS0xNzQ3NA_6e906543-fa1e-4793-8bbd-7861e25d1db3"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NatureOfOperations
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zNy9mcmFnOjBkM2Y4ODY0NjI3MDQ3ZDY5ZTU5MThmMjZiMzU4MDQwL3RleHRyZWdpb246MGQzZjg4NjQ2MjcwNDdkNjllNTkxOGYyNmIzNTgwNDBfMjg1OA_6898819a-d7a0-4411-94b7-f3540a8233a5">Nature of Operations&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SpringWorks Therapeutics, Inc., together with its wholly-owned subsidiaries, collectively, the Company, is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The Company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. Two of the programs are late-stage clinical product candidates: nirogacestat and mirdametinib.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred losses and negative operating cash flows since inception and had an accumulated deficit of $354.3 million and $292.5 million, and working capital of $332.7 million and $352.9 million, as of March&#160;31, 2022 and December&#160;31, 2021, respectively. The Company is subject to those risks associated with any biopharmaceutical company that has substantial expenditures for development. There can be no assurance that the Company&#x2019;s development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees, advisors, consultants and vendors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had cash, cash equivalents and marketable securities of $380.7 million and $432.7 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively. Based on the Company's cash, cash equivalents and marketable securities as of March&#160;31, 2022, management estimates that its current liquidity will enable it to meet operating expenses through at least twelve&#160;months after the date that these financial statements are issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;COVID-19 Pandemic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On March 11, 2020, the World Health Organization designated the outbreak of the disease associated with the novel strain of coronavirus known as COVID-19 as a global pandemic. This disease continues to spread, including recent acceleration of the spread of the Delta and Omicron variants of COVID-19 in the areas in which the Company operates. Governments and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including, but not limited to, shelter-in-place orders, quarantines, significant restrictions on travel, as well as restrictions that prohibit many employees from going to work. Uncertainty with respect to the economic impacts of the pandemic has introduced significant volatility in the financial markets. The global pandemic caused by COVID-19 (including the impact of emerging variant strains of the COVID-19 virus and stagnant vaccination rates) did not have significant impacts on the Company's financial condition, results of operations or cash flows during the periods presented. While the extent to which the ongoing COVID-19 pandemic impacts the Company&#x2019;s future results will depend on future developments, the pandemic and associated impacts, including the duration, spread and intensity of the pandemic (including any resurgences), the impact of emerging variant strains of the COVID-19 virus and the rollout of COVID-19 vaccines, all of which remain uncertain and difficult to predict, could result in a material impact to the Company&#x2019;s future financial condition, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <swtx:NumberOfClinicalTrials
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zNy9mcmFnOjBkM2Y4ODY0NjI3MDQ3ZDY5ZTU5MThmMjZiMzU4MDQwL3RleHRyZWdpb246MGQzZjg4NjQ2MjcwNDdkNjllNTkxOGYyNmIzNTgwNDBfNDkw_0409f2e0-0b56-4a6d-8490-d2576cdb1b33"
      unitRef="trial">2</swtx:NumberOfClinicalTrials>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zNy9mcmFnOjBkM2Y4ODY0NjI3MDQ3ZDY5ZTU5MThmMjZiMzU4MDQwL3RleHRyZWdpb246MGQzZjg4NjQ2MjcwNDdkNjllNTkxOGYyNmIzNTgwNDBfODYw_018f7c10-9e8c-47e1-96f3-503dc53ababa"
      unitRef="usd">-354300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zNy9mcmFnOjBkM2Y4ODY0NjI3MDQ3ZDY5ZTU5MThmMjZiMzU4MDQwL3RleHRyZWdpb246MGQzZjg4NjQ2MjcwNDdkNjllNTkxOGYyNmIzNTgwNDBfODY3_2ac22f02-56b2-44a5-b14f-87e639a9dda5"
      unitRef="usd">-292500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <swtx:WorkingCapital
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zNy9mcmFnOjBkM2Y4ODY0NjI3MDQ3ZDY5ZTU5MThmMjZiMzU4MDQwL3RleHRyZWdpb246MGQzZjg4NjQ2MjcwNDdkNjllNTkxOGYyNmIzNTgwNDBfODk0_fc432eb1-5cfa-4efa-9ffa-76405bb4da37"
      unitRef="usd">332700000</swtx:WorkingCapital>
    <swtx:WorkingCapital
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zNy9mcmFnOjBkM2Y4ODY0NjI3MDQ3ZDY5ZTU5MThmMjZiMzU4MDQwL3RleHRyZWdpb246MGQzZjg4NjQ2MjcwNDdkNjllNTkxOGYyNmIzNTgwNDBfOTAx_cb697c03-f6f7-49fa-9b7b-256dc9e00d64"
      unitRef="usd">352900000</swtx:WorkingCapital>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zNy9mcmFnOjBkM2Y4ODY0NjI3MDQ3ZDY5ZTU5MThmMjZiMzU4MDQwL3RleHRyZWdpb246MGQzZjg4NjQ2MjcwNDdkNjllNTkxOGYyNmIzNTgwNDBfMTUyNg_701b372f-428a-4f40-a80f-2ae9ae4b9025"
      unitRef="usd">380700000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N18zNy9mcmFnOjBkM2Y4ODY0NjI3MDQ3ZDY5ZTU5MThmMjZiMzU4MDQwL3RleHRyZWdpb246MGQzZjg4NjQ2MjcwNDdkNjllNTkxOGYyNmIzNTgwNDBfMTUzMw_d2f649ec-b776-4321-9521-5b929e03bbc1"
      unitRef="usd">432700000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180MC9mcmFnOjNjZGEwOGM2NDk5YzQ1MTliMmEzZTBiZWE0NTZhNmNkL3RleHRyZWdpb246M2NkYTA4YzY0OTljNDUxOWIyYTNlMGJlYTQ1NmE2Y2RfNDIzMw_41bc2552-4286-4ab9-9536-fe6f4a5c50fc">Basis of Presentation&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the pet States, or U.S. GAAP, for interim financial information and Article 10 of Regulation S-X of the Securities and Exchange Commission, or SEC, and should be read in conjunction with the Company's consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February 24, 2022. The condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q are unaudited; however, in the opinion of management, such financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses and the valuation of stock-based compensation awards. Management bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actual results may differ from those estimates or assumptions. On an ongoing basis, management evaluates its estimates, and adjusts those estimates and assumptions when facts or circumstances change. Changes in estimates are recorded in the period in which they become known. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 730, &#x201c;Research and Development&#x201d;, expenditures for clinical development, including upfront licensing fees and milestone payments associated with products that have not yet been approved by the U.S. Food and Drug Administration, are charged to research and development expense as incurred. These expenses consist of expenses incurred in performing development activities, including salaries and benefits, stock-based compensation expense, preclinical expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. Expenses incurred for certain research and development activities, including expenses associated with particular activities performed by contract research organizations, investigative sites in connection with clinical trials and contract manufacturing organizations, are recognized based on an evaluation of the progress or completion of specific tasks using either time-based measures or data such as information provided to the Company by its vendors on actual activities completed or costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of expense recognition. Expenses for research and development activities incurred that have yet to be invoiced by the vendors that perform the related activities are reflected in the consolidated financial statements as accrued research and development expenses. Advance payments for goods or services to be received in the future for research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no recently adopted accounting pronouncements that had a material impact on the Company's financial statements, and no recently issued accounting pronouncements that are expected to have a material impact on the Company's financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180MC9mcmFnOjNjZGEwOGM2NDk5YzQ1MTliMmEzZTBiZWE0NTZhNmNkL3RleHRyZWdpb246M2NkYTA4YzY0OTljNDUxOWIyYTNlMGJlYTQ1NmE2Y2RfNDIzNA_74902508-d039-4efa-b1ca-68c834de2501">Basis of PresentationThe Company&#x2019;s unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the pet States, or U.S. GAAP, for interim financial information and Article 10 of Regulation S-X of the Securities and Exchange Commission, or SEC, and should be read in conjunction with the Company's consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February 24, 2022. The condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q are unaudited; however, in the opinion of management, such financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180MC9mcmFnOjNjZGEwOGM2NDk5YzQ1MTliMmEzZTBiZWE0NTZhNmNkL3RleHRyZWdpb246M2NkYTA4YzY0OTljNDUxOWIyYTNlMGJlYTQ1NmE2Y2RfNDIzNQ_1c277a86-f039-4431-ab06-23c6ed5af628">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses and the valuation of stock-based compensation awards. Management bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. &lt;/span&gt;&lt;/div&gt;Actual results may differ from those estimates or assumptions. On an ongoing basis, management evaluates its estimates, and adjusts those estimates and assumptions when facts or circumstances change. Changes in estimates are recorded in the period in which they become known.</us-gaap:UseOfEstimates>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180MC9mcmFnOjNjZGEwOGM2NDk5YzQ1MTliMmEzZTBiZWE0NTZhNmNkL3RleHRyZWdpb246M2NkYTA4YzY0OTljNDUxOWIyYTNlMGJlYTQ1NmE2Y2RfNDIzNg_6ef8eb13-54c7-422d-b9ca-d04c387f4673">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 730, &#x201c;Research and Development&#x201d;, expenditures for clinical development, including upfront licensing fees and milestone payments associated with products that have not yet been approved by the U.S. Food and Drug Administration, are charged to research and development expense as incurred. These expenses consist of expenses incurred in performing development activities, including salaries and benefits, stock-based compensation expense, preclinical expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. Expenses incurred for certain research and development activities, including expenses associated with particular activities performed by contract research organizations, investigative sites in connection with clinical trials and contract manufacturing organizations, are recognized based on an evaluation of the progress or completion of specific tasks using either time-based measures or data such as information provided to the Company by its vendors on actual activities completed or costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of expense recognition. Expenses for research and development activities incurred that have yet to be invoiced by the vendors that perform the related activities are reflected in the consolidated financial statements as accrued research and development expenses. Advance payments for goods or services to be received in the future for research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180MC9mcmFnOjNjZGEwOGM2NDk5YzQ1MTliMmEzZTBiZWE0NTZhNmNkL3RleHRyZWdpb246M2NkYTA4YzY0OTljNDUxOWIyYTNlMGJlYTQ1NmE2Y2RfNDIzNw_67e0b73d-0b13-44f8-b5f3-772550a2b60d">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180MC9mcmFnOjNjZGEwOGM2NDk5YzQ1MTliMmEzZTBiZWE0NTZhNmNkL3RleHRyZWdpb246M2NkYTA4YzY0OTljNDUxOWIyYTNlMGJlYTQ1NmE2Y2RfMzgzMw_d7cf5f9a-6a7d-488d-893e-8aa1c6943e10"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180MC9mcmFnOjNjZGEwOGM2NDk5YzQ1MTliMmEzZTBiZWE0NTZhNmNkL3RleHRyZWdpb246M2NkYTA4YzY0OTljNDUxOWIyYTNlMGJlYTQ1NmE2Y2RfNDIzOA_0f959ab3-fae9-4757-aefd-60898dc85ee8">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no recently adopted accounting pronouncements that had a material impact on the Company's financial statements, and no recently issued accounting pronouncements that are expected to have a material impact on the Company's financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RleHRyZWdpb246MDE4ZjcwZDNmZTMwNDI2Y2JlZmEwYTA2NWFlNDFiNTFfODk3_5f945bb6-2282-4e6b-94b9-1ffbc7f6e1ef">Marketable Securities&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s available-for-sale marketable securities as of March&#160;31, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.212%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.212%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.212%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash Equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;309,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.212%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.212%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.212%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Government securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s marketable securities are available-for-sale securities and consist of high-quality, highly liquid debt securities including corporate debt securities, U.S. government securities and commercial paper.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s available-for-sale securities classified as short-term marketable securities in the condensed consolidated balance sheets mature within one year or less of the balance sheet date. Marketable securities that mature greater than one year from the balance sheet date are classified as long-term. As of March&#160;31, 2022, the Company did not hold any investments with maturity dates greater than five years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of, and for the three months ended March&#160;31, 2022, the Company did not have any allowance for credit losses or impairments of its marketable securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RleHRyZWdpb246MDE4ZjcwZDNmZTMwNDI2Y2JlZmEwYTA2NWFlNDFiNTFfODk4_60c79e6c-fa0f-4334-8da2-997b79f98444">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s available-for-sale marketable securities as of March&#160;31, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.212%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.212%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.212%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash Equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;309,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.212%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.212%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.212%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Government securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic96e90b96953469abcc2db764348a6e1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNC0xLTEtMS0xNzcxNg_8855d957-21a3-4b41-9c81-76fb35418f67"
      unitRef="usd">11091000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic96e90b96953469abcc2db764348a6e1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNC0zLTEtMS0xNzcxNg_fdc2af08-08fc-42df-ab55-b76da9096974"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic96e90b96953469abcc2db764348a6e1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNC01LTEtMS0xNzcxNg_48e756fb-90a7-426e-a1e5-c31ae9a77996"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic96e90b96953469abcc2db764348a6e1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNC03LTEtMS0xNzcxNg_efd57af6-5f47-469c-b9ab-fa6fcace8bdb"
      unitRef="usd">11093000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic8b06dfad0e4445b9def4cf77df1caf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNC0xLTEtMS0xNTUyMw_152848c7-3f2e-42d0-8835-70471889f4ea"
      unitRef="usd">117894000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic8b06dfad0e4445b9def4cf77df1caf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNC0zLTEtMS0xNTUyMw_19e81a70-0a89-43a4-bba2-e7eaf7548c64"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic8b06dfad0e4445b9def4cf77df1caf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNC01LTEtMS0xNTUyMw_357f91b0-0f3a-48cc-ac82-ec05433fb950"
      unitRef="usd">645000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic8b06dfad0e4445b9def4cf77df1caf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNC03LTEtMS0xNTUyMw_ab5914b7-cd10-4a00-9029-1dcf973b4fe3"
      unitRef="usd">117249000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i67ce1d0e7f26429d9c2e120dd4006a6d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNS0xLTEtMS0xNTUyMw_829bab5b-ae1e-486d-9294-c325b8687567"
      unitRef="usd">73451000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i67ce1d0e7f26429d9c2e120dd4006a6d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNS0zLTEtMS0xNTUyMw_4d8e8520-a16f-4c92-9ceb-80219efca339"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i67ce1d0e7f26429d9c2e120dd4006a6d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNS01LTEtMS0xNTUyMw_b13cb361-73d1-48f0-80a4-d54a61717d0f"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i67ce1d0e7f26429d9c2e120dd4006a6d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNS03LTEtMS0xNTUyMw_8a516ee0-0821-4af0-93db-e69959670348"
      unitRef="usd">73151000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie516370bcc604882a6b3b1072c5423ed_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNi0xLTEtMS0xNTUyMw_cee2c783-793a-4858-adbd-d2456d99ad60"
      unitRef="usd">75938000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie516370bcc604882a6b3b1072c5423ed_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfNi03LTEtMS0xNTUyMw_af924523-142f-4415-9ae3-e68e68a2a4be"
      unitRef="usd">75938000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i65431ed7c312413eb40bd20210448df7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfOC0xLTEtMS0xNTUyMw_01a9b208-7644-44c1-b0bf-1bb823c7b681"
      unitRef="usd">32990000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i65431ed7c312413eb40bd20210448df7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfOC0zLTEtMS0xNTUyMw_258ff2aa-2415-453f-b58f-2151718bc2d2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i65431ed7c312413eb40bd20210448df7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfOC01LTEtMS0xNTUyMw_3af59b45-fc66-427f-9c14-0f28de8e6ed0"
      unitRef="usd">515000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i65431ed7c312413eb40bd20210448df7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfOC03LTEtMS0xNTUyMw_602228f2-33f3-4c4e-b284-a9d0c4fe399e"
      unitRef="usd">32475000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfMTAtMS0xLTEtMTU1MjM_9218ff50-f165-41b5-80e3-0dfeb4f91ebc"
      unitRef="usd">311364000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfMTAtMy0xLTEtMTU1MjM_733df1e0-9010-4bb2-91fe-4d91547825f2"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfMTAtNS0xLTEtMTU1MjM_2ea5f9f8-fe47-4510-83b5-fa8437ef3e3a"
      unitRef="usd">1460000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjJmNDA0OWVhOTY3NDRmNjBiMjZiOTNkZDg1NmFhZjY3L3RhYmxlcmFuZ2U6MmY0MDQ5ZWE5Njc0NGY2MGIyNmI5M2RkODU2YWFmNjdfMTAtNy0xLTEtMTU1MjM_acf7b361-c412-4e2b-9f82-2adebfb43492"
      unitRef="usd">309906000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i300f6154df4c49c19cae97a30ab27fca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfNC0xLTEtMS0xNTUyMw_6597575d-3a08-4555-9ef9-50fb460cbc67"
      unitRef="usd">105043000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i300f6154df4c49c19cae97a30ab27fca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfNC0zLTEtMS0xNTUyMw_65c03e49-5161-43b2-863e-0715b959e377"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i300f6154df4c49c19cae97a30ab27fca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfNC01LTEtMS0xNTUyMw_763198d2-d14e-4614-a8c0-a22c53515aaa"
      unitRef="usd">79000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i300f6154df4c49c19cae97a30ab27fca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfNC03LTEtMS0xNTUyMw_d168d20b-b281-40cf-af09-88a0b2dbe23d"
      unitRef="usd">104967000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i150fe21584a54235b4ee8a7eab45b761_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfNS0xLTEtMS0xNTUyMw_3504cf81-3f83-424e-9248-3790aad21c82"
      unitRef="usd">78729000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i150fe21584a54235b4ee8a7eab45b761_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfNS0zLTEtMS0xNTUyMw_49706152-4ecf-4c40-a4ac-3311acb0494f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i150fe21584a54235b4ee8a7eab45b761_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfNS01LTEtMS0xNTUyMw_0427abd3-d94e-47d3-82c8-f085c1c5f648"
      unitRef="usd">52000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i150fe21584a54235b4ee8a7eab45b761_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfNS03LTEtMS0xNTUyMw_df1bddbb-b84b-4830-93fb-ffffa4ab5381"
      unitRef="usd">78677000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id08a9791d8bf499dbcb446a78165cc74_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfNi0xLTEtMS0xNTUyMw_3df3b294-befe-45ce-ab0e-f92b1481edab"
      unitRef="usd">85896000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id08a9791d8bf499dbcb446a78165cc74_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfNi03LTEtMS0xNTUyMw_0448954d-be58-4539-89de-438e5d75f2e8"
      unitRef="usd">85896000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7fe7159edfa24359996120ecad894ca9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfOC0xLTEtMS0xNTUyMw_ee76c545-59e8-47c0-917c-329a28485e8b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7fe7159edfa24359996120ecad894ca9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfOC0zLTEtMS0xNTUyMw_24e5b514-a23d-4885-8203-dcf31f5c099c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7fe7159edfa24359996120ecad894ca9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfOC03LTEtMS0xNTUyMw_28148336-02cc-4336-be47-77bf60c674a5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfOS0xLTEtMS0xNTUyMw_96a7cf4c-1380-4e8e-b085-b60b92cdafdb"
      unitRef="usd">269668000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfOS0zLTEtMS0xNTUyMw_74ee428c-ebb0-4420-9eb8-7ee2879108f7"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfOS01LTEtMS0xNTUyMw_9f8ad36e-cf71-41eb-a585-5bd65c0730dc"
      unitRef="usd">131000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180My9mcmFnOjAxOGY3MGQzZmUzMDQyNmNiZWZhMGEwNjVhZTQxYjUxL3RhYmxlOjBmNTY5MDVlZjgwZDQ3YTRiNmIyMTUwNjY2MDQzNWFiL3RhYmxlcmFuZ2U6MGY1NjkwNWVmODBkNDdhNGI2YjIxNTA2NjYwNDM1YWJfOS03LTEtMS0xNTUyMw_fa9a6c54-6c08-4c2b-959c-26c639fc4b41"
      unitRef="usd">269540000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RleHRyZWdpb246NmI1NjJkODJiNzE5NGQwNWJiNjg2N2E4MGM1OWFmYjNfMjQ0Mg_a5328e11-3232-4049-a9ef-8ddda1112e3d">Fair Value Measurements&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company&#x2019;s financial assets measured on a recurring basis are classified based upon a fair value hierarchy consisting of the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&#160;&#x2014; Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets, or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&#160;&#x2014; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3&#160;&#x2014; Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy is based on inputs to valuation techniques used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources while unobservable inputs reflect a reporting entity's pricing based upon their own market assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022 and December&#160;31, 2021, the Company's financial assets and liabilities recognized at fair value on a recurring basis consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value Hierarchy&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;117,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;117,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;73,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;73,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;75,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;75,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;336,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;176,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;160,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value Hierarchy&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;418,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;254,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;164,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022 and December&#160;31, 2021, the Company&#x2019;s financial assets measured at fair value on a recurring basis using a market approach included cash equivalents, which consist of money market funds, and marketable securities, which consist of high-quality, highly liquid available-for-sale debt securities including corporate debt securities, U.S. government securities and commercial paper.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s money market funds are readily convertible into cash and the net asset value of each fund on the last day of the quarter is used to determine fair value. The U.S. Government securities are classified as Level 1 and valued utilizing quoted market prices. The Company&#x2019;s corporate debt securities and commercial paper are classified as Level 2 and valued utilizing various market and industry inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid instruments that have maturities of three months or less when acquired to be cash equivalents. The carrying amounts reflected in the Company&#x2019;s condensed consolidated balance sheets for cash equivalents, accounts payable, and accrued expenses approximate fair value due to their short-term maturities.&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"/&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RleHRyZWdpb246NmI1NjJkODJiNzE5NGQwNWJiNjg2N2E4MGM1OWFmYjNfMjQ0Mw_b96e953a-4672-41ac-981d-3cdd7e85e6ba">As of March&#160;31, 2022 and December&#160;31, 2021, the Company's financial assets and liabilities recognized at fair value on a recurring basis consisted of the following:&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value Hierarchy&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;117,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;117,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;73,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;73,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;75,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;75,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;336,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;176,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;160,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value Hierarchy&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;418,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;254,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;164,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic4afc949d12f47acb07e3840b1a868ac_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfNS0xLTEtMS0xNTUyMw_d5ecd255-414c-4f85-ab09-deac55719af1"
      unitRef="usd">26735000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ieaa89fe2a4c24ac598f43e035f41aa5b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfNS0zLTEtMS0xNTUyMw_a935ca4e-949a-48f4-90df-a5edeebe64cb"
      unitRef="usd">26735000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib7e42a60b7564e79bc3c7c48d5590c00_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfNS01LTEtMS0xNTUyMw_58abee60-c4ba-45ff-a0f7-9deff7a76db4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icb7ddd9a5fdb4cf3abb770f8dbe58b35_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfNS03LTEtMS0xNTUyMw_129a024f-8940-4892-bd9f-802630960b35"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5a06e303f7d247fe94023b4d619218aa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfNi0xLTEtMS0xNjkzNA_182dccdf-6ac2-4ab4-a66d-6f54a25f28f0"
      unitRef="usd">11093000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifd4bd8059ca34abfb81ea2cc6436bce6_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfNi0zLTEtMS0xNjkzNA_ac645ee6-8a53-4b87-b737-6eba676499a6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i26bf9156508046f3a787efd142360d06_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfNi01LTEtMS0xNjkzNA_4240480e-dfcf-49ac-871f-04f63a9a4f8b"
      unitRef="usd">11093000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if81ad8f0dc3845e892842d063335a2c0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfNi03LTEtMS0xNjkzNA_f17c7675-162a-4f85-b08b-b08fe9560627"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia50bc0b54e7b411cbc0c32ee73246291_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfNy0xLTEtMS0xNTUyMw_ea6769e7-1d49-4600-a63b-04ba0dbba30a"
      unitRef="usd">117249000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i83db6194bc09401ea9d4f8dbf3dd05ef_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfNy0zLTEtMS0xNTUyMw_9ac07fbb-417a-4295-ad4c-374a84bf49e6"
      unitRef="usd">117249000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i8d2ba195827a4b65a9c8591347ec440e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfNy01LTEtMS0xNTUyMw_e6e53d85-eb4f-4e39-a9c3-0ca2ab3d6e30"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iac009ae2fcd34d3cad26b302a0e27bc8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfNy03LTEtMS0xNTUyMw_ca81afab-6dbb-4cf5-b562-042db0b4cf76"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i60cfe3f50c6b4c5892a4f8065819a89a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfOC0xLTEtMS0xNTUyMw_29b0e4b2-b066-4f58-a9c7-02afb7e63a3b"
      unitRef="usd">73151000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id10a160829dd4d6988d22ab73639351d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfOC0zLTEtMS0xNTUyMw_6f6909b4-e5df-4de9-9b66-b606850b6dab"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib1994ec146e34e20b804657cf2ba88e0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfOC01LTEtMS0xNTUyMw_13c4a3b6-6bdf-4d15-a578-d185e9dc2424"
      unitRef="usd">73151000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i35144578669449479c826d121a4a39af_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfOC03LTEtMS0xNTUyMw_fdcf892e-3bf3-43a5-a049-0c95dd5bdeee"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i07d72b0a1c1041edbe9b872760e69623_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfOS0xLTEtMS0xNTUyMw_86f169c8-9735-4f52-b3e6-d21c30340df7"
      unitRef="usd">75938000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2b0faab11338417da46a57af69648a69_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfOS0zLTEtMS0xNTUyMw_7016e5a5-ff2d-4b1d-b460-b467e60e4da3"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i96e7836def764eae8d4fccf746bff3ed_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfOS01LTEtMS0xNTUyMw_6bc44ad0-f72e-4c5e-8621-4f72a1424891"
      unitRef="usd">75938000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i52195f7f2e1149f0bfc9825b28eb3e9d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfOS03LTEtMS0xNTUyMw_6e60e259-82e5-440a-bd0e-b14b6346c6ce"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <swtx:LongTermInvestmentsFairValueDisclosure
      contextRef="ia50bc0b54e7b411cbc0c32ee73246291_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfMTEtMS0xLTEtMTU1MjM_e06a91bf-5700-4b8e-9cb2-2963dd242969"
      unitRef="usd">32475000</swtx:LongTermInvestmentsFairValueDisclosure>
    <swtx:LongTermInvestmentsFairValueDisclosure
      contextRef="i83db6194bc09401ea9d4f8dbf3dd05ef_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfMTEtMy0xLTEtMTU1MjM_d0c5478d-dbed-4cd6-b21f-f83f545c80e7"
      unitRef="usd">32475000</swtx:LongTermInvestmentsFairValueDisclosure>
    <swtx:LongTermInvestmentsFairValueDisclosure
      contextRef="i8d2ba195827a4b65a9c8591347ec440e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfMTEtNS0xLTEtMTU1MjM_8bd430f1-4eeb-403d-ac96-c0e3c3089a16"
      unitRef="usd">0</swtx:LongTermInvestmentsFairValueDisclosure>
    <swtx:LongTermInvestmentsFairValueDisclosure
      contextRef="iac009ae2fcd34d3cad26b302a0e27bc8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfMTEtNy0xLTEtMTU1MjM_054cd606-123a-462a-bd46-1e3fcabdcf3a"
      unitRef="usd">0</swtx:LongTermInvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6c5e5caf0cc0466db2575b43a6561e92_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfMTMtMS0xLTEtMTU1MjM_44fb357b-eb61-4286-b9b6-e97b3e3467f1"
      unitRef="usd">336641000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i34e57c62cb4b46b18943ea2ade2bb811_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfMTMtMy0xLTEtMTU1MjM_ac69dc0c-038f-4415-86e9-9e2b4eab8b2a"
      unitRef="usd">176459000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if853b5ddc3f24be599e3d8610e8928e9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfMTMtNS0xLTEtMTU1MjM_853bbd5b-e571-4d37-8f70-1ee9db8b6b31"
      unitRef="usd">160182000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i685d1982ea314317b0b57e4839162cc6_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjZjZWJhZjFjNTY0ZjRhMjA5Nzk0MWU4MmEzOWQxYWI2L3RhYmxlcmFuZ2U6NmNlYmFmMWM1NjRmNGEyMDk3OTQxZTgyYTM5ZDFhYjZfMTMtNy0xLTEtMTU1MjM_fe82f488-5b1f-4db5-a142-5d8960087f04"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i16725e0ada024661899310a4ee93bfcc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfNS0xLTEtMS0xNTUyMw_1a75996e-7d4d-4d27-9e58-e03db67473bb"
      unitRef="usd">89905000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i25f5c527da6b4872a8eeb9f36a3e424e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfNS0zLTEtMS0xNTUyMw_5f0b3fd3-067e-4156-9079-62cd440472d9"
      unitRef="usd">89905000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i582a7aa81bf94063ad30c2ae9cd74ef1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfNS01LTEtMS0xNTUyMw_9e8323ac-1e9e-4763-af9a-6f18de063350"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4381bd10810f415e80d931113c9f98aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfNS03LTEtMS0xNTUyMw_b90375a0-5789-4f2f-81ca-981a98fa1ea4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2d343dab4b5444209fd3ed76c2203491_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfNy0xLTEtMS0xNTUyMw_8e0af25e-828d-47cb-b3ef-4e27f3c3117e"
      unitRef="usd">104967000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iafd101aebef746019f6ce6cfeb3ee12b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfNy0zLTEtMS0xNTUyMw_2c888138-ae8d-452e-8788-0a65e9c5d791"
      unitRef="usd">104967000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iffe9941ac0af4829ae1f8653c196fcf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfNy01LTEtMS0xNTUyMw_466e103a-5943-48f2-8cf7-b1677fbda899"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i3b0bf57bc62646ee88f4c37260c3618a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfNy03LTEtMS0xNTUyMw_1a7727f0-894b-4efe-bb08-bcacbbdfddc6"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if240cefa329a43f5985a94cbabaaf6bf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfOC0xLTEtMS0xNTUyMw_4554caa1-71c6-4ff2-a025-7c5f8050502e"
      unitRef="usd">78677000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iadafdf4d3eea47f18794b5f1ab930fc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfOC0zLTEtMS0xNTUyMw_ef05002e-dab7-44cb-b2d8-5d77b31c135a"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib9fd763563b24d6aa1f44bd42f945197_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfOC01LTEtMS0xNTUyMw_e3333b20-81a3-48fa-9a5e-b75517075f72"
      unitRef="usd">78677000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i3b14ef11391b4c02b03d75aee65c957f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfOC03LTEtMS0xNTUyMw_0e9e52c8-179d-4a6a-9fe7-d0e0b505a60f"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia01bf0d0d0004d6da16a34e81942ea85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfOS0xLTEtMS0xNTUyMw_34900265-4a31-442a-a0c1-82948afb443c"
      unitRef="usd">85896000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i310af46a88e3405dae093107956ce302_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfOS0zLTEtMS0xNTUyMw_d9588358-ff3e-4390-a31f-946e9bf7ebae"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i3757e607d7cc45e0ae3411908f9b244f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfOS01LTEtMS0xNTUyMw_80d2bc05-a885-4e1e-b25b-4f5b94ec64a4"
      unitRef="usd">85896000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib5e9ce2dfe7e45279052b07d7cd8b812_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfOS03LTEtMS0xNTUyMw_d94654c8-7163-4acf-986d-413d199ceabe"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <swtx:LongTermInvestmentsFairValueDisclosure
      contextRef="i2d343dab4b5444209fd3ed76c2203491_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfMTEtMS0xLTEtMTU1MjM_2c54d7b2-2d78-4797-9fa5-620192ecc176"
      unitRef="usd">59230000</swtx:LongTermInvestmentsFairValueDisclosure>
    <swtx:LongTermInvestmentsFairValueDisclosure
      contextRef="iafd101aebef746019f6ce6cfeb3ee12b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfMTEtMy0xLTEtMTU1MjM_b326476f-8729-4623-8331-04441f5974b9"
      unitRef="usd">59230000</swtx:LongTermInvestmentsFairValueDisclosure>
    <swtx:LongTermInvestmentsFairValueDisclosure
      contextRef="iffe9941ac0af4829ae1f8653c196fcf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfMTEtNS0xLTEtMTU1MjM_6fda54d7-7689-4a5d-b84e-cdbc3067bfbb"
      unitRef="usd">0</swtx:LongTermInvestmentsFairValueDisclosure>
    <swtx:LongTermInvestmentsFairValueDisclosure
      contextRef="i3b0bf57bc62646ee88f4c37260c3618a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfMTEtNy0xLTEtMTU1MjM_425f3d79-2716-442b-a822-ec393b49c5ff"
      unitRef="usd">0</swtx:LongTermInvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i31f65ade5edf48fc9494eade358d77e2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfMTItMS0xLTEtMTU1MjM_dae00a52-e600-449a-819a-e5d61572d2c8"
      unitRef="usd">418675000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i03111218aab744f3a7bce0157ba6e7fb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfMTItMy0xLTEtMTU1MjM_2162815e-7247-421a-8653-dd9c4310fb17"
      unitRef="usd">254102000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i075a5d5199b1444fb36eab85ce242914_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfMTItNS0xLTEtMTU1MjM_3f40a75c-2b09-4dea-a075-8e1a4fe5a24a"
      unitRef="usd">164573000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i863575ed748a4e7b919599b8c6e813af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180Ni9mcmFnOjZiNTYyZDgyYjcxOTRkMDViYjY4NjdhODBjNTlhZmIzL3RhYmxlOjRjY2VlNTFmYjk3ZjRkNzM4ZjhiM2IzZTQyNjc1YzUxL3RhYmxlcmFuZ2U6NGNjZWU1MWZiOTdmNGQ3MzhmOGIzYjNlNDI2NzVjNTFfMTItNy0xLTEtMTU1MjM_16e10c58-8dcd-45d0-b4c0-588ac3def97a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180OS9mcmFnOmRmNTJhYWE0MWI3YzQ1YTZhNDE1MzE1MDAzNjhkZTZhL3RleHRyZWdpb246ZGY1MmFhYTQxYjdjNDVhNmE0MTUzMTUwMDM2OGRlNmFfMTgyMQ_cd780436-eddb-4542-9561-c3ef58d63af2">Investment and Variable Interest Entity&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;MapKure&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June&#160;2019, the Company announced the formation of MapKure LLC., or MapKure, an entity jointly owned by the Company and BeiGene Ltd., or BeiGene. BeiGene licensed to MapKure exclusive rights to BGB-3245, an oral, small molecule selective inhibitor of specific BRAF driver mutations and genetic fusions. MapKure is advancing BGB-3245 through clinical development for solid tumor patients harboring BRAF driver mutations and genetic fusions that were observed to be sensitive to the compound in preclinical studies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the Company&#x2019;s ownership interest in MapKure was 38.9%. In addition to the Company&#x2019;s equity ownership in MapKure, the Company has appointed a member to each of MapKure&#x2019;s joint steering committee and board of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;directors. The Company also contributes to clinical development and other operational activities for BGB-3245 through a service agreement with MapKure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that MapKure is a variable interest entity. The Company is not the primary beneficiary, as the Company does not have the power to direct the activities that most significantly impact the economic performance of MapKure. Accordingly, the Company does not consolidate the financial statements of this entity and accounts for this investment using the equity method of accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 323-10-35-6, the Company records MapKure&#x2019;s earnings or losses based on a one quarter lag.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized an equity loss of $0.3 million for each of the three month periods ended March&#160;31, 2022 and March&#160;31, 2021. The Company&#x2019;s ownership interest in MapKure is included in &#x201c;Equity method investments&#x201d; in the condensed consolidated balance sheets. The balance of the Company&#x2019;s investment was $2.5 million as of March&#160;31, 2022, representing the maximum exposure to loss as a result of the Company&#x2019;s involvement with MapKure.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i7eba2f99c15b49c2a91337a9f21c9f15_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180OS9mcmFnOmRmNTJhYWE0MWI3YzQ1YTZhNDE1MzE1MDAzNjhkZTZhL3RleHRyZWdpb246ZGY1MmFhYTQxYjdjNDVhNmE0MTUzMTUwMDM2OGRlNmFfNjE0_47216429-bf64-4c7b-9f31-35fd70cfc823"
      unitRef="number">0.389</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i60df7d63a68a48d59113cc28df86b1f4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180OS9mcmFnOmRmNTJhYWE0MWI3YzQ1YTZhNDE1MzE1MDAzNjhkZTZhL3RleHRyZWdpb246ZGY1MmFhYTQxYjdjNDVhNmE0MTUzMTUwMDM2OGRlNmFfMTQ3Nw_3ca84002-065d-4e6d-8969-7bc69ab5d7a4"
      unitRef="usd">-300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ic15d05a5ead7496488cbe289375b0b77_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180OS9mcmFnOmRmNTJhYWE0MWI3YzQ1YTZhNDE1MzE1MDAzNjhkZTZhL3RleHRyZWdpb246ZGY1MmFhYTQxYjdjNDVhNmE0MTUzMTUwMDM2OGRlNmFfMTQ3Nw_4c39e4aa-0ada-48c3-b28c-d2de47a01d19"
      unitRef="usd">-300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i9c3264a753fa40f19ce07bcf42665c50_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N180OS9mcmFnOmRmNTJhYWE0MWI3YzQ1YTZhNDE1MzE1MDAzNjhkZTZhL3RleHRyZWdpb246ZGY1MmFhYTQxYjdjNDVhNmE0MTUzMTUwMDM2OGRlNmFfMTA5OTUxMTYyOTYzMA_4c9aecc9-b1b3-4293-bf27-7d8a0a566710"
      unitRef="usd">2500000</us-gaap:EquityMethodInvestments>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181Mi9mcmFnOmNhNDlkN2JjYWJhNjQwYTdiOGM0MDljYjFiYTI0OGJiL3RleHRyZWdpb246Y2E0OWQ3YmNhYmE2NDBhN2I4YzQwOWNiMWJhMjQ4YmJfNzA_0964b6e9-f568-48e0-ba8c-ad521c4cc2f6">Accrued Expenses&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181Mi9mcmFnOmNhNDlkN2JjYWJhNjQwYTdiOGM0MDljYjFiYTI0OGJiL3RleHRyZWdpb246Y2E0OWQ3YmNhYmE2NDBhN2I4YzQwOWNiMWJhMjQ4YmJfNzE_449eeb41-57d5-47a1-bed2-aab068f5bc58">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181Mi9mcmFnOmNhNDlkN2JjYWJhNjQwYTdiOGM0MDljYjFiYTI0OGJiL3RhYmxlOmM0MjY0ZjljZjIzMDQ5YTRiNDJjMDE1ZWM2N2FiYTcwL3RhYmxlcmFuZ2U6YzQyNjRmOWNmMjMwNDlhNGI0MmMwMTVlYzY3YWJhNzBfMi0yLTEtMS0xNTUyMw_26994d41-c018-4059-837c-dff4cbe4c649"
      unitRef="usd">975000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181Mi9mcmFnOmNhNDlkN2JjYWJhNjQwYTdiOGM0MDljYjFiYTI0OGJiL3RhYmxlOmM0MjY0ZjljZjIzMDQ5YTRiNDJjMDE1ZWM2N2FiYTcwL3RhYmxlcmFuZ2U6YzQyNjRmOWNmMjMwNDlhNGI0MmMwMTVlYzY3YWJhNzBfMi00LTEtMS0xNTUyMw_6352aa47-5f04-4549-a670-59fe6f9f171e"
      unitRef="usd">1108000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181Mi9mcmFnOmNhNDlkN2JjYWJhNjQwYTdiOGM0MDljYjFiYTI0OGJiL3RhYmxlOmM0MjY0ZjljZjIzMDQ5YTRiNDJjMDE1ZWM2N2FiYTcwL3RhYmxlcmFuZ2U6YzQyNjRmOWNmMjMwNDlhNGI0MmMwMTVlYzY3YWJhNzBfMy0yLTEtMS0xNTUyMw_3c7eb8c4-cbab-4825-bbe6-6cd87b374748"
      unitRef="usd">4528000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181Mi9mcmFnOmNhNDlkN2JjYWJhNjQwYTdiOGM0MDljYjFiYTI0OGJiL3RhYmxlOmM0MjY0ZjljZjIzMDQ5YTRiNDJjMDE1ZWM2N2FiYTcwL3RhYmxlcmFuZ2U6YzQyNjRmOWNmMjMwNDlhNGI0MmMwMTVlYzY3YWJhNzBfMy00LTEtMS0xNTUyMw_9128585c-6c60-4a28-bf58-b4db5f57475f"
      unitRef="usd">12081000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <swtx:AccruedResearchAndDevelopmentExpenses
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181Mi9mcmFnOmNhNDlkN2JjYWJhNjQwYTdiOGM0MDljYjFiYTI0OGJiL3RhYmxlOmM0MjY0ZjljZjIzMDQ5YTRiNDJjMDE1ZWM2N2FiYTcwL3RhYmxlcmFuZ2U6YzQyNjRmOWNmMjMwNDlhNGI0MmMwMTVlYzY3YWJhNzBfNC0yLTEtMS0xNTUyMw_1132a91c-e6b9-4012-85db-0a8c2ac6edd5"
      unitRef="usd">12235000</swtx:AccruedResearchAndDevelopmentExpenses>
    <swtx:AccruedResearchAndDevelopmentExpenses
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181Mi9mcmFnOmNhNDlkN2JjYWJhNjQwYTdiOGM0MDljYjFiYTI0OGJiL3RhYmxlOmM0MjY0ZjljZjIzMDQ5YTRiNDJjMDE1ZWM2N2FiYTcwL3RhYmxlcmFuZ2U6YzQyNjRmOWNmMjMwNDlhNGI0MmMwMTVlYzY3YWJhNzBfNC00LTEtMS0xNTUyMw_e0d9b22e-28e5-4451-8e88-13774490ad79"
      unitRef="usd">10069000</swtx:AccruedResearchAndDevelopmentExpenses>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181Mi9mcmFnOmNhNDlkN2JjYWJhNjQwYTdiOGM0MDljYjFiYTI0OGJiL3RhYmxlOmM0MjY0ZjljZjIzMDQ5YTRiNDJjMDE1ZWM2N2FiYTcwL3RhYmxlcmFuZ2U6YzQyNjRmOWNmMjMwNDlhNGI0MmMwMTVlYzY3YWJhNzBfNS0yLTEtMS0xNTUyMw_80cccdc1-9e7a-4d6f-8c6f-a59cf4dff802"
      unitRef="usd">3519000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181Mi9mcmFnOmNhNDlkN2JjYWJhNjQwYTdiOGM0MDljYjFiYTI0OGJiL3RhYmxlOmM0MjY0ZjljZjIzMDQ5YTRiNDJjMDE1ZWM2N2FiYTcwL3RhYmxlcmFuZ2U6YzQyNjRmOWNmMjMwNDlhNGI0MmMwMTVlYzY3YWJhNzBfNS00LTEtMS0xNTUyMw_d58a529a-e6ec-4880-bf3a-b7984caf99d1"
      unitRef="usd">2120000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181Mi9mcmFnOmNhNDlkN2JjYWJhNjQwYTdiOGM0MDljYjFiYTI0OGJiL3RhYmxlOmM0MjY0ZjljZjIzMDQ5YTRiNDJjMDE1ZWM2N2FiYTcwL3RhYmxlcmFuZ2U6YzQyNjRmOWNmMjMwNDlhNGI0MmMwMTVlYzY3YWJhNzBfNi0yLTEtMS0xNTUyMw_b5126e5e-6869-4b95-ad67-3f3ea05b40de"
      unitRef="usd">21257000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id73789b2c218404991bfa981f4cb6592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181Mi9mcmFnOmNhNDlkN2JjYWJhNjQwYTdiOGM0MDljYjFiYTI0OGJiL3RhYmxlOmM0MjY0ZjljZjIzMDQ5YTRiNDJjMDE1ZWM2N2FiYTcwL3RhYmxlcmFuZ2U6YzQyNjRmOWNmMjMwNDlhNGI0MmMwMTVlYzY3YWJhNzBfNi00LTEtMS0xNTUyMw_3c03d0b8-8918-4fdf-9df6-3a971509a1a8"
      unitRef="usd">25378000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RleHRyZWdpb246ZDE4Y2UzZjRkOGFkNGFmOTkyNGNmNzEyMDlkMWExYTNfMTQxNQ_f1a20a20-96e5-40f0-a1dc-74daa2c0dd02">Commitments and Contingencies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into contracts in the normal course of business for clinical trials, preclinical studies, manufacturing and other services and products for operating purposes. These contracts generally provide for termination following a certain period after notice and therefore the Company believes that non-cancelable obligations under these agreements are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company has excluded milestone or royalty payments or other contractual payment obligations as the timing and amounts of such obligations are unknown or uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into a lease for its corporate headquarters in Stamford, CT. In January 2022, the Company amended this lease agreement to extend the lease term through April 2028, with two five-year renewal options or one ten-year renewal option. Pursuant to the amendment, the Company is entitled to $0.5&#160;million in tenant allowances, which may be used to offset certain future capital expenditures, and the lease payments increase by 2.5% in each year commencing December 1, 2022. The amendment was treated as a modification and the lease liability and Operating lease right-of-use asset were updated to reflect minimum lease payments and any other adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, future lease payments under non-cancelable leases with terms greater than one year are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.116%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.629%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(874)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be involved in disputes or regulatory inquiries that arise in the ordinary course of business. When the Company determines that a loss is both probable and reasonably estimable, a liability is recorded and disclosed if the amount is material to the financial statements taken as a whole. When a material loss contingency is only reasonably possible, the Company does not record a liability, but instead discloses the nature and the amount of the claim, and an estimate of the loss or range of loss, if such an estimate can reasonably be made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, there was no litigation or contingency with at least a reasonable possibility of a material loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <swtx:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="i65b72505f5de4b88b1745e53289c8346_I20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RleHRyZWdpb246ZDE4Y2UzZjRkOGFkNGFmOTkyNGNmNzEyMDlkMWExYTNfNjU5NzA2OTc3MDcyOA_6fb2f5d1-64aa-4cbf-80d8-c9bf1d976917"
      unitRef="option">2</swtx:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i65b72505f5de4b88b1745e53289c8346_I20220131"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RleHRyZWdpb246ZDE4Y2UzZjRkOGFkNGFmOTkyNGNmNzEyMDlkMWExYTNfNjU5NzA2OTc3MDc0MA_f113f825-d1ed-4e5f-bb06-30ddd3b7c83f">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <swtx:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="i7f3b13792a2240b6bb59248690c98652_I20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RleHRyZWdpb246ZDE4Y2UzZjRkOGFkNGFmOTkyNGNmNzEyMDlkMWExYTNfNjU5NzA2OTc3MDc0MQ_167dd735-5078-4673-9146-74c409e03edd"
      unitRef="option">1</swtx:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i7f3b13792a2240b6bb59248690c98652_I20220131"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RleHRyZWdpb246ZDE4Y2UzZjRkOGFkNGFmOTkyNGNmNzEyMDlkMWExYTNfNjU5NzA2OTc3MDc1Mg_bc79ada3-1282-457e-8795-4426e338752e">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <swtx:LesseeOperatingLeaseEntitledTenantAllowance
      contextRef="i37565722b4fa4a69ba807d2fba2e932f_I20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RleHRyZWdpb246ZDE4Y2UzZjRkOGFkNGFmOTkyNGNmNzEyMDlkMWExYTNfNjU5NzA2OTc3MDc1Ng_dac4700d-a012-4691-99d4-4722942f53a2"
      unitRef="usd">500000</swtx:LesseeOperatingLeaseEntitledTenantAllowance>
    <swtx:AnnualIncreaseInLeasePaymentsPercentage
      contextRef="i37565722b4fa4a69ba807d2fba2e932f_I20220131"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RleHRyZWdpb246ZDE4Y2UzZjRkOGFkNGFmOTkyNGNmNzEyMDlkMWExYTNfNjU5NzA2OTc3MDc3MA_c30be0f2-e1c1-4dc6-9be2-293ae67fbf2a"
      unitRef="number">0.025</swtx:AnnualIncreaseInLeasePaymentsPercentage>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RleHRyZWdpb246ZDE4Y2UzZjRkOGFkNGFmOTkyNGNmNzEyMDlkMWExYTNfMTQxNg_83dcf31d-40e7-43be-a924-7c80ba3da79c">As of March&#160;31, 2022, future lease payments under non-cancelable leases with terms greater than one year are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.116%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.629%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(874)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RhYmxlOjVkZDk2NDllNzQ4YTRhYjliZDVhZWE4ZTU4ZWU2NTNjL3RhYmxlcmFuZ2U6NWRkOTY0OWU3NDhhNGFiOWJkNWFlYThlNThlZTY1M2NfMS0yLTEtMS0xODY2OQ_35334997-fc72-40d6-9c2f-3109a94ecdf6"
      unitRef="usd">257000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RhYmxlOjVkZDk2NDllNzQ4YTRhYjliZDVhZWE4ZTU4ZWU2NTNjL3RhYmxlcmFuZ2U6NWRkOTY0OWU3NDhhNGFiOWJkNWFlYThlNThlZTY1M2NfMi0yLTEtMS0xODY2OQ_f9c048cf-bd31-4132-94ea-3f8cc3be6a81"
      unitRef="usd">1262000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RhYmxlOjVkZDk2NDllNzQ4YTRhYjliZDVhZWE4ZTU4ZWU2NTNjL3RhYmxlcmFuZ2U6NWRkOTY0OWU3NDhhNGFiOWJkNWFlYThlNThlZTY1M2NfMy0yLTEtMS0xODY2OQ_eebb85af-00f2-4996-a476-7afb133855e6"
      unitRef="usd">1155000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RhYmxlOjVkZDk2NDllNzQ4YTRhYjliZDVhZWE4ZTU4ZWU2NTNjL3RhYmxlcmFuZ2U6NWRkOTY0OWU3NDhhNGFiOWJkNWFlYThlNThlZTY1M2NfNC0yLTEtMS0xODY2OQ_e31fbd41-a371-40df-9801-342aa9ed0de5"
      unitRef="usd">1184000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <swtx:LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RhYmxlOjVkZDk2NDllNzQ4YTRhYjliZDVhZWE4ZTU4ZWU2NTNjL3RhYmxlcmFuZ2U6NWRkOTY0OWU3NDhhNGFiOWJkNWFlYThlNThlZTY1M2NfNS0yLTEtMS0xODY2OQ_c9aa4240-4103-4137-af07-89b0f222f1bb"
      unitRef="usd">2881000</swtx:LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RhYmxlOjVkZDk2NDllNzQ4YTRhYjliZDVhZWE4ZTU4ZWU2NTNjL3RhYmxlcmFuZ2U6NWRkOTY0OWU3NDhhNGFiOWJkNWFlYThlNThlZTY1M2NfNi0yLTEtMS0xODY2OQ_c86730c6-1557-4212-8b46-14a9d91da8fa"
      unitRef="usd">6739000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RhYmxlOjVkZDk2NDllNzQ4YTRhYjliZDVhZWE4ZTU4ZWU2NTNjL3RhYmxlcmFuZ2U6NWRkOTY0OWU3NDhhNGFiOWJkNWFlYThlNThlZTY1M2NfNy0yLTEtMS0xODY2OQ_b94f92d0-a907-44fa-b5ea-92aec119b4e1"
      unitRef="usd">874000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i4858197abb9f421195cb86f9528f4108_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RhYmxlOjVkZDk2NDllNzQ4YTRhYjliZDVhZWE4ZTU4ZWU2NTNjL3RhYmxlcmFuZ2U6NWRkOTY0OWU3NDhhNGFiOWJkNWFlYThlNThlZTY1M2NfOC0yLTEtMS0xODY2OQ_69cba53d-e7e9-4389-af01-479058ccf736"
      unitRef="usd">5865000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LitigationSettlementExpense
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181NS9mcmFnOmQxOGNlM2Y0ZDhhZDRhZjk5MjRjZjcxMjA5ZDFhMWEzL3RleHRyZWdpb246ZDE4Y2UzZjRkOGFkNGFmOTkyNGNmNzEyMDlkMWExYTNfMTMyOQ_110f1aee-c9c0-4257-b9aa-2b74449349e8"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMjU2Mw_a9b5e3c8-a944-454f-a82a-47f282c24432">Stock-Based Compensation&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2019 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2019 Equity Incentive Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards and dividend equivalent rights to the Company&#x2019;s officers, employees, directors and other key persons (including consultants). The number of shares reserved for issuance under the 2019 Equity Incentive Plan is cumulatively increased each January 1, through and including January 1, 2030, by 5% of the number of shares of the Company&#x2019;s common stock outstanding on the immediately preceding December&#160;31 or such lesser number of shares determined by the Company&#x2019;s compensation committee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The terms of stock options and restricted stock units and awards, including vesting requirements, are determined by the Board of Directors or its delegates, subject to the provisions of the 2019 Equity Incentive Plan. Restricted stock units and awards granted by the Company to employees generally vest over three years, and stock options granted by the Company to employees generally vest over four years. Restricted stock units and awards and stock options granted by the Company to directors generally vest over one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, there were 4,785,168 shares available for issuance in connection with future awards under the 2019 Equity Incentive Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022, the Company granted 1,350,479 stock option awards, 464,513 restricted stock units and 36,625 restricted stock awards to its officers, employees and directors under the 2019 Equity Incentive Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022, 104,985 restricted stock awards previously issued to employees of the Company vested, and 142,657 stock options were exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, there were 2,991,905 stock options vested and exercisable. In June 2019, the Company&#x2019;s CEO received an award of 176,411 stock options, or the 2019 CEO Performance Award. During the quarter ended March&#160;31, 2022, 11,026 options of the CEO Performance Award became exercisable upon the satisfaction of the market condition applicable to this award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense included in the condensed consolidated statements of operations for each of the periods presented is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the unrecognized compensation expense related to unvested stock options, restricted stock units and restricted stock awards was $153.9 million, $25.3 million and $18.4 million, respectively, which is expected to be recognized over a weighted-average remaining period of approximately 2.78, 2.77 years and 1.78 years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the Company had 7,832,865 stock options outstanding, 459,614 unvested restricted stock units and 398,510 unvested restricted stock awards.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <swtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock
      contextRef="ia34d861b8e7c40f69f8da029b428f1a0_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfNTIy_e90296dd-2891-47a3-93e6-1987ee376f20"
      unitRef="number">0.05</swtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i74cc340c1aa4424ba3726c91ee26d876_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfNjU5NzA2OTc3MTU2NQ_71b9485d-35da-4a95-a697-5a0160c48690">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i022436fef9574100a67fd5ee74396304_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfNjU5NzA2OTc3MTU2Ng_ed45984f-a69a-40be-a686-dd7ec1e96c70">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i3948092549294997927bcdcb9f543aa4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfNjU5NzA2OTc3MTU2Nw_e049748a-1c53-4471-9730-8add067e9353">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i09e3d5011a2c4255b31c3514190f2c5b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMTIxMA_74d7e858-7c89-42e4-85e5-02c982af9ff8"
      unitRef="shares">4785168</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id21cc7dd1c9e49d7b59a05c489a69c95_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMTM4NA_281a5b04-12bd-4886-a682-548f623dd5c0"
      unitRef="shares">1350479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="iaf02bd13545f44a9bb747e767c85e226_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMTA5OTUxMTYzMTI3MQ_ffc4eb89-5087-4810-8aeb-00ceff8c16f5"
      unitRef="shares">464513</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ia76c9558fc764171b39ba192df90d64a_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMTA5OTUxMTYzMjYzNg_279cf159-7f30-4528-9518-aaf030cbf5c5"
      unitRef="shares">36625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i147d6c8ff5e4443d9e538dcf1cb66057_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMTU0OA_51408795-0317-4526-9180-81913cfe5e52"
      unitRef="shares">104985</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i05cb736fa4db484e8bc7a1b84df8778d_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMTYzMw_8ac9ce20-aee0-4306-b3c0-d1dab5535c33"
      unitRef="shares">142657</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i2e392b95e3564143b67b20dfaa88de74_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMTY4Nw_73b6a873-0c2c-419e-b32f-80d2fadb1073"
      unitRef="shares">2991905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="idd87f05bb1d645db8de68c02ff92440f_D20190601-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMTc4MQ_0b3d1fd0-adc6-4c2c-a8d0-b3f9369418f5"
      unitRef="shares">176411</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i2db6208a117f44e39e09d534da69e196_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMTg2Mw_625d5dba-30b6-48af-b64d-ab89f15012c1"
      unitRef="shares">11026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfNjU5NzA2OTc3MTU2NA_7ee27594-9f23-4103-a715-75e8c90bcfd3">Stock-based compensation expense included in the condensed consolidated statements of operations for each of the periods presented is as follows: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i75b5d0e6891445328c454b9d1ec87a5a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RhYmxlOmUwMGM5MDQ2NDgyZjQ3N2Y5OWVkNmJmMGNiNjVlYjJiL3RhYmxlcmFuZ2U6ZTAwYzkwNDY0ODJmNDc3Zjk5ZWQ2YmYwY2I2NWViMmJfMy0xLTEtMS0xNjMwMw_170d3377-50b7-411d-9948-801861100cbd"
      unitRef="usd">7072000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1c5e6b459a3f46278653aaa6c0dccad1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RhYmxlOmUwMGM5MDQ2NDgyZjQ3N2Y5OWVkNmJmMGNiNjVlYjJiL3RhYmxlcmFuZ2U6ZTAwYzkwNDY0ODJmNDc3Zjk5ZWQ2YmYwY2I2NWViMmJfMy0zLTEtMS0xNjMwMw_23970200-920f-4c52-9403-f79a18b48ad7"
      unitRef="usd">2282000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i61eb5ddf4b7047d8bf7f1bfb229fd7ab_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RhYmxlOmUwMGM5MDQ2NDgyZjQ3N2Y5OWVkNmJmMGNiNjVlYjJiL3RhYmxlcmFuZ2U6ZTAwYzkwNDY0ODJmNDc3Zjk5ZWQ2YmYwY2I2NWViMmJfNC0xLTEtMS0xNjMwMw_7aef7ccc-9a15-4c62-ac44-68a79a23c7b8"
      unitRef="usd">10022000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8f25ec114c634fc4865cc49981bd981f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RhYmxlOmUwMGM5MDQ2NDgyZjQ3N2Y5OWVkNmJmMGNiNjVlYjJiL3RhYmxlcmFuZ2U6ZTAwYzkwNDY0ODJmNDc3Zjk5ZWQ2YmYwY2I2NWViMmJfNC0zLTEtMS0xNjMwMw_bcff033a-2ac8-4b6f-a76a-5db82af53ff3"
      unitRef="usd">4773000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RhYmxlOmUwMGM5MDQ2NDgyZjQ3N2Y5OWVkNmJmMGNiNjVlYjJiL3RhYmxlcmFuZ2U6ZTAwYzkwNDY0ODJmNDc3Zjk5ZWQ2YmYwY2I2NWViMmJfNS0xLTEtMS0xNjMwMw_1259854a-a6d0-44d6-9476-512dcbf99089"
      unitRef="usd">17094000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RhYmxlOmUwMGM5MDQ2NDgyZjQ3N2Y5OWVkNmJmMGNiNjVlYjJiL3RhYmxlcmFuZ2U6ZTAwYzkwNDY0ODJmNDc3Zjk5ZWQ2YmYwY2I2NWViMmJfNS0zLTEtMS0xNjMwMw_70ac8ee4-2090-4389-a741-62af1d33ae41"
      unitRef="usd">7055000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i2e392b95e3564143b67b20dfaa88de74_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMjM0MA_d08352a9-d0a8-489d-9365-53ae970e6abb"
      unitRef="usd">153900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i1807ff5c5c8841e9b42432e38c96459d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMTA5OTUxMTYzMTM2NA_26e2c562-d605-4787-94f5-8fc5941723cc"
      unitRef="usd">25300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ifc237dbb79e949169c0b49053a2a8980_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMjM0Nw_15f8aebd-0b12-403a-97fd-4efe0f8f5581"
      unitRef="usd">18400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i05cb736fa4db484e8bc7a1b84df8778d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMjQ0NA_67f95167-1184-4e61-9353-d6772d82cb87">P2Y9M10D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ia3e71bacda9e4305913d6ceeac24be0d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMTA5OTUxMTYzMTM5Mg_4a587054-4973-4a62-9166-1122d155be1b">P2Y9M7D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i6d1841e76bd84918b42a921397d98d2e_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMjQ1MQ_7cf435f7-86da-4ac3-8e42-c297c26650b6">P1Y9M10D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2e392b95e3564143b67b20dfaa88de74_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMjQ5NQ_9e11cbc1-2df8-4799-ad08-98d9ec034ec4"
      unitRef="shares">7832865</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i1807ff5c5c8841e9b42432e38c96459d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMTA5OTUxMTYzMTQ2Nw_27d664b5-1b7a-45f7-a92a-e59d2cda178f"
      unitRef="shares">459614000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ifc237dbb79e949169c0b49053a2a8980_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N181OC9mcmFnOmI3ODc3ODEwODc1MzQ4NDE5N2I1MTBlYjZkMmRmMzE1L3RleHRyZWdpb246Yjc4Nzc4MTA4NzUzNDg0MTk3YjUxMGViNmQyZGYzMTVfMjUyOA_9cb7db22-d884-4f3a-8497-3784bb43c9dc"
      unitRef="shares">398510</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N182MS9mcmFnOjhiYmRlMDE3NzgxMDQwNDg5N2ZhZGEzMTg5MTExNWM3L3RleHRyZWdpb246OGJiZGUwMTc3ODEwNDA0ODk3ZmFkYTMxODkxMTE1YzdfMzQy_a5d24c69-5a7f-4d10-ad64-d9c1b33995b9">Net Loss per Share&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since the Company had a net loss in each of the periods presented, basic and diluted net loss per share are the same. The table below provides potentially dilutive securities not included in the computation of the diluted net loss per share for the periods ended March&#160;31, 2022 and March&#160;31, 2021, because to do so would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock options issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,832,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,692,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;459,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock awards subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;398,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;686,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,690,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,378,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N182MS9mcmFnOjhiYmRlMDE3NzgxMDQwNDg5N2ZhZGEzMTg5MTExNWM3L3RleHRyZWdpb246OGJiZGUwMTc3ODEwNDA0ODk3ZmFkYTMxODkxMTE1YzdfMzQz_ead68837-5f74-4c2a-8129-c08fe6482675">The table below provides potentially dilutive securities not included in the computation of the diluted net loss per share for the periods ended March&#160;31, 2022 and March&#160;31, 2021, because to do so would be anti-dilutive:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock options issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,832,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,692,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;459,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock awards subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;398,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;686,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,690,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,378,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4e6ea28cc5b746708a2447e6c1e2b5d9_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N182MS9mcmFnOjhiYmRlMDE3NzgxMDQwNDg5N2ZhZGEzMTg5MTExNWM3L3RhYmxlOjI2ODQ0Y2FlMjMzZDRjZjFiNjE1NzUzMmJiNzU1ZTFhL3RhYmxlcmFuZ2U6MjY4NDRjYWUyMzNkNGNmMWI2MTU3NTMyYmI3NTVlMWFfMi0xLTEtMS0xNTUyMw_2e792c3a-f311-4460-a56b-e470852bd164"
      unitRef="shares">7832865</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i074022392378431ca43171749ce67e70_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N182MS9mcmFnOjhiYmRlMDE3NzgxMDQwNDg5N2ZhZGEzMTg5MTExNWM3L3RhYmxlOjI2ODQ0Y2FlMjMzZDRjZjFiNjE1NzUzMmJiNzU1ZTFhL3RhYmxlcmFuZ2U6MjY4NDRjYWUyMzNkNGNmMWI2MTU3NTMyYmI3NTVlMWFfMi0zLTEtMS0xNTUyMw_e76c7827-1863-4c24-af38-633bc30e0d11"
      unitRef="shares">5692100</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i701fc5f7822543f5afa349b588446470_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N182MS9mcmFnOjhiYmRlMDE3NzgxMDQwNDg5N2ZhZGEzMTg5MTExNWM3L3RhYmxlOjI2ODQ0Y2FlMjMzZDRjZjFiNjE1NzUzMmJiNzU1ZTFhL3RhYmxlcmFuZ2U6MjY4NDRjYWUyMzNkNGNmMWI2MTU3NTMyYmI3NTVlMWFfMy0xLTEtMS0xNzYzMg_56db437e-8139-40cb-b106-3c01206fed48"
      unitRef="shares">459614</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8962a5ad7a90438bac9fc74322fc41db_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N182MS9mcmFnOjhiYmRlMDE3NzgxMDQwNDg5N2ZhZGEzMTg5MTExNWM3L3RhYmxlOjI2ODQ0Y2FlMjMzZDRjZjFiNjE1NzUzMmJiNzU1ZTFhL3RhYmxlcmFuZ2U6MjY4NDRjYWUyMzNkNGNmMWI2MTU3NTMyYmI3NTVlMWFfMy0zLTEtMS0xNzYzMg_81e04f5a-4ab7-4153-bb27-c872003f6b5f"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie455f786f4cb4de6b10f9237538eb2b1_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N182MS9mcmFnOjhiYmRlMDE3NzgxMDQwNDg5N2ZhZGEzMTg5MTExNWM3L3RhYmxlOjI2ODQ0Y2FlMjMzZDRjZjFiNjE1NzUzMmJiNzU1ZTFhL3RhYmxlcmFuZ2U6MjY4NDRjYWUyMzNkNGNmMWI2MTU3NTMyYmI3NTVlMWFfMy0xLTEtMS0xNTUyMw_14a6086f-0b97-464f-a4b4-08ca4e75e2af"
      unitRef="shares">398510</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6723bcf58742472287b2d9590f8e52df_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N182MS9mcmFnOjhiYmRlMDE3NzgxMDQwNDg5N2ZhZGEzMTg5MTExNWM3L3RhYmxlOjI2ODQ0Y2FlMjMzZDRjZjFiNjE1NzUzMmJiNzU1ZTFhL3RhYmxlcmFuZ2U6MjY4NDRjYWUyMzNkNGNmMWI2MTU3NTMyYmI3NTVlMWFfMy0zLTEtMS0xNTUyMw_d584ff56-f383-489a-a914-8c4f043b2ebe"
      unitRef="shares">686241</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9ccede58414f4148821842e315a905d7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N182MS9mcmFnOjhiYmRlMDE3NzgxMDQwNDg5N2ZhZGEzMTg5MTExNWM3L3RhYmxlOjI2ODQ0Y2FlMjMzZDRjZjFiNjE1NzUzMmJiNzU1ZTFhL3RhYmxlcmFuZ2U6MjY4NDRjYWUyMzNkNGNmMWI2MTU3NTMyYmI3NTVlMWFfNC0xLTEtMS0xNTUyMw_92fb91e9-d5ca-4c2f-a8ed-27ef2bc93911"
      unitRef="shares">8690989</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icacf497fddd5425b9c502ffcdd257867_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDI2YTQ3OTMwZjQxMGQ5MWY4OWI0MjQ0Mjg1Yjc3L3NlYzoxNDAyNmE0NzkzMGY0MTBkOTFmODliNDI0NDI4NWI3N182MS9mcmFnOjhiYmRlMDE3NzgxMDQwNDg5N2ZhZGEzMTg5MTExNWM3L3RhYmxlOjI2ODQ0Y2FlMjMzZDRjZjFiNjE1NzUzMmJiNzU1ZTFhL3RhYmxlcmFuZ2U6MjY4NDRjYWUyMzNkNGNmMWI2MTU3NTMyYmI3NTVlMWFfNC0zLTEtMS0xNTUyMw_0b5ec8fd-53ac-4457-958c-843d62ae8a55"
      unitRef="shares">6378341</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>61
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MPX SGTOS -S?"*%/)^8'BKW3\;]02P,$%     @ 93BE5$T/<&=K!0  $A8
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M3\XRX</,K>+EPX[7%17RYY]R!+/?^IV2>@I55#2R!(59HO?B6ZJ7507ZEB[
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M-24R,@H@_U\Q)G[<J/<"AW=9L^]02P,$%     @ 93BE5$1"_'KH!0  :!8
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MQ2V?/&_ >N%PTVD?6$'_D?/Z?U!+ P04    " !E.*54[D/U@74$  #="P
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MB@ES3#[BEPR(@Q:^(W>2)O\ J^& AT+A)]<\!C?P*D"!W/H>,=N46@>-QK#
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MA<:7XRP W6N_-ZSJO-YR94F]?EO3N$3M'.B^4LH>#9=@&,#+7U!+ P04
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M)H5 T3[:[AKS F3H6C:F8C$J%&:87D @NH9%T0UZR:7L2UQZIYP;^OE0_"5
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M!&[-'WRI$[H:B&5N0X.OQ$KF8S&WONZ->*P +CP3=A%2;:$B,K]6!CIZV5/
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MC8L ;\#[I<6%K/[!"MIOQM?_!5!+ P04    " !E.*54F/+-B9,#  #F"
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MI-#X:IP%H'O]]X95K=?<1EE2L-]6-#)1.P>Z+Y6R!\,E&(;PXB]02P,$%
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M%X#[*Z7LV\2UINZ?:/(?4$L#!!0    ( &4XI52]4< W!0(  %$$   9
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;'U42X_3,!#^*U9.(*&Z3;J 5FFD
M=A<$AT75KH #XN FD\1:/X(]:99_S]A)0Y%H+XW'GN\Q]DSSP;IGWP(@>]'*
M^$W2(G:WG/NR!2W\PG9@Z*2V3@NDT#7<=PY$%4%:\72Y?,NUD"8I\KBW=T5N
M>U32P-XQWVLMW.\=*#MLDE5RVGB438MA@Q=Y)QIX OS:[1U%?&:II ;CI37,
M0;U)MJO;W3KDQX1O$@9_MF:ADH.USR'X7&V293 $"DH,#((^1[@#I0(1V?@U
M<2:S9 ">KT_L'V/M5,M!>+BSZKNLL-TD[Q-602UZA8]V^ 13/3>!K[3*QU\V
MC+E9FK"R]VCU!"8'6IKQ*UZF>S@#I*L+@'0"I-'W*!1=W@L41>[LP%S()K:P
MB*5&-)F3)CS*$SHZE83#8B>\],S6;._ @T$1[^K5/:"0RK_..9)(2.7E1+@;
M"=,+A!E[L 9;SSZ8"JI_\9S,S0[3D\-=>I7P0;@%RU9O6+I,4P\-=01>H<WF
MPK-(FUV@W9:E[0U*T["]5;*4X-F/[<&CHT;Y>45@/0NLH\#Z@L"77A_ A:NE
M"7(B*DWV_?^N=62[B6QAE([%*N?'<P/\[)DUN"8VLV>QCO'%Y]UY7K9CF_Q-
M'X>-+K61QC,%-4&7BW>DZ\8&'@.T76R:@T5JP;AL:>;!A00ZKZW%4Q $YG^1
MX@]02P,$%     @ 93BE5"LA-')A!   )A4  !D   !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&ULM9A=;]LV%(;_"B'TH@462R3U&=@&6J?-!K1 4"_=-6W3
MMA!)=$G:;H?]^%&R(BJBQ-BK=Q.+TCF'+S_>)P3'1\:?Q)92"7[D62$FSE;*
MW:WKBN66YD2,V(X6ZLN:\9Q(U>0;5^PX):LJ*<]<Y'FAFY.T<*;CZMT#GX[9
M7F9I01\X$/L\)_SG!YJQX\2!SO.+K^EF*\L7[G2\(QLZI_)Q]\!5RVVJK-*<
M%B)E!>!T/7'>P]L9]LN$*N);2H^B]0S*H2P8>RH;?ZPFCE<JHAE=RK($43\'
M.J-95E92.K[719VFSS*Q_?Q<_5,U>#68!1%TQK*_TI7<3IS8 2NZ)OM,?F7'
MWVD]H*"LMV29J/Z"XRDVB!RPW O)\CI9*<C3XO1+?M03T4J _D "JA/0N0FX
M3L#50$_*JF'=$4FF8\Z.@)?1JEKY4,U-E:U&DQ;E,LXE5U]3E2>G7PA_HI(L
M,@KF=+GGJ4RI &_OU+LT$^_ #7B<WX&W;]Z!-R MP)];MA>D6(FQ*U7O90UW
M6??TX=03&NYI!##\#2 /H9[TF3W]CBZ;=/@RW55C;@:.FH&CJAX>J#=C?,<X
MD50M^D("T0S>4ALWM7%5VQ^H_3YG7*9_TQ68,2'[INJ4'U;YI=,.4PPA#OVQ
M>VA/B1F&PB0,XR;LA3R_D>=;Y=US)@1X+)3MLTKEO;)[[XJ>Z@3M_CL*S0C<
M+RYHQ 67B?NLVMU5.:D+C+YOH!]Z'85]41CVBPP;D:%5Y$<A4X40I>X323GX
M1K(][5,8FK/C)8D7=B2:86J9 ]_K%QDU(B.KR,?1? 3NV8'R0G&WO<7!/V"^
M55OT1E*>*UL?J)!EB+BU;/ZXZ3:^NK&2IG;RB\9*C*F$,(J3KK%ZPKS \P?V
M+O0T3;TK6:LNU);0W;D](4,"6[B'U[)77>F%<T(_Z(KLB8J2 9D:SA!=Q6!U
MF<YZ(S_IJNR)\_PDC :$:M)#.^JM)OO,BLU%'H,:X="_NLN@9C"T0_AUGT$3
MJQ@IM'7GW0P;H!K4[(5V^%[@,1.LAD!;R$N!FKO0#MY+/!:9[@E@,*! (QC&
MU[%/W+.*?F1XW P;FB1-<FA'^> &5KZ9$;$%'[_OTP/)7K,,TFQ&WM4M@S18
MD1VLKUL&F:2$T$L&CB*H=9"UL_)\/R"3@FB@=PU 9 ?@!9N]KG3&-D*:@\A^
MECUWIR/SH%I._L#_4Z1)B>RDM&WCR\]82$,0A=??S)I@R$ZP,S:S":X(^P'L
MD*,O+([0P/D :< A.^ NV/,V=M4BS\8;TGA#=KQ=8@OS,'J#/4-D3U0PX%ZL
MF8CMY]5S[8/-HVB$H;'<?6%Q& V<LK"&*[;#=<;RG/)E2C*P(SO*_Y.YL"8J
M_A_N!EJ7 []\.V"",@H2''=GVPR+@S@)!V9;,Q5?AZEUF? UF698GTRW=8E5
MWB!^(7RC/ TRNE9YWBA2X^2G2[E30[)==:^U8%*RO'K<4K*BO Q0W]>,R>=&
M>5767(U._P502P,$%     @ 93BE5,%7Y3?-!0  ZB4  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&ULK9K;;MLX$(9?A3!ZT0+;6#S;16)@FZ"["S1
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M*=_^^G"'7K]Z@UZA,$%?-NDN4\DJNY[:/)<BXG19'_=]=5QRY+CWREPABO]
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M0C"GPZH1P!%QX^BCWNL(.6L2( ;!GC4BK8*'>*I+ZD =I:1@_'#I'+ CG.&
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M:9 Y3;JIM9KF)T#V(E!P !(7ON4%"/$3/:0Q\O;;V8Y.# =(<3>D*OVH:QS
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M]Q-*ASS-%[!8Y+]H5YSM>P8*,B%94H*5@H30XHM?RT#4 /8Y@%,"G/> [AF
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M.#4*WS*T,Y-8<LX,YL5H0D5*8BD,$PL0"0--6N=@*,OT^Y%OT)DU\9,2^*P
MC@X =\@50BTU^2!22/^T]Y%DQ33:,CV+&@&OJ&J33GA$HB"*[J?GI/6NCE;<
MC/*9BA<H,K=?5 /%3B5FQX%W#H!?2JV?*?C]$O>0"P-<_VCPT*T\=)V'[B$/
MS+ %=0= *I)4KC8$GO!D:R"_R+NZ9!6P?0=KC_;C)!CYCS5,>A637B.3J:$<
MJTAZ1.*[AL#Z%5S_C:0;5!X&C83O0%!A",VP<E&1'%(J'KQ0JA?87[U<QY7W
MXT;OIT*L:$:82+#88IJ8()D;Y'13G+X6Q1-(<E )3FN_[,+#<#^'[2#JU1,;
M5L2&_YQ'E.3:G05R+:!!\C#859?@C=(:[E6PL#&"+RL^ T7D'*\5 6M4N3C0
M&L.I.]J%F"5H;T_-J%[),-HQB1J9W);^#2A.6ICB#5!56SSCOR#U"M,F?79%
M*>R\(L-W:]F$OBM(8?>M,KPK-6%SK7EEAGLO,AP>R/"N2H7]_Y;A9J0P.)QB
M?^\^YZ 6KLW16.Y7PA17>[5:M5*GKH'P=]N+/@QOS05#H3*8HVG0'J <JFAM
MBHF1N>L.9M)@K^&&2VP'0=D-^'XNI=E.K(.JP9S\!E!+ P04    " !E.*54
M5=J=()D"   K!P  &0   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6R%E6MO
MVC 4AO^*%?5#*VW-!1)"%9!6JFF36@WULGTVY(18=>+,/H'VW\]VTHP- U^(
M;^_[G&/LXVPGY*LJ 9"\5;Q6,Z]$;&Y\7ZU+J*BZ%@W4>J80LJ*HNW+CJT8"
MS:VHXGX4!(E?459[\\R.+>4\$RUR5L-2$M56%97OM\#%;N:%WL? (]N4: ;\
M>=;0#3P!OC1+J7O^X)*S"FK%1$TD%#/O2WAS&P9&8%?\9+!3>VUB4ED)\6HZ
MW_.9%YB(@,,:C075GRTL@'/CI./XW9MZ ],(]]L?[E]M\CJ9%56P$/P7R[&<
M>:E'<BAHR_%1[+Y!GU!L_-:"*_M+=OW:P"/K5J&H>K&.H&)U]Z5O_4;L":+P
MB"#J!9&-NP/9*.\HTGDFQ8Y(LUJ[F89-U:IU<*PV_\H32CW+M [G"U%5#/4V
MHR*TSLE"U,CJ#=1K!HI\)@\46\G0=$1!]&&0U,P3#GHK"&=TQ7@W?7D'2!E7
M5^2"L)H\EZ)5VE%E/NHX#<U?]S'==C%%1V)ZH/*:C,)/) JBZ.7ICEQ>7/WK
MXNLLAU2C(=7(VHZ.V/X8@K\WP:L3EJ/!<F0MQT<L38"N_#I58E7F7FSG43S)
M_*T#-1Y0XW.HD0O5J>(]5!@ED9L5#ZSX'&OL8L6'K#".W:QD8"7G6+&+E3A8
MZ=C-F@RLR3E68D\YEJ!+6($@7>C) 3I*T]"-3@=T>A+]+)#R_M8T]-U>.!<[
M/6 GD]'4S9X.[.E)]CTH=4-8U;0(N;Z;.FU0Z*)/#^B?T\F130^#OR4F.,E?
M:IS.EVPI;\&4D8/BX:P1P<$EBM/D_]/F[Y4^\XSHVK%AM=*(0LN"ZXE.1G:5
MN>N@:&PU7 G4M=4V2_V:@30+]'PA!'YT3($=WL?Y'U!+ P04    " !E.*54
M]G#UX:L&  "?)0  &0   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6S-6FMO
MVS84_2N$T0$IL,3BRX\B"= D7M<!W8)DZ3[3,FUKE467I.QDV(\?2<FB'$MT
M7H.;#[$D\UY>WD.><TGK="WD-S7G7(/[19JIL\Y<Z^6';E?%<[Y@ZD0L>6:^
MF0JY8-K<REE7+25G$V>T2+LHBGK=!4NRSOFI>W8MST]%KM,DX]<2J'RQ8/+A
M@J=B?=:!G<V#FV0VU_9!]_QTR6;\ENN[Y;4T=]W*RR19\$PE(@.23\\Z'^&'
M$1U8 ]?B:\+7JG8-[%#&0GRS-Y\G9YW(1L13'FOK@IF/%;_D:6H]F3B^ETX[
M59_6L'Z]\?Z+&[P9S)@I?BG2OY*)GI]U!ATPX5.6I_I&K'_EY8"H]1>+5+G_
M8%VVC3H@SI46B]+81+!(LN*3W9>)J!D8/\T&J#1 CPQ0FP$N#?#C'DB+ 2D-
MR&.#7HL!+0W<T+O%V%WBKIAFYZ=2K(&TK8TW>^&R[ZQ-OI+,3I1;+<VWB;'3
MY[=:Q-^.+TRJ)^!2+,S\4\PA> Q0!(=@]#U/] /XG,4\LY""ZY1EX.B*:Y:D
MZKUI=G=[!8[>O0?O0)*!/^<B5RR;J-.N-M'9/KIQ&<E%$0EJB02"+R+3<P5&
MV81/&NPOP_9XG_UH3_\HX*!KTEKE%FUR>X&"'G_+LQ. HY]=)IL&%#;_PJ0Q
MA]8<H0;SJZ>;PZ9TA,VO>+PQ?QS\5C)P-=&P\X?;)MJ<27X\WIUH'Z5DV8P;
M\M%@_ #J[:[9@WO\<<UD"!!2Q4!<#"0TV4%<[YW?VVO>A$[AJ^=\6;Y=G<-^
M-"2GW54=A-U6_8C2JM%6G+2*DP;C'"V6J7C@')B5!'XW458/_@4W7&F9Q-JD
MIQC.799H!8YN;N_4^T".>E7?O8/AU*]BZ ?'_]6,,<EF8,EE(B;@R!#+ V?R
M\?@*F,*N<&$9"&I0!35X,2@%$F)I$Q7J:UCU-3P8"##RTA"]'0Q[?)&].,":
M9,&@KZM$FC)#R) SY)VAPZ7:DR/$;YCJL"_H3$-A>;Z$8<+\Q#,N6>JF/)N8
M\B,QY,-L'1!R[VD.TL/EWA,>[+VA*I3.MF0A<@*])0ME,UIK1OI]W*P+T!,C
M#-.987^#;3QWB$SXRA3Z2YN.4"(\P<'!X>#PU >';PG'L$%_^SMH[+9":(":
MT4">(%&8U-HKY%#UZ'D.P8/A@3Q!(A0<Y#67=F1FUPC$U,R[+#>$D&2QV98J
M;FM^/>= V1":BO[1'N_T)(I^"L7I*12%:<]E00&V,AL3-DXY,+MH,,UU+DV4
M2N7, .2(M8BUD5G++K97[8#"WJ!EJG@F16$F#6RF7E[3(<^TZ'!,BSS3HC#3
MWF5&N,4L2_XQ[IM6.) \938-6IC+*BG*)879.)KFV"7:Y61$<12U@.;9%H79
M=G^\]C,N Q[;\*OF8L4E8&#M3BKXY)B9>[N&)+?'-T_6^CT1HL(4#,&BV+OV
MP80]A,HLY.4 A0O>NVQE(#!#:48"B%PK;73(CF7?NAKLKBLZ[$$2N;\6G+QD
MH+!D!!?74VMS[&D?1P=;3-BK PY7P:-[0\R)<JRLZF/<!T;IMPX&)*A'^\TP
M8*\4.,SE6YD&Y>2QA0HO0G6LO"\XM!,<&@[A,&K94N/:^4-8'YY%/OEF[JOV
MV5,&C'?K08J';9,:>\7 8<7X <AG3X0[Y .C?>R#O6+A\!G(]F1Z!M>4?NLS
MJ#_ :-!KFT%>OG!8OIZJX76Y BH?_VU0LAB5Q<BJV.N%LN05"O</1T5>*? ^
MI?A_=+WL=FMM#4CKTO)Z@<-Z\2,LK7"$Q1[^.2N+>/DBX5W+&^IZV5-]K>&A
MJ9=;$")>W$A8W-YVJ1F;S6%=,(5>Z<CA#HV(5S025K2V/)3P[L-N=Z\#(V+0
M:\&N=LC^BJV.J5KBW#T0TVD2<R,?KD+8P/.*W1#QVD(.MQLB7DY(6$Y>"5_#
M 5./4-ARQ$2\I) ]6XI7PO?4>IMX>2&'.Y<B7C1(F)(_F;Z>@LMP=UEA&I'^
ML.4W(<_;]*6G3<]>5Z^N4*AG<GJX0RSJ"9N&MR:O6VMT=U.">SW4]BN?)W :
M)O#+T1_@FDOWNH<]G7+C?<82HIZ3*3D<"K6?-9]3T[]L@TAWRWL((]1KP<*S
M,0VS<1L6]ODS$/$T2P]7N5-/K31<N3^-U"[H[OD-[/<(A(^RWJV]B++@<N;>
M %*FQ,XS7;PW43VMWC+ZZ-ZM>?3\$GZX*MX5\FZ*5Y>^,#E+S.Q)^=2XC$[Z
M)BA9O U4W&BQ=*^[C(768N$NYYQ-N+0-S/=3(?3FQG90O9-U_A]02P,$%
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M2P$"% ,4    " !E.*54P[C_..X    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !E.*54F5R<(Q &  "<)P
M$P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( &4XI53U.H#U+04  $<5   8              " @0T(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !E.*5430]P9VL%   2%@
M&               @(%P#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ 93BE5/>H79CX @  40H  !@              ("!$1,  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( &4XI51)'U7+!00
M .<-   8              " @3\6  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    " !E.*54R3"E,.$"  "_!P  &               @(%Z
M&@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 93BE5)L7
MW\3/!0  UQH  !@              ("!D1T  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( &4XI51$0OQZZ 4  &@6   8
M  " @98C  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !E
M.*54 \MHAN,'  !H$@  &               @(&T*0  >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ 93BE5*S]*:@_"   \!0  !@
M         ("!S3$  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( &4XI53N0_6!=00  -T+   9              " @4(Z  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ 93BE5 W4^R63!@  (1(
M !D              ("![CX  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    " !E.*54+/Y8LB$%   F#   &0              @(&X10
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( &4XI528'ERB
MD (  (P%   9              " @1!+  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ 93BE5+3+>%3T!0  > T  !D
M ("!UTT  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !E
M.*54MWA"(RT&  !Q$   &0              @($"5   >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( &4XI53U3CR7'0,  -0&   9
M          " @69:  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#
M%     @ 93BE5"K8NCA#"   /Q8  !D              ("!NET  'AL+W=O
M<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !E.*54F/+-B9,#  #F
M"   &0              @($T9@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM
M;%!+ 0(4 Q0    ( &4XI53.38)4F ,  "H)   9              " @?YI
M  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ 93BE5&3<
M= .B @  D 4  !D              ("!S6T  'AL+W=O<FMS:&5E=',O<VAE
M970R,"YX;6Q02P$"% ,4    " !E.*547DEY?- "  #=!0  &0
M    @(&F<   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M &4XI53ZT;>OQP(   P&   9              " @:US  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ 93BE5/PY4,T. P  IP8  !D
M             ("!JW8  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    " !E.*54"UN]H[8"  "5!@  &0              @('P>0  >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( &4XI52]4< W!0(
M %$$   9              " @=U\  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ 93BE5"LA-')A!   )A4  !D              ("!
M&7\  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !E.*54
MP5?E-\T%  #J)0  &0              @(&Q@P  >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( &4XI51AB!MY_P(  'D)   9
M      " @;6)  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ 93BE5%&_/*.7 @  !0<  !D              ("!ZXP  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !E.*54EC>QFB,#  !L"@
M&0              @(&YCP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( &4XI515VIT@F0(  "L'   9              " @1.3  !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ 93BE5/9P]>&K
M!@  GR4  !D              ("!XY4  'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    " !E.*54C^(N3^<"  #""   &0
M@('%G   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( &4X
MI529ID<0% ,  (<*   9              " @>.?  !X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ 93BE5.S)HI,; P  <!$   T
M         ( !+J,  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !E.*54EXJ[
M',     3 @  "P              @ %TI@  7W)E;',O+G)E;'-02P$"% ,4
M    " !E.*54NQKPEC$#   Y%P  #P              @ %=IP  >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ 93BE5(S?7ZUN 0  W10  !H
M     ( !NZH  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ 93BE5 970G>/ 0  <!4  !,              ( !8:P  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&     "H *@!="P  (:X

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>123</ContextCount>
  <ElementCount>171</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>40</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)???</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)???</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)???</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss (Unaudited)???</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (Unaudited)???</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity (Unaudited)???</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)???</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)???</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/NatureofOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/BasisofPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2109104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2112105 - Disclosure - Investment and Variable Interest Entity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/InvestmentandVariableInterestEntity</Role>
      <ShortName>Investment and Variable Interest Entity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2114106 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2117107 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2121108 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2125109 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/NetLossperShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/BasisofPresentationPolicies</Role>
      <ShortName>Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.springworkstx.com/role/MarketableSecurities</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.springworkstx.com/role/FairValueMeasurements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.springworkstx.com/role/AccruedExpenses</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2318304 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.springworkstx.com/role/CommitmentsandContingencies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2322305 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.springworkstx.com/role/StockBasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2326306 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/NetLossperShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.springworkstx.com/role/NetLossperShare</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Nature of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/NatureofOperationsDetails</Role>
      <ShortName>Nature of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.springworkstx.com/role/NatureofOperations</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/BasisofPresentationDetails</Role>
      <ShortName>Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.springworkstx.com/role/BasisofPresentationPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.springworkstx.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.springworkstx.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Investment and Variable Interest Entity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/InvestmentandVariableInterestEntityDetails</Role>
      <ShortName>Investment and Variable Interest Entity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.springworkstx.com/role/InvestmentandVariableInterestEntity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.springworkstx.com/role/AccruedExpensesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2419407 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.springworkstx.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2420408 - Disclosure - Commitments and Contingencies - Maturities of operating lease liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Maturities of operating lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2423409 - Disclosure - Stock-Based Compensation - 2019 Equity Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails</Role>
      <ShortName>Stock-Based Compensation - 2019 Equity Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2424410 - Disclosure - Stock-Based Compensation - Equity-based compensation expense related to restricted stock and stock options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/StockBasedCompensationEquitybasedcompensationexpenserelatedtorestrictedstockandstockoptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Equity-based compensation expense related to restricted stock and stock options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="swtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2427411 - Disclosure - Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.springworkstx.com/role/NetLossperShareDetails</Role>
      <ShortName>Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.springworkstx.com/role/NetLossperShareTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="swtx-20220331.htm">swtx-20220331.htm</File>
    <File>springworks-retentionbonus.htm</File>
    <File>springworks-retentionbonusa.htm</File>
    <File>stamfordsecondleasemodif.htm</File>
    <File>swtx-20210331xex322.htm</File>
    <File>swtx-20220331.xsd</File>
    <File>swtx-20220331_cal.xml</File>
    <File>swtx-20220331_def.xml</File>
    <File>swtx-20220331_lab.xml</File>
    <File>swtx-20220331_pre.xml</File>
    <File>swtx-20220331xex311.htm</File>
    <File>swtx-20220331xex312.htm</File>
    <File>swtx-20220331xex321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="367">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "swtx-20220331.htm": {
   "axisCustom": 1,
   "axisStandard": 15,
   "contextCount": 123,
   "dts": {
    "calculationLink": {
     "local": [
      "swtx-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "swtx-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "swtx-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "swtx-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "swtx-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "swtx-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 282,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 5
   },
   "keyCustom": 11,
   "keyStandard": 160,
   "memberCustom": 9,
   "memberStandard": 24,
   "nsprefix": "swtx",
   "nsuri": "http://www.springworkstx.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.springworkstx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Marketable Securities",
     "role": "http://www.springworkstx.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109104 - Disclosure - Fair Value Measurements",
     "role": "http://www.springworkstx.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112105 - Disclosure - Investment and Variable Interest Entity",
     "role": "http://www.springworkstx.com/role/InvestmentandVariableInterestEntity",
     "shortName": "Investment and Variable Interest Entity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114106 - Disclosure - Accrued Expenses",
     "role": "http://www.springworkstx.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117107 - Disclosure - Commitments and Contingencies",
     "role": "http://www.springworkstx.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121108 - Disclosure - Stock-Based Compensation",
     "role": "http://www.springworkstx.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125109 - Disclosure - Net Loss per Share",
     "role": "http://www.springworkstx.com/role/NetLossperShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Basis of Presentation (Policies)",
     "role": "http://www.springworkstx.com/role/BasisofPresentationPolicies",
     "shortName": "Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Marketable Securities (Tables)",
     "role": "http://www.springworkstx.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.springworkstx.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i4858197abb9f421195cb86f9528f4108_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i4858197abb9f421195cb86f9528f4108_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://www.springworkstx.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318304 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.springworkstx.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322305 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.springworkstx.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326306 - Disclosure - Net Loss per Share (Tables)",
     "role": "http://www.springworkstx.com/role/NetLossperShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i4858197abb9f421195cb86f9528f4108_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "swtx:NumberOfClinicalTrials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "trial",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Nature of Operations (Details)",
     "role": "http://www.springworkstx.com/role/NatureofOperationsDetails",
     "shortName": "Nature of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i4858197abb9f421195cb86f9528f4108_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "swtx:NumberOfClinicalTrials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "trial",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Basis of Presentation (Details)",
     "role": "http://www.springworkstx.com/role/BasisofPresentationDetails",
     "shortName": "Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i4858197abb9f421195cb86f9528f4108_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Marketable Securities (Details)",
     "role": "http://www.springworkstx.com/role/MarketableSecuritiesDetails",
     "shortName": "Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i4858197abb9f421195cb86f9528f4108_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i6c5e5caf0cc0466db2575b43a6561e92_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.springworkstx.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i6c5e5caf0cc0466db2575b43a6561e92_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Investment and Variable Interest Entity (Details)",
     "role": "http://www.springworkstx.com/role/InvestmentandVariableInterestEntityDetails",
     "shortName": "Investment and Variable Interest Entity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i60df7d63a68a48d59113cc28df86b1f4_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i4858197abb9f421195cb86f9528f4108_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - Accrued Expenses (Details)",
     "role": "http://www.springworkstx.com/role/AccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i4858197abb9f421195cb86f9528f4108_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i4858197abb9f421195cb86f9528f4108_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i4858197abb9f421195cb86f9528f4108_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationSettlementExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419407 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.springworkstx.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationSettlementExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i4858197abb9f421195cb86f9528f4108_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420408 - Disclosure - Commitments and Contingencies - Maturities of operating lease liabilities (Details)",
     "role": "http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails",
     "shortName": "Commitments and Contingencies - Maturities of operating lease liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i4858197abb9f421195cb86f9528f4108_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423409 - Disclosure - Stock-Based Compensation - 2019 Equity Incentive Plan (Details)",
     "role": "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails",
     "shortName": "Stock-Based Compensation - 2019 Equity Incentive Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i74cc340c1aa4424ba3726c91ee26d876_D20220101-20220331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424410 - Disclosure - Stock-Based Compensation - Equity-based compensation expense related to restricted stock and stock options (Details)",
     "role": "http://www.springworkstx.com/role/StockBasedCompensationEquitybasedcompensationexpenserelatedtorestrictedstockandstockoptionsDetails",
     "shortName": "Stock-Based Compensation - Equity-based compensation expense related to restricted stock and stock options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427411 - Disclosure - Net Loss per Share (Details)",
     "role": "http://www.springworkstx.com/role/NetLossperShareDetails",
     "shortName": "Net Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)\u200b",
     "role": "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)\u200b",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)\u200b",
     "role": "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)\u200b",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i658acb93480c4b5393f0f53a36eab567_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (Unaudited)\u200b",
     "role": "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (Unaudited)\u200b",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i658acb93480c4b5393f0f53a36eab567_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)\u200b",
     "role": "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)\u200b",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of Operations",
     "role": "http://www.springworkstx.com/role/NatureofOperations",
     "shortName": "Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Basis of Presentation",
     "role": "http://www.springworkstx.com/role/BasisofPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "swtx-20220331.htm",
      "contextRef": "i9ccede58414f4148821842e315a905d7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 40,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Street"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol(s)"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.springworkstx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "CEO"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/InvestmentandVariableInterestEntityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/InvestmentandVariableInterestEntityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r132",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "swtx_AccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.springworkstx.com/role/AccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of research and development expenses.",
        "label": "Accrued Research and Development Expenses",
        "terseLabel": "Accrued research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://www.springworkstx.com/20220331",
     "presentation": [
      "http://www.springworkstx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "swtx_AnnualIncreaseInLeasePaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Increase In Lease Payments, Percentage",
        "label": "Annual Increase In Lease Payments, Percentage",
        "terseLabel": "Annual increase in lease payments (as a percent)"
       }
      }
     },
     "localname": "AnnualIncreaseInLeasePaymentsPercentage",
     "nsuri": "http://www.springworkstx.com/20220331",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "swtx_CeoPerformanceAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent information pertaining to CEO Performance Award.",
        "label": "Ceo Performance Award [Member]",
        "terseLabel": "CEO Performance Award"
       }
      }
     },
     "localname": "CeoPerformanceAwardMember",
     "nsuri": "http://www.springworkstx.com/20220331",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "swtx_EquityIncentivePlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2019 Equity Incentive Plan (\"2019 Public Company Plan\").",
        "label": "Equity Incentive Plan2019 [Member]",
        "terseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2019Member",
     "nsuri": "http://www.springworkstx.com/20220331",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "swtx_ExecutiveOfficersAndEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents executive officers and employees.",
        "label": "Executive Officers And Employees [Member]",
        "terseLabel": "Executive officers and employees"
       }
      }
     },
     "localname": "ExecutiveOfficersAndEmployeesMember",
     "nsuri": "http://www.springworkstx.com/20220331",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "swtx_IncreaseDecreaseInLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in lease liability.",
        "label": "Increase (Decrease) in Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiability",
     "nsuri": "http://www.springworkstx.com/20220331",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "swtx_LesseeOperatingLeaseEntitledTenantAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Entitled Tenant Allowance",
        "label": "Lessee, Operating Lease, Entitled Tenant Allowance",
        "terseLabel": "Tenant allowance"
       }
      }
     },
     "localname": "LesseeOperatingLeaseEntitledTenantAllowance",
     "nsuri": "http://www.springworkstx.com/20220331",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "swtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Liability Payments Due After Three Year",
        "label": "Lessee Operating Lease Liability Payments Due After Three Year",
        "terseLabel": "2026 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear",
     "nsuri": "http://www.springworkstx.com/20220331",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "swtx_LesseeOperatingLeaseNumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Renewal Options",
        "label": "Lessee, Operating Lease, Number Of Renewal Options",
        "terseLabel": "Number of renewal options"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalOptions",
     "nsuri": "http://www.springworkstx.com/20220331",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "swtx_LesseeOperatingLeaseRenewalOptionOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Renewal Option One",
        "label": "Lessee Operating Lease Renewal Option One [Member]",
        "terseLabel": "Option One"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalOptionOneMember",
     "nsuri": "http://www.springworkstx.com/20220331",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "swtx_LesseeOperatingLeaseRenewalOptionTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Renewal Option Two",
        "label": "Lessee Operating Lease Renewal Option Two [Member]",
        "terseLabel": "Option Two"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalOptionTwoMember",
     "nsuri": "http://www.springworkstx.com/20220331",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "swtx_LesseeOperatingLeaseRenewalTermAxisAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Renewal Term Axis",
        "label": "Lessee Operating Lease Renewal Term Axis [Axis]",
        "terseLabel": "Lessee Operating Lease Renewal Term Axis [Axis]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTermAxisAxis",
     "nsuri": "http://www.springworkstx.com/20220331",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "swtx_LesseeOperatingLeaseRenewalTermAxisDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Renewal Term Axis [Domain]",
        "label": "Lessee Operating Lease Renewal Term Axis [Domain]",
        "terseLabel": "Lessee Operating Lease Renewal Term Axis [Domain]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTermAxisDomain",
     "nsuri": "http://www.springworkstx.com/20220331",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "swtx_LongTermInvestmentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of long-term investment securities.",
        "label": "Long Term Investments, Fair Value Disclosure",
        "terseLabel": "Long term investments"
       }
      }
     },
     "localname": "LongTermInvestmentsFairValueDisclosure",
     "nsuri": "http://www.springworkstx.com/20220331",
     "presentation": [
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "swtx_LongTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to hold for more than one year from the date of the balance sheet.",
        "label": "Long Term Investments [Member]",
        "terseLabel": "Long-term investments:"
       }
      }
     },
     "localname": "LongTermInvestmentsMember",
     "nsuri": "http://www.springworkstx.com/20220331",
     "presentation": [
      "http://www.springworkstx.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "swtx_MapkureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Mapkure [Member]",
        "terseLabel": "MapKure"
       }
      }
     },
     "localname": "MapkureMember",
     "nsuri": "http://www.springworkstx.com/20220331",
     "presentation": [
      "http://www.springworkstx.com/role/InvestmentandVariableInterestEntityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "swtx_NonCashOperatingLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of non cash operating lease expenses.",
        "label": "Non-cash Operating Lease Expense",
        "terseLabel": "Non-cash operating lease expense"
       }
      }
     },
     "localname": "NonCashOperatingLeaseExpense",
     "nsuri": "http://www.springworkstx.com/20220331",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "swtx_NumberOfClinicalTrials": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of clinical trials reported by the entity.",
        "label": "Number Of Clinical Trials",
        "terseLabel": "Number of clinical trials (trials)"
       }
      }
     },
     "localname": "NumberOfClinicalTrials",
     "nsuri": "http://www.springworkstx.com/20220331",
     "presentation": [
      "http://www.springworkstx.com/role/NatureofOperationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "swtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of annual increase in the shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Annual Increase in Outstanding Stock",
        "terseLabel": "Percentage of annual increase in the shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInOutstandingStock",
     "nsuri": "http://www.springworkstx.com/20220331",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "swtx_ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Payment Arrangement Employee And Non Employee",
        "label": "Share Based Payment Arrangement Employee And Non Employee [Member]",
        "terseLabel": "Employee and Non Employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember",
     "nsuri": "http://www.springworkstx.com/20220331",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "swtx_StamfordConnecticutMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stamford Connecticut",
        "label": "Stamford Connecticut [Member]",
        "terseLabel": "Stamford, CT"
       }
      }
     },
     "localname": "StamfordConnecticutMember",
     "nsuri": "http://www.springworkstx.com/20220331",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "swtx_WorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The capital of a business which is used in its day-to-day trading operations, calculated as the current assets minus the current liabilities.",
        "label": "Working Capital",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://www.springworkstx.com/20220331",
     "presentation": [
      "http://www.springworkstx.com/role/NatureofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r25",
      "r278"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/AccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/AccruedExpensesDetails",
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r28"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/AccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r18",
      "r37",
      "r38",
      "r39",
      "r327",
      "r342",
      "r343"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r36",
      "r39",
      "r46",
      "r47",
      "r48",
      "r76",
      "r77",
      "r78",
      "r247",
      "r338",
      "r339",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r16",
      "r234",
      "r278"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r231",
      "r232",
      "r233",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Shares of common stock used to satisfy tax withholding obligations"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r213",
      "r216",
      "r236",
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r216",
      "r227",
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense",
        "verboseLabel": "Stock compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails",
      "http://www.springworkstx.com/role/StockBasedCompensationEquitybasedcompensationexpenserelatedtorestrictedstockandstockoptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total potentially dilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/NetLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/NetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/NetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/NetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r74",
      "r116",
      "r125",
      "r129",
      "r149",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r244",
      "r248",
      "r261",
      "r276",
      "r278",
      "r312",
      "r326"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r34",
      "r74",
      "r149",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r244",
      "r248",
      "r261",
      "r276",
      "r278"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/MarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/MarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r136",
      "r157"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/MarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r134",
      "r137",
      "r157",
      "r314"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/MarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r217",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r22",
      "r70"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r22"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/NatureofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r65",
      "r70",
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents including Restricted cash, end of period",
        "periodStartLabel": "Cash and cash equivalents including Restricted cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r65",
      "r262"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash Equivalents:"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r73",
      "r74",
      "r90",
      "r91",
      "r92",
      "r94",
      "r96",
      "r102",
      "r103",
      "r104",
      "r149",
      "r180",
      "r184",
      "r185",
      "r186",
      "r189",
      "r190",
      "r195",
      "r196",
      "r197",
      "r198",
      "r261",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/InvestmentandVariableInterestEntityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails",
      "http://www.springworkstx.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r30",
      "r169",
      "r315",
      "r331"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r176",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares available for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r76",
      "r77",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common",
        "verboseLabel": "Common stock options issued and outstanding"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
      "http://www.springworkstx.com/role/NetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15",
      "r278"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common Stock, Value, Issued"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r42",
      "r44",
      "r45",
      "r52",
      "r321",
      "r336"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r204",
      "r211",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails",
      "http://www.springworkstx.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r68",
      "r162"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/NetLossperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/AccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensationEquitybasedcompensationexpenserelatedtorestrictedstockandstockoptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Unrecognized compensation expense expected to be recognized over a weighted-average remaining period (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "verboseLabel": "Unrecognized compensation expense related to restricted stock awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "verboseLabel": "Unrecognized compensation expense related to unvested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r46",
      "r47",
      "r48",
      "r76",
      "r77",
      "r78",
      "r80",
      "r85",
      "r87",
      "r101",
      "r151",
      "r200",
      "r201",
      "r231",
      "r232",
      "r233",
      "r240",
      "r241",
      "r251",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r338",
      "r339",
      "r340",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership interest (in percent)"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/InvestmentandVariableInterestEntityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r23",
      "r117",
      "r146"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Investment in Mapkure",
        "verboseLabel": "Equity investment"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.springworkstx.com/role/InvestmentandVariableInterestEntityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "verboseLabel": "Investment and Variable Interest Entity"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/InvestmentandVariableInterestEntity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of financial assets subject to fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r191",
      "r193",
      "r194",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r254",
      "r282",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r253",
      "r254",
      "r256",
      "r257",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r191",
      "r204",
      "r205",
      "r210",
      "r211",
      "r254",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r191",
      "r193",
      "r194",
      "r204",
      "r205",
      "r210",
      "r211",
      "r254",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r191",
      "r193",
      "r194",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r254",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r191",
      "r193",
      "r194",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r282",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r258",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r140",
      "r141",
      "r143",
      "r144",
      "r145",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r192",
      "r199",
      "r250",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails",
      "http://www.springworkstx.com/role/StockBasedCompensationEquitybasedcompensationexpenserelatedtorestrictedstockandstockoptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r212",
      "r214",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r49",
      "r53",
      "r79",
      "r81",
      "r82",
      "r83",
      "r84",
      "r90",
      "r94",
      "r95",
      "r252",
      "r317",
      "r319",
      "r322",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Net loss per share, basic (usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r49",
      "r53",
      "r79",
      "r81",
      "r82",
      "r83",
      "r84",
      "r90",
      "r94",
      "r95",
      "r96",
      "r252",
      "r322",
      "r333",
      "r335",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Net loss per share, diluted (usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r50",
      "r68",
      "r115",
      "r146",
      "r318",
      "r332"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Equity investment loss",
        "terseLabel": "Equity investment loss",
        "verboseLabel": "Equity investment loss"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.springworkstx.com/role/InvestmentandVariableInterestEntityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r164",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails",
      "http://www.springworkstx.com/role/StockBasedCompensationEquitybasedcompensationexpenserelatedtorestrictedstockandstockoptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails",
      "http://www.springworkstx.com/role/StockBasedCompensationEquitybasedcompensationexpenserelatedtorestrictedstockandstockoptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Assets [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r56",
      "r58"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails",
      "http://www.springworkstx.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails",
      "http://www.springworkstx.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r142",
      "r311",
      "r324",
      "r360",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingenciesDetails",
      "http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of future minimum lease obligations"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r27",
      "r74",
      "r126",
      "r149",
      "r180",
      "r181",
      "r182",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r245",
      "r248",
      "r249",
      "r261",
      "r276",
      "r277"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r74",
      "r149",
      "r261",
      "r278",
      "r313",
      "r329"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r29",
      "r74",
      "r149",
      "r180",
      "r181",
      "r182",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r245",
      "r248",
      "r249",
      "r261",
      "r276",
      "r277",
      "r278"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation or contingency expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r177",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Marketable Securities [Line Items]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Long-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]",
        "terseLabel": "Marketable Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Summary of available-for-sale marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r105",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/NatureofOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r65",
      "r66",
      "r69"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r40",
      "r43",
      "r48",
      "r51",
      "r69",
      "r74",
      "r79",
      "r81",
      "r82",
      "r83",
      "r84",
      "r86",
      "r87",
      "r93",
      "r116",
      "r124",
      "r127",
      "r128",
      "r130",
      "r149",
      "r180",
      "r181",
      "r182",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r252",
      "r261",
      "r320",
      "r334"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total interest and other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/BasisofPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r116",
      "r124",
      "r127",
      "r128",
      "r130"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CommitmentsandContingenciesMaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, long-term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r269"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r28"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/AccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Changes in other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r41",
      "r44",
      "r242",
      "r243",
      "r246"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Total changes in other comprehensive income",
        "verboseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r35",
      "r37"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on marketable securities, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Interest and other income (expense):"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Shares of common stock repurchased to satisfy tax withholding obligations"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r217",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14",
      "r278"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred Stock, Value, Issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r60",
      "r61",
      "r135"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sale and maturity of debt securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r63",
      "r230"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r163",
      "r278",
      "r325",
      "r330"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r239",
      "r309",
      "r372"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails",
      "http://www.springworkstx.com/role/StockBasedCompensationEquitybasedcompensationexpenserelatedtorestrictedstockandstockoptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r5",
      "r12",
      "r71",
      "r361"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock awards subject to future vesting"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/NetLossperShareDetails",
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)",
        "verboseLabel": "Restricted stock units subject to future vesting"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/NetLossperShareDetails",
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r201",
      "r234",
      "r278",
      "r328",
      "r341",
      "r343"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.springworkstx.com/role/NatureofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r76",
      "r77",
      "r78",
      "r80",
      "r85",
      "r87",
      "r151",
      "r231",
      "r232",
      "r233",
      "r240",
      "r241",
      "r251",
      "r338",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r272",
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/NetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potential common shares not included in the calculation of the diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/NetLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r216",
      "r226",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensationEquitybasedcompensationexpenserelatedtorestrictedstockandstockoptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r216",
      "r226",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of equity-based compensation expense related to restricted stock and stock options"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "verboseLabel": "Schedule of Equity Method Investments"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/InvestmentandVariableInterestEntityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r1",
      "r74",
      "r148",
      "r149",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "verboseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/InvestmentandVariableInterestEntityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r217",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred units"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/InvestmentandVariableInterestEntityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Unvested restricted stock award outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "verboseLabel": "Restricted stock awards vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r220",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Stock options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "verboseLabel": "Stock options vested and exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r215",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r214",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Employee [Member]",
        "terseLabel": "Employees"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "terseLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "terseLabel": "Shares of common stock used to satisfy tax withholding obligations (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term investments:"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r72",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/BasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r73",
      "r74",
      "r90",
      "r91",
      "r92",
      "r94",
      "r96",
      "r102",
      "r103",
      "r104",
      "r149",
      "r180",
      "r184",
      "r185",
      "r186",
      "r189",
      "r190",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r261",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/InvestmentandVariableInterestEntityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r33",
      "r46",
      "r47",
      "r48",
      "r76",
      "r77",
      "r78",
      "r80",
      "r85",
      "r87",
      "r101",
      "r151",
      "r200",
      "r201",
      "r231",
      "r232",
      "r233",
      "r240",
      "r241",
      "r251",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r338",
      "r339",
      "r340",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r101",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r14",
      "r15",
      "r200",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "negatedTerseLabel": "Forfeiture of restricted stock awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r200",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of restricted stock award (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r200",
      "r201",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
      "http://www.springworkstx.com/role/StockBasedCompensation2019EquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r33",
      "r200",
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r19",
      "r20",
      "r74",
      "r133",
      "r149",
      "r261",
      "r278"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r140",
      "r141",
      "r143",
      "r144",
      "r145",
      "r192",
      "r199",
      "r250",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r32",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r32",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock (shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r32",
      "r202",
      "r203"
     ],
     "calculation": {
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury Stock, Value"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by the United States government.",
        "label": "US Government Debt Securities [Member]",
        "terseLabel": "U.S. Government securities"
       }
      }
     },
     "localname": "USGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/FairValueMeasurementsDetails",
      "http://www.springworkstx.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r89",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r88",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.springworkstx.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r373": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r374": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r375": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r376": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r377": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r378": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r379": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r380": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r381": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r382": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r383": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r384": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r385": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r386": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001773427-22-000023-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001773427-22-000023-xbrl.zip
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MIBI)5'B\#P/<"YU(AP=]'LA9=)R(AR1[G(U]<+0;/Q3D%D2?G7H*^)F-X:A
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M%QK8Z!YA5KCT<9&[&IO/Y*\SG1JP4SY'7H,*OW0(9WL^2SN=M,1;'1 EP87
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M%!@!D1OU,F&Z19D[MA/5K UO#0+;QXX='$91E]"D5VALDZR.4Q03P(Z+?92
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MOOKZV=5PL29LP&T\EP1W=U>Z/7D5#]I="^S;6[;ION^S_P!02P,$%     @
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M;N.].OW86ALVMM Q_ MM63_]'J.R1B9=E,H"J!J=:VY#'H3F @G%&1(+RPA
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M':3-7X^-HE5[SW Q#'Y_ M2[,))I(,<@^/I0CW\GVL>HL<XQ$N#66"1R[6B
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MU2WZO1T#+84'+O[T"<3>\(A.T??@3H&Z%[;J*#RES+>KX+'L2HH AG'=XS(
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M5/7Z,LVLK@F]1*2\]3):PK=>^]%C,5TB5-_KL3^^)AE]E,:R.S?HAK#"1(Q
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MPW$L#6@!I)REB#O#D,N7*@ ['-4T"&+YV@91;:863./[<-BQ<EQOH1#)AI/
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M.ZJ:<Q"UTG!P.*6K@_X+I*F+9(I: D^])F74F>X[3P]5M-_2M-\5)Z-"8<R
MJ K/#>+*4.088RCX8)-Q0;@@KZ6LUV:-*FRUN;*[!+I:9/=)9'>6N8I(60Q<
M(:MR;5$A+-*>>)0HQLE(SHR,US+7ALGNRO&;YQ!.^3['WL;1N#JJK//A=BO1
M;?UCXJ[[Y[WB*PO/+E&25T7Q7KG3;L&X5THQ+UR$X0%)=9[PSJ _N*R@SP[.
MBAJ^M1K>F??Z8BZU9K J.'"-N*,8&1\EPD3;:*C4U)JU#6)N7R:K$11Y]83M
M27VV1<26*&*S3!='2[6C$2F<0,2L2<@D81#\DE5%%303:QN-"=U=.1+QG,+O
MSDAM33#:K7Y\.=5XG_S ^7W_.\Q]CDVN ; 3QP7\%@E WMV<RXR7%5).<0BT
M(N=P4D8AP[U WGC'B;>F*K!+S'Q=AJ9%WI1HNL8<,A=!78*@SB1;T]CS: -&
M/B6#N!$!65@B9"Q K- ^"N/6-BA5C1?4E6,PJQLBU[W."5=*0C2"T12C;CEP
M.5]Q*BICK=) :9R@8-5%A5RT G&LN?5"JA!\E25M-;+ E_H/J\R'BI@O3<QG
M6!%FA$?B/ *1!E;D-$?.<8H<42X)P8BB'%@1NW=2[Z<5])6C3,_A!+-.(0V$
M:6K,E!*>3W3&=![S\78X.*S793N.]P?AW-(<%2Q="$O?SU$F%SV7-@@D9,B7
MT8-"UDJ,*&A!Y0B7@H'X,S9O8982G<]!?A\N>*O([X/([PP7,A3D5C*'O,<>
M#!UED?' BH #*24"+&F^(43E_"7*!LGORC&=%2(TG7@UA;DSZ7W.Q5L6>_=G
MHP0>CL3![BNQNP^A">9+H'*?K"4QPH0*!YK )F3 'D96224\ULX(707>:WP?
M9;"0B#RQYZM@7,&XAR>Z!>,>#N-FBT]%)BB3 45+(^*2261BM(@:*B1QU/+H
MZ@L*^CX&ZQ-BW,I1X>8->%5:EHDM$[M:+<O$EHE=K99-2Q2QV@4"7M*]MYN,
MO8>I]K.83R_7HZFKT[1;SHZZOBX3T,W%"L,S*!& 5S[-]\UW]OZ(PX]Y!9?K
MDJ.W/);)Q0.[_6.8Q_/Z=#"BW_-FF@QK8K+B8K+>;+(>S,?:6Q.$TU@C%PQ#
M'!."#$D):1$]ARV<8M*_#E1JY [9JD&F[)%E[!'8!2H9'I"*+B'N*47&<8DT
M<1&6DUF:\GV,=3J?=:'!5T"+PEDEA7-/_VB!DR>$DQDO*:?8,HY!QTBL$!<\
M(4>80LX%05(@.FI_)Y7SM'NDD)*E[1!'2+1>P@XQL#DX<P8933 B7 65).4,
MF[4-O"YI$Q7.RIF6RPJ,?4J;\^_J'S&T+ S*[D5XS\-#@(W*_!RU!L?CT1BL
M3WB;6]BBSSO^[EIDK>=JN3P>SV+I=*$VZW7J'!^Z.-Q)%7".=LZ7J8+3VQU7
M%IB]#<S.WT?RQA 9LPYV(2*>I$364-#&6$3J10#;D#9TNUPD9!=W3=DP#[EA
M8!Z=Y $L/Q\PXEQHI'E(2 %_(S%B6&38,%RW#5-7)N%K_#W@$JI]#U5Q3_Y=
M9+]1LC_#R0EC*;D()%PYT!C>*F0%E8@XE2C-%]Y$:.B&*=SB\;>+IXH%IPF2
M#',$3$ @PVB$'XY&1X*N+D&"JJ#4M 6;S[7<>%714#/O7V/K>O&RMKB#?B#X
M=@IBNARA^WWCW_!C^LA#.]SK]NM#6GI9R_F8,T L6Z&=#[CJ\55W#$_SMWB%
MC_$L\\0##>B7CV\]\,,7G WKP7"&D9R"T)1I.1O.<=\>AV[V+_0'8WC0>) U
M6<CWY;-X]JL@!)L_3]V^[?NN[<&@X1?5-;*KWN7I9+(&MU<,5T2V;NN&_[K^
M>Y/>.5U7 D9P-!AU,R*_&L9>59#PMY-N&.]/DU)>^.+D2?C\*];!3 %[N_8K
MCX@3OYQ$>7DV+O[,HZTX >&82LN581AL71P,2=JX7 "4:N&4^DK%VO1+^\-S
MQ^->1&X8[3=D$[S@*]L[L:>CM7]=7BM8J)EYGYVR:R<FI0>;F!K'@20-:L?W
M*]"X<9A;P9AL8\;2VA]F@OD_-R\1P6L;NUECM@:IE3W[M;S:C:O6OQGZ;3(E
MZFIM=C0$Y/Y[,/PV:NWN PT^BL? ;$;MUON^7[]6Q)LR_-=GH/KZ(JA^/(/2
M>ID.CX9Q']H!^+2J:C;_^#0%Z'\V!&ROF]$;L/:JKU6,[AQ3J^@W6)">/1K%
M5].__#9EA-U^-<KJ2[]=AOR,(C-,MWI>_?$$8!1?UX+E5YN<&$P>/(&?]?JM
M+]/O^C,IUZ5BUWZ,U\FUG_VJ6\+7!15WZO;7GRDE'V:PM^YV=<R*FP,3K_6,
MF=O$,-:;_7%\7_I64+0+.B2VMJ'=_JCU!F IM+;MT.^W&&G?HDA$DX)!GW(:
M_]'MM\;[@V/H(HRN+WIPP06[0#JC9N^@?,"QK!>^3<#T<YHX\N BML('[2N5
ML&&1JP6K$(2WX'WFA5^_T0=")6W#'?WXG8\3/_[AVQ[T=]HY"+V==^_I]M:?
M9.?O_)P/O0[]LM_9_?U@FWXXR/V=^?$/W] O6]_$]KN_#K\<_/ZML_5A?_L
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M['X_'\STB/:6,U7=$(VP&GFVZL/:*HP^[_&)K_7\%V<>A_RMR7@S*;PT6_5
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M9,3H0%$@/"(N"4=6>XPLI5XP082U=FU#S=<A6N6KTP695@>9&@!,+SE*[=&
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M;J7H^2?3NVD"H9^M_'33R <JY+W^IIC_;W..);)+MERY.@ KY[/ ?X1NW;Q
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M %,1)=(>W$AII/"6W5LBJ :>&GAZ&"?/2N^]-CR"^+I(C;52%E'YE!G=4M[
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MY5H45O1@10UF&O"EEBRWW'HC"BYB03UECCDCO&,A%E@9"WP=[VRAHG3,Z7]
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MON56RA*=IW1]3*^U;]_')/T1S&)<:3MG_]6@M>\FPW3>%RR?6A: C!(Y?Q+
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M 4CA^FSZZ:B939C-HK,')!#3F/9^>QQ2(D$>D;4%.&= _SRU$L8^[CR)Y:>
MSH,9K5*VUJ@:Z%:EN-G W$ZY9:064ZF)(8055E@+#CU30A=.*\%)H]P/)PZO
M/V AO9>4(UY(\-6%I$AC)L G<*S0H:#!^YTGP"YNI]RWF>1&N>]E-G'GZ(-U
M4AMO*,)$$<2X#$A)G39=@1M%J9*<@(\&EOLFNKW;^A/\C*FI#'[.BIQ(06(
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MIG42V&V/3GSC>.XF3)\MXYQWJI*"YUN5@/&[!'6//BCJ7:08J'P1)&+4!F2
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M!C 00+XK?75)*489'H[-I]3OF8$":Y6L:H)$(/SE,"G\N)^H67\(&@D8T)K
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M.:X*HRSU.QN5/R-(XZCVI^%]U=_)6VGM38\ ',#AQ[(];U/JU5%V2S.\[8]
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MCF=GQ\O9@=Q:9>'$Y!JD_7EP;M [)(IIW/V/>Q<5B3=0R*45/,K&1N@KGDH
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M$)EW7E\AJ19^IK81D5N8?5R[@!0:]_&.]]%#"'VTM9M*%K>L)BKE<4<^UH[
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M=0P]X^,HIG&$G]4(#SZ*<_I_[:,XP?]]=MQ'<J@>\U;GLK4,[1T[9/G.)@]
MGWW57J6#9FAG1OQJQS2U1X^3\[-''('YD%GJ,3A@MJ/(?9DB=_XL>?3LR2AR
MH\C=G<@]39Y=/'_P(N>?<7&8C=(K?D>W22^>WLL&W<-,__53.(0/P0H=!L%]
M4O]PVW'I6<R'<5PNX!I]>NB1V2(ZGTJG?=&;='Z1/'I^/F[2<6_2X^3%\T,-
MTG&3[OHDW<\Q>GCF0;]9=,QFP6\E]G;ODE5^BN#4(3;T?HFHAW%^GIXGCY^^
MN)V%O7="[J$X1Y_3QEZ\2)X]N:7K-&[L$6_LH_/DV?DM0[/CQA[QQIZ?/3NR
M77UX1L[#2XK_B!455![10_I\3V[ YW2JOF8+IP/?^CAK\(!\N\]J4]FZ&3?U
ML]I4MFS&3?V<-O5PH^93[^K#,VH>7N1FL+3X=H"_?1V&\1F?US.^H!1HJY8^
MF13N=B"\+SL;\.)0-,>8K[GCL.3%+>V!<8?NSK<ZV 0?-^>N-N<6_M%H+S\8
M*^"M9>'Y&KE3]BD[' &#K3/RXH!#,L(Y[SA]-<)MCWI_X/0<$%<==^>NPVEG
M(QKZ0T,!YX^.VPI@W%,^2,_W 8;!#N/Y$T:FCVV1]R]K.6SN1WVF;HEF?1 9
MEE%V/V_9O7ATZ-4W2N\HO<<RZ:\O+IZ,F>W/*;/]]8OGQ[.A#\\^?WA)[1TT
MSB,"]B,@@!X].SCV<!Q*<MS1@6OOZ?FXHY_5CCX[/#PX;N@1;^C%L55_/3Q;
MYN%5'?SL/L!Z^3BNK'!L/P(!R<H&&;MUUJ.O^^&+<]3'#6LRGI\=8!A\W,5Y
M&*&>\7Q\N><#RUN>'^ *C>=C/!]?TOEX=)&<G3_^0L_'+0*NG^2L')U8?&BM
MT3W(Q7'X.G^AYC?_<?^=AP;;1062XC<]),7W/>S^ADE#W,K*8^,[;F;8YORK
M\Z>GSR8PC 6V.5V7DZ\>/3X]]W\XL(D2%91_=?[L]/'MGG".[:)-2]#YY,73
M?[UMY\7!$,)=[02VKK*]3W<U6I_<I+;W9;I>5_FT64MS:UV%^Y"I20J[>G;Z
MQ.^JG18AAK##+S?)S:K\VA4H6[CML $WZRMJ:+Q<+<J-<]I+MZY+[*X+<G"3
MTS?XB;5VB2V:Y11[Y<Y#7V3;2CF-!S'465G75KK#3[YZ8F33/@ [>IM9V+;T
M57,Y@25LYNELW53\\DSZKA]9 ]]^36:)+E_U$UW>]\!OVXZ;SLQ7%[?6.!<=
MC?/5^9/3,_\P>-;YQ?F_JF:[N+5F.QX9V4]9[>[N#$O?IY/N7>T>L0Y]\9!5
MJ#3L#JVX03=JC^VFVK//MM?#ULJPH^CTC$]:[\6G3YM\D4T*V)A9NDJGTF'=
MS@TFL'05K,[B='(T)V^/1MY<BO/#0VCDC1HC<RTA[D4.HXX.,GV42B.-IF)'
M3S71R<'M1&LZ0VG%Y^2 >V+RVU5>A]'@VK6TV.2KL],+<WC@/^N96RS2PI5-
M[?DJ#QQRSP6U9]_F%W\Z AGM/UL_YO]H\@SQ,RB4K],5MMF=@(L$&FOF'E[S
MWU]YW*C2_=3N?Q);3];O;G*57I-QT51X' *SJG1IQZU!H:UR5\P<ZO5+-C3"
M-V=I?369+\J;>E+#@QS=./@?*[JAZ$Z!ZV&6K^ Z!(%/UWAEW, 1B>X-&H-O
M#@_' [ZW@&/&]Q3\ 3PT1Z=LWH"I[TXG;^'[A60MV=9\>G[ZW!\^?/%7%R_,
M7SY.V^$$G<65F^$R+#:G$UI$G"/VH&^6#3LGF9O#E-=DM3YZ\OCT47M<%\;>
M2$EJAL;PQLT<&@O;A_$M&0=H%L.RX)XDO#,.1/$Z76 W<'H:2-Y[)_V0'2PY
M7<^3:0HJ"J5W<"@)^EGII6.ON%Z#&;>&[]-^XBL7_CBORCJGK:<]=@6]"Y8"
M-GGI8+^Z]+VX(V5S>67V_,8MKAV/0#:*>LS3_F5>D-:HC_^G22OX"$S*=XX,
M&_C;/%^XC$6D?\(@>C68S3C9P4/::ENO\_J&'%!8]DXC>W]E<MCP+/PDG=;E
MHED/_Z33GO">5$*[Z;C]OU>5CF8%@G RA5OP_0EMRS?IXB;=U'_Z2ZSD0,.U
MUK ]_<%)SN>?;)(<BX5;O&2C^!LP;4!\X%LPIO1HQC(!+37_OW_ZE]VW_/D9
M6'PDX"#-K^&->-C__2_I?_1MY=%=0E?PWR?_:$#VUYMD@O^"D\S:9))>I_D"
M9W8"NOND!C4&BG6ZM@?9^A75"I>Q\YUD\K?37T\G?RVOP9,C_65^CSHQ>"23
M50K:Z0@" @<:'Z]1U7^/E_#]#WVG9S(O%S!2W#)6R^!77N<9[25L\Y(]VPHL
MC8KV52\T,3(^SBW^S3[K](262>X.5>V4]X'E6J2KVGVC__$RR^O5(MU\DQ<T
M:?K12WF6W >H %MI'SK^_+'HQA=@L3QYA.I1\&;RXMV-V)^=G[YX.OSQ\76-
M?U M[A^]&%O<WVV+^\^B;?S9O;6-[\E%'[=@?&CG>#OA+VWAS@\Y.8<7H^U8
MDKL[;[NM# ]F)I.A0:<8HX;>YTS18R;3[ZCH$MHK?,]8M#W7^>,5[G;F?T^(
MF3TG_O7CY\G3YQ^QW+/GA-T%HNQ6RG04\B]$R"_.D_.S6X,J/YV0/^C2XD.O
M,/&."1+VM=QG?Y::XX]PH7VFY%E[KO+%T^3QQ>.1@.ZX=^GK1V?)B_,#;MN/
MN$,/NO3O0W3-/"_28O;I3>9#P.L/4'8OGHY=?8]\BQX].;3@^2-NT9=BRU@@
M&>D:2KRT,M3W;<%\F.=R?)+]]<5%<G9V./?QT;BIAXQGW'BS\4_.DZ=/CW#C
MOP1SZO60>DLF4W>9%P5E-0GYFY?9?=M4GYOHGY\]3IY<'-KG^'.*SWW1N__X
M6?+TR:$>_1BXNA/MYQ!]_D%Z;X>MM^?U)GB,[AY_L9'KC[X^QZTEGE_ %?%A
M'=,_?(V.V78>#])XD/99F!=/DA<O#@UP'<M!>@A,!Q@ZH1OU;X)D>.N1#*^Z
M8=G[GD,_YG,O- 97<#Q^;B@/#JT6OKG*9U>MBK8TE(A@*4:G0H0_]R5=5$L\
MNTJ+2R[5-".M:R<E%(O<US720Q^',2>350H2ERX6&_AH#C_!0>PLWZ3:YF>A
M[#*9%&5Q0FMF2G)HA/8G9ZVR$MA:UTM)W/[VZ>2 /;DXORWK!/S?P9VPE3G)
MH6L5+14_V,<7;[6%YZ&N_).O_=&<UAT:YQ>3#,(9J@;ZP:>>'YX&L@FNOA2Z
M2/S36W,6T$H5[<,U_*I'9Z<O;DM;,-E_6@=.PE!LX*^H\(*+Q]9:-P%2O4=U
M!LK^DPM[6OOTXZJ!(5!U_/Y/O7AD"FW9W>0*4CJD68XU@O+-L)D]>N_#E^N<
M=K*U9#JE V;TW$A=LGU*9W9%PSK2BZMRYEQ6LQ[LV[W-(7OW))0I/DC%];W/
M8C]L9=67C3_T5$O-H^,@3"0G=.O"?2<W+19#U5@X-6C-@+RKB)/,XR5=SS>!
M!V.=_D'4%U?E@JMXIF"!"PD%E??4ZRJ?X6#T>73'U@-:[</G?W[X_(^!G^+
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M_A$B,L@ AYR25QSMV'6BQ2:7!V7EK#$LK!JN\>'"W9$3'V+[];O7-&+U(,0
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M4 1":=",L%JKDN<9+2,M+ANN/K:.&4]NJ"&O5,PBZ-D=KZ?_OT*D:"Z=3JC
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M]E@Q;OMI&GN L!*AE"((?EX A$BML-!)<AC5/ +]:]\^G._T%M=D6[U:D1N
MDXY O-WF1^A^=8"84 -)Z1Y]L)S8V#(]@'>2S790O?HO?U6'PAH,5*/BPI?,
M7!4*R\'E<&GMAA! OAFX)'@HI]"B/.X,%&_>"N279OVMR_\*GOGDQW5V*MU1
MV#.2#_X_^->[5]_#0)9$O7J53U&+\G)%*]KW*MJ3R;>O?WIUPIU2&"PCLY;$
MSK+,TH7R8U9E<WDE*CMB=Z7G"92-01[HALO>,M7%["H\_#BUW7XV<VP=>"LU
MPQ#&(EKT)-[M(8?"7$^]VY065CY%!GDIF<<@C7Z#66?)>>5SOO^&?YZ5KJ8I
MF2"$&#P\LPA3(W3<Z4).TX[*A%8T:6@4A&%#2*$/T5;4 2)S]:S*ISTX_@&
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M#$OV$(_$<S"CU;1QD3F5\7UN+@MVRA07QBBG048@*7&.\$7F68))SO<F2'N
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M+9!L+6D.&2&^VF\!7S9X2V!J9+?/%A8H<IT,"U K #IXWTPK 6PL6X3W3&=
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M\0K8T+S NDA/P^W=![:@O1.'OV/\"M$02-Q5!*S_SI"JNF G4A35Y)\E</(
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MMUU76>?@V_2+9$2!Z/Y MA#.[ZY3C+:&?C(][6"Z3(G#,7\ZE27EAU"[^N+
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M.X 7D@5QB$"2"Z;&'KD^&;DV4W-*JS4V!^FYG!BG'ZE"CN6I?:EB\PF["JB
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M:YVQ=M8="'>AY.$X*(GWHY)&&SA@L1KI6(-%%'J.Q4;:Q^=9;H0M6IOLF56
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MUUW%Y&PW57E;$V*>NH_>-^W=JYOV[AR5:T*)2AR-L0+JR=A9&5&;%<J>(C>
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M<U>'J44[#=\:VN*?FA,"/,JQ3(&.+[&?^/N;,:6:]!TJ8:'"(C+CGM\*^4E
MY(D]0@HI)Z811+/K&?>JL',XF[5"5KX/7F'?4G"J!)QDIN/V#F%.#1))UW2>
M^_W.X1N541@]$XVVR.UDA ?+9&&0M'^5[*&_J8^]$LGI(72_K/<K7XV<68OW
M@-]ZX0^;JFOT_K?8@SJZK8>NW.W*NNN=S0:Q0W@ N<B-%K=C:IBY/ :PPHR1
M.YLO*B/L#4;(N#K\FQE#7JUIWO?5<9AZM\@4V8TTH?HD19DC$R=J]V5":6K,
M[NKLN8V!KI@S\YE0ZC30D+6FIC@-DMIDGJ:N\C0&OKF&[N4]7?/;9/Z725YE
M\F5J&UK,?0@*.])%6-TP<7ZK!!M5N*>5 5.7F4X#_]8%?.?!=[^[@.^>QUB>
M _CN VW"<UYZJ5>8I3R-.V3"60W72>XE%[4?26%Y%+R*B40\(HY&UN%ZI#8L
M#?/FHN1%?9O3)+/["_HI__RLU_/(-G[O]70,OC3/-*3L1+#WH&.*<H3@ADU
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MWB>"@GF];N)5DH\AD\+UQP4%EB@^73<A5.ZJC21,ZYY?9 </=1[:@]^'4]G
MHU&S(A"-NI?8O\@S=7[+K(F0XRZ,ZL<6ZD9TQF6#A/<SG1N>+@9\AB!J'*"8
MV>P%JUL1T,.4*L*3A81<&-39$MZ&=R0'7<G(RQ4?.>39R1!OJ3S*VI/M+M,D
M&ESMSK5-),EDS]W.*D6)WFEKZ]L7G@>5&M!C.M3E05VFD(D.Z8; 1G28%'"
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MHE,FCTA/PZL2+GSJF\-%YCI/4X7[#)<HM^L"2P=@25$M6CN-6STC(1ZB?/S
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MF;:%/)P],WL=13O!N^9$ :<$C'>A1!M^Q15BIM)*<%WBEQ/NAUN4?:CW[__
M;'UZI%$WUZ_VU6[X]X]_'_X%UU"-[H5_?_7ZCQ]L1HE%[\WO/YT+69]F".G<
MO/[=U2<T%U$"<WK=_-WN@C7U=Q*G>+(3,BK.3R\+]X0+!QO+;1[6YCHC1>M6
M3T(C7&ZX&/=E@S0>3O5E]9YR]3KRC>"RJ+#3G'(LX^VT)$$.W6???=.GGAQ6
MCSISM(F<OVE]J&*L9\-N)QIB;+>W!!YRUR;E$0\$%23,$Q(QYP=QV4<?QGR;
M]T*J;B6TXR>+ ]YP*L3$AKZOOOLSB).&&P(;;-2UNJSBTUJ#33?6 ].SU6P
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M8Y(XMTKD+0N7N"M-C/T%D_#U?YTO<SED-@(USIXWE,"1JG$O8+3\6"H.8W7
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MQ%L:)^LE&#Z&_7H[?1\[GZ*T='C\ X4D*!V/M*:2[60,/+M1UIF>&T5\%ZQ
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MSO)QW4$"=<7V?4F%SX8]EAD?<TI7Q4(:>3BZH+)#3(BU/$"IB_9)Y!(W^<W
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M.J0EYY*^"PC>XF>E *-US\H!;=K:X;S)X[?GYI.EY:WC0.CB$AQD^OO"<Z4
MJDY:CSFX?7;6!>5<Y%N?23Z3W"69;W3R!!'ME(.4L,,4W'=1Y\RWS*\HWX2$
M_&%8W^:\,7YT,"B3JUT6&#US3-=>>37NQOV"<5M*7EGR@ZP4VH[E>5--QA!]
MV.RU'A37IZJQQ=#!$%Q:H]ZWBZJWQ2X\[?O;O#5%WJ77N<U3T8UN%/FTL *F
M;/6^!QA?"#O'!EV^?+_IMO+GCFIO\YAIE'/23F@[4Z?U>VVK80^]\' B*3)J
MT_()Y+W2+AI6(N&DZ\D38Z0:8L;5."XTZW91CZ(C$KA 6Z[HPLM<YG0/)@$0
M7BB<YQ%F9)MQ+EJMY^: ((%(4&#3".<E/%9VA'WE,[UG0XYP&W'C83'L^_25
M7O *MW8'*=V,5MH( RDU)5^_X$;2Y@DXK:MT</'5*2"^U&I(VA^#%7 D2K7"
MY74+3ZF1953N_KNWDF<,0W^U>>\!L&(!9G03&UD)5O=+:W^SQ=EBEO7ED'PA
M:4G\^34PM[7* ?72D*]>6^!>:?K1R^2VC@VJBC#.G!21B7?FNW' ;66 OF3(
M)@1JVQJMUI'!X";(*Z#,VSS*4.$="RM_K?6,23-7A$<RKEH7,\'TD2=:OVFW
ME/#4PF0:N&J,O1NGI25J9*>ONK<M 6*LOZS]EVG_#Y/[L<@Z=]&R+Z$0(;JK
M$/9^_%<XA4<'+&V(577-U8\C;)U>W4;9N;+US,7!(<*&(;*&F0CY'Y<;4%CE
M,O8&J<M\9):RS&B(IHP08QD\6;&=1L6^%%![;EM;2L_:!E:BK],RP[X,Q5U#
MD1*-I6.201G-GEB$P!'G-P/GXG#(; W&BC?'E[^8D?4>*9HEHUZJ<V(KK*MN
MW4_X&IUSD:$ALD_;6_&H2>L*]I3.NY8.PG&28K::QMTZJW)+E? (YZ\=;FW?
M93;S4,'4)*!I=?H[&BPZ5#AE\1<]=V6MJ>UDCW% L3C:.&',33$+>L71+*<H
MAYL94"XA(P&5D;PV#6RCFLE^EO;"ES<H1/_=K4&YI(5=/BYIM";4V\U9! [X
ME(XC9CO>].A/[X(U#/2 NB8!\BYI9ZP)FL6\F.LUD=S6+S+0C2ERVCC*)!6A
M S&&006:!&-YLI9S>N[YS\\,[/P""DFK6Y=E>O;LQ?E1QILFD-*"RE>?74+&
MBZZMT)>0;!5'.]S-V? FO*3E]M>J0"#CBSL8*D^ZI.%%_?6J46^=!B_+@R2C
M7/^"/+Q!X-5&UD&H8607RJK'G[]_<2Y(KI&JXMC&Y7O>=*#A5ND$C*$<C#,R
M;1'>]9-]N-05$D2H>BY;Y5LQ3EVLQ'6U8W8VJTRJ&T^Q*YT".&RY#:#$R=M3
MQCP'R4RK9JOHL$RYA(Z35D!+;H(# 8K<VFQ:0!'Q?+H@![@6<P)I$0F+\@IY
MTU)%8GZQVAI]*2_F2_7%RW,=P_2O -H4J1K5<T;=)R-X1NK*RJA=1A?B6LZ.
M$1E91-:$ 5,V4^/#."M1]GX<\3-4U0I91YI-I!%"7+<4PI31+?+6ROO)+KUJ
MNRYCV=S6QH4NS1=^M?;Z<(834*XJ[@&7H=##8QW2WMR6BR&<9C)"/@GQ!$I'
M=]<J])=)TXET-9<].TQ>OH"X)Q*WP.^+W_YFV"(6S'YXL874;K@#&6QTO7_3
M=))Q+(C&XN%C9NNH39#WP0B$10AR;PL3+?C0$)&+,R+.ZOT5#JR=<^VNR-//
MISKA*4( \?E')SS%XWB6_ST\Q?N)D]I-:"YD\4X(MUE&<8^2[DC>Y%Y&*N1L
M8S%'"^66-S+F.+J,<+MI'B)OFS80A9(/$CN/,_J_3UC43@]3C9VIWK)6GH.3
MLG ;8JM1@7C:,IB-JOL<:>IF_+=QHUAYZGF:652J<WYYK$B-&N?S\X"$&,?&
MX>CT:I >^O*L4LN+>04F-0>487!NR:GRG20Y%]_@JR^RO_#2O[=<_.[YS[]'
M>?JS/WSV^9=T=;[[YL5+,)&N0/6<=1U;)6C^U$AZI?&ETM2DY?"/!<HR=DK9
M 5&%'?PS33'2L\"G]+G3$WBK;67.OM5]M!94[!501[%4@$-]U'(C[Y/]JN*+
M<3%<56]4_P!57U#3F$=O+S7KZ\1+!/Y%+?+:;[2 FL5&*^/(V8!ID6)^JW*U
M66\^DWO/"]]07TVV0&8!7:-G;*M.BR"P\@U+U;9RJB0 FE_4IH<\^_+<,/72
MQLX\4[OTN";/3+DD0FKAFC4W9O[>0@YIKQS>QE((Y$7IQ5--CEVW:H3.':T!
MXL(JQ:06^^]ZT:ZF'"2FPLR 113H#58'L%S5'E9:U=]M[]A)=PYA<8XM]54(
M*%;75$R-(^D^/CB#*)\8>B#&'](8$(%-WW/8EUY"DOZDY-%DJ>L^ QV$" '0
MBGHKF+39Z2YZ<3J^<>/J,GW<O:8C,!)9YM*S\CV[RHT(9S5&WZB9E_A.*P+[
M=G^6C]0BHA0@P&8Q7..R3S]*P8]H8<""\FR4OWS\[^;C'UHD.E)(NUW?B. "
M%7Q!*DUMF,@E*[4_JRLD]T^ZW56R(5_\Z&W_^$ZW)>@:AR<RHG:?)XOO7![0
MJBXQV:>Q-L<?(HS,-=W44H2($5.5PYI?JI6JNA1R\ >-2<9&EL\OAUB9XAU2
MD,B&D<U \'C!>PJV2V=Q\@+LQ>W1/:)Y)[)?]\+*<^P)TTGX83HX&2^[+#$Z
M@C&(X !]711X.D?A!#D'Z3NOUM6U)2+&:(Y,'"NGX4%ET8II*I\B.U9\4NY>
M2+$BZ^,$IUQKBDS#>0-J,_:P%CF)(["0Y:)O/56N]5M3_BTRPE5Z_H;X3SF;
M0_%A;Z?CD\7YMF^9*6LL'#=%)S^-PI&+<4,1&'P3DB7V]RFI?%!/[D=C(UF*
M4?*8[ASWK2$GRMW3C=KT\'GW[GA9-H5=A9*WC>=ZD2[$WKUH2_GRE*:O(4:#
M.$$/RO!48=^/)%TL8;AQE9:N_J4Q)8&E-#8J^&T$;>2!L-7T]KI+>\)71%JD
M(?7E0FS"2V_*S\A2B(SJ!<&IR/*++"]?"&GK#W-3YP.+)YJ2^\[X_^[3P812
ME!WX6>N2U3WAZ ^'8CL9KS@\>P.1%,NZ]%!&#$_J2 ;S4SJ3>M;%F'4<@I2,
M):![<KUN>6[1/PF]GD=.(!-2N:-P2QA ,"5BR/R)8CP4^HW@*X&?R+J;Q&P:
MNXLQ-QQ]+W?5/*+C"V0<KL6 ZL<$ZJ:"0X9G&,406%^Y]WY-X'0B!LMK/65;
MJ&/ER_KQ?M+">3ATU<KZ!K5A\P;+T2S2#)XGK8L]JSU_#710F."NX6).WG"#
MK@,R2X"QP<IE7;T9>L'+^IO"E1G2&)VY_7RKFQ==VG-D4HS5D7;4QF5OE\X@
M#))6I>=61M),(&$[P1 @OZN4DC2>R%+[_/V=J78Y BRJW5&*R:0'[ICA67?&
M'H;JB24>%&<29.575V\Y>#YKVIVLTC5[51&"NR]!C>TUV>N4 I0#Q @/E_RW
MJ+T#4B<_\Q!.&S0;](*NIJ7[WF@51ZL;G6!0(<>RKGG2PT-M\PKF;K<2:Q;<
MD.9WXT_U-MD)@H)1,*,\ 04K!5AFE9<]@/F7)IE_K:[CS%8VCSK)& @- ;TP
MXUFUHVP_V6_Y(/JU[SZB>1R4I95Q>G%T8&J:48_IM6A<U26GK.5^1X>78UIF
MYP2:NI LCC@'_-(C8NBS!$]8HFOF>[]5],"SM@.YRN*%ET2M7ODMBXG6C]/3
M"O"KH:6@#64N(9.J;HG>0<#9"8Y'[-;?F1 PLJ'./X#+4O>0[&C5=B">!L7!
M[6T$^XHE$2R5/CKS&0U $8$2APA*')H&;G-<RK6(X H+X68++ER]_T(7J2L]
M::K ;J2%Q8BOK7K0X8T[+.)PX-/>I\<=8#]D2@;,QK>L+,+6ZL' $]P2D3?,
MP6DRJ7$03C]6IQ@M&W>35PR45)E,VJ<L?K;#P0#2; ]7;_&B;5_;<I,TCP"
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M*?>V#15$)H*&GGZ3)-S6]47R5)R<(IS)="FKE;!2_W2E#*'8M 1M\"JDZKT
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MI;Y(S%NPV>E)*Y2B.JH#>:J-7#B/Q$1%69,X@:8TH"SEP8F#HX6\[U 3(<$
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M &0F*;]G&"9 3RB5LN0):A_8.JSGWI=C: *G8^[+,39C+KM9CD%$*&T$NJ?
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M+)$7*N,6-U'F#O1)_G-^\4:$\C8F:N=41^T:@]A_@#]N9I/Q+_\'4$L#!!0
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MOIR-%,;$2=<^[*XGL4).T,<$K^F#I$X.,^&8DUC/+3ED&IG$/F/"?L=A##>
ME7/T0JX2,\4(YC36=_1N8XX3A8,T$%I&:CH7-3*9"<>8RN3DLC[A;^"EB<FL
MT+%ULID1R)C.',<M/70:F="NHB?@0MF/(_]WS(B*TJM(@+1*7$:"B.=*5)7!
M,R8[1^:[_57&%JA(PJ(,%V7 *$%^YVW9SW5&6@58\[CKNK59;.0X//4\%H-_
M.9NH/>-JI*W*FL>7Z^@?*W+,I @H@VBNXVO4#\4(YLIAO[M>9:^2T,228<67
M=5+8!@ASNCIPMP^*1N:E<SH>$YVSN<S9YU1FZ&@(4>5-3Q...5\=.OJGM1PU
M2VAZ*LGAO;/CU=O2V8YF3FJ][GJM;62JB1G.X.0ZV:X$G#GS]=V*P^L]#>;=
M?*-^I=0[8C2@R>^4T3"4ZTH(97E+PMI[>#]+IY'_CNW:O6K\J_W 3+WZ96/>
M :1[@):Z\!XK]7G[[OP5T?+=>8^7-XX7?0KL3'K"5V<#9:E9_0?^#1#&PDJ6
M5NM,:B!+(Z%EJ,;34:.<,@(9*ZE.I[N^>[*)FB864<6N[=A./SD^>15YTCCR
M!'<AKG4&H)8"<^+LNG:_-*<64KJRPZ!S;4BI>T^2<S\E_E$/6/G>TF5(5NP,
M0G7D4E"UN<B()S]S!2.G*/T_G:C&M6JS-^B..9I<U[$K1%/2,TMW#2WW#:6=
M0VGOD*!HT3^D.Z;G].13VL=&AN 7$.JXOJQ>[D>80;5CD2NRYIEYWUE/%1(A
M>5I 8B -TES7UYB,BQ',L_!!=WU3<)V&)LZ_*]ZL=5"X&,*<]0Y=9_V4< $C
M?^_L]*F=?VM \CWW9@'U7H'T52::,/5(\_=KX!S@-EM^7:O5UY=X/ !V&WR%
M"*8XO$WR>POA@9P#L">.6P$.U0/2ZF4)QZTJ$!$)0S4RCEN"Q>H1:_4RF",I
M2JC_H!^"3EZ2H5[I$$MU1,1*\C^,QI/C5M*:"!BW4/+(='HE$C $=B5O*)#%
MJQ76S-6QL#9'GS*&Y=)4-3U[7C2YP\_JTND4,_\.F*JW\!!N@],HBG$H"S"F
M3+V*;F.A^JS>%Z2GVXV>>B/MVYWLQRQ=4);R\OP5/ I$=:2$IR]GX,6J/KT-
M N(!XZ>1?SF>A/09@-^ "H]E/R4]3=Q42O05C?3I&).HA(U%D9^+^-L(S*96
M0=@%B[-Q?2Y3D'HF^8$1'&Y.#9N:_]5IX)I&PP=@X\7I@RTA:1#8!5KT*\6B
MX3F>$*$>==] QVJS"C0DMP;)\^FRCS @U<@9RS6/P.RYA#7G0&7""R@;*V4Z
M 9K9,0CL CLW>/(HZQ*S#2N-=J'?!4$_/W6W*+<VUP4EQ7<T"HM2\W6Z+?V<
M3L[\(H;30 ![&#& _P)FE:JD,G#UO2,+!/_UW/.%1NI!U;Q!Z;&(S?.!4:A*
MS+]E)*S79(N*+:M+9(DBC<N^F8=Z?;R=R J;2Q8UVD]GA%]HK!HUSRK KMJK
M#R6&X#] )$?>:1C2:?)"P J#?R/&CN;#@DUNM1^]I90W"^T"O]E*Z@*R%54^
M-V\D=;O@KB:T$B-0_7W! $[$?P*]OCCRR5B]&85J,O,VJSWI:%C"XM5%L^YS
M-NLN5M<;N2XM_SHKFXDLE'[&>O1A2E^X'EU"V(7!FY['_ I<%DO>2,Z:%_ $
M(9WHN71^<'H3J^6D=[4$NQ=X+!<]ZF!'!)X@7BRV%!Z;!=Z43+TYF;P^]>3#
M_P!02P,$%     @ 93BE5*IBH-J+%   ]L$  !4   !S=W1X+3(P,C(P,S,Q
M7V-A;"YX;6S=75ES6[>2?L^OT/B^3L?8EU226XJ7W%39L<NQ)W>>6%@:%BL4
MJ2$I+_?73X.2;$G60I$ =907+=31P=?H#XUN -WX\9^?#B=['W"^&,^F/SWB
MW[-'>SA-LSR>OO_IT;NWS\$]^N?/WWWWXW\!_/N7-R_VGL[2\2%.EWM/YAB6
MF/<^CI<'>W]F7/RU5^:SP[T_9_._QA\"P,^K?WHR._H\'[\_6.X))L3EO\Y_
M$"QY++* 1R5 >1DAZ)3!U*_*)N5]^N_W/Q1TUD:5P$;M0$6GP&6)D!EFZX/3
M,;O52R?CZ5\_U"\Q+'"/A)LN5K_^].A@N3SZX?'CCQ\_?O\ISB??S^;O'PO&
MY..SIQ^=/O[IF^<_RM73W'O_>/77+X\NQE<]2*_EC__]\L4?Z0 / XRGBV68
MIMK 8OS#8O7ABUD*RU6?WXIK[]HGZF]P]AC4CX +D/S[3XO\Z.?O]O9.NF,^
MF^ ;+'OU^[LWOUUH<G$T)U5_)+4LEI^^3[/#Q_6IQT]FTXS3!6;Z83&;C'/5
M]2]A4L7XXP!QN2!A5B]??C["GQXMQH='$SS[[&".A3[[N/P$5>M,GD#ZQQIO
M??P5=@J3=#Q9]=(+^OWTW15>#PGPTQ+I/T[Z[0S"9)8N/#2I6IO-S_YS$B).
M5I^.CA?P/H2CT1_+6?KK8#;)-*2>_=_Q>/EYQ%$;I5*!)(GGBA4&#GV";+.*
MB05NLKW8<U6Z!8FWTG8)B[A2^6D3I'K!'^-DN3C[I'8R!\9/-?^/Z[&<=._F
MTNWG/*[Z")/789Q_FSX)1^-EF(P<9LXP) )A:'C*'"$JQD#2R!8Y>A:*["+B
M-8 NRGF.2/OSM#>;4X>0K7NT]Q&K93HU>R?HPCQ]P["+@^[TB<>+X\/#U3MA
MO,3#L_^O-K I(Y:S]BHX43<)LBT?GLP.#V?3E83_$R;'.,HL9J93@A2")LG0
M0V0V05#:>\-BD9EU(<)E).LP0#Q,!FS5Z<U4_P:783S%_"S,IV1_%_N)'(/:
MQYB?8AFG\7)DK$G690[6%ZR3=B9</ (RH3UC2D@KNI#A=FSKT$,^3'HT5DPS
MPKPEAW%Q//]\CKA51O2L-HP65 @1G"P1?)08BLLB6=^%(-]B68<0ZBLAX"$Q
M8LN>;\: <TQ\M3S .1FRHSD>D)<V_H"_4=1QB"]FB\7ON'Q5WH9/(ZV<#-%I
M""P' EEJ;) 3H"N1N2C0H.KC5=P-Z#K<T0_3F/1463->O2;=XWR.^1S!>5#2
M9$-AHB26*VDM1,<#V(2,.RY0".S"G2O K,,/\S#YL6W7M[,MBP6%=*.2A4U6
M>-!DP4#YQ"%ZXA^YPS;3#QZ]ZV,R5NUO[U0MEO-QHM'V)"P.?I]-TS%U[G0Y
MLH:KZ+TG]3#2D5:>QI45P%!FFZ1%S?K0^3I$0XJP-M#]MTY3@XYO3.8GIQ"H
M/2F"*^ ,<L+!,[A0"F3.M4J:W#7;*;@^#V-( 54#A6_>Q<VT?&)^7^+R8$9Q
M_ =B8%U878R,T#)P*2&GQ$ 5:< Y1994%X)9O'0F=M'W-8"&%"LUT'R+;F_&
M@953=2+4.:-#4ZXUZ"5PIPTHKB5!B1QR%3<YU,KH+@RX$LX=0Z.AZW_[+F^G
M_2.<D]33]R\H0,,WM?]>E7<+7*$;D0>=!=D?L%@DJ.05A*P4)%.BX)(Q'E(?
M%MP$:TC!3@LV-%-!PW!F1J"6GU]/PG2Y/\W58!U5&T51UHC<$7+++;GH29-M
M\CE#1%U ,E^$*@+)9G6*:ZY'-:0 IP$GFBF@&25>AOE?N QQ@G\@6:SQ<HSG
MC5?6%&2S%*%8BMN4<@E"<1PX]U:XXKS/?3S$FW&M0PO[<&C14 F=(@5# 7;D
M4H,38;6J1Q"")@@>LW4V!*7*KB.%#3:5* *C45>_U9'W(4RJ?[:_?!+F\\]D
MJ4]6&3"5C"62NZ8DN6NVKEH8-&2:/;H0O3&ICZQKP1M>>+P)1[[9>6JNF:X6
M<H1>B\*C@Z $.7620'@;/5@M#!=),5/XSNSB\ +H%I38NM];K@(?A7%^]NFH
M'OL@FIYS]$?18139:D@J97+DL@.'T@$7UKA<E$JLSU;D3:B&%UBW8$0S/31C
MQHMQB./)BIIG LJBD[-,@'%*@Q*(X!U9JR2,YH)IYD*?V>-;+ UVU6;'9(9?
MA\]U&)Y)Z%QVNHX\RV)5(4'Q+&12H<G&%ZX1^ZPA7(UG2!/BEGRX8H]L6P5T
M6E$X$_3S&29MG)>^D#E>#3_'"YEH1P+KD+T10AO9:6'I1EQ#FAH;DZ.A0EKN
MP\^/,5\A*9'4N42NFW=U'3Q0C.0I;H%2*+;AO"YY=-MQOQK2D.;(]G:C@1IZ
MS)(C);5.A6?(1BD*DX,'FKF1HF:7C)4T5]L^6Q#G0'28]4UP-1(1@,%0B%Y"
M@,#H2PZ*">6CMK+/.LEFO+Z'^?!.FK],Z"U[O/<D>'ZU/Z'!+')=JPF@4&9P
MT3.0&%-ARD@9^VRGWPIMH%/A5KQHJX\>!H^BE"L.QCC!BHI"0?#U7"VO49"7
M"$S5_2"&,90^!_=O0];2U',596&99C!&89GR)4),=14S,LF-M;NPB0,UAMNS
MX@8+>:>.;WI@?WRRX5T7\F;3.BQQFBH@<C83%\C ,5U *8KWHR!H(JB<3&$^
MZSZ3_@V@!FH.VS.CE6*:,>4*^90I0D8*84LHU4IK!I%X"[IDQYE@O*#I0I#;
M+.!@PH+VO-A2#9?H\./CR_WU@GYOGRGXQY*^KL@\*Z>S/_WUW30<9^K+?!'=
M%KF#M[73-YOP3E(VRB_\XDN=KJ\N1M*60KP*$'TPY&)'A* I;,00DC-:1A<[
M'Q,Y@[*MR?D5I_3&"0VB_7PXGHX7R_K^#WCZ_I$W+$<C) 0GB/B69'9(P\JF
M$)E. :WMDUQV"[ AN2_;\>.R]6FID8:99PNDU]2=R*?X 2>SU=F,,TA1>E&B
MTN"-\34/TD$,3%$H0=;6>AZC[+/G=R.L(?DQ;2G23AO-"$*!Y>Q,QI,<E3,X
MQ646(H^D0T=\C<K23.PJ:2VS03.F=9^([EI(30Z0WB"PB5X9+L":DLGU8!18
MR^0@"Q-)+5%KWV<TW(QK2!:S#5NN/&7:1B_-QL77T\XG8.IQ-N?(D]0N 9=*
MUOH;#ESV$@0YJ(S"#L]+'Y_^"C!#,I)]6+&M!MJ92%Q^S=X;%9VT0Q4H(J$H
M4V55P&F,-!-DXQ@C0YWZY.%>@-%LV?><9$YPJ[UV8(,7H*@[P=>3>?2K<3DS
MRV3GA=[KY+MGH[>Q_J]=W-VPUW<PZ]L@=2R%0S%5/),\N$*A<S#<<<.3+2S<
MYZQ_SY:N&17::*#A='<FU7,2^KJT'\>9$U(PL(JD5C[5HTXY0DJ)L5@"\MPG
M?%X+WI#6N=H1I;UFVN\=GA,UA*"35!Q$K"=Y7-;@8E:@I5%!*Q]<IWV@6R>1
M%NM'V6!6U?<4RI'ZA*%AZ8VFH:J,%SJ'S/MX@+>L']TZ0?:MP;$M$:Z=)S?J
M^ &LXUXH_5"[H^]R[@W-[6Y5=UV9&RWN7E%=XTME#5%01D7FS_ELZG'""#[4
M_7CM(P8NK'=]YJD;0+6-0DR603HEP%M#7B,R!L%J17.+,S9$YYSIL[Q[0Q1R
MOUYZ*SY\XZAMW.]M$Y]OJ2;S>C9?=?QR.1_'XU62P=O9Z[ Z,:*"L3DC&<]2
M=\\U1P@\18B<$!OI>,$^/OV6P(?D^?>BURYU.QA">JY2EEY"28[&CJ; -RCE
M@&M??)1"(^^TTM"2D.WZ[=UTCF$R_@_F?\TFM9SPKV$\K9A>3;]F"NW/QPOZ
MT]/C.CV_QOEXEK\RD&Q/9!Z!T]=:2LJ!3T0%*:+FG)GJ->VT0[>5:$@SRR[9
MOJYYV"ECAN!0A\7!\\GL8V]'^MMF=NA WR)C(\>9*%!;>CV??1C3VW[Y_(XP
M_39]/IZ&:2+@^VDY_G!R[$Z4+(OE$9C72%$7D21:8<"1NT-A';I4^F0"KH^Q
M00&)A)A7BRNK\T.OCE8G4YY]PGD:4ZLC)S$'CAR*JR-%Q00AB4(#1Q?GI4,1
M>J5#W@)M2$:R$ZNN*#?14%WM\FG#Y]4@?H.K\H]O9V1B_QPO#PY.C//SV?R/
M YH,?@FKX7]8%S56G3HBN94J6H-1@A%:3."URD#811;TDV*Y#[DV1'Q'G[SO
MNM.N2+<+[;8[MDP]<JGJP,6*??O3?/&#<T^>> GD8]0RN/@43[X_^Y0FQWFU
M'I<.PO0]OJ%^>%8*IN4H>X,E902G4P!EA*,PR!N0RF;TP2G%.YV$WJF<#99O
MUJ6J8RQE6XLG)B'(-7,"?%&*7#-?F',>C>^36+CIK'O/"S_#Y?L5:TD]2-#R
MI,-5^$XVFB[B0QM2T-E P;KF(0Q"*!399#)W0OL0M=FI:W@%QD$M'SUXDFY+
M@MXD_;)G= Y?DCJX>A-2#,92Y$W=$)770&/($VSI"N]TA'%MC$/:M'[X)-V6
M!/=!4LL8"XEG$+R6-6"!@<])U/1.P9F0+,M.)VXV).G=>^,I'LTQC4^<XEK6
MW%IO0=I,,YM49#1J.JO**9K "_5%G\7?\RB&Y,!TXLKE(;.Q$EH>,KI@''Z;
M7BH',Y*<&:^#)(?'U.P]E! 8:9)3[!Z%<-VX<2NT(3D3.R),6W7U9=&EXB C
MQHJ2UD>P6M9<"K00R1L!=,QR9RPRVV?F7P?=D.;\^^32-DKK2*>3/9>3:@NG
MI=@$]Y;LHZ%H+"I"YCD$S@61("5,CBQIZ'/H>QUT@[J.Z=[XM*76>O/I:P&/
M\XRW6@F9,TW#V6@RH)9!$"*!<=&BU<[A;GEU)<HA53&_7WIMK\2.-#NM)?GT
M])*AJVM*"K3<UU.9QM1BE9S\OD@V%WARB2EC4XQ]5FLWPWO'8NE_4]/67+.=
M4J.R%UEF:X%)K%<E*@'.UN)'140GR=ZJN//4J/NMI+XCRFRNAG8E4*[> 3.8
M.9G&"-2N(=MH*$)0U4IRE7-"F]#TJ1V[^>ZE^WMQHX%B=IQE5%),-<L>DJOY
MO@QU+083R;!E;TO6EG>ZTZE9EI'_^TU)C?6V-:7JX:XKILJ+5?-&0>2H V9(
M1J5:,C92!("I5FP@K$XY$RX=D__VT-A:+:VUGLC^'I:E?=>W80-YYU7LBQ44
MS[(JF19,R2@ :Q:1BI)#S,%!R<QA-#Z0V[06$VYJ92T6_$V6E=MV^7UL80N3
M=:Y%!7WPI1;N#^0BV0Q>:LY5="R4/EE"FVYA;WFZ,4QJS/ R+.OQX,^OROZ'
M,)[4==QZ@"E<N)3":4S<2J3!:U@MFQ;K)IVKI6BLE3K['/L4NMP0\ /8SMF6
M@3>>A.RDVN;G(]_.]A-Y#W.\]MJP4?".T&4)7,=:SYLA>",59,D4YSYC,GU/
M1-Z.\2&<@6Q.MSX:[,>P*R_;"39'E5B$G)T'I2GJ<9%IBI1UTL4@_:W/E==K
MP;OCOM#?DU=;ZZU_MLI5$)_2!^/)8I.LE)M>URS[9&W,C;),+L] 3S$NSV4F
M'=9\J?_4-8G%\I>P&"]&4BM>-+=@ZXZ-2C1#Q8@>:G6O8EARK-,==7=%NO6-
M(M?.S1=;'NFH!)>I%O&P%$'Y6)=H+(>ZIZ55,)[Q3G>9KXEP2%Y75[Y]<QM)
M#Q6VN[+FYJY(Z?CP>)7(\.M\5:7A+).PKN_\@F4VQU6"(*?N8#'1W(WUV%RA
M^-V3$,)(*51=-8Q]2ITT@3^DXSKW2LW^RK]WWM;4UZ_0C1->,D?>IV<TY)A6
M$)CD-.X*=[$D;U*?J+X)_$&Y@ ^"N)MKO[^C^#R,YZM[7E]B6!S/3Q)]M_ 4
M;WQ?,U=Q?=2M?,75#O:79I^.%VDRJRV/5'$)E=! F@OU<J^:.E\5&TNVZ+$(
MW<D%N@Y2N[JR5PJ<R27P/)1:%;P*G!-$H0P$U))9Y6+6?7*_;L8U*$^O"5NN
MKS:[M5Z:9G)^>X7T5?"8B]R[8@!9G:^E9>#K)1H&I8DUSZ&H/CD$:T,<E$/6
MA4%]M-5F:^S%;/K^+<X/;V$YY]S*4A@8Q13-WQA@1?I@+??)1J,NES>\9I-L
MO?:&= ZZ+2=Z=7I_E^7T6/99X<4MG)5KWM3,35D':2L'Y=K;1QV+1 8T$+%6
MN:RWDSE.'J]/@6MCG<RV3QKLFI? ;BSKZ_FLX&)!J@F3Y_A58.:TCTQ&<O&9
MH\B01D,LY/$+GK4IT6;>:::Y&=>@')0F;+GF!MP6>FGFH#PC.S#[C'A:&.,*
MB46*H40?H605R62F#*XD!=(EAS0%4EC8YTCHK= &Y9!T84Q;[;1Q1$XEO?$B
MG,6HY.(CTD1HN:0ID=4[OZ5WH%V.F:/V/)>U_)"UFAN4&]*4"9VZO&T=R>M%
M%H6%E%P&9BP'50NH!Q\X!%9<L$(HEOOLUMZ,ZX[Y5@^(+QWTLHO:@5]N PV7
M;@,]/1!#/\W*E]L6)O6,VN2K5%NXN*V:;EACL$-?-'*B7Y#;@GC-_=9GQP">
M'N.H6":RY1IR,:9N]BLB+1.0O:))25@>>)]AOR["K:^47K.=WZGGWW[$R0=\
M29H\6-WRP%B@4#19LL\*2X88I05D=3W!*=.K6MRFB(?DEG?AWS>75N]"M8W6
MA-:$NE^6.']+=,+_)0=BQ#5SUJ>:7594S?DO$)TL]9I[GDP2TE^.>*];(]JH
M_2&Y[5T9M2L=-7/FUL5:$;[].!MID;!H(4&K6CS", G.DN_I@F=)D0 E]*GU
M<4>@0PH/!F7#-E'D;MGV!@_#F%R7^:OR?+P@U:U&A],^>'*-:4P87F]P):?8
M$%-XE,P$QIE5?4Z:;8YY2"''<#BXO7KOQ_A5.ST*5A-*BV"5CJ "Q=K!E02A
M2)KSM=2NT_FJ.T,=4OV'X9!O8V4^F(AX=.E6W9W&Q-3XT*+BR_VQZ[A8V&29
M#!983=I13-:K7AB#;'4IT3G%.I5<'41<_&Z:R<;7\F-USR_1H_N'];<1:JF2
MRXR\V[HKJQP#I[R%H'W,EM7+5/ML,6P$]T%&Q'=AWIV,:1.EMK_/\E(JLS66
M.8_4.JN)K#*46JB406%<I6BB2YTV>:\!]"!CX&TXU$(Q:TZ[IY_7+Y':^OF[
M_P=02P,$%     @ 93BE5)L/:!8W(@  /W$! !4   !S=W1X+3(P,C(P,S,Q
M7V1E9BYX;6SM?5EW&SFRYGO_"H_[=5#&OM3IZGM<7FI\CJOL8[NZ[SSQ8 E8
MG**8ODS*2__Z"7"192X2*2:2M.0758FB,[] ?  B$ O^\5^?ST<//L*D'3;C
M7QZRG^C#!S".31J.W__R\,]WSXE]^%___-O?_O&_"/GO7]^\?/"TB1?G,)X^
M>#(!/X7TX--P>O;@WPG:OQ[D27/^X-_-Y*_A1T_(/V?_Z$GSX<MD^/YL^H!3
MSE?_.OF9T^@@BTP<2$ZD$X%X%1/1Y:<T43H7__?[GS-88X*,Q 1EB0Q6$IL$
MD$0A&>>M"LG.'CH:CO_ZN?P(OH4'*-RXG?WZR\.SZ?3#SX\>??KTZ:?/83+Z
MJ9F\?\0I%8^6WWZX^/KGM>]_$K-O,^?<H]E?+[_:#C=]$1_+'OWW[R_?QC,X
M]V0X;J=^'+^^ %^?II?_\"H:]6C^1_QJ._RYG?W[ETWTTYEZ;A3AP=9OE-_(
M\FND?$08)X+]]+E-#__YMP</YB/G)W'2C. -Y >+__WSS8MUI,/Q]%$:GC]:
M?.>1'XT0\>P)TR\?X)>'[?#\PPB6GYU-(&]%OQ2Y@%(%SM_+TQX=C.D,@4SB
M14"2#)&QA> =8MST],,Q7SZ+),C^8C3M$/'ZLSO%VYS[89<#O/;H#M#.'D3.
MX3S I$NHWSSW"LXER%6$Y9'MAPFNL9]P/6RGGW^*S?FC&<8GS3BAW)#P?]IF
M-$QED7T[Q9]EU6V;_';:Q+_.FE'"-?O9_UP,IU_^'/N+-,2OW2Q2^VGZF92%
MF(KYU/_[0>^[(BIR:C@>EF7J)?ZZ>&F1J%^AX?,4\%GXZ3#]\G!H '1TTC#E
ME*02@I)9B.QI#-H%Z@<'O;E(OY1_U,1O@(S*HMU<LFSD XQFGPXN6O+>^P^#
MR[?@@,$+_-]VX(T0-$M+C("$FV%2Q%OI24K.NIASBD&N<[1=<C[[-LQ8NG@%
MLI6S1S":MLM/BNX9H6RQ\/]].Y:Y;F\OW8MQ1 .AA:<P_^^+\?I(OFE&H^?-
MY).?I$&VU@B*FWBBV1&9 45W&HBEQFO4(MH"NHKH>P+]=ER^LO[Q9#E"B]7F
MELM1L:$ZY<FTZ4\Q<W*@? \?-!-\W"\/Z:$\>GOF)]"^:-L+2 .JLDH>C47N
M52!2JDRL,Y%DYC(-W'D=;9WY<05%_PRHJK*FH_%>UST[6/=K4@Z"8D9*$4ER
M 1$I2TDPAA.']-?&<V"BSC*QCN6.\^"PL5]G S^4#8_3_[MHI[-M^5WS.*79
M8/O1:S],+\9/_(?AU(]F["T>#N[GYQ]P8Y\Y3F\ !6AQRWX+DX_#"*]A,FS2
M&XC-^[G*_N5'%S"P7'H?523!)H^K*A+=,DE)Y#90EAAX0ZMPJ[9D=YNI)\6+
M==Z+3E;!^8+\]**8SW.8\X7Z#;33R3#.C%;\VN,RFK]-FK8=B)RRU0IM!)\R
MD5%(G*T42 S (5$IA-W@[W2U4NZ-]VYSM <=KC-/]LX\'*H,Q34:>-#,,*V(
M% HM5(.6@T.;@>C G!6:I<3%:;#O$O,/!G:@RW46JJHLG/WQU8>BI_;99YC$
M(:[Q PN2<^4LR989M%LC(@XX>4P,PCLJ8K*Y?_9MQ'J/67>X[M;9IBNQ;68)
M; :L<O!>X7R(CFLBN<1%&M! 3E0EP+G#9>9]DFT[U'O)M8XTMTXUT\W11K%3
M4?QW_O._A].S,C(('3^8_?7759-UP(VBTH5(I'6(67M#/*>2*!9$*G]1NHZ3
M<ANT=YQPM?6WSCG;H1/]!D;EL/M=LRMTQU207"F2;$)C +(BE@=/M#)&!LZI
MDG5VU0- WVT&]J7-=2*Z0XGX:GH&DP)H F<ESO<1!RHVY_ 2_9X_8/HJHQRO
MF\E,5U,T3L/%U(<1O&M>HS3CZ2 9:25.&6*2$6B9:HKSB%.B0O0ZZR!!IBID
M/!#XW29DGUK=<.!\<+0!,7X%/- ^*LZE)=Y3BU.$.^(9>&)!&Y]M-JG2@O<-
MC+O-F-N/^ ;]'QYQN!K],."H9"J2[,KIBV6<N.0Y25&'++@1RE0Z0=L:;>HD
MAF*9H RT1R]>>B(#[@$VQ(0CG;SFU@9OZBR=-\50#HBAORO+R "L5UIK]!VU
MI$1ZRXB-P1#FN!3)\>1%I?C@-S@ZG+%7$JNJ1X8/&,Q-P;\'\S29G^.H0=OC
MEX?3R05\_; 93^'S]-EH]L)?'K;P_GQM=SR #W-ZE9VH&1?SZ/'G83L05.@8
M5"(:+"?22%Q=<D9EEN-4:T 958OXU\#JD"W7I+Q=PYY;J'L;<PX>]@I1Y!5,
M3V=[X$Z@!BM)>)UR8B.L+O?Z;:F$US#A</4UM<:^-V)PW (I</3(#<5=W\>,
M&R-:I($;EHQA+EGWO1/BFUS-X_-AGR&OP .$<][,3=S?9Y;Q@*$]Y'*.B$6@
M;YRT),X )<P"?BK!6!JJ<& -2O_&?P<J:KH<WPHY9>^*5W,Q^7(5DA4NZ@B!
M  \ETJ51P,@2<<QFM(NIRU#'V-\ YBXH_= QKC#/M^2&+,!I!@%$H:.5Q8FU
MEH3,.?'"Z*@UF&CK&(?7PKH+5.ANW&MDE<5X<7XQ.SO==GBU!*J-%1S=9AX<
MNLW@T8$N54<.6-0^>(GF<QV"[ KQ3I"EBCXJI&6]@2G*"NF9GXR'X_?M<HU3
MWJ2<2N2:EF-U:TB0AI*$^UJDB4MFZIP9;L9S%RC1P4AO38[ZQZ.5@7F)OQY4
MP/.[G_P%LU/MMQ O)OA0:)\6"4;M;>ISKGM<5^4W.T->J:[ATLNHK+<J)>E\
M#LE+D0V.O0HT23ZX[L&'S;Y-3[YR"F:UD%8S8D).1&JFB14FD\2C$509IG,=
M^_U:6 =O51]QX,JS2U#/C^ IA.G7USP^+W&5_Y0H7SO]U;?HJ049N>=)D$"9
M*"ND)6AH 0%%@_%)!9[J'(?NB[3_5:H[_JQM8#6U5,$9N@'OU^UXEI+ZYQCM
M^E$1X#<<YE\A-Q-XYS\/A P)A'$DX, 17) E"A$B<3)0ZE*)F]1QGSJ!?X_X
M5T&?-5RU6PI1@HA7A.#*":"::!HDD0%',$C'2M6*!E"9!55G&^@$_@]2'J+/
M&J[BBA!7;9JKX@Q4L()17,*-4.C2*F:(4TR2E"RW@)]!JN0I[HCP+E.K$ZU4
M\!<WC< \\L9QL76!E18H)>,Y1DM"B=G2[(P'0476OC=KM=< =CU6=#/:IQ+6
M?CX<^W$<^M&+<8OO*X^<A6+0<0Y!2R ^!DUD"HQX"YYP0UDPH*)3=9BS!="Q
M0MD=:;OI?M0KV$;O)G[<9IBTC\=I7KB(/OVKO %M^PX?V6[^T^)<9A=9JH;!
MNY3F.-'S3FBR%CTYLHY/GK>1LZ!5)%KC$B&%,<1ZCC^,-SJ#M4'6,>U/GZ\W
M!/=/GZY[J+8"3?]\^UOS$2;C NE;"W)Q[NQR$"9$1:A6G$C. _%< V$R:0,L
MF^!C%>K=A*Q_J_YX>F\J*JW"(=N39O*AF:"#NQ&<<5DYK2G1QJMBI"CBC4PD
M2<]5LM+8P"JEFUP#ZQ[3J3MU54I7*A6,)9R.-O("E.32<<,%44Y$=):T)3XI
M3<!E7+@Y^KY&54M96H-SK[ESJ'HJ'%V]&'^$>:%8$7Z^WVO/."]UKTI1(G.I
M N FD0#90N#,.%=GT5G'<K?<Q@/'NKKVG^"Z]KZ9#/\SJP-<KFD[(*SJ!]Z,
M\3C>W:':O)8<G:FBPC:S U(;%2YB3!(F),(%A8L:0_,JB""]21 "U&GR<BRR
MW.!:]<^5?310PQ3Q[5G)]_GH1V7W7( 22ABK:2:1YHR@T)-TUC.2?3)4:I%Q
M;:UCBFR"<XSRR6[UMFI@'#SH5=IT-I/I.YB<?Q7^$AF(;"-(7&M+LI:&4M.K
M''IB+%+I1<BJ5L>*;9CN'"<Z&OX.EXB2R39XV8S?;T;EG<;%#STGAJ84D0$E
MQM70D:P#L]88<*OG=^NI<=>_XL[HN,.1W&I;=I\&^=P/)[/6.[_/Z@#F[;0/
MR(.\]GE=)4+N#GHE$S)D$(P:SZ41,DH=DF.HB<1*,90V,+CVR0<&!Y>/?MRV
M,"W^[\NA#\/1XLAB]KKT:ORFN#A%:OS"'\UXLOQUEH3V\DH!,94912#::49D
MLFBKX/)!-"XCQH%2VM;I9M6I&%T8-OB"E:WV$N+385O"OXBH./8LZAB)L*DX
M]L&3H)4@WGNM05-G6)W=;6>(_2^$QV/D)ENI>SU6L)^NK.N;T-ELE991$\5!
M$>FB0.N.)\)C,$)(87RE@L3K<=UG:G6HL1[,KHV4SQ#!.8.8A".2"T.L0NE3
MA.!UEDJN%C3M;H/]($M5==3(;IR-T29@3(&-,M&""5U+(32NBBD1D Z<SC3&
M4,<DV KI/E*I6SU52'#L8HCFI^\.0F;1>N2_09<52H"-LM*A4S.4(\ELZUR#
MTYD(?250G@XMCZ/]DTG07$K_ZY?+__T_0Y@@LK,O+^$CC.:GP4[B6$J%HH52
MMQ@<<8!&00;)N&$X456=XM#=\!TK#G<D[FQC<'<ZK'#DOO$@81WO,I"] ]BJ
M8;V]X!XI?[."WK=1JYK2CL^TS(QG+A#NV,QZ3<1)R4A,AN<4)+A<IWW&"3#L
MIHS+DR/8'KJJ2:P7XP\7TW8V FP9_):<2YX,H<XD(CU0XG %+^MYMIZ[$'R=
M.M)K0!W1V^A>G=N(<Z N*AR);8+&%] X6"=%CB3STL*T=(ZQ-$4"F6KA)$"N
MU)KU&E#WC2:WT45/JXGX&OM,2N-JFI5U)=QFB#,R$N%]D#$PS62=5.UK0-TW
MFMQ&%Q6.MZYLPE>&X?D$_N<"QO'+; =.@EH3*">1QG+16W+$E[3/Y+2VWN>$
M>W!M]VP;N!^^69?:JTFP30 7<VL7B+V[8RL@C^Z$=:/@'0SD+K33D]^U"C4J
M7#.-\20R!T1JH]!7$#BU.-,!I 55Z8*SHQ%H=Q_K:/S91RE]^>N7Z_*R\VIR
MS@7PQ!C<XM''+/5^BA.KO4QHJN'/RA;1->A.PS0Z2*V[^.6'Z*1&;=K&'(G9
MC%&IN'HA$BL8+[F#0$+$7[7D2G#A/$ZG'I-;?MA!'>FJ2CO,Y16BFS%N_G0Q
M W;!7M4N.@3]<0RFKIBPUFNS9S56V @/DH%GD[FFM*1+HY% :3F/]:5EJ8,B
M@K"\3L_$TZ/@#2;7*3)P'^U58-[OS1B^S*L*GU^,TV7QN7':.DB$>4\1E:1H
M>&I#C AH6 CF.*\3&]F,IW\SJS^=KK:!.EPAO7<#H"I*[0"5J1W:!X+F4LGC
M4;<:168Y4%GG;/O$N@$<C33=J:=Z6>9LM0TI!,_+B7MRJ52 ()LSM\0D"RFR
MLA37R<\[G4KNT[#.#]3-UB;E58MX=T'XH_+[%MK<OYKW-JHX3N5W:1254X[$
M)V^)-#F3D+0G.B0>9<K!RCH9FM]/Y7=MKNRA@6-TR1)<&PF*$3W#IY0GOM0\
M<JV2P.T3?*43ZM/KDM6U-O?M?;6/*OJW=BF30>'D,$DP-*=PKEC/RCFK-#*$
MG+2MTROYQ*S=RB3I3@F]=;02O)RZ.T#=(7<E2(F""T&2A."RE])5NF_I1#I:
M56?$H8/>8S7YU['PX_0O/QD66_W%> H3_/C9>#J<?CF@MGR/IW=5:7Y;@5;J
MSF.D+EI>[DF+,DJ<Q,& =LQGI@5H.MCC/0<V (EGD"Y&\"K/+X#Z':9G3;I2
M\O;RLLR$4BHH\T"$=^B12Q.(!0D$W2Y%?0Q4Y4H-07;&V,W5LJO/?_5I#)/V
M;/CA-4Z\HI+W,%".:0<F$\=SR9Z+D5BN$V'4..TA)@IU!F-GB/VO?)6XM/DR
MVJZ55*4XO%Q[5^[">(YCM65,!AQP;38"B)E5L/M2/VJU("XFY811'+BIY)/M
M ._.LJA[Y52PL+;!\CJ[P*,GUI0^A[PTNM2E@PQHD%[JH'D=&^N^L:0+!51(
M6KQ1^OFAJ#51NIQ$,2QE.12E)# K"!H>0E&:@S)U[IG8#5]?U;8]<:6"4HY=
M)]M.IC>*M?XIP!_^?'F:)@*3$?V;R$L?15PZT<>Q)$>>&*#<S.VT4"&0*^S#
MWU:9=RC28T5 :I"F.8+RNNR%@KBWX5KD]NV";)_@QT[TNAY3O\&.?G7;5%5,
MO]0IB:":>D,X]Z6>!;':F P)@CNM@G/>[Y34<;*4V1+R.%7&[*./KALN_>X_
M_'4Q65Y,GE3$/9[1<H::B'0<$(E/Q67,+$B.PJ\X8EOZ*GWSV/Y,XZX'N^ED
MI&HTK9WZZ<R^>3+R;?LJOYTV\:\91W6(T3 *A$:.VZ0*R-;%)71>R<"E]'6R
M +="NH-V1;=JJ. =7<6S(/XNB*IF2ZQC.DYV1$=*6PU*=#/B-6)4Z\@ *9^T
M8$130&1&HQ<O-2>66:LA!)LK72_<%P=N2'KHC0+[#'0%U;^%2;FD^#6J$"83
M2#-HR^[+ +C694Y4\>ZER8(XFC5)3%!C#5C!ZM1370.J_T.T0W6VNB%T-.!;
M38;N Y0EFCJ<;XA^G)XTXRE^"\9Q=@WQK0.3.SRUJX#DO@*L!"(5=9 D*AB$
MEM)$FYA4F6;I@05-\V"'YQ\V2\L)_#>/_7H89[72.3M6FJ]&(B-CQ(-&C\-0
MRR./1LLZN4C;,1W6WQ7:%N 56G&^//HE^!;^N"C3XU5^ V/XY$>O/A0>M(-(
MI1-.6O2ST+B65J.-;G$ESF6%ULI0:ME.OLCN[^Q_^>E(]=\V;:TSQA6\F$U(
M%PA+U]F!S[A4)EMN?,CHJ^FD$9[AQ%.3O 859*AS2\\-P+Y[GM100.>MH#=@
MFZ5]C""]@[$?3Q^/1LTG/XXP .IQU@=#DDJ,R!+J]MD)] 6XD8ZJ&+B_]5JQ
MY:7?/0FJCG*'/NT,Y^/Q^*+<=Q@G!>&+\0SH:_]EMBU?R7?(F@=G,R.,,C3>
M<C*E\U<DV7-'A4DL1KL3$W9\X=U@08W1K5"I_1*']OTLB_ M3*?S -^SSQ_0
MZ8,!1\O<HU%-&+<HNTJ46",%4=8$8X.A7-7I@'0-J.^>'%T/?(4ZH36)YZ=Z
M.NID=0Y$*SJ[-9D1RQ,Z\]0Z99B7R=>Y5'8SGK[B_+7T?_@@GT(<_PWXT;.V
MG/T\'J?',5Z<7XSPE_04/DP@#F<$?PIMG QG]O&K_'K2X,XXG3?A01N9Z40#
MB6%6/IDM"0*-(:IX$D88:=).)^L[A<T.@GJL$_<N:-(<0UT=QU]W 5Y"4E\1
M+X-3.V#N/*A_6[3]A_M[),2>-.Q,FZ?"1"$%Q "*(%!-9,(MPT=5^J,JQU@T
MY73@CC+PFNR![XR ^RBQ:_?][=2?9WP2[@=CB--AO)@N&QSPP'DVD3A:&AQH
M#21 !,(#Y6"5TK!:7[G%1=OZBGX3#OI13]/YV'9XH+?U*.'*85*9 K-I $;(
M;)DAWBF!YH#5))2;1 V(!$EQ99S:2?\[OO N6$.UQK?K8YH=,"ZC;#N@W&SJ
MW)X-1[%;JJEN3VX<,.Y]'.UN1NNIM(C%$^L]3A;+'?$B.J+!< @Y.:=WVRN.
MS(YM-L6)D6.?X>Z1%/-PU:OQ,ODNN*25M9*$*"*1S)82!9N)<$8#UUF8</O0
MX.9W]FA25%39CJPX9+Q[M"KF,-]]:I85X%YEY17#"6(9D=E0XK7+!(+U0JAH
M@SK8L%AYYSVDQ>W&>^MJT7U"RRSGYE>$C?;Q>3FCGEG@G#(WSP-],2[AC.%'
M>#WRXP-27&[UGJZ27@X7<B4-1OADF3<Q4U#2!VZEXX[R6/ZCM&6#6[WQP/2U
M,S^!M5<^GDP\FM3E,/C7+U^_L@A7/?[D)^GKJ7?6WH2,UK9AI2E:3J4%=I#E
M=DB353&X8YV6A(=C/\S]ONWKOT;[7N75L."KBVE;NC$@(6=L&&CCC3 ID>AP
M8"4X3AQ/C'!IG80HDEOMLKW-E>\#[A%*=/LE\+>'!"?'@!IU$+<5<O;C7]"6
M/0X%'C:)#2RS*K+("&Z/I=L4&CS>J$ATBJXD."1)3VRMV"#%O2'YT2E0J9U4
M,Y[-K"?^PW#J1S/H[1MH8?(1TO-F\OQB>C&!%VU[,<O)80:<=#X@S*C*G5>E
M'W"I;A+..B=Q%KHZ#9KWAGKOB%E7F35:*MQVO!;II+_A%Z?MB_%\,OTV:=IV
MX"BU)?. ,%EN"$D>Q\XH2H3!;4(J9IA@I[6F;A?FWC'XV(2HD$)V:Y&63DX[
MG5S,TN)>3<]@\N[,CQ?"EIT$TE+8 3=%+,:)XDX0Z7%/";E<2^^LI5:E+'2=
M?+2^)/PQ&TZ!.A4RZF8[5MF3(#V]F%P:1_/-:_;'!>QGGTL71A1V (ZJH)0I
M%TV5/'$%Q!J- XR.7D ?(&=9IYYP?ZSWC[9UU;E.0'5L.V0^G1Z/4TE1+;<P
MO&O*1POY2A!V7@XS$)ZAA5]N_=4EG1D%Q;TH,.(E%59);5T\3>-D5PGO']E/
MD3KK4T0?.D5*448L22:;!5[F9D.T(3(JB,TAE/H=6_KMEALD TA(U(=0I]G]
M;OCN'3TKJ&V=7.;@EHOG'T;-%X"WZ*8.(VS&^D<S[ZTR/T9IWS7HWU[]^Y.F
MG?[13/\O3-] ;-Z/A_]95$,O:P\USA-6\F"R%3B."23QX"*A,2IT=X7AJ<[=
M+[V(=^^H?7JD69\9]G1GQN63YO]HU4,84*G9K/9.<5,JKV8=?9DF"9>*D)R)
MK-*U)4<3^<<,.DERK<\J=[*S:N[I/&\FBX_*]UC)9HDTB]+RJZ1&1 'X?R$2
MIT/,UBA0E>[)[%?.'_/G=&BT(51TO-#G8M9?">4N?!I0,:BH@:"!27%S+:GH
M4FGBG*&1)^UHJG2*T[4H]X[[QR7#!GH?WKJJVFGKY1*PD#3I"-$E30Q-9=Q-
MN61*)>(\#XYR%62E$&IO(OZ8#B=!G@W3I,,V^#?*W&X3>M$'4VDMHK-$ZX@3
M/JI O&:"),8M&'2NJ*[3;*<S$7IKIG]D<A]%Y<>NWU]*7[)++QLR.ZT]UYH1
ML#H3&9S $62>1.DBI5Z%Q.I<0705Q?'[V_;*@Z8C?51(GUIB6>3 [X*F:L?;
M;_$<I]OM[?6S1=$'#&Y]E7L!(I>(3#"VG)<CIQWZ843DS'D,S*E0Y[J7/E1]
M0U/;6IK>9TR[+@K;4%I0*@Z6'55MDL8Y0/<DTY)\;(GUTA#@(@9.4Z*P6[.O
M:U_3O_5\B *:*J/7=577$VA>PR0WD_.2^#C;BI:-]3GXY!W'"18TD50)X@-Z
MH(9"MHYI([S<2:=;7_']ZK.;4:MR[WJY2>ZRJ_;+\@_*B):52#BP694>!$J6
M;"9MB-,^$RTRY=(8&2M=IWT-J/MMLG6EK0HIR%N@+1MF[ "NJD%W+;SCV'>=
M*7,WDAR@B?[6G05(1K6*3BO"@D ;R!I;#N<IH=&[R*W3?+71R/=+DQMLP^.P
M9!\%5&#';S"&B1^5KCSI'$>YG9::YH^P2+-9MLP165B6;+D<%T$FFXGSD(B*
M&J'[D+BIPY*=X!WC\O;.5-K4UD>%BL)2G8,//$.43^$CC)H/5YJ=+B!2QPTS
M$C6:(UI;&30)42E"#15&J.0-KU,HN .XNT28KG71<7.]=Z5+]JO\8IR&'X?I
M ID]6TY5Y,HS17A, 05&>]PEY"]JU'L0U!N_4U+Q3IWS-D*XG]9M-QKIL.1H
M(Z!_#Z=G;V T&X]R5?N[YEGIMG[9$FX'J)TW -T39/]]/SM0ZW4DJ:"3VBO-
M#9!92#)R+XE1P1"I*9ITDN.O$8R2.N./G6)YWP]]KFG:>5SV[*.*SGMPKBVQ
M7U?@9;84[JU_-./E;\M-->4 AOJR_DHB773$1@J$22$B"$0=5G*S;^SKL1^"
M?CMX5M7IYIX<%172Y5DM#L[3X00B_GEIGF>5N<2]."ANR@5YI0M=3D0$ .5]
MRIYW=YWYM^^^@Z0X;'P[C[9\AGA1/+)7.0\C3-I2"+4@8KML^L5IS,)1XGAI
M8IQ2*B?-F03-C#)>6[NZM6R+N=S\LCNH\!K#W&435QR')V=#R*L8%["<HTA+
MH8@%5KPY8"1(].LL;IHY,F:IW:FJ?:?9?PV0.\B,#D>^0M^$N7.&7YX93PKW
M(Z!*DBS+1>A1<U+:DQ K$J/&)A=UG4SA;V#<3S_W<(W4Z!EPZX'X*L8XK<1)
M=Y&I:KBGAE3'B1(=0)9]4VO[TG2-ZY)KR$;+>39(0WB6*%NFD5A;:GL#0V$]
M]8KN=)/&'6;O#<&K$R?O/@JN0-HWT$XGP]*K8%8I^R<JI'WS]L^%V< ,-4&@
M%1*U+9=.@R'6<$N8E=%;ED)B=>I&KX5U@@4)U36_'MOH2&T5@F"7I71?:Z\7
MP$HX6/BDRI9C<?:AM$[C/-0L0D:PB*M.E<!62#^XU)&ZZJ]-"U!@)+.\=!9B
M@A$I6"!.H5.3T1QFFBIFH$[6_D8X/_C3@9HJI(+-F@?"+*Y\,;\ @X-6$I=%
M4GKL$,D1D.4L$26]CI99X=5.1X_[9VJL0KG?GN=AFJG0,.P;0(OYL NDJL[C
M!E#'\?T.5-=URC]@K&OD>VV %BA([G$1,S0@-!HD<0GU%81*(N%RIFBE[*Z^
MU'^#\U1?^_L,<56G?7M,;;&C*>LX."H)$T5RC3^"9Y$X$[71D6<::E=ZWX2Q
M?VOD8)5N];$[U<=6+Z>O"V3FQ32A?!RO? SS;+0)S.Y\1*I>VE)M>8P?S__;
MS,O'.[]NIE-4=2^GJ3> *U?91#2$HS<B)LFE$<K:S WH<OFJYM;++5?9=(JO
MAXY(BV:"PW+/[&JSFM+&YLK=[\$9+P3GZ/RE7.Z<E,12DX@V.1@)GKEPQ)9'
MNPO24]M,;2 Z'Q@QK,3:>,S$>X-F,DU!F<A#-O>K;>8Q^7C+'IK[Z+#&Q327
MGEHW8S?WVH EG@)%6PWQ$XEN&PD2Q7,LNAPL U.IO+F*.'WUZS@E]AZ?%Z?2
MR..ZDJ2D-<2(3,P!2G=E[HA-/I:D_J2-21Y8G0*+DZX9/1IC]J@?W4=SO1<$
M[@+N1_WH+96Y5V7@;331.UUR,MES8TB,JLP1@R:$0SO")HC6"?2(99W=]ONJ
M'ZW'DGT44"=Z=6/Y67(Q1,4%B8P"D2 #"3P9(K117@J;;:7F@=]A*>!>ZKQ%
M*> ^NJA@\N]6WFIPY\V4<B*SQ=D22@/9R"-)W%#MA97950IB?8_EQH=0IGM]
M]'B)]1^ 0]&V:"?.S+P#S@VW/*FKL[Y=@*Z<SX$PTOJHP3(T/ UW0J _+C1X
MG8T-9K#EF0>>_8RGPS0<S5*KWT*\F*#$T#[['$<7".TY$K.8T1?3A>W\S$_&
M*&_[>@'BJ_MG=;3<2R"FY%\C)37Q.5$2DDB:4JOM:G%45Z=#'4EP\"G:83@>
MGS<7X^G .*84R$QT HI>-$YRYQ0G$=T0%T1P4M;I"]0)_/X7RJ/P=^WPK7?5
M5SV;.U"<N2NM1-"),MPW4NGEZJ(D7F1*-#= DP6EH7;CW"[DZ.LT[B1X?$0*
MG,KYVX&"__IE\P-F+F%@S.B,JG$I1#2JT AW"@TX<,+8*+4,H4[.>T6ACG_^
MUS]5NUW].Z-,!5]_,[(K^96[X*MZ=G@3PB,5%IT*)7:BZH'Z/ ;O#,_*&N!$
M42:(9-KCS*6:&"L8NE%.1U$G='\<OMU4"O2]TFT?-5:@&8[*>3.^FMTM9 93
M N*))DFD#XI8[B(!2H/T+%&EZ]Q]NP;E5%RIVVJKZ7*HZW2TNZ;2*%!(+AA&
M=$2C0(K(B)72XP_CO?(LQEC'>SFQ K&JG.A.!;T5Z0B:19)&$&=-0#M1EE(2
M:DGT 85E8&B]P,8I%.GTR8=;#/G6@ILM1]&+C\N/DN'XS[_]?U!+ P04
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M#82$K6<"VR)VQ&"M-1<]$9-U6?-RJ3H,<@<B>]Q*>5 1*P_'[7[*W*S&FM[
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MZ<)181?,@I*?EP*#TET7:(X)KM,S.A<@K^G2AJSN[7X30041$(*8:D-?&5*
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M\]1AV&IZW0 Z*:K7\3%=F](HK99+)?<B^6_7JX?%<OI?2DX2FB"62 RP1#%
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M%A$(@PQ)!I!*%& JM6W,N8)<))IQOV21BZ+&YA34ZD6SG<:>840-L#HN((*
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M7H_SRT:@GN+=8[!I,UC> :87'O>R0:7--K8&DK;<WFU1M]=_JCSCFV"F\L1
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MB5* 4BD T\K0"%.0IDA0S)#?&:*;X/&=_94Q9&</_3S36UV!Y\:EI;;^ -<
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M$#_H:M8?EN.%;(<G='5LZL*R57$YVV/=.-3K8L()P@G,&8BY[?&3)[:CI%(
M<X63C!(>$^?:CTV"1NK:U,I&6VVC2EU?W^8"NJ[.S?68#>/=>,/5P;UIQN)*
M_^;"PP=V<)I-//5P6J[OYN(X-<#]5&:12[O0^GE:"#8K>S^GF19QAAF0$&F
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MU[9B_M91,LM;K9 PGP,E!$!0QM8;S8&FB* D%IIPIR)O)T\>&XF7RGG[FJ>
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MT PAVXPA280[#+Y4\6Y/+UXJ^AT&4D<L//!!_8LFW-[T>3KHJ2Z$F-$*,2Q
M52F[G82\ J(T$&C#.>8PEZ8@87KTWK9#7LAAY.C?'*3(AV>^^X'NR7 I@$S-
M;)MT]>.D]K"VFKU2UX/0BIZF[F=]\)3T(%!.I9^'/:"OXORM4O:#N/JT6%EV
M_'_3AS<+I2<5PD7):0XTH:RMMX1* :5S*#CAL"!>IWG=9L:V(&OETUM7;S+K
M9N;\#)69/PEI-_?$ RHQT1QBU/AY&:H>$O-=2%PI,'_RT0/+RW<-[UA<OO/J
MOH=[=EG4Y&V_?5S:C>.GINJQ7B'5OVS;=;W[H9=RNM)J4A8<2D$EP%QK@#63
M@"MM_TI(J0M(6,59V/E>J NCXXS6,7?NU.0!M'T4KZBX")\7W^.]E&BG/N%S
M7@+A>MYG^TWOL]OETE[7'/Z)IVS_NE97/+MU.M<WFXZ -]EF?+4&QZ?N8LL>
MAX)]48Y\+ACLQL!'@WUA.CX=[/VD?L3Y5SW]^FVMU:W='?&OVQZ';YU2FV[M
M?GQ<6Z:N:[ FA"DH"DY!P2O+FI 9P!@K0"F$-D(4N"J"C@X#[8^-,C?N9[SQ
M/YMO>]$V?)DM=L[?9*H95G\^#9TN/S)-. F)F72+?^MZMNL%W(;"/N[CWXXH
M'D'V1"XJ.X;Z,"@U]@3HD!?[/J8?*;Z?SOE<3OGLPWRU7M95$'6-6:$,XR6&
M0! ( <Z))3]1V9\TD:)4I<8TJ'[YC)VQD=S6S6SG9Z_JO7.X^K%4!+02LU$?
MH((IYP(,4:GEG*U!*>3"@ ^IXM+E/1.IG.*D5C_OBH7:E(T)Y)A A N0&T$!
MKC@'C.<",(IS6B!14!.4+7[6TMAHH74TTS_<!B94G_$\H!Q)61BH ).2NX =
M P+)$I1&D%PPR4AA-^:+-9\-">C67CI [YR-C">"U8]DHX"5F&8W'[P])[?9
M:Q%3UBXA$3=M[:RU85/7+@WZ*'WMX@T]EV";XX%?ZCH W?94<T6;=GW7-LXH
M%4-"EA)@BNUFU&Y- 2_MRLS02C#%2X:8EY1BB-&QL?#6O<"EF ^^GNNRR*BE
M7J1MSQ"=2%;K98(N1R&PQ%VT^1@>=@47 ,71<B[DWAZ:#(TB[ <[CKEK3?#)
M?E8*F+--!Z2BPA(5[GS Y<0RG .F" ;<5,*N]P05BGM+-'2:&ANO.,\V^LU;
MES/G<X!N03>XW?02%[+41XFG@*HAO$@LH:@%B#]$0V\@+8C/^L$^KA66-(OE
M?7,J\M H-#N:7B^R\Q_,[-7?U[_\]"AF4UF?K/#Y4_VKO_\IEK:#%Z:=4@_=
M3QA.^<%K),^$(/SNB*;1>SM77[XMENL[O;S?D_6>&%0H*D4.<EFX#:(F@',&
M@>1E:11GN49!RSY_TV,CZ4;\\TB5U25/W>]4^%<]6R@$3(G?2C$-T(FI_9S
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M3H<!%96R/$T/2E=A<!Q25>#=_6CJEVT)^BX9V*WL/JSU_6I"9$Z5T024D@F
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M0GU9\^5Z"& /S:6#][7^.IW/'94);G\A0YOV'./))2&%0!I(H2' )2) Z*H
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MKB:4E%H7V*F'8@)P:300!@I &5-&5$C1W"L/P-_DZ-:];2G?LO6Z?M?4SN^
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M2^C9L."X0<%V".DX SJ8>'N"R=OY<A5._L_TR]J5DE)$P[V"DI%$$VR$Z&6
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M=Z1BKZ&4UH&MI##IO.=+^H_3Z0*)5]ILJ^]O3P*%[;-<D_5?ZJ],4BA&*6]
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MKJW%:AEU[@"Y8JSA3">0IB2"G*V57DE"#HR+I'.1V"8P&]EDK><Z"*FBC[R
M1V[K.P)'KH4*0!&1#2B9+#<K"5N:JZWG;?1@JG;!S5:F:F>%=)"JO:B >S4C
ML9Q6P3W[-JW%WCQ&HQ!"BH:L;>00' 80EO%H42>OV^#J'H+&1=5 ZIX/+_L.
M($21QFQ)*Z]+'''Q=5H[I5RIK;SD;OF!/G)Y]X]>S#]3U#*Q2?!H:%,:$^O]
M+44E+@CZPP9K"CH751O_<T@NQ@7K(+":=Z+C#O#]^_M?YE]Q,:LLU#/ET@3\
MBC57.?$E2AN3!F:T "5$A" , B<GU2(O-H;4!+./438N#L?#S,T2D2$5V $@
MG\\77^:+L,([F;&^:&\, V.#KB=2G2NG,F05A,Y.61<;-9AYB*QQ:X^Z@>)P
MJNL"AY\_UQY]X>1M^(*+,R:44%Y808&YE^16&^,@9&T ?:$#1D0G&[T[OY.<
M<0N4.L+=H:KJ &^7L5T5UL:G,8$+(<B=T9J!*EJ#$S9#Q.(P"FY]HXJEV[2,
M:^':1"@'2KP[S#PGR_MQOCA[&W:V"US2A'JN@,OU( 9-NX"3'Q!E5,%FC!';
MS!=ZG+9><BG[:?]!,!VLB@[ =>.)WQD34DOK3.T4PDHA)BC.\B[P6IEEF3*R
MT'YL<P#>14Y/$#I<YW>\LSQ, 1V@Z*YGH>><H"RNSD[-F,EV&V04F&A/<0I/
M3 49BV[SU/=^FL8>XMT43P.I8NQN Z_GLX]W<Q&\(2--<067M6P]DH3(:GLH
M)G+GK$5_,[UV3^.!>Y<8>]QV$WP,*-4.#,Y=ON+KZ0Q?K?#S<A*<D<H9#C:6
M3$#G!B@.*)!%LI)IRTVC"H 'R1H75FV\Z^'TT &H;LZ*NI[@>/:Y/F_XSSI9
M8KE:%S!/HDHBB"PAUDI1A<&!*QP!-8N6=F@4N4V+\%TI[>_J:4^0S(^HL0[Z
M=#_"WV5#H5\6\^7R]]D"PTEE^)<PG?V$9;[ #^';A/9W1FEKL4E]\,"T(J9C
M C+IC/GL<Q!M'@4/0GY_28FC8+>!;OLWL?<R_9J^NL(T>:T2F0'#HB)GA20>
M51W(9JU!U(5'W>9\'X3\_OR <0&]OV[[&=5T_YC)ZU*8Z.@D9W3B6$F1E]+D
M<?GJR>?LA$/Z'C9Z@K,MA>,^43T>.@?14-=%FC^'Z>+?PLDI_HJAULUO'ESM
M49YY]P<-5YBY!:$#E61>K'3YFN!*M[1HDC Z0M2)@U)>0>2TEPAA14L31&HT
M\.<AJ@XNCKOCLR\+DF6.1A47P6A50/EH*>I7&IR6R16&M!':S(][D*R1:X^&
MPLBM6KG!5/'TS,[^CUD>^KC&)JCA<Y8'029="O5)%4@O$OGTJ@Y8SQZ*CI[Q
M4'VB-J_<CF*(-L^YSN2<W\S>U:.W*F4=H5]NB"!S0I,#L$"4JJC)!Y3)DU]H
MO>%*BL+;#!;<E=*.S=4N2+K77+50V-.S8 <\;WGP\QK;L)8/7!Z$GE6$K8*T
MP7SUU5E1X 2SP&(63L0LC6YSA7Q$(_9LEL_'^JPKX&[M$/J%W^84Z%[;,.ND
MN\=8>*H/:+6UH+#6R3&*9Y2@J*:P3*Y FWYJ@['0L=G;!7N/F+TCJ;B#U-P%
MXS]]O_CG_YCBHK81^_ZZ-A';E,]X95"N'5-R496*'CR*# 45%Y:C\KJQ<_(@
M?9V@\KC@N0_"PVFR)WQ>/=YN\W=>:5JX#=Q'$+[.-A8R@U>*0\I6E!P5DF5H
M"]-MR.P$K0/BY#XH#JZTGA#Y:O;E=+5<2XR?U\$K(93(=.9X2T=00 :^NL6T
MG8L+PL<8VMRY/4!4)V@;'@KW@>Y O70*,7'&BD#GE2P)BE !E%,>',L)L# C
MO4(L]G@0$SV4UHT+L7WTTBG$Y&7%8-:&K'[1SM=",PO>J@0RA*A2Y!36MWD6
M^ !1XUZ?C@NQ??32$\1^^GY%;#\O\#].<9:^K[V,+)FSD0E(+-&N\=E#J$^#
MLC?&A5 R^1FMXXK[B.O$JO425 RBPYY@>1=#9SLX:=I0U@9(W",H8S4YOY(D
M*+B)J!QJUSC<O9^X3ORYH0"Q1>APB'8Z!=SR8M^>V7:>O?<1 UA+!P=%6[7;
M@1;@3%"9G ?ZL_&9^P!UG4!N*$AL$ZT>HI\.,%??%]66BC=&N=7=J7,->F("
M)[FH[T$08J(OC1):"ND#;=TF2+N?IDZ<NU%/VH$TU@'VWN%RM9BF%>:[>;K[
MN^=A5+%%&,;J:R4Z.QBK":A0*&;W6%F53K0IQSF$ZG'MXU#(N3U,Y#AJ[ "R
MO\YG^'U3A?CSZ2Q?M%>QWCB/&7@([.PB/1@+5D8Z;"3W0K1))]]-S[@P.QX>
M;KXV.EPY'4#LX08J3"=E/!(0C*>30[)27_X&PH4A$?$2F6J3U>NX]\UH@!M.
M51W@[HY>"#''&$3-3>;:U3O6G5.$ YL=YL3KD=&F_G//WB/-ZL[[\/P.U%!W
M&+OS\7+MWU=R21!R<% K-2#6L6,F9I%4+M$U&A[\!'N5[*3]W7N5[***#L#U
M:!,\*8Q5J#F8-3]:!PCUA;PP.DLRU!@:)>OZ[F(X-!)V[4VXBUHZ@-DCAS[C
M*FK:B#9+3H<^[4L7>,TT*:MB+-FX-@^X.O;/&@-L.(5T@:Z[VMA)47.6'DGO
MM$\4*D6"DA*RPNA+4,J;5JCJKN-@<S0=JH .4#2$O_KZ\EVE9:JHI,!X0\QG
MER&ZA&!0%NM1:],H#!B4C7$'6_8108R'BPXVQ=UI@#LJQ6O74)Y,2B!=KEU#
M8X!HM(00@C%HF+?\F#<?=Y#8R47;\6&TU67(H3K=&ZRW)[H.,A_F+GY<<=JH
M9$ +U*!\DN"=R"!2M%(J:0-K/L9J7V!V70LS## 'U%Z'O?;NW& %$WIOB0>Y
M+F:S=$*1M'+"&$Q16MWT4;=OO+<OT+J^"CX,:*U4T\%!O9'I78QPC8X<>%9Y
M*!3,24/V.V= Y=&3\Y-2;..)WDO2T\]+#V/OAM'98#W56KS[O=QD89;_+2RF
MU1U_-2/<T[=?SE;3U??K?&SW_'>;CQWN%?#.3 ST&'@SH^Q77'V:YRO6B@#Y
M/^?3V>K?Z(MK;S2-+HY+A>!-/2"10G@?&9V2W*9"+IP4JHT+OB.AA]JZ>Y:[
M:YQM9*@<N;!@!2,/EL?:>8A$(FV.(8K@?6Y39+ ]C>.&)2TQ=M/>-=+;@)''
M2";P@$8(.WSZ40UBRR8)NV*6_#6>F)! 6U4 X4J!+SR#Y2EI%B,/LDWY[Y'M
MXOOT"?/I";XI]RR\288YFY0O6=;4KJK), :1.TF.KI&:L1*U;3/$<3OZGI8]
MW 5;M_K*#Z^O4;,PR\7J49YN?Q?QM_#Y_&Y>1JY2@9A$G2-B)-3V$E"2R!R)
M:>ZWNK(A0JZ@DKZZB<A#*1T7HRUP,Q]!A6,F:8C/^_@X>_50WSD8%BP(<C>J
M^ JXE"U$*;S1T7N*R 8#X\.TC .WXV)AWD0Q8^<!?PU?_D'GQ=F-:-9T)@3.
MZFUZ!N4%$N4A@Q.F\*@$"<L^YO#=_MCQT#&DHN:#2*V#3-Q[DOWZF=/SD[!<
MOBGO5Q30K/>#B2E9SA!8$F20=:2=<=9U-V@5A5*AS?.+>TD:]^:AX3DVK#(Z
M0-55^L^V%Y)8LI$<# 7+H*P)X)01X+AS!F-TI5'+]MNTC.P/#:/DF]>DATF\
M \R\QT7M$O_V?/DU*^?#B1!I(Q4!&A76<A\)GA4#F4MFG44G>9N8^ &B1G[I
M=:"^;UJ>@83? XX>L].7UR&,EF<\(,C@"RAE([C*(T^.SO 4F2Z-1M-M3>.X
MEZ#'.//:J*N+ H^[.7KSQXS _FGZY2TN4M7F1YQHSXU'6\"+4EL&I50=Q@R\
MMLX-F#+#8UZ&W$%BYTF$/5&R5<[_4(5U8!1?S=+\,]9!*S^3;.^1X42@-\9*
M!+NNH JUBL!1'.Q3UEY:+5#8)BC<BKS.W?]A$#B\HCJVA,M),,5'D<A3L77T
MH*CSX$T=/8D&55 F&M&F[/T0C(UWW+:T<KLIH^O^[<]26IQB?OGM"\Z6^TV=
MN/D1PUU'/DC<0'>.;\/W]>B*9[.\7BZ<7-X!H;5*R5AGO I?"Q-UK=9Q0(A2
ML4A5(F]SH?8 40?7DZ4T/R4(GRUQO@)>+9:ZZ^*>-@G+6@3P]0!7:!2$1"XL
M"QAM1&VCDDUDL2?!XSIA0Z'J5F79$;3WE.S5_K-R[OZ@9K:KX7R<A["FHK+&
M:(3@/&'-V0"A=F$H141G"@\FM<D&-;1@ET?_;>ROQ7REVD@ZE)8[R/5ZBG87
M \\2I[.:H?04CRAL\\AY>QK[M5.[8.?^5,6@.GI*INF VJ][/JF9<6I9T_40
MP@HFS6UDD$RI)=&A@&,N $I>//,IQD;M&]OZ5U6T;Q?S@LLEJ2><_(RX?'ZZ
MJ/MQPI,LQE(DRE/.H&Q"B#$F""IDJ2R&TBA[]3!=_5JA73!RA[<TE"XZ2$R]
M)-,Q_XYDEM:3@:]8U'.&<O329B;(BAJRV,5RB,4QR,)SS9DL.K?I"_TH:>,F
MI%KA:UB-C%W2<K9;WI%NB(CZDO1%[:,^_[*N!SH[*B8Z).FY5%#HU*[OK 7$
MD#UD<A:88B5EQAX[W[9?;MPDT]"X:23F#FS3F]4G7-QV]<ZW ?/UU9,J8$R]
M]1(.P=4G>"F@*BC0AYOU40,9IH?I&O>]6BNK-* N.D#6_8P8,B?,"0T6+1(C
MQ%(,FFRKSUH'RXQ7;<ID#L-3LZX:C;VH S70]6O&VN=FNDGMAUE^/I^MZ+=P
MEJ;[Y98>^KCA@KBMB1XHDKNRWK,;ZUVF'"\01_#2VE@%EB4*ZY,3X*25( W:
M8'7FKM$#O9W('*)#U:.+7<EU<(6>107)5J&0*:[CC@)(Y$D@YIAX&P=]-SI'
MKM=JAK.[VELUTE[7F:H'+,?^"?7'/_0HIJ]AHGTW8$:K0K':0E$\4?Q')Z3G
M7$/2$@53*&/F3]\ OL;E$O'-%UR$NLQK#(3>,T_A^Z]A5?L/?K^1\36"7 65
M*:P)]0+,8("8C($<?/1*6U,:.6Y[$/N43.$NB+MI"EOK\:G:PP.R^%M\ZE$L
M8LOL_FX U387C,H!"[4\6HD,/M)1*@4S')/00K2IIQC=)+[ 95I,OZSMQD7'
MA<!M$.2J9-(#*!(->%&OP)2.0DG/E6[C#&Y)X%,R?;L@:QO3=ZB^.DB<U,+(
MVY[1Q"23G2D1C*YI:4$(<2)3X,Z<UY8'E8-N@[H[Z1GW8N"((#M<&R._JGZ'
MX>3ELK[(VB283C^?KF\]7B!1DZ9KG5W9-F_*V\6<]M1J,]U0%<%-9A%27,__
M* ZBM *8%IG"-:MLWNJ)Y%:/K@\B=5RS-P1.YF,H[0F@L[Y@ON3P["F85!)3
M1 W$D"&K7N]_DZYCJ#4YS\E:H[>ZFA@,F'=1.=Y+\",":$?8'JS-L>];WZ_"
MYT*ZH^T^P[2:IM/5^1@F$84H-H&OZ25E#$+$A" B$UC377AS-L<]=ZSW+M$W
MH Y7[7QP.8^-EKN\U'<XPS_"26UZ6K?;>LNAE:HX;B%X+>OUGH'(M0"+DMQ6
M+;3U>BOL;+G@N [<D,=E*RD_ >2<;;' E,,2 K@0:L\KX2'(Y,&@%1A+]MYL
M9W>V7G(D.]1,U3MB:0^Y=XRF-QL78';>WR7Z;+1S"F*2M=>CJP^O7 'IK4%A
MBK21'PJG&VOVC:=]U+TEH@Z1??>0^O#'_'ST3-!%!\UI,SI>Z^D8!.,+8'1!
M2IU<U >?;C?6'.> ZP92^\F^Q_S7ZXL7H<YH4XKG=<( ;8[$B2<T#H@E)Y)(
MUJ@VST+NIVG<0L<!W:B!Q=^C;?KMM.Z'-^7:/EE.$E->>N5H:PBD/6@L1%<R
ME-JKB((3QMS^Q]W=:W:6J]I3Q8_9HP'DW8,]>MB83T+1J++SP$RIMZF9_$QG
M!01F<S"HHXIM'M@^0EAG =YA&&NAC!Y-U,O:J_L$\P><A=GJV<G)_(\P2SA!
M%LC:1 M99SK#:T.64+R$C,(JSW2*-V]@=[!1]RS:V='6R$@-(?&QD?1L-CL-
M)Z]F:5$Y>C5;,_8V?%]?D%WIZ%.,B-X5#IQQ1>8W6_"!)2A!>"9MYBFYK5"T
MY8+CUNFW0% +2?=PQDU7TX]KQ;S'%>V&*T]:)A2'Q*!L 2X<R4IG!LXJ"=K9
M:%VT3+0J=[B?J'$+]EN=;0,IX:F6;)U5J]&_YF5^;J-/Z@8[N=(DHTE=UTY+
M'Z7X:W]AC%,TRUWM+: (Z*XV S"&<)\0)#*GA!(NIQ$+Y(]=(5:R9$8Q":F(
M $H%BG"L8V"RD(:;I/G-<_:_*L2&0-:^%6*[Z*N'T_JAFM]S9^0=U@1CKO'W
MSR35</+O&!83(\DA099!:')ME<?:W5%ZP,RSBHI[L]U CV%+N!^D>>1<20L(
M[5+#/9P^GPIR7YSB;W2(??@#3[[BKV0>/BW)GPZ92T'1/%.LMM\-X+7PD++)
MA27M/(Z(VSLH'CG[T@MJ#]7E$\)LW8\?_IA/N,JY)(9@4J@A@"S@5)W1[43P
M4OABL4USG!T)'3F]TQ%"]]'<4P,F(0TG,66TE2.IM:+3PB9PN7CP.1"!V86B
MVCQMVYG4D3-'O8%S9^V-G9'<EKMGA19<L[=V9R+M-UVT %94K+6"6.<P<-"N
M"%Z[/I/GOW>:^_'U1TXK-43=L93RA,SB1 FA9"1G.=8,G;)>@=-*0C%2LH!!
MV2->W-U%X59P-$\1CDUU-5C'DD88_'V6*8"K[8!K)\=$O_KL<_UJXK--QO("
M4M3>4=D;\+*V\$0AG=!2T %P?$#>1^Y6Z+1_6G0.HL7=H>HW4)WAQUI\_V&X
M1F!W<SGQUBI6<PM%.$$\4,06@DS@E8M9!):D;5-R=0]!6Z'./674#:&)_S]<
M 4UN.+M'O02BQ;N[!KHID(N+H!\/4M=Z3MI/M")1]KG>1J[9W$?V]WS2<(+<
MAM2!KL<N;RK>E*N+G;44?3Y?KI;O/Y%1B96<<U?F\DER#%9BC) 8(P,1=0!O
M%4*U#C+:K,S->NB!S.IA=!]ZRFR]^D]75[_L7&)Y%EX5)+$AG:A29Z@7X&"3
MMIIQ;DERXXKM;L+'O<,X(E9O'F;'5'C7A][=IFG_KET/?EYKB]JP5]>!6"TQ
M<Q/)Y3;UA8.*5H!+T0$SCA-<BW6J3??"<>WJE:E:9ZVMW^/BZS3AY=ZZ2E2M
M<DQA\^[[':;YQ]GT/XDH7$SG&THO-R#1:YTV"8(,&531%KQW]?%(8#D%8V5N
M<U U8^E)V^)=\/W &-(10?($K;1@W&\&RKV:U0+/Z5=\>Q)F!Y2B[;5.:ZN^
M"YM]6'LO%=?2<G!YG16LT\1M5( 8L[*N>&=&=@<;6_M[=NYB$2B 7*_YT_=;
M[M6S/\(BGTTUUL;(Y!V9D\1 )1TA&"XA<^'0>N>9:9,"'XR%)VW-=\'O_=;\
MF"#HX'ZGVJ3::&3]R-\;$X0Q'-"9>AYZ"='Q $GY&JUH.B[;C.6Y2D4O<Z./
M"H3Y0%KI"%'G;[(ERF*XJBE;BG?)DZGU20YD*4*DR#T%Q$TQ-6:+C</U>0\P
M]A#NV$4,=SA#U4<Z>U8?'-EH[[%VE*QE;+6K>% 64,@4!<N9X7:/J1Y<I@\4
M[*.\>1-)CHV)YSBG$*C,%Y_K*\&U\3SC(@L,.7A!N[K.B&6U<"Q&!I9A<9Y3
M$!345GBX=XF1AW$-A(5A)-C!L;&98_^^MD2K!^GKLVAY;3&E1U=T;4E6JQ04
MA<#@32A@9&%"6:O2S4YP YTA#Q U+GSZ<%.&TEF_\#O;GIP9G;S1P*,L=0@L
M;4]#>XFEX)-PWHB;[>3: K 'GV8PY6\'JCTTT0&L?L$9+L));?*8/T]GTQJJ
MUC/[["7J>0=&6:3CF8)6EXBI[ KX@!ET,L1JB%G8-O#:BKPN8;8/'.:M==,!
MX!X<J'C&$O/"<JL(#2619U#00$Q: [-,6JESL*)-9=P6Q(U[K+8#V]!Z&;G1
M](?:Y>-->37+TZ_3?$J[:&WV=1(Z< TBY4@"(K_3URD!A(804+)@PU8O(K;J
M(GTG">,^PQG7*QM&+[T!Z^_3U:=U KAVN_HT_?)A_K+VF#GOA\QC5DD$!7;]
M9-,P\C24H"\36JU,H3^VRKGO![F'B1NOO?0 ,'@(5 /J9.P,Q.U->+E'SR]V
MR6;_-I^=?W5NK'.):%FH.[2^'TH>7'WMQI64"25Q&<5UX-W7G7Q/"CI"UY!X
MF!];.2,;O!?3!2;Z\;F[6701BBQ]U()DI6/MLUPRR(BH0\@EB*V>9F]ESZZO
M/5*+UV,!ZC!9CVVG7G[#=%JCDS>E3!-])N'^'/3+\]:T@J4B/0,OZIR)G'/-
M^!6(AEMM@W'NYEEX7P[]\<7&<;2.:GV&%OG(AN;YIRF6FSR=L>$]HRT@-3CD
M-;)!#E'5!]OD&)3$N6-NJX9#6UF=!P@9YZ'R,4W04%KH(-6P"5?HE]?.I:8S
M%YE64)2H$8L1)!#EP,G,F779)]-H#OU5,L9]Z=Y'5GY_O70 JOT%=\GV+-^X
M76,UAX?*@BBU1TIA"9QC$ESD))3 @F9;3;?:O3"K 3?CIF,/ -?-DJNQ-=T!
MVM_A<K68IA7F=1'I[[/I:OGN_>]GYP&WS$9)QTLR#D%9M."L<,"=2L'Q'#-O
M4Y#Y(%DCUV>-CIK;B=V!5-@!'B]*V2LKFP[S9XS4.SL9LH:,Q=%.)^EX0WO>
M\(2%F",^VM2VWDO2R!?PO>%P&-5U@,$;&^J,";2*.U$?_G/)04D>P6ORD@MY
M2MPPS2VV*4V]DYR1KQEZP][A*NL =[^0^%:XOOP[W<P\$VAT;84"BDG:.((8
M<()GT"J8Y+B30;=IDWB+E'%;*?41UARFG]X =K;K(D,E NT1RR*QP*("GPD3
M4>HL,^T6S1I5?MPF9ES'[D#U/@26/63= 5RVN?PXL[3:>8&>*>"R2LK0'S'P
M!+[VSC%)%!;;O-/=GL:.P+4/'.Z-70?535>HN\?"WV?@7U],;2@FV%A*!,NM
MK=,Z-'@DZ4:7;-%U9-K-MH/'RK8\2ONX/>+Z.&>/C("Q+];V9O=R/LV;<G.0
MS9O3U7(59GDZ^[CVB"?&!BMMSI \"4.A%^!%YB"4\PJ3S#[>"%\>K19H2&[G
M*9Z! 7AWQ4$O:'C*9\+ZCW^CX) XW[0ZX!-RW'3BB4/)9)^4=@J"U0E,3KZ.
M LN*=78ZW,%%Y[FG-AMD=#ATL!5J<[GY;+V+GX<OTU4X6;.ZK.6]BZ^8?YXO
M?CY=G2[PU7)YNIY\QRUZY0,=P#;17A>R-AH,%H2D8[A>EGC?QC??F=3.DUIM
M0=U6L1T@=V_YG@V:78=0RU>SS<;]93%?+B>>,5=GM %7OO:R#O7]HF8@+1UG
M2G/+99L.^ V8&;ERX(F:](' \93WQ_EK[.5J<;H.S=ZL/M6&[V%V)IQZXF$^
M%\Y$V"H&+D +7]_&T=D7B\L0O7/,Z5RD:3/<[5@<CIRL?J([J26,]MY>7W$1
MYT-ML'JVUM,3\XO3Q84+N#EFK]Q:+E]^HUAJ2N*9H&<Z:FTA\7J-9#2"LX94
M0F%QI"BI%-6FIFQW6D?.'(T,^K:J?<JGP[7-6PN(OWW!>E'Z85Z_=2:/FK/[
M[7134!PXQ4#*@ZO=(!0)IC:QXA#J)8A6QOG4ITNU+8?C#CH8>Z/T"*,N3H>S
M_IB8[Q;1^>1F3"XF7LL22B2GTF0'(8?:,26BPLQ"C&U*XK:C;]QY"B.#NX$*
MNX#F5OU=?YO/OFXV9Q7H\D,=?G/UY[5YX6_SU;_CZK+[Z]63<6)H7W)#DB]N
M/>@$%03T"5A*VCLOK<BB";*/PMY6&\/_23=&?P#ZD^^KBT_:_$<W(ZD)4X8+
M%BW%3I9.QV+KG%]N()-IBMG;Q%6;4V0TEK>[T6/_M0%'1-J?>U-N0L*?YXNS
M;]7?XY/H<V*%[%640=0AL4C_BJGV54G%68U:N*>U$^_D<[OM]V>[47\"F.IB
MSQT:%5ZI+S@+_U"GJ)-!(&^:D2^@?9V];,![RY+(QK/<*'$V-"O;[9S_NFIO
M@8RGG'=[-)U^86_.!)--PN2S <MR59,-$.J )!]$]$SHJ!K=TQ^-Q>VVTI_U
M@K]/)#W!^2T;>:Q',*0KW\9->F>QF=5 N_KB3="R?@P9H?7?\XW,!I_V,BA5
MK6?#M!-A'Y-DG$>)MCXVE+61A<P2Z@@."H**ME&@D+;-%7<ODV0&&@FUKN5&
MGD6.+)/T(@E3)0U1D5@]3[Y$Q]$V&J#0A)TG/6%F%UPWGQ>V,S@Z<.<>ZAF=
MC<&4"(DE8KVR$N29YI!J]]-LK,T!>9O"X$.;O!]A%LUHD-FAX?LN^NL7BF>/
MPTJV)0AR,E/254BV0/"I$$>8G)<^"]7&Z#[1AN\[*7^GAN^[:*(#6&W3YSG[
M%),6$A)G6&?/1XB"0@5IK Y*NN(:A9I#]=\>J=G[3E#8H__V+GKI &K;]:^W
M9.\+8X("44<[,]:\:!()LK#,!.E4\8V:& PV6V"D=N^'P&UXW70 N&&\D,MT
M3O0V2"D$>)-)P$(H<,QF,+9$JS!P'T>\_-F>D5Y& ?7B)8Z)DPZVR99U4,9B
M\B%RL+P&DX(L2PB6@6(Y:IM([+;[4K9FCL"H$-JOKFT7?7:=]OT-Z21<+K_@
M8LWP/CG:FQ\Q7$+U0>(&RGZ^#(L9K;U\>[;(1?Z'*7($79T2C]J DJ*V#O<9
MF-9%H](VFC8IBOLH.OA$O_&YET/H98Z&N#*0T-;&A3Y!=#J %,Z0#(S4KDT
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MN+.0<JMB0W2-#MJ<?5T:E!<J!TAK2P/"4*K(*F")X91E4-T%(!M:6(Y+!D6
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M\QS-<\.3 'EI'O^P8+WR/(2_?_9[BU)NF%7HD8A.&)%LPMD4=4]'R,-O&95
M;SPC?98*J8E(R+F08^)52[\1$9+K5&(@4_\4&41,TI1EFONJ2'J)7T:JCE]^
MJFJ[EJJ/5"%!2,5X1FX3,8U9,&)%ES'I\A0(>) (R!A,0'E":#(C6:)EQA
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M971E;G1I;VYB;VYU<RYH=&U02P$"% ,4    " !E.*54_/$3_GL.  !*7
M'P              @ '&#@  <W!R:6YG=V]R:W,M<F5T96YT:6]N8F]N=7-A
M+FAT;5!+ 0(4 Q0    ( &4XI52J^/.#IP$  ,4,   <              "
M 7X=  !S=&%M9F]R9'-E8V]N9&QE87-E;6]D:68N:'1M4$L! A0#%     @
M93BE5(#D[<(#!0  KA4  !<              ( !7Q\  '-W='@M,C R,3 S
M,S%X97@S,C(N:'1M4$L! A0#%     @ 93BE5!GS@0BM?0( >DT4 !$
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M+FAT;5!+ 0(4 Q0    ( &4XI51?&.R1 P4  *@5   7              "
M 22Z P!S=W1X+3(P,C(P,S,Q>&5X,S(Q+FAT;5!+!08     #0 - ($#  !<
%OP,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
